"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2009/0024478 A1,195-784-123-292-235,2009-01-22,2009,US 18690808 A,2008-08-06,US 18690808 A;;US 4175202 A;;US 26017801 P,2001-01-05,System and Method for Asset Accumulation and Risk Management,"The system and method of the present invention removes barriers that undermine efficient risk-management. The invention prioritizes consumers by predicting their unmet demand for risk protection. Once deemed eligible, consumers are enrolled and funds are allocated to the payment of a premium for income insurance, contribution to a financial vehicle such as a savings or investment product, and payment of a premium for savings loss insurance. Active participants are eligible for income protection in case of job loss, systematic savings and ownership of public equities, principal protection and incentives based on utilization. The system and method of the present invention is calibrated on an ongoing basis to the behaviors of target consumers.",DIXON DEBORAH A;;DIXON DELORES A,DIXON DEBORAH A;;DIXON DELORES A,,https://lens.org/195-784-123-292-235,Patent Application,yes,20,38,9,9,0,G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/08;;G06Q40/03;;G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/03;;G06Q40/08,G06Q40/00;;G06Q90/00,705/14;;705/35,1,0,,,"Gardner et al: “College and University Programs in 'Risk Management'”, Financial Practice & Education, Fall/Winter 1996, Vol. 6 Issue 2, p 68-77, Financial Management Association, College of Business Administration, University of South Florida, Tampa Florida.",EXPIRED
2,US,A,US 3752504 A,131-870-291-115-798,1973-08-14,1973,US 3752504D A,1971-09-20,US 18179871 A,1971-09-20,SHEET HOLDER,"An improved sheet holder having a substantially rigid base plate and a clamping member hingedly connected to the base plate along one edge thereof for clamping engagement with one edge of a sheet for securely maintaining same in position adjacent the upper surface of the base plate. A substantially channel-shaped hinge member is fixedly secured to the base plate and extends into substantially parallel slots formed in the clamping member for permitting relative pivotal movement therebetween. A leaf spring is disposed between the legs of the hinge member and is positioned to resiliently urge the clamping member toward an open or closed position. The hinge assembly, including the spring, is substantially hidden by the clamping member, even when in the open position.",MASTER CRAFT CORP,DIXON A,AF ACQUISITION CORP. A DE CORP (1988-08-01);;MASTER-CRAFT CORPORATION (1988-08-31);;REYNOLDS AND REYNOLDS COMPANY THE A CORP. OF OHIO (1991-03-01);;SHAW-WALKER COMPANY THE A CORP. OF DE (1989-11-01),https://lens.org/131-870-291-115-798,Granted Patent,no,6,11,1,1,0,B41L3/02;;B41L3/02,B41L3/02,282-029   B,0,0,,,,EXPIRED
3,IN,B,IN 138321 B,123-248-923-829-183,1976-01-17,1976,IN 848CA1974 A,1974-04-16,GB 1965373 A,1973-04-25,FLUID PRESSURE BRAKE SYSTEMS,,GIRLING LTD,DIXON A,,https://lens.org/123-248-923-829-183,Granted Patent,no,0,0,8,8,0,B60T11/224;;B60T11/34;;B60T17/226,B60T11/224;;B60T11/34;;B60T17/22,,0,0,,,,EXPIRED
4,US,A1,US 2002/0198801 A1,084-520-017-076-412,2002-12-26,2002,US 4175202 A,2002-01-07,US 4175202 A;;US 26017801 P,2001-01-05,System and method for asset accumulation and risk management,"
   The system and method of the present invention removes barriers that undermine efficient risk-management. The invention prioritizes consumers by predicting their unmet demand for risk protection. Once deemed eligible, consumers are enrolled and funds are allocated to the payment of a premium for income insurance, contribution to a financial vehicle such as a savings or investment product, and payment of a premium for savings loss insurance. Active participants are eligible for income protection in case of job loss, systematic savings and ownership of public equities, principal protection and incentives based on utilization. The system and method of the present invention is calibrated on an ongoing basis to the behaviors of target consumers. 
",DIXON DEBORAH A.;;DIXON DELORES A.,DIXON DEBORAH A;;DIXON DELORES A,,https://lens.org/084-520-017-076-412,Patent Application,yes,12,98,9,9,0,G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/08;;G06Q40/03;;G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/03;;G06Q40/08,G06Q40/00,705/35,0,0,,,,EXPIRED
5,BR,A,BR 7807085 A,060-205-753-004-459,1979-05-08,1979,BR 7807085 A,1978-10-26,GB 4485777 A;;GB 1127178 A,1977-10-27,APERFEICOAMENTO EM UNIDADE DE CONTROLE DE FREIO HIDRAULICO PARA UM VEICULO,,GIRLING LTD,DIXON A,,https://lens.org/060-205-753-004-459,Patent Application,no,0,0,6,8,0,B60T8/1831;;B60T8/265;;B60T8/285;;B60T8/265;;B60T8/1831;;B60T8/285,B60T8/18;;B60T8/26;;B60T8/28,,0,0,,,,DISCONTINUED
6,FI,A0,FI 935005 A0,011-923-430-021-798,1993-11-12,1993,FI 935005 A,1993-11-12,US 69900291 A;;US 9203785 W,1991-05-13,Kylcontainer,,REEFCO MFG CORP,DIXON DAVID A,,https://lens.org/011-923-430-021-798,Patent Application,no,0,0,14,14,0,B60H1/3232;;B60H1/3232;;B65D88/745;;B65D88/745;;B65D90/00;;B65D90/00;;F25D11/003;;F25D11/003;;F25B2347/021;;F25B2347/021;;F25D2317/0651;;F25D2317/0651;;F25D2317/0665;;F25D2317/0665,B60H1/32;;F25D11/00;;F25D17/08;;F25D21/06,,0,0,,,,DISCONTINUED
7,CA,A,CA 913484 A,047-005-924-789-864,1972-10-31,1972,CA 913484D A,,CA 913484T A,,OXYGEN TENT,,DIXON TED A,DIXON TED A,,https://lens.org/047-005-924-789-864,Granted Patent,no,0,0,1,1,0,,A61G10/04,,0,0,,,,EXPIRED
8,CA,A,CA 538936 A,130-461-675-821-022,1957-04-02,1957,CA 538936D A,,CA 538936T A,,SULFURIZED GREASE COMPOSITIONS,,CALIFORNIA RESEARCH CORP,DIXON JOSEPH A,,https://lens.org/130-461-675-821-022,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
9,US,A,US 2830954 A,132-615-928-105-027,1958-04-15,1958,US 54875155 A,1955-11-23,US 54875155 A,1955-11-23,Polyamide grease composition,,CALIFORNIA RESEARCH CORP,DIXON JOSEPH A,,https://lens.org/132-615-928-105-027,Granted Patent,no,2,8,1,1,0,C10M119/24;;C10M119/24;;C10M2203/06;;C10M2203/06;;C10M2205/02;;C10M2205/02;;C10M2205/024;;C10M2205/024;;C10M2205/026;;C10M2205/026;;C10M2207/282;;C10M2207/282;;C10M2207/34;;C10M2207/34;;C10M2209/103;;C10M2209/103;;C10M2209/104;;C10M2209/104;;C10M2209/105;;C10M2209/105;;C10M2209/108;;C10M2209/108;;C10M2209/109;;C10M2209/109;;C10M2217/044;;C10M2217/044;;C10M2217/045;;C10M2217/045;;C10M2223/041;;C10M2223/041;;C10M2223/065;;C10M2223/065;;C10M2227/02;;C10M2227/02;;C10M2229/02;;C10M2229/02;;C10M2229/04;;C10M2229/04;;C10M2229/041;;C10M2229/041;;C10M2229/043;;C10M2229/043;;C10M2229/044;;C10M2229/044;;C10M2229/045;;C10M2229/045;;C10M2229/046;;C10M2229/046;;C10M2229/047;;C10M2229/047;;C10M2229/048;;C10M2229/048;;C10M2229/05;;C10M2229/05,C10M119/24,C5F F452          -;;C5F F537          -;;C5F F618          -;;C5F F661          -;;C5F F674          -;;C5F F691          -,0,0,,,,EXPIRED
10,GB,A,GB 2215431 A,136-370-851-981-987,1989-09-20,1989,GB 8806187 A,1988-03-16,GB 8806187 A,1988-03-16,Hydraulic shock absorber,"A hydraulic shock absorber has an inner cylinder (1), an outer cylinder and a bidirectional valve (4) located at the lower end of the inner cylinder (1) to permit fluid to flow from the inner cylinder to the outer cylinder. A piston having circumferentially spaced apertures therethrough is provided in the inner cylinder and a valve is located over the top of the apertures. At a speed up to 10 cycles per minute of the piston, oil below the piston passes through slots (102) of the valve (4) into the space between the inner and outer cylinders. At speeds above 10 cycles per minute, oil is forced through a hole (96) against a disc (101) of the valve (4) to cause a pin (95) to move against the bias of a spring (100) so that a hole (97) is exposed below the bottom of a support member (89) so that fluid passes through the holes (96, 97) into a recess (87) and thence into the space between the inner and outer cylinders. A manually adjustable valve (60, Fig 1) is provided to control the firmness of the shock absorber on bump and rebound movements of the piston, the manually adjustable valve controlling oil flow between the space between the inner and outer cylinders and the space above the piston. <IMAGE>",LEDA SUSPENSION LTD,DIXON LEONARD A,,https://lens.org/136-370-851-981-987,Patent Application,no,6,1,2,2,0,F16F9/34;;F16F9/44,F16F9/34;;F16F9/44,F2S SBF           SBF;;F2S S102          SBF;;F2S S111          SBF;;F2S S121          SBF;;F2S S123          SBF;;F2S S125          SBF;;F2S S301          SBF;;F2S S302          SBF;;F2S S307          SBF;;U1S S1820;;U1S S1847,0,0,,,,DISCONTINUED
11,AT,T1,AT E271889 T1,168-822-717-129-924,2004-08-15,2004,AT 97916996 T,1997-03-25,US 62197396 A;;US 9704862 W,1996-03-25,TROPFENFÖRMIG AUSGEBILDETES DRUCKGERÄT,"A pressurizing apparatus for pressurizing fluid contained in a patient fluid bag is described which has a novel teardrop pressurizing chamber. The pressure apparatus includes a door and base which each have complimentary teardrop cavities formed therein. When the door is in the closed position over the base, the teardrop pressurizing chamber is formed. A teardrop bladder bag is located interior to the base and can be inflated to apply pressure to a patient fluid bag. A regulator allows adjustment of the desired pressure. A gauge allows monitoring of the pressure. A valve allows the pressurizing device to be turned on and off. The teardrop pressurizing chamber allows the pressurizing apparatus to come up to pressure in a more expeditious manner. The conformance of the pressurizing means to the teardrop pressurizing chamber also adds to the efficiency of the pressurizing of the patient fluid bag and, additionally, allows for uniform pressure throughout a procedure.",MALLINCKRODT INC,FORD DIXON A,,https://lens.org/168-822-717-129-924,Granted Patent,no,0,0,14,14,0,A61M3/0233;;A61M5/1483;;A61M3/022;;A61M3/0208;;A61M3/0245;;A61M5/1483;;A61M3/0208;;A61M3/022;;A61M3/0233;;A61M3/0245,A61M5/152;;A61M1/02;;A61M3/02;;A61M5/148,,0,0,,,,DISCONTINUED
12,EP,A1,EP 0891196 A1,191-539-474-391-732,1999-01-20,1999,EP 97916996 A,1997-03-25,US 9704862 W;;US 62197396 A,1996-03-25,TEARDROP SHAPED PRESSURIZING APPARATUS,"A pressurizing apparatus for pressurizing fluid contained in a patient fluid bag is described which has a novel teardrop pressurizing chamber. The pressure apparatus includes a door and base which each have complimentary teardrop cavities formed therein. When the door is in the closed position over the base, the teardrop pressurizing chamber is formed. A teardrop bladder bag is located interior to the base and can be inflated to apply pressure to a patient fluid bag. A regulator allows adjustment of the desired pressure. A gauge allows monitoring of the pressure. A valve allows the pressurizing device to be turned on and off. The teardrop pressurizing chamber allows the pressurizing apparatus to come up to pressure in a more expeditious manner. The conformance of the pressurizing means to the teardrop pressurizing chamber also adds to the efficiency of the pressurizing of the patient fluid bag and, additionally, allows for uniform pressure throughout a procedure.",MALLINCKRODT INC,FORD DIXON A,,https://lens.org/191-539-474-391-732,Patent Application,yes,0,0,14,14,0,A61M3/0233;;A61M5/1483;;A61M3/022;;A61M3/0208;;A61M3/0245;;A61M5/1483;;A61M3/0208;;A61M3/022;;A61M3/0233;;A61M3/0245,A61M5/152;;A61M1/02;;A61M3/02;;A61M5/148,,0,0,,,,EXPIRED
13,US,A,US 2301262 A,048-316-107-043-004,1942-11-10,1942,US 19033738 A,1938-02-12,US 19033738 A,1938-02-12,Tin gas meter,,DIXON LLOYD A,DIXON LLOYD A,,https://lens.org/048-316-107-043-004,Granted Patent,no,0,3,1,1,0,G01F3/226;;G01F3/226,G01F3/22,,0,0,,,,EXPIRED
14,CA,A1,CA 2108773 A1,145-990-740-195-207,1992-11-14,1992,CA 2108773 A,1992-05-13,US 69900291 A,1991-05-13,REFRIGERATED CONTAINER,"2108773 9220542 PCTABS00017 A refrigerated container (10) incorporating welded corrugated steel external walls (12) having insulation disposed within the interior to form an insulated structure. Refrigeration evaporators (35, 36) extend longitudinally at the juncture of the sidewalls and the internal ceiling (40) of the container with evaporator coils distributed along both sides of the container; air is forced over the evaporator coils by strategically placed tandem centrifugal blowers (42, 44) directing air outwardly generally parallel to the ceiling and transverse to the length of the container. Air return is provided by extruded T-shaped floor rails (47) spaced apart to provide a passageway for air penetration into the floor and which are provided with transverse holes to permit the transverse flow of return air through the floor to a sidewall. Alternate evaporators are defrosted in accordance with a timing system using a defrost technique that evaporates a single evaporator at a timee.",REEFCO MFG CORP,DIXON DAVID A,,https://lens.org/145-990-740-195-207,Patent Application,no,0,1,14,14,0,B60H1/3232;;B60H1/3232;;B65D88/745;;B65D88/745;;B65D90/00;;B65D90/00;;F25D11/003;;F25D11/003;;F25B2347/021;;F25B2347/021;;F25D2317/0651;;F25D2317/0651;;F25D2317/0665;;F25D2317/0665,B60H1/32;;F25D11/00;;F25D17/08;;F25D21/06,,0,0,,,,DISCONTINUED
15,EP,A1,EP 0585388 A1,048-228-518-436-689,1994-03-09,1994,EP 92913191 A,1992-05-13,US 69900291 A,1991-05-13,REFRIGERATED CONTAINER.,"Conteneur réfrigéré (10) comprenant des parois externes (12) en tôle ondulée soudée comportant une isolation placée à l'intérieur de façon à former une structure isolante. Des évaporateurs frigorifiques (35, 36) sont placés longitudinalement au niveau de la jonction des parois latérales et du plafond interne (40) du conteneur et les serpentins des évaporateurs sont répartis le long des deux côtés du conteneur; l'air est refoulé au-dessus des serpentins par des souffleries centrifuges (42, 44) placées stratégiquement en tandem dirigeant l'air à l'extérieur, généralement parallèlement au plafond et dans le sens trasversal du conteneur. L'air refoulé passe par des traverses du plancher en forme de T extrudées (47) écartées les unes des autres pour former un passage et faciliter la pénétration de l'air dans le plancher. Ces traverses comportent des trous transversaux pour permettre à l'air refoulé de s'écouler en traversant le plancher pour aller vers les parois latérales. Les évaporateurs sont dégivrés en alternance d'après unsystème de minuterie utilisant une technique de dégivrage d'un seul évaporateur à la fois.",REEFCO MFG CORP,DIXON DAVID A,,https://lens.org/048-228-518-436-689,Patent Application,yes,0,1,14,14,0,B60H1/3232;;B60H1/3232;;B65D88/745;;B65D88/745;;B65D90/00;;B65D90/00;;F25D11/003;;F25D11/003;;F25B2347/021;;F25B2347/021;;F25D2317/0651;;F25D2317/0651;;F25D2317/0665;;F25D2317/0665,B60H1/32;;F25D11/00;;F25D17/08;;F25D21/06,,0,0,,,,DISCONTINUED
16,US,B2,US 9045174 B2,055-062-088-796-815,2015-06-02,2015,US 201213435287 A,2012-03-30,US 201213435287 A,2012-03-30,Flexible mud flap hanger-bracket,"Mud flap hanger is disclosed which includes a post member that is configured to allow attachment of the hanger to a vehicle and a hanger arm extending from the post member having a flexible core of a composite material, for example, a fiber-reinforced plastic (FRP) and that is clad with a substantially inelastic polymer. Preferably, the hanger arm is formed with a cross-section shape of a polygon so that clips for hanging the mud flap from the arm may be conformed to that polygonal shape.",DIXON IAN A;;FONTAINE SPRAY SUPPRESSION COMPANY,DIXON IAN A,FONTAINE SPRAY SUPPRESSION COMPANY (2012-03-29),https://lens.org/055-062-088-796-815,Granted Patent,yes,17,14,4,4,0,B62D25/182;;B62D25/182;;B62D25/188;;B62D25/188;;F16B5/121;;F16B5/123,B62D25/18,,0,0,,,,INACTIVE
17,US,A1,US 2007/0039181 A1,051-148-938-174-839,2007-02-22,2007,US 45984606 A,2006-07-25,US 45984606 A;;US 70599805 P,2005-08-05,MULTI-TUBE INSERTION FIXTURE AND PROCESS,A method and fixture for assembling a plurality of tubes to a tubesheet. A first end of each of the tubes is situated over a corresponding support rod that extends from a pattern block of the fixture. A first end of a plurality of locating members is inserted into a second end of each of the tubes such that a second end of the locating member extends from the tube second end. The tubesheet is then slid over the locating members and tubes such that each of a plurality of holes in the tubesheet receive corresponding ones of the tubes.,LIEBERT CORP,DIXON MATTHEW A,VERTIV CORPORATION (2006-07-19),https://lens.org/051-148-938-174-839,Patent Application,yes,7,2,7,7,0,B23P15/26;;B23P19/022;;F28F9/16;;Y10S165/492;;Y10T29/49368;;Y10T29/49895;;Y10T29/49396;;Y10T29/49377;;Y10T29/4938;;Y10T29/53117;;Y10T29/49364;;Y10T29/49387;;Y10T29/49373;;Y10T29/49368;;Y10T29/49895;;Y10T29/49396;;Y10T29/49377;;Y10T29/4938;;Y10T29/53117;;Y10T29/49364;;Y10T29/49387;;Y10T29/49373;;B23P19/022;;B23P15/26;;F28F9/16;;Y10S165/492,B23P15/26;;B21D53/00;;B23Q3/00,29/890.07;;29/890.038;;29/464;;29/726.5,0,0,,,,ACTIVE
18,CA,A,CA 1102570 A,083-667-070-670-808,1981-06-09,1981,CA 308051 A,1978-07-25,US 83022177 A,1977-09-02,SEA-FLOOR TEMPLATE,"SEA-FLOOR TEMPLATE A folding sea-floor compactable template for proper positioning and spacing of subsea piles and wells in the sea floor. Anchor pile templates or well templates are provided at the end of long hinged arms which extend radially out from a central section (which may also be used as a well template). The arms are folded back over the central section for transportation. Flotation can be in the main central section. With additional flotation at the outer ends of the arms, installation can be carried out by controlled submergence in stages from a single barge.",STANDARD OIL CO,DIXON DAVID A,,https://lens.org/083-667-070-670-808,Granted Patent,no,0,0,18,18,0,E21B41/08;;E21B41/08,E02D13/04;;E21B15/02;;E21B43/017,61-10,0,0,,,,EXPIRED
19,US,A,US 2756213 A,117-354-831-690-008,1956-07-24,1956,US 30528852 A,1952-08-19,US 30528852 A,1952-08-19,Amate-dicarboxylate-thickened grease,,CALIFORNIA RESEARCH CORP,DIXON JOSEPH A,,https://lens.org/117-354-831-690-008,Granted Patent,no,4,11,2,2,0,C10M5/00;;C10M2203/06;;C10M2203/104;;C10M2203/106;;C10M2205/02;;C10M2205/024;;C10M2205/026;;C10M2207/123;;C10M2207/129;;C10M2207/22;;C10M2207/282;;C10M2207/34;;C10M2209/103;;C10M2209/104;;C10M2209/105;;C10M2209/108;;C10M2209/109;;C10M2215/12;;C10M2223/04;;C10M2223/041;;C10M2223/042;;C10M2223/065;;C10M2227/02;;C10M2229/04;;C10M2229/041;;C10M2229/043;;C10M2229/044;;C10M2229/045;;C10M2229/046;;C10M2229/047;;C10M2229/048;;C10N2010/08;;C10N2010/06;;C10N2010/02;;C10N2010/04;;C10N2030/08;;C10N2040/02;;C10N2040/13;;C10N2040/12;;C10N2050/10;;C10M5/00;;C10M2229/041;;C10M2203/06;;C10M2223/042;;C10M2229/043;;C10M2229/048;;C10M2227/02;;C10M2203/104;;C10M2205/026;;C10M2203/106;;C10M2207/34;;C10M2209/103;;C10M2215/12;;C10M2229/047;;C10M2229/046;;C10M2223/04;;C10M2205/024;;C10M2229/044;;C10M2209/105;;C10M2229/045;;C10M2207/129;;C10M2207/282;;C10M2223/065;;C10M2229/04;;C10M2209/104;;C10M2209/108;;C10M2223/041;;C10M2207/22;;C10M2205/02;;C10M2207/123;;C10M2209/109;;C10N2010/02;;C10N2010/04;;C10N2010/06;;C10N2010/08;;C10N2030/08;;C10N2040/02;;C10N2040/12;;C10N2040/13;;C10N2050/10,,C5F F519          -;;C5F F537          -;;C5F F601          -;;C5F F661          -;;C5F F672          -;;C5F F674          -;;C5F F691          -;;C5F F731          -;;C5F F733          -;;C5F F761          -;;C5F F762          -;;C5F F763          -;;C5F F764          -,0,0,,,,EXPIRED
20,ES,T3,ES 2224233 T3,198-914-517-971-419,2005-03-01,2005,ES 97916996 T,1997-03-25,US 62197396 A,1996-03-25,APARATO DE PRESURIZACION EN FORMA DE GOTA.,"A pressurizing apparatus for pressurizing fluid contained in a patient fluid bag is described which has a novel teardrop pressurizing chamber. The pressure apparatus includes a door and base which each have complimentary teardrop cavities formed therein. When the door is in the closed position over the base, the teardrop pressurizing chamber is formed. A teardrop bladder bag is located interior to the base and can be inflated to apply pressure to a patient fluid bag. A regulator allows adjustment of the desired pressure. A gauge allows monitoring of the pressure. A valve allows the pressurizing device to be turned on and off. The teardrop pressurizing chamber allows the pressurizing apparatus to come up to pressure in a more expeditious manner. The conformance of the pressurizing means to the teardrop pressurizing chamber also adds to the efficiency of the pressurizing of the patient fluid bag and, additionally, allows for uniform pressure throughout a procedure.",MALLINCKRODT INC,FORD DIXON A,,https://lens.org/198-914-517-971-419,Granted Patent,no,0,0,14,14,0,A61M3/0233;;A61M5/1483;;A61M3/022;;A61M3/0208;;A61M3/0245;;A61M5/1483;;A61M3/0208;;A61M3/022;;A61M3/0233;;A61M3/0245,A61M5/152;;A61M1/02;;A61M3/02;;A61M5/148,,0,0,,,,EXPIRED
21,US,A,US 4146157 A,180-185-862-869-334,1979-03-27,1979,US 74385076 A,1976-11-22,US 74385076 A,1976-11-22,Anti-spill drinking cup,"A top (or lid) for an existing drinking cup which permits the insertion of a liquid into the cup without removal of the top and which also prevents the liquid from splashing or spilling from the cup during the filling or drinking operation. The top comprises means for fixing same to the cup or similar receptacle. The top includes suitable holes or apertures for permitting the passage of fluid therethough. Likewise, the top includes suitable openings or apertures for permitting the passage of air therethrough when the fluid is being inserted into the cup. A lip or rim describes the outer periphery of the top. In one embodiment, a mouth piece may be integrally formed with the lip. In another embodiment, the apertured member may be separate from the top.",DIXON SR LESTER A;;DIXON JR LESTER A,DIXON SR LESTER A;;DIXON JR LESTER A,,https://lens.org/180-185-862-869-334,Granted Patent,yes,6,67,1,1,0,A47G19/2272;;A47G19/2272,A47G19/22,222/424,0,0,,,,EXPIRED
22,US,A,US 2830955 A,014-114-799-722-366,1958-04-15,1958,US 54875055 A,1955-11-23,US 54875055 A,1955-11-23,Polyamide-thickened grease,,CALIFORNIA RESEARCH CORP,DIXON JOSEPH A,,https://lens.org/014-114-799-722-366,Granted Patent,no,2,6,1,1,0,C10M119/24;;C10M119/24;;C10M2203/06;;C10M2203/06;;C10M2205/02;;C10M2205/02;;C10M2205/024;;C10M2205/024;;C10M2205/026;;C10M2205/026;;C10M2207/282;;C10M2207/282;;C10M2207/34;;C10M2207/34;;C10M2209/103;;C10M2209/103;;C10M2209/104;;C10M2209/104;;C10M2209/105;;C10M2209/105;;C10M2209/108;;C10M2209/108;;C10M2209/109;;C10M2209/109;;C10M2217/044;;C10M2217/044;;C10M2217/045;;C10M2217/045;;C10M2223/041;;C10M2223/041;;C10M2223/065;;C10M2223/065;;C10M2227/02;;C10M2227/02;;C10M2229/02;;C10M2229/02;;C10M2229/04;;C10M2229/04;;C10M2229/041;;C10M2229/041;;C10M2229/043;;C10M2229/043;;C10M2229/044;;C10M2229/044;;C10M2229/045;;C10M2229/045;;C10M2229/046;;C10M2229/046;;C10M2229/047;;C10M2229/047;;C10M2229/048;;C10M2229/048;;C10M2229/05;;C10M2229/05;;C10N2030/08;;C10N2030/08;;C10N2040/02;;C10N2040/02;;C10N2040/12;;C10N2040/12;;C10N2040/13;;C10N2040/13,C10M119/24,C5F F452          -;;C5F F537          -;;C5F F618          -;;C5F F661          -;;C5F F674          -;;C5F F691          -;;C5F F731          -;;C5F F733          -,0,0,,,,EXPIRED
23,US,A,US 1551808 A,033-059-291-781-242,1925-09-01,1925,US 74204624 A,1924-10-06,US 74204624 A,1924-10-06,Ball cock,,C E IPOCK,DIXON PHILLIP A,,https://lens.org/033-059-291-781-242,Granted Patent,no,0,8,1,1,0,F16K31/26;;Y10T137/7488;;Y10T137/7488;;F16K31/26,F16K31/26,,0,0,,,,EXPIRED
24,US,B2,US 8905418 B2,032-423-292-809-042,2014-12-09,2014,US 201213480580 A,2012-05-25,US 201213480580 A;;US 201161489980 P,2011-05-25,Mounting assembly for vehicle mud flaps,"A mounting assembly for mud flaps has an elongated mounting arm defining an interior elongated chamber with a slot opening at the bottom. The assembly includes a one or more biased clips that attach to the top edge of the mud flap, which is inserted into the chamber with the lower portion of the mud flap extending through the bottom slot and the clips seated within the chamber. The clips include a pair of protrusions that engage the interior of the chamber, and are configured such that sufficient downward force on the mud flap causes the clip to open and release the mud flap.",DIXON IAN A;;FONTAINE SPRAY SUPPRESSION COMPANY,DIXON IAN A,FONTAINE SPRAY SUPPRESSION COMPANY (2012-05-23),https://lens.org/032-423-292-809-042,Granted Patent,yes,21,4,3,3,0,B62D25/188;;B62D25/188;;Y10T24/44684;;Y10T24/44684,B62D25/18,280/154;;24/535,0,0,,,,INACTIVE
25,CA,A,CA 136259 A,062-322-372-139-371,1911-10-17,1911,CA 136259D A,1911-02-01,CA 136259T A,1911-02-01,TWINE HOLDER,,DIXON JOHN A,DIXON JOHN A,,https://lens.org/062-322-372-139-371,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
26,NO,D0,NO 934089 D0,059-283-293-031-496,1993-11-12,1993,NO 934089 A,1993-11-12,US 9203785 W;;US 69900291 A,1991-05-13,KJOELECONTAINER,,REEFCO MFG CORP,DIXON DAVID A,,https://lens.org/059-283-293-031-496,Patent Application,no,0,0,14,14,0,B60H1/3232;;B60H1/3232;;B65D88/745;;B65D88/745;;B65D90/00;;B65D90/00;;F25D11/003;;F25D11/003;;F25B2347/021;;F25B2347/021;;F25D2317/0651;;F25D2317/0651;;F25D2317/0665;;F25D2317/0665,B60H1/32;;F25D11/00;;F25D17/08;;F25D21/06,,0,0,,,,PENDING
27,US,A,US 3540446 A,068-666-590-921-879,1970-11-17,1970,US 3540446D A,1968-07-02,US 74200668 A,1968-07-02,OXYGEN TENT,,TED A DIXON,DIXON TED A,,https://lens.org/068-666-590-921-879,Granted Patent,no,0,6,1,1,0,A61G10/04;;A61G10/04,A61G10/04,128/191,0,0,,,,EXPIRED
28,US,A,US 768737 A,099-983-382-935-153,1904-08-30,1904,US 1903/0182807 A,1903-11-27,US 1903/0182807 A,1903-11-27,CAN-CAPPING MACHINE.,,DIXON FRANK A,DIXON FRANK A,,https://lens.org/099-983-382-935-153,Granted Patent,no,0,0,1,1,0,B23K37/047;;B23K37/047,,,0,0,,,,EXPIRED
29,US,A,US 689388 A,120-501-095-927-390,1901-12-24,1901,US 1901/0054334 A,1901-04-04,US 1901/0054334 A,1901-04-04,RAIL-JOINT FASTENING.,,DIXON FREDERICK A,DIXON FREDERICK A,,https://lens.org/120-501-095-927-390,Granted Patent,no,0,0,1,1,0,E01B11/10;;E01B11/10,,,0,0,,,,EXPIRED
30,US,A1,US 2007/0000033 A1,084-854-108-434-772,2007-01-04,2007,US 45541606 A,2006-06-19,US 45541606 A;;US 10828005 A,2005-04-18,Periscope swim goggles,"Periscope Swim Goggles are swimmer's goggles with a periscope situated above the water line that projects the view that is ahead of the swimmer through a fiber optic cable to a viewer located on the goggle's eyepiece. Generally, an open-water swimmer using the free style or crawl stroke must occasionally sight on a landmark to swim toward. Periscope Swim Goggles would enable the swimmer to continually swim directly along the desired path without lifting the head for sighting. Conventional swimming goggles are typically comprised of two eyepieces contoured and gasketed for an air-tight fit around each eye socket and an elastic strap that wraps around the head holding the eyepieces tight to the face. In one embodiment of the invention, the periscope is positioned and secured at the back of the head by the elastic strap of the goggles. The fiber optic cable leaves the periscope and follows the elastic strap to the viewer which is mounted to the front of the eyepiece.",DIXON PHILIP A,DIXON PHILIP A,,https://lens.org/084-854-108-434-772,Patent Application,yes,11,13,2,2,0,G02B6/00;;G02B6/4206;;G02B6/4214;;G02B23/08;;G02B27/017;;G02B27/0172;;G02B2027/0178;;A63B2071/0666;;A63B33/004;;G02B2027/0178;;G02B6/00;;G02B23/08;;G02B6/4206;;G02B27/017;;G02B27/0172;;G02B6/4214;;A63B2071/0666;;A63B33/004,A61F9/02,2/426,0,0,,,,DISCONTINUED
31,NO,L,NO 934089 L,105-031-699-431-516,1994-01-11,1994,NO 934089 A,1993-11-12,US 9203785 W;;US 69900291 A,1991-05-13,Kjoelecontainer,,REEFCO MFG CORP,DIXON DAVID A,,https://lens.org/105-031-699-431-516,Abstract,no,0,0,14,14,0,B60H1/3232;;B60H1/3232;;B65D88/745;;B65D88/745;;B65D90/00;;B65D90/00;;F25D11/003;;F25D11/003;;F25B2347/021;;F25B2347/021;;F25D2317/0651;;F25D2317/0651;;F25D2317/0665;;F25D2317/0665,B60H1/32;;F25D11/00;;F25D17/08;;F25D21/06,,0,0,,,,PENDING
32,US,A,US 1789519 A,124-984-390-300-691,1931-01-20,1931,US 26555228 A,1928-03-29,US 26555228 A,1928-03-29,Log raft,,LINCOLN COUNTY LOGGING COMPANY,DIXON WILLIAM A,,https://lens.org/124-984-390-300-691,Granted Patent,no,0,2,1,1,0,B63B35/62;;B63B35/62,B63B35/62,,0,0,,,,EXPIRED
33,US,A,US 3269133 A,133-681-396-140-05X,1966-08-30,1966,US 42056464 A,1964-12-23,US 42056464 A;;US 35662464 A,1964-04-01,Apparatus for transporting produce under controlled atmosphere,,BEST FERTILIZERS CO,DIXON DAVID A,AERIFORM LTD (1982-08-05),https://lens.org/133-681-396-140-05X,Granted Patent,no,6,23,1,2,0,A23B7/148;;F25D17/042;;A23B7/148;;F25D17/042,A23B7/148;;F25D17/04,,0,0,,,,EXPIRED
34,US,A,US 2585375 A,131-359-289-126-385,1952-02-12,1952,US 77796947 A,1947-10-04,US 77796947 A,1947-10-04,Window pivot and lock,,DIXON WILLIAM A,DIXON WILLIAM A,,https://lens.org/131-359-289-126-385,Granted Patent,no,8,7,1,1,0,E05D7/083;;E05D7/083;;E05Y2900/148;;E05Y2900/148;;Y10T70/5146;;Y10T70/5146,E05D7/08,,0,0,,,,EXPIRED
35,WO,A1,WO 2007/019013 A1,191-631-321-731-101,2007-02-15,2007,US 2006/0028324 W,2006-07-21,US 70599805 P,2005-08-05,MULTI-TUBE INSERTION FIXTURE AND PROCESS,A method and fixture for assembling a plurality of tubes (120) to a tubesheet (124) . A first end of each of the tubes (120) is situated over a corresponding support rod (102) that extends from a pattern block (100) of the fixture. A first end of a plurality of locating members (104) is inserted into a second end of each of the tubes (120) such that a second end of the locating member (104) extends from the tube second end. The tubesheet (124) is then slid over the locating members (104) and tubes (120) such that each of a plurality of holes in the tubesheet (124) receive corresponding ones of the tubes (120) .,LIEBERT CORP;;DIXON MATTHEW A,DIXON MATTHEW A,,https://lens.org/191-631-321-731-101,Patent Application,yes,4,2,7,7,0,B23P15/26;;B23P19/022;;F28F9/16;;Y10S165/492;;Y10T29/49368;;Y10T29/49895;;Y10T29/49396;;Y10T29/49377;;Y10T29/4938;;Y10T29/53117;;Y10T29/49364;;Y10T29/49387;;Y10T29/49373;;Y10T29/49368;;Y10T29/49895;;Y10T29/49396;;Y10T29/49377;;Y10T29/4938;;Y10T29/53117;;Y10T29/49364;;Y10T29/49387;;Y10T29/49373;;B23P19/022;;B23P15/26;;F28F9/16;;Y10S165/492,B23P15/26;;B23P19/02,,0,0,,,,PENDING
36,US,A,US 3563757 A,190-663-628-317-28X,1971-02-16,1971,US 3563757D A,1967-07-28,US 67151667 A,1967-07-28,APPARATUS FOR MINIMIZING PERISHABLE PRODUCTS,,OXYTROL CORP,DIXON DAVID A,AERIFORM LTD (1982-08-05),https://lens.org/190-663-628-317-28X,Granted Patent,no,0,28,1,1,0,A23L3/3418;;A23L3/3418;;A23B7/148;;A23B7/148;;B60H1/00014,A23B7/148;;A23L3/3418,99/271,0,0,,,,EXPIRED
37,US,A,US 747151 A,021-040-646-939-438,1903-12-15,1903,US 1903/0144039 A,1903-02-19,US 1903/0144039 A,1903-02-19,STEAM-COOKER.,,DIXON FRANK A,DIXON FRANK A,,https://lens.org/021-040-646-939-438,Granted Patent,no,0,2,1,1,0,A23L3/04;;A23L3/04,,,0,0,,,,EXPIRED
38,US,A1,US 2007/0069486 A1,028-161-870-753-73X,2007-03-29,2007,US 23548305 A,2005-09-26,US 23548305 A,2005-09-26,Angular adjustment mechanism for snowboard bindings,The Angular Adjustment Mechanism for Snowboard Bindings positioned between the snowboard and boot bindings allows angular adjustment between the snowboard rider's boot bindings and the snowboard without the need for any tools or levers. The user can make adjustments at any time by weighting the board with either foot and lifting and rotating the opposite foot. A lifting action releases the mechanism allowing for the adjustment of angular orientation. Removal of the lifting force engages the locking mechanism preventing further angular movement.,DIXON PHILIP A,DIXON PHILIP A,,https://lens.org/028-161-870-753-73X,Patent Application,yes,9,0,2,2,0,A63C10/14;;A63C10/18;;A63C10/18;;A63C10/14,B62B15/00,280/14.24,0,0,,,,INACTIVE
39,HU,A,HU T68606 A,042-708-804-613-476,1995-06-28,1995,HU 9303067 A,1992-05-13,US 69900291 A,1991-05-13,REFRIGERATED CONTAINER,,REEFCO MFG CORP,DIXON DAVID A,,https://lens.org/042-708-804-613-476,Unknown,no,0,0,14,14,0,B60H1/3232;;B60H1/3232;;B65D88/745;;B65D88/745;;B65D90/00;;B65D90/00;;F25D11/003;;F25D11/003;;F25B2347/021;;F25B2347/021;;F25D2317/0651;;F25D2317/0651;;F25D2317/0665;;F25D2317/0665,B60H1/32;;F25D11/00;;F25D17/08;;F25D21/06,,0,0,,,,DISCONTINUED
40,US,A1,US 2003/0000746 A1,121-758-528-137-184,2003-01-02,2003,US 17491302 A,2002-06-19,US 17491302 A;;US 30014201 P,2001-06-22,Load cell apparatus having a gap measuring device,"
   A load cell apparatus for use with a structure comprises a cell block that flexes in response to an applied load and a transducer that is adapted to measure a distance across a gap. In some embodiments, the gap is defined between the transducer and the structure, and in other embodiments, the gap is defined between the transducer and the cell block. 
",DIXON STEVEN A.,DIXON STEVEN A,HILL-ROM SERVICES INC (2002-08-15),https://lens.org/121-758-528-137-184,Patent Application,yes,0,6,6,6,0,A61G7/0527;;A61G7/0527;;G01G9/00;;G01G9/00;;G01G19/445;;G01G19/445,G01G3/00;;A61G7/05;;G01G9/00;;G01G19/44;;G01G19/52,177/144;;177/229,0,0,,,,EXPIRED
41,MX,A,MX PA02010432 A,129-106-800-706-436,2003-04-25,2003,MX PA02010432 A,2001-03-23,US 19208600 P;;US 0109398 W,2000-03-24,METHOD FOR MODIFYING LIGNIN COMPOSITION AND INCREASING IN VIVO DIGESTIBILITY OF FORAGES.,"Methods for transforming forage legumes or woody plants with a DNA construct comprising at least one open reading frame encoding for a caffeoyl CoA 3 O methyltransferase enzyme or a Medicago sativa caffeic acid 3 O methyltransferase enzyme or a fragment thereof in either a sense or antisense orientation under a lignification associated tissue specific promoter have been found, resulting in the down regulation of the corresponding homologous gene either through antisense inhibition or sense suppression, as well as reduced lignin content and modified lignin composition in the transgenic plants. The expression of the caffeoyl CoA 3 O methyltransferase transgene produces an increased syringyl lignin to guaiacyl lignin ratio in the transformed plant, and greatly improved forage digestibility.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A,,https://lens.org/129-106-800-706-436,Patent Application,no,0,0,9,9,0,C12N9/1007;;C12N15/8255,C12N9/10;;C12N15/82,,0,0,,,,PENDING
42,US,A,US 5187945 A,170-776-414-665-33X,1993-02-23,1993,US 69900291 A,1991-05-13,US 69900291 A,1991-05-13,REFRIGERATED CONTAINER,"A refrigerated container incorporating welded corrugated steel external walls having insulation disposed within the interior to form an insulated structure. A refrigeration compressor power by an electric motor together with a diesel engine operatively connected to an electrical generator for supplying power to the electric motor is secured integral with the container externally of the insulated interior but positioned at one end and protected by the extended sides, top and bottom of the container walls. Fuel storage is also provided at one end of the container. Refrigeration evaporators extend longitudinally at the juncture of the sidewalls and the internal ceiling of the container with evaporator coils distributed along both sides of the container; air is forced over the evaporator coils by strategically placed tandem centrifugal blowers directing air outwardly generally parallel to the ceiling and transverse to the length of the container. Air return is provided by extruded T-shaped floor rails spaced apart to provide a passageway for air penetration into the floor and which are provided with transverse holes to permit the transverse flow of return air through the floor to a sidewall. Return air is routed from the floor through ducts formed by false walls on either side of the container extending upwardly from the floor and terminating at an intake area to the evaporator coils. Alternate evaporators are defrosted in accordance with a timing system using a defrost technique that evaporates a single evaporator at a time while permitting the remaining evaporator or evaporators to continue to refrigerate the container interior.",REEFCO MFG CORP,DIXON DAVID A,REEFCO MANUFACTURING CORPORATION A BRITISH COLUMBIA CORP (1991-04-25);;CORNERSTRONE TECHNOLOGIES LIMITED (1996-06-18);;CORNERSTONE TECHNOLOGIES LIMITED (1996-06-18),https://lens.org/170-776-414-665-33X,Granted Patent,yes,10,99,14,14,0,B60H1/3232;;B60H1/3232;;B65D88/745;;B65D88/745;;B65D90/00;;B65D90/00;;F25D11/003;;F25D11/003;;F25B2347/021;;F25B2347/021;;F25D2317/0651;;F25D2317/0651;;F25D2317/0665;;F25D2317/0665,B60H1/32;;F25D11/00;;F25D17/08;;F25D21/06,62/234;;62/239;;62/457.1,0,0,,,,EXPIRED
43,BR,A,BR 9205988 A,005-943-683-131-849,1994-08-02,1994,BR 9205988 A,1992-05-13,US 9203785 W;;US 69900291 A,1991-05-13,Container refrigerado de expedição,,REEFCO MFG CORP,DIXON DAVID A,,https://lens.org/005-943-683-131-849,Patent Application,no,0,0,14,14,0,B60H1/3232;;B60H1/3232;;B65D88/745;;B65D88/745;;B65D90/00;;B65D90/00;;F25D11/003;;F25D11/003;;F25B2347/021;;F25B2347/021;;F25D2317/0651;;F25D2317/0651;;F25D2317/0665;;F25D2317/0665,B60H1/32;;F25D11/00;;F25D17/08;;F25D21/06,,0,0,,,,DISCONTINUED
44,US,A,US 2562713 A,048-676-047-610-714,1951-07-31,1951,US 18703450 A,1950-09-27,US 18703450 A,1950-09-27,Barbecue oven having rotatable basket,,HARRISON DIXON A,HARRISON DIXON A,,https://lens.org/048-676-047-610-714,Granted Patent,no,5,5,1,1,0,A47J37/047;;A47J37/047,A47J37/04,,0,0,,,,EXPIRED
45,US,A,US 3925680 A,052-791-033-034-996,1975-12-09,1975,US 56522475 A,1975-04-04,US 56522475 A,1975-04-04,Method and system for regulating peak residential power demand,"A temperature monitoring means monitors temperature outside the residence and a supply system responsive to the monitoring means controls the supply of electrical power to major home appliances such as air conditioning devices, food preparation devices, clothes drying devices and water heating devices and the like. In one embodiment, major home appliances are arranged in pairs and connected to a main power distribution system in these pair arrangements through a load dispatcher including continuity sensitive switches. The appliances are continuously connected to the electrical power distribution system when the outdoor temperature is below a predetermined value. However, when the outdoor temperature exceeds the predetermined value, the continuity switches then control the supply of power to the appliances by supplying power to one of the appliances to the exclusion of the other in each pair arrangement. Whenever electrical power is not being supplied to the one of the appliances in the pair arrangement requiring power, the other of the appliances is supplied with electrical power. In accordance with another aspect of the invention, the outdoor temperature is monitored and controls the operation of an air conditioning unit. When the outdoor temperature exceeds a predetermined value, the air conditioner is cycled between on and off conditions on a timed, periodic basis without regard to the temperature inside the residence at least until the temperature outside the residence drops below the predetermined value. The air conditioner may be cycled between on and off conditions on the periodic basis until the outdoor temperature drops a predetermined amount below the predetermined value, for example, drops at least 5 DEG or 6 DEG below the predetermined value.",DIXON WILLIAM A,DIXON WILLIAM A,,https://lens.org/052-791-033-034-996,Granted Patent,no,7,48,1,1,0,Y02B70/3225;;Y04S20/222;;Y04S20/244;;Y04S20/242;;H02J2310/14;;H02J2310/12;;H02J3/14;;Y02B70/30;;H02J3/14;;Y02B70/3225;;Y04S20/244;;Y04S20/222;;Y04S20/242;;Y02B70/30,H02J3/14,307/39,0,0,,,,EXPIRED
46,CA,A,CA 626713 A,056-464-612-647-452,1961-09-05,1961,CA 626713D A,,CA 626713T A,,POLYAMIDE-POLYAMATE-THICKENED GREASES,,CALIFORNIA RESEARCH CORP,DIXON JOSEPH A,,https://lens.org/056-464-612-647-452,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
47,US,A,US 3374778 A,071-916-571-594-144,1968-03-26,1968,US 50109465 A,1965-10-22,US 50109465 A,1965-10-22,Electronic ignition system,,JOHN A. DIXON,DIXON JOHN A,,https://lens.org/071-916-571-594-144,Granted Patent,no,2,6,1,1,0,F02P3/0552;;F02P3/0552;;F02P3/0435;;F02P3/0435,F02P3/04;;F02P3/055,123/148,0,0,,,,EXPIRED
48,US,A,US 1033161 A,174-440-356-750-910,1912-07-23,1912,US 1911/0630652 A,1911-06-01,US 1911/0630652 A,1911-06-01,SHOW-CASE CONSTRUCTION.,,DIXON FREDERICK A,DIXON FREDERICK A,,https://lens.org/174-440-356-750-910,Granted Patent,no,0,7,1,1,0,A47F5/005;;A47F5/005,,,0,0,,,,EXPIRED
49,US,A,US 3703173 A,199-922-236-069-02X,1972-11-21,1972,US 3703173D A,1970-12-31,US 10310170 A,1970-12-31,NEBULIZER AND TENT ASSEMBLY,"An improved apparatus for treating a patient in a therapeutic atmosphere includes a disposable canopy which is supported by a foldable canopy frame to at least partially enclose the patient. The canopy frame is firmly held against the head of the patient's bed by a foldable frame which supports a disposable nebulizer. To reduce the possibility of cross-contamination and cleanup costs, the nebulizer assembly and canopy are thrown away after treatment of the patient is completed. The tent and nebulizer frames can then be folded and stored at either the head of the bed or another storage location.",TED A DIXON,DIXON TED A,,https://lens.org/199-922-236-069-02X,Granted Patent,no,3,95,2,2,0,A61G10/04;;Y10S128/909;;A61G10/04;;Y10S128/909,A61G10/04,128/194,0,0,,,,EXPIRED
50,AT,T1,AT E552938 T1,005-440-697-996-558,2012-04-15,2012,AT 06788076 T,2006-07-21,US 70599805 P;;US 2006/0028324 W,2005-08-05,VERFAHREN ZUR MULTIROHREINFÜHRUNG,A method for assembling a plurality of tubes to a tubesheet. A first end of each of the tubes is situated over a corresponding support rod that extends from a pattern block of the fixture. A first end of a plurality of locating members is inserted into a second end of each of the tubes such that a second end of the locating member extends from the tube second end. The tubesheet is then slid over the locating members and tubes such that each of a plurality of holes in the tubesheet receive corresponding ones of the tubes.,LIEBERT CORP,DIXON MATTHEW A,,https://lens.org/005-440-697-996-558,Granted Patent,no,0,0,7,7,0,B23P15/26;;B23P19/022;;F28F9/16;;Y10S165/492;;Y10T29/49368;;Y10T29/49895;;Y10T29/49396;;Y10T29/49377;;Y10T29/4938;;Y10T29/53117;;Y10T29/49364;;Y10T29/49387;;Y10T29/49373;;Y10T29/49368;;Y10T29/49895;;Y10T29/49396;;Y10T29/49377;;Y10T29/4938;;Y10T29/53117;;Y10T29/49364;;Y10T29/49387;;Y10T29/49373;;B23P19/022;;B23P15/26;;F28F9/16;;Y10S165/492,,,0,0,,,,ACTIVE
51,CA,A,CA 626712 A,005-960-927-579-282,1961-09-05,1961,CA 626712D A,,CA 626712T A,,POLYAMIDE GREASE COMPOSITION,,CALIFORNIA RESEARCH CORP,DIXON JOSEPH A,,https://lens.org/005-960-927-579-282,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
52,CA,A,CA 869490 A,047-878-552-736-691,1971-04-27,1971,CA 869490D A,,CA 869490T A,,APPARATUS AND METHOD FOR TRANSPORTING PRODUCE UNDER CONTROLLED ATMOSPHERE,,BEST FERTILIZERS CO,DIXON DAVID A,,https://lens.org/047-878-552-736-691,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
53,US,B2,US 7856716 B2,073-576-031-492-336,2010-12-28,2010,US 45984606 A,2006-07-25,US 45984606 A;;US 70599805 P,2005-08-05,Method for assembling a plurality of tubes to a tubesheet,A method for assembling a plurality of tubes to a tubesheet. A first end of each of the tubes is situated over a corresponding support rod that extends from a pattern block of the fixture. A first end of a plurality of locating members is inserted into a second end of each of the tubes such that a second end of the locating member extends from the tube second end. The tubesheet is then slid over the locating members and tubes such that each of a plurality of holes in the tubesheet receive corresponding ones of the tubes.,LIEBERT CORP,DIXON MATTHEW A,VERTIV CORPORATION (2006-07-19),https://lens.org/073-576-031-492-336,Granted Patent,yes,8,1,7,7,0,B23P15/26;;B23P19/022;;F28F9/16;;Y10S165/492;;Y10T29/49368;;Y10T29/49895;;Y10T29/49396;;Y10T29/49377;;Y10T29/4938;;Y10T29/53117;;Y10T29/49364;;Y10T29/49387;;Y10T29/49373;;Y10T29/49368;;Y10T29/49895;;Y10T29/49396;;Y10T29/49377;;Y10T29/4938;;Y10T29/53117;;Y10T29/49364;;Y10T29/49387;;Y10T29/49373;;B23P19/022;;B23P15/26;;F28F9/16;;Y10S165/492,B21D51/24,29/890.051;;29/890.047;;29/890.043;;29/890.038;;29/890.045;;29/890.04;;165/178;;X165DIG 492,0,0,,,,ACTIVE
54,CA,A,CA 869491 A,107-902-592-882-88X,1971-04-27,1971,CA 869491D A,,CA 869491T A,,METHOD AND APPARATUS FOR MINIMIZING DETERIORATION OF PERISHABLE PRODUCTS,,BEST FERTILIZERS CO,DIXON DAVID A,,https://lens.org/107-902-592-882-88X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
55,HU,D0,HU 9303067 D0,135-815-665-168-688,1994-03-28,1994,HU 9303067 A,1992-05-13,US 69900291 A,1991-05-13,REFRIGERATION CONTAINER,,REEFCO MFG CORP,DIXON DAVID A,,https://lens.org/135-815-665-168-688,Patent Application,no,0,0,14,14,0,B60H1/3232;;B60H1/3232;;B65D88/745;;B65D88/745;;B65D90/00;;B65D90/00;;F25D11/003;;F25D11/003;;F25B2347/021;;F25B2347/021;;F25D2317/0651;;F25D2317/0651;;F25D2317/0665;;F25D2317/0665,B60H1/32;;F25D11/00;;F25D17/08;;F25D21/06,,0,0,,,,DISCONTINUED
56,US,A,US 4126008 A,154-746-565-204-277,1978-11-21,1978,US 83022177 A,1977-09-02,US 83022177 A,1977-09-02,Sea-floor template,"A folding sea-floor compactable template for proper positioning and spacing of subsea piles and wells in the sea floor. Anchor pile templates or well templates are provided at the end of long hinged arms which extend radially out from a central section (which may also be used as a well template). The arms are folded back over the central section for transportation. Flotation can be in the main central section. With additional flotation at the outer ends of the arms, installation can be carried out by controlled submergence in stages from a single barge.",STANDARD OIL CO INDIANA,DIXON DAVID A,AMOCO CORPORATION (1985-04-23),https://lens.org/154-746-565-204-277,Granted Patent,yes,4,32,18,18,0,E21B41/08;;E21B41/08,E21B15/02;;E02D13/04;;E21B43/017,405/207,0,0,,,,EXPIRED
57,RO,A,RO 90399 A,171-299-134-856-905,1986-10-30,1986,RO 11333984 A,1984-01-17,RO 11333984 A,1984-01-17,EMBRAYAGE A FRICTION,,AUTOMOTIVE PRODUCTS PLC,GEOFFREY DIXON A,,https://lens.org/171-299-134-856-905,Unknown,no,0,0,1,1,0,,F16D13/50,,0,0,,,,DISCONTINUED
58,US,A,US 5720728 A,011-136-245-401-884,1998-02-24,1998,US 62197396 A,1996-03-25,US 62197396 A,1996-03-25,Teardrop shaped pressurizing apparatus,"A pressurizing apparatus for pressurizing fluid contained in a patient fluid bag is described which has a novel teardrop pressurizing chamber. The pressure apparatus includes a door and base which each have complimentary teardrop cavities formed therein. When the door is in the closed position over the base, the teardrop pressurizing chamber is formed. A teardrop bladder bag is located interior to the base and can be inflated to apply pressure to a patient fluid bag. A regulator allows adjustment of the desired pressure. A gauge allows monitoring of the pressure. A valve allows the pressurizing device to be turned on and off. The teardrop pressurizing chamber allows the pressurizing apparatus to come up to pressure in a more expeditious manner. The conformance of the pressurizing means to the teardrop pressurizing chamber also adds to the efficiency of the pressurizing of the patient fluid bag and, additionally, allows for uniform pressure throughout a procedure.",MALLINCKRODT MEDICAL INC,FORD DIXON A,TYCO HEALTHCARE GROUP LP (2011-06-23);;MALLINCKRODT MEDICAL INC (1997-04-02);;ALTON DEAN MEDICAL (1996-03-20),https://lens.org/011-136-245-401-884,Granted Patent,yes,10,95,14,14,0,A61M3/0233;;A61M5/1483;;A61M3/022;;A61M3/0208;;A61M3/0245;;A61M5/1483;;A61M3/0208;;A61M3/022;;A61M3/0233;;A61M3/0245,A61M1/02;;A61M3/02;;A61M5/152;;A61M5/148,604/131;;604/132;;604/141,0,0,,,,EXPIRED
59,US,A,US 973264 A,052-611-193-418-47X,1910-10-18,1910,US 1910/0554062 A,1910-04-07,US 1910/0554062 A,1910-04-07,SIPHON-FILLER.,,DIXON GEORGE A,DIXON GEORGE A,,https://lens.org/052-611-193-418-47X,Granted Patent,no,0,0,1,1,0,Y10T137/8634;;B01F23/23611;;Y10T137/8634;;B01F23/23611,,,0,0,,,,EXPIRED
60,US,B1,US 11738832 B1,064-379-210-810-724,2023-08-29,2023,US 202318118564 A,2023-03-07,US 202318118564 A,2023-03-07,Watersport support system,"A watersport support system includes a flotation vest having a back surface, a front surface and side surfaces. At least one adjustment belt is positioned horizontally around the main body of the vest. A pair of tethers engage the adjustment belt along both sides of the vest, and a pair of handle gripping devices are removably connected to the end of the pair of tethers. Each of the handle gripping devices includes an elongated strap that terminates into a malleable curved gripper body, and a hand strap is positioned adjacent to each gripper body. As the user squeezes the gripper body and the tow handle, the pulling force from the handle is transferred from the user's arms to the pair of tethers and the adjustment strap that loops around the back of the user's torso. When the user releases the gripper body, the body disengages the handle.",DIXON BILL A,DIXON BILL A,,https://lens.org/064-379-210-810-724,Granted Patent,yes,3,0,1,1,0,B63B34/63;;B63B34/60;;B63B34/54;;B63B34/63,B63B34/63,,0,0,,,,ACTIVE
61,CA,A,CA 505760 A,109-301-007-391-107,1954-09-14,1954,CA 505760D A,,CA 505760T A,,THREAD WIPER-GUIDE FOR USE IN THREAD SPINNING APPARATUS,,INT PAPER CANADA,DIXON JULIAN A,,https://lens.org/109-301-007-391-107,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
62,CA,A,CA 797482 A,133-918-417-718-168,1968-10-29,1968,CA 797482D A,,CA 797482T A,,THERAPEUTIC DEVICE,,CONTINENTAL HOSPITAL IND,DIXON TED A,,https://lens.org/133-918-417-718-168,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
63,EP,B1,EP 1910019 B1,134-294-863-867-087,2012-04-11,2012,EP 06788076 A,2006-07-21,US 2006/0028324 W;;US 70599805 P,2005-08-05,MULTI-TUBE INSERTION PROCESS,A method for assembling a plurality of tubes to a tubesheet. A first end of each of the tubes is situated over a corresponding support rod that extends from a pattern block of the fixture. A first end of a plurality of locating members is inserted into a second end of each of the tubes such that a second end of the locating member extends from the tube second end. The tubesheet is then slid over the locating members and tubes such that each of a plurality of holes in the tubesheet receive corresponding ones of the tubes.,LIEBERT CORP,DIXON MATTHEW A,"VERTIV CORP., COLUMBUS, US (2018-10-25)",https://lens.org/134-294-863-867-087,Granted Patent,yes,2,0,7,7,0,B23P15/26;;B23P19/022;;F28F9/16;;Y10S165/492;;Y10T29/49368;;Y10T29/49895;;Y10T29/49396;;Y10T29/49377;;Y10T29/4938;;Y10T29/53117;;Y10T29/49364;;Y10T29/49387;;Y10T29/49373;;Y10T29/49368;;Y10T29/49895;;Y10T29/49396;;Y10T29/49377;;Y10T29/4938;;Y10T29/53117;;Y10T29/49364;;Y10T29/49387;;Y10T29/49373;;B23P19/022;;B23P15/26;;F28F9/16;;Y10S165/492,B23P15/26;;B23P19/02,,0,0,,,,ACTIVE
64,SE,L,SE 8900834 L,168-578-185-436-824,1989-09-12,1989,SE 8900834 A,1989-03-09,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,NYA ANVAENDNINGAR AV 4-(3-FOSFONO-2-PROPENYL)-2-PIPERAZINKARBOXYLSYRA,,SANDOZ AG,DIXON A K,,https://lens.org/168-578-185-436-824,Abstract,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
65,US,A1,US 2015/0259013 A1,171-153-128-264-67X,2015-09-17,2015,US 201514725575 A,2015-05-29,US 201514725575 A;;US 201213435287 A;;US 201213435284 A,2012-03-30,FLEXIBLE MUD FLAP HANGER-BRACKET,"Mud flap hanger is disclosed which includes a post member that is configured to allow attachment of the hanger to a vehicle and a hanger arm extending from the post member having a flexible core of a composite material, for example, a fiber-reinforced plastic (FRP) and that is clad with a substantially inelastic polymer. Preferably, the hanger arm is folined with a cross-section shape of a polygon so that clips for hanging the mud flap from the arm may be conformed to that polygonal shape.",FONTAINE SPRAY SUPPRESSION COMPANY,DIXON IAN A,FONTAINE SPRAY SUPPRESSION COMPANY (2012-03-29),https://lens.org/171-153-128-264-67X,Patent Application,yes,0,2,4,4,0,B62D25/182;;B62D25/182;;B62D25/188;;B62D25/188;;F16B5/121;;F16B5/123,B62D25/18;;F16B5/12,,0,0,,,,DISCONTINUED
66,US,B2,US 9836792 B2,178-308-752-911-71X,2017-12-05,2017,US 18690808 A,2008-08-06,US 18690808 A;;US 4175202 A;;US 26017801 P,2001-01-05,System and method for asset accumulation and risk management,"The system and method of the present invention removes barriers that undermine efficient risk-management. The invention prioritizes consumers by predicting their unmet demand for risk protection. Once deemed eligible, consumers are enrolled and funds are allocated to the payment of a premium for income insurance, contribution to a financial vehicle such as a savings or investment product, and payment of a premium for savings loss insurance. Active participants are eligible for income protection in case of job loss, systematic savings and ownership of public equities, principal protection and incentives based on utilization. The system and method of the present invention is calibrated on an ongoing basis to the behaviors of target consumers.",DIXON DEBORAH A;;DIXON DELORES A,DIXON DEBORAH A,,https://lens.org/178-308-752-911-71X,Granted Patent,yes,20,7,9,9,0,G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/08;;G06Q40/03;;G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/03;;G06Q40/08,G06Q40/00;;G06Q30/02;;G06Q40/02;;G06Q40/06;;G06Q40/08,,2,1,051-225-523-567-24X,10.1080/13511610020017363,"The Final Instance, Unemployment Insurance Going Private, A study of the Future Social Security Scenario in the UK and Germany, Andreas Cebulla, Innovation, Nov. 4, 2000.;;Gardner et al: “College and University Programs in ‘Risk Management’”, Financial Practice & Education, Fall/Winter 1996, vol. 6 Issue 2, p. 68-77, Financial Management Association, College of Business Administration, University of South Florida, Tampa Florida.",ACTIVE
67,US,A1,US 2012/0298814 A1,190-790-415-494-444,2012-11-29,2012,US 201213480580 A,2012-05-25,US 201213480580 A;;US 201161489980 P,2011-05-25,Mounting Assembly for Vehicle Mud Flaps,"A mounting assembly for mud flaps has an elongated mounting arm defining an interior elongated chamber with a slot opening at the bottom. The assembly includes a one or more biased clips that attach to the top edge of the mud flap, which is inserted into the chamber with the lower portion of the mud flap extending through the bottom slot and the clips seated within the chamber. The clips include a pair of protrusions that engage the interior of the chamber, and are configured such that sufficient downward force on the mud flap causes the clip to open and release the mud flap.",DIXON IAN A,DIXON IAN A,FONTAINE SPRAY SUPPRESSION COMPANY (2012-05-23),https://lens.org/190-790-415-494-444,Patent Application,yes,21,7,3,3,0,B62D25/188;;B62D25/188;;Y10T24/44684;;Y10T24/44684,B60R11/00,248/205.1,0,0,,,,INACTIVE
68,WO,A1,WO 1997/035628 A1,004-726-146-678-366,1997-10-02,1997,US 9704862 W,1997-03-25,US 62197396 A,1996-03-25,TEARDROP SHAPED PRESSURIZING APPARATUS,"A pressurizing apparatus for pressurizing fluid contained in a patient fluid bag (14) is described which has a novel teardrop pressurizing chamber. The pressure apparatus includes a door and base which each has complimentary teardrop cavities formed therein. When the door (24) is in the closed position over the base (26), the teardrop pressurizing chamber is formed. A teardrop bladder bag (90) is located interior to the base and can be inflated to apply pressure to a patient fluid bag. A regulator (16) allows adjustment of the desired pressure. A gauge allows monitoring of the pressure. A valve allows the pressurizing device to be turned on and off. The teardrop pressurizing chamber allows the pressurizing apparatus (10) to come up to pressure in a more expeditious manner. The conformance of the pressurizing means to the teardrop pressurizing chamber also adds to the efficiency of the pressurizing of the patient fluid bag and, additionally, allows for uniform pressure throughout a procedure.",MALLINCKRODT MEDICAL INC,FORD DIXON A,,https://lens.org/004-726-146-678-366,Patent Application,yes,3,3,14,14,0,A61M3/0233;;A61M5/1483;;A61M3/022;;A61M3/0208;;A61M3/0245;;A61M5/1483;;A61M3/0208;;A61M3/022;;A61M3/0233;;A61M3/0245,A61M1/02;;A61M5/152;;A61M3/02;;A61M5/148,,0,0,,,,PATENTED
69,US,A,US 2572120 A,030-983-843-491-118,1951-10-23,1951,US 12130749 A,1949-10-14,US 12130749 A,1949-10-14,Ventilated table,,NED MAY;;MIKE MAY,DIXON FATE A,,https://lens.org/030-983-843-491-118,Granted Patent,no,3,17,1,1,0,A47B37/00;;A47B37/00,A47B37/00,,0,0,,,,EXPIRED
70,US,S,US D0304689 S,069-335-388-473-144,1989-11-21,1989,US 93359986 F,1986-11-21,US 93359986 F,1986-11-21,Collapsible cargo container,,DIXON GERALD A,DIXON GERALD A,,https://lens.org/069-335-388-473-144,Design Right,yes,7,3,1,1,0,,,D 9424,0,0,,,,EXPIRED
71,US,A,US 3665596 A,080-869-597-412-561,1972-05-30,1972,US 3665596D A,1970-01-20,US 425270 A,1970-01-20,MAGNETIC CORE WIRING MACHINE,"A machine for automatically inserting the drive conductors in a magnetic core memory array. The cores to be threaded are first located in a core nest to form an array of rows and columns of cores. The wires to be threaded through the apertures in the toroidal cores are automatically loaded into elongated channels or barrels and subsequently, a jet of compressed gas is applied to the ends of the wires in the barrels which forces the wires out of the barrels and through the core array.",SPERRY RAND CORP,FORD DIXON A,,https://lens.org/080-869-597-412-561,Granted Patent,no,3,3,1,1,0,B23P19/04;;Y10T29/53165;;Y10T29/53265;;Y10T29/49838;;Y10T29/53696;;Y10T29/49069;;Y10T83/2048;;Y10T83/6472;;Y10T29/53165;;Y10T29/53265;;Y10T29/49838;;Y10T29/53696;;Y10T29/49069;;Y10T83/2048;;Y10T83/6472;;B23P19/04,B23P19/04,29/604;;29/241;;29/433;;29203   MM;;83/99;;83/402,0,0,,,,EXPIRED
72,US,A1,US 2013/0256483 A1,089-163-856-530-97X,2013-10-03,2013,US 201213435287 A,2012-03-30,US 201213435287 A,2012-03-30,FLEXIBLE MUD FLAP HANGER-BRACKET,"Mud flap hanger is disclosed which includes a post member that is configured to allow attachment of the hanger to a vehicle and a hanger arm extending from the post member having a flexible core of a composite material, for example, a fiber-reinforced plastic (FRP) and that is clad with a substantially inelastic polymer. Preferably, the hanger arm is formed with a cross-section shape of a polygon so that clips for hanging the mud flap from the arm may be conformed to that polygonal shape.",DIXON IAN A,DIXON IAN A,FONTAINE SPRAY SUPPRESSION COMPANY (2012-03-29),https://lens.org/089-163-856-530-97X,Patent Application,yes,17,11,4,4,0,B62D25/182;;B62D25/182;;B62D25/188;;B62D25/188;;F16B5/121;;F16B5/123,B60R11/00,248/222.14;;248/205.1;;248/224.8,0,0,,,,INACTIVE
73,US,A,US 3090718 A,140-533-142-460-095,1963-05-21,1963,US 2369560 A,1960-04-21,US 2369560 A,1960-04-21,Flexible cushioned horse shoe,,DIXON ELLSWORTH A,DIXON ELLSWORTH A,,https://lens.org/140-533-142-460-095,Granted Patent,no,14,16,1,1,0,A01L1/02;;Y10T29/49833;;Y10T29/49938;;Y10T29/49833;;Y10T29/49938;;A01L1/02,A01L1/02,,0,0,,,,EXPIRED
74,US,A,US 2519639 A,042-103-977-833-993,1950-08-22,1950,US 67561646 A,1946-06-10,US 67561646 A,1946-06-10,Permanent hair-waving mechanism,,DIXON CHARLES A,DIXON CHARLES A,,https://lens.org/042-103-977-833-993,Granted Patent,no,6,0,1,1,0,A45D2/34;;A45D2/34,A45D2/34,,0,0,,,,EXPIRED
75,US,B2,US 6680443 B2,047-821-576-204-270,2004-01-20,2004,US 17491302 A,2002-06-19,US 17491302 A;;US 30014201 P,2001-06-22,Load cell apparatus having a gap measuring device,"
    A load cell apparatus for use with a structure comprises a cell block that flexes in response to an applied load and a transducer that is adapted to measure a distance across a gap. In some embodiments, the gap is defined between the transducer and the structure, and in other embodiments, the gap is defined between the transducer and the cell block. 
",HILL ROM SERVICES INC,DIXON STEVEN A,HILL-ROM SERVICES INC (2002-08-15),https://lens.org/047-821-576-204-270,Granted Patent,yes,45,40,6,6,0,A61G7/0527;;A61G7/0527;;G01G9/00;;G01G9/00;;G01G19/445;;G01G19/445,G01G3/00;;A61G7/05;;G01G9/00;;G01G19/44;;G01G19/52,177/144;;X177210 R;;177/229,2,0,,,"""Linear proximity Sensing Technology"", 3 pages, 2001 MTS Systems Corporation.;;G. Ulbers, Integrated-optical sensors for the measurement of displacement, force and refractive index on the basis of silicon, 8008 Technisches Messen 58 (1991), Apr., No. 4, pp. 146-151.",EXPIRED
76,AU,A,AU 1997/025463 A,069-874-658-716-672,1997-10-17,1997,AU 1997/025463 A,1997-03-25,US 62197396 A;;US 9704862 W,1996-03-25,Teardrop shaped pressurizing apparatus,"A pressurizing apparatus for pressurizing fluid contained in a patient fluid bag is described which has a novel teardrop pressurizing chamber. The pressure apparatus includes a door and base which each have complimentary teardrop cavities formed therein. When the door is in the closed position over the base, the teardrop pressurizing chamber is formed. A teardrop bladder bag is located interior to the base and can be inflated to apply pressure to a patient fluid bag. A regulator allows adjustment of the desired pressure. A gauge allows monitoring of the pressure. A valve allows the pressurizing device to be turned on and off. The teardrop pressurizing chamber allows the pressurizing apparatus to come up to pressure in a more expeditious manner. The conformance of the pressurizing means to the teardrop pressurizing chamber also adds to the efficiency of the pressurizing of the patient fluid bag and, additionally, allows for uniform pressure throughout a procedure.",MALLINCKRODT MEDICAL INC,FORD DIXON A,,https://lens.org/069-874-658-716-672,Patent Application,no,0,0,14,14,0,A61M3/0233;;A61M5/1483;;A61M3/022;;A61M3/0208;;A61M3/0245;;A61M5/1483;;A61M3/0208;;A61M3/022;;A61M3/0233;;A61M3/0245,A61M5/152;;A61M1/02;;A61M3/02;;A61M5/148,,0,0,,,,PENDING
77,US,B1,US 6631524 B1,179-557-731-361-45X,2003-10-14,2003,US 21726302 A,2002-08-13,US 21726302 A,2002-08-13,Height-adjustable footrest for toilets,"
    A height-adjustable footrest for toilets for preferably using while a user is seated upon a toilet stool. The height-adjustable footrest for toilets includes a base being adapted to rest upon a floor; and also includes upright adjustable support assemblies being mounted upon the base and including tubular base members each having an open top end and a bore extending therein, and also including shaft members being movably disposed inwardly and outwardly of the tubular base members; and further includes elongate cross members being mounted upon the shaft members with each of the cross members interconnecting a pair of the shaft members; and also includes elongate footrest support member being pivotally disposed between and interconnecting the elongate cross members; and further includes footrest members being mounted to the elongate footrest support member; and also includes an assembly of raising and lowering the footrest members. 
",DIXON MARCIA A.,DIXON MARCIA A,,https://lens.org/179-557-731-361-45X,Granted Patent,yes,7,28,1,1,0,A47K17/028;;A47K17/028;;A47C16/025;;A47C16/025,A47C16/02;;A47K17/02,4/254;;297/423.45,0,0,,,,EXPIRED
78,EP,A4,EP 0585388 A4,177-323-323-072-54X,1994-08-17,1994,EP 92913191 A,1992-05-13,US 69900291 A,1991-05-13,REFRIGERATED CONTAINER,,REEFCO MFG CORP,DIXON DAVID A,,https://lens.org/177-323-323-072-54X,Search Report,no,1,0,14,14,0,B60H1/3232;;B60H1/3232;;B65D88/745;;B65D88/745;;B65D90/00;;B65D90/00;;F25D11/003;;F25D11/003;;F25B2347/021;;F25B2347/021;;F25D2317/0651;;F25D2317/0651;;F25D2317/0665;;F25D2317/0665,B60H1/32;;F25D11/00;;F25D17/08;;F25D21/06,,1,0,,,See also references of WO 9220542A1,DISCONTINUED
79,CA,A1,CA 2810695 A1,182-815-155-519-067,2013-09-30,2013,CA 2810695 A,2013-03-27,US 201213435287 A,2012-03-30,FLEXIBLE MUD FLAP HANGER-BRACKET,"A mud flap hanger is disclosed which includes a post member that is configured to allow attachment of the hanger to a vehicle and a hanger arm extending from the post member having a flexible core of a composite material, for example, a fiber-reinforced plastic (FRP) and that is clad with a substantially inelastic polymer. Preferably, the hanger arm is formed with a cross-section shape of a polygon so that clips for hanging the mud flap from the arm may be conformed to that polygonal shape,",FONTAINE SPRAY SUPPRESSION COMPANY,DIXON IAN A,,https://lens.org/182-815-155-519-067,Patent Application,no,0,1,4,4,0,B62D25/182;;B62D25/182;;B62D25/188;;B62D25/188;;F16B5/121;;F16B5/123,B62D25/18;;F16B5/00;;F16B9/02,,0,0,,,,DISCONTINUED
80,US,A,US 3251197 A,005-973-694-967-171,1966-05-17,1966,US 44699965 A,1965-04-09,US 44699965 A,1965-04-09,Therapeutic device,,CONTINENTAL HOSPITAL IND INC,DIXON TED A,,https://lens.org/005-973-694-967-171,Granted Patent,no,4,1,1,1,0,A61G10/04;;A61M2205/3606;;A61G10/04;;A61M2205/3606,A61G10/04,,0,0,,,,EXPIRED
81,US,A1,US 2009/0012614 A1,028-004-450-548-407,2009-01-08,2009,US 11735808 A,2008-05-08,US 11735808 A;;US 91663507 P,2007-05-08,DEVICE AND METHOD FOR TETHERING A SPINAL IMPLANT,"A device for tethering an implant device along the posterior spine of a human has first and second elements, as well as a means for fixing, in a quick connect manner, the first and second elements to each other. The first element is adapted for being secured to an interspinous ligament and the second element is adapted for attachment to the implant device. The first element may be a beam that is adapted for placement through the interspinous ligament in a direction substantially horizontal to a long axis of the spine.",DIXON ROBERT A,DIXON ROBERT A,,https://lens.org/028-004-450-548-407,Patent Application,yes,51,7,1,1,0,A61B17/0401;;A61B17/0401;;A61B2017/0414;;A61B2017/0414;;A61B2017/044;;A61B2017/044;;A61B2017/0453;;A61B2017/0453,A61F2/08;;A61B17/08,623/13.14;;606/151,0,0,,,,DISCONTINUED
82,CA,A,CA 530172 A,019-492-123-459-406,1956-09-11,1956,CA 530172D A,,CA 530172T A,,AMATE-DICARBOXYLATE-THICKENED GREASE,,CALIFORNIA RESEARCH CORP,DIXON JOSEPH A,,https://lens.org/019-492-123-459-406,Granted Patent,no,0,1,1,1,0,,,,0,0,,,,EXPIRED
83,CA,A,CA 71603 A,079-254-905-404-859,1901-06-04,1901,CA 71603D A,1901-03-18,CA 71603T A,1901-03-18,RAIL JOINT FASTENER,,DIXON FREDERICK A,DIXON FREDERICK A,,https://lens.org/079-254-905-404-859,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
84,US,A,US 5108277 A,116-230-952-712-161,1992-04-28,1992,US 54367290 A,1990-06-25,US 54367290 A,1990-06-25,Apparatus for cooling extruded material,An apparatus is located downstream of an extruder for cooling extruded material exiting the extruder. The apparatus includes a housing having a material passage. The material passage is dimensioned so as to have a larger cross section than a cross section of the extruded material. The apparatus further includes a system for controlling the temperature of at least a portion of the housing. The apparatus further includes a plurality of fluid passages in the housing and connectable to a source of pressurized fluid for providing fluid communication between the source of pressurized fluid and the material passage in the housing. The fluid passing through the fluid passages changes to a temperature having a value functionally related to the temperature of the temperature-controlled portion of the housing. The pressurized fluid passing through the fluid passages supports and cools the extruded material as the extruded material passes through the material passage.,DIXON JOHN A,DIXON JOHN A,ECLIPSE BLIND SYSTEMS INC (1996-05-29),https://lens.org/116-230-952-712-161,Granted Patent,yes,7,13,1,1,0,B29C48/03;;B29C48/911;;B29C48/9135;;B29C48/9135;;B29C48/03;;B29C48/911,B29C48/03,425/72.1;;264/211.13;;264/211.18;;425/143;;425/404;;425/445,0,0,,,,EXPIRED
85,CA,A1,CA 2248864 A1,192-101-159-839-920,1997-10-02,1997,CA 2248864 A,1997-03-25,US 62197396 A;;US 9704862 W,1996-03-25,TEARDROP SHAPED PRESSURIZING APPARATUS,"A pressurizing apparatus for pressurizing fluid contained in a patient fluid bag is described which has a novel teardrop pressurizing chamber. The pressure apparatus includes a door and base which each have complimentary teardrop cavities formed therein. When the door is in the closed position over the base, the teardrop pressurizing chamber is formed. A teardrop bladder bag is located interior to the base and can be inflated to apply pressure to a patient fluid bag. A regulator allows adjustment of the desired pressure. A gauge allows monitoring of the pressure. A valve allows the pressurizing device to be turned on and off. The teardrop pressurizing chamber allows the pressurizing apparatus to come up to pressure in a more expeditious manner. The conformance of the pressurizing means to the teardrop pressurizing chamber also adds to the efficiency of the pressurizing of the patient fluid bag and, additionally, allows for uniform pressure throughout a procedure.",MALLINCKRODT INC,FORD DIXON A,,https://lens.org/192-101-159-839-920,Patent Application,no,0,0,14,14,0,A61M3/0233;;A61M5/1483;;A61M3/022;;A61M3/0208;;A61M3/0245;;A61M5/1483;;A61M3/0208;;A61M3/022;;A61M3/0233;;A61M3/0245,A61M5/152;;A61M1/02;;A61M3/02;;A61M5/148,,0,0,,,,EXPIRED
86,US,A,US 2677949 A,005-368-766-351-689,1954-05-11,1954,US 22350551 A,1951-04-28,US 22350551 A,1951-04-28,Thread wiper-guide for use in thread-spinning apparatus,,INT PAPER CANADA,DIXON JULIAN A,,https://lens.org/005-368-766-351-689,Granted Patent,no,2,5,1,1,0,D01D10/0445;;D01D10/0445,D01D10/04,,0,0,,,,EXPIRED
87,US,A,US 2622685 A,012-173-059-115-322,1952-12-23,1952,US 15164350 A,1950-03-24,US 15164350 A,1950-03-24,Flexible racing horseshoe,,DIXON ELLSWORTH A,DIXON ELLSWORTH A,,https://lens.org/012-173-059-115-322,Granted Patent,no,9,14,1,1,0,A01L1/04;;A01L1/04,A01L1/04,,0,0,,,,EXPIRED
88,AU,B2,AU 2002/311745 B2,042-738-440-601-016,2006-04-27,2006,AU 2002/311745 A,2002-01-07,US 26017801 P;;US 0200475 W,2001-01-05,System and method for asset accumulation and risk management,,DIXON DELORES A;;NOLAN LAUREL DIXON;;PHELAN STACY DIXON,DIXON DEBORAH A,,https://lens.org/042-738-440-601-016,Granted Patent,no,2,0,9,9,0,G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/08;;G06Q40/03;;G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/03;;G06Q40/08,G06F19/00;;G06Q40/00,,0,0,,,,EXPIRED
89,US,A,US 3365307 A,090-324-246-574-510,1968-01-23,1968,US 53492266 A,1966-01-10,US 53492266 A,1966-01-10,Method for minimizing deterioration of plant and animal products,,OCCIDENTAL PETROLEUM CORP,DIXON DAVID A,AERIFORM LTD (1982-08-05),https://lens.org/090-324-246-574-510,Granted Patent,no,6,30,1,1,0,A23L3/34095;;A23L3/3418;;B60H1/00014;;A23L3/3418;;A23L3/34095,A23L3/3409;;A23L3/3418,99/150,0,0,,,,EXPIRED
90,FI,A,FI 935005 A,093-461-309-589-622,1993-11-12,1993,FI 935005 A,1993-11-12,US 69900291 A;;US 9203785 W,1991-05-13,KYLCONTAINER,,REEFCO MFG CORP,DIXON DAVID A,,https://lens.org/093-461-309-589-622,Patent Application,no,0,0,14,14,0,B60H1/3232;;B60H1/3232;;B65D88/745;;B65D88/745;;B65D90/00;;B65D90/00;;F25D11/003;;F25D11/003;;F25B2347/021;;F25B2347/021;;F25D2317/0651;;F25D2317/0651;;F25D2317/0665;;F25D2317/0665,B60H1/32;;F25D11/00;;F25D17/08;;F25D21/06,,0,0,,,,DISCONTINUED
91,AU,A,AU 1992/020049 A,124-168-536-672-055,1992-12-30,1992,AU 1992/020049 A,1992-05-13,US 69900291 A,1991-05-13,REFRIGERATED CONTAINER,,REEFCO MANUFACTURING CORPORATION,DAVID A DIXON,,https://lens.org/124-168-536-672-055,Patent Application,no,0,0,14,14,0,B60H1/3232;;B60H1/3232;;B65D88/745;;B65D88/745;;B65D90/00;;B65D90/00;;F25D11/003;;F25D11/003;;F25B2347/021;;F25B2347/021;;F25D2317/0651;;F25D2317/0651;;F25D2317/0665;;F25D2317/0665,B60H1/32;;F25D11/00;;F25D17/08;;F25D21/06,,0,0,,,,PENDING
92,CA,C,CA 2248864 C,030-018-290-810-267,2000-12-26,2000,CA 2248864 A,1997-03-25,US 62197396 A;;US 9704862 W,1996-03-25,TEARDROP SHAPED PRESSURIZING APPARATUS,"A pressurizing apparatus for pressurizing fluid contained in a patient fluid bag (14) is described which has a novel teardrop pressurizing chamber. The pressure apparatus includes a door and base which each has complimentary teardrop cavities formed therein. When the door (24) is in the closed position over the base (26), the teardrop pressurizing chamber is formed. A teardrop bladder bag (90) is located interior to the base and can be inflated to apply pressure to a patient fluid bag. A regulator (16) allows adjustment of the desired pressure. A gauge allows monitoring of the pressure. A valve allows the pressurizing device to be turned on and off. The teardrop pressurizing chamber allows the pressurizing apparatus (10) to come up to pressure in a more expeditious manner. The conformance of the pressurizing means to the teardrop pressurizing chamber also adds to the efficiency of the pressurizing of the patient fluid bag and, additionally, allows for uniform pressure throughout a procedure.",MALLINCKRODT INC,FORD DIXON A,,https://lens.org/030-018-290-810-267,Granted Patent,no,0,0,14,14,0,A61M3/0233;;A61M5/1483;;A61M3/022;;A61M3/0208;;A61M3/0245;;A61M5/1483;;A61M3/0208;;A61M3/022;;A61M3/0233;;A61M3/0245,A61M5/152;;A61M1/02;;A61M3/02;;A61M5/148,,0,0,,,,EXPIRED
93,US,A,US 3239360 A,050-519-996-081-319,1966-03-08,1966,US 35662464 A,1964-04-01,US 35662464 A,1964-04-01,Method for transporting produce under controlled atmosphere,,BEST FERTILIZERS CO,DIXON DAVID A,AERIFORM LTD (1982-08-05),https://lens.org/050-519-996-081-319,Granted Patent,no,11,28,1,2,0,A23B7/148;;A23L3/34095;;A23L3/3418;;B60P3/20;;F25D17/042;;B60P3/20;;A23L3/3418;;A23L3/34095;;A23B7/148;;F25D17/042,A23B7/148;;A23L3/3409;;A23L3/3418;;B60P3/20;;F25D17/04,,0,0,,,,EXPIRED
94,US,A1,US 2008/0097442 A1,048-672-392-223-151,2008-04-24,2008,US 77101007 A,2007-06-29,US 77101007 A;;US 81746306 P,2006-06-29,METHOD AND DEVICE FOR IMPROVING THE FUNCTION OF TAPER LOCKS USED FOR SPINAL STABILIZATION,"A locking system for use in spinal implantation has a plate member with a screw-receiving hole and a bone screw with a shank threaded at one end and having a head at the other end. The screw has a primary locking feature for engaging a screw-receiving hole in which it is received as well as a secondary locking feature for engaging the screw-receiving hole while providing a signal that the primary locking feature is engaged. The signal may be tactile, audible, visual or a combination thereof.",DIXON ROBERT A,DIXON ROBERT A,,https://lens.org/048-672-392-223-151,Patent Application,yes,14,14,1,1,0,A61B17/8052;;A61B90/92;;A61B17/8052;;A61B90/92,A61B17/56;;A61B17/58,606/69;;606/61;;606/73,0,0,,,,DISCONTINUED
95,US,A,US 3487769 A,104-744-604-625-662,1970-01-06,1970,US 3487769D A,1965-04-26,US 45093365 A,1965-04-26,APPARATUS FOR CONTROLLED ADMISSION OF AIR TO CONTROLLED ATMOSPHERE,,OCCIDENTAL PETROLEUM CORP,DIXON DAVID A,AERIFORM LTD (1982-08-05),https://lens.org/104-744-604-625-662,Granted Patent,no,5,31,1,1,0,B60P3/20;;F25D17/042;;F25D17/042;;B60P3/20,B60P3/20;;F25D17/04,99/271,0,0,,,,EXPIRED
96,EP,B1,EP 0891196 B1,124-911-140-801-55X,2004-07-28,2004,EP 97916996 A,1997-03-25,US 9704862 W;;US 62197396 A,1996-03-25,TEARDROP SHAPED PRESSURIZING APPARATUS,"A pressurizing apparatus for pressurizing fluid contained in a patient fluid bag is described which has a novel teardrop pressurizing chamber. The pressure apparatus includes a door and base which each have complimentary teardrop cavities formed therein. When the door is in the closed position over the base, the teardrop pressurizing chamber is formed. A teardrop bladder bag is located interior to the base and can be inflated to apply pressure to a patient fluid bag. A regulator allows adjustment of the desired pressure. A gauge allows monitoring of the pressure. A valve allows the pressurizing device to be turned on and off. The teardrop pressurizing chamber allows the pressurizing apparatus to come up to pressure in a more expeditious manner. The conformance of the pressurizing means to the teardrop pressurizing chamber also adds to the efficiency of the pressurizing of the patient fluid bag and, additionally, allows for uniform pressure throughout a procedure.",MALLINCKRODT INC,FORD DIXON A,,https://lens.org/124-911-140-801-55X,Granted Patent,yes,6,0,14,14,0,A61M3/0233;;A61M5/1483;;A61M3/022;;A61M3/0208;;A61M3/0245;;A61M5/1483;;A61M3/0208;;A61M3/022;;A61M3/0233;;A61M3/0245,A61M5/152;;A61M1/02;;A61M3/02;;A61M5/148,,0,0,,,,EXPIRED
97,SE,D0,SE 8900834 D0,190-970-039-007-339,1989-03-09,1989,SE 8900834 A,1989-03-09,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,NEW USES OF 4-(3-PHOSPHONO-2-PROPENYL)-2-PIPERAZINECARBOXYLIC ACID,,SANDOZ AG,DIXON A K,,https://lens.org/190-970-039-007-339,Patent Application,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
98,US,A,US 3962477 A,195-358-117-870-754,1976-06-08,1976,US 15767671 A,1971-06-28,US 15767671 A;;US 71316368 A,1968-03-14,Storing comestibles in a cryogenic liquid,"A process for maintaining a mixture of liquified gases in a uniformly-dispersed state by subjecting the liquified gases to at least periodic vibration. The process is especially useful for maintaining as a uniform mixture, an inert fluid and up to a few percent, by total volume, of oxygen for periodic delivery to a storage compartment containing fresh perishable comestibles to prevent the degradation of the comestibles.",DIXON DAVID A,DIXON DAVID A,,https://lens.org/195-358-117-870-754,Granted Patent,yes,6,7,1,1,0,A23L3/363;;A23L3/363,A23L3/36,426/419,0,0,,,,EXPIRED
99,CA,A,CA 190681 A,195-996-983-852-006,1919-06-03,1919,CA 190681D A,1918-03-30,CA 190681T A,1918-03-30,GASOLINE LAMP,,DIXON ROBERT A,DIXON ROBERT A,,https://lens.org/195-996-983-852-006,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
100,EP,A4,EP 0891196 A4,099-411-952-847-822,1999-06-23,1999,EP 97916996 A,1997-03-25,US 9704862 W;;US 62197396 A,1996-03-25,TEARDROP SHAPED PRESSURIZING APPARATUS,"A pressurizing apparatus for pressurizing fluid contained in a patient fluid bag is described which has a novel teardrop pressurizing chamber. The pressure apparatus includes a door and base which each have complimentary teardrop cavities formed therein. When the door is in the closed position over the base, the teardrop pressurizing chamber is formed. A teardrop bladder bag is located interior to the base and can be inflated to apply pressure to a patient fluid bag. A regulator allows adjustment of the desired pressure. A gauge allows monitoring of the pressure. A valve allows the pressurizing device to be turned on and off. The teardrop pressurizing chamber allows the pressurizing apparatus to come up to pressure in a more expeditious manner. The conformance of the pressurizing means to the teardrop pressurizing chamber also adds to the efficiency of the pressurizing of the patient fluid bag and, additionally, allows for uniform pressure throughout a procedure.",MALLINCKRODT INC,FORD DIXON A,,https://lens.org/099-411-952-847-822,Search Report,no,3,0,14,14,0,A61M3/0233;;A61M5/1483;;A61M3/022;;A61M3/0208;;A61M3/0245;;A61M5/1483;;A61M3/0208;;A61M3/022;;A61M3/0233;;A61M3/0245,A61M5/152;;A61M1/02;;A61M3/02;;A61M5/148,,0,0,,,,EXPIRED
101,US,A,US 631203 A,107-235-889-513-990,1899-08-15,1899,US 1898/0685327 A,1898-07-07,US 1898/0685327 A,1898-07-07,NAIL-MACHINE.,,A R WHITNEY & COMPANY,DIXON CHARLES A,,https://lens.org/107-235-889-513-990,Granted Patent,no,0,0,1,1,0,B21G3/16;;B21G3/16,,,0,0,,,,EXPIRED
102,US,A,US 2666744 A,101-013-924-910-560,1954-01-19,1954,US 27502752 A,1952-03-05,US 27502752 A,1952-03-05,Sulfurized grease compositions,,CALIFORNIA RESEARCH CORP,DIXON JOSEPH A,,https://lens.org/101-013-924-910-560,Granted Patent,no,2,5,1,1,0,C10M5/00;;C10M5/00;;C10M7/00;;C10M7/00;;C10M2201/105;;C10M2201/105;;C10M2203/06;;C10M2203/06;;C10M2205/02;;C10M2205/02;;C10M2205/024;;C10M2205/024;;C10M2205/026;;C10M2205/026;;C10M2207/282;;C10M2207/282;;C10M2207/34;;C10M2207/34;;C10M2209/103;;C10M2209/103;;C10M2209/105;;C10M2209/105;;C10M2209/108;;C10M2209/108;;C10M2209/109;;C10M2209/109;;C10M2219/02;;C10M2219/02;;C10M2223/04;;C10M2223/04;;C10M2223/041;;C10M2223/041;;C10M2223/042;;C10M2223/042;;C10M2223/065;;C10M2223/065;;C10M2227/02;;C10M2227/02;;C10M2229/02;;C10M2229/02;;C10M2229/04;;C10M2229/04;;C10M2229/041;;C10M2229/041;;C10M2229/043;;C10M2229/043;;C10M2229/044;;C10M2229/044;;C10M2229/045;;C10M2229/045;;C10M2229/046;;C10M2229/046;;C10M2229/047;;C10M2229/047;;C10M2229/048;;C10M2229/048;;C10M2229/05;;C10M2229/05;;C10N2010/02;;C10N2010/02;;C10N2010/04;;C10N2010/04;;C10N2010/06;;C10N2010/06;;C10N2040/02;;C10N2040/02;;C10N2050/10;;C10N2050/10,,C5F F621          -;;C5F F731          -;;C5F F761          -;;C5F F762          -;;C5F F763          -,0,0,,,,EXPIRED
103,CA,A,CA 964953 A,127-959-782-558-303,1975-03-25,1975,CA 123720 A,1971-09-27,US 10310170 A,1970-12-31,NEBULIZER AND TENT ASSEMBLY,,DIXON TED A,DIXON TED A,,https://lens.org/127-959-782-558-303,Granted Patent,no,0,2,2,2,0,A61G10/04;;Y10S128/909;;A61G10/04;;Y10S128/909,A61G10/04,128-72,0,0,,,,EXPIRED
104,US,A,US 2752312 A,137-060-351-700-985,1956-06-26,1956,US 30528752 A,1952-08-19,US 30528752 A,1952-08-19,Polyamide-polyamate-thickened grease,,CALIFORNIA RESEARCH CORP,DIXON JOSEPH A,,https://lens.org/137-060-351-700-985,Granted Patent,no,11,11,2,2,0,C10M119/24;;C10M2203/06;;C10M2203/10;;C10M2203/104;;C10M2203/106;;C10M2205/02;;C10M2205/024;;C10M2205/026;;C10M2207/282;;C10M2207/34;;C10M2209/103;;C10M2209/104;;C10M2209/105;;C10M2209/108;;C10M2209/109;;C10M2217/044;;C10M2217/045;;C10M2223/041;;C10M2223/065;;C10M2227/02;;C10M2229/04;;C10M2229/041;;C10M2229/043;;C10M2229/044;;C10M2229/045;;C10M2229/046;;C10M2229/047;;C10M2229/048;;C10N2010/08;;C10N2010/06;;C10N2010/02;;C10N2010/04;;C10N2040/02;;C10M119/24;;C10M2207/34;;C10M2203/104;;C10M2203/10;;C10M2209/104;;C10M2223/041;;C10M2205/026;;C10M2209/105;;C10M2229/041;;C10M2227/02;;C10M2205/02;;C10M2229/048;;C10M2229/04;;C10M2217/044;;C10M2203/106;;C10M2209/109;;C10M2229/044;;C10M2229/047;;C10M2209/103;;C10M2209/108;;C10M2205/024;;C10M2229/046;;C10M2203/06;;C10M2229/045;;C10M2229/043;;C10M2207/282;;C10M2217/045;;C10M2223/065;;C10N2010/02;;C10N2010/04;;C10N2010/06;;C10N2010/08;;C10N2040/02,C10M119/24,C5F F452          -;;C5F F537          -;;C5F F618          -;;C5F F661          -;;C5F F674          -;;C5F F691          -;;C5F F731          -;;C5F F761          -;;C5F F762          -;;C5F F763          -;;C5F F764          -,0,0,,,,EXPIRED
105,CA,A,CA 33184 A,129-645-578-373-492,1889-12-19,1889,CA 33184D A,,CA 33184T A,,RELEASING VALVE GEAR,,WHITEHILL ROBERT;;DIXON CHARLES A,DIXON CHARLES A,,https://lens.org/129-645-578-373-492,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
106,GB,A,GB 2386232 A,133-342-723-236-029,2003-09-10,2003,GB 0315447 A,2002-01-07,US 0200475 W;;US 26017801 P,2001-01-05,System and method for asset accumulation and risk management,"The system and method of the present invention removes barriers that undermine efficient risk-management. The invention prioritizes consumers by predicting their unmet demand for risk protection. Once deemed eligible, consumers are enrolled and funds are allocated to the payment of a premium for income insurance, contribution to a financial vehicle such as a savings or investment product, and payment of a premium for savings loss insurance. Active participants are eligible for income protection in case of job loss, systematic savings and ownership of public equities, principal protection and incentives based on utilization. The system and method of the present invention is calibrated on an ongoing basis to the behaviors of target consumers.",DIXON DELORES A;;PHELAN STACY DIXON;;NOLAN LAUREN DIXON,DIXON DEBORAH A,,https://lens.org/133-342-723-236-029,Patent Application,no,0,0,9,9,0,G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/08;;G06Q40/03;;G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/03;;G06Q40/08,G06Q40/00,G4A AUXB          UXB,0,0,,,,DISCONTINUED
107,CA,A,CA 794965 A,155-942-730-803-287,1968-09-17,1968,CA 794965D A,,CA 794965T A,,VEHICLE DETECTORS,,LAB FOR ELECTRONICS,DIXON HAROLD A,,https://lens.org/155-942-730-803-287,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
108,US,A,US 4711343 A,146-761-808-126-927,1987-12-08,1987,US 91524186 A,1986-10-03,US 91524186 A;;US 86441786 A,1986-05-19,Power-and-free conveyor apparatus for handling pallet-supported workpieces,"Workpieces are supported on pallets which are advanced in an endless path by continuously driven power-and-free conveyor means adapted to permit each pallet to dwell in a work station when the pallet is stopped in the work station during continued driving of the conveyor. The conveyor means are formed by several self-contained modules detachably secured to one another in end-to-end relation and each including its own track for supporting the pallets, its own power-and-free conveyor for advancing the pallets along the track and its own motor for driving the conveyor. Curved end modules may be linked together with straight side modules in various arrangements to form conveyor systems of different capacities and shapes.",DIXON AUTOMATIC TOOL,DIXON PAUL A,DIXON AUTOMATIC TOOL INC. A CORP. OF ILLINOIS (1986-10-02),https://lens.org/146-761-808-126-927,Granted Patent,yes,3,9,9,9,0,B23Q7/1457;;B23Q37/00;;B65G19/02;;B65G19/02;;B23Q7/1457;;B23Q37/00,B23Q7/14;;B61B10/04;;B23Q37/00;;B65G19/02;;B65G35/06,198/465.2;;104/172.5,0,0,,,,EXPIRED
109,US,B1,US 6224253 B1,150-429-133-340-721,2001-05-01,2001,US 59106000 A,2000-06-09,US 59106000 A,2000-06-09,Liquid pitcher with mixing device,"A liquid pitcher with mixing device for quickly and easily stirring settled liquids or powdered mixes in the pitcher. The liquid pitcher with mixing device includes a container having a side wall, a bottom wall, an open top, a pouring spout disposed at a top of the side wall, and a handle member securely attached to an exterior of the side wall and being essentially diametrically opposed to the pouring spout; and also includes a lid having a main wall and a side wall depending from a perimeter of the main wall and having a pouring slot extending therethrough; and further includes a stirring device including a shaft having a top end and a bottom end with, the top end being rotatably extended through a central portion of the lid and with the shaft extending to near the bottom wall of the container and with the stirring device also including a pair of paddle members removably and securely attached to the shaft, and further including a crank securely attached to the top end of the shaft for rotating the shaft.",DIXON ROBERT A.,DIXON ROBERT A,,https://lens.org/150-429-133-340-721,Granted Patent,yes,19,41,1,1,0,A47J43/27;;B01F27/88;;B01F33/5011;;A47J43/27;;B01F27/88;;B01F33/5011,A47J43/27;;B01F13/00,366/247;;366/325.92,0,0,,,,EXPIRED
110,US,A1,US 2006/0214443 A1,191-643-625-779-575,2006-09-28,2006,US 9103605 A,2005-03-28,US 9103605 A,2005-03-28,Foot-Assisted Snow Shovel,"A foot-assisted snow shovel with a stepbar whereas the user presses down with the foot to initiate the scooping of snow, a guide bar which travels in parallel with the stepbar, a guide channel which the upper pivot points of both stepbar and guide bar are constrained within, a linkage member which holds the stepbar and guide bar parallel throughout their movement, and a scoop clevis fastened to the rear of the snow scoop to which both stepbar and guide bar attach. The parallel configuration of the stepbar and guide bar maintains the scoop in a horizontal orientation during the scooping and the tossing of snow. A protruding feature of the upper end of the guide channels allows the scoop to remain level maintaining its load of snow even as the machine is tilted backward. Rigid uprights with grips provide the framework and the means of handling and control for the user.",DIXON PHILIP A,DIXON PHILIP A,,https://lens.org/191-643-625-779-575,Patent Application,yes,18,18,1,1,0,E01H5/02;;E01H5/02,E01H5/02,294/54.5,0,0,,,,DISCONTINUED
111,US,A,US 3346842 A,087-973-970-252-629,1967-10-10,1967,US 45354165 A,1965-04-20,US 45354165 A,1965-04-20,Vehicle detectors,,LAB FOR ELECTRONICS INC,DIXON HAROLD A,,https://lens.org/087-973-970-252-629,Granted Patent,no,0,16,1,1,0,G08G1/042;;G08G1/042,G08G1/042,,0,0,,,,EXPIRED
112,WO,A1,WO 1992/020542 A1,130-411-342-927-069,1992-11-26,1992,US 9203785 W,1992-05-13,US 69900291 A,1991-05-13,REFRIGERATED CONTAINER,"A refrigerated container (10) incorporating welded corrugated steel external walls (12) having insulation disposed within the interior to form an insulated structure. Refrigeration evaporators (35, 36) extend longitudinally at the juncture of the sidewalls and the internal ceiling (40) of the container with evaporator coils distributed along both sides of the container; air is forced over the evaporator coils by strategically placed tandem centrifugal blowers (42, 44) directing air outwardly generally parallel to the ceiling and transverse to the length of the container. Air return is provided by extruded T-shaped floor rails (47) spaced apart to provide a passageway for air penetration into the floor and which are provided with transverse holes to permit the transverse flow of return air through the floor to a sidewall. Alternate evaporators are defrosted in accordance with a timing system using a defrost technique that evaporates a single evaporator at a timee.",REEFCO MFG CORP,DIXON DAVID A,,https://lens.org/130-411-342-927-069,Patent Application,yes,9,10,14,14,0,B60H1/3232;;B60H1/3232;;B65D88/745;;B65D88/745;;B65D90/00;;B65D90/00;;F25D11/003;;F25D11/003;;F25B2347/021;;F25B2347/021;;F25D2317/0651;;F25D2317/0651;;F25D2317/0665;;F25D2317/0665,B60H1/32;;F25D11/00;;F25D17/08;;F25D21/06,,1,0,,,See also references of EP 0585388A4,PENDING
113,DE,A1,DE 2431863 A1,130-375-706-447-934,1975-01-23,1975,DE 2431863 A,1974-07-03,CA 175755 A,1973-07-05,ELEKTROMAGNETISCH HYDRAULISCH BETAETIGTE SCHEIBENBREMSE,,ITT IND GMBH DEUTSCHE,DIXON A KEITH,,https://lens.org/130-375-706-447-934,Patent Application,no,0,2,4,4,0,F16D55/224;;F16D2121/20;;F16D2125/10;;F16D2127/085;;F16D2127/12;;F16D55/224;;F16D2125/10;;F16D2127/12;;F16D2121/20;;F16D2127/085,F16D65/74;;F16D55/224;;F16D65/14;;F16D65/18,,0,0,,,,DISCONTINUED
114,EP,A1,EP 1910019 A1,156-332-353-887-216,2008-04-16,2008,EP 06788076 A,2006-07-21,US 2006/0028324 W;;US 70599805 P,2005-08-05,MULTI-TUBE INSERTION PROCESS,A method for assembling a plurality of tubes to a tubesheet. A first end of each of the tubes is situated over a corresponding support rod that extends from a pattern block of the fixture. A first end of a plurality of locating members is inserted into a second end of each of the tubes such that a second end of the locating member extends from the tube second end. The tubesheet is then slid over the locating members and tubes such that each of a plurality of holes in the tubesheet receive corresponding ones of the tubes.,LIEBERT CORP,DIXON MATTHEW A,"VERTIV CORP., COLUMBUS, US (2018-10-25)",https://lens.org/156-332-353-887-216,Patent Application,yes,0,0,7,7,0,B23P15/26;;B23P19/022;;F28F9/16;;Y10S165/492;;Y10T29/49368;;Y10T29/49895;;Y10T29/49396;;Y10T29/49377;;Y10T29/4938;;Y10T29/53117;;Y10T29/49364;;Y10T29/49387;;Y10T29/49373;;Y10T29/49368;;Y10T29/49895;;Y10T29/49396;;Y10T29/49377;;Y10T29/4938;;Y10T29/53117;;Y10T29/49364;;Y10T29/49387;;Y10T29/49373;;B23P19/022;;B23P15/26;;F28F9/16;;Y10S165/492,B23P15/26;;B23P19/02,,0,0,,,,ACTIVE
115,US,A,US 4696336 A,158-992-762-156-584,1987-09-29,1987,US 82318886 A,1986-01-27,US 82318886 A,1986-01-27,Vertical blinds chain,"A chain for attachment to a vertical blind. A longitudinally extending continuous length of thread has a plurality of plastic clips fixedly secured thereto at spaced intervals. Each of the plastic clips has means for engaging a portion of a vertical blind, and each of the plastic clips has a portion completely circumscribing a portion of the thread. A plurality of plastic objects are fixedly secured to the length of thread at a plurality of locations spaced between the clips, with each of the plastic objects completely circumscribing a portion of the thread. The thread is preferably a braided polyester material, and the plastic clips and the plastic objects are preferably molded to the length of thread.",DIXON JOHN A,DIXON JOHN A,,https://lens.org/158-992-762-156-584,Granted Patent,yes,5,9,1,1,0,E06B9/38;;E06B9/386;;Y10S160/90;;E06B9/38;;E06B9/386;;Y10S160/90,E06B9/38;;E06B9/386,160178R;;X160166A;;59/93,0,0,,,,EXPIRED
116,US,A,US 1404589 A,004-525-589-347-194,1922-01-24,1922,US 19579417 A,1917-10-10,US 19579417 A,1917-10-10,"Inking, coating, and impregnating machine",,DIXON LEWIS M;;DIXON HAROLD W A,DIXON LEWIS M;;DIXON HAROLD W A,,https://lens.org/004-525-589-347-194,Granted Patent,no,0,8,1,1,0,B41J31/14;;B41J31/14,B41J31/14,,0,0,,,,EXPIRED
117,US,A,US 1297809 A,158-925-963-368-014,1919-03-18,1919,US 24769918 A,1918-07-31,US 24769918 A,1918-07-31,EXPANSIBLE MANDREL,,DIXON LEWIS M;;DIXON HAROLD W A,DIXON LEWIS M;;DIXON HAROLD W A,,https://lens.org/158-925-963-368-014,Granted Patent,no,0,21,1,1,0,B65H75/2437;;Y10S24/26;;B65H75/2437,,,0,0,,,,EXPIRED
118,CA,A,CA 234979 A,121-765-784-503-329,1923-10-16,1923,CA 234979D A,,CA 234979T A,,INKING MACHINE,,COLUMBIA RIBBON & CARBON,DIXON HAROLD W A;;DIXON LEWIS M,,https://lens.org/121-765-784-503-329,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
119,US,A,US 1601162 A,062-751-941-838-312,1926-09-28,1926,US 71358924 A,1924-05-15,US 71358924 A,1924-05-15,"Machine for testing carbon paper, typewriter ribbon, etc.",,COLUMBIA RIBBON CARBON MFG;;CARBON MFG CO INC,DIXON HAROLD W A;;DIXON LEWIS M,,https://lens.org/062-751-941-838-312,Granted Patent,no,0,0,1,1,0,G01N33/32;;G01N33/32,G01N33/32,,0,0,,,,EXPIRED
120,US,A1,US 2013/0298913 A1,160-269-779-316-184,2013-11-14,2013,US 201213467120 A,2012-05-09,US 201213467120 A,2012-05-09,Condom-Containing Underwear,A condom-containing underwear includes a body portion for receiving a wearer's waist and covering at least 30 percent of the wearer's abdominal area; and a condom portion connected to the body portion and for receiving a penis. The body portion may include a shell and a lining. The lining may be detachable from the shell. The condom portion may be collapsible such that it takes the form of a penis only upon a full insertion of the penis within the condom portion.,DIXON JR DARRYL W;;DIXON DANTE A,DIXON JR DARRYL W;;DIXON DANTE A,,https://lens.org/160-269-779-316-184,Patent Application,yes,5,5,3,3,0,A41B9/02;;A41B9/02;;A41B9/004;;A61F6/00;;A61F6/00;;A61F6/04;;A61F6/04;;A61F6/065;;A61F6/065;;A61F2006/041;;A61F2006/041,A61F6/04;;A41B9/02;;A61F13/72,128/844;;604/396,0,0,,,,INACTIVE
121,WO,A1,WO 2013/169628 A1,126-897-562-905-206,2013-11-14,2013,US 2013/0039650 W,2013-05-06,US 201213467120 A,2012-05-09,CONDOM-CONTAINING UNDERWEAR,A condom-containing underwear includes a body portion for receiving a wearer's waist and covering at least 30 percent of the wearer's abdominal area; and a condom portion connected to the body portion and for receiving a penis. The body portion may include a shell and a lining. The lining may be detachable from the shell. The condom portion may be collapsible such that it takes the form of a penis only upon a full insertion of the penis within the condom portion.,DIXON DARRYL W JR;;DIXON DANTE A,DIXON DARRYL W JR;;DIXON DANTE A,,https://lens.org/126-897-562-905-206,Patent Application,yes,5,0,3,3,0,A41B9/02;;A41B9/02;;A41B9/004;;A61F6/00;;A61F6/00;;A61F6/04;;A61F6/04;;A61F6/065;;A61F6/065;;A61F2006/041;;A61F2006/041,A41B9/02;;A41B9/12,,0,0,,,,PENDING
122,US,B2,US 9392820 B2,103-918-543-803-920,2016-07-19,2016,US 201213467120 A,2012-05-09,US 201213467120 A,2012-05-09,Condom containing underwear,A condom-containing underwear includes a body portion for receiving a wearer's waist and covering at least 30 percent of the wearer's abdominal area; and a condom portion connected to the body portion and for receiving a penis. The body portion may include a shell and a lining. The lining may be detachable from the shell. The condom portion may be collapsible such that it takes the form of a penis only upon a full insertion of the penis within the condom portion.,DIXON JR DARRYL W;;DIXON DANTE A,DIXON JR DARRYL W;;DIXON DANTE A,,https://lens.org/103-918-543-803-920,Granted Patent,yes,23,0,3,3,0,A41B9/02;;A41B9/02;;A41B9/004;;A61F6/00;;A61F6/00;;A61F6/04;;A61F6/04;;A61F6/065;;A61F6/065;;A61F2006/041;;A61F2006/041,A61F6/00;;A41B9/00;;A41B9/02;;A61F6/04;;A61F6/06,,1,0,,,"International Search Report and Written Opinion mailed Aug. 23, 2013 for corresponding application PCT/US2013/039650 filed May 6, 2013.",INACTIVE
123,NO,B,NO 125823 B,117-614-208-994-913,1972-11-06,1972,NO 15961865 A,1965-09-07,GB 1396665 A;;GB 3679764 A,1964-09-08,NO 125823 B,,DIXON MALT CO LTD;;ENZYMIC MALT CO LTD,COMRIE A;;DIXON B,,https://lens.org/117-614-208-994-913,Unknown,no,0,0,12,25,0,C12C1/18;;C12C1/18;;C12C1/047;;C12C1/047;;C12C1/067;;C12C1/067,C12C1/047;;C12C1/067,,0,0,,,,DISCONTINUED
124,SE,B,SE 338455 B,178-923-222-542-819,1971-09-06,1971,SE 1066067 A,1967-07-18,US 56854066 A,1966-07-28,SE 338455 B,,COLUMBIA CONTROLS RES CORP,VACCARO A;;DIXON H,,https://lens.org/178-923-222-542-819,Unknown,no,0,0,6,7,0,G06V30/2253,G06K9/00,,0,0,,,,DISCONTINUED
125,BR,A,BR 7907447 A,002-082-976-618-051,1980-08-05,1980,BR 7907447 A,1979-11-14,GB 7844355 A,1978-11-14,CONJUNTO DE SERVO FREIO PARA SISTEMAS DE FRENAGEM DE VEICULOS,,LUCAS INDUSTRIES LTD,APPELBOAM J;;DIXON A,,https://lens.org/002-082-976-618-051,Patent Application,no,0,0,8,12,0,B60T13/56,B60T13/56;;B60T13/44;;B60T13/52;;B60T13/57;;B60T15/00;;B60T17/00;;F15B13/01;;F15B15/10,,0,0,,,,DISCONTINUED
126,NZ,A,NZ 183381 A,065-317-168-859-323,1980-03-05,1980,NZ 18338177 A,1977-02-18,GB 671676 A,1976-02-20,ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING (2-CARBOMOYL-PHENYL) 2-ACETOXY BENZOATE,,BEECHAM GROUP LTD,DIXON G;;DAVIS A,,https://lens.org/065-317-168-859-323,Patent Application,no,0,0,36,38,0,A61K31/60;;A61P25/04;;A61P29/00;;A61K31/60,A61K31/60;;A61P25/04;;A61P29/00;;C07C67/00;;C07C231/00;;C07C235/46,,0,0,,,,DISCONTINUED
127,US,A,US 1925235 A,113-888-812-460-363,1933-09-05,1933,US 51094531 A,1931-01-24,US 51094531 A,1931-01-24,Carbon paper,,DIXON HAROLD W A,DIXON HAROLD W A,,https://lens.org/113-888-812-460-363,Granted Patent,no,0,14,1,1,0,B41M5/08;;Y10T428/31812;;Y10T428/31812;;B41M5/08,B41M5/08,,0,0,,,,EXPIRED
128,US,A,US 3391427 A,012-873-473-597-221,1968-07-09,1968,US 61666667 A,1967-02-16,US 61666667 A,1967-02-16,Quick release calender roller assembly,,GOSSETT MACHINE WORKS INC,DIXON JR JAMES A,,https://lens.org/012-873-473-597-221,Granted Patent,no,4,2,1,1,0,B65H54/80;;B65H54/80;;B65H2701/31;;B65H2701/31,B65H54/80,19   23,0,0,,,,EXPIRED
129,CA,A,CA 280354 A,028-195-139-776-786,1928-05-22,1928,CA 280354D A,,CA 280354T A,,PAPER MARKING PROCESS,,COLUMBIA RIBBON & CARBON,DIXON HAROLD W A,,https://lens.org/028-195-139-776-786,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
130,SE,B,SE 342648 B,032-551-049-368-159,1972-02-14,1972,SE 32867 A,1967-01-10,GB 4389466 A;;GB 130266 A,1966-01-11,SE 342648 B,,ENZYMIC MALT CO LTD;;DIXON MALT CO LTD,COMBRIE A;;DIXON B,,https://lens.org/032-551-049-368-159,Unknown,no,0,0,5,8,0,C12C1/047,,,0,0,,,,DISCONTINUED
131,KR,B1,KR 820000578 B1,066-022-620-759-387,1982-04-15,1982,KR 790003973 A,1979-11-14,GB 7844355 A,1978-11-14,SERVO BOOSTERS FOR VEHICLE BRAKING SYSTEMS,The valve assembly for the booster has a poppet valve member(29) secured to a sleeve(34) which is slidable in the valve body(3). It is connected by a part-pherical thrust coupling(41) centered at the ball(13) with the input rod(12). The sleeve and input rod are biassed rearwardly by a single spring(46). The resilient valve member is provided with a sealing lip(39) to effect a sliding seal between the sleeve & the valve body. The valve body has a stepped bore with a reduced dia. intermediate position(10) in which is located a valve control member(11).,LUCAS INDUSTRIES LTD,APPELBOAM J;;DIXON A,,https://lens.org/066-022-620-759-387,Granted Patent,no,0,0,8,12,0,B60T13/56,B60T13/56;;B60T13/44;;B60T13/52;;B60T13/57;;B60T15/00;;B60T17/00;;F15B13/01;;F15B15/10,,0,0,,,,EXPIRED
132,DE,D1,DE 69822199 D1,071-488-213-101-567,2004-04-08,2004,DE 69822199 T,1998-12-14,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,ARZNEIMITTEL UND VERFAHREN ZUR BEHANDLUNG VON AUFMERKSAMKEITSSTÖRUNGEN UND AUFMERKSAMKEITS-/HYPERAKTIVITÄTSSTÖRUNGEN MIT METHYLPHENIDAT,,NOVEN PHARMA,MANTELLE JUAN;;DIXON A,,https://lens.org/071-488-213-101-567,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
133,IN,B,IN 149322 B,081-445-318-949-612,1981-10-24,1981,IN 202MA1979 A,1979-11-08,GB 7844355 A,1978-11-14,A SERVO BOOSTER ASSEMBLY FOR A VEHICLE BRAKING SYSTEM,,LUCAS INDUSTRIES LTD,DIXON A;;APPELBOAM J,,https://lens.org/081-445-318-949-612,Granted Patent,no,0,0,8,12,0,B60T13/56,B60T13/56;;B60T13/44;;B60T13/52;;B60T13/57;;B60T15/00;;B60T17/00;;F15B13/01;;F15B15/10,,0,0,,,,EXPIRED
134,BR,D0,BR 6242821 D0,134-613-687-772-219,1973-05-29,1973,BR 14282162 A,1962-09-10,BR 14282162 A,1962-09-10,PROCESSO DE MALTACAO DE CEVADA E OUTROS CEREAIS,,DIXON MALT CO LTD;;ENZYMIC MALT CO LTD,COMRIE A;;DIXON B,,https://lens.org/134-613-687-772-219,Patent Application,no,0,0,1,1,0,,,2-1-10,0,0,,,,DISCONTINUED
135,US,A,US 1988723 A,144-446-178-240-14X,1935-01-22,1935,US 55300131 A,1931-07-24,US 55300131 A,1931-07-24,Marking compound,,DIXON HAROLD W A,DIXON HAROLD W A,,https://lens.org/144-446-178-240-14X,Granted Patent,no,0,0,1,1,0,C09D11/02;;C09D11/02,C09D11/02,,0,0,,,,EXPIRED
136,SE,B,SE 306511 B,003-720-149-295-260,1968-12-02,1968,SE 897162 A,1962-08-17,GB 2791362 A;;GB 2977961 A;;GB 1071862 A,1961-08-17,SE 306511 B,,ENZYMIC MALT CO LTD;;DIXON MALT CO LTD,COMRIE A;;DIXON B,,https://lens.org/003-720-149-295-260,Unknown,no,0,0,9,12,0,C12C1/00;;C12C1/02;;C12C1/047,C12C1/00;;C12C1/02;;C12C1/047,,0,0,,,,DISCONTINUED
137,US,A,US 1703481 A,075-277-259-357-264,1929-02-26,1929,US 24747328 A,1928-01-18,US 24747328 A,1928-01-18,Wide fabric prepared to be slit and method of preparing the same,,COLUMBIA RIBBON CARBON MFG,DIXON HAROLD W A,,https://lens.org/075-277-259-357-264,Granted Patent,no,0,1,1,1,0,D06H7/18;;D06H7/18;;Y10T83/04;;Y10T83/04,D06H7/18,,0,0,,,,EXPIRED
138,US,A,US 3724453 A,164-605-707-396-301,1973-04-03,1973,US 3724453D A,1970-08-04,GB 3934169 A,1969-08-06,SPLINTS,"A splint which is of particular value in extricating persons from vehicle crashes where an injury of the spine or neck is to be feared comprises a solid backing member which is of a length to stretch from adjacent the bottom of the spine to behind the head of an injured person, and which has secured thereto a harness for holding the head in position against the splint and further harness for rigidly securing the torso to the splint (which harness may also hold the arms rigidly).",DIXON A;;PROCTOR M,DIXON A;;PROCTOR M,,https://lens.org/164-605-707-396-301,Granted Patent,no,10,23,4,4,0,A61F5/05883;;A61F5/05883,A61F5/058,128-087   R,1,0,,,"U.S. Naval Medical Bulletin, Transport Splint for Fractured Spines, by Wagner et al., Oct. 1939.",EXPIRED
139,WO,A1,WO 1981/002469 A1,179-634-835-665-622,1981-09-03,1981,US 8100202 W,1981-02-18,US 12356280 A,1980-02-22,THE SOLID PHASE ANTI-C3 ASSAY FOR DETECTION OF IMMUNE COMPLEXES,An assay and means for determining immune complexes. The sample suspected of containing immune complexes is permitted to contact a solid substrate (110) to which has been bound F(ab') 2 anti-C3 reagent (111). The thus-treated solid substrate may then be examined in a conventional immunoassay protocol.,SCRIPPS CLINIC RES,THEOFILOPOULOS A;;DIXON F,,https://lens.org/179-634-835-665-622,Patent Application,yes,8,12,5,6,0,G01N33/564;;Y10S435/971;;G01N33/564,G01N33/53;;G01N33/536;;G01N33/543;;G01N33/00;;G01N33/564,G1B BAG           BAG;;G1B BBT           BBT;;G1B B103          BAG;;G1B B104          BAG;;G1B B308          BAG;;G1B B524          BAG,1,0,,,"NOEL R. ROSE et al, editors, 'Manual of Clinical Immunology', published 1976, by American Society for Microbiology (Washington), pages 676-681.",PENDING
140,US,A,US 1780007 A,021-983-191-282-380,1930-10-28,1930,US 18974727 A,1927-05-07,US 18974727 A,1927-05-07,Process of marking paper,,COLUMBIA RIBBON CARBON MFG,DIXON HAROLD W A,,https://lens.org/021-983-191-282-380,Granted Patent,no,0,0,1,1,0,B41M5/10;;B41M5/10,B41M5/10,,0,0,,,,EXPIRED
141,SE,B,SE 339328 B,129-882-389-365-724,1971-10-04,1971,SE 275868 A,1968-03-01,GB 963467 A;;GB 28868 A,1967-03-01,SE 339328 B,,ICI LTD,DIXON A;;MASON J,,https://lens.org/129-882-389-365-724,Unknown,no,0,0,8,9,0,C08K3/22;;C08K5/02,C08K3/22;;C08K5/02,,0,0,,,,DISCONTINUED
142,BR,A,BR 7907448 A,121-998-749-146-861,1980-08-05,1980,BR 7907448 A,1979-11-14,GB 7844355 A,1978-11-14,SERVO FREIO PARA SISTEMA DE FRENAGEM DE VEICULO,,LUCAS INDUSTRIES LTD,APPLELBOAM J;;DIXON A,,https://lens.org/121-998-749-146-861,Patent Application,no,0,0,8,12,0,B60T13/56,B60T13/56;;B60T13/44;;B60T13/52;;B60T13/57;;B60T15/00;;B60T17/00;;F15B13/01;;F15B15/10,,0,0,,,,DISCONTINUED
143,SE,B,SE 320722 B,147-836-364-956-97X,1970-02-16,1970,SE 4764 A,1964-01-03,GB 46763 A,1963-01-04,SE 320722 B,,MUIRHEAD & CO LTD,DIXON J;;ANANIN A,,https://lens.org/147-836-364-956-97X,Unknown,no,0,0,3,3,0,G01M1/22;;G01R31/34;;Y10T74/1412;;Y10T279/13;;Y10T74/1412;;Y10T279/13;;G01R31/34;;G01M1/22,G01M1/22;;G01R31/34,21C  46 02,0,0,,,,DISCONTINUED
144,US,A,US 3759745 A,004-450-841-276-284,1973-09-18,1973,US 3759745D A,1971-07-14,US 16251771 A,1971-07-14,HYDROGEN ANNEALING OF SUBSTITUTED MAGNETIC GARNETS AND MATERIALS SO PRODUCED,,BELL TELEPHONE LABOR INC,DIXON M;;KURTZIG A,,https://lens.org/004-450-841-276-284,Granted Patent,no,0,13,1,1,0,C04B35/2675;;H01F10/24;;Y10S428/90;;H01F10/24;;C04B35/2675;;Y10S428/90,C04B35/26;;H01F10/24,117-237,0,0,,,,EXPIRED
145,ZA,B,ZA 771017 B,134-972-790-944-802,1978-01-25,1978,ZA 771017 A,1977-02-21,GB 671676 A,1976-02-20,ANALGESIC COMPOUND,,BEECHAM GROUP LTD,DAVIS A;;DIXON G,,https://lens.org/134-972-790-944-802,Granted Patent,no,0,0,36,38,0,A61K31/60;;A61P25/04;;A61P29/00;;A61K31/60,A61K31/60;;A61P25/04;;A61P29/00;;C07C67/00;;C07C231/00;;C07C235/46,,0,0,,,,EXPIRED
146,US,A,US 1702380 A,005-126-249-846-972,1929-02-19,1929,US 17772627 A,1927-03-23,US 17772627 A,1927-03-23,Colloid-treating apparatus,,DIXON HAROLD W A,DIXON HAROLD W A,,https://lens.org/005-126-249-846-972,Granted Patent,no,0,0,1,1,0,B02C2/10;;B02C2/10,B02C2/10,,0,0,,,,EXPIRED
147,WO,A2,WO 2002/079919 A2,128-248-946-855-757,2002-10-10,2002,US 0200475 W,2002-01-07,US 26017801 P,2001-01-05,SYSTEM AND METHOD FOR ASSET ACCUMULATION AND RISK MANAGEMENT,"Bases on risk determinations, eligible consumers are enrolled and funds allocated to the payment of a premium for income insurance, contribution to a financial vehicle such as a savings or investment product and payment of a premium for savings loss insurance (Figures 8). Active participants are eligible for income protection in case of job loss, systematic savings and ownership of public equities, principal protection and incentives based on utilization. The system and method of the invention is calibrated on an ongoing basis to the behaviors of target consumers (Figures 3).",DIXON DELORES A;;PHELAN STACY DIXON;;NOLAN LAUREL DIXON,DIXON DEBORAH A DI,,https://lens.org/128-248-946-855-757,Patent Application,yes,0,0,9,9,0,G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/08;;G06Q40/03;;G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/03;;G06Q40/08,G06Q40/00,,0,0,,,,PENDING
148,US,A,US 3443282 A,191-740-705-659-260,1969-05-13,1969,US 3443282D A,1967-09-19,US 66888767 A,1967-09-19,CALENDER ROLLER STOP MECHANISM,,GOSSETT MACHINE WORKS INC,DIXON JAMES A JR,,https://lens.org/191-740-705-659-260,Granted Patent,no,3,5,1,1,0,D01H13/1616;;D01H13/1616,D01H13/16,19   23,0,0,,,,EXPIRED
149,US,A,US 1565310 A,055-825-408-377-293,1925-12-15,1925,US 73030724 A,1924-08-05,US 73030724 A,1924-08-05,Marking or branding of carbon paper,,COLUMBIA RIBBON CARBON MFG,DIXON HAROLD W A,,https://lens.org/055-825-408-377-293,Granted Patent,no,0,2,1,1,0,B44B7/00;;B44B7/00;;B44B2700/08;;B44B2700/08;;Y10T428/24934;;Y10T428/24934,B44B7/00,,0,0,,,,EXPIRED
150,US,A,US 1718949 A,061-656-301-799-763,1929-07-02,1929,US 17772727 A,1927-03-23,US 17772727 A,1927-03-23,Process of preparing carbon dopes,,DIXON HAROLD W A,DIXON HAROLD W A,,https://lens.org/061-656-301-799-763,Granted Patent,no,0,0,1,1,0,B41M5/10;;B41M5/10,B41M5/10,,0,0,,,,EXPIRED
151,NO,B,NO 119309 B,082-683-153-692-424,1970-05-04,1970,NO 14543162 A,1962-08-16,GB 2791362 A;;GB 2977961 A;;GB 1071862 A,1961-08-17,NO 119309 B,,DIXON MALT CO LTD;;ENZYMIC MALT CO LTD,DIXON B;;COMRIE A,,https://lens.org/082-683-153-692-424,Unknown,no,0,0,9,12,0,C12C1/00;;C12C1/02;;C12C1/047,C12C1/00;;C12C1/02;;C12C1/047,,0,0,,,,DISCONTINUED
152,DK,B,DK 113211 B,035-851-831-403-616,1969-03-03,1969,DK 459265 A,1965-09-07,GB 1396665 A;;GB 3679764 A,1964-09-08,Fremgangsmåde til behandling af grønmalt.,,DIXON MALT CO LTD;;ENZYMIC MALT CO LTD,DOUGLAS A;;DIXON B,,https://lens.org/035-851-831-403-616,Patent Application,no,0,0,12,25,0,C12C1/18;;C12C1/18;;C12C1/047;;C12C1/047;;C12C1/067;;C12C1/067,C12C1/047;;C12C1/067,6A2,0,0,,,,DISCONTINUED
153,US,A,US 1717012 A,048-333-088-226-212,1929-06-11,1929,US 17772527 A,1927-03-23,US 17772527 A,1927-03-23,Rotary disk valve,,DIXON HAROLD W A,DIXON HAROLD W A,,https://lens.org/048-333-088-226-212,Granted Patent,no,0,8,1,1,0,F16K11/0743;;F16K11/0743;;Y10T137/6579;;Y10T137/6579;;Y10T137/86839;;Y10T137/86839,F16K11/074,,0,0,,,,EXPIRED
154,US,A,US 1760045 A,194-720-223-342-480,1930-05-27,1930,US 10408726 A,1926-04-23,US 10408726 A,1926-04-23,Apparatus for manufacturing carbon paper,,COLUMBIA RIBBON CARBON MFG,DIXON HAROLD W A,,https://lens.org/194-720-223-342-480,Granted Patent,no,0,2,1,1,0,B41L1/00;;B41L1/00,B41L1/00,,0,0,,,,EXPIRED
155,US,A,US 1783226 A,074-683-307-148-14X,1930-12-02,1930,US 25151128 A,1928-02-03,US 25151128 A,1928-02-03,Wrapping machine,,COLUMBIA RIBBON CARBON MFG,DIXON HAROLD W A,,https://lens.org/074-683-307-148-14X,Granted Patent,no,0,1,1,1,0,B65B11/54;;B65B11/54,B65B11/54,,0,0,,,,EXPIRED
156,DK,B,DK 117892 B,102-579-735-140-957,1970-06-15,1970,DK 267568 A,1968-06-07,GB 2661967 A,1967-06-08,Fremgangsmåde til maltning af korn.,,ENZYMIC MALT CO LTD;;DIXON MALT CO LTD,DIXON B;;COMRIE A,,https://lens.org/102-579-735-140-957,Patent Application,no,0,0,11,25,0,C12C1/18;;C12C1/18;;C12C1/047;;C12C1/047;;C12C1/067;;C12C1/067,C12C/;;C12C1/00;;C12C1/18,6A2,0,0,,,,DISCONTINUED
157,US,A,US 3304770 A,149-348-054-065-581,1967-02-21,1967,US 52299466 A,1966-01-25,US 52299466 A,1966-01-25,Straw bending device,,DIXON JR CHARLES A,DIXON JR CHARLES A,,https://lens.org/149-348-054-065-581,Granted Patent,no,5,3,1,1,0,G01N3/20;;G01N3/20,G01N3/20,,0,0,,,,EXPIRED
158,WO,A3,WO 2002/079919 A3,037-249-839-470-128,2003-08-21,2003,US 0200475 W,2002-01-07,US 26017801 P,2001-01-05,SYSTEM AND METHOD FOR ASSET ACCUMULATION AND RISK MANAGEMENT,"Bases on risk determinations, eligible consumers are enrolled and funds allocated to the payment of a premium for income insurance, contribution to a financial vehicle such as a savings or investment product and payment of a premium for savings loss insurance (Figures 8). Active participants are eligible for income protection in case of job loss, systematic savings and ownership of public equities, principal protection and incentives based on utilization. The system and method of the invention is calibrated on an ongoing basis to the behaviors of target consumers (Figures 3).",DIXON DELORES A;;PHELAN STACY DIXON;;NOLAN LAUREL DIXON,DIXON DEBORAH A DI,,https://lens.org/037-249-839-470-128,Search Report,yes,2,0,9,9,0,G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/08;;G06Q40/03;;G06Q30/0226;;G06Q40/00;;G06Q40/06;;G06Q40/03;;G06Q40/08,G06Q40/00,,0,0,,,,PENDING
159,CA,A,CA 825897 A,076-970-206-240-187,1969-10-28,1969,CA 825897D A,,CA 825897T A,,STRAW BENDING DEVICE,,US GOV SEC ARMY,DIXON CHARLES A JR,,https://lens.org/076-970-206-240-187,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
160,SE,B,SE 364241 B,109-191-393-300-300,1974-02-18,1974,SE 827168 A,1968-06-18,US 64740367 A,1967-06-20,SE 364241 B,,COLUMBIA CONTROLS RES CORP,DIXON H;;VACCARE A,,https://lens.org/109-191-393-300-300,Unknown,no,0,0,5,5,0,B65H43/04;;B65H43/04;;Y10T83/2024;;Y10T83/2024;;Y10T83/2085;;Y10T83/2085;;Y10T83/4737;;Y10T83/4737;;Y10T83/4838;;Y10T83/4838;;Y10T83/527;;Y10T83/527;;Y10T83/533;;Y10T83/533,B65H43/04,,0,0,,,,DISCONTINUED
161,JP,A,JP 2002336933 A,164-637-513-939-685,2002-11-26,2002,JP 2002066940 A,2002-03-12,US 80542601 A,2001-03-13,METHOD FOR TREATING CERAMIC CORE,"PROBLEM TO BE SOLVED: To provide a method for treating an unfired molded ceramic core in which the surface of a core is agreed with the surface of a setter, the distor tion of the core is reduced, and the yield of the core within the tolerance of the preselected dimension is improved. SOLUTION: This treating method includes a step of placing the unfired (green) ceramic core having thermosetting and/or thermoplastic binder on at least one setter, a step of placing the setter and the green ceramic core thereon on a conveyor, and a step of carrying the setter and the green core through a heating oven, and heating the setter and the green ceramic core at the high superambient temperature or at the temperature higher than the softening temperature of the binder present in the basic core.",HOWMET RES CORP,DIXON BOBBY A;;HOLT JENNIFER A,,https://lens.org/164-637-513-939-685,Patent Application,no,0,1,11,11,0,B22C9/12;;B22C9/12,B22C9/04;;B22C9/10;;B22C9/12;;B22C9/16;;F02C7/00,,0,0,,,,EXPIRED
162,US,A1,US 2006/0072960 A1,101-560-648-457-087,2006-04-06,2006,US 95550204 A,2004-10-01,US 95550204 A,2004-10-01,MULTI PURPOSE HAND HELD CLEANING DEVICE,"Multi purpose hand held cleaning device comprising a gun shaped handle portion, a first tubular portion perpendicularly attached at one end to the handle portion, a U shaped frame attached at the opposite end, the legs of the U frame terminating in transverse roller bearings, a second hollow tube placed concentrically inside the first hollow tube, one end of the second hollow tube terminating in a sponge member, the first hollow tube having a slot so that a trigger member attached to the second hollow tube can slidably fit within the slot, the second hollow tube enclosing a compression spring. A preferred embodiment includes the the handle being hollow so as to be capable of retaining a cleaning fluid and an internal fluid pump activated by an external trigger member.",DIXON MARCIA A;;TARLOW KENNETH A,DIXON MARCIA A;;TARLOW KENNETH A,,https://lens.org/101-560-648-457-087,Patent Application,yes,4,0,2,2,0,A47L1/08;;A47L13/144;;A47L13/51;;B08B1/00;;B08B3/026;;B08B1/00;;B08B3/026;;A47L1/08;;A47L13/51;;A47L13/144,A47L1/08;;A47L13/46;;B43K5/02,40118800R;;401/205;;401/25;;401/23,0,0,,,,INACTIVE
163,CA,A,CA 1052193 A,175-256-863-386-144,1979-04-10,1979,CA 252249 A,1976-05-11,CA 252249 A,1976-05-11,RISER SPACERS FOR VERTICALLY MOORED PLATFORMS,"This invention relates to a structure floating on a body of water, and particularly a structure for drilling or producing wells from below the water. Boyant members support at least a part of the structure above the surface of the water. The structure is connected to anchors in the floor of the body of water by a series of parallel leg members. Each leg member is composed of a plurality of elongated members, such as large diameter pipe usually called risers. These risers are parallel. Vertically spaced spacers are provided along the risers of each leg to (1) maintain the risers a fixed distance apart and (2) change the natural or resonant frequency of the individual riser pipes to be greater than the flutter frequency caused by the motion of the water past the risers.",AMOCO PROD CO,BEYNET PIERRE A;;DIXON DAVID A,,https://lens.org/175-256-863-386-144,Granted Patent,no,0,0,1,1,0,,B63B35/44,114-58.5,0,0,,,,EXPIRED
164,US,A,US 3559410 A,047-974-490-014-14X,1971-02-02,1971,US 3559410D A,1968-07-30,US 74886768 A,1968-07-30,SYSTEM FOR RELIEVING STRESS AT THE TOP AND BOTTOM OF VERTICAL TUBULAR MEMBERS IN VERTICALLY MOORED PLATFORMS,,PAN AMERICAN PETROLEUM CORP,BLENKARN KENNETH A;;DIXON DAVID A,,https://lens.org/047-974-490-014-14X,Granted Patent,no,0,16,1,1,0,B63B35/4413;;B63B1/107;;B63B21/502;;B63B35/4413;;B63B21/502;;B63B1/107,B63B35/44;;E02B17/02,61/46.5,0,0,,,,EXPIRED
165,CA,A,CA 890147 A,120-241-882-708-404,1972-01-11,1972,CA 890147D A,,CA 890147T A,,SYSTEM FOR RELIEVING STRESS AT THE TOP AND BOTTOM OF VERTICAL TUBULAR MEMBERS IN VERTICALLY MOORED PLATFORMS,,AMOCO CANADA PETROLEUM CO,DIXON DAVID A;;BLENKARN KENNETH A,,https://lens.org/120-241-882-708-404,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
166,AU,A,AU 1987/083225 A,153-810-963-115-752,1988-05-25,1988,AU 1987/083225 A,1987-10-19,US 92202786 A,1986-10-22,CASSETTE LOCKING SYSTEM,,SECURITY TWO INC,HANNAN FORREST A;;DIXON DALE A,,https://lens.org/153-810-963-115-752,Patent Application,no,0,0,3,3,0,G11B23/08721;;G11B23/08721,G11B23/087,,0,0,,,,DISCONTINUED
167,FR,A1,FR 2822092 A1,002-655-816-202-079,2002-09-20,2002,FR 0203072 A,2002-03-12,US 80542601 A,2001-03-13,PROCEDE DE TRAITEMENT DE NOYAUX DE CERAMIQUE,"<P>L'invention concerne le moulage de matières métalliques fondues.Le procédé de traitement d'un noyau de céramique comprend les étapes consistant à placer, sur un support d'enfournement (42), un noyau de céramique cru (10) incorporant un liant et à placer le support d'enfournement (42) et le noyau de céramique cru (10) situé dessus sur un transporteur (50) qui transporte l'ensemble à travers un four de chauffage, afin de chauffer cet ensemble à une température élevée supérieure à la température ambiante.L'invention s'applique notamment à la réalisation d'ailes ou d'aubes de turbine à moulage de précision.</P>",HOWMET RES CORP,DIXON BOBBY A;;HOLT JENNIFER A,,https://lens.org/002-655-816-202-079,Patent Application,no,6,0,11,11,0,B22C9/12;;B22C9/12,B22C9/04;;B22C9/10;;B22C9/12;;F02C7/00;;B22C9/16,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 014, no. 237 (M - 0976) 21 May 1990 (1990-05-21)",EXPIRED
168,US,A,US 3978804 A,002-561-905-903-515,1976-09-07,1976,US 40643473 A,1973-10-15,US 40643473 A,1973-10-15,Riser spacers for vertically moored platforms,"This invention relates to a structure floating on a body of water, and particularly a structure for drilling or producing wells from below the water. Buoyant members support at least a part of the structure above the surface of the water. The structure is connected to anchors in the floor of the body of water by a series of parallel leg members. Each leg member is composed of a plurality of elongated members, such as large diameter pipe usually called risers. These risers are parallel. Vertically spaced spacers are provided along the risers of each leg to (1) maintain the risers a fixed distance apart and (2) change the natural or resonant frequency of the individual riser pipes to be greater than the flutter frequency caused by the motion of the water past the risers.",AMOCO PROD CO,BEYNET PIERRE A;;DIXON DAVID A,,https://lens.org/002-561-905-903-515,Granted Patent,yes,5,20,3,3,0,B63B21/502;;B63B21/502;;E21B17/01;;E21B17/01,B63B21/50;;E02B17/02;;E21B17/01,B7V VFA           VFA,0,0,,,,EXPIRED
169,WO,A1,WO 1988/003312 A1,033-228-373-572-14X,1988-05-05,1988,US 8702747 W,1987-10-19,US 92202786 A,1986-10-22,CASSETTE LOCKING SYSTEM,"The locking and unlocking of the cassette (10) is provided by utilizing a mechanism which cooperates with the reel brakes (16) which are currently unutilized in video cassettes. When a cassette is inserted into a cassette player, a standard pin (44) in the player protrudes upwardly through a hole (46) in the base of the cassette and pivots a crank or lever (28) which releases the brakes. A locking or disabling mechanism (36) is operated or inactivated by a separate tool in the control of the retail rental outlet so that the brake release mechanism will function in the usual manner upon being engaged by the standard pin found in a cassette player. Further, activating the brake release lever (28) operates or readies the disabling mechanism in the cassette so that when the cassette is removed from the cassette player, the brake release lever (28) is once more disabled so that the cassette cannot be replayed without once again being unlocked or operated by the unlocking device in the possession of the rental outlet.",SECURITY TWO INC,HANNAN FORREST A;;DIXON DALE A,,https://lens.org/033-228-373-572-14X,Patent Application,yes,6,4,3,3,0,G11B23/08721;;G11B23/08721,G11B23/087,B8M ME129         MFF;;B8M ME135         MFF;;B8M MFF           MFF;;B8M MF112         MFF;;B8M MF113         MFF;;B8M MF119         MFF;;B8M M602          MFF;;G5R RB335         RHB;;G5R RB789         RHB;;G5R RHB           RHB,0,0,,,,PENDING
170,DE,A1,DE 10211039 A1,104-026-140-071-81X,2002-09-26,2002,DE 10211039 A,2002-03-13,US 80542601 A,2001-03-13,Verfahren zum Behandeln eines keramischen Kerns,"Verfahren zum Behandeln eines ungebrannten gegossenen keramischen Kerns, bei dem der ungebrannte (grüne) keramische Kern, welcher ein wärmeaushärtendes und/oder thermoplastisches Bindemittel enthält, auf mindestens einem Setzglied angeordnet wird, das Setzglied mit dem darauf befindlichen grünen keramischen Kern auf einem Förderer angeordnet wird, das Setzglied und der grüne Kern durch einen Ofen bewegt werden, um das Setzglied und den grünen keramischen Kern auf eine höhere überatmosphärische Temperatur zu erwärmen, welche der Erweichungstemperatur des in dem grünen Kern vorhandenen Bindemittels entspricht und darüber liegt. Durch Erwärmen des grünen keramischen Kerns wird der Kern an eine Oberfläche des Setzgliedes angepasst, um eine Verformung des Kerns zu verringern und Abweichungen des Kerns, die innerhalb vorgegebener Abmessungstoleranzen liegen, zu verbessern.",HOWMET RES CORP,DIXON BOBBY A;;HOLT JENNIFER A,"HOWMET CORPORATION, US (2011-09-12);;HOWMET CORPORATION, INDEPENDENCE, US (2011-09-12)",https://lens.org/104-026-140-071-81X,Patent Application,no,0,0,11,11,0,B22C9/12;;B22C9/12,B22C9/04;;F02C7/00;;B22C9/10;;B22C9/12;;B22C9/16,,0,0,,,,EXPIRED
171,US,A,US 4276636 A,167-940-589-011-93X,1981-06-30,1981,US 83388877 A,1977-09-16,US 83388877 A,1977-09-16,Cushion disc for phonograph records,"A protective device for phonograph records comprising a cushion platter including a circular hoop, a circular inner ring and a plurality of spoke-like attachments supporting said inner circular ring from and within said hoop, and having a soft cover that envelops the hoop and spoke-like attachments; and means for disconnectably attaching the cushion platter to the center ungrooved portion of a phonograph record, said means comprising a pair of ring attachments, each having pressure-sensitive adhesive applied to one side, said ring attachments being affixed to opposite sides of a phonograph record; whereby the protective disc may be selectively connected and disconnected to either of said circular ring attachments.",MORGAN STANLEY A;;DIXON EDGAR A,MORGAN STANLEY A;;DIXON EDGAR A,,https://lens.org/167-940-589-011-93X,Granted Patent,yes,8,7,1,1,0,G11B17/02;;G11B17/02,G11B17/02,369/291,0,0,,,,EXPIRED
172,FR,B1,FR 2822092 B1,052-399-603-814-745,2005-01-14,2005,FR 0203072 A,2002-03-12,US 80542601 A,2001-03-13,PROCEDE DE TRAITEMENT DE NOYAUX DE CERAMIQUE,,HOWMET RES CORP,DIXON BOBBY A;;HOLT JENNIFER A,,https://lens.org/052-399-603-814-745,Granted Patent,no,0,0,11,11,0,B22C9/12;;B22C9/12,B22C9/04;;B22C9/10;;F02C7/00;;B22C9/12;;B22C9/16,,0,0,,,,EXPIRED
173,CA,A,CA 882498 A,095-405-340-028-977,1971-10-05,1971,CA 882498D A,,CA 882498T A,,MOORING SYSTEM USING CABLES AND BUCKLED RISER PIPE,,AMOCO CANADA PETROLEUM CO,DIXON DAVID A;;BLENKARN KENNETH A,,https://lens.org/095-405-340-028-977,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
174,US,B2,US 7044674 B2,145-667-348-239-471,2006-05-16,2006,US 95550204 A,2004-10-01,US 95550204 A,2004-10-01,Multi purpose hand held cleaning device,"Multi purpose hand held cleaning device comprising a gun shaped handle portion, a first tubular portion perpendicularly attached at one end to the handle portion, a U shaped frame attached at the opposite end, the legs of the U frame terminating in transverse roller bearings, a second hollow tube placed concentrically inside the first hollow tube, one end of the second hollow tube terminating in a sponge member, the first hollow tube having a slot so that a trigger member attached to the second hollow tube can slidably fit within the slot, the second hollow tube enclosing a compression spring. A preferred embodiment includes the handle being hollow so as to be capable of retaining a cleaning fluid and an internal fluid pump activated by an external trigger member.",DIXON MARCIA A;;TARLOW KENNETH A,DIXON MARCIA A;;TARLOW KENNETH A,,https://lens.org/145-667-348-239-471,Granted Patent,yes,4,9,2,2,0,A47L1/08;;A47L13/144;;A47L13/51;;B08B1/00;;B08B3/026;;B08B1/00;;B08B3/026;;A47L1/08;;A47L13/51;;A47L13/144,B43K5/00,401/205;;401/27;;401/139;;401/263;;401/270;;15/119.2,0,0,,,,INACTIVE
175,US,A,US 3572272 A,039-264-538-320-714,1971-03-23,1971,US 3572272D A,1969-03-05,US 80459069 A,1969-03-05,MOORING SYSTEM USING CABLES AND BUCKLED RISER PIPE,,PAN AMERICAN PETROLEUM CORP,DIXON DAVID A;;BLENKARN KENNETH A,,https://lens.org/039-264-538-320-714,Granted Patent,no,0,14,1,1,0,B63B21/502;;B63B21/502;;E02B3/24;;E02B3/24;;E21B7/128;;E21B7/128;;E21B17/01;;E21B17/01,B63B21/50;;E02B3/24;;E21B7/128;;E21B17/01,B7V VFA           VFA,0,0,,,,EXPIRED
176,NO,B1,NO 329974 B1,175-149-596-510-767,2011-01-31,2011,NO 20003096 A,2000-06-15,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,"Sammensetning for topisk applikasjon av metylfenidat, og anvendelse av metylfenidat i fremstillingen av et fleksibelt, endelig system for behandling av ADHD og ADD.",,NOVEN PHARMA,MANTELLE JUAN A;;DIXON TERESE A,,https://lens.org/175-149-596-510-767,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K31/435;;A61K9/70;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
177,SE,B,SE 470251 B,012-962-637-299-381,1993-12-20,1993,SE 8900834 A,1989-03-09,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,Nya användningar av 4-(3-fosfono-2-propenyl)-2- piperazinkarboxylsyra,,SANDOZ AG,DIXON A K;;GRAY J A,,https://lens.org/012-962-637-299-381,Unknown,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
178,GB,B,GB 2373205 B,073-341-238-477-276,2004-11-03,2004,GB 0205553 A,2002-03-08,US 80542601 A,2001-03-13,Method for treating ceramic cores,,HOWMET RES CORP,DIXON BOBBY A;;HOLT JENNIFER A,,https://lens.org/073-341-238-477-276,Granted Patent,no,5,0,11,11,0,B22C9/12;;B22C9/12,B22C9/04;;B22C9/10;;B22C9/12;;F02C7/00;;B22C9/16,B3G G8V2          G8V2;;F4B BHA           BHA;;F4B B102          BHA;;F4B B104          BHA;;F4B B106          BHA;;U1S S2036,0,0,,,,EXPIRED
179,US,B2,US 6808010 B2,046-722-068-327-629,2004-10-26,2004,US 80542601 A,2001-03-13,US 80542601 A,2001-03-13,Method for treating ceramic cores,"
    A method for treating an unfired, molded ceramic core comprises placing an unfired (green) ceramic core having a thermosetting and/or thermoplastic binder on at least one setter, placing the setter and the green ceramic core thereon on a conveyor, conveying the setter and the green core through the heating oven to heat the setter and the green ceramic core to an elevated superambient temperature at or above a softening temperature of the binder present in the green core. Heating of the green ceramic core in this manner conforms the core to a surface of the setter to reduce distortion of the core and improve yields of cores that are within preselected dimensional tolerances. 
",HOWMET RES CORP,DIXON BOBBY A;;HOLT JENNIFER A,HOWMET CORPORATION (2001-06-13);;ARCONIC INC (2016-10-31),https://lens.org/046-722-068-327-629,Granted Patent,yes,22,9,11,11,0,B22C9/12;;B22C9/12,B22C9/04;;F02C7/00;;B22C9/10;;B22C9/12;;B22C9/16,164/520;;164/518;;164/369,0,0,,,,EXPIRED
180,GB,A,GB 2373205 A,056-458-587-370-584,2002-09-18,2002,GB 0205553 A,2002-03-08,US 80542601 A,2001-03-13,Reducing the distortion of unfired ceramic cores,"An unfired green ceramic core 10 having a thermosetting and/or thermoplastic binder is placed on at least one setter 42. The setter 42 and core 10 are then placed on a conveyor 50, conveyed through an oven 52 where the core 10 is heated to above the softening temperature of the binder and then the setter 42 and core 10 allowed to cool to ambient. Distortion of the core 10 is thereby reduced by conforming the surface of the core 10 to that of the setter 42. The core 10 is preferably placed between a top setter 40 and a bottom setter 42. The core can be used in the manufacture of turbine blades.",HOWMET RES CORP,DIXON BOBBY A;;HOLT JENNIFER A,,https://lens.org/056-458-587-370-584,Patent Application,no,5,0,11,11,0,B22C9/12;;B22C9/12,B22C9/04;;B22C9/10;;F02C7/00;;B22C9/12;;B22C9/16,B3G G8V2          G8V2;;F4B BHA           BHA;;F4B B102          BHA;;F4B B104          BHA;;F4B B106          BHA;;U1S S2036,0,0,,,,EXPIRED
181,DE,B4,DE 10211039 B4,006-251-028-523-968,2015-09-24,2015,DE 10211039 A,2002-03-13,US 80542601 A,2001-03-13,Verfahren zum Behandeln eines keramischen Kerns,"Verfahren zum Behandeln eines keramischen Kerns (10) nach dem Gießen und vor dem Brennen zur Verwendung beim Gießen geschmolzenen metallischen Materials, bei dem ein eine gegossene Kernform aufweisender und mit einem organischen Bindemittel versehener ungebrannter keramischer Kern (10) auf mindestens einem Setzglied (40, 42) angeordnet wird, das mindestens eine Setzglied (40, 42) mit dem darauf befindlichen grünen keramischen Kern (10) auf einem Förderer (50) angeordnet wird und dann das mindestens eine Setzglied (40, 42) und der grüne keramische Kern (10) mit dem Förderer (50) durch einen Ofen (52) gefördert werden, um das mindestens eine Setzglied (40, 42) und den grünen keramischen Kern (10) auf eine Temperatur zu erwärmen, die bei oder oberhalb einer Erweichungstemperatur des im grünen keramischen Kern (10) enthaltenen organischen Bindemittels liegt, um Verformungen des grünen keramischen Kerns (10) zu verringern, wobei es das Bindemittel zulässt, dass der grüne keramische Kern (10) nachgiebig wird und innere Spannungen abbaut und sich an eine Oberfläche des mindestens einen Setzglieds (40, 42) anpasst, nachdem er auf die besagte Temperatur erwärmt wurde, während das mindestens eine Setzglied (40, 42) und der ungebrannte keramische Kern (10) nach Verlassen des Ofens (52) vom Förderer (50) entfernt werden, so dass das mindestens eine Setzglied (40, 42) und der grüne keramische Kern (10) auf Umgebungstemperatur abkühlen können.",HOWMET CORP,DIXON BOBBY A;;HOLT JENNIFER A,"HOWMET CORPORATION, INDEPENDENCE, US (2011-09-12);;HOWMET CORPORATION, US (2011-09-12)",https://lens.org/006-251-028-523-968,Granted Patent,no,2,0,11,11,0,B22C9/12;;B22C9/12,C04B35/64;;B22C9/04;;F02C7/00;;B22C9/10;;B22C9/12;;B22C9/16,,0,0,,,,EXPIRED
182,US,A1,US 2002/0129925 A1,087-177-287-691-54X,2002-09-19,2002,US 80542601 A,2001-03-13,US 80542601 A,2001-03-13,Method for treating ceramic cores,"
   A method for treating an unfired, molded ceramic core comprises placing an unfired (green) ceramic core having a thermosetting and/or thermoplastic binder on at least one setter, placing the setter and the green ceramic core thereon on a conveyor, conveying the setter and the green core through the heating oven to heat the setter and the green ceramic core to an elevated superambient temperature at or above a softening temperature of the binder present in the green core. Heating of the green ceramic core in this manner conforms the core to a surface of the setter to reduce distortion of the core and improve yields of cores that are within preselected dimensional tolerances. 
",DIXON BOBBY A.;;HOLT JENNIFER A.,DIXON BOBBY A;;HOLT JENNIFER A,HOWMET CORPORATION (2001-06-13);;ARCONIC INC (2016-10-31),https://lens.org/087-177-287-691-54X,Patent Application,yes,0,7,11,11,0,B22C9/12;;B22C9/12,B22C9/04;;B22C9/10;;F02C7/00;;B22C9/12;;B22C9/16,164/525;;164/369,0,0,,,,EXPIRED
183,FR,B1,FR 2628322 B1,074-256-299-060-028,1994-09-09,1994,FR 8903014 A,1989-03-05,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,NOUVELLES UTILISATIONS THERAPEUTIQUES DE L'ACIDE 4-(3-PHOSPHONO-2-PROPENYL)-PIPERAZINE-2-CARBOXYLIQUE,,SANDOZ SA,KEITH DIXON ARNOLD;;GRAY JULIAN A;;DIXON ARNOLD KEITH,,https://lens.org/074-256-299-060-028,Granted Patent,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
184,ZA,B,ZA 891858 B,064-339-797-410-036,1990-11-28,1990,ZA 891858 A,1989-03-10,GB 8805875 A,1988-03-11,NEW USES OF 4-(3-PHOSPHONO-2-PROPENYL)-2-PIPERAZINECARBOXYLIC ACID,,SANDOZ LTD,DIXON ARNOLD KEITH;;ARNOLD KEITH DIXON;;GRAY JULIAN A;;JULIAN A GRAY,,https://lens.org/064-339-797-410-036,Granted Patent,no,0,0,3,32,0,,A61K/;;A61K31/675,,0,0,,,,EXPIRED
185,CA,A,CA 135897 A,035-610-459-426-020,1911-10-03,1911,CA 135897D A,1911-01-24,CA 135897T A,1911-01-24,SAW SETTING MACHINE,,HENSCHELL FERDINAND;;DIXON A HERBERT,HENSCHELL FERDINAND;;DIXON A HERBERT,,https://lens.org/035-610-459-426-020,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
186,WO,A2,WO 2001/073090 A2,047-822-295-673-665,2001-10-04,2001,US 0109398 W,2001-03-23,US 19208600 P,2000-03-24,METHOD FOR MODIFYING LIGNIN COMPOSITION AND INCREASING IN VIVO DIGESTIBILITY OF FORAGES,"Methods for transforming forage legumes or woody plants with a DNA construct comprising at least one open reading frame encoding for a caffeoyl CoA 3-O-methyltransferase enzyme or a Medicago sativa caffeic acid 3-O-methyltransferase enzyme or a fragment thereof in either a sense or antisense orientation under a lignification-associated tissue specific promoter have been found, resulting in the down-regulation of the corresponding homologous gene either through antisense inhibition or sense suppression, as well as reduced lignin content and modified lignin composition in the transgenic plants. The expression of the caffeoyl CoA 3-O-methyltransferase transgene produces an increased syringyl lignin to guaiacyl lignin ratio in the transformed plant, and greatly improved forage digestibility.",SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;GUO DIANJING,DIXON RICHARD A;;GUO DIANJING,,https://lens.org/047-822-295-673-665,Patent Application,yes,0,38,9,9,4,C12N9/1007;;C12N15/8255,C12N9/10;;C12N15/82,,0,0,,,,PATENTED
187,HU,B1,HU 226615 B1,107-062-184-745-537,2009-04-28,2009,HU P0004539 A,1998-12-14,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,COMPOSITION AND METHOD FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,,NOVEN PHARMACEUTICALS,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/107-062-184-745-537,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61F13/02;;A61K31/445;;A61K9/70;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26;;A61P25/28,,0,0,,,,EXPIRED
188,US,B2,US 10420690 B2,122-139-633-904-537,2019-09-24,2019,US 201313941161 A,2013-07-12,US 201313941161 A;;US 201261671048 P;;US 201361801492 P;;US 201361798207 P,2012-07-12,Monitoring systems devices and methods for patient lifts,A monitoring system comprises a lift assembly configured to lift a patient; a control system configured to control operation of the lift system; and a reporting system in communication with the control system and configured to receive operational information for the lift assembly. The reporting system compares the operational information to a predetermined set of values to determine if the operation of the lift is in compliance with the protocols.,LIKO RES & DEV AB,DIXON STEVEN A;;RIBBLE DAVID,LIKO RESEARCH & DEVELOPMENT AB (2013-07-23),https://lens.org/122-139-633-904-537,Granted Patent,yes,23,7,6,6,0,A61G7/018;;A61G7/1017;;A61G7/1042;;A61G7/1051;;A61G7/1061;;A61G7/1065;;A61G2203/12;;A61G2203/20;;A61G2203/44;;A61G2203/72;;A61B5/11;;A61B2562/0257;;G16H40/63;;A61G7/1015;;G16H40/63;;A61B5/11;;A61B2562/0257;;A61G7/018;;A61G7/1017;;A61G7/1042;;A61G7/1051;;A61G7/1061;;A61G7/1065;;A61G2203/12;;A61G2203/20;;A61G2203/44;;A61G2203/72;;A61G7/1073;;A61G7/108,A61G7/10;;A61B5/11;;A61G7/018;;G16H40/63,,6,0,,,"Letter dated Sep. 15, 2014 From Ari M. Bai with Polsinelli; One East Street, Suite 1200; Phoenix , AZ 85004-2568 RE: U.S. Appl. No. 13/941,161 Monitoring Systems Devices and Methods for Patient Lift. Refers to U.S. Pat. No. 8,538,710 and US Publication No. 2014/0013503.;;Claim Chart for U.S. Patent Application Publication No. 2014/0013503 ('503 Application), Dixon et al. Monitoring Systems Devices and Methods for Patient Lifts and U.S. Pat. No. 8,538,710 (the '710 Patent) Todd et al. Methods and Systems for Monitoring Lift Usage.;;Unirope LTD; RFID Tags; [retrieved online on Jul. 11, 2013], http://www.unirope.com/chainmeshslings/rfid_tags_shtml. pp. 1-2.;;LiftAll; RFID Tagging; [online], www.lift-all.com; (Nov. 2009). p. 1.;;Extended European Search Report & Written Opinion dated Feb. 27, 2015 relating to EP Patent Application No. 13176406.0. pp. 1-12.;;Non-Final Office Action dated Sep. 10, 2015 relating to U.S. Appl. No. 13/941,179, filed Jul. 12, 2013. pp. 1-9.",ACTIVE
189,TW,B,TW I242452 B,129-857-777-817-433,2005-11-01,2005,TW 87120741 A,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,A composition for topical application of methylphenidate and a pharmaceutical composition for treating attention deficit disorder and attention deficit/hyperactivity disorder,"The invention relates to a method of treating attention deficit disorder (ADD) and attention deficit/hyperactivity disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",NOVEN PHARMA,MANTELL JUAN;;DIXON TERESE A,,https://lens.org/129-857-777-817-433,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
190,TW,A,TW 200406231 A,184-372-554-537-628,2004-05-01,2004,TW 92128573 A,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,A composition for topical application of methylphenidate and a pharmaceutical composition for treating attention deficit disorder and attention deficit/hyperactivity disorder,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system, wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/184-372-554-537-628,Patent of Addition,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K9/70;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
191,US,A1,US 2008/0107736 A1,000-281-923-096-332,2008-05-08,2008,US 55599506 A,2006-11-02,US 55599506 A,2006-11-02,Pharmaceutically Active Nanosuspensions,"The present disclosure is directed at a pharmaceutically active nanoparticle suspension that may be optically clear. Such suspensions may be formed by selective dissolution of a pharmaceutically active compound in a first solvent followed by introduction into a second solvent, such as an aqueous medium, without substantial use of surfactants and/or mechanical shear.",MCDONOUGH JOSEPH A;;DIXON HONG,MCDONOUGH JOSEPH A;;DIXON HONG,SOUTHWEST RESEARCH INSTITUTE (2006-11-27),https://lens.org/000-281-923-096-332,Patent Application,yes,60,2,2,2,0,A61K31/57;;A61K31/57;;A61K9/14;;A61K9/14,A61K9/14;;A61K31/57;;C07J5/00,424/489;;977/915;;514/179;;552/566,2,2,035-230-547-171-641;;041-352-630-698-05X,10.1021/cr950066q;;11848856;;10.1007/bf00619738,"Patani et al. (Chem. Rev., Vol. 96, No. 8, pages 3147-3176; 1996).;;Giuliani et al. (Optical and Quantum Electronics, Vol. 9, pages 263-264; 1977).",ACTIVE
192,NZ,A,NZ 570395 A,009-979-055-177-352,2010-10-29,2010,NZ 57039507 A,2007-02-08,US 77235406 P;;US 2007/0061865 W,2006-02-09,Methods and compositions for modifying plant biosynthetic pathways,"Disclosed is a DNA construct comprising a promoter functional in a plant operably linked to a nucleic acid sequence encoding a fusion polypeptide comprising a first enzyme and a second enzyme, wherein the first enzyme is a membrane-bound enzyme and the second enzyme is a soluble enzyme, wherein a product of the first enzyme is a substrate of the second enzyme or wherein a product of the second enzyme is a substrate of the first enzyme, and wherein the fusion polypeptide comprises the enzymatic activity of the first and second enzymes, and wherein the first enzyme and second enzymes are isoflavone synthase and chalcone isomerase. The construct can be used to produce isoflavones in plants.",SAMUEL ROBERTS NOBLE FOUND INC,TIAN LI;;DIXON RICHARD A,,https://lens.org/009-979-055-177-352,Patent Application,no,0,0,10,10,0,C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,C12N15/82;;A01H5/00;;C07K19/00;;C12N15/62,,0,0,,,,PENDING
193,PT,E,PT 1037615 E,056-762-415-516-512,2004-07-30,2004,PT 98963170 T,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,COMPOSICOES E METODOS PARA O TRATAMENTO DA DESORDEM DE DEFICIENCIA DE ATENCAO E DESORDEM DE DEFICIENCIA DE ATENCAO/HIPERACTIVIDADE COM METILFENIDATO,,NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/056-762-415-516-512,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
194,US,A1,US 2017/0095783 A1,078-594-478-682-225,2017-04-06,2017,US 201615282042 A,2016-09-30,US 201615282042 A;;US 201562235763 P,2015-10-01,PULSED GAS MIXING APPARATUS,"A pulsed gas mixing apparatus is provided. The pulsed gas mixing apparatus may include a mixing plate having a top side that is substantially smooth, and a bottom side that includes a plurality of ribs. The pulsed gas mixing apparatus may also include a supply tube configured to be coupled to the mixing plate and supply a mixing gas that is used to mix the contents a container in which the pulsed gas mixing apparatus is installed.",MICRO MATIC USA LLC,TOMLINSON MICHAEL A;;DIXON DAVID,MICRO MATIC USA LLC (2016-09-28);;MICRO MATIC USA INC (2017-12-07),https://lens.org/078-594-478-682-225,Patent Application,yes,7,2,2,2,0,B01F23/023;;B01F33/405;;B01F33/409;;B01F33/409;;B01F33/405;;B01F23/023,B01F33/40;;B01F23/00,,0,0,,,,ACTIVE
195,US,B2,US 9040080 B2,084-751-567-496-671,2015-05-26,2015,US 25544708 A,2008-10-21,US 25544708 A,2008-10-21,Processing of heat-sensitive active agents,"The present disclosure relates to a method of melt processing an active agent. The method may include encapsulating an active agent in a first polymer material exhibiting a first processing temperature T 1 and forming capsules including the active agent. The method may also include melt processing the capsules with a second polymer material exhibiting a second processing temperature T 2 , wherein T 1 >T 2 .",DIXON HONG;;MCDONOUGH JOSEPH A;;SOUTHWEST RES INST,DIXON HONG;;MCDONOUGH JOSEPH A,SOUTHWEST RESEARCH INSTITUTE (2008-11-04),https://lens.org/084-751-567-496-671,Granted Patent,yes,7,1,2,2,0,A61J3/07;;A61J3/07;;A61K9/1647;;A61K9/1647;;A61K9/70;;A61K9/70,A61J3/07;;A61K9/16;;A61K9/48;;A61K9/50;;A61K9/70,424/451;;424/490;;424/497;;424/425;;427/213.34;;427/213.31;;427/213.36,0,0,,,,ACTIVE
196,US,A1,US 2020/0181632 A1,106-081-658-844-295,2020-06-11,2020,US 201816476895 A,2018-01-17,US 201816476895 A;;US 201762447701 P;;US 2018/0013983 W,2017-01-18,METHODS FOR ENGINEERING PROANTHOCYANIDINS (PAS) IN PLANTS BY AFFECTING MYB TRANSCRIPTION FACTORS,"The amount of proanthocyanidins (PAs) found in cells of plants can be engineered or adjusted through regulation of transcription factors that affect PA biosynthesis. Increasing expression of genes encoding TT2-type MYB transcription factors, including homologs of AtTT2 of Arabidopsis thaliana such as GHMYB36 or GHMYB IO of cotton plants or GmTT2A or GmTT2B of soybean plants, leads to increased PA content. Expression of these genes can be increased through any suitable methods, including mutation of the genes and transformation of plant cells to include exogenous genes resulting in increased expression.",UNIV NORTH TEXAS,DIXON RICHARD A;;LU NAN,UNIVERSITY OF NORTH TEXAS (2019-09-04),https://lens.org/106-081-658-844-295,Patent Application,yes,0,1,2,2,32,C07K14/415;;C12N15/8243;;C12N15/8243,C12N15/82,,0,0,,,,DISCONTINUED
197,US,A1,US 2010/0098754 A1,008-876-035-913-22X,2010-04-22,2010,US 25544708 A,2008-10-21,US 25544708 A,2008-10-21,PROCESSING OF HEAT-SENSITIVE ACTIVE AGENTS,"The present disclosure relates to a method of melt processing an active agent. The method may include encapsulating an active agent in a first polymer material exhibiting a first processing temperature T 1 and forming capsules including the active agent. The method may also include melt processing the capsules with a second polymer material exhibiting a second processing temperature T 2 , wherein T 1 >T 2 .",SOUTHWEST RES INST,DIXON HONG;;MCDONOUGH JOSEPH A,SOUTHWEST RESEARCH INSTITUTE (2008-11-04),https://lens.org/008-876-035-913-22X,Patent Application,yes,7,1,2,2,0,A61J3/07;;A61J3/07;;A61K9/1647;;A61K9/1647;;A61K9/70;;A61K9/70,A61J3/07;;A61K9/48,424/451;;264/4,0,0,,,,ACTIVE
198,CZ,A3,CZ 2009132 A3,008-427-422-961-877,2016-03-23,2016,CZ 2009132 A,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,Mixtures and methods for treating light brain dysfunction and disorders related to deficit of attention and hyperactivity by employing methylphenidate,"Řešení se týká kompozice pro topickou aplikaci methylfenidátu a použití této kompozice pro výrobu léčiva pro léčení lehké mozkové dysfunkce (ADD) a poruch lehké mozkové dysfunkce a hyperaktivity (ADHD). Kompozice pro topickou aplikaci methylfenidátu obsahující methylfenidát ve flexibilním uzavřeném systému, přičemž methylfenidát je přítomen v účinném aplikovaném od 3,96 až 10,56 mg methylfenidátu na 10 cm.sup.2.n.ve flexibilním uzavřeném systému, během prvních 10 hodin v jednom provedení a další provedení je kompozice s účinným aplikovaným množstvím od 23,76 do 63,36 mg methylfenidátu.",NOVEN PHARMACEUTICALS,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/008-427-422-961-877,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K31/435;;A61K9/70;;A61K31/445;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
199,WO,A3,WO 2020/251698 A3,060-430-757-090-965,2021-01-21,2021,US 2020/0030799 W,2020-04-30,US 201962841361 P;;US 202016814988 A,2019-05-01,COMPOSITIONS OF DIMETHYL TRISULFIDE (DMTS) AS A CYANIDE ANTIDOTE,The present disclosure is directed at compositions of dimethyl trisulfide (DMTS) suitable for use for treatment of cyanide intoxication. The compositions show particularly useful stability such that the DMTS remains stable for therapeutic use at the identified time periods. The compositions are therefore particularly suitable for use in autoinjectors.,SOUTHWEST RES INST,DIXON HONG;;MCDONOUGH JOSEPH A,,https://lens.org/060-430-757-090-965,Search Report,yes,4,0,9,9,0,A61K31/10;;A61K9/08;;A61K9/0019;;A61K9/1075;;A61K47/10;;A61M5/3157;;A61M5/30;;A61K31/10;;A61M5/20;;A61K9/1075;;A61K9/0019,A61K31/10;;A61K47/02;;A61P25/30;;A61P39/02,,0,0,,,,PENDING
200,WO,A2,WO 2007/092934 A2,092-813-602-705-792,2007-08-16,2007,US 2007/0061865 W,2007-02-08,US 77235406 P,2006-02-09,METHODS AND COMPOSITIONS FOR MODIFYING PLANT BIOSYNTHETIC PATHWAYS,"The invention provides bifunctional plant biosynthetic enzymes that increase the efficiency by which modification can be made to plant biosynthetic pathways. In certain aspects of the invention, bifunctional isoflavone biosynthetic enzymes are provided. The invention therefore allows the modification of plants for isoflavone content. The inventors have demonstrated increased isoflavone biosynthesis can be obtained even in non-legume plants.",SAMUEL ROBERTS NOBLE FOUND INC;;TIAN LI;;DIXON RICHARD A,TIAN LI;;DIXON RICHARD A,,https://lens.org/092-813-602-705-792,Patent Application,yes,0,0,10,10,38,C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,C12N15/82,,0,0,,,,PENDING
201,WO,A1,WO 1994/023044 A1,086-505-001-330-006,1994-10-13,1994,US 9403356 W,1994-03-31,US 4526393 A,1993-04-02,METHOD FOR REDUCING LIGNING CONTENT IN PLANTS,"The present invention relates to a method and reagent for reducing the lignin content in plants. Specifically, the invention entails the incorporation of an antisense gene for caffeic acid 3-O-methyltransferase into the genome of plants.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;NI WEITING,,https://lens.org/086-505-001-330-006,Patent Application,yes,2,32,2,2,2,C12N15/8255;;C12N9/10,C12N9/10;;C12N15/82,,4,1,079-288-032-108-078,10.1104/pp.97.1.7;;16668418;;pmc1080956,"NI, W., ET AL.: ""Modification of lignin biosynthesis by genetic manipulation of caffeic acid O-methyltransferase"", J. CELL. BIOCHEM. SUPPL., KEYSTONE SYMPOSIUM ON CROP IMPROVEMENT VIA BIOTECHNOLOGY : AN INTERNATIONAL PERSPECTIVE, HELD APRIL 10-16, 1992., vol. 16F, 1992, pages 219;;BIOLOGICAL ABSTRACTS /RRM ABSTRACT NO. BR46:67408 see abstract;;GOWRI, G., ET AL.: ""Stress responses in alfalfa (Medicago sativa L.) . X. Molecualr cloning and expression of S-adenosyl-L-methionine:caffeic acid 3-O-methyltransferase, a key enzyme of lignin biosynthesis"", PLANT PHYSIOLOGY, vol. 97, 1991, pages 7 - 14;;PODILA, G.K., ET AL.: ""Antisense expression of an aspen O-methyltransferase construct in transgenic tobacco via Agrobacterium"", PLANT PHYSIOLOGY SUPPLEMENT, vol. 99, no. 1, May 1992 (1992-05-01), pages 19",PENDING
202,SI,A,SI 20360 A,185-247-877-479-550,2001-04-30,2001,SI 9820083 A,1998-12-14,US 9826560 W;;US 6951097 P;;US 16335198 A,1997-12-15,COMPOSITIONS AND METHODS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/185-247-877-479-550,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K31/435;;A61K9/06;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
203,CA,C,CA 2315237 C,196-050-010-657-30X,2009-12-01,2009,CA 2315237 A,1998-12-14,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,COMPOSITIONS AND METHODS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",NOVEN PHARMA,DIXON TERESE A;;MANTELLE JUAN,,https://lens.org/196-050-010-657-30X,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K31/4458;;A61K9/70;;A61K31/435;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
204,US,A1,US 2004/0049802 A1,066-667-378-336-439,2004-03-11,2004,US 23946302 A,2002-09-23,US 23946302 A;;US 0109398 W,2001-03-23,Method for modifying lignin composition and increasing in vivo digestibility of forages,"
    Methods for transforming forage legumes or woody plants with a DNA construct comprising at least one open reading frame encoding for a caffeoyl CoA 3-O-methyltransferase enzyme or a Medicago sativa caffeic acid 3-O-methyltransferase enzyme or a fragment thereof in either a sense or antisense orientation under a lignification-associated tissue specific promoter have been found, resulting in the down-regulation of the corresponding homologous gene either through antisense inhibition or sense suppression, as well as reduced lignin content and modified lignin composition in the transgenic plants. The expression of the caffeoyl CoA 3-O-methyltransferase transgene produces an increased syringyl lignin to guaiacyl lignin ratio in the transformed plant, and greatly improved forage digestibility. 
",DIXON RICHARD A.;;GUO DIANJING,DIXON RICHARD A;;GUO DIANJING,SAMUEL ROBERTS NOBLE FOUNDATION INC (2003-02-10),https://lens.org/066-667-378-336-439,Patent Application,yes,3,29,3,3,4,C12N9/1007;;C12N15/8255;;C12N9/1007;;C12N15/8255,C12N9/10;;C12N15/82,800/278;;800/313;;435/468;;435/193;;435/320.1,0,0,,,,DISCONTINUED
205,US,A1,US 2010/0209830 A1,082-246-966-831-529,2010-08-19,2010,US 37119309 A,2009-02-13,US 37119309 A,2009-02-13,Multi-Pitch Scatterometry Targets,"The invention can provide a method of processing a substrate using multi-pitch scatterometry targets (M-PSTs) for de-convolving lithographic process parameters during Single-Patterning (S-P), Double-Patterning (D-P) procedures, and Double-Exposure (D-E) procedures.",TOKYO ELECTRON LTD,CARCASI MICHAEL A;;DIXON DAVID,TOKYO ELECTRON LIMITED (2009-02-09),https://lens.org/082-246-966-831-529,Patent Application,yes,26,18,2,2,0,G03F7/70625;;G03F7/70625;;G03F1/44;;G03F1/44;;G03F7/70641;;G03F7/70641,G03F7/20,430/30,0,0,,,,ACTIVE
206,PL,B1,PL 195315 B1,108-753-131-644-694,2007-08-31,2007,PL 34159698 A,1998-12-14,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,PHARMACOLOGICAL COMPOSITION FOR TREATING CONCENTRATION DISORDERS AND HYPERKINESIA,,NOVEN PHARMACEUTICALS,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/108-753-131-644-694,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K31/435;;A61K9/70;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
207,US,B2,US 10173186 B2,122-009-148-685-865,2019-01-08,2019,US 201615282042 A,2016-09-30,US 201615282042 A;;US 201562235763 P,2015-10-01,Pulsed gas mixing apparatus,"A pulsed gas mixing apparatus is provided. The pulsed gas mixing apparatus may include a mixing plate having a top side that is substantially smooth, and a bottom side that includes a plurality of ribs. The pulsed gas mixing apparatus may also include a supply tube configured to be coupled to the mixing plate and supply a mixing gas that is used to mix the contents a container in which the pulsed gas mixing apparatus is installed.",MICRO MATIC USA LLC,TOMLINSON MICHAEL A;;DIXON DAVID,MICRO MATIC USA LLC (2016-09-28);;MICRO MATIC USA INC (2017-12-07),https://lens.org/122-009-148-685-865,Granted Patent,yes,7,0,2,2,0,B01F23/023;;B01F33/405;;B01F33/409;;B01F33/409;;B01F33/405;;B01F23/023,B01F23/00;;B01F33/40,,0,0,,,,ACTIVE
208,US,A,US 5442835 A,189-119-103-247-691,1995-08-22,1995,US 26701094 A,1994-06-15,US 26701094 A,1994-06-15,Screens for a carding machine,"A card screen and a lickerin screen are provided for a forty inch carding machine having the usual side ribs and end blanks. The grid bars in both the card screen and the lickerin screen are of triangular configuration in cross-section and are structured to provide increased air flow for the removal of trash. One side of each grid bar extends downwardly in use at an angle of about 50.degree. to the radii of the main cylinder, or lickerin roll, another side extends radially from the main cylinder, and the third side extends between the first two sides in closely spaced substantially parallel relation to the main screen. There is no center rib and the grid bars extend the entire distance between the side ribs.",JENKINS METAL CORP,WALKER FLETCHER;;DIXON THOMAS A,JENKINS METAL CORPORATION (1994-05-16),https://lens.org/189-119-103-247-691,Granted Patent,yes,10,3,1,1,0,D01G15/34;;D01G15/34,D01G15/34,19/95;;19/107,1,0,,,"Jenkins Metal Corp., the Even Flow Screen , Jan. 1, 1995.",EXPIRED
209,US,A1,US 2014/0045159 A1,000-113-799-079-662,2014-02-13,2014,US 201313964871 A,2013-08-12,US 201313964871 A;;US 201261682108 P,2012-08-10,Using Conditional Logic to Provide an Online Health Assessment,"The present invention extends to methods, systems, and computer program products for providing an online health assessment. The online health assessment collects information from an individual and applies conditional logic to the collected information to identify information to be included in a lifestyle, nutrition, and/or product plan for the individual.",USANA HEALTH SCIENCES INC,WENTZ DAVID A;;DIXON BRIAN,USANA HEALTH SCIENCES INC (2013-10-15),https://lens.org/000-113-799-079-662,Patent Application,yes,2,0,1,1,0,G09B19/0092;;G16H20/60;;G09B19/00;;G09B19/00;;G09B19/0092;;G16H20/60,G09B19/00,434/247,0,0,,,,DISCONTINUED
210,US,A1,US 2020/0345658 A1,013-769-869-956-100,2020-11-05,2020,US 202016814988 A,2020-03-10,US 202016814988 A;;US 201962841361 P,2019-05-01,Compositions Of Dimethyl Trisulfide (DMTS) As A Cyanide Antidote,The present disclosure is directed at compositions of dimethyl trisulfide (DMTS) suitable for use for treatment of cyanide intoxication. The compositions show particularly useful stability such that the DMTS remains stable for therapeutic use at the identified time periods. The compositions are therefore particularly suitable for use in autoinjectors.,SOUTHWEST RES INST,DIXON HONG;;MCDONOUGH JOSEPH A,SOUTHWEST RESEARCH INSTITUTE (2019-05-03),https://lens.org/013-769-869-956-100,Patent Application,yes,2,0,9,9,0,A61K31/10;;A61K9/08;;A61K9/0019;;A61K9/1075;;A61K47/10;;A61M5/3157;;A61M5/30;;A61K31/10;;A61M5/20;;A61K9/1075;;A61K9/0019,A61K31/10;;A61K9/00;;A61K9/107;;A61M5/20,,2,1,012-925-236-739-646,30843331;;10.1111/bcpt.13220,"Rice, Basic Clin Pharmacol Toxicol. 2019; 125:289–303 (Year: 2019);;Prieto, Hindawi Publishing Corporation Journal of Applied Chemistry Volume 2013, Article ID 930356, 10 pages. (Year: 2013)",PENDING
211,LV,A,LV 12558 A,046-169-337-266-414,2000-11-20,2000,LV 000092 A,2000-07-17,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/046-169-337-266-414,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
212,AU,B2,AU 2001/247731 B2,117-601-975-058-533,2006-10-12,2006,AU 2001/247731 A,2001-03-23,US 19208600 P;;US 0109398 W,2000-03-24,Method for modifying lignin composition and increasing in vivo digestibility of forages,,THE SAMUEL ROBERTS NOBLE FOUNDATION INC,GUO DIANJING;;DIXON RICHARD A,,https://lens.org/117-601-975-058-533,Granted Patent,no,3,0,9,9,0,C12N9/1007;;C12N15/8255,C12N15/82;;C12N9/10,,1,1,030-421-171-545-835,10.1105/tpc.10.12.2033;;10.2307/3870782;;pmc143971;;9836743,"Zhong R et al., Plant Cell, 1998, 10, 2033-45",EXPIRED
213,AU,B2,AU 2007/213711 B2,149-326-975-964-322,2012-08-30,2012,AU 2007/213711 A,2007-02-08,US 77235406 P;;US 2007/0061865 W,2006-02-09,Methods and compositions for modifying plant biosynthetic pathways,"The invention provides bifunctional plant biosynthetic enzymes that increase the efficiency by which modification can be made to plant biosynthetic pathways. In certain aspects of the invention, bifunctional isoflavone biosynthetic enzymes are provided. The invention therefore allows the modification of plants for isoflavone content. The inventors have demonstrated increased isoflavone biosynthesis can be obtained even in non-legume plants.",THE SAMUEL ROBERTS NOBLE FOUNDATION INC,TIAN LI;;DIXON RICHARD A,,https://lens.org/149-326-975-964-322,Granted Patent,no,0,0,10,10,0,C12N15/8243;;C12N15/825;;C12N15/8243;;C12N15/825,C12N15/82;;A01H5/00;;C07K19/00;;C12N15/62,,1,1,030-560-996-409-192,pmc137925;;12384577;;10.1073/pnas.212522099,"LIU, C-J. et al., 2002, PNAS, vol. 99, no. 22, pages 14578-14583",ACTIVE
214,LV,B,LV 12558 B,124-980-109-771-558,2001-03-20,2001,LV 000092 A,2000-07-17,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,COMPOSITIONS AND METHODS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/124-980-109-771-558,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
215,AU,B2,AU 752027 B2,157-213-029-583-186,2002-09-05,2002,AU 1999/018249 A,1998-12-14,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate,,NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/157-213-029-583-186,Granted Patent,no,1,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K9/70;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
216,EP,A2,EP 1981980 A2,172-945-998-625-872,2008-10-22,2008,EP 07763394 A,2007-02-08,US 2007/0061865 W;;US 77235406 P,2006-02-09,METHODS AND COMPOSITIONS FOR MODIFYING PLANT BIOSYNTHETIC PATHWAYS,,SAMUEL ROBERTS NOBLE FOUND INC,TIAN LI;;DIXON RICHARD A,,https://lens.org/172-945-998-625-872,Patent Application,yes,0,0,10,10,0,C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,C12N15/82;;A01H5/00;;C07K19/00;;C12N15/62,,1,0,,,See references of WO 2007092934A3,DISCONTINUED
217,AU,A1,AU 2020/292167 A1,017-914-504-295-163,2021-11-11,2021,AU 2020/292167 A,2020-04-30,US 201962841361 P;;US 202016814988 A;;US 2020/0030799 W,2019-05-01,Compositions of dimethyl trisulfide (DMTS) as a cyanide antidote,The present disclosure is directed at compositions of dimethyl trisulfide (DMTS) suitable for use for treatment of cyanide intoxication. The compositions show particularly useful stability such that the DMTS remains stable for therapeutic use at the identified time periods. The compositions are therefore particularly suitable for use in autoinjectors.,SOUTHWEST RES INST,DIXON HONG;;MCDONOUGH JOSEPH A,,https://lens.org/017-914-504-295-163,Patent Application,no,0,0,9,9,0,A61K31/10;;A61K9/08;;A61K9/0019;;A61K9/1075;;A61K47/10;;A61M5/3157;;A61M5/30;;A61K31/10;;A61M5/20;;A61K9/1075;;A61K9/0019,A61K31/10;;A61K47/02;;A61P25/30;;A61P39/02,,0,0,,,,ACTIVE
218,EP,A2,EP 3962469 A2,035-456-810-317-620,2022-03-09,2022,EP 20822063 A,2020-04-30,US 201962841361 P;;US 202016814988 A;;US 2020/0030799 W,2019-05-01,COMPOSITIONS OF DIMETHYL TRISULFIDE (DMTS) AS A CYANIDE ANTIDOTE,,SOUTHWEST RES INST,DIXON HONG;;MCDONOUGH JOSEPH A,,https://lens.org/035-456-810-317-620,Patent Application,yes,0,0,9,9,0,A61K31/10;;A61K9/08;;A61K9/0019;;A61K9/1075;;A61K47/10;;A61M5/3157;;A61M5/30;;A61K31/10;;A61M5/20;;A61K9/1075;;A61K9/0019,A61K31/10;;A61K47/02;;A61P25/30;;A61P39/02,,0,0,,,,PENDING
219,US,B2,US 8024676 B2,056-501-216-941-692,2011-09-20,2011,US 37119309 A,2009-02-13,US 37119309 A,2009-02-13,Multi-pitch scatterometry targets,"The invention can provide a method of processing a substrate using multi-pitch scatterometry targets (M-PSTs) for de-convolving lithographic process parameters during Single-Patterning (S-P), Double-Patterning (D-P) procedures, and Double-Exposure (D-E) procedures used to control transistor structures. The M-PSTs) can have critical dimension (CD) and sidewall angle (SWA) sensitivity to exposure focus variations, exposure dose variations, and post exposure bake (PEB) temperature variations. In addition, the variation can be de-convolved so that the individual measurement process variable contributor can be identified.",TOKYO ELECTRON LTD,CARCASI MICHAEL A;;DIXON DAVID,TOKYO ELECTRON LIMITED (2009-02-09),https://lens.org/056-501-216-941-692,Granted Patent,yes,26,14,2,2,0,G03F7/70625;;G03F7/70625;;G03F1/44;;G03F1/44;;G03F7/70641;;G03F7/70641,G06F17/50;;G03F1/00;;G06F19/00;;G21K5/00;;H01L21/00,716/54;;716/52;;716/55;;430/5;;378/35;;438/7;;438/16;;700/108;;700/121,1,0,,,"Qian et al., ""Advanced Physical Models for Mask Data Verification and Impacts on Physical Layout Synthesis"", Fourth International Symposium on Quality Electronic Design, Mar. 24-26, 2003, pp. 125-130.",ACTIVE
220,US,S,US D0524941 S,108-848-001-308-651,2006-07-11,2006,US 19006103 F,2003-09-15,US 19006103 F,2003-09-15,Absorbable threaded bone cage implant,,DIXON ROBERT A;;HACKMAN DONALD,DIXON ROBERT A;;HACKMAN DONALD,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/108-848-001-308-651,Design Right,no,0,2,1,1,0,,,2403;;D24/155,0,0,,,,EXPIRED
221,WO,A1,WO 2018/035115 A1,188-609-196-061-890,2018-02-22,2018,US 2017/0046929 W,2017-08-15,US 201662375756 P,2016-08-16,METHODS FOR REGULATING EXTRACTABLE PROANTHOCYANIDINS (PAS) IN PLANTS BY AFFECTING LEUCOANTHOCYANIDIN REDUCTASE (LAR),"Adjustments to the amount of soluble and insoluble proanthocyanidins (PAs) in plants can be accomplished through regulation of leucoanthocyanidin reductase (LAR) functionality. Reducing LAR functionality increases epicatechin polymerization, leading to greater amounts of insoluble PAs and effects on astringency and other characteristics.",UNIV NORTH TEXAS,DIXON RICHARD A;;LIU CHENGGANG,,https://lens.org/188-609-196-061-890,Patent Application,yes,4,0,2,2,13,C12N15/8243;;C12N15/8243;;C12N15/8216;;C12N15/8218,C12N15/82,,21,21,048-681-233-820-623;;040-366-477-307-702;;062-535-164-352-222;;150-790-918-306-74X;;120-583-429-774-921;;088-170-610-345-220;;002-485-351-554-971;;006-783-899-030-648;;015-010-359-455-866;;087-655-643-690-134;;036-160-849-503-061;;002-302-213-407-020;;048-681-233-820-623;;027-306-014-726-278;;016-241-180-652-848;;059-413-667-379-466;;034-228-045-089-243;;106-011-301-189-837;;050-294-299-636-310;;077-780-956-171-896;;062-728-886-727-736,10.1074/jbc.m302783200;;12788945;;10.1021/jf401041q;;23889258;;10.1093/ajcn/81.1.330s;;15640499;;10.1016/s0300-483x(00)00210-9;;10962138;;10.2174/0929867043365288;;15134524;;11121513;;10.1007/978-1-4615-3476-1_55;;1417702;;10.1046/j.1365-313x.1999.00529.x;;10504561;;10.1126/science.1078540;;12532018;;10.1104/pp.105.064238;;pmc1255985;;16169968;;pmc4233638;;10.1186/1471-2229-13-202;;24308601;;10.1104/pp.107.107326;;17885080;;pmc2048810;;10.1074/jbc.m302783200;;12788945;;10.1111/j.1365-313x.2008.03418.x;;18208518;;10.1021/jo00136a021;;10.1016/j.jmb.2010.02.002;;20138891;;24948832;;10.1104/pp.114.241877;;pmc4119029;;10.1016/s0968-0896(02)00127-x;;12057639;;10.1016/j.phytochem.2004.12.003;;16153406;;10.1038/srep08742;;25735226;;pmc4348662;;25914714;;pmc4392590;;10.3389/fpls.2015.00243,"TANNER GJ; FRANCKI KT; ABRAHAMS S; WATSON JM; LARKIN PJ; ASHTON AR: ""Proanthocyanidin biosynthesis in plants. Purification of legume leucoanthocyanidin reductase and molecular cloning of its cDNA"", J BIOL CHEM, vol. 278, 2003, pages 31647 - 31656, XP055182725, DOI: doi:10.1074/jbc.M302783200;;GONZALO-DIAGO, A.; DIZY, M.; FERNANDEZ-ZURBANO, P.: ""Taste and Mouthfeel Properties of Red Wines Proanthocyanidins and Their Relation to the Chemical Composition"", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 61, 2013, pages 8861 - 8870;;LESSCHAEVE, I; NOBLE, A. C.: ""Polyphenols: factors influencing their sensory properties and their effects on food and beverage preferences"", THE AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 81, 2005, pages 330s - 335s;;BAGCHI, D. ET AL.: ""Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention"", TOXICOLOGY, vol. 148, 2000, pages 187 - 197, XP001080447, DOI: doi:10.1016/S0300-483X(00)00210-9;;COS, P. ET AL.: ""Proanthocyanidins in health care: current and new trends"", CURRENT MEDICINAL CHEMISTRY, vol. 11, 2004, pages 1345 - 1359, XP008146778, DOI: doi:10.2174/0929867043365288;;MIDDLETON, E., JR.; KANDASWAMI, C.; THEOHARIDES, T. C.: ""The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer"", PHARMACOLOGICAL REVIEWS, vol. 52, 2000, pages 673 - 751, XP008047405;;LEES, G. L.: ""Condensed tannins in some forage legumes: their role in the prevention of ruminant pasture bloat"", BASIC LIFE SCIENCES, vol. 59, 1992, pages 915 - 934;;DEVIC, M. ET AL.: ""The BANYULS gene encodes a DFR-like protein and is a marker of early seed coat development"", THE PLANT JOURNAL : FOR CELL AND MOLECULAR BIOLOGY, vol. 19, 1999, pages 387 - 398, XP002982937, DOI: doi:10.1046/j.1365-313X.1999.00529.x;;XIE, D. Y.; SHARMA, S. B.; PAIVA, N. L.; FERREIRA, D.; DIXON, R. A: ""Role of anthocyanidin reductase, encoded by BANYULS in plant flavonoid biosynthesis"", SCIENCE, vol. 299, 2003, pages 396 - 399, XP002982939, DOI: doi:10.1126/science.1078540;;BOGS, J. ET AL.: ""Proanthocyanidin synthesis and expression of genes encoding leucoanthocyanidin reductase and anthocyanidin reductase in developing grape berries and grapevine leaves"", PLANT PHYSIOLOGY, vol. 139, 2005, pages 652 - 663;;LIU, Y.; SHI, Z.; MAXIMOVA, S.; PAYNE, M. J.; GUILTINAN, M. J.: ""Proanthocyanidin synthesis in Theobroma cacao: genes encoding anthocyanidin synthase, anthocyanidin reductase, and leucoanthocyanidin reductase"", BMC PLANT BIOLOGY, vol. 13, 2013, pages 202, XP021170728, DOI: doi:10.1186/1471-2229-13-202;;PANG, Y.; PEEL, G. J.; WRIGHT, E.; WANG, Z.; DIXON, R. A.: ""Early steps in proanthocyanidin biosynthesis in the model legume Medicago truncatula"", PLANT PHYSIOLOGY, vol. 145, 2007, pages 601 - 615;;TANNER, G. J. ET AL.: ""Proanthocyanidin biosynthesis in plants. Purification of legume leucoanthocyanidin reductase and molecular cloning of its cDNA"", J BIOL CHEM, vol. 278, 2003, pages 31647 - 31656, XP055182725, DOI: doi:10.1074/jbc.M302783200;;TADEGE, M. ET AL.: ""Large-scale insertional mutagenesis using the Tntl retrotransposon in the model legume Medicago truncatula"", THE PLANT JOURNAL, vol. 54, 2008, pages 335 - 347;;KIATGRAJAI, P.; WELLONS, J. D.; GOLLOB, L.; WHITE, J. D.: ""Kinetics of epimerization of (+)-catechin and its rearrangement to catechinic acid"", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 47, 1982, pages 2910 - 2912;;MAUGE, C. ET AL.: ""Crystal structure and catalytic mechanism of leucoanthocyanidin reductase from Vitis vinifera"", JOURNAL OF MOLECULAR BIOLOGY, vol. 397, 2010, pages 1079 - 1091, XP026982529, DOI: doi:10.1016/j.jmb.2010.02.002;;LIU, C.; JUN, J. H.; DIXON, R. A.: ""MYB5 and MYB14 Play Pivotal Roles in Seed Coat Polymer Biosynthesis in Medicago truncatula"", PLANT PHYSIOLOGY, vol. 165, 2014, pages 1424 - 1439;;TORRES, J. L. ET AL.: ""Cysteinyl-flavan-3-ol Conjugates from Grape Procyanidins. Antioxidant and Antiproliferative Properties"", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 10, 2002, pages 2497 - 2509, XP002980981, DOI: doi:10.1016/S0968-0896(02)00127-X;;TORRES, J. L.; LOZANO, C.; MAHER, P.: ""Conjugation of catechins with cysteine generates antioxidant compounds with enhanced neuroprotective activity"", PHYTOCHEMISTRY, vol. 66, 2005, pages 2032 - 2037, XP005076920, DOI: doi:10.1016/j.phytochem.2004.12.003;;JIANG, X. ET AL.: ""Analysis of accumulation patterns and preliminary study on the condensation mechanism of proanthocyanidins in the tea plant [Camellia sinensis"", SCIENTIFIC REPORTS, vol. 5, 2015, pages 8742;;LIAO, L. ET AL.: ""Molecular characterization of genes encoding leucoanthocyanidin reductase involved in proanthocyanidin biosynthesis in apple"", FRONTIERS IN PLANT SCIENCE, vol. 6, 2015, pages 243",PENDING
222,JP,A,JP 2013056944 A,198-692-434-596-042,2013-03-28,2013,JP 2012282405 A,2012-12-26,US 6951097 P;;US 16335198 A,1997-12-15,COMPOSITION AND METHOD FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"PROBLEM TO BE SOLVED: To provide a method and compositions for treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) by means of topical application.SOLUTION: The invention relates to the compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours, and the treatment method for administering the same.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/198-692-434-596-042,Patent Application,no,1,2,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K9/70;;A61K31/4458;;A61K31/435;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/18;;A61P25/26,,0,0,,,,PENDING
223,PL,A1,PL 341596 A1,028-987-936-755-860,2001-04-23,2001,PL 34159698 A,1998-12-14,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,PHARMACOLOGICAL COMPOSITION FOR TREATING CONCENTRATION DISORDERS AND HYPERKINESIA,,NOVEN PHARMACEUTICALS,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/028-987-936-755-860,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K31/435;;A61K9/06;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
224,US,A1,US 2007/0059349 A1,040-056-169-276-63X,2007-03-15,2007,US 37862906 A,2006-03-20,US 37862906 A;;US 2451301 A;;US 61862600 A;;US 16335198 A;;US 6951097 P,1997-12-15,Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein said composition comprises about 10 to 30 wt % methylphenidate, about 30 to 50 wt % acrylic adhesive, and about 30 to 50 wt % silicone adhesive and wherein said methylphenidate is delivered to a subject in need thereof such that the plasma concentration of methylphenidate increases over a period of about 6-16 hours, and more preferably over a period of about 6-12 hours followed by a steady decrease in plasma concentration of methylphenidate.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/040-056-169-276-63X,Patent Application,yes,13,3,7,65,0,A61K9/7061;;A61K9/7069;;A61K31/445;;A61K31/4458;;A61P25/00;;A61K31/445;;A61K9/7061;;A61K9/7069;;A61K31/4458;;A61K47/32,A61K31/445;;A61F13/02;;A61K9/70;;A61K31/4458,424/448;;514/317,0,0,,,,DISCONTINUED
225,WO,A2,WO 1999/030694 A2,066-824-270-143-180,1999-06-24,1999,US 9826560 W,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,COMPOSITIONS AND METHODS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",NOVEN PHARMA;;MANTELLE JUAN;;DIXON TERESE A,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/066-824-270-143-180,Patent Application,no,0,8,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,PATENTED
226,EP,A2,EP 1037615 A2,133-009-326-058-792,2000-09-27,2000,EP 98963170 A,1998-12-14,US 9826560 W;;US 6951097 P;;US 16335198 A,1997-12-15,COMPOSITIONS AND METHODS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,,NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/133-009-326-058-792,Patent Application,yes,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
227,US,A1,US 2014/0046679 A1,137-671-741-742-26X,2014-02-13,2014,US 201313964865 A,2013-08-12,US 201313964865 A;;US 201261682105 P,2012-08-10,Online Health Assessment for Identifying Risk Areas,"The present invention is directed to providing an online health assessment. The online health assessment collects information from an individual and uses the information to identify areas of a person's lifestyle, nutrition, and/or products that pose the greatest risk to future health. The online health assessment can also make recommendations for addressing the areas of greatest risk, as well as make lifestyle, nutrition, and/or product recommendations for assisting the person in improving his lifestyle to improve the areas of risk.",USANA HEALTH SCIENCES INC,WENTZ DAVID A;;DIXON BRIAN,USANA HEALTH SCIENCES INC (2013-10-15),https://lens.org/137-671-741-742-26X,Patent Application,yes,6,1,1,1,0,G16H50/30;;G16H50/20;;G16H50/30,G06F19/00,705/2,1,0,,,"Oracle, How to Use Sliders, November 14, 2011, https://docs.oracle.com/javase/tutorial/uiswing/components/slider.html",DISCONTINUED
228,CA,C,CA 2404104 C,179-850-379-640-937,2012-12-11,2012,CA 2404104 A,2001-03-23,US 19208600 P;;US 0109398 W,2000-03-24,METHOD FOR MODIFYING LIGNIN COMPOSITION AND INCREASING IN VIVO DIGESTIBILITY OF FORAGES,"Methods for transforming forage legumes or woody plants with a DNA construct comprising at least one open reading frame encoding for a caffeoyl CoA 3-O-methyltransferase enzyme or a Medicago sativa caffeic acid 3-O-methyltransferase enzyme or a fragment thereof in either a sense or antisense orientation under a lignification-associated tissue specific promoter have been found, resulting in the down-regulation of the corresponding homologous gene either through antisense inhibition or sense suppression, as well as reduced lignin content and modified lignin composition in the transgenic plants. The expression of the caffeoyl CoA 3-O-methyltransferase transgene produces an increased syringyl lignin to guaiacyl lignin ratio in the transformed plant, and greatly improved forage digestibility.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;GUO DIANJING,,https://lens.org/179-850-379-640-937,Granted Patent,no,0,0,9,9,8,C12N9/1007;;C12N15/8255,C12N15/82;;A01H5/00;;C12N9/10,,0,0,,,,EXPIRED
229,TW,B,TW I244396 B,012-644-753-906-544,2005-12-01,2005,TW 92128573 A,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,A composition for topical application of methylphenidate and a pharmaceutical composition for treating attention deficit disorder and attention deficit/hyperactivity disorder,"The invention relates to a method of treating attention deficit disorder (ADD) and attention deficit/hyperactivity disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system, wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/012-644-753-906-544,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K31/435;;A61K9/06;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
230,US,B2,US 7888553 B2,017-862-258-409-345,2011-02-15,2011,US 15267108 A,2008-05-14,US 15267108 A;;US 23946302 A;;US 0109398 W;;US 19208600 P,2000-03-24,Method for modifying lignin composition and increasing in vivo digestibility of forages,"Methods for transforming forage legumes or woody plants with a DNA construct comprising at least one open reading frame encoding for a caffeoyl CoA 3-O-methyltransferase enzyme and a caffeic acid 3-O-methyltransferase enzyme or fragment thereof in either a sense or antisense orientation under a lignification-associated tissue specific promoter have been found, resulting in the down-regulation of the corresponding homologous gene either through antisense inhibition or sense suppression, as well as reduced lignin content and modified lignin composition in the transgenic plants. The expression of the caffeoyl CoA 3-O-methyltransferase transgene produces an increased syringyl lignin to guaiacyl lignin ratio in the transformed plant, and greatly improved forage digestibility.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;GUO DIANJING,NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/017-862-258-409-345,Granted Patent,yes,6,13,3,3,4,C12N9/1007;;C12N15/8255;;C12N9/1007;;C12N15/8255,C12N15/82;;A01H5/00;;C12N9/10,800/278;;800/287;;800/286;;800/285;;800/298,57,53,137-763-157-344-033;;030-421-171-545-835;;130-701-103-467-718;;068-562-748-374-304;;137-763-157-344-033;;002-939-646-141-676;;111-635-184-947-622;;048-188-266-680-461;;031-132-193-330-865;;064-020-317-605-308;;165-340-312-268-159;;004-653-636-407-484;;059-011-946-503-122;;033-023-171-256-035;;109-380-746-715-935;;050-831-791-646-757;;027-553-285-495-940;;000-549-954-183-978;;079-288-032-108-078;;016-686-242-147-938;;093-332-288-704-386;;067-999-241-399-305;;039-231-167-687-603;;057-100-866-399-056;;012-127-022-258-453;;018-591-372-975-943;;118-019-749-845-208;;088-905-113-810-237;;101-055-519-489-966;;045-236-736-103-314;;082-539-154-761-763;;056-125-717-707-945;;103-681-277-448-950;;028-802-401-621-133;;140-864-469-916-361;;130-701-103-467-718;;043-592-224-847-318;;001-206-827-782-566;;029-227-844-003-412;;050-622-349-025-009;;038-051-659-302-074;;057-197-921-747-927;;009-258-278-749-661;;000-830-989-125-916;;031-910-226-178-168;;102-338-276-945-192;;002-379-420-271-205;;005-025-673-594-96X;;049-296-783-971-229;;148-102-434-508-595;;083-000-996-514-985;;009-587-054-079-790;;030-421-171-545-835,10092173;;10.1023/a:1006182925584;;10.1105/tpc.10.12.2033;;10.2307/3870782;;pmc143971;;9836743;;10.1073/pnas.86.23.9284;;2594769;;pmc298479;;10.1046/j.1365-313x.1995.8040465.x;;10092173;;10.1023/a:1006182925584;;10.1007/bf00171349;;33874561;;10.1111/j.1469-8137.1995.tb04292.x;;2315699;;10.1126/science.2315699;;10.2135/cropsci1988.0011183x002800030026x;;10.2135/cropsci1987.0011183x002700050021x;;10.1007/s004250050523;;6326095;;pmc345422;;10.1073/pnas.81.7.1991;;9349273;;10.1023/a:1005821801228;;10.1007/bf00017577;;24272898;;10.1007/978-1-4615-3430-3_11;;14561401;;10.1016/j.cub.2003.09.035;;10849340;;10.1046/j.1365-313x.2000.00727.x;;10.1007/bf00040579;;8111011;;10.1104/pp.97.1.7;;16668418;;pmc1080956;;10.2135/cropsci1992.0011183x003200030046x;;10.1016/s0031-9422(96)00431-1;;10.1021/jf970029v;;pmc102215;;10.1105/tpc.13.1.73;;11158530;;10.2307/3871154;;10.1046/j.1365-313x.1994.06030339.x;;10468559;;pmc17839;;10.1073/pnas.96.18.10045;;9662519;;10.1104/pp.117.3.761;;pmc34931;;10.1006/abbi.1999.1674;;10683265;;10.1023/a:1006082815434;;9700079;;10.2527/jas1986.6261703x;;3733564;;10.1007/bf01415700;;18987794;;10.1080/02773818508085193;;11543592;;10.1146/annurev.pp.41.060190.002323;;10322202;;10.1016/s1369-5266(99)80030-2;;10.1105/tpc.4.3.263;;pmc160127;;10.2307/3869538;;1498596;;10692459;;10.1074/jbc.275.9.6537;;10.1073/pnas.86.23.9284;;2594769;;pmc298479;;11395776;;10.1038/35079635;;10.1073/pnas.95.12.6619;;pmc22575;;9618461;;0009618461;;10.1007/bf01974090;;pmc17714;;10430877;;10.1073/pnas.96.16.8955;;2499260;;10.1016/0003-9861(89)90299-3;;10.1046/j.1365-313x.1998.00014.x;;10.1094/mpmi-6-323;;8324249;;10322194;;10.1016/s1369-5266(99)80029-6;;10.1002/(sici)1097-0010(199606)71:2<195::aid-jsfa568>3.0.co;2-#;;8401614;;10.1111/j.1365-313x.1993.00835.x;;10.1046/j.1365-313x.1993.03060835.x;;8119592;;10.1007/bf01435039;;10.1016/0168-9452(90)90117-7;;10.1046/j.1365-313x.1995.8060855.x;;10069073;;10.1046/j.1365-313x.1998.00337.x;;10.1016/0378-1127(91)90133-g;;7994176;;10.1105/tpc.6.10.1427;;pmc160531;;10.2307/3869979;;10.1105/tpc.10.12.2033;;10.2307/3870782;;pmc143971;;9836743,"Baucher et al (1999, Plant Molecular Biology 39:437-447).;;Zhong et al (1998, The Plant Cell 10:2033-2045).;;Liang et al (1989, PNAS 86:9284-9288).;;Albrecht et al., ""Cell-wall composition and digestibility of alfalfa stems and leaves,"" Crop Sci., 27:735-741, 1987.;;Atanassova et al., ""Altered lignin composition in transgenic tobacco expressing O-methyltransferase sequences in sense and antisense orientation,"" Plant J., 8:465-477, 1995.;;Baucher et al., ""Down-regulation of cinnamyl alcohol dehydrogenase in transgenic alfalfa (Medicago sativa L.) and the effect on lignin composition and digestibility,"" Plant Mol. Biol., 39:437-447, 1999.;;Boudet et al., ""Lignin genetic engineering,"" Molecular Breeding, 2:25-39, 1996.;;Boudet et al., ""Tansley review No. 80: Biochemistry and molecular biology of lignification,"" New Phytologist, 129:203-236, 1995.;;Bowie et al., ""Deciphering the message in protein sequences: tolerance to amino acid substitution,"" Science, 247:1306-1310, 1990.;;Buxton et al., ""Lignin constituents and cell wall digestibility of grass and legume stems,"" Crop Sci., 28:553-558, 1988.;;Casler, ""In vitro digestibility of dry matter and cell wall constituents of smooth bromegrass forage,"" Crop Sci., 27:931-934, 1987.;;Chen et al., ""Evidence for a novel biosynthetic pathway that regulates the ratio of syringyl to guaiacyl residues in lignin in the differentiating xylem of Magnolia kobus DC,"" Planta, 207:597-603, 1999.;;Church et al., ""Genomic sequencing,"" Proc. Natl. Acad. Sci. USA, 81:1991-1995, 1984.;;Colliver et al, ""Differential modification of flavonoid and isoflavonoid biosynthesis with an antisense chalcone synthase construct in transgenic Lotus corniculatus,"" Plant Mol. Biol., 35:509-522, 1997.;;Cox et al., ""Analysis of plant gene expression,"" In: Plant Molecular Biology. A Practical Approach, C.H. Shaw, Ed., Oxford, IRL Press, pp. 1-35, 1988.;;Cramer et al., ""Phenylalanine ammonia-lyase gene organization and structure,"" Plant Mol. Biol., 12:367-383, 1989.;;Davin et al., ""Phenylpropanoid metabolism: biosynthesis of monolignols, lignans and neolignans, lignins and suberins,"" Rec. Adv. Phytochem., 26:325-375, 1992.;;Dixon et al., ""Genetic manipulation of lignin and phenylpropanoid compounds involved in interactions with microorganisms,"" Rec. Adv. Phytochem., 28:153-178, 1994.;;Emery et al., ""Radial patterning of arabidopsis shoots by class III HD-ZIP and Kanadi genes,"" Current Biology, 13:1768-1774, 2003.;;Franke et al., ""Modified lignin in tobacco and poplar plants over-expressing the arabidopsis gene encoding ferulate 5-hybdroxylase,"" The Plant J., 22(3)::223-234, 2000.;;Garbarino et al., ""Isolation of a ubiquitin-ribosomal protein gene (ubi3) from potato and expression of its promoter in transgenic plants,"" Plant Mol. Biol., 24:119-127, 1994.;;Gowri et aL, ""Stress responses in alfalfa (Medicago sativa L.) X. Molecular cloning and expression of S-adenosyl-L-methionine: caffeic acid 3-O-methyltransferase, a key enzyme of lignin biosynthesis,"" Plant Physiol., 97:7-14, 1991.;;Grabber et al., ""Digestion kinetics of parenchyma and sclerenchyma cell walls isolated from orchardgrass and switchgrass,"" Crop Sci., 32:806-810, 1992.;;Grabber et al., ""p-Coumaroylated syringyl units in maize lignin: implications for beta-ether cleavage by thioacidolysis,"" Phytochemistry, 43:1189-1194, 1996.;;Grabber et al., ""p-hydroxyphenyl, guaiacyl, and syringyl lignins have similar inhibitory effects on wall degradability,"" J. Agric. Food Chem., 45:2530-2532, 1997.;;Guo et al., ""Downregulation of cafeic acid 3-O-methyltransferase and caffeoyl 3-O-methyltransferase in transgenic alfalfa: impacts on lignin structure and implications for the biosynthesis of G and S lignin,"" Plant Cell, 13:73-88, 2001.;;Halpin et al., ""Manipulation of lignin quality by down-regulation of cinnamyl alcohol dehydrogenase,"" Plant J., 6:339-350, 1994.;;Humphreys et al., ""New routes for lignin biosynthesis defined by biochemical characterization of recombinant ferulate 5-hydroxylase, a multifunctional cytochrome P450-dependent monooxygenase,"" Proc. Natl. Acad Sci., 96:10045-10050, 1999.;;Inoue et al., ""Developmental expression and substrate specificities of alfalfa caffeic acid 3-O-methyltranferase and caffeoyl CoA 3-O-methyltransferase in relation to lignification,"" Plant Physiol., 117:761-770, 1998.;;Inoue et al., ""Substrate preferences of caffeic acid/5-hydroxyferulic acid 3-O-methyltransferases in developing stems of alfalfa (Medicago sativa L.),"" Arch Biochem Biophys., 375:175-182, 2000.;;Irdani et aL, ""Construction of a new vector conferring methotrexate resistance in Nicotiana tabacum plants,"" Plant Mol. Biol., 37:1079-1084, 1998.;;Jung et al., ""Influence of lignin on digestibility of forage cell wall material,"" J. Anim. Sci., 62:1703-1712, 1986.;;Kersey et al., ""Immunolocalization of two lignin O-methyltransferases in stems of alfalfa (Medicago sativa L.,"" Protoplasma, 209:46-57, 1999.;;Lapierre et al., ""Thioacidolysis of lignin: Comparison with acidolysis,"" J. Wood Chem. Technol., 5:277-283, 286-292, 1985.;;Lewis et al., ""Lignin: occurrence, biogenesis and biodegradation,"" Annu. Rev. Plant Physiol. Plant Mol. Biol., 41:455-496, 1990.;;Lewis, ""A 20th century roller coaster ride: a short account of lignification,"" Current Opinion in Plant Biology, 2:153-162, 1999.;;Leyva et al., ""Cis-element combinations determine phenylalanine ammonia-lyase gene tissue specific expression patterns,"" Plant Cell, 4:263-271, 1992.;;Li et al., ""5-hydroxyconiferyl aldehyde modulates enzymatic methylation for syringyl monolignol formation, a new view of monolignol biosynthesis in angiosperms,"" J. Biol. Chem., 275:6537-6545, 2000.;;Liang et al., ""Developmental and environmental regulation of a phenylalanine ammonia-lyase 13-glucuronidase gene fusion in transgenic tobacco plants,"" Proc. Natl. Acad. Sci. USA, 86:9284-9288, 1989.;;McConnell et al., ""Role of phabulosa and phavoluta in determining radial patterning in shoots,"" Nature, 411(6838):709-713, 2001.;;Meyer et al., ""Lignin monomer composition is determined by the expression of a cytochrome P450-dependent monoxygenase in arabidopsis,"" Proc. Natl. Acad. Sci. USA, 95:6619-6623, 1998.;;Ni et al., ""Reduced lignin in transgenic plants containing an engineered caffeic acid O-methyltransferase antisense gene,"" Transgenic Res., 3:120-126, 1994.;;Osakabe et al., ""Coniferyl aldehyde 5-hydroxylation and methylation direct syringyl lignin biosynthesis in angiosperms,"" Proc. Natl. Acad. Sci. USA, 96:8955-8960, 1999.;;Pakusch et al., ""S-adenosyl-L-methionine: trans-caffeoyl-coenzyme A 3-O-methyltransferase from elicitor-treated parsley cell suspension cultures,"" Arch. Biochem Biophys., 271:488-494, 1989.;;Piquemal et al., ""Down-regulation of cinnamoyl-CoA reductase induces significant changes of lignin profiles in transgenic tobacco plants,"" Plant J., 13:71-83, 1998.;;Reimann-Philipp et al., ""Coat protein-mediated resistance in transgenic tobacco expressing the tobacco mosaic virus coat protein from tissue-specific promoters,"" Mol. Plant Microbe Interact, 6:323-330, 1993.;;Sederoff et al., ""Unexpected variation in lignin,"" Current Opinion in Plant Biology, 2:145-152, 1999.;;Sewalt et al., ""Lignin impact on fiber degradation. 1. Quinone methide intermediates formed from lignin during in vitro fermentation of corn stover,"" J. Sci. Food Agric., 71:195-203, 1996.;;Shahin et al., ""Transformation of cultivated alfalfa using disarmed Agrobacterium tumefaciens,"" Crop Sci., 26:1235-1239, 1986.;;Shufflebottom et al., ""Transcription of two members of a gene family encoding phenylalanine ammonia-lyase leads to remarkably different cell specificities and induction patterns,"" Plant J., 3:835-845, 1993.;;Tabe et al., ""Genetic engineering of grain and pasture legumes for improved nutritive value,"" Genetica, 90:181-200, 1993.;;Thomas et al., ""Selection of interspecific somatic hybrids of Medicago by using Agrobacterium-transformed tissues,"" Plant Sci., 69:189-198, 1990.;;Van Doorsselaere et al., ""A novel lignin in popular trees with a reduced caffeic acid/5-hydroxyferulic acid O-methyltransferase activity,"" Plant J., 8:855-864, 1995.;;Vaucheret et al., ""Transgene-induced gene silencing in plants,"" Plant J., 16:651-659, 1998.;;Whetten et al., ""Genetic engineering of wood,"" Forest Ecology and Management, 43:301-316, 1991.;;Ye et al., ""An alternative methylation pathway in lignin biosynthesis in Zinnia,"" Plant Cell, 6:1427-1439, 1994.;;Zhong et al., ""Duel methylation pathways in lignin biosynthesis,"" Plant Cell, 10:2033-2045, 1998.",EXPIRED
231,US,A1,US 2014/0046680 A1,066-664-497-082-415,2014-02-13,2014,US 201313964868 A,2013-08-12,US 201313964868 A;;US 201261682097 P,2012-08-10,Online Health Assessment Providing Lifestyle Recommendations,"The present invention provides an online health assessment that collects information from an individual and uses the information to recommend changes to the individual's lifestyle, nutrition, and/or products that will assist the individual to maintain or improve a current level of health.",USANA HEALTH SCIENCES INC,WENTZ DAVID A;;DIXON BRIAN,USANA HEALTH SCIENCES (2013-10-15),https://lens.org/066-664-497-082-415,Patent Application,yes,13,11,1,1,0,G16H40/67;;G16H20/70;;G16H50/30;;G16H20/70;;G16H40/67,G06F19/00,705/2,1,0,,,"Oracle, How to Use Sliders, November 14, 2011, http://docs.oracle.com/javase/tutorial/uiswing/components/slider.html",DISCONTINUED
232,US,A,US 4801107 A,093-480-406-376-040,1989-01-31,1989,US 92202786 A,1986-10-22,US 92202786 A,1986-10-22,Cassette locking system,"A conventional reel brake in a video cassette is modified so that it will not function to release the brake when the cassette is placed in a cassette player unless a disabling device in the cassette is first unlocked or reset by external means. Further, when the cassette is unlocked and allowed to be played, it is once more disabled when the cassette is removed from the player. Thus, the cassette must be once more reset or unlocked before it can be played again.",SOTAR INC,DIXON DALE A;;HANNAN FORREST,SOTAR INC (1986-10-20),https://lens.org/093-480-406-376-040,Granted Patent,yes,6,10,3,3,0,G11B23/08721;;G11B23/08721,G11B23/087,242/198;;242/199,0,0,,,,EXPIRED
233,SI,B,SI 20360 B,103-244-076-231-872,2008-06-30,2008,SI 9820083 A,1998-12-14,US 9826560 W;;US 6951097 P;;US 16335198 A,1997-12-15,COMPOSITIONS AND METHODS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/103-244-076-231-872,Amended Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/00;;A61K9/70;;A61K9/06;;A61K31/00;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
234,CA,A1,CA 2404104 A1,113-052-305-503-672,2001-10-04,2001,CA 2404104 A,2001-03-23,US 19208600 P;;US 0109398 W,2000-03-24,METHOD FOR MODIFYING LIGNIN COMPOSITION AND INCREASING IN VIVO DIGESTIBILITY OF FORAGES,"Methods for transforming forage legumes or woody plants with a DNA construct comprising at least one open reading frame encoding for a caffeoyl CoA 3-O- methyltransferase enzyme or a Medicago sativa caffeic acid 3-O- methyltransferase enzyme or a fragment thereof in either a sense or antisens e orientation under a lignification-associated tissue specific promoter have been found, resulting in the down-regulation of the corresponding homologous gene either through antisense inhibition or sense suppression, as well as reduced lignin content and modified lignin composition in the transgenic plants. The expression of the caffeoyl CoA 3-O-methyltransferase transgene produces an increased syringyl lignin to guaiacyl lignin ratio in the transformed plant, and greatly improved forage digestibility.",SAMUEL ROBERTS NOBLE FOUND INC,GUO DIANJING;;DIXON RICHARD A,,https://lens.org/113-052-305-503-672,Patent Application,no,0,0,9,9,8,C12N9/1007;;C12N15/8255,C12N9/10;;C12N15/82,,0,0,,,,EXPIRED
235,US,B2,US 8946200 B2,124-489-194-129-016,2015-02-03,2015,US 55599506 A,2006-11-02,US 55599506 A,2006-11-02,Pharmaceutically active nanosuspensions,"The present disclosure is directed at a pharmaceutically active nanoparticle suspension that may be optically clear. Such suspensions may be formed by selective dissolution of a pharmaceutically active compound in a first solvent followed by introduction into a second solvent, such as an aqueous medium, without substantial use of surfactants and/or mechanical shear.",MCDONOUGH JOSEPH A;;DIXON HONG;;SOUTHWEST RES INST,MCDONOUGH JOSEPH A;;DIXON HONG,SOUTHWEST RESEARCH INSTITUTE (2006-11-27),https://lens.org/124-489-194-129-016,Granted Patent,yes,72,1,2,2,0,A61K31/57;;A61K31/57;;A61K9/14;;A61K9/14,A01N43/00;;A61K9/14;;A61K31/33;;A61K31/57;;B29B9/00,514/183;;264/5,84,56,060-549-919-189-73X;;080-127-572-157-768;;035-230-547-171-641;;041-352-630-698-05X;;065-745-366-158-377;;020-711-788-338-222;;033-105-832-073-199;;058-971-233-291-643;;022-124-730-878-417;;045-064-651-203-57X;;013-460-526-508-781;;067-396-135-255-110;;026-377-215-887-811;;020-317-537-639-586;;044-172-026-673-906;;037-114-652-426-030;;035-320-259-635-279;;047-382-068-025-143;;054-766-749-738-639;;021-991-833-069-160;;104-715-357-676-493;;000-560-546-318-818;;003-245-473-199-537;;020-649-853-103-071;;010-365-910-651-844;;087-369-412-617-194;;044-124-157-368-542;;038-074-861-608-626;;129-785-372-749-268;;053-903-911-051-176;;063-421-470-582-430;;002-679-196-036-124;;016-994-665-735-437;;046-776-116-900-21X;;130-099-343-741-14X;;028-317-930-994-008;;102-430-547-461-862;;009-042-394-096-263;;027-537-795-950-560;;032-382-262-966-161;;103-835-505-738-861;;039-472-959-626-478;;039-210-843-240-370;;108-779-808-821-249;;069-267-496-570-740;;011-367-293-495-262;;005-740-409-518-178;;125-954-371-954-752;;150-154-596-880-505;;043-633-374-263-578;;080-122-871-425-598;;030-023-524-915-675;;015-875-458-563-830;;071-195-716-275-252;;110-234-105-014-063;;090-343-887-082-448,pmc1112762;;10.1136/bmj.316.7134.789;;9549442;;10.1007/bf00808599;;10.1021/cr950066q;;11848856;;10.1007/bf00619738;;10.18388/abp.2007_3232;;17713603;;17265683;;10.1021/bi701002f;;17900152;;10.3121/cmr.2007.701;;pmc1855336;;17456837;;19075873;;10.2174/187221107779814104;;10.1039/b401644k;;10.1016/j.ijpharm.2004.07.035;;15607268;;15869447;;10.1089/cbr.2005.20.141;;17509234;;10.1179/016164107x187017;;10518158;;10.1176/ajp.156.10.1500;;8094968;;10.1177/096032719301200101;;10.1002/9780470060032.ch15;;13523283;;7488679;;3713965;;10.3987/r-1986-07-1883;;10.1016/j.tox.2004.07.019;;15590116;;10.1016/j.tox.2006.04.030;;16720069;;16426779;;10.1016/j.ijpharm.2005.11.040;;10.1042/bj0750363;;14402133;;pmc1204433;;16092078;;10.1002/jat.1084;;10.1016/j.biomaterials.2007.11.014;;18155137;;10.1016/j.jpba.2009.01.015;;19217737;;10.1016/0378-5173(96)04511-5;;10213373;;10.1023/a:1018829920158;;10.1358/mf.1998.20.3.485666;;9646283;;10.1002/jps.1168.abs;;11782895;;10.1002/jps.1168;;10.1016/j.minpro.2004.07.025;;10.1016/j.ejpb.2009.09.003;;19755158;;10.1080/10611860903112842;;19694610;;19537130;;19285109;;10.1016/j.jconrel.2009.03.002;;10.1016/j.ejpb.2008.08.021;;18805484;;10.1016/j.toxlet.2008.01.020;;18374523;;10.1177/030089160809400220;;18564616;;10.1016/j.ijpharm.2006.10.021;;17110063;;16980278;;10.1080/02652040600788080;;16608736;;10.1080/10611860600636135;;10.1080/10611860500411043;;16390814;;10.1016/j.bbrc.2005.02.019;;15737630;;10.1016/j.ics.2005.02.014;;10.1166/jnn.2003.077;;15503433;;12669961;;10.1023/a:1022604120952;;10.2174/1568015023357950;;12164380;;10.1080/10611860290031877;;10.1016/s0378-4274(01)00456-8;;11751017;;10.1016/s0169-409x(00)00122-8;;11251246;;10886334;;10.1046/j.1460-9568.2000.00078.x;;10.3109/07420529909016944;;10584177;;18154426;;08111/aim.0015;;10.14429/dsj.58.1660;;10.1007/bf03033389;;17449453,"Dennison et al (British Medical Journal, vol. 316, pp. 789-790; 1998).;;Farcasiu et al (Catalysis Letters, vol. 31, pp. 351-358; 1995).;;Kenalog (triamcinolone acetonide) Ointment [online], www.dailymed.nlm.nh.gov, Jan. 2006 [retrieved on Jun. 21, 2008]. Retrieved from the Internet: <URL: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=1872&type=display.;;Patani et al. (Chem. Rev., vol. 96, No. 8, pp. 3147-3176; 1996).;;Giuliani et al. (Optical and Quantum Electronics, vol. 9, pp. 263-264; 1977).;;Chemistry and Industry; Applied Chemistry; Nigel Freestone; Nov. 7, 2005 (4 pgs).;;Chemistry and Industry; New Drug Delivery Systems; Alexander T. Florence; Dec. 20, 1993 (7 pgs).;;Advanstar Communications, Inc.; Pharmaceutical Technology; Vivek Kharb; Meenakshi Bhatia; Harish Dureja; Deepak Kaushik; Feb. 1, 2006 (11 pgs).;;Advanstar Communications, Inc.; Pharmaceutical Technology Europe; Magdalene Radtke; Eliana B. Souto; Rainer H. Muller; Apr. 1, 2005 (4 pgs).;;Radic, et al., ""Evaluation of HI-6 oxime: potential use in protection of human acetylcholinesterase inhibited by antineoplastic drug irinotecan and its cyto/genotoxicity in vitro,"" Acta Biochimica Polonica vol. 54 No. 3/2007, 583-593, Aug. 23, 2007.;;Stojiljkovic, et al., ""Pryidinum Oximes: Rationale for their Selection as casual Antidotes against Organophosphate Poisonings and current solutions for auto-injectors,"" Arh Hig Toksikol 2006, 57:435-443.;;International Search Report and Written Opinion of the ISA issued in PCT/US09/35539 dated Jul. 17, 2009 (8 pgs).;;International Search Report and Written Opinion of the ISA issued in PCT/US09/52457 dated Oct. 6, 2009 (9 pgs).;;Luo et al, ""An In Vitro Comparative Study on the Reactivation of Nerve Agent-Inhibited Guinea Pig and Human Acetylcholinesterases by Oximes""; Biochemistry 2007, 46, pp. 11771-11779.;;Garcia et al, ""Sensitive and Rapid Blood and Tissue HPLC Oxime Assay and Pharmacokinetics of MMB-4 in Guinea Pigs and African Green Monkeys""; Walter Reed Army Institute of Research, Nov. 1, 2006, (8 pgs).;;Antonijevic et al., ""Unequal Efficacy of Pyridinium Oximes in Acute Organophosphate Poisoning,"" Clinical Medicine & Research, vol. 5, No. 1:71-82.;;Praetorius, et al., ""Engineered Nanoparticles in Cancer Therapy,"" Recent Patents on Drug Delivery & Formation 2007,vol. 1 No. 1, pp. 37-51.;;BIOSANTE Pharmaceuticals, ""Hormone Therapy-A Multi-Billion Dollar Market,"" Investor Fact Sheet Sep. 2007; www.biosantepharma.com; (2 pages).;;T.Welzel, et al., ""Transfection of Cells With Custom-made Calcium Phosphate Nanoparticles Coated With DNA""; The Royal Society of Chemistry 2004; J. Mater. Chem. 2004, 14, pp. 2213-2217.;;S. Bisht, et al., ""pDNA Loaded Calcium Phosphate Nanoparticles: Highly Efficient Non-Viral Vector for Gene Delivery""; International Journal of Pharmaceutics 288 (2005), pp. 157-168.;;T.Liu, et al., ""Calcium Phosphate Nanoparticles as a Novel Nonviral Vector for Efficient Transfection of DNA in Cancer Gene Therapy""; Cancer Biotherapy & Radiopharmaceuticls, vol. 20, No. 2, 2005, pp. 141-150.;;A. Brioschi, et al, ""Solid Lipid Nanoparticles: Could They Help . . . ""; Neurological Research 2007, vol. 29, Apr. 2007; pp. 324-330.;;M. Nahar, et al, ""Functional Polymeric Nanoparticles: An Efficient . . . ""; Critical Reviews(TM) In Therapeutic Drug Carrier Systems, 23(4):259-318 (2006); Begell House Inc., http://begellhouse.com; downloaded Sep. 18, 2009 from IP 129.162.1.41 by Celia Frausto.;;International Search Report and Written Opinion dated Nov. 23, 2009 issued in related International Patent Application No. PCT/US0959386.;;DiGiovanni, JR., M.D., Cleto, Domestic Terrorism With Chemical or Biological Agents: Psychiatric Aspects, Am J Psychiatry, Oct. 1999, pp. 1500-1505, vol. 156:10.;;D'Mello, G.D., Behavioural Toxicity of Anticholinesterases in Humans and Animals-A Review, Human & Experimental Toxicology, 1993, pp. 3-7, vol. 12.;;Eyer, et al., Oximes-Chapter 15, Chemical Warfare Agents: Toxicology and Treatment, 2007, pp. 305-329, 2nd Edition.;;Jager, et al., Toxicity of Diacetyl Monoxime and of Pyridine-2-Aldoxime Methiodide in Man, Bull John Hopkins Hosp., 1958, pp. 203-211, vol. 102.;;Jamal, Goran A., Long term neurotoxic effects of organophosphate compounds, Adverse Drug React. Toxicol. Rev, 1995, pp. 85-99, vol. 14(2).;;Marrs et al., Chemical Warfare Agents: Toxicology and Treatment Second Edition, 2007, pp all. Table of contents attached electronically, physical book is cited and supplied in U.S. Appl. No. 12/702,095 which was mailed to USPTO Oct. 8, 2010.;;McDonough, et al., Behavioral Correlates of Soman-Induced Neuropathology: Deficits in DRL Acquisition, Neurobehavioral Toxicology and Teratology, 1986, pp. 179-187, vol. 8.;;Luo, et al., ""Development of a broad-spectrum Oxime for the treatment of nerve agent toxicity,"" Conference paper, Division of Biochemistry, Walter Reed Army Institute of Research, Silver Spring, MD 20910, Report Date: Nov. 2006 Report No. A376184. Available at http://www.dtic.mil/cgi-bin/GetTRDoc?Location=U2&doc=GetTRDoc.pdf&AD=ADA481673, retrieved on Mar. 9, 2011.;;U.S. Office Action dated Mar. 11, 2011 issued in related U.S. Appl. No. 12/245,450.;;U.S. Office Action dated May 25, 2011 issued in related U.S. Appl. No. 12/192,400.;;Munavalli, et al; Preparation and Properties of Methylenebispyridinium Derivatives; Heterocycles 1986, vol. 24. No. 7; pp. 1883-1892.;;U.S. Office Action mailing dated Jun. 22, 2011 issued in related U.S. Appl. No. 12/047,988.;;European Supplementary Search Report-mailing date Sep. 27, 2011, issued in related European Appln. No. 09718843.7.;;Sevelova et al, ""Antidotal Treatment of GF-agent intoxication in mice with bispyridinium Oximes"", Toxicology, vol. 207, No. 1, pp. 1-6, 2005.;;Aurbek et al, ""Analysis of Inhibition, Reactivation and Aging Kinetics of Highly Toxic Organophosphorus Compounds with Human and Pig Acetylcholinesterase"", Toxicology, vol. 224, No. 1-2. pp. 91-99, 2006.;;Office Action dated Dec. 29, 2011 issued in related U.S. Appl. No. 12/047,988.;;Office Action dated Nov. 29, 2011 issued in related U.S. Appl. No. 12/245,450.;;Office Action dated Jan. 26, 2012 issued in related U.S. Appl. No. 12/192,400.;;Office Action dated Jan. 5, 2012 issued in related U.S. Appl. No. 12/702,095.;;European Search Report dated Oct. 31, 2011 issued in related European Patent Application No. 09807064.2.;;Bagryanskaya, et al., ""Study of alkaloids from the flora of the Siberian and Altai regions. 6.* Crystal and molecular structure of songorine Z-oxime,"" Russian Chemical Bulletin, International Edition, vol. 50, No. 11, pp. 2092-2094, Nov. 2001.;;Gao, et al., ""Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles,"" International Journal of Pharmaceutics 310 (2006) 213-219.;;Hobbiger, et al., ""Reactivation of Phosphorylated Acetocholinesterases by Pyridinium Aldoximes and Related Compounds,"" Biochem J. May 1960; 75(2): 363-372.;;Kuca, et al., ""Effective bisquaternary reactivators of tabun-inhibited AChE,"" J. Appl. ToxiCol. 2005; 25: 491-495.;;Liu, et al., ""Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier,"" Biomaterials 29 (2008) 1509-1517.;;Macauley, et al., Chromatographic separation and NMR characterization of the isomers of MMB-4 a bis-(pyridiniumaldoxime), Journal of Pharmaceutical and Biomedical Analysis 49 (2009) 889-894.;;Thiermann, ""HI 6 dimethanesulfonate has better dissolution properties than HI 6 dichloride for application in dry/wet autoinjectors,"" International Journal of Pharmaceutics vol. 137, Issue 2, Jun. 28, 1996, pp. 167-176.;;Wu, et al., ""Blood-Brain Barrier Transport of Reduced Folic Acid,"" Pharm Res. Mar. 1999;16(3):415-9.;;Office Action dated Sep. 14, 2012 issued in related U.S. Appl. No. 12/047,988.;;Office Action dated Sep. 27, 2012 issued in related U.S. Appl. No. 12/702,095.;;Office Action dated Oct. 11, 2012 issued in related U.S. Appl. No. 12/192,400.;;Chaumeil; ""Micronization: A Method of Improving the Bioavailability of Poorly Soluble Drugs""; Methods and Findings in Experimental and Clinical Pharmacology, Apr. 1998, vol. 20 (3): pp. 211-215; Copyright 1998 Prous Science, CCC: 0379-0355/98.;;Garner, et al; Comparison of the Absorption of Micronized (Daflon 500 mg) and Nonmicronized 14 C-Diosmin Tablets After Oral Administration to Healthy Volunteers by Accelerator Mass Spectrometry and Liquid Scintillation Counting; Journal of Pharmaceutical Sciences, vol. 91, No. 1, Jan. 2002, pp. 32-40.;;Choi, et al; Amorphous Ultrafine Particle Preparation for Improvement of Bioavailability of Insoluble Drugs: Grinding Characteristics of Fine Grinding Mills; Elsevier, International Journal of Mineral Processing, vol. 74, Supplement 1, Dec. 2004, pp. S165-S172.;;Gelperina, et al., ""Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters,"" European Journal of Pharmaceutics and Biopharmaceutics (2009) doi:10.1016/j.ejpb.2009.09.003.;;Kurakhmaeva, et al., ""Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles,"" Journal of Drug Targeting, 2009; 17(8): 564-574.;;Hekmatara, et al., ""Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects,"" Clinical Neuropathology, vol. 28-No. 3/2009 (153-164).;;Zensi, et al., ""Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones,"" Journal of Controlled Release 137 (2009) 78-86.;;Ulbrich, et al., ""Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB),"" European Journal of Pharmaceutics and Biopharmaceutics 71 (2009) 251-256.;;Pereverzeva, et al., ""Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats,"" Toxicology Letters 178 (2008) 9-19.;;Kreuter, et al., ""Use of nanoparticles for cerebral cancer,"" Tumori: 9-4: 271-277, 2008.;;Kreuter, ""Nanoparticles-a historical perspective,"" International Journal of Pharmaceutics 331 (2007) 1-10.;;Petri, et al., ""Mechanism of Action and Surfactant Influence During Chemotherapy of Brain Tumour Using Doxorubicin-Loaded Poly(butyl Cyanoacrylate) Nanoparticles,"" NSTI-Nanotech 2007, vol. 2, 2007, p. 386-389.;;Ambruosi, et al., ""Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model,"" Journal of Microencapsulation, Aug. 2006; 23(5): 582-592.;;Ambruosi, et al., ""Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats,"" Journal of Drug Testing, Feb. 2006; 14(2): 97-105.;;Ambruosi, et al., ""Body distribution of polysorbate-80 and doxorubicin-loaded [14C]-(poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats,"" Journal of Drug Targeting, Dec. 2005; 13(10): 535-542.;;Schuller et al., ""Degradation of microvascular brain endothelial cell beta-catenin after co-culture with activated neutrophils from patients undergoing cardiac surgery with prolonged cardiopulmonary bypass,"" Biochemical and Biophysical Research Communications 329 (2005) 616-623.;;Kreuter, ""Application of nanoparticles for the delivery of drugs to the brain,"" International Congress Series 1277 (2005) 85-94.;;Kreuter, ""Influence of the Surface Properties on Nanoparticle-Mediated Transport of Drugs to the Brain,"" Journal of Nanoscience and Nanotechnology, 2004, vol. 4, No. 5; p. 484-488.;;Kreuter, ""Direct Evidence that Polysorbate-80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles,"" Pharmaceutical Research, vol. 20, No. 3, Mar. 2003; p. 409-416.;;Kreuter, ""Transport of Drugs Across the Blood-Brain Barrier by Nanoparticles,"" Curr. Med. Chem.-Central Nervous System Agents, 2002, 2, 241-249.;;Kreuter, et al.""Apolipoprotein-medicated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier,"" Journal of Drug Testing, 2002 vol. 10 (4), pp. 317-325.;;Gelperina, et al., ""Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrykate) nanoparticles in healthy rats and rats with intracranial glioblastoma,"" Toxicology Letters 126 (2002) 131-141.;;Kreuter, ""Nanoparticulate systems for brain delivery of drugs,"" Advanced Drug Delivery Reviews 47 (2001) 65-81.;;Ramge, et al., ""Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells,"" European Journal of Neuroscience, vol. 12, pp. 1931-1940 (2000).;;Ramge, et al., ""Circadian Phase-dependent Antinociceptive Reaction in Mice and the Tail-flick Test after Intravenous Injection of Dalargin-Loaded Nanoparticles,"" Chronobiology International, 16(6), 767-777 (1999).;;Alyautdin, et al., ""Drug delivery to brain by nanoparticles,"" (2003) eksperimental'naya i Klinicheskaya Farmakologiya, 66 (2), pp. 65-68.;;Balali-Mood MD PHD, et al., ""Neurotoxic Disorders of Organophosphorous Compounds and Their Managements,"" Arch Iranian Med 2008; 11 (1): 65-89.;;Kuca, et al., ""Preparation of Oxime HI-6 (Dichloride and Dimethanesulphonate)-Antidote against Nerve Agents,"" Defense Science Journal, vol. 58, No. 3, May 2008, pp. 399-404.;;Kuca, et al., ""In Vitro Reactivation Potency of Acetylcholinesterase Reactivators-K074 and K075-to Reactivate Tabun-inhibited Human Brain Cholinesterases,"" Neurotoxicity Research, 2007, vol. 11(2), pp. 101-106.",ACTIVE
236,CZ,B6,CZ 305817 B6,047-907-453-107-427,2016-03-23,2016,CZ 2009132 A,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,Mixtures and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate,"The present invention relates to a composition for topical application of methylphenidate and the use of this composition for the preparation of a medicament intended for the treatment of Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD). The composition for the topical application of methylphenidate comprises methylphenidate in a flexible, finite system wherein the methylphenidate is present in an effective amount in the range of 3.96 to 10.56 mg of methylphenidate per 10 cme2 within a flexible enclosed system over a period of time at least 10 hours in one embodiment while another embodiment is a composition with an effective applicable amount of methylphenidate in the range of 23.76 to 63.36 mg of methylphenidate per 10 cme2.",NOVEN PHARMACEUTICALS,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/047-907-453-107-427,Granted Patent,no,2,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K31/435;;A61K9/70;;A61K31/445;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
237,GB,B,GB 2193650 B,139-488-466-383-385,1990-08-01,1990,GB 8619540 A,1986-08-11,GB 8619540 A,1986-08-11,TOYS,,DIXON MANNING SALES AND MARKET,DIXON A JOHN;;MANNING PETER,,https://lens.org/139-488-466-383-385,Granted Patent,no,1,0,7,7,0,A63H9/00,A63H3/36;;A63H3/04;;A63H3/46;;A63H9/00;;G01R13/20,A6S S1B           S1;;A6S S1F1          S1;;B5A AA2           AA2;;B5A A1R214H       AA2;;B5A A1R314C1X     AA2;;B5A A1R314C3      AA2;;B5A A1R448        AA2;;B5A A1R461        AA2;;B5A A2E7A         AA2;;B5A A2E9          AA2;;B5A A20N5         AA2;;B5A A20T14        AA2;;U1S S1205,0,0,,,,EXPIRED
238,PE,A1,PE 20000120 A1,009-474-915-928-408,2000-02-19,2000,PE 00121998 A,1998-12-15,US 6951097 P;;US 16335198 A,1997-12-15,COMPOSICION DE METILFENIDATO EN FORMA SOLIDA PARA USO TOPICO,"SE REFIERE A UNA COMPOSICION PARA LA APLICACION TOPICA DE METILFENIDATO PRESENTADO EN UN SISTEMA LIMITADO Y FLEXIBLE PARA LA ADMINISTRACION EN LA PIEL O EN LAS MUCOSAS POR 10 HORAS Y EN CANTIDAD SUFICIENTE PARA LOGRAR UNA CINETICA DE ORDEN CERO; EL METILFENIDATO SE PRESENTA COMO BASE, SAL BASICA, ESTER, ENANTIOMERO d-TREO-METILFENIDIATO. LA COMPOSICION COMPRENDE ADEMAS UN MATERIAL ADHESIVO SIENDO DE PREFERENCIA ACRILICOS; CAUCHOS NATURALES; CAUCHOS SINTETICOS; ADHESIVOS BIOLOGICOS TAL COMO POLISACARIDOS NATURALES O SINTETICOS; POLISILOXANOS; POLIACRILATOS, POLIVINIL PIRROLIDONAS, COPOLIMEROS DE VINILPIRROLIDONA; COPOLIMEROS DE BLOQUES DE ESTIRENO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL METILFENIDATO ES UN ESTIMULANTE DEL SISTEMA NERVIOSO CENTRAL POR LO QUE LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNO DE DEFICIT DE LA ATENCION Y DEFICIT DE LA ATENCION CON HIPERACTIVIDAD",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/009-474-915-928-408,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K31/435;;A61K9/06;;A61K31/445;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
239,WO,A2,WO 2020/251698 A2,002-562-928-729-075,2020-12-17,2020,US 2020/0030799 W,2020-04-30,US 201962841361 P;;US 202016814988 A,2019-05-01,COMPOSITIONS OF DIMETHYL TRISULFIDE (DMTS) AS A CYANIDE ANTIDOTE,The present disclosure is directed at compositions of dimethyl trisulfide (DMTS) suitable for use for treatment of cyanide intoxication. The compositions show particularly useful stability such that the DMTS remains stable for therapeutic use at the identified time periods. The compositions are therefore particularly suitable for use in autoinjectors.,SOUTHWEST RES INST,DIXON HONG;;MCDONOUGH JOSEPH A,,https://lens.org/002-562-928-729-075,Patent Application,yes,4,1,9,9,0,A61K31/10;;A61K9/08;;A61K9/0019;;A61K9/1075;;A61K47/10;;A61M5/3157;;A61M5/30;;A61K31/10;;A61M5/20;;A61K9/1075;;A61K9/0019,A61K31/10,,3,2,025-128-011-374-711;;009-174-340-786-482,26861644;;pmc4767715;;10.1007/s40268-016-0122-3;;28110144;;10.1016/j.jchromb.2017.01.010,"C.M. BARTLINGJ.C. ANDREC.A. HOWLANDM.E. HESTERJ.T. CAFMEYERA. KERRI. PETRIKOVICSG.A. ROCKWOODDRUGS RD: ""Furthermore, in the paper Stability Characterization of a Polysorbate 80-Dimethylsulfide Formulation"", A CYANIDE ANTIDOTE CANDIDATE, vol. 15, 2016, pages 109 - 127;;KISS LORAND ET AL.: ""Method development for detecting the novel cyanide antidote dimethyl trisulfide from blood and brain, and its interaction with blood"", JOURNAL OF CHROMATOGRAPHY B, ELSEVIER, AMSTERDAM, NL, vol. 1044, 9 January 2017 (2017-01-09), pages 149 - 157, XP029907609, DOI: 10.1016/j.jchromb.2017.01.010;;See also references of EP 3962469A4",PENDING
240,TR,T2,TR 200001736 T2,013-153-370-222-006,2001-01-22,2001,TR 200001736 T,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,Dikkat noksanlığı rahatsızlığının tedavisi için yöntem ve terkipler.,"Bu bulus dikkat eksikligi rahatsizligi (ADD) ve dikkat eksikligi/hiperaktivite rahatsizliginin (ADHD) tedavisine iliskin bir yöntemle ve metilfenidatin, bu maddeye ihtiyaç duyan bir hastanin derisi veya mukozasi yoluyla iletimi için en az 10 saatlik bir zaman peryodu içerisinde sifir-düzey kinetigini önemli ölçüde korumaya yeterli miktarda bulundugu ve ihtiva ettigi asit fonksiyonel monomer orani agirlik bazinda yaklasik %5'ten fazla olmayan esnek, sonlu bir sistemde metilfenidatin topik olarak uygulanmasini saglayan bilesimlerle ilgilidir.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/013-153-370-222-006,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K31/435;;A61K31/4458;;A61K9/06;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,PENDING
241,US,A,US 5381921 A,018-140-996-317-903,1995-01-17,1995,US 95252192 A,1992-12-08,GB 9013050 A;;GB 9100934 W,1990-06-12,Refuse containers,"A refuse container comprising a hollow body with an upper access opening closed by a displaceable cover, and a bag suspension frame, carried by a body wall, said wall movable between a closed position in which the frame is positioned below an access opening, and an open position in which the frame is exposed for bag replacement. The frame has a movable frame element projecting away from the wall. The body has internal surfaces for deflecting the frame element upwardly during closing movement and downwardly during opening movement of the body wall.",GLASDON LTD,BRAY DAVID A;;DIXON ROBERT,GLASDON GROUP LIMITED (1992-11-25),https://lens.org/018-140-996-317-903,Granted Patent,yes,20,26,11,11,0,B65F1/06;;Y10S220/908;;B65F1/06;;Y10S220/908,B65F1/06,220/404;;220/409;;220/908,1,0,,,Rubbermaid Brochure (estimated 1978).,EXPIRED
242,US,A1,US 2011/0160245 A1,031-804-795-356-340,2011-06-30,2011,US 98115410 A,2010-12-29,US 98115410 A;;US 81219807 A;;US 37862906 A;;US 2451301 A;;US 61862600 A;;US 16335198 A;;US 6951097 P,1997-12-15,COMPOSITIONS AND METHODS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein said composition comprises about 10 to 30 wt % methylphenidate, about 30 to 50 wt % acrylic adhesive, and about 30 to 50 wt % silicone adhesive and wherein said methylphenidate is delivered to a subject in need thereof such that the plasma concentration of methylphenidate increases over a period of about 6-16 hours, and more preferably over a period of about 6-12 hours followed by a steady decrease in plasma concentration of methylphenidate.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/031-804-795-356-340,Patent Application,yes,20,6,7,65,0,A61K9/7061;;A61K9/7069;;A61K31/445;;A61K31/4458;;A61P25/00;;A61K31/445;;A61K9/7061;;A61K9/7069;;A61K31/4458;;A61K47/32,A61K31/4458;;A61K9/70;;A61P25/00,514/317,1,0,,,EPO-T 0036/02 [online] retrieved from: http://www.epo.org/law-practice/case-law-appeals/recent/t020036eu1.html on 9/20/12; date of decision 3/29/06; 4 pages.).,DISCONTINUED
243,US,A1,US 2014/0013503 A1,044-094-380-999-035,2014-01-16,2014,US 201313941161 A,2013-07-12,US 201313941161 A;;US 201261671048 P;;US 201361801492 P;;US 201361798207 P,2012-07-12,Monitoring Systems Devices and Methods for Patient Lifts,A monitoring system comprises a lift assembly configured to lift a patient; a control system configured to control operation of the lift system; and a reporting system in communication with the control system and configured to receive operational information for the lift assembly. The reporting system compares the operational information to a predetermined set of values to determine if the operation of the lift is in compliance with the protocols.,DIXON STEVEN A;;RIBBLE DAVID,DIXON STEVEN A;;RIBBLE DAVID,LIKO RESEARCH & DEVELOPMENT AB (2013-07-23),https://lens.org/044-094-380-999-035,Patent Application,yes,16,43,6,6,0,A61G7/018;;A61G7/1017;;A61G7/1042;;A61G7/1051;;A61G7/1061;;A61G7/1065;;A61G2203/12;;A61G2203/20;;A61G2203/44;;A61G2203/72;;A61B5/11;;A61B2562/0257;;G16H40/63;;A61G7/1015;;G16H40/63;;A61B5/11;;A61B2562/0257;;A61G7/018;;A61G7/1017;;A61G7/1042;;A61G7/1051;;A61G7/1061;;A61G7/1065;;A61G2203/12;;A61G2203/20;;A61G2203/44;;A61G2203/72;;A61G7/1073;;A61G7/108,A61G7/10,5/85.1;;5/83.1,0,0,,,,ACTIVE
244,DK,T3,DK 1037615 T3,068-883-592-702-195,2004-07-12,2004,DK 98963170 T,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,Præparater og fremgangsmåder til behandling af attention deficit desorder og attention deficit/hyperactivity disorder med methylphenidat,,NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/068-883-592-702-195,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
245,HK,A,HK 106990 A,072-861-998-002-057,1990-12-28,1990,HK 106990 A,1990-12-18,GB 8619540 A,1986-08-11,TOYS,,DIXON MANNING SALES & MARKETIN,DIXON A JOHN;;MANNING PETER,,https://lens.org/072-861-998-002-057,Granted Patent,no,0,0,7,7,0,A63H9/00,A63H3/36;;A63H3/04;;A63H3/46;;A63H9/00;;G01R13/20,,0,0,,,,EXPIRED
246,WO,A8,WO 2007/092934 A8,107-322-267-455-293,2009-08-27,2009,US 2007/0061865 W,2007-02-08,US 77235406 P,2006-02-09,METHODS AND COMPOSITIONS FOR MODIFYING PLANT BIOSYNTHETIC PATHWAYS,"The invention provides bifunctional plant biosynthetic enzymes that increase the efficiency by which modification can be made to plant biosynthetic pathways. In certain aspects of the invention, bifunctional isoflavone biosynthetic enzymes are provided. The invention therefore allows the modification of plants for isoflavone content. The inventors have demonstrated increased isoflavone biosynthesis can be obtained even in non-legume plants.",SAMUEL ROBERTS NOBLE FOUND INC;;TIAN LI;;DIXON RICHARD A,TIAN LI;;DIXON RICHARD A,,https://lens.org/107-322-267-455-293,Amended Application,yes,0,0,10,10,0,C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,C12N15/82;;A01H5/00;;C07K19/00;;C12N15/62,,0,0,,,,PENDING
247,JP,A,JP 2009073856 A,108-010-938-024-069,2009-04-09,2009,JP 2008291364 A,2008-11-13,US 6951097 P;;US 16335198 A,1997-12-15,COMPOSITION AND METHOD FOR TREATMENT OF ATTENTION-DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"<P>PROBLEM TO BE SOLVED: To provide a composition and method for treatment of attention-deficit disorder (ADD) and attention-deficit/hyperactivity disorder (ADHD) by topical application. <P>SOLUTION: The invention relates to a method and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours. <P>COPYRIGHT: (C)2009,JPO&INPIT",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/108-010-938-024-069,Patent Application,no,1,1,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K9/70;;A61K31/4458;;A61K31/435;;A61K47/04;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26;;A61P25/28,,0,0,,,,PENDING
248,US,A,US 4576038 A,143-794-923-969-702,1986-03-18,1986,US 65072584 A,1984-09-14,GB 8325107 A;;GB 8400643 A,1983-09-20,Apparatus for use in leak detection,"Apparatus for use in the detection of leaks comprising an annular flexible, gas permeable skirt carried by and projecting from a carrier member which closes one axial end of the skirt. The opposite axial end of the skirt is closed in use by engagement with the surface being searched, such that the surface and the carrier member contain between them a sample volume bounded by the skirt. The apparatus further includes a sensing probe communicating with the sample volume for detecting the presence of a signal gas in the sample volume.",BROWN JOHN AUTOMATION,DIXON DEREK;;RICHARDSON BARRY A,JOHN BROWN AUTOMATION LIMITED A BRITISH COMPANY (1984-08-28),https://lens.org/143-794-923-969-702,Granted Patent,yes,15,5,3,6,0,G01M3/04;;G01M3/04;;G01M3/205;;G01M3/205,G01M3/04;;G01M3/20,73/40.7,1,0,,,"Jet Probe of a Halide Leak Detector , V. F. Royal, A. I. Zapunnyi, & L. S. Feldman, Pribory i Tekhnika Eksperimenta, No. 6, pp. 128 430, Nov. Dec. 1976.",EXPIRED
249,CA,A,CA 34377 A,170-145-874-240-120,1890-05-21,1890,CA 34377D A,,CA 34377T A,,CIRCULAR KNITTING MACHINE,,STANDARD NEEDLE COMPANY;;DAVIDSON GEORGE;;DIXON RICHARD A,DAVIDSON GEORGE;;DIXON RICHARD A,,https://lens.org/170-145-874-240-120,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
250,EP,A3,EP 0256818 A3,178-628-770-137-564,1988-04-27,1988,EP 87307038 A,1987-08-07,GB 8619540 A,1986-08-11,TOYS,"A toy includes a plurality of portions adapted for articulation relative to each other. The toy has a skeleton for which there are at least skeleton members corresponding to each portion of the toy other than portions at the extremeties of the toy. The skeleton is moulded as a single integrated structure with each skeleton member generally rigidly connected to the or each neighbouring skeleton member by a respective relatively narrow breakable region. The toy additionally comprises, for each portion of the toy for which there is a corresponding skeleton member, a body member injection moulded generally around an end part of the corresponding skeleton member and also around the adjacent end part of each or any skeleton member to which the first mentioned end part is connected by one of the relatively narrow breakable regions. To complete the articulated toy, the various narrow breakable regions are broken after moulding of the body members. ",DIXON MANNING SALES MARKETING,"DIXON, JOHN A.;;MANNING, PETER",,https://lens.org/178-628-770-137-564,Search Report,yes,4,0,7,7,0,A63H9/00,A63H3/36;;A63H3/04;;A63H3/46;;A63H9/00;;G01R13/20,,0,0,,,,DISCONTINUED
251,NZ,A,NZ 521545 A,060-600-098-815-836,2004-04-30,2004,NZ 52154501 A,2001-03-23,US 19208600 P;;US 0109398 W,2000-03-24,Method for modifying lignin composition and increasing in vivo digestibility of forages,"A method for improving the digestibility of a forage legume comprises stably incorporating into the genome of the plant a DNA construct comprising at least one open reading frame encoding for a caffeoyl or caffeic acid CoA 3-O-methyltransferase enzyme ( CCoAMT ) under the expression control of a lignification-associated tissue specific promoter, wherein the expression produces a change in lignin composition in the legume and improves its digestibility. Preferably the promoter is a PAL2 promoter.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;GUO DIANJING,,https://lens.org/060-600-098-815-836,Patent Application,no,0,0,9,9,0,C12N9/1007;;C12N15/8255,C12N9/10;;C12N15/82,,0,0,,,,DISCONTINUED
252,US,A1,US 2011/0288124 A1,059-568-179-233-86X,2011-11-24,2011,US 201113071048 A,2011-03-24,US 201113071048 A;;US 98115410 A;;US 81219807 A;;US 37862906 A;;US 2451301 A;;US 61862600 A;;US 16335198 A;;US 6951097 P,1997-12-15,COMPOSITIONS AND METHOD FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein said composition comprises about 10 to 30 wt % methylphenidate, about 30 to 50 wt % acrylic adhesive, and about 30 to 50 wt % silicone adhesive and wherein said methylphenidate is delivered to a subject in need thereof such that the plasma concentration of methylphenidate increases over a period of about 6-16 hours, and more preferably over a period of about 6-12 hours followed by a steady decrease in plasma concentration of methylphenidate.",MANTELLE JUAN;;DIXON TERESE A;;NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/059-568-179-233-86X,Patent Application,yes,1,7,7,65,0,A61K9/7061;;A61K9/7069;;A61K31/445;;A61K31/4458;;A61P25/00;;A61K31/445;;A61K9/7061;;A61K9/7069;;A61K31/4458;;A61K47/32,A61K31/4458;;A61K9/70;;A61P25/00,514/317,0,0,,,,DISCONTINUED
253,US,A,US 4404825 A,061-338-573-514-57X,1983-09-20,1983,US 26303681 A,1981-05-12,US 26303681 A,1981-05-12,Padlock having a replaceable cylinder,A stop disposed in the bottom of the shackle heel bore normally blocks movement of a pin holding the cylinder in the casing. Raising the stop when the lock is unlocked permits the pin to move away from the cylinder freeing the cylinder for replacement.,SCOVILL INC,DIXON DAVID;;KRUPICKA WILLIAM A,SCOVILL INC. A CORP. OF CT (1981-05-05);;YALE SECURITY INC. A CORP. OF DE (1985-10-28),https://lens.org/061-338-573-514-57X,Granted Patent,yes,12,28,1,1,0,E05B9/084;;E05B9/084;;E05B67/24;;E05B67/24;;Y10T70/7644;;Y10T70/7644;;Y10T70/7661;;Y10T70/7661,E05B9/08;;E05B67/24,70/368;;70/371,0,0,,,,EXPIRED
254,ES,T3,ES 2219926 T3,080-245-434-271-244,2004-12-01,2004,ES 98963170 T,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,COMPOSICIONES Y METODOS PARA EL TRATAMIENTO DEL TRASTORNO DEFICITARIO DE LA ATENCION Y DEL TRASTORNO DE LA HIPERACTIVIDAD CON DEFICIT DE LA ATENCION POR MEDIO DE METILFENIDATO.,"Una composición para aplicación tópica de metilfenidato que comprende metilfenidato en un sistema flexible y finito, en donde el sistema comprende un polímero natural o sintético capaz de adherirse al punto de aplicación tópica y en donde el metilfenidato está presente en una cantidad de 20-180 mg de metilfenidato por 2 a 2 a 60 cm2 aproximadamente con una velocidad de suministro de 0, 5 a 100 mg/24 horas, más preferentemente de 2, 5 a 20 mg/24 horas, resultando ello en niveles de metilfenidato en sangre que no varían en más de 40% respecto de la media en estado de equilibrio para el suministro a la piel o mucosa de un paciente necesitado del mismo durante un período de tiempo de al menos 10 horas, y en donde, si el polímero es un polímero acrílico, la composición no comprende más de 5% en peso de monómeros con funcionalidad ácida, basado en el peso del polímero acrílico.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/080-245-434-271-244,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
255,US,A1,US 2019/0345505 A1,119-872-787-568-402,2019-11-14,2019,US 201716325432 A,2017-08-15,US 201716325432 A;;US 201662375756 P;;US 2017/0046929 W,2016-08-16,METHODS FOR REGULATING EXTRACTABLE PROANTHOCYANIDINS (PAS) IN PLANTS BY AFFECTING LEUCOANTHOCYANIDIN REDUCTASE (LAR),"Adjustments to the amount of soluble and insoluble proanthocyanidins (PAs) in plants can be accomplished through regulation of leucoanthocyanidin reductase (LAR) functionality. Reducing LAR functionality increases epicatechin polymerization, leading to greater amounts of insoluble PAs and effects on astringency and other characteristics.",UNIV NORTH TEXAS,DIXON RICHARD A;;LIU CHENGGANG,UNIVERSITY OF NORTH TEXAS (2019-04-16),https://lens.org/119-872-787-568-402,Patent Application,yes,1,1,2,2,13,C12N15/8218;;C12N15/8243;;C12N15/8216;;C12N15/8243,C12N15/82,,0,0,,,,DISCONTINUED
256,CA,A1,CA 2315237 A1,140-127-690-242-183,1999-06-24,1999,CA 2315237 A,1998-12-14,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,COMPOSITIONS AND METHODS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/140-127-690-242-183,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K9/70;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
257,CA,A1,CA 3138565 A1,171-593-118-779-804,2020-12-17,2020,CA 3138565 A,2020-04-30,US 201962841361 P;;US 202016814988 A;;US 2020/0030799 W,2019-05-01,COMPOSITIONS OF DIMETHYL TRISULFIDE (DMTS) AS A CYANIDE ANTIDOTE,The present disclosure is directed at compositions of dimethyl trisulfide (DMTS) suitable for use for treatment of cyanide intoxication. The compositions show particularly useful stability such that the DMTS remains stable for therapeutic use at the identified time periods. The compositions are therefore particularly suitable for use in autoinjectors.,SOUTHWEST RES INST,DIXON HONG;;MCDONOUGH JOSEPH A,,https://lens.org/171-593-118-779-804,Patent Application,no,0,0,9,9,0,A61K31/10;;A61K9/08;;A61K9/0019;;A61K9/1075;;A61K47/10;;A61M5/3157;;A61M5/30;;A61K31/10;;A61M5/20;;A61K9/1075;;A61K9/0019,A61K31/10;;A61K47/02;;A61P25/30;;A61P39/02,,0,0,,,,PENDING
258,EP,A1,EP 1459741 A1,193-855-047-244-153,2004-09-22,2004,EP 04004843 A,1998-12-14,EP 98963170 A;;US 6951097 P;;US 16335198 A,1997-12-15,Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with menthylphenidate,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and to compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system capable of sticking to the side of topical application wherein the methylphenidate is present in amount of 20 - 180 mg methylphenidate per 2 to 60 cm 2  of flexible, finite system with a delivery rate of 0.5 to 100 mg/24 h resulting in blood levels of methylphenidate that do not vary more than up to 40 % from the mean at steady state for delivery to the skin or mucosa of a patient need thereof over a period of time of at least 10 hours.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/193-855-047-244-153,Patent Application,yes,2,0,1,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458,A61K9/70;;A61K31/4458,,0,0,,,,DISCONTINUED
259,WO,A3,WO 2001/073090 A3,016-947-007-924-269,2002-05-23,2002,US 0109398 W,2001-03-23,US 19208600 P,2000-03-24,METHOD FOR MODIFYING LIGNIN COMPOSITION AND INCREASING IN VIVO DIGESTIBILITY OF FORAGES,"Methods for transforming forage legumes or woody plants with a DNA construct comprising at least one open reading frame encoding for a caffeoyl CoA 3-O-methyltransferase enzyme or a Medicago sativa caffeic acid 3-O-methyltransferase enzyme or a fragment thereof in either a sense or antisense orientation under a lignification-associated tissue specific promoter have been found, resulting in the down-regulation of the corresponding homologous gene either through antisense inhibition or sense suppression, as well as reduced lignin content and modified lignin composition in the transgenic plants. The expression of the caffeoyl CoA 3-O-methyltransferase transgene produces an increased syringyl lignin to guaiacyl lignin ratio in the transformed plant, and greatly improved forage digestibility.",SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;GUO DIANJING,DIXON RICHARD A;;GUO DIANJING,,https://lens.org/016-947-007-924-269,Search Report,yes,3,0,9,9,0,C12N9/1007;;C12N15/8255,C12N9/10;;C12N15/82,,4,4,030-421-171-545-835;;018-591-372-975-943;;039-231-167-687-603;;002-939-646-141-676,10.1105/tpc.10.12.2033;;10.2307/3870782;;pmc143971;;9836743;;9662519;;10.1104/pp.117.3.761;;pmc34931;;pmc102215;;10.1105/tpc.13.1.73;;11158530;;10.2307/3871154;;10.1007/bf00171349,"ZHONG R. ET AL.: ""Dual Methylation Pathway in Lignin Biosynthesis"", PLANT CELL, vol. 10, December 1998 (1998-12-01), pages 2033 - 2045, XP002187458;;INOUE K. ET AL.: ""Developmental Expression and Substrate Specificities of Alfalfa Caffeic Acid 3-O-Methyltransferase and Caffeoyl Coenzyme A 3-O-Methyltransferase in Relation to Lignification"", PLANT PHYSIOLOGY, vol. 117, 1998, pages 761 - 770, XP002187459;;DIANJING G. ET AL.: ""Downregulation of Caffeic Acid 3-O-Methyltransferase and Caffeoyl 3-O-Methyltransferase in Transgenic Alfalfa: Impacts on Lignin Structure and Implications for the Biosynthesis of G and S Lignin"", PLANT CELL, vol. 13, January 2001 (2001-01-01), pages 73 - 88, XP002187460;;BOUDET A M ET AL: ""Lignin Genetic Engineering"", MOLECULAR BREEDING, vol. 2, 1996, pages 25 - 39, XP002025844, ISSN: 1380-3743",PATENTED
260,US,A1,US 2002/0102291 A1,093-101-158-500-432,2002-08-01,2002,US 2451301 A,2001-12-21,US 2451301 A;;US 61862600 A;;US 16335198 A;;US 6951097 P,1997-12-15,Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate,"
   The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein said composition comprises about 10 to 30 wt % methylphenidate, about 30 to 50 wt % acrylic adhesive, and about 30 to 50 wt % silicone adhesive and wherein said methylphenidate is delivered to a subject in need thereof such that the plasma concentration of methylphenidate increases over a period of about 6-16 hours, and more preferably over a period of about 6-12 hours followed by a steady decrease in plasma concentration of methylphenidate. 
",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,NOVEN PHARMACEUTICALS INC (2002-03-11),https://lens.org/093-101-158-500-432,Patent Application,yes,11,19,7,65,0,A61K9/7061;;A61K9/7069;;A61K31/445;;A61K31/4458;;A61P25/00;;A61K31/445;;A61K9/7061;;A61K9/7069;;A61K31/4458;;A61K47/32,A61K9/70;;A61K31/4458,424/448;;X42468,0,0,,,,DISCONTINUED
261,CA,A1,CA 2085241 A1,139-556-153-682-44X,1991-12-13,1991,CA 2085241 A,1991-06-11,GB 9013050 A,1990-06-12,REFUSE CONTAINERS,"A refuse container comprising a hollow body with an upper access opening closed by a displaceable cover, and bag suspension frame carried by a body wall movable between a closed position in which the frame is positioned below the access opening and an open position in which the frame is exposed for bag replacement, said frame having a movable frame element projecting away from the wall and the body having internal surfaces for deflecting said frame element upwardly during closing movement and downwardly during opening movement of the wall.",GLASDON LTD,BRAY DAVID A;;DIXON ROBERT,,https://lens.org/139-556-153-682-44X,Patent Application,no,0,0,11,11,0,B65F1/06;;Y10S220/908;;B65F1/06;;Y10S220/908,B65F1/06,,0,0,,,,DISCONTINUED
262,AU,A1,AU 2007/213711 A1,157-177-585-426-741,2007-08-16,2007,AU 2007/213711 A,2007-02-08,US 77235406 P;;US 2007/0061865 W,2006-02-09,Methods and compositions for modifying plant biosynthetic pathways,,SAMUEL ROBERTS NOBLE FOUND INC,TIAN LI;;DIXON RICHARD A,,https://lens.org/157-177-585-426-741,Patent Application,no,0,0,10,10,0,C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,C12N15/82;;A01H5/00;;C07K19/00;;C12N15/62,,0,0,,,,ACTIVE
263,CZ,A3,CZ 20002209 A3,170-720-803-519-755,2000-11-15,2000,CZ 20002209 A,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,Mixtures and methods for treating light brain dysfunction and disorders related to deficit of attention and hyperactivity by employing methylphenidate,,NOVEN PHARMACEUTICALS,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/170-720-803-519-755,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K31/435;;A61K9/06;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
264,US,A1,US 2009/0044294 A1,167-714-222-490-49X,2009-02-12,2009,US 15267108 A,2008-05-14,US 15267108 A;;US 23946302 A;;US 0109398 W;;US 19208600 P,2000-03-24,Method for modifying lignin composition and increasing in vivo digestibility of forages,"Methods for transforming forage legumes or woody plants with a DNA construct comprising at least one open reading frame encoding for a caffeoyl CoA 3-O-methyltransferase enzyme or a Medicago sativa caffeic acid 3-O-methyltransferase enzyme or a fragment thereof in either a sense or antisense orientation under a lignification-associated tissue specific promoter have been found, resulting in the down-regulation of the corresponding homologous gene either through antisense inhibition or sense suppression, as well as reduced lignin content and modified lignin composition in the transgenic plants. The expression of the caffeoyl CoA 3-O-methyltransferase transgene produces an increased syringyl lignin to guaiacyl lignin ratio in the transformed plant, and greatly improved forage digestibility.",DIXON RICHARD A;;GUO DIANJING,DIXON RICHARD A;;GUO DIANJING,NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/167-714-222-490-49X,Patent Application,yes,3,13,3,3,4,C12N9/1007;;C12N15/8255;;C12N9/1007;;C12N15/8255,C12N15/54;;A01H5/00;;C12N9/10;;C12N15/82,800/278;;800/298,0,0,,,,EXPIRED
265,CN,C,CN 1251814 C,021-241-545-755-323,2006-04-19,2006,CN 01810072 A,2001-05-25,AU PQ779900 A,2000-05-26,Hot rolling thin strip,"Thin steel strip is passed through a pinch roll stand comprising pinch rolls to a rolling mill comprising a pair of work rolls and upper and lower backing rolls. Strip passes through the bite between the work rolls and strip squeezing forces are applied between the work rolls to reduce the thickness of the strip. The pinch rolls apply tension to the strip passing to the work rolls. In order to minimize generation of crimping defects in the strip, the tension applied by the pinch rolls is high enough to ensure no part of the strip entering the work rolls is in longitudinal compression such as to exceed the buckling stress of the strip. The applied tension is sufficiently low as to produce no more than 1% strip elongation through creep. The strip may be hot rolled by the work rolls at a temperature in the range of 700° C.-1200° C.",CASTRIP LLC,DIXON JOHN A ZIEGELAAR MICHAEL,,https://lens.org/021-241-545-755-323,Granted Patent,no,0,0,23,25,0,B21B1/26;;B21B1/463;;B21B37/28;;B21B37/48;;B21B37/56;;B21B39/006;;B21B39/08;;B21B45/008;;B21B2001/225;;B21B2265/04;;B21B2265/08;;Y10T29/49991;;Y02P70/10;;B21B1/40;;Y10T29/49991;;B21B37/28;;B21B2265/04;;B21B1/463;;B21B39/08;;B21B2265/08;;B21B45/008;;B21B2001/225;;B21B1/26;;B21B37/48;;B21B37/56;;B21B39/006;;Y02P70/10,B21B1/26;;B21B1/22;;B21B1/46;;B21B37/28;;B21B37/48;;B21B37/56;;B21B37/58;;B21B39/00;;B21B39/08;;B21B45/00;;B22D11/06;;B22D11/12,,0,0,,,,EXPIRED
266,AT,T1,AT E260652 T1,019-685-291-230-900,2004-03-15,2004,AT 98963170 T,1998-12-14,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,ARZNEIMITTEL UND VERFAHREN ZUR BEHANDLUNG VON AUFMERKSAMKEITSSTÖRUNGEN UND AUFMERKSAMKEITS- /HYPERAKTIVITÄTSSTÖRUNGEN MIT METHYLPHENIDAT,,NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/019-685-291-230-900,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K9/70;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,PENDING
267,US,B2,US 7816507 B2,103-132-352-320-892,2010-10-19,2010,US 67283207 A,2007-02-08,US 67283207 A;;US 77235406 P,2006-02-09,Methods and compositions for modifying plant biosynthetic pathways,"The invention provides bifunctional plant biosynthetic enzymes that increase the efficiency by which modification can be made to plant biosynthetic pathways. In certain aspects of the invention, bifunctional isoflavone biosynthetic enzymes are provided. The invention therefore allows the modification of plants for isoflavone content. The inventors have demonstrated increased isoflavone biosynthesis can be obtained even in non-legume plants.",SAMUEL ROBERTS NOBLE FOUND INC,TIAN LI;;DIXON RICHARD A,NOBLE RESEARCH INSTITUTE LLC (2017-05-01);;SAMUEL ROBERTS NOBLE FOUNDATION (2007-12-12),https://lens.org/103-132-352-320-892,Granted Patent,yes,11,2,10,10,38,C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,C12N15/29;;A01H5/00;;A01H5/10;;C12N15/52;;C12N15/82,536/23.6;;536/23.4;;536/23.2;;536/23.1;;435/320.1;;435/182;;800/260;;800/287;;800/298,50,49,064-537-099-272-526;;024-774-830-141-268;;010-214-063-649-840;;000-692-534-159-244;;041-601-268-755-801;;109-361-270-458-131;;070-856-398-089-073;;020-609-497-841-564;;088-434-188-167-057;;064-537-099-272-526;;047-725-477-114-683;;127-644-094-774-460;;020-241-505-274-14X;;032-073-114-204-14X;;058-188-052-702-496;;027-346-493-289-672;;013-107-845-203-427;;016-260-898-220-124;;018-948-663-101-09X;;080-895-672-569-905;;005-634-666-446-76X;;012-141-614-538-580;;079-288-032-108-078;;082-981-051-785-035;;102-694-481-185-381;;015-211-613-664-534;;022-731-799-415-925;;090-471-782-699-122;;076-650-562-664-397;;133-569-281-575-184;;032-015-405-987-054;;174-010-872-876-915;;060-059-297-556-205;;030-560-996-409-192;;008-831-818-058-304;;026-826-499-158-725;;028-474-712-033-769;;102-862-868-293-328;;029-409-447-008-102;;021-517-286-890-129;;073-698-679-143-185;;009-675-870-178-527;;012-737-030-621-863;;033-329-354-962-890;;035-532-023-409-018;;014-373-646-721-06X;;135-894-153-029-324;;000-711-245-539-874;;009-534-056-736-871,15734910;;pmc1065389;;10.1104/pp.104.056747;;17904596;;10.1016/j.phytochem.2007.08.006;;10.1046/j.1365-313x.1998.00099.x;;9681028;;12226498;;pmc166551;;10.1104/pp.005801;;10.1038/88150;;11329019;;11129571;;10.1271/bbb.64.2025;;10.1104/pp.106.1.17;;pmc159494;;7972515;;10.1034/j.1399-3054.1999.100119.x;;10.1021/bp020057k;;12467448;;15734910;;pmc1065389;;10.1104/pp.104.056747;;10.1093/protein/14.8.529;;11579220;;15113976;;10.1093/jn/134.5.1225s;;10.1002/1097-0290(20001005)70:1<9::aid-bit2>3.0.co;2-7;;10940858;;2129191;;10.1016/j.phytochem.2004.03.005;;15110680;;10.1104/pp.105.062539;;pmc1183411;;16006598;;10411494;;10.1126/science.285.5426.375;;12031439;;10.1016/s0031-9422(02)00116-4;;10.1016/j.pbi.2005.03.008;;15860431;;10.1038/35081178;;11459067;;10.1146/annurev.arplant.55.031903.141729;;15377220;;11800569;;10.1006/mben.2001.0203;;10.1104/pp.97.1.7;;16668418;;pmc1080956;;10.1016/j.tibtech.2005.07.007;;16054718;;10.1074/jbc.m209362200;;12381722;;11888290;;10.1021/bi0159074;;10.1104/pp.007237;;12586876;;pmc166828;;10966651;;10.1038/79025;;pmc45849;;8433985;;10.1073/pnas.90.4.1247;;pmc101465;;10788392;;10.1128/aem.66.5.2133-2138.2000;;10.1111/j.1467-7652.2005.00136.x;;17173631;;10.1111/j.0105-2896.2004.0129.x;;15199968;;10.1074/jbc.271.42.25738;;8824199;;pmc137925;;12384577;;10.1073/pnas.212522099;;10.1046/j.1365-313x.2003.01893.x;;14617078;;10.1038/41024;;9237751;;10.1016/s0167-7799(98)01204-9;;9652137;;1912490;;10.1007/bf00037051;;pmc1283808;;10.1073/pnas.0505749102;;16263933;;12207646;;10.1046/j.1365-313x.2002.01378.x;;10.1074/jbc.m104047200;;11429408;;pmc110565;;10831428;;10.1128/aem.66.6.2484-2490.2000;;12644647;;10.1104/pp.004820;;pmc166860;;10.1016/j.cbpa.2003.10.012;;14644176;;11474068;;10.1126/science.1062249;;11800570;;10.1006/mben.2001.0204;;10.1007/s00425-006-0233-0;;16482434;;10.1016/s1097-2765(00)80408-6;;10678174;;10.1104/pp.104.054502;;15778463;;pmc1088328,"Akashi T. et al. Plant Physiology, Mar. 25, 2005; vol. 137, pp. 882-891.;;Lapcik, O. Phytochemistry 2007, vol. 68, pp. 2909-2916.;;Batard et al., ""Molecular cloning and functional expression in yeast of CYP76B1, a xenobiotic-inducible 7-ethoxycoumarin O-de-ethylase from helianthus tuberosus,"" The Plant Journal, 14(1):111-120, 1998.;;Didierjean et al., ""Engineering herbicide metabolism in tobacco and arabidopsis with CYP76B1, a cytochrome P450 enzyme from jerusalem artichoke,"" Plant Physiology, 130:179-189, 2002.;;Liu et al., ""Metabolic engineering of isoflavonoid biosynthesis in arabidopsis thaliana,"" Plant Biology, Abstracts of the Annual Meeting of the American Society of Plant Physiologists, Abst. #269, p. 1, 2000.;;Muir et al., ""Overexpression of petunia chalcone isomerase in tomato results in fruit containing increased levels of flavonols,"" Nature Biotechnology, 19:470-474, 2001.;;Shiota et al., ""Expression of human cytochromes P450 1A1 and P450 1A2 as fused enzymes with yeast NADPH-cytochrome P450 oxidoreductase in transgenic tobacco plants,"" Biosci. Biotechnol. Biochem., 64(10):2025-2033, 2000.;;Shiota et al., ""Herbicide-resistant tobacco plants expressing the fused enzyme between rat cytochrome P4501A 1 (CYP1A1) and yeast NADPH-cytochrome P450 oxidoreductase,"" Plant Physiol., 106:17-23, 1994.;;Winkel-Shirley, ""Evidence for enzyme complexes in the phenylpropanoid and flavonoid pathways,"" Physiol. Plant, 107:142-149, 1999.;;Yilmaz et al., ""Enhanced stress tolerance in Escherichia coli and nicotiana tabacum expressing a betaine aldehyde dehydrogenase/choline dehydrogenase fusion protein,"" Biotechnol. Prog., 18:1176-1182, 2002.;;Akashi et al., ""Molecular and biochemical characterization of 2-hydroxyisoflavanone dehydratase. Involvement of carboxylesterase-like proteins in leguminous isoflavone biosynthesis,"" Plant Physiol., 137:882-891, 2005.;;Arai et al., ""Design of the linkers which effectively separate domains of a bifunctional fusion protein,"" Protein Eng., 14:529-532, 2001.;;Barnes, ""Soy isoflavones-phytoestrogens and what else?,"" J. Nutr., 134:1225S-1228S, 2004.;;Beaujean et al., ""Engineering direct fructose production in processed potato tubers by expressing a bifunctional alpha-amylase/glucose isomerase gene complex,"" Biotechnol. Bioeng., 70:9-16, 2000.;;Bülow, ""Preparation of artificial bifunctional enzymes by gene fusion,"" Biochem. Soc. Symp., 57:123-133, 1990.;;Cornwell et al., ""Dietary phytoestrogens and health,"" Phytochemistry, 65:995-1016, 2004.;;Deavours and Dixon, ""Metabolic engineering of isoflavonoid biosynthesis in alfalfa,"" Plant Physiol., 138:2245-2259, 2005.;;DellaPenna, ""Nutritional Genomics: Manipulating Plant Micronutrients to Improve Human Health,"" Science, 285:375-379, 1999.;;Dixon and Ferreira, ""Genistein,"" Phytochemistry, 60:205-211, 2002.;;Dixon, ""Engineering of plant natural product pathways,"" Curr. Opin. Plant Biol., 8:329-336, 2005.;;Dixon, ""Natural products and plant disease resistance,"" Nature, 411:843-847, 2001.;;Dixon, ""Phytoestrogens,"" Annu. Rev. Plant Biol., 55:225-261, 2004.;;Galili and Hofgen, ""Metabolic engineering of amino acids and storage proteins in plants,"" Metab. Eng., 4:3-11, 2002.;;Gowri et al., ""Stress Responses in Alfalfa (Medicago sativa L.): X. Molecular Cloning and Expression of S-Adenosyl-l-Methionine:Caffeic Acid 3-O-Methyltransferase, a Key Enzyme of Lignin Biosynthesis,"" Plant Physiol., 97:7-14, 1991.;;Hey et al., ""Artificial, non-antibody binding proteins for pharmaceutical and industrial applications,"" Trends Biotech., 23(10):514-522, 2005.;;Hoffmann et al., ""Purification, cloning, and properties of an acyltransferase controlling shikimate and quinate ester intermediates in phenylpropanoid metabolism,"" J. Biol. Chem., 278:95-103, 2003.;;James and Viola, ""Production and Characterization of Bifunctional Enzymes. Substrate Channeling in the Aspartate Pathway,"" Biochemistry, 41:3726-3731, 2002.;;Jang et al., ""Expression of a bifunctional fusion of the Escherichia coli genes for trehalose-6-phosphate synthase and trehalose-6-phosphate phosphatase in transgenic rice plants increases trehalose accumulation and abiotic stress tolerance without stunting growth,"" Plant Physiol., 131:516-524, 2003.;;Jez et al., ""Structure and mechanism of the evolutionarily unique plant enzyme chalcone isomerase,"" Nat. Struct. Biol., 7:786-791, 2000.;;Keung and Vallee, ""Daidzin: a potent, selective inhibitor of human mitochondrial aldehyde dehydrogenase,"" Proc. Natl Acad. Sci. USA, 90:1247-1251, 1993.;;Kim et al., ""Construction and evaluation of a novel bifunctional N-carbamylase-D-hydantoinase fusion enzyme,"" Appl. Environ. Microbiol., 66:2133-2138, 2000.;;Kourtz et al., ""A novel thiolase-reductase gene fusion promotes the production of polyhydroxybutyrate in Arabidopsis,"" Plant Biotech J., 3:435-447, 2005.;;La Camera et al., ""Metabolic reprogramming in plant innate immunity: the contributions of phenylpropanoid and oxylipin pathways,"" Immunol. Rev., 198:267-284, 2004.;;Li et al., ""A novel bifunctional fusion enzyme catalyzing ethylene synthesis via 1-aminocyclopropane1-carboxylic acid,"" J. Biol. Chem., 271:25738-25741, 1996.;;Liu et al., ""Bottlenecks for metabolic engineering of isoflavone glycoconjugates in Arabidopsis,"" Proc. Natl. Acad Sci. USA, 99:14578-14583, 2002.;;Liu et al., ""Regiospecific hydroxylation of isoflavones by cytochrome p450 81E enzymes from Medicago truncatula,"" Plant J., 36:471-484, 2003.;;Netzer and Hartl, ""Recombination of protein domains facilitated by co-translational folding in eukaryotes,"" Nature, 388:343-349, 1997.;;Nixon et al., ""Hybrid enzymes: manipulating enzyme design,"" Trends Biotechnol., 16:258-264, 1998.;;Paiva et al., ""Stress responses in alfalfa (Medicago sativa L.) 11. Molecular cloning and expression of alfalfa isoflavone reductase, a key enzyme of isoflavonoid phytoalexin biosynthesis,"" Plant Mol. Biol., 17:653-667, 1991.;;Reddy et al., ""Targeted down-regulation of cytochrome P450 enzymes for forage quality improvement in alfalfa (Medicago sativa L.),"" Proc. Natl. Acad. Sci. USA, 102:16573-16578, 2005.;;Sawada et al., ""Key amino acid residues required for aryl migration catalysed by the cytochrome P450 2-hydroxyisoflavanone synthase,"" Plant J., 31:555-564, 2002.;;Schoch et al., ""CYP98A3 from Arabidopsis thaliana is a 3'-hydroxylase of phenolic esters, a missing link in the phenylpropanoid pathway,"" J. Biol. Chem., 276:36566-36574, 2001.;;Seo et al., ""Characterization of a bifunctional enzyme fusion of trehalose-6-phosphate synthetase and trehalose-6-phosphate phosphatase of Escherichia coli,"" Appl. Environ. Microbio., 66:2484-2490, 2000.;;Shimada et al., ""A cluster of genes encodes the two types of chalcone isomerase involved in the biosynthesis of general flavonoids and legume-specific 5-deoxy(iso)flavonoids in Lotus japonicus,"" Plant Physiol., 131:941-951, 2003.;;Skerra, ""Imitating the humoral immune response,"" Curr. Opin. Chem. Biol., 7:683-693, 2003.;;Tattersall et al., ""Resistance to an Herbivore Through Engineered Cyanogenic Glucoside Synthesis,"" Science, 293:1826-1828, 2001.;;Thelen and Ohlrogge, ""Metabolic engineering of fatty acid biosynthesis in plants,"" Metab. Eng., 4:12-21, 2002.;;Tian and Dixon, ""Engineering isoflavone metabolism with an artificial bifunctional enzyme,"" Planta, 224:496-507, 2006.;;Williams et al., ""Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity,"" Mol. Cell, 5:121-131, 2000.;;Ralston et al., ""Partial Reconstruction of Flavonoid and Isoflavonoid Biosynthesis in Yeast Using Soybean Type I and Type II Chalcone Isomerases,"" Plant Physiology, 137:1375-1388, 2005.",ACTIVE
268,US,A1,US 2006/0137201 A1,098-978-337-196-803,2006-06-29,2006,US 2255304 A,2004-12-23,US 2255304 A,2004-12-23,Laser goniometer for measuring the angle of a surface,A goniometer for measuring an angle of a surface of an object is provided. The goniometer includes a frame with an engagement element configured for engaging the object. A laser generator is carried by the frame and is configured for emitting a laser beam onto the surface of the object when the object engages the engagement element. The goniometer further includes a scale carried by the frame. The laser beam is reflected from the object towards the scale and the scale is configured for indicating an angle of the surface of the object onto which the laser beam is directed when emitted by the laser generator. The object may be a creping blade and the goniometer may be used in order to measure the grind angle of the creping blade.,KIMBERLY CLARK CO,DIXON SCOTT A;;BURCHAM KIM,KIMBERLY-CLARK WORLDWIDE INC (2005-03-21),https://lens.org/098-978-337-196-803,Patent Application,yes,19,2,2,2,0,G01B11/26;;G01B11/26;;G01B9/10;;G01B9/10,B23Q17/22,33/628,0,0,,,,DISCONTINUED
269,AU,A,AU 1999/018249 A,183-868-989-216-017,1999-07-05,1999,AU 1999/018249 A,1998-12-14,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate,,NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/183-868-989-216-017,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K9/70;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
270,AU,A,AU 2001/047731 A,010-088-382-630-077,2001-10-08,2001,AU 2001/047731 A,2001-03-23,US 19208600 P;;US 0109398 W,2000-03-24,Method for modifying lignin composition and increasing in vivo digestibility of forages,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;GUO DIANJING,,https://lens.org/010-088-382-630-077,Patent Application,no,0,2,9,9,0,C12N9/1007;;C12N15/8255,C12N9/10;;C12N15/82,,0,0,,,,PENDING
271,US,A,US 634231 A,003-432-359-248-706,1899-10-03,1899,US 1899/0719566 A,1899-06-06,US 1899/0719566 A,1899-06-06,ELECTRIC BELT.,,DIXON LESTER A;;CHRYSTAL ANDREW,DIXON LESTER A;;CHRYSTAL ANDREW,,https://lens.org/003-432-359-248-706,Granted Patent,no,0,2,1,1,0,A61N1/0524;;A61N1/0524;;A61B2018/00523;;A61B2018/00523,,,0,0,,,,EXPIRED
272,AU,A,AU 1994/066211 A,040-664-313-139-824,1994-10-24,1994,AU 1994/066211 A,1994-03-31,US 4526393 A;;US 9403356 W,1993-04-02,Method for reducing ligning content in plants,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;NI WEITING,,https://lens.org/040-664-313-139-824,Patent Application,no,0,0,2,2,0,C12N15/8255;;C12N9/10,C12N9/10;;C12N15/82,,0,0,,,,PENDING
273,CA,C,CA 3138565 C,052-782-388-440-702,2024-01-02,2024,CA 3138565 A,2020-04-30,US 201962841361 P;;US 202016814988 A;;US 2020/0030799 W,2019-05-01,COMPOSITIONS OF DIMETHYL TRISULFIDE (DMTS) AS A CYANIDE ANTIDOTE,The present disclosure is directed at compositions of dimethyl trisulfide (DMTS) suitable for use for treatment of cyanide intoxication. The compositions show particularly useful stability such that the DMTS remains stable for therapeutic use at the identified time periods. The compositions are therefore particularly suitable for use in autoinjectors.,SOUTHWEST RES INST,DIXON HONG;;MCDONOUGH JOSEPH A,,https://lens.org/052-782-388-440-702,Granted Patent,no,0,0,9,9,0,A61K31/10;;A61K9/08;;A61K9/0019;;A61K9/1075;;A61K47/10;;A61M5/3157;;A61M5/30;;A61K31/10;;A61M5/20;;A61K9/1075;;A61K9/0019,A61K31/10;;A61K47/02;;A61P25/30;;A61P39/02,,0,0,,,,PENDING
274,EP,A4,EP 3962469 A4,074-426-851-428-72X,2023-01-18,2023,EP 20822063 A,2020-04-30,US 201962841361 P;;US 202016814988 A;;US 2020/0030799 W,2019-05-01,COMPOSITIONS OF DIMETHYL TRISULFIDE (DMTS) AS A CYANIDE ANTIDOTE,,SOUTHWEST RES INST,DIXON HONG;;MCDONOUGH JOSEPH A,,https://lens.org/074-426-851-428-72X,Search Report,no,1,0,9,9,0,A61K31/10;;A61K9/08;;A61K9/0019;;A61K9/1075;;A61K47/10;;A61M5/3157;;A61M5/30;;A61K31/10;;A61M5/20;;A61K9/1075;;A61K9/0019,A61K31/10;;A61K47/02;;A61P25/30;;A61P39/02,,2,1,009-174-340-786-482,28110144;;10.1016/j.jchromb.2017.01.010,"KISS LÓRÁND ET AL: ""Method development for detecting the novel cyanide antidote dimethyl trisulfide from blood and brain, and its interaction with blood"", JOURNAL OF CHROMATOGRAPHY B, ELSEVIER, AMSTERDAM, NL, vol. 1044, 9 January 2017 (2017-01-09), pages 149 - 157, XP029907609, ISSN: 1570-0232, DOI: 10.1016/J.JCHROMB.2017.01.010;;See also references of WO 2020251698A2",PENDING
275,NO,L,NO 20003096 L,096-867-027-693-56X,2000-08-15,2000,NO 20003096 A,2000-06-15,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,Sammensetninger og fremgangsmÕter for behandling av ADD,,NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/096-867-027-693-56X,Abstract,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K31/435;;A61K9/06;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
276,US,A1,US 2008/0282423 A1,187-430-078-988-39X,2008-11-13,2008,US 67283207 A,2007-02-08,US 67283207 A;;US 77235406 P,2006-02-09,METHODS AND COMPOSITIONS FOR MODIFYING PLANT BIOSYNTHETIC PATHWAYS,"The invention provides bifunctional plant biosynthetic enzymes that increase the efficiency by which modification can be made to plant biosynthetic pathways. In certain aspects of the invention, bifunctional isoflavone biosynthetic enzymes are provided. The invention therefore allows the modification of plants for isoflavone content. The inventors have demonstrated increased isoflavone biosynthesis can be obtained even in non-legume plants.",SAMUEL ROBERTS NOBLE FOUND INC,TIAN LI;;DIXON RICHARD A,NOBLE RESEARCH INSTITUTE LLC (2017-05-01);;SAMUEL ROBERTS NOBLE FOUNDATION (2007-12-12),https://lens.org/187-430-078-988-39X,Patent Application,yes,3,2,10,10,38,C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,A01H5/00;;C12N5/10;;C12N15/11;;C12N15/62;;C12N15/82,800/278;;536/24.1;;536/23.4;;435/320.1;;435/419;;800/298,0,0,,,,ACTIVE
277,CZ,B6,CZ 300535 B6,038-293-323-139-746,2009-06-10,2009,CZ 20002209 A,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,Compositions for topical application of methylphenidate,"The present invention relates to compositions for topical application of methylphenidate, comprising methylphenidate in a flexible, enclosed system wherein the methylphenidate is present in an amount sufficient for reaching kinetics of substantially zero-order while penetrating under epidermis or mucous membrane of the patient being in need thereof, for a period of at least 10 hours. The compositions are designed for treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD).",NOVEN PHARMACEUTICALS,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/038-293-323-139-746,Granted Patent,no,1,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K9/70;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
278,CA,A,CA 885176 A,023-369-608-183-891,1971-11-09,1971,CA 885176D A,1968-09-30,CA 31212 A,1968-09-30,ROTARY DISC FOR ROOT RAKE,,DIXON DONALD;;HOLLINGWORTH A BRUCE,DIXON DONALD;;HOLLINGWORTH A BRUCE,,https://lens.org/023-369-608-183-891,Granted Patent,no,0,0,1,1,0,A01D80/02,A01D78/00,,0,0,,,,EXPIRED
279,NO,D0,NO 20003096 D0,039-780-213-850-195,2000-06-15,2000,NO 20003096 A,2000-06-15,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,Sammensetninger og fremgangsmÕter for behandling av ADD,,NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/039-780-213-850-195,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
280,WO,A8,WO 2007/092934 A8,044-269-466-814-822,2008-09-12,2008,US 2007/0061865 W,2007-02-08,US 77235406 P,2006-02-09,METHODS AND COMPOSITIONS FOR MODIFYING PLANT BIOSYNTHETIC PATHWAYS,"The invention provides bifunctional plant biosynthetic enzymes that increase the efficiency by which modification can be made to plant biosynthetic pathways. In certain aspects of the invention, bifunctional isoflavone biosynthetic enzymes are provided. The invention therefore allows the modification of plants for isoflavone content. The inventors have demonstrated increased isoflavone biosynthesis can be obtained even in non-legume plants.",SAMUEL ROBERTS NOBLE FOUND INC;;TIAN LI;;DIXON RICHARD A,TIAN LI;;DIXON RICHARD A,,https://lens.org/044-269-466-814-822,Patent Application,no,0,0,10,10,0,C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,C12N15/82;;A01H5/00;;C07K19/00;;C12N15/62,,0,0,,,,PENDING
281,WO,A1,WO 2018/136476 A1,052-891-916-842-83X,2018-07-26,2018,US 2018/0013983 W,2018-01-17,US 201762447701 P,2017-01-18,METHODS FOR ENGINEERING PROANTHOCYANIDINS (PAS) IN PLANTS BY AFFECTING MYB TRANSCRIPTION FACTORS,"The amount of proanthocyanidins (PAs) found in cells of plants can be engineered or adjusted through regulation of transcription factors that affect PA biosynthesis. Increasing expression of genes encoding TT2-type MYB transcription factors, including homologs of AtTT2 of Arabidopsis thaliana such as GHMYB36 or GHMYB IO of cotton plants or GmTT2A or GmTT2B of soybean plants, leads to increased PA content. Expression of these genes can be increased through any suitable methods, including mutation of the genes and transformation of plant cells to include exogenous genes resulting in increased expression.",UNIV NORTH TEXAS,DIXON RICHARD A;;LU NAN,,https://lens.org/052-891-916-842-83X,Patent Application,yes,4,3,2,2,32,C07K14/415;;C12N15/8243;;C12N15/8243,C07K14/415;;C12N15/82,,56,55,117-515-052-137-232;;102-262-645-477-761;;041-068-196-667-681;;051-864-225-921-790;;045-313-928-419-029;;027-678-744-192-519;;047-345-160-917-862;;020-840-788-584-58X;;062-366-520-331-15X;;008-442-081-084-92X;;040-001-463-452-384;;049-427-391-860-033;;093-249-017-631-296;;120-639-540-415-038;;067-418-067-405-475;;011-806-609-814-883;;002-694-156-804-964;;004-200-462-255-879;;099-461-723-087-538;;087-443-222-806-376;;010-802-758-917-072;;053-007-879-121-123;;023-782-262-863-337;;008-858-322-691-181;;008-372-377-417-227;;019-187-204-358-315;;086-645-796-684-442;;046-141-901-474-835;;034-228-045-089-243;;036-160-849-503-061;;039-738-245-895-807;;021-724-398-369-137;;006-470-893-916-774;;114-073-709-470-108;;123-127-395-374-005;;002-302-213-407-020;;035-696-008-633-282;;106-366-996-995-001;;031-897-584-367-985;;028-196-979-497-207;;092-613-692-992-396;;078-146-802-412-659;;012-171-003-145-654;;059-116-604-685-035;;123-731-528-636-98X;;037-211-967-047-187;;064-024-054-212-26X;;083-487-454-284-713;;015-010-359-455-866;;135-926-819-985-421;;097-622-284-795-39X;;024-810-496-573-158;;086-365-149-110-809;;020-455-759-986-01X;;091-822-947-474-73X,pmc5066740;;10.1111/pbi.12524;;26806316;;10.1093/jxb/erv524;;26687179;;10.1186/s12870-015-0529-y;;pmc4481123;;26109181;;10.1111/ppl.12199;;24730512;;10.1111/nph.12017;;23157553;;pmc2785967;;19783643;;10.1104/pp.109.146985;;9076994;;10.1046/j.1365-313x.1997.11020289.x;;10.1002/mnfr.200700137;;18081206;;10.1007/978-1-4615-3476-1_32;;17208963;;10.1104/pp.106.093203;;pmc1820911;;10.1104/pp.114.256172;;pmc4378173;;25659381;;10.1046/j.1365-313x.1998.00343.x;;10069079;;10.1002/(sici)1097-0010(199807)77:3<368::aid-jsfa52>3.0.co;2-v;;pmc280558;;14555692;;10.1105/tpc.014043;;10.1016/j.copbio.2012.07.004;;22901316;;15720617;;10.1111/j.1469-8137.2004.01217.x;;10.1093/jxb/eru286;;25086591;;10.1371/journal.pone.0058820;;23527031;;pmc3602603;;18992236;;10.1016/j.ydbio.2008.10.005;;22566493;;10.1104/pp.112.195420;;pmc3387705;;27567364;;10.1093/jxb/erw312;;pmc5049394;;10.3835/plantgenome2014.08.0041;;33228286;;23870988;;10.1016/j.foodchem.2013.05.039;;26410301;;10.1105/tpc.15.00476;;pmc4682322;;22107112;;10.1021/jf2033939;;25893780;;10.1038/nbt.3208;;17618453;;10.1007/s00425-007-0573-4;;10.1007/s11738-011-0858-x;;24948832;;10.1104/pp.114.241877;;pmc4119029;;pmc4233638;;10.1186/1471-2229-13-202;;24308601;;27869786;;10.1038/nplants.2016.182;;pmc2801402;;10.4161/psb.4.8.9237;;19820325;;pmc139454;;10.2307/3871430;;10.1105/tpc.13.9.2099;;11549766;;10.1105/tpc.010098;;pmc3585583;;23288883;;10.1104/pp.112.212050;;pmc2544603;;10.1073/pnas.0805954105;;18772380;;10.1104/pp.107.107326;;17885080;;pmc2048810;;10.1111/j.1365-313x.2009.03885.x;;19368693;;10.1046/j.1365-313x.2002.01458.x;;12472686;;pmc2845569;;10.1186/1746-4811-6-8;;20222981;;pmc3414463;;22905202;;10.1371/journal.pone.0043064;;10.1093/jxb/54.381.239;;10.1093/jxb/erg022;;12493851;;pmc4367961;;10.1111/j.1365-313x.2006.02829.x;;16889650;;10.1093/molbev/mst197;;pmc3840312;;24132122;;19098092;;pmc2633825;;10.1104/pp.108.131862;;10.1007/978-94-015-9423-3_1;;10.1126/science.1160550;;18801998;;10.1371/journal.pone.0086344;;24466041;;pmc3897678;;10.1016/j.abb.2003.12.011;;14725861;;10.1126/science.1078540;;12532018;;10.1111/j.1365-313x.2006.02655.x;;16507081;;24721726;;pmc4091501;;10.1093/pcp/pcn009;;18202001;;10.1002/jsfa.2740630103;;pmc2751950;;19684242;;10.1105/tpc.109.067819;;25575669;;10.1007/s00425-014-2238-4,"PENGHUI LI ET AL: ""Metabolic engineering of proanthocyanidin production by repressing the isoflavone pathways and redirecting anthocyanidin precursor flux in legume"", PLANT BIOTECHNOLOGY JOURNAL, vol. 14, no. 7, 1 July 2016 (2016-07-01), GB, pages 1604 - 1618, XP055456327, ISSN: 1467-7644, DOI: 10.1111/pbi.12524;;RUI ZHAI ET AL: ""Two MYB transcription factors regulate flavonoid biosynthesis in pear fruit ( Pyrus bretschneideri Rehd.)"", JOURNAL OF EXPERIMENTAL BOTANY, vol. 67, no. 5, 18 December 2015 (2015-12-18), GB, pages 1275 - 1284, XP055456331, ISSN: 0022-0957, DOI: 10.1093/jxb/erv524;;YI LIU ET AL: ""Tc-MYBPA is an Arabidopsis TT2-like transcription factor and functions in the regulation of proanthocyanidin synthesis in Theobroma cacao"", BMC PLANT BIOLOGY, vol. 15, no. 1, 25 December 2015 (2015-12-25), XP055456051, DOI: 10.1186/s12870-015-0529-y;;YUE-CHEN BAI ET AL: ""Characterization of two tartary buckwheat R2R3-MYB transcription factors and their regulation of proanthocyanidin biosynthesis"", PHYSIOLOGIA PLANTARUM., vol. 152, no. 3, 1 November 2014 (2014-11-01), DK, pages 431 - 440, XP055456350, ISSN: 0031-9317, DOI: 10.1111/ppl.12199;;JAN G. SCHAART ET AL: ""Identification and characterization of MYB-bHLH-WD40 regulatory complexes controlling proanthocyanidin biosynthesis in strawberry ( Fragaria x ananassa ) fruits"", NEW PHYTOLOGIST, vol. 197, no. 2, 1 January 2013 (2013-01-01), GB, pages 454 - 467, XP055456052, ISSN: 0028-646X, DOI: 10.1111/nph.12017;;AKAGI T; IKEGAMI A; TSUJIMOTO T; KOBAYASHI S; SATO A; KONO A; YONEMORI K: ""DkMyb4 is a Myb transcription factor involved in proanthocyanidin biosynthesis in persimmon fruit"", PLANT PHYSIOLOGY, vol. 151, 2009, pages 2028 - 2045;;ALBERT S; DELSENY M; DEVIC M: ""BANYULS, a novel negative regulator of flavonoid biosynthesis in the Arabidopsis seed coat"", PLANT JOURNAL, vol. 11, 1997, pages 289 - 299, XP002982936, DOI: doi:10.1046/j.1365-313X.1997.11020289.x;;ARON PM; KENNEDY JA: ""Flavan-3-ols: Nature, occurrence and biological activity"", MOLECULAR NUTRITION & FOOD RESEARCH, vol. 52, 2008, pages 79 - 104;;BELL AA; EL-ZIK KM; THAXTON PM: ""Plant Polyphenols"", 1992, SPRINGER, article ""Chemistry, biological significance, and genetic control of proanthocyanidins in cotton (Gossypium spp."", pages: 571 - 595;;BOGS J; JAFFE FW; TAKOS AM; WALKER AR; ROBINSON SP: ""The grapevine transcription factor VvMYBPAl regulates proanthocyanidin synthesis during fruit development"", PLANT PHYSIOLOGY, vol. 143, 2007, pages 1347 - 1361;;CAVALLINI E; MATUS JT; FINEZZO L; ZENONI S; LOYOLA R; GUZZO F; SCHLECHTER R; AGEORGES A; ARCE-JOHNSON P; TORNIELLI GB: ""The phenylpropanoid pathway is controlled at different branches by a set of R2R3-MYB C2 repressors in grapevine"", PLANT PHYSIOLOGY, vol. 167, 2015, pages 1448 - 1470;;CLOUGH SJ; BENT AF: ""Floral dip: a simplified method for Agrobacterium-mediated transformation ofArabidopsis thaliana"", PLANT JOURNAL, vol. 16, 1998, pages 735 - 743, XP002132452, DOI: doi:10.1046/j.1365-313x.1998.00343.x;;DE COLMENARES NG; RAMIREZ-MARTINEZ JR; ALDANA JO; RAMOS-NINO ME; CLIFFORD MN; PEKERAR S; MENDEZ B: ""Isolation, characterisation and determination of biological activity of coffee proanthocyanidins"", JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, vol. 77, 1998, pages 368 - 372;;DEBEAUJON I; NESI N; PEREZ P; DEVIC M; GRANDJEAN O; CABOCHE M; LEPINIEC L: ""Proanthocyanidin-accumulating cells in Arabidopsis testa: regulation of differentiation and role in seed development"", PLANT CELL, vol. 15, 2003, pages 2514 - 2531, XP002443344;;DIXON RA; LIU C; JUN JH: ""Metabolic engineering of anthocyanins and condensed tannins in plants"", CURRENT OPINION IN BIOTECHNOLOGY, vol. 24, 2013, pages 329 - 335;;DIXON RA; XIE D-Y; SHARMA SB: ""Proanthocyanidins - a final frontier in flavonoid research?"", NEW PHYTOLOGIST, vol. 165, 2005, pages 9 - 28, XP002516051, DOI: doi:10.1111/j.1469-8137.2004.01217.x;;FENG H; LI Y; WANG S; ZHANG L; LIU Y; XUE F; SUN Y; WANG Y; SUN J: ""Molecular analysis of proanthocyanidins related to pigmentation in brown cotton fibre (Gossypium hirsutum L."", JOURNAL OF EXPERIMENTAL BOTANY, vol. 65, 2014, pages 5759 - 5769;;FENG H; TIAN X; LIU Y; LI Y; ZHANG X; JONES BJ; SUN Y; SUN J: ""Analysis of flavonoids and the flavonoid structural genes in brown fiber of upland cotton"", PLOS ONE, vol. 8, 2013, pages e58820;;GONZALEZ A; MENDENHALL J; HUO Y; LLOYD A: ""TTG1 complex MYBs, MYB5 and TT2, control outer seed coat differentiation"", DEVELOPMENTAL BIOLOGY, vol. 325, 2009, pages 412 - 421, XP026916066, DOI: doi:10.1016/j.ydbio.2008.10.005;;HANCOCK KR; COLLETTE V; FRASER K; GREIG M; XUE H; RICHARDSON K; JONES C; RASMUSSEN S: ""Expression of the R2R3-MYB transcription factor TaMYB14 from Trifolium arvense activates proanthocyanidin biosynthesis in the legumes Trifolium repens and Medicago sativa"", PLANT PHYSIOLOGY, vol. 159, 2012, pages 1204 - 1220;;HINCHLIFFE DJ; CONDON BD; THYSSEN G; NAOUMKINA M; MADISON CA; REYNOLDS M; DELHOM CD; LI P; MCCARTY J: ""The GhTT2_A07 gene is linked to the brown colour and natural flame retardancy phenotypes of Lcl cotton (Gossypium hirsutum L.) fibres"", JOURNAL OF EXPERIMENTAL BOTANY: ERW312, 2016;;HOVAV R; FAIGENBOIM-DORON A; KADMON N; HU G; ZHANG X; GALLAGHER JP; WENDEL JF: ""A transcriptome profile for developing seed of polyploid cotton"", PLANT GENOME, 2015, pages 8;;ITO C; OKI T; YOSHIDA T; NANBA F; YAMADA K; TODA T: ""Characterisation of proanthocyanidins from black soybeans: Isolation and characterisation of proanthocyanidin oligomers from black soybean seed coats"", FOOD CHEMISTRY, vol. 141, 2013, pages 2507 - 2512, XP028678893, DOI: doi:10.1016/j.foodchem.2013.05.039;;JUN JH; LIU C; XIAO X; DIXON RA: ""The transcriptional repressor MYB2 regulates both spatial and temporal patterns of proanthocyandin and anthocyanin pigmentation in Medicago truncatula"", PLANT CELL, vol. 27, 2015, pages 2860 - 2879;;KOVINICH N; SALEEM A; ARNASON JT; MIKI B: ""Identification of two anthocyanidin reductase genes and three red-brown soybean accessions with reduced anthocyanidin reductase 1 mRNA, activity, and seed coat proanthocyanidin amounts"", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 60, 2012, pages 574 - 584;;LI F; FAN G; LU C; XIAO G; ZOU C; KOHEL RJ; MA Z; SHANG H; MA X; WU J: ""Genome sequence of cultivated Upland cotton (Gossypium hirsutum TM-1) provides insights into genome evolution"", NATURE BIOTECHNOLOGY, vol. 33, 2015, pages 524 - 530;;LI H; FLACHOWSKY H; FISCHER TC; HANKE MV; FORKMANN G; TREUTTER D; SCHWAB W; HOFFMANN T; SZANKOWSKI I: ""Maize Lc transcription factor enhances biosynthesis of anthocyanins, distinct proanthocyanidins and phenylpropanoids in apple (Malus domestica Borkh."", PLANTA, vol. 226, 2007, pages 1243 - 1254, XP019542372, DOI: doi:10.1007/s00425-007-0573-4;;LI TC; FAN HH; LI ZP; WEI J; LIN Y; CAI YP: ""The accumulation of pigment in fiber related to proanthocyanidins synthesis for brown cotton"", ACTA PHYSIOLOGIAE PLANTARUM, vol. 34, 2012, pages 813 - 818, XP035016443, DOI: doi:10.1007/s11738-011-0858-x;;LIU C; JUN JH; DIXON RA: ""MYB5 and MYB14 play pivotal roles in seed coat polymer biosynthesis in Medicago truncatula"", PLANT PHYSIOLOGY, vol. 165, 2014, pages 1424 - 1439;;LIU Y; SHI Z; MAXIMOVA S; PAYNE MJ; GUILTINAN MJ: ""Proanthocyanidin synthesis in Theobroma cacao: genes encoding anthocyanidin synthase, anthocyanidin reductase, and leucoanthocyanidin reductase"", BMC PLANT BIOLOGY, vol. 13, 2013, pages 1 - 19;;LIU, C.; SHULAEV, V.; DIXON, R.A.: ""Role of leucoanthocyanidin reductase in extension of proanthocyanidins in Medicago"", NATURE PLANTS, 2016;;MELLWAY RD; CONSTABEL CP: ""Metabolic engineering and potential functions of proanthocyanidins in poplar"", PLANT SIGNALING & BEHAVIOR, vol. 4, 2009, pages 790 - 792;;NESI N; JOND C; DEBEAUJON I; CABOCHE M; LEPINIEC L: ""The Arabidopsis TT2 gene encodes an R2R3 MYB domain protein that acts as a key determinant for proanthocyanidin accumulation in developing seed"", PLANT CELL, vol. 13, 2001, pages 2099 - 2114, XP002982938, DOI: doi:10.1105/tpc.13.9.2099;;PANG Y; ABEYSINGHE ISB; HE J; HE X; HUHMAN D; MEWAN KM; SUMNER LW; YUN J; DIXON RA: ""Functional characterization of proanthocyanidin pathway enzymes from tea and their application for metabolic engineering"", PLANT PHYSIOLOGY, vol. 161, 2013, pages 1103 - 1116;;PANG Y; PEEL GJ; SHARMA SB; TANG Y; DIXON RA: ""A transcript profiling approach reveals an epicatechin-specific glucosyltransferase expressed in the seed coat of Medicago truncatula"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 105, 2008, pages 14210 - 14215, XP009127069, DOI: doi:10.1073/pnas.0805954105;;PANG Y; PEEL GJ; WRIGHT E; WANG Z; DIXON RA: ""Early steps in proanthocyanidin biosynthesis in the model legume Medicago truncatula"", PLANT PHYSIOLOGY, vol. 145, 2007, pages 601 - 615;;PEEL GJ; DIXON RA: ""Detection and quantification of engineered proanthocyanidins in transgenic plants"", NATURAL PRODUCT COMMUNICATIONS, vol. 2, 2007, pages 1009 - 1014;;PEEL GJ; PANG Y; MODOLO LV; DIXON RA: ""The LAP1 MYB transcription factor orchestrates anthocyanidin biosynthesis and glycosylation in Medicago"", PLANT JOURNAL, vol. 59, 2009, pages 136 - 149, XP055061702, DOI: doi:10.1111/j.1365-313X.2009.03885.x;;PETERS DJ; CONSTABEL CP: ""Molecular analysis of herbivore-induced condensed tannin synthesis: cloning and expression of dihydroflavonol reductase from trembling aspen (Populus tremuloides)"", PLANT JOURNAL, vol. 32, 2002, pages 701 - 712;;PETRIE JR; SHRESTHA P; LIU Q; MANSOUR MP; WOOD CC; ZHOU XR; NICHOLS PD; GREEN AG; SINGH SP: ""Rapid expression of transgenes driven by seed-specific constructs in leaf tissue: DHA production"", PLANT METHODS, vol. 6, 2010, pages 8, XP021069348;;PRASAD R; VAID M; KATIYAR SK: ""Grape proanthocyanidins inhibit pancreatic cancer cell growth in vitro and in vivo through induction of apoptosis and by targeting the PI3K/Akt pathway"", PLOS ONE, vol. 7, 2012, pages e43064;;ROBBINS MP; PAOLOCCI F; HUGHES JW; TURCHETTI V; ALLISON G; ARCIONI S; MORRIS P; DAMIANI F: ""Sn, a maize bHLH gene, modulates anthocyanin and condensed tannin pathways in Lotus corniculatus"", JOURNAL OF EXPERIMENTAL BOTANY, vol. 54, 2003, pages 239 - 248, XP002492558, DOI: doi:10.1093/jxb/erg022;;SAMUEL YANG S; CHEUNG F; LEE JJ; HA M; WEI NE; SZE SH; STELLY DM; THAXTON P; TRIPLETT B; TOWN CD: ""Accumulation of genome-specific transcripts, transcription factors and phytohormonal regulators during early stages of fiber cell development in allotetraploid cotton"", PLANT JOURNAL, vol. 47, 2006, pages 761 - 775;;TAMURA K; STECHER G; PETERSON D; FILIPSKI A; KUMAR S: ""MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0"", MOLECULAR BIOLOGY AND EVOLUTION, vol. 30, 2013, pages 2725 - 2729;;TERRIER N; TORREGROSA L; AGEORGES A; VIALET S; VERRIES C; CHEYNIER V; ROMIEU C: ""Ectopic expression of VvMybPA2 promotes proanthocyanidin biosynthesis in grapevine and suggests additional targets in the pathway"", PLANT PHYSIOLOGY, vol. 149, 2009, pages 1028 - 1041;;VERPOORTE R: ""Metabolic engineering of plant secondary metabolism"", 2000, SPRINGER, article ""Secondary metabolism"", pages: 1 - 29;;WU K-M; LU Y-H; FENG H-Q; JIANG Y-Y; ZHAO J-Z: ""Suppression of cotton bollworm in multiple crops in China in areas with Bt toxin-containing cotton"", SCIENCE, vol. 321, 2008, pages 1676 - 1678;;XIAO YH; YAN Q; DING H; LUO M; HOU L; ZHANG M; YAO D; LIU HS; LI X; ZHAO J: ""Transcriptome and biochemical analyses revealed a detailed proanthocyanidin biosynthesis pathway in brown cotton fiber"", PLOS ONE, vol. 9, 2014, pages e86344;;XIE D-Y; SHARMA SB; DIXON RA: ""Anthocyanidin reductases from Medicago truncatula and Arabidopsis thaliana"", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 422, 2004, pages 91 - 102, XP004483523, DOI: doi:10.1016/j.abb.2003.12.011;;XIE D-Y; SHARMA SB; PAIVA NL; FERREIRA D; DIXON RA: ""Role of anthocyanidin reductase, encoded by BANYULS in plant flavonoid biosynthesis"", SCIENCE, vol. 299, 2003, pages 396 - 399, XP002982939, DOI: doi:10.1126/science.1078540;;XIE DY; SHARMA SB; WRIGHT E; WANG ZY; DIXON RA: ""Metabolic engineering of proanthocyanidins through co-expression of anthocyanidin reductase and the PAP1 MYB transcription factor"", PLANT JOURNAL, vol. 45, 2006, pages 895 - 907, XP003012516;;XU W; LEPINIEC L; DUBOS C: ""New insights toward the transcriptional engineering of proanthocyanidin biosynthesis"", PLANT SIGNALING & BEHAVIOR, vol. 9, 2014, pages e28736;;YOSHIDA K; IWASAKA R; KANEKO T; SATO S; TABATA S; SAKUTA M: ""Functional differentiation of Lotus japonicus TT2s, R2R3-MYB transcription factors comprising a multigene family"", PLANT AND CELL PHYSIOLOGY, vol. 49, 2008, pages 157 - 169, XP002663746, DOI: doi:10.1093/pcp/pcn009;;YU F; BARRY T; MOUGHAN P; WILSON G: ""Condensed tannin and gossypol concentrations in cottonseed and in processed cottonseed meal"", JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, vol. 63, 1993, pages 7 - 15;;ZHAO J; DIXON RA: ""MATE transporters facilitate vacuolar uptake of epicatechin 3 -0-glucoside for proanthocyanidin biosynthesis in Medicago truncatula and Arabidopsis"", PLANT CELL, vol. 21, 2009, pages 2323 - 2340;;ZHU Y; WANG H; PENG Q; TANG Y; XIA G; WU J; XIE D-Y: ""Functional characterization of an anthocyanidin reductase gene from the fibers of upland cotton (Gossypium hirsutum)"", PLANTA, vol. 241, 2015, pages 1075 - 1089, XP035485018, DOI: doi:10.1007/s00425-014-2238-4",PENDING
282,HK,A1,HK 1049447 A1,083-099-754-752-393,2003-05-16,2003,HK 03101632 A,2003-03-05,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,COMPOSITIONS AND METHODS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,,NOVEN PHARMA,JUAN MANTELLE;;TERESE A DIXON,,https://lens.org/083-099-754-752-393,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K/;;A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,PENDING
283,CN,A,CN 1368876 A,082-746-594-706-647,2002-09-11,2002,CN 98813634 A,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,Compositions and methods of treatment of attention deficit disorder and attention dificit/hyperactivity disorder with methylphenidate,,NOVEN PHARMA,MANTELLA J;;DIXON T A,,https://lens.org/082-746-594-706-647,Patent Application,no,0,1,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K9/70;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,DISCONTINUED
284,AU,B2,AU 2020/292167 B2,124-708-806-922-216,2023-11-09,2023,AU 2020/292167 A,2020-04-30,US 201962841361 P;;US 202016814988 A;;US 2020/0030799 W,2019-05-01,Compositions of dimethyl trisulfide (DMTS) as a cyanide antidote,The present disclosure is directed at compositions of dimethyl trisulfide (DMTS) suitable for use for treatment of cyanide intoxication. The compositions show particularly useful stability such that the DMTS remains stable for therapeutic use at the identified time periods. The compositions are therefore particularly suitable for use in autoinjectors.,SOUTHWEST RES INST,DIXON HONG;;MCDONOUGH JOSEPH A,,https://lens.org/124-708-806-922-216,Granted Patent,no,0,0,9,9,0,A61K31/10;;A61K9/08;;A61K9/0019;;A61K9/1075;;A61K47/10;;A61M5/3157;;A61M5/30;;A61K31/10;;A61M5/20;;A61K9/1075;;A61K9/0019,A61K31/10;;A61K47/02;;A61P25/30;;A61P39/02,,0,0,,,,ACTIVE
285,NZ,A,NZ 505689 A,183-972-203-307-401,2003-01-31,2003,NZ 50568998 A,1998-12-14,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,Transdermal delivery system for 0.5-100 mg methylphenidate having zero-order kinetics for 10-16 hours,"Described is a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD). Also described are compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours",NOVEN PHARMACUETICALS INC,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/183-972-203-307-401,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,DISCONTINUED
286,WO,A3,WO 2007/092934 A3,018-576-081-385-526,2008-04-10,2008,US 2007/0061865 W,2007-02-08,US 77235406 P,2006-02-09,METHODS AND COMPOSITIONS FOR MODIFYING PLANT BIOSYNTHETIC PATHWAYS,"The invention provides bifunctional plant biosynthetic enzymes that increase the efficiency by which modification can be made to plant biosynthetic pathways. In certain aspects of the invention, bifunctional isoflavone biosynthetic enzymes are provided. The invention therefore allows the modification of plants for isoflavone content. The inventors have demonstrated increased isoflavone biosynthesis can be obtained even in non-legume plants.",SAMUEL ROBERTS NOBLE FOUND INC;;TIAN LI;;DIXON RICHARD A,TIAN LI;;DIXON RICHARD A,,https://lens.org/018-576-081-385-526,Search Report,yes,2,0,10,10,0,C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,C12N15/82;;A01H5/00;;C07K19/00;;C12N15/62,,14,13,135-894-153-029-324;;030-560-996-409-192;;028-474-712-033-769;;041-601-268-755-801;;027-346-493-289-672;;020-609-497-841-564;;009-534-056-736-871;;088-434-188-167-057;;070-856-398-089-073;;109-361-270-458-131;;032-015-405-987-054;;000-692-534-159-244;;010-214-063-649-840,10.1007/s00425-006-0233-0;;16482434;;pmc137925;;12384577;;10.1073/pnas.212522099;;10.1016/s0167-7799(98)01204-9;;9652137;;10.1038/88150;;11329019;;10.1104/pp.105.062539;;pmc1183411;;16006598;;10.1034/j.1399-3054.1999.100119.x;;10.1104/pp.104.054502;;15778463;;pmc1088328;;10.1021/bp020057k;;12467448;;10.1104/pp.106.1.17;;pmc159494;;7972515;;11129571;;10.1271/bbb.64.2025;;10.1111/j.1467-7652.2005.00136.x;;17173631;;12226498;;pmc166551;;10.1104/pp.005801;;10.1046/j.1365-313x.1998.00099.x;;9681028,"TIAN L ET AL: ""Engineering isoflavone metabolism with an artificial bifunctional enzyme"", PLANTA ; AN INTERNATIONAL JOURNAL OF PLANT BIOLOGY, SPRINGER-VERLAG, BE, vol. 224, no. 3, 16 February 2006 (2006-02-16), pages 496 - 507, XP019427478, ISSN: 1432-2048;;LIU C-J ET AL: ""Bottlenecks for metabolic engineering of isoflavone glycoconjugates in Arabidopsis"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 99, no. 22, 29 October 2002 (2002-10-29), pages 14578 - 14583, XP002983901, ISSN: 0027-8424;;LIU CHANG-JUN ET AL: ""Metabolic engineering of flavonoid/isoflavonoid biosynthesis in arabidopsis thaliana"", PLANT BIOLOGY. ABSTRACTS OF THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, XX, XX, vol. 2000, no. POSTER 29, 2000, pages 1, XP002397321;;NIXON A E ET AL: ""Hybrid enzymes: manipulating enzyme design"", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 16, no. 6, June 1998 (1998-06-01), pages 258 - 264, XP004121067, ISSN: 0167-7799;;MUIR SHELAGH R ET AL: ""Overexpression of petunia chalcone isomerase in tomato results in fruit containing increased levels of flavonols"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 19, no. 5, May 2001 (2001-05-01), pages 470 - 474, XP002295920, ISSN: 1087-0156;;DEAVOURS BETTINA E ET AL: ""Metabolic engineering of isoflavonoid biosynthesis in alfalfa"", PLANT PHYSIOLOGY (ROCKVILLE), vol. 138, no. 4, August 2005 (2005-08-01), pages 2245 - 2259, XP002454526, ISSN: 0032-0889;;WINKEL-SHIRLEY BRENDA: ""Evidence for enzyme complexes in the phenylpropanoid and flavonoid pathways"", PHYSIOLOGIA PLANTARUM, vol. 107, no. 1, September 1999 (1999-09-01), pages 142 - 149, XP002454527, ISSN: 0031-9317;;RALSTON LYLE ET AL: ""Partial reconstruction of flavonoid and isoflavonoid biosynthesis in yeast using soybean type I and type II chalcone isomerases"", PLANT PHYSIOLOGY (ROCKVILLE), vol. 137, no. 4, April 2005 (2005-04-01), pages 1375 - 1388, XP002454528, ISSN: 0032-0889;;YILMAZ J L ET AL: ""Enhanced stress tolerance in Escherichia coli and Nicotiana tabacum expressing a betaine aldehyde dehydrogenase/choline dehydrogenase fusion protein"", BIOTECHNOLOGY PROGRESS, XX, XX, vol. 18, 19 November 2002 (2002-11-19), pages 1176 - 1182, XP002386178, ISSN: 8756-7938;;SHIOTA N ET AL: ""Herbicide-resistant tobacco plants expressing the fused enzyme between rat cytochrome P4501A1 (CYP1A1) and yeast NADPH-cytochrome P450 oxidoreductase"", PLANT PHYSIOLOGY, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, US, vol. 106, 1994, pages 17 - 23, XP002100395, ISSN: 0032-0889;;SHIOTA N ET AL: ""EXPRESSION OF HUMAN CYTOCHROMES P450 1A1 AND P450 1A2 AS FUSED ENZYMES WITH YEAST NADPH-CYTOCHROME P450 OXIDOREDUCTASE IN TRANSGENIC TOBACCO PLANTS"", BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, JAPAN SOC. FOR BIOSCIENCE, BIOTECHNOLOGY AND AGROCHEM, TOKYO, JP, vol. 64, no. 10, 2000, pages 2025 - 2033, XP001062629, ISSN: 0916-8451;;KOURTZ L ET AL: ""A novel thiolase-reductase gene fusion promotes the production of polyhydroxybutyrate in Arabidopsis"", PLANT BIOTECHNOLOGY JOURNAL, BLACKWELL, OXFORD, GB, vol. 3, no. 4, 2005, pages 435 - 447, XP003014824, ISSN: 1467-7644;;DIDIERJEAN LUC ET AL: ""Engineering herbicide metabolism in tobacco and Arabidopsis with CYP76B1, a cytochrome P450 enzyme from Jerusalem artichoke"", PLANT PHYSIOLOGY (ROCKVILLE), vol. 130, no. 1, September 2002 (2002-09-01), pages 179 - 189, XP002454529, ISSN: 0032-0889;;BATARD YANNICK ET AL: ""Molecular cloning and functional expression in yeast of CYP76B1, a xenobiotic-inducible 7-ethoxycoumarin O-de-ethylase from Helianthus tuberosus"", PLANT JOURNAL, vol. 14, no. 1, April 1998 (1998-04-01), pages 111 - 120, XP002454530, ISSN: 0960-7412",PENDING
287,US,A1,US 2008/0008746 A1,041-323-542-206-729,2008-01-10,2008,US 81219807 A,2007-06-15,US 81219807 A;;US 37862906 A;;US 2451301 A;;US 61862600 A;;US 16335198 A;;US 6951097 P,1997-12-15,Compositions and method for treatment of Attention Deficit Disorder and Attention Deficit/Hyperactivity Disorder with methylphenidate,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein said composition comprises about 10 to 30 wt % methylphenidate, about 30 to 50 wt % acrylic adhesive, and about 30 to 50 wt % silicone adhesive and wherein said methylphenidate is delivered to a subject in need thereof such that the plasma concentration of methylphenidate increases over a period of about 6-16 hours, and more preferably over a period of about 6-12 hours followed by a steady decrease in plasma concentration of methylphenidate.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/041-323-542-206-729,Patent Application,yes,2,3,7,65,0,A61K9/7061;;A61K9/7069;;A61K31/445;;A61K31/4458;;A61P25/00;;A61K31/445;;A61K9/7061;;A61K9/7069;;A61K31/4458;;A61K47/32,A61K9/70;;A61K31/445;;A61K31/4458;;A61P25/00,424/448;;424/447;;514/317,0,0,,,,DISCONTINUED
288,HU,A2,HU P0004539 A2,096-276-124-677-495,2001-06-28,2001,HU P0004539 A,1998-12-14,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,COMPOSITION AND METHOD FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"A találmány tárgya készítmény metilfenidát topikális adagolására,amely metilfenidátot tartalmaz egy rugalmas, körülhatároltrendszerben, ahol a metilfenidát a beteg bőrén vagy nyálkahártyájánkeresztül lényegében nulla nagyságrendű kinetikával legalább tíz óránkeresztül történő adagoláshoz elegendő mennyiségben van jelen, aholkészítmény legfeljebb mintegy 5 tömeg% savas funkciós csoportokathordozó monomert tartalmaz. Ó",NOVEN PHARMA,DIXON TERESE A;;MANTELLE JUAN,,https://lens.org/096-276-124-677-495,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
289,EP,A2,EP 0256818 A2,105-385-211-193-496,1988-02-24,1988,EP 87307038 A,1987-08-07,GB 8619540 A,1986-08-11,Toys.,"A toy includes a plurality of portions adapted for articulation relative to each other. The toy has a skeleton for which there are at least skeleton members corresponding to each portion of the toy other than portions at the extremeties of the toy. The skeleton is moulded as a single integrated structure with each skeleton member generally rigidly connected to the or each neighbouring skeleton member by a respective relatively narrow breakable region. The toy additionally comprises, for each portion of the toy for which there is a corresponding skeleton member, a body member injection moulded generally around an end part of the corresponding skeleton member and also around the adjacent end part of each or any skeleton member to which the first mentioned end part is connected by one of the relatively narrow breakable regions. To complete the articulated toy, the various narrow breakable regions are broken after moulding of the body members. ",DIXON MANNING SALES MARKETIN,DIXON JOHN A;;MANNING PETER,,https://lens.org/105-385-211-193-496,Patent Application,yes,0,8,7,7,0,A63H9/00,A63H3/36;;A63H3/04;;A63H3/46;;A63H9/00;;G01R13/20,,0,0,,,,DISCONTINUED
290,BR,A,BR 9814282 A,139-868-955-003-341,2000-10-03,2000,BR 9814282 A,1998-12-14,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,"""composições e métodos para tratamento de distúrbio de déficit de atenção e distúrbio de déficit/hiperatividade de atenção com metilfenidato""","Patente de Invenção: <B>""COMPOSIçõES E MéTODOS PARA TRATAMENTO DE DISTúRBIO DE DéFICIT DE ATENçãO E DISTúRBIO DE DéFICIT/HIPERATIVIDADE DE ATENçãO COM METILFENIDATO""<D>. A invenção refere-se a um método de tratamento de Distúrbio de Déficit de Atenção (ADD) e Distúrbio de Déficit de Atenção/Hiperatividade (ADHD) e a composições para aplicação tópica de metilfenidato compreendendo metilfenidato em um sistema finito flexível, em que o metilfenidato está presente em uma proporção suficiente para atingir substancialmente uma cinética de ordem zero para transferência para a pele ou mucosa de um paciente carente dele por um período de pelo menos 10 horas.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/139-868-955-003-341,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K9/70;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,DISCONTINUED
291,MX,A,MX 9300979 A,156-188-508-690-597,1994-08-31,1994,MX 9300979 A,1993-02-23,MX 9300979 A,1993-02-23,TARJETA DE CREDITO CON LENTE AMPLIFICADOR.,"La invención se refiere a una tarjeta con crédito que incluye una lupa o lente amplificador integral colocado en el área que no tiene datos en una tarjeta de crédito, para permitir ampliar la forma de transacción de tarjeta de crédito en el punto-de-venta. La colocación del lente asegura que la legibilidad de la máquina de la tira de codificación magnética y las señales realzadas asociadas con la tarjeta no se deterioran. La lupa incorpora un lente de contorno tipo fresnal montado en una ventana que se proporciona en la base de tarjeta de crédito.",FINKELSTEIN ALAN;;DONALD A DIXON,FINKELSTEIN ALAN;;DIXON DONALD A,,https://lens.org/156-188-508-690-597,Patent Application,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
292,GB,A,GB 2193650 A,172-953-147-766-079,1988-02-17,1988,GB 8619540 A,1986-08-11,GB 8619540 A,1986-08-11,TOYS HAVING SKELETAL FRAMEWORK,"A toy, e.g. a doll, including a plurality of portions adapted for relative articulation, has a skeleton for which there are skeleton members corresponding to each portion of the toy other than extremities e.g., hands, feet. The skeleton is moulded as a single integrated structure with each skeleton member generally rigidly connected to the or each neighbouring skeleton member by a respective relatively narrow breakable region 12. The toy additionally comprises, for each portion of the toy for which there is a corresponding skeleton member, a body member (not shown) injection moulded generally around an end part of the corresponding skeleton member and also around the adjacent end part of each or any skeleton member to which the first mentioned end part is connected by one of the relatively narrow breakable regions. To complete the articulated toy, the various narrow breakable regions are broken after moulding of the body members. <IMAGE>",DIXON MANNING SALES AND MARKET,DIXON A JOHN;;MANNING PETER,,https://lens.org/172-953-147-766-079,Patent Application,no,1,1,7,7,0,A63H9/00,A63H3/36;;A63H3/04;;A63H3/46;;A63H9/00;;G01R13/20,A6S S1B           S1;;A6S S1F1          S1;;B5A AA2           AA2;;B5A A1R214H       AA2;;B5A A1R314C1X     AA2;;B5A A1R314C3      AA2;;B5A A1R448        AA2;;B5A A1R461        AA2;;B5A A2E7A         AA2;;B5A A2E9          AA2;;B5A A20N5         AA2;;B5A A20T14        AA2;;U1S S1205,0,0,,,,EXPIRED
293,WO,A3,WO 1999/030694 A3,180-500-315-199-922,1999-08-19,1999,US 9826560 W,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,COMPOSITIONS AND METHODS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",NOVEN PHARMA;;MANTELLE JUAN;;DIXON TERESE A,MANTELLE JUAN;;DIXON TERESE A,,https://lens.org/180-500-315-199-922,Search Report,yes,2,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K31/435;;A61K9/06;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,PATENTED
294,SE,B,SE 433349 B,043-470-301-881-603,1984-05-21,1984,SE 7701723 A,1977-02-16,GB 671676 A,1976-02-20,FORFARANDE FOR FRAMSTELLNING AV 2-(KARBAMOYL)FENYL-2-ACETOXIBENSOAT,,BEECHAM GROUP LTD,DAVIS A F;;DIXON G J A,,https://lens.org/043-470-301-881-603,Unknown,no,0,0,36,38,0,A61K31/60;;A61P25/04;;A61P29/00;;A61K31/60,A61K31/60;;A61P25/04;;A61P29/00;;C07C67/00;;C07C231/00;;C07C235/46,,0,0,,,,DISCONTINUED
295,SE,L,SE 7701723 L,179-006-402-057-683,1977-08-21,1977,SE 7701723 A,1977-02-16,GB 671676 A,1976-02-20,ANALGETISKA OCH ANTI-INFLAMMATORISKA KOMPOSITIONER,,BEECHAM GROUP LTD,DAVIS A F;;DIXON G J A,,https://lens.org/179-006-402-057-683,Abstract,no,0,0,36,38,0,A61K31/60;;A61P25/04;;A61P29/00;;A61K31/60,A61K31/60;;A61P25/04;;A61P29/00;;C07C67/00;;C07C231/00;;C07C235/46,,0,0,,,,DISCONTINUED
296,DK,A,DK 73877 A,084-859-343-715-593,1977-08-21,1977,DK 73877 A,1977-02-18,GB 671676 A,1976-02-20,FREMGANGSMADE TIL FREMSTILLING AF ET ANALGETIKUM,,BEECHAM GROUP LTD,DAVIS A F;;DIXON G J A,,https://lens.org/084-859-343-715-593,Patent Application,no,0,0,36,38,0,A61K31/60;;A61P25/04;;A61P29/00;;A61K31/60,A61K31/60;;A61P25/04;;A61P29/00;;C07C67/00;;C07C231/00;;C07C235/46,,0,0,,,,DISCONTINUED
297,YU,A,YU 45777 A,185-829-026-425-327,1982-10-31,1982,YU 45777 A,1977-02-18,GB 671676 A,1976-02-20,PROCESS FOR BTAINING 2-(CARBAMOYL)-PHENYL-2-ACETOXYBENZOATE,,BEECHAM GROUP LTD,DAVIS A F;;DIXON G J A,,https://lens.org/185-829-026-425-327,Patent Application,no,0,0,36,38,0,A61K31/60;;A61P25/04;;A61P29/00;;A61K31/60,A61K31/60;;A61P25/04;;A61P29/00;;C07C67/00;;C07C231/00;;C07C235/46,,0,0,,,,EXPIRED
298,US,A,US 2664360 A,015-410-554-147-60X,1953-12-29,1953,US 24279851 A,1951-08-20,US 24279851 A,1951-08-20,Manufacture of cellulose,,INT PAPER CANADA,CHARLES FRANK R;;DIXON JULIAN A,,https://lens.org/015-410-554-147-60X,Granted Patent,no,6,22,1,1,0,D01F2/08;;D01F2/08,D01F2/08,,0,0,,,,EXPIRED
299,US,A,US 3529886 A,019-739-398-810-690,1970-09-22,1970,US 3529886D A,1968-07-31,US 74992868 A,1968-07-31,IODIC ACID ACOUSTO-OPTIC DEVICES,,BELL TELEPHONE LABOR INC,DIXON RICHARD W;;PINNOW DOUGLAS A,,https://lens.org/019-739-398-810-690,Granted Patent,no,0,3,10,10,0,G02F1/33;;G02F1/33,G02F1/33,350/161,0,0,,,,EXPIRED
300,EP,B1,EP 0740944 B1,048-349-163-546-598,2004-07-21,2004,EP 96302194 A,1996-03-28,US 43299895 A,1995-05-02,Pivot assisted retainer assembly and defibrillator comprising same,,KONINKL PHILIPS ELECTRONICS NV,ANDREWS JONATHAN N;;DIXON WILLIAM A,"HEWLETT-PACKARD COMPANY, A DELAWARE CORPORATION (2001-03-28);;AGILENT TECHNOLOGIES INC. A DELAWARE CORPORATION (2001-08-08);;KONINKLIJKE PHILIPS N.V., NL (2014-11-26);;AGILENT TECHNOLOGIES, INC. (A DELAWARE CORPORATION (2001-10-10);;AGILENT TECHNOLOGIES INC. (2001-08-01);;KONINKLIJKE PHILIPS ELECTRONICS N.V. (2003-08-06)",https://lens.org/048-349-163-546-598,Granted Patent,yes,5,1,8,8,0,A61N1/3904;;A61N1/3904;;B25H3/006;;B25H3/006,A61N1/39;;B25H3/00,,0,0,,,,EXPIRED
301,US,A1,US 2009/0142471 A1,040-302-909-858-231,2009-06-04,2009,US 25995108 A,2008-10-28,US 25995108 A;;US 97619004 A;;US 51555903 P,2003-10-29,PLANT ISOFLAVONOID HYDROXYLASES AND METHODS OF USE THEREOF,"The invention provides plant isoflavonoid hydroxylase coding sequences. Also provided are constructs comprising these sequences, plants transformed therewith and methods of use thereof. In certain aspects of the invention, plants transformed with the nucleic acids are provided exhibiting improved pest and disease resistance. Plants provided by the invention may also exhibit improved nutritional qualities.",DIXON RICHARD A;;LIU CHANG-JUN,DIXON RICHARD A;;LIU CHANG-JUN,NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/040-302-909-858-231,Patent Application,yes,3,1,8,8,21,C12N9/0073;;C12N9/0073,A23L19/00;;A01H5/00;;C12N5/04;;C12N9/02;;C12N15/00;;C12N15/11;;C12N15/82,426/615;;536/23.2;;435/320.1;;435/189;;800/298;;435/419;;800/278,0,0,,,,ACTIVE
302,US,A,US 3186369 A,057-028-200-960-27X,1965-06-01,1965,US 26770763 A,1963-03-25,US 26770763 A,1963-03-25,Buoyant article transporter,,MCLENNAN CHARLES A;;DIXON DOUGLAS G,MCLENNAN CHARLES A;;DIXON DOUGLAS G,,https://lens.org/057-028-200-960-27X,Granted Patent,no,3,15,1,1,0,B63B25/006;;B63B25/006,B63B25/00,,0,0,,,,EXPIRED
303,US,B2,US 7442851 B2,075-718-936-511-371,2008-10-28,2008,US 97619004 A,2004-10-28,US 97619004 A;;US 51555903 P,2003-10-29,Plant isoflavonoid hydroxylases and methods of use thereof,"The invention provides plant isoflavonoid hydroxylase coding sequences. Also provided are constructs comprising these sequences, plants transformed therewith and methods of use thereof. In certain aspects of the invention, plants transformed with the nucleic acids are provided exhibiting improved pest and disease resistance. Plants provided by the invention may also exhibit improved nutritional qualities.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;LIU CHANG-JUN,SAMUEL ROBERTS NOBLE FOUNDATION THE (2005-02-21),https://lens.org/075-718-936-511-371,Granted Patent,yes,8,2,8,8,21,C12N9/0073;;C12N9/0073,A23L19/00;;C12N15/29;;A01H5/00;;A01H5/10;;C12N9/02;;C12N15/52;;C12N15/82,800/279;;800/298;;800/287;;800/320;;800/312;;536/23.1;;536/23.2;;536/24.1;;435/419,40,28,030-560-996-409-192;;006-713-586-398-958;;029-444-788-587-249;;064-627-264-538-308;;111-423-948-356-968;;049-116-326-914-471;;016-260-898-220-124;;022-840-884-390-841;;053-522-357-177-636;;048-425-634-797-396;;030-730-200-090-470;;002-689-313-687-938;;040-238-080-165-869;;032-569-428-744-527;;079-620-757-564-531;;030-995-480-883-515;;009-730-205-489-885;;030-560-996-409-192;;008-831-818-058-304;;031-855-736-737-194;;021-790-234-568-506;;019-370-215-214-515;;010-860-681-994-410;;032-860-477-848-422;;045-664-788-381-085;;172-889-478-463-474;;023-730-405-857-029;;093-860-659-276-472,pmc137925;;12384577;;10.1073/pnas.212522099;;9790908;;10.1006/bbrc.1998.9414;;10.1039/p19920000839;;10.1007/bf00232133;;24226376;;10.1016/0031-9422(95)00618-4;;10.1016/s0031-9422(00)95150-1;;12031439;;10.1016/s0031-9422(02)00116-4;;pmc1540287;;12644640;;10.1104/pp.102.017319;;10.1046/j.1364-3703.2002.00131.x;;20569344;;10.1016/b978-0-08-091283-7.00030-8;;10.1515/znc-1991-1-210;;10.2307/3871183;;11006341;;pmc149079;;10.1105/tpc.12.9.1689;;10.1016/0014-5793(87)80021-2;;10.1016/0003-9861(89)90514-6;;2505672;;10.1016/s0031-9422(00)90838-0;;11027686;;10.1074/jbc.m006277200;;pmc139479;;10.2307/3871525;;10.1105/tpc.010382;;11752378;;10.1105/tpc.13.12.2643;;pmc137925;;12384577;;10.1073/pnas.212522099;;10.1046/j.1365-313x.2003.01893.x;;14617078;;6649792;;10.1515/znc-1983-9-1007;;10.1016/s0176-1617(11)81242-3;;10540749;;10.1271/bbb.63.1618;;10773344;;10.1016/s0168-9452(00)00214-4;;10.1016/s0076-6879(96)72008-6;;8791762;;10.1016/s0168-9452(00)00355-1;;11164575;;11471948;;10.1023/a:1010339104206;;11413204;;10.1093/jexbot/52.357.681;;12166960;;10.1021/jf025549r,"Liu C. et al. PNAS, 2002, vol. 99, No. 22; pp. 14578-14583.;;Akashi et al., ""CYP81E1, a Cytochrome P450 cDna of Licorice (Glycyrrhiza echinata L.) Encodes isoflavone 2'-hydroxylase,"" Biochemical and Biophysical Research Communications, 251:67-70, 1998.;;Bhandari et al., ""Biosynthesis of the A/B/C/D- ring system of the rotenoid amorphigenin by Amorpha fruticosa seedlings,"" J. Chem. Soc. Perkin Trans., 839-849, 1992.;;Choudhary et al., ""Stress responses in alfalfa (Medicago sativa L.) IV. Expression of defense gene constructs in electroporated suspension cell photoplasts,"" Plant Cell Rep., 9:42-46, 1990.;;Clemens and Barz, ""Cytochrome P450- dependant methylenedioxy bridge formation in Cicer Arietinum,"" Phytochemistry, 41:457-460, 1996.;;Clemens et al., ""Characterization of Cytochrome P450-dependent isoflavone hydroxylasas from chickpea,"" Phytochemistry, 32:653-657, 1993.;;Dewick, ""Isoflavonoids,"" The Flavonoids: Advances in Research Since 1986., Harborne (Ed.), London: Chapman and Hall, 117-238, 1993.;;Dixon and Ferreira, ""Molecules of Interest Genistein,"" Phytochemistry, 60:205-211, 2002.;;Dixon and Sumner, ""Legume natural products: understanding and manipulating complex pathways for human and animal health,"" Plant Physiol., 131:878-885, 2003.;;Dixon et al., ""The phenylpropanoid pathway and plant defence-a genomics perspective,"" Mol. Plant Pathol., 3:371-390, 2002.;;Dixon, ""Isoflavonoids: biochemistry, molecular biology, and biological functions,"" Comprehensive Natural Products Chemistry, Barton et al. (ed), Elsevier, 1:773-823, 1999.;;GenBank Accession No. AB001379, Apr. 21, 2000.;;GenBank Accession No. AB022732, Apr. 21, 2000.;;GenBank Accession No. AB025016, Jul. 19, 2003.;;GenBank Accession No. AJ012581, May 1, 1999.;;GenBank Accession No. AJ238439, Oct. 22, 1999.;;GenBank Accession No. AY166658, Apr. 20, 2004.;;GenBank Accession No. AY278227, Nov. 21, 2003.;;GenBank Accession No. AY278229, Nov. 21, 2003.;;Gunia et al., ""Elicitor induction of cytochrome P450 monooxygenases in cell suspension cultures of chickpea (Cicer arietinum L.) and their involvement in pterocarpan phytoalexin biosynthesis,"" Z. Naturforsch: 46:58-66, 1991.;;Hahn et al., ""ESTs from roots of Medicago truncatula treated with oligogalacturonides of DP 6-20,"" 2001, Accession #BG648057..;;He and Dixon, ""Genetic manipulation of isoflavone 7-O-methyltransferase enhances biosynthesis of 4'0-methylated isoflavonoid phytoalexins and disease resistance in alfalfa,"" Plant Cell, 12:1689-1702, 2000.;;Hinderer et al., ""Microsomal isoflavone 2'-and 3'-hydroxylases from chickpea (Cicer arietinum L.) cell suspensions induced for pterocarpan phytoalexin formation,"" Febs Letters, 214:101-106, 1987.;;Kochs and Grisebach, ""Phytoalexin synthesis in soybean: purification and reconstitution of cytochrome P450 3,9-dihydroxypterocarpan 6a-hydroxylase and separation from Cytochrome P450 cinnamate 4-hydroxylase,"" Arch. Biochem. Biophys., 273:543-553, 1989.;;Lambert et al., ""Production of rotenoids by heterotrophic and photomixotrophic cell cultures of tephrosia vogelii,"" Phytochemistry, 34:1515-1520, 1993.;;LatundeDada et al., ""Flavonoid 6-hydroxylase from soybean (Glycine max. L.), a novel plant P-450 monooxygenase,"" J. Biol. Chem., 276:1688-1695, 2001.;;Liu and Dixon, ""Elicitor-induced association of isoflavone O-methyltransferase with endomembranes prevents the formation and 7-O-methylation of daidzein during isoflavonoid phytoalexin biosynthesis,"" Plant Cell, 13:2643-2658, 2001.;;Liu et al., ""Bottlenecks for metabolic engineering of isoflavone glycocojugates in Arabidopsis,"" Proc. Natl. Acad. Sci USA, 99:14578-14583, 2002.;;Liu et al., ""Regiospecific hydroxylation of isoflavones by ctyochrome P450 81E enzymes from medicago truncatula,"" The Plant Journal, 36:471-484, 2000.;;Mackenbrock and Barz, ""3'-Hydroxylation of 4'-Methoxyisoflavones by Fusarium oxysporum f. lycopersici,"" Z. Naturforsch. 38:708-710, 1983.;;Mackenbrock et al., ""Accumulation and metabolism of medicarpin and maackiain maolnylgucosides in elicited chickpea (Cicer arietinum L.) cell suspension cultures,"" J. Plant Physiol., 142:385-391. 1993.;;Mihaliak et al., ""Cytochrome P450 terpene hydroxylases,"" Meth. Plant Biochem., 9:261-279, 1993.;;Nakamura et al., ""Induction of isoflavonoid and retrochalcone branches of the flavonoid pathway in cultured Glycyrrhiza echinata cells treated with yeast extract,"" Biosci. Biotechnol. Biochem., 63:1618-1620, 1999.;;Overkamp and Barz, ""Cloning of two cicer arietinum L. cDNA's encoding Cytochrome P450's highly homologous Isoflavone 2'-Hydroxylase from licorice,"" Plant Physiol., 120:935, 1999.;;Overkamp et al., Cloning and characterization of eight cytochrome P450 cDNAs from chickpea (Cicer arietinum L.) cell suspension cultures, Plant Science, 155:101-108, 2000.;;Pompon et al., ""Yeast expression of animal and plant P450s in optimized redox environments,"" Meth. Enzymol., 272:51-64, 1996.;;Shimada et al., ""Induction of isoflavonoid pathway in the model legume Lotus japonicus: molecular characterization of enzymes involved in phytoalexin biosynthesis,"" Plant Science, 160:37-47, 2000.;;Simmonds and Stevenson, ""Effects of isoflavonoids from Cicer on larve of Heliocoverpa armigera,"" J. Chem. Ecol., 27:965-977, 2001.;;Tebayashi et al., ""Elicitor-induced changes in isoflavonoid metabolism in red clover roots,"" J. Exp. Bot., 52:681-668, 2001.;;Tolleson et al., ""Metabolism of Biochanin A and formononetin by human liver microsomes in vitro,"" J. Agric. Food Chem., 50:4783-4790, 2002.",INACTIVE
304,US,B2,US 7140954 B2,105-198-478-685-090,2006-11-28,2006,US 97021404 A,2004-10-21,US 97021404 A,2004-10-21,High pressure cleaning and decontamination system,"Abrasive cleaning and decontamination methods and systems are disclosed. The methods and systems use a high pressure liquefied gas, such as carbon dioxide, which produces insignificant quantities of secondary waste. These principles of the invention exploit the properties of the relatively high triple point of CO 2 in order to first pressurize it to 35,000 to 60,000 PSI from a pressurized liquid. In the pressurized state, such a fluid can be at or above room temperature, allowing for transport over long distances in a flexible high pressure hose. At a point of use, a heat exchanger may subsequently chill the liquid, so that after expansion through a small high pressure orifice, a significant fraction of the liquid is converted to solid phase crystals exiting at high velocity to effectively clean and decontaminate. For more aggressive cleaning, abrasive particles and/or small diameter solid CO 2 pellets can be entrained into the high pressure CO 2 slipstream.",ROBOTICS SA,JOHNSON SAMUEL A;;DIXON JOSEPH E,KURION INC (2014-02-05);;S.A. ROBOTICS (2004-10-19);;SPECIAL APPLICATIONS TECHNOLOGY INC (2010-02-26);;SPECIAL APPLICATION ROBOTICS INC (2008-05-07),https://lens.org/105-198-478-685-090,Granted Patent,yes,7,5,2,2,0,B24C1/003;;B24C3/06;;B24C1/003;;B24C3/06,B24C3/00,451/75;;451/99,0,0,,,,INACTIVE
305,WO,A3,WO 2007/027240 A3,090-072-025-848-41X,2007-08-16,2007,US 2006/0017111 W,2006-05-03,US 12232705 A,2005-05-04,RADIATION ATTENUATION SYSTEM,"A radiation attenuation system for shielding from scatter radiation one or more portions of a patient that are not of primary interest to a particular radiological procedure (i.e., non-target areas, etc.). The radiation attenuation system may be configured to shield the head of a patient (such as the head of a pediatric patient), and/or any other portion of the patient that may benefit from being shielded from scatter radiation. The radiation attenuation system is preferably configured to conform to the contours of the patient. The radiation attenuation system may be a flexible member that can be reconfigured to accommodate patients of varying size.",WORLDWIDE INNOVATIONS & TECHNO;;CADWALADER JOHN A;;DIXON DAVID G,CADWALADER JOHN A;;DIXON DAVID G,,https://lens.org/090-072-025-848-41X,Search Report,yes,1,0,4,4,0,A61B6/107;;G21F3/02;;G21K1/10;;A61B6/4423;;G21K1/10;;G21F3/02;;A61B6/107,G21C1/00;;G21C11/00;;G21C3/00;;G21C5/00;;G21C7/00,,0,0,,,,PENDING
306,US,A,US 4701322 A,133-187-871-586-808,1987-10-20,1987,US 70689885 A,1985-02-28,US 70689885 A;;US 14229780 A,1980-04-21,Conditioning shampoo,"A conditioning shampoo containing as the conditioning agent a saturated, straight chain fatty acid having from about 14 to about 18 carbon atoms.",PROCTER & GAMBLE,DIXON THOMAS J;;UCHTMAN VERNON A,,https://lens.org/133-187-871-586-808,Granted Patent,yes,11,24,1,8,0,A61K8/361;;A61K8/463;;A61Q5/02;;A61Q5/12;;A61Q5/12;;A61Q5/02;;A61K8/463;;A61K8/361,A61K8/36;;A61K8/46;;A61Q5/02;;A61Q5/12;;C11D3/20,424/70;;132/7,4,0,,,"Redgrove, Hair Dyes and Hair Dyeing, 1939, pp. 117 121.;;Pharmaceutical Formulas, vol. II, The Chemist and Druggist, London, Great Britain, 1946, pp. 241 247.;;Miall, A New Dictionary of Chemistry, Interscience Pub., Inc., New York, 1961, p. 391.;;1972 Cosmetic Formulary, Emery Products for Cosmetics & Drug Industries, p. B 25.",EXPIRED
307,US,A1,US 2015/0098821 A1,136-392-415-364-330,2015-04-09,2015,US 201314048106 A,2013-10-08,US 201314048106 A,2013-10-08,REVERSE FLOW LOAD MITIGATION DEVICE FOR A WIND TURBINE BLADE,"A reverse wind load mitigation device ( 30 ) is provided for a wind turbine blade ( 20 ). The device ( 30 ) comprises a hinge member ( 32 ) attachable to a trailing edge ( 26 ) of a wind turbine blade ( 20 ). The separated flow inducer ( 34 ) is associated with the hinge member ( 32 ) and is configured to pivot about or with the hinge member ( 32 ) toward at least one of the surfaces ( 40, 42 ) in response to wind ( 45 ) traveling from a direction of the trailing edge ( 28 ). The separated flow inducer ( 34 ) is effective to induce flow separation ( 50 ) over at least one of the surfaces ( 40, 42 ).",MAYDA EDWARD A;;DIXON KRISTIAN R,MAYDA EDWARD A;;DIXON KRISTIAN R,SIEMENS AKTIENGESELLSCHAFT (2014-02-11);;SIEMENS WIND POWER A/S (2013-10-21);;SIEMENS ENERGY INC (2013-09-17),https://lens.org/136-392-415-364-330,Patent Application,yes,2,12,2,2,0,F03D1/0633;;F03D1/0641;;F05B2240/31;;F03D7/0232;;Y02E10/72;;F05B2240/3052;;F03D1/0675;;F03D7/0232;;F03D7/04;;F05B2240/31;;F03D1/0633;;F03D1/0641;;Y02E10/72;;F03D1/0675,F03D7/02;;F03D7/04,416/23,0,0,,,,DISCONTINUED
308,US,A,US 3272718 A,146-082-466-893-952,1966-09-13,1966,US 21911162 A,1962-08-24,US 21911162 A,1962-08-24,Malting of barley and other cereals,,ENZYMIC MALT COMPANY LTD;;DIXON MALT COMPANY LTD,DOUGLAS COMRIE ALAN A;;BERNARD DIXON,,https://lens.org/146-082-466-893-952,Granted Patent,no,5,3,1,1,0,C12C1/00;;C12C1/00,C12C1/00,,0,0,,,,EXPIRED
309,US,A1,US 2005/0172354 A1,162-214-953-044-220,2005-08-04,2005,US 97619004 A,2004-10-28,US 97619004 A;;US 51555903 P,2003-10-29,Plant isoflavonoid hydroxylases and methods of use thereof,"The invention provides plant isoflavonoid hydroxylase coding sequences. Also provided are constructs comprising these sequences, plants transformed therewith and methods of use thereof. In certain aspects of the invention, plants transformed with the nucleic acids are provided exhibiting improved pest and disease resistance. Plants provided by the invention may also exhibit improved nutritional qualities.",SAMUEL ROBERT NOBLE FOUNDATION,DIXON RICHARD A;;LIU CHANG-JUN,SAMUEL ROBERTS NOBLE FOUNDATION THE (2005-02-21),https://lens.org/162-214-953-044-220,Patent Application,yes,2,3,8,8,21,C12N9/0073;;C12N9/0073,A23L19/00;;C12N9/02;;C12N15/82,800/279;;435/6;;435/189;;435/419;;435/468;;536/23.2,0,0,,,,INACTIVE
310,US,B2,US 7432425 B2,164-994-983-987-521,2008-10-07,2008,US 7196405 A,2005-03-04,US 7196405 A;;US 92657101 A;;US 0013389 W;;US 13502699 P,1999-05-20,Isoflavonoid methylation enzyme,"Methods of genetically manipulating biology active 4′-O-methylated isoflavonoids have been found based upon the regiospecifity of isoflavone 7-OMT in vivo. Upon transformation and expression of an isoflavonoid O-methyltransferase gene, up-regulation of IOMT in the transgenic plants can be used to increase the accumulation of 4′-O-methylated isoflavonoid phytolalexins, providing for increased disease resistance to the plant. Similar methods can be used to increase accumulation of 4′-O-methylated isoflavonoid nutraceuticals in plants. For down-regulation of IOMT in plants that naturally make 4′O-isoflavonoid phytoalexins and 4′-O-methylated isoflavonoid nutraceuticals, IOMT gene sequences can be transformed in the antisense orientation.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;HE XIAN Z,NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/164-994-983-987-521,Granted Patent,yes,3,0,3,10,5,C12N9/1007;;C12N15/8243;;C12N15/825;;C12N15/8282;;C12N15/8282;;C12N15/825;;C12N15/8243;;C12N9/1007,C12N15/29;;A01H5/00;;C12N9/10;;C12N15/52;;C12N15/54;;C12N15/82,800/313;;800/298;;800/312;;435/419,67,63,002-689-313-687-938;;018-178-707-907-477;;034-139-367-126-612;;013-048-650-582-159;;000-838-167-967-125;;070-914-008-321-23X;;012-544-595-835-438;;028-056-276-490-709;;040-986-663-076-693;;010-214-063-649-840;;037-439-894-311-127;;019-027-340-670-167;;008-120-631-983-38X;;045-870-011-974-882;;048-884-231-380-863;;104-586-507-621-730;;159-599-470-754-246;;061-037-398-447-63X;;048-425-634-797-396;;043-413-805-164-105;;071-551-288-641-153;;047-802-453-136-120;;050-857-911-966-735;;116-984-034-376-470;;005-198-454-419-972;;095-404-749-938-170;;014-560-833-522-836;;102-449-251-149-642;;010-635-987-157-26X;;075-809-971-728-078;;011-670-242-525-259;;042-566-187-298-704;;070-803-686-771-828;;143-147-057-242-468;;097-066-123-319-638;;054-150-480-227-565;;001-906-076-969-393;;089-544-742-570-358;;072-985-352-165-177;;036-072-457-855-80X;;094-195-650-610-197;;035-134-085-004-573;;031-757-758-717-523;;140-864-469-916-361;;158-937-458-595-089;;055-090-138-911-307;;066-337-522-311-649;;077-580-667-120-981;;163-472-490-948-263;;140-466-892-558-422;;030-257-753-926-660;;013-043-410-189-072;;144-745-219-737-532;;049-414-985-018-203;;044-347-068-901-534;;005-025-673-594-96X;;071-677-336-342-646;;092-944-718-518-390;;065-822-480-588-377;;024-855-853-923-988;;140-312-630-916-46X;;009-730-205-489-885;;024-311-396-967-380,10.2307/3871183;;11006341;;pmc149079;;10.1105/tpc.12.9.1689;;10.1038/85029;;11224575;;10.1016/0031-9422(91)85107-b;;3364982;;10.1016/0003-9861(88)90410-9;;4452353;;10.1111/j.1432-1033.1974.tb03881.x;;1659780;;10.1093/ajcn/54.6.1093;;9187225;;10.3109/07853899709113696;;pmc1075288;;16664813;;10.1104/pp.81.1.86;;10.1093/emboj/16.12.3675;;9218808;;pmc1169991;;10.1046/j.1365-313x.1998.00099.x;;9681028;;10.1016/0885-5765(87)90052-x;;10.1016/0168-9452(94)04051-6;;9812895;;10.1126/science.282.5392.1315;;1932694;;10.1007/bf00028736;;pmc1062311;;16667295;;10.1104/pp.92.2.440;;10.1016/s0031-9422(00)84267-3;;10.1016/s0031-9422(00)84266-1;;9781295;;10.1007/978-1-4615-5335-9_5;;10.1016/b978-0-08-091283-7.00030-8;;10.1105/tpc.7.7.1085;;10.2307/3870059;;12242399;;pmc160915;;2239449;;10.1016/s0065-2660(08)60527-1;;2030957;;pmc333874;;10.1093/nar/19.6.1349;;10205892;;10.1046/j.1365-313x.1999.00379.x;;10.1007/bf00041401;;9002616;;10.1006/abbi.1997.0554;;9514654;;10.1094/phyto-74-1312;;10.1016/s0040-4020(01)86489-9;;10.1016/s0031-9422(98)00266-0;;9484461;;10.1023/a:1005938121453;;8951042;;10.1006/abbi.1996.0539;;10.1016/0048-4059(72)90012-4;;17757866;;10.1126/science.227.4691.1229;;10.1016/s0031-9422(00)81789-6;;10.1023/a:1005939803300;;9484457;;10.1515/znc-1983-3-407;;10.1023/a:1006035210889;;9687070;;10.1038/72671;;10657130;;24226375;;10.1007/bf00232132;;10.1099/00221287-130-10-2605;;10.1073/pnas.85.22.8502;;pmc282486;;16593993;;3956488;;10.1111/j.1432-1033.1986.tb09492.x;;1369021;;10.1038/nbt1192-1436;;1673746;;10.1016/0140-6736(91)92867-2;;10692459;;10.1074/jbc.275.9.6537;;10.1094/phyto-75-235;;12228391;;pmc157182;;10.1104/pp.107.3.679;;10.1016/0048-4059(82)90008-x;;10.1111/j.1399-3054.1962.tb08052.x;;10.1007/bf00033879;;10.1139/b73-310;;10.1105/tpc.2.10.987;;2136629;;pmc159947;;10.2307/3869238;;7910406;;pmc43777;;10.1073/pnas.91.10.4323;;62660;;10.1016/0160-9327(76)90004-1;;10.1006/abbi.1999.1238;;10375412;;10.1002/(sici)1096-9888(199605)31:5<472::aid-jms318>3.0.co;2-e;;8799289;;10.1016/0168-9452(90)90117-7;;10.1105/tpc.6.9.1191;;10.2307/3869817;;pmc160512;;12244269;;10.1016/s0031-9422(00)85668-x;;8242641;;9823337;;10.1007/s11103-006-9050-x;;17001495;;pmc2862459;;pmc139479;;10.2307/3871525;;10.1105/tpc.010382;;11752378;;10.1105/tpc.13.12.2643;;16569852;;pmc1426963;;10.1128/aac.50.4.1352-1364.2006,"He X. and Dixon R., The Plant Cell, Sep. 2000; vol. 12 pp. 1689-1702.;;Zubieta C. et al. Nature Structural Biology, 2001, vol. 8, No. 3; pp. 271-279.;;Edwards and Dixon, ""Isoflavone O-methyltransferase activities in elicitor-treated cell suspension cultures of Medicago sativa,"" Phytochemistry, 30:2597-2606, 1991.;;Khouri et al., ""Partial purification, characterization, and kinetic analysis of isoflavone 5-O-methyltransferases from yellow lupin roots,"" Arch. Biochem. Biophys, 262:592-598, 1988.;;Wengenmayer, et al., ""Purification and properties of a S-adenosylmethionine: isoflavone 4'-O-methyltransferase from cell suspension cultures of Cicer arietinum L,"" Eur. J. Biochem., 50:135-143, 1974.;;Adlercreutz, et al., ""Urinary excretion of ligans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet,"" Am J Clin Nutr 54: 1093-1100, 1991.;;Adlercreutz and Mazur. ""Phyto-estrogens and western diseases,"" Ann Mes 29: 95-120, 1997.;;An, ""Development of plant promoter expression vectors and their use for analysis differential activity of nopaline synthase promoter is transformed tobacco cells,"" Plant Physiol 81: 86-91, 1986.;;Angell and Baulcombe, ""Consistent gene silencing in transgenic plants expressing a replicating potato virus X RNA,"" EMBO J 16: 3675-3684, 1997.;;Barnes et al., ""Soybeans inhibit mammary tumors in models of breast cancer."" In M.W. Puriza, eds, Mutagenes and Carcinogens in the Diet, Wiley-Liss, Inc, New York, pp. 239-253, 1990.;;Batard et al., ""Molecular cloning and functional expression in yeast of CYP76B1, a xenobiotic-inducible 7-ethoxycoumarin O-de-ethylase from Helianthus tuberosus,"" Plant J, 14: 111-120, 1998.;;Bhattacharyya. and Ward, ""Biosynthesis and metabolism of glyceollin I in soybean hypocotyls following wounding or inoculation with Phytophthora megasperma f. sp. Glycinea,"" Physiol Mol Plant Pathol 31:387-405, 1987.;;Bourque, ""Antisense strategies for genetic manipulations in plants,"" Plant Sci 105: 125-149, 1995.;;Broun et al., ""Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids,"" Science, 282:1315-1317, 1998.;;Bugos et al., ""cDNA cloning, sequence analysis and seasonal expression of lignin-bispecific caffeic acid/5-hydroxyferulic acid O-methyltransferase of aspen,"" Plant Mol Biol, 17: 1203-1215, 1991.;;Dalkin et al., ""Stress responses in alfalfa (Medicago sativa L.) I. Elicitor-induction of phenylpropanoid biosynthesis and hydrolytic enzymes in cell suspension cultures,"" Plant Physiol, 92: 440-446, 1990.;;Dewick and Martin, ""Biosynthesis of pterocarpan, isoflavan and coumestan metabolites of Medicago sativa : chalcone, isoflavone and isoflavanone precursors,"" Phytochemistry 18: 597-602, 1979.;;Dewick and Martin, ""Biosynthesis of pterocarpan and isoflavan phytoalexins in Medicago sativa: the biochemical interconversion of pterocarpans and 2'-hydroxyisoflavans,"" Phytochemistry, 18: 591-596, 1979.;;Dixon et al., ""Prospects for the metabolic engineering of bioactive flavonoids and related phenylpropanoid compounds,"" Adv Exp Med and Biolog, 439:55-66, 1998.;;Dixon et al., ""Molecular controls for isoflavonoid biosynthesis in relation to plant and human health,"" Recent Advances in Phytochemistry, 33: 133-160, 1999.;;Dixon, ""Isoflavonoids: biochemistry, molecular biology and biological functions."" In U. Sankawa, eds, Comprehensive Natural Products Chemistry, Elsevier, pp. 773-823, 1999.;;Dixon and Paiva, ""Stress-induced phenylpropanoid metabolism,"" Plant Cell, 7: 1085-1097, 1995.;;Dixonand Harrison, ""Activation, structure and organization of genes involved in microbial defense in plants,"" Adv Genet, 28: 165-234, 1990.;;Edwards et al., ""A simple and rapid method for the preparation of plant genomic DNA for PCR analysis,"" Nucleic Acids Res, 19: 1349, 1991.;;Frick and Kutchan. ""Molecular cloning and functional expression of O-methyltransferases common to isoquinoline alkaloid and phenylpropanoid biosynthesis,"" Plant J, 17: 329-339, 1999.;;Gauthier et al., ""cDNA cloning and characterization of a 3'/5'-O-methyltransferase for partially methylated flavonols from Chrysosplenium americanum,"" Plant Mol Biol, 32: 1163-1169, 1996.;;Gauthier et al., ""Characterization of two cDNA clones which encode O-methyltransferases for the methylation of both flavonoid and phenylpropanoid compounds,"" Arch Biochem Biophys, 351: 243-249, 1998.;;Hadwiger and Webster., ""Phytoalexin production in five cultivars of pea differentially resistance to three races of Pseudomonas syringae pv. Pisi,"" Phytopathology, 74: 1312-1314, 1984.;;Hakamatsuka et al., ""P-450-dependent oxidative rearrangement in isoflavone biosynthesis: reconstitution of P-450 and NADPH:P450 reductase"", Tetrahedron, 47: 5969-5978, 1991.;;Hakamatsuka et al., ""Purification of 2-hydroxyisflavanone dehydratase from the cell cultures of Pueraria lobata,"" Phytochemistry, 49: 497-505, 1998.;;He et al., ""Stress responses in alfalfa (Medicago sativa L.) XXII. cDNA cloning and characterization of an elicitor-inducible isoflavone 7-O-methyltransferase,"" Plant Mol Biol, 36: 43-54, 1998.;;He and Dixon, GenBank accession No. AF023481 see also Plant Physiology vol. 115, p. 1289, 1997.;;He and Dixion, ""Affinity chromatography, substrate/product specificity and amino acid sequence analysis of an isoflavone O-methyltransferase from alfalfa (Medicago sativa L.),"" Arch Biochem Biophys, 336: 121-129, 1996.;;Higgins, ""Role of the phytoalexin medicarpin in three leaf spot diseases of alfalfa,"" Physiol Plant Pathol, 2:289-300, 1972.;;Horsch et al., ""A simple and general method for transferring genes into plants,"" Science, 227: 1229-1231, 1985.;;Ibrahim et al., ""Enzymology and compartmentation of polymethylated flavonol glucosides in Chrysasplenium americamum,"" Phytochemistry, 26: 1237-1245, 1987.;;Ibrahim et al., ""Plant O-methyltransferases: molecular analysis, common signature and classification,"" Plant Mol Biol 36: 1-10, 1998.;;Ingham et al., ""Fungitoxic isoflavones from Lupinus albus and other Lupinus species,"" Zeitschrift fur Naturforschung, C38: 194-200, 1983.;;Joshi and Chiang, ""Conserved sequence motifs in plant S-adenosyl-L-methionine-dependent methyltransferases,"" Plant Mol. Biol, 37: 663-674, 1998.;;Jung et al., ""Identification and expression of isoflavone synthase: the key enzyme for biosynthesis of isoflavones in legunmes,"" Nature Biotechnology, 18:208-212, 2000.;;Kessmann et al., ""Stress responses in alfalfa (Medicago sativa L.) III. Induction of medicarpin and cytochrome P450 enzyme activities in elicitor-treated cell suspension cultures and protoplasts,"" Plant Cell Rep, 9: 38-41, 1990.;;Kistler and VanEtten, ""Regulation of pisatin demethylation in Nectria haematococca and its influence on pisatin tolerance and virulence,"" J Gen Micro, 130: 2605-2613, 1984.;;Klein et al., ""Stable genetic transformation of intact Nicotiana cells by the particle bombardment process,"" Proc Natl Acad Sci USA, 85: 8502-8505, 1998.;;Kochs and Grisebach, ""Enzymatic synthesis of isoflavones,"" Eur J Biochem, 155: 311-318, 1986.;;Lamb et al., ""Emerging strategies for enhancing crop resistance to microbial pathogens,"" Bio/technology, 10: 1436-1445, 1992.;;Lee et al., ""Dietary effects on breast-cancer risk in Singapore,"" Lancet, 337: 1197-1200, 1991.;;Li et al., ""5-Hydroxyconiferyl aldehyde modulates enzymatic methylation for syringyl monolignol formation, a new view of monolignol biosynthesis in angiosperms,"" J Biol Chem, 275: 6537-6545, 2000.;;Long et al., ""Further studies on the relationship between glycollin accumulation and the resistance of soybean leaves to Pseudomonas syringae pv. Glycinea,"" Phytopathology, 75: 235-239, 1985.;;Matzke and Matzke,. ""How and why do plants inactivate homologous (trans)genes?"" Plant Physiol, 107: 679-685, 1995.;;Moesta and Grisebach,, ""L-2-Aminooxy-3-phenylpropionic acid inhibits phytoalexin accumulation in soybean with concomitant loss of resistance against Phytophthora megasperma f. sp. Glycinea,"" Physiol Plant Pathol, 21: 65-70, 1982.;;Murashige and Skoog, ""A revised media for rapid growth and bioassay with tobacco tissue culture,"" Physiol Plant, 15:473-497, 1962.;;Paiva et al., ""Regulation of isoflavonoid metabolism in alfalfa,"" Plant Cell, Tissue and Organ Cult, 38: 213-220, 1994.;;Rahe, ""Occurrence and levels of the phytoalex in phasecollin in relation to delimination at sites of infection of Phaseolus vulgaris by Colletotrichum lindemuthianum,"" Can J Botany, 51: 2423-2430, 1973.;;Restrepo et al., ""Nuclear transport of plant polyviral proteins,"" Plant Cell, 2: 987-998, 1990.;;Sambrook et al. Molecular Cloning A Laboratory Manual (2nd Ed), Cold Spring Harbor Laboratory Press, New York: pp. 1.53-1.110, 1989.;;Shorrosh et al., ""Molecular cloning, characterization and elicitation of acetyl-CoA carboxylase in alfalfa,"" Proc Natl Acad Sci USA, 91:4323-4327, 1994.;;Shutt, ""The effects of plant oestrogens on animal reproduction,"" Endeavour, 75: 110-113, 1976.;;Steele et al., ""Molecular characterization of the enzyme catalyzing the aryl migration reaction of isoflavonoid biosynthesis in soybean,"" Arch Biochem Biophys, 367: 146-150, 1999.;;Summer et al., ""High-performance liquid chromatography/continuous-flow liquid secondary ion mass spectrometry of flavonoid glucosides in leguminous plant extracts,"" J. Mass Spectrom, 31:472-485, 1996.;;Thomas et al., ""Selection of interspecific somatic hybrids of Medicago by using Agrobacterium-transformed tissue,"" Plant Sci, 69: 189-198, 1990.;;VanEtten et al., ""Two classes of plant antibiotics: phytoalexins versus phytoanticipins,"" The Plant Cell, 6:1191-1192, 1994.;;Wong, and Francis, ""Flavonoids in genotypes of Trifolium subterraneum-II. Mutants of the Geraldton variety,"" Phytochemistry, 7: 2131-2137, 1968.;;Yanagihara et al., ""Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract,"" Cancer Res, 53: 5815-5821, 1993.;;Zhou-Jin Rong et al., ""Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis,"" Cancer Res, 58: 5231-523, 1998.;;Deavours et al., ""Functional analysis of members of the isoflavone and isoflavonone O-methyltransferase enzyme families from the model legume Medicago truncatla,"" Plant Mol. Biol., 62:715-733, 2006.;;Liu et al., ""Elicitor-induced association of isofavone O-methyltransferase with endomembranes prevents the formation and 7-O-methylation of daidzein during isofavonoid phytoalexin biosynthesis,"" The Plant Cell, 13:2643-2658, 2001.;;Tasdemir et al., ""Antitrypansosomal and antileishmanial activities of flavonoids and their analogues: in vitro, in vivo, structure-activity relationship, and quantitative structure-activity relationship studies,"" Antimocrobial Agents and Chemotherapy, 4:1352-1364, 2006.",EXPIRED
311,US,A1,US 2003/0135210 A1,185-348-992-384-429,2003-07-17,2003,US 34096703 A,2003-01-13,US 34096703 A;;US 34818002 P,2002-01-14,Dynamized vertebral stabilized using an outrigger implant,"
   A device and a method for stabilizing lumbar and thoracic vertebra or individual bones in human spine or bone column is provided for the purpose of fixing a vertebra or individual bone with respect to other vertebra or individual bones and with respect to other parts of the spinal or bone column. While providing spinal stabilization, the stabilizer allows axial load sharing or construct dynamized action. The device allows the vertebra or individual bones to be held in compression allowing subsidence along the plate axis or to be fixed with respect to the plate for rigid stabilization. The vertebra or individual bones will be prevented from distraction by a stop lock clamp. The device may be configured as a fully or partially rigid system. 
",DIXON ROBERT A.;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/185-348-992-384-429,Patent Application,yes,5,57,2,2,0,A61B17/7007;;A61B17/701;;A61B17/7044;;A61B17/7058;;A61B17/7044;;A61B17/7007;;A61B17/7058;;A61B17/701,A61B17/70,606/61,0,0,,,,EXPIRED
312,CA,A,CA 1104735 A,192-119-671-593-670,1981-07-07,1981,CA 315275 A,1978-10-31,US 87885878 A,1978-02-17,PHOTOSENSITIVE SOLVENTLESS OIL FREE LOW VISCOSITY COATING COMPOSITION,"47,799 A PHOTOSENSITIVE SOLVENTLESS OIL FREE LOW VISCOSITY COATING COMPOSITION A photosensitive, solventless, low viscosity, oil free coating composition is made by admixing: (A) about 40 wt.% to about 90 wt.% of an alkyd component, consisting essentially of a polyhydric alcohol and a dibasic aromatic and aliphatic acid mixture with (B) about 10 wt.% to about 60 wt.% of an acrylate monomer and (C) an effective amount of a photoinitiator; the composition characterized by having a viscosity of up to about 2,000 cps. at 25.degree.C, and being capable of forming an ultraviolet radiation cured, hard, pin hole free film, having a thickness of under about 5 mils.",WESTINGHOUSE ELECTRIC CORP,SATTLER FRANK A;;DIXON GEORGE D,,https://lens.org/192-119-671-593-670,Granted Patent,no,0,0,11,11,0,C08F283/01;;C08F299/0478;;C08G63/6854;;C09D167/00;;Y10T428/31681;;Y10T428/31681;;C08F299/0478;;C08G63/6854;;C08F283/01;;C09D167/00,C08F299/00;;C08F2/50;;C08F283/01;;C08F299/04;;C08G63/00;;C08G63/52;;C08G63/685;;C09D4/00;;C09D167/00,400-86,0,0,,,,EXPIRED
313,US,B2,US 7709701 B2,012-127-546-790-539,2010-05-04,2010,US 17906405 A,2005-07-11,US 17906405 A;;US 58702004 P,2004-07-09,Genetic manipulation of condensed tannins,The invention provides method and compositions for the modulation of condensed tannin production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of condensed tannins in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased condensed tannin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content. The invention may also be used to modify plant pigmentation.,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;SHARMA SHASHI B,NOBLE RESEARCH INSTITUTE LLC (2017-05-01);;SAMUEL ROBERTS NOBLE FOUNDATION THE (2005-10-18),https://lens.org/012-127-546-790-539,Granted Patent,yes,11,3,9,9,79,C12N9/0004;;C12N9/0004;;C07K14/415;;C07K14/415;;C12N9/0093;;C12N9/0093;;C12N15/8223;;C12N15/8223;;C12N15/8234;;C12N15/8234;;C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,A01H1/00;;C07H21/04;;C07K14/415;;C12N15/00,800/295;;435/6;;435/468;;435/419;;435/320.1;;435/183;;530/370;;536/23.1;;536/23.6;;800/278,75,46,005-624-735-715-806;;047-345-160-917-862;;021-053-676-958-106;;015-279-533-554-483;;038-223-383-026-010;;010-265-093-402-056;;049-427-391-860-033;;059-011-946-503-122;;006-871-749-415-905;;007-312-958-698-855;;127-437-090-611-785;;120-639-540-415-038;;023-953-046-860-282;;006-783-899-030-648;;185-333-724-522-184;;034-896-105-669-762;;061-809-241-139-003;;034-329-448-921-172;;109-371-707-140-011;;004-012-388-259-688;;030-560-996-409-192;;044-560-896-492-580;;037-600-532-041-631;;006-470-893-916-774;;036-181-789-228-143;;147-270-016-436-484;;027-655-982-060-35X;;117-198-995-757-529;;017-454-462-991-878;;026-753-097-919-005;;014-703-604-069-682;;053-728-441-408-680;;006-191-344-749-449;;028-607-177-761-532;;022-722-154-225-230;;083-487-454-284-713;;015-010-359-455-866;;025-934-122-339-691;;047-345-160-917-862;;021-053-676-958-106;;015-279-533-554-483;;061-809-241-139-003;;034-329-448-921-172;;004-012-388-259-688;;044-560-896-492-580;;037-600-532-041-631,10.1016/s0167-8809(99)00062-6;;9076994;;10.1046/j.1365-313x.1997.11020289.x;;10.1111/j.1365-313x.2004.02138.x;;15255866;;pmc102225;;10.2307/3871236;;11148285;;10.1105/tpc.12.12.2383;;10.1007/bf00225796;;24190536;;10.1016/s0076-6879(99)99018-3;;10.1046/j.1365-313x.1998.00343.x;;10069079;;9349273;;10.1023/a:1005821801228;;10.1002/(sici)1097-0010(199811)78:3<405::aid-jsfa133>3.0.co;2-g;;10.1071/pp98121;;10.1071/pp99115;;pmc280558;;14555692;;10.1105/tpc.014043;;10.1105/tpc.13.4.853;;10.2307/3871345;;11283341;;pmc135529;;10.1046/j.1365-313x.1999.00529.x;;10504561;;10.1080/00288233.1999.9513353;;10.1016/s0031-9422(00)83807-8;;10.1093/jn/134.3.613;;14988456;;10.1021/jf020214v;;12166971;;10.2135/cropsci1991.0011183x003100030009x;;24221384;;10.1007/bf00226735;;pmc137925;;12384577;;10.1073/pnas.212522099;;10.1016/s0031-9422(03)00377-7;;12943753;;10.1007/bf00029615;;pmc139454;;10.2307/3871430;;10.1105/tpc.13.9.2099;;11549766;;10.1105/tpc.010098;;12368498;;10.1105/tpc.004127;;pmc151229;;11041882;;pmc149125;;10.2307/3871198;;10.1105/tpc.12.10.1863;;10.1104/pp.103.025361;;pmc167084;;12857826;;7665384;;10.2527/1995.7351516x;;9501146;;10.1104/pp.116.3.1133;;pmc35083;;10.1101/gad.212702;;11782451;;pmc155310;;10074715;;10.1046/j.1365-313x.1999.00365.x;;10.1111/j.1365-313x.2005.02510.x;;16167896;;10.2307/2446026;;10.1071/ar9951101;;10.2307/3870753;;10.1105/tpc.11.7.1337;;pmc144274;;10402433;;10.1016/j.abb.2003.12.011;;14725861;;10.1126/science.1078540;;12532018;;10.1242/dev.00681;;12917293;;9076994;;10.1046/j.1365-313x.1997.11020289.x;;10.1111/j.1365-313x.2004.02138.x;;15255866;;pmc102225;;10.2307/3871236;;11148285;;10.1105/tpc.12.12.2383;;10.1093/jn/134.3.613;;14988456;;10.1021/jf020214v;;12166971;;24221384;;10.1007/bf00226735;;10.1016/s0031-9422(03)00377-7;;12943753;;10.1007/bf00029615,"Aerts et al, ""Polyphenols and agriculture: beneficial effects of proanthocyanidins in forages,"" Agriculture, Ecosystems and Environment, 75:1-12, 1999.;;Albert et al., ""Banyuls, a novel negative regulator of flavinoid biosynthesis in the arabidopsis seed coat,"" The Plant Journal, 11:289-299, 1997.;;Baudry et al., ""TT2, TT8, and TTG1 synergistically specify the expression of Banyuls and proanthocyanidin biosynthesis in Arabidopsis thaliana,"" The Plant Journal, 39:366-380, 2004.;;Borevitz et at, ""Activation Tagging Identifiers a conserved MYB Regulator of Phenylpropanoid Biosynthesis,"" Plant Cell, 12:2383-2393, 2000.;;Carron et al., ""Genetic modification of condensed tannin biosynthesis in Lotus comiculatus. 1. Heterologous antisense dihydroflavonol reductase down-regulates tannin accumulation in 'hairy root' cultures,"" Theoretical and Applied Genetics, 87:1006-1015, 1994.;;Cheynier et al., ""Size Separation of Condensed Tannins by Normal-Phase High-Performance Liquid Chromatography,"" Methods Enzymology, 299:178-184, 1999.;;Clough and Bent, ""Floral dip: a simplified method for agrobacterium-mediated transformation of Arabidopsis thalia,"" Plant J., 16:735-743, 1998.;;Colliver et al.,""Differential modification of flavonoid and isoflavonoid biosynthesis with an antisense chalcone synthase construct in transgenic Lotus corniculatus,"" Plant Molecular Biology, 35:509-522, 1997.;;Dalzell and Kerven, ""A rapid method for the measurement of Leucaena spp proanthocyanidins by the proanthocyanidin ,"" J. Sci. Food Agric., 78:405-416, 1998.;;Damiani et al., ""The maize transcription factor Sn alters proanthocyanidin synthesis in transgenic Lotus corniculatus plants,"" Australian Journal of Plant Physiology, 26:159-169, 1999.;;de Majnik et al., ""Anthocyanin regulatory gene expression in transgenic white clover can result in an altered pattern of pigmentation,"" Australian Journal of Plant Physiology, 27:659-667, 2000.;;Debeaujon et al., ""Proanthocyanidin-accumulating cells in Arabidopsis testa: regulation of differentiation and role in seed development,"" The Plant Cell, 15:2514-2531, 2003.;;Debeaujon et al., ""The TRANSPARENT TESTA12 gene of Arabidopsis encodes a multidrug secondary transporter-like protein required for flavonoid sequestration in vacuoles of the seed coat endothelium,"" Plant Cell, 13:853-872, 2001.;;Devic et al., ""The BANYULS gene encodes a DFR-like protein and is a marker of early seed coat development,"" Plant J., 19:387-398, 1999.;;Douglas et al., ""Effect of condensed tannins in birdsfoot trefoil (Lotus corniculatus) and sulla (Hedysarum coronarium) on body weight, carcass fat depth, and wool growth of lambs in New Zealand,"" New Zealand Journal of Agricultural Research. 42:55-64, 1999.;;Foo and Porter, ""The Phytochemistry of Proanthocyanidin Polymers,"" Phytochemistry, 19:1747-1754, 1980.;;GenBank Accession No. ADO02032.;;Genbank Accession No. AF092912.;;GenBank Accession No. AF190298.;;GenBank Accession No. AJ133743.;;GenBank Accession No. AJ277509.;;GenBank Accession No. AJ294464.;;Genbank Accession No. AJ299452.;;Gu et al., ""Concentrations of proanthocyanidins in common foods and estimations of normal consumption,"" J. Nutr., 134:613-617, 2004.;;Gu et al., ""Fractionation of Polymeric Procyanidins from Lowbus Blueberry and Quantification of Procyanidins in Selected Foods with an Optimized Normal-Phase HPLC-MS Fluorescent Detection Method,"" J. Agricultural and Food Chem., 50:4852-4860, 2002.;;Horsley et al.,""Effects of Gene ant13 on Agronomic and Malt Quality Traits of Barley,"" Crop Science, 593-598, 1991.;;Jende-Strid, ""Gene-enzyme relations in the pathway of flavonoid biosynthesis in barley,"" Theoretical and Applied Genetics, 81:668-674, 1991.;;Liu et al., ""Bottlenecks for metabolic engineering of isoflavone glycoconjugates in Arabidopsis,"" Proc. Natl. Acad Sci USA, 99, 14578-14583, 2002.;;Marles et al., ""New perspectives on proanthocyanidin biochemistry and molecular regulation,"" Phytochemistry, 64:367-383, 2003.;;Marshall et al., ""The annual and perennial Medicago species,"" Australian Journal of Experimental Agriculture and Animal Husbandry, 21:47-50, 1980.;;McKhann and Hirsch, ""Isolation of chalcone synthase and chalcone isomerase cDNAs from alfalfa (Medicago sativa L.): highest transcript levels occur in young roots and root tips,"" Plant Mol Biol., 24(5):767-77, 1994.;;Nesi et al., ""The Arabidopsis TT2 gene encodes an R2R3 MYB domain protein that acts as a key determinant for proanthocyanidin accumulation in developing seed,"" The Plant Cell, 13:2099-2114, 2001.;;Nesi et al., ""The TRANSPARENT TESTA16 locus encodes the Arabidopsis bsister Mads domain protein and is required for proper development and pigmentation of the seed coat,"" The Plant Cell, 14:2463-2479, 2002.;;Nesi et al.,""The TT8 gene encodes a basic helix-loop-helix domain protein required for expression of DFR and BAN genes in Arabidopsis siliques,"" The Plant Cell, 12:1863-1878, 2000.;;Ray et al., ""Expression of anthocyanins and proanthocyanidins after transformation of alfalfa with maize Lc,"" Plant Physiol, 132:1448-1463, 2003.;;Reed, ""Nutritional toxicology of tannins and related polyphenols in forage legumes,"" Journal of Animal Science, 73:1516-1528, 1995.;;Robbins et al., ""Genetic Manipulation of Condensed Tannins in Higher Plants,"" Plant Physiology, 116:1133-1144, 1998.;;Sagasser et al., ""A. thaliana TRANSPARENT TESTA 1 is involved in seed coat development and defines the WIP subfamily of plant zinc finger proteins,"" Genes and Dev., 16:138-149, 2002.;;Saito et al., ""Direct evidence for anthocyanidin synthase as a 2-oxoglutarate-dependent oxygenase: molecular cloning and functional expression of cDNA from a red forma of Perilla frutescens,"" Plant J.,17:181-189, 1999.;;Sharma and Dixon, ""Metabolic engineering of proanthocyanidins by ectopic expression of transcription factors in Arabidopsis thaliana,"" The Plant Journal, 44:62-75, 2005.;;Skadhauge et al., ""Leucocyanidin reductase activity and accumulation of proanthocyanidins in developing legume tissues,"" Am. J. Bot., 84:494-502, 1997.;;Tanner et al., ""Proanthocyanidins (condensed tannin) destabilise plant protein foams in a dose dependent manner,"" Austr. J. Agric. Res., 46:1101-1109, 1995.;;TC Identifier: barley TC49014.;;TC Identifier: barley TC55701.;;TC Identifier: sorghum TC34457.;;TC Identifier: sorghum TC34925.;;von Wettstein et al, ""Proanthocyanidin-Free Barley for Brewing: Progress in Breeding for High Yield and Research Tool in Polyphenol Chemistry,"" Tech Q Mast Brew Assoc Am, 22:41-52, 1985.;;Walker et al, ""The TRANSPARENT TESTA GLABRA1 locus, which regulates trichome differentiation and anthocyanin biosynthesis in Arabidopsis, encodes a WD40 repeat protein,"" The Plant Cell, 11:1337-1350, 1999.;;Xie et al., ""Anthocyanidin reductases from Medicago truncatula and Arabidopsis thaliana,"" Archives of Biochemistry and Biophysics, 422:91-102, 2004.;;Xie et al., ""Role of anthocyanidin reductase, encoded by BANYULS in plant flavonoid biosynthesis,"" Science, 299:396-399, 2003.;;Zhang et al., ""A network of redundant bHLH proteins functions in all TTG1-dependent pathways of Arabidopsis,"" Development, 130:4859-4869, 2003.;;Aerts et al., ""Polyphenols and agriculture: beneficial effects of proanthocyanidins in forages,"" Agriculture, Ecosystems and Environment, 75:1-12, 1999.;;Albert et al., ""BANYULS, a novel negative regulator of flavinoid biosynthesis in the arabidopsis seed coat,"" The Plant Journal, 11:289-299, 1997.;;Baudry et al., ""TT2, TT8, and TTG1 synergistically specify the expression of BANYULS and proanthocyanidin biosynthesis in Arabidopsis thaliana,"" The Plant Journal, 39:366-380, 2004.;;Borevitz et al., ""Activation Tagging Identifiers a conserved MYB Regulator of Phenylpropanoid Biosynthesis, ""Plant Cell, 12:2383-2393, 2000.;;GenBank Accession No. ADO02032, Jul. 1, 2004.;;Genbank Accession No. AF092912, Jan. 11, 2000.;;GenBank Accession No. AF190298, Jan. 25, 2002.;;GenBank Accession No. AJ133743, Jan. 6, 2001.;;GenBank Accession No. AJ277509, Nov. 2, 2000.;;GenBank Accession No. AJ294464, Apr. 30, 2001.;;Genbank Accession No. AJ299452, Nov. 14, 2006.;;Gu et al., ""Concentrations of proanthocyanidins in common foods and estimations of normal consumption,"" J. Nutr., 134:613-617, 2004.;;Gu et al., ""Fractionation of Polymeric Procyanidins from Lowbus Blueberry and Quantification of Procyanidins in Selected Foods with an Optimized Normal-Phase HPLC-MS Fluorescent Detection Method,"" J. Agricultural and Food Chem., 50:4852-4860, 2002.;;Horsley et al., ""Effects of Gene ant13 on Agronomic and Malt Quality Traits of Barley,"" Crop Science, 593-598, 1991.;;Jende-Strid, ""Gene-enzyme relations in the pathway of flavonoid biosynthesis in barley,"" Theoretical and Applied Genetics, 81:668-674, 1991.;;Liu et al., ""Bottlenecks for metabolic engineering of isoflavone glycoconjugates in Arabidopsis,"" Proc. Natl. Acad. Sci USA, 99, 14578-14583, 2002.;;Marles et al., ""New perspectives on proanthocyanidin biochemistry and molecular regulation,"" Phytochemistry, 64:367-383, 2003.;;Marshall et al., ""The annual and perennial Medicago species,"" Australian Journal of Experimental Agriculture and Animal Husbandry, 21:47-50, 1980.;;McKhann and Hirsch, ""Isolation of chalcone synthase and chalcone isomerase cDNAs from alfalfa (Medicago sativa L.): highest transcript levels occur in young roots and root tips,"" Plant Mol Biol., 24(5):767-77, 1994.;;TC Identifier: barley TC49014, undated.;;TC Identifier: barley TC55701, undated.;;TC Identifier: sorghum TC34457, undated.;;TC Identifier: sorghum TC34925, undated.;;Sequence isolated from Medicago truncatula, undated.",ACTIVE
314,DE,T2,DE 69632935 T2,012-155-305-085-626,2005-08-25,2005,DE 69632935 T,1996-03-28,US 43299895 A,1995-05-02,Halteelement mit drehbarem Teil und Defibrillator mit solchem Halteelement,,KONINKL PHILIPS ELECTRONICS NV,ANDREWS JONATHAN N;;DIXON WILLIAM A,,https://lens.org/012-155-305-085-626,Granted Patent,no,0,0,8,8,0,A61N1/3904;;A61N1/3904;;B25H3/006;;B25H3/006,A61N1/39;;B25H3/00,,0,0,,,,EXPIRED
315,US,A,US 1439310 A,011-533-652-718-773,1922-12-19,1922,US 49535221 A,1921-08-25,US 49535221 A,1921-08-25,Holster and supporting belt,,HAY JOHN A;;DIXON CHARLES E,HAY JOHN A;;DIXON CHARLES E,,https://lens.org/011-533-652-718-773,Granted Patent,no,0,6,1,1,0,A45F5/021;;A45F5/021;;F41C33/0245;;F41C33/0245;;F41C33/046;;F41C33/046;;Y10S224/911;;Y10S224/911,F41C33/02,,0,0,,,,EXPIRED
316,WO,A1,WO 2000/053771 A1,045-450-547-126-047,2000-09-14,2000,US 0005915 W,2000-03-08,US 12326799 P,1999-03-08,GENETIC MANIPULATION OF ISOFLAVONOIDS,"Soybean and Medicago truncatula CYP93C genes have been isolated which encode a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone. Plants can now be genetically engineered to produce isoflavones that provide potential human health benefits and increase disease resistance in plants. Isoflavones can now be produced in transgenic plants species in which isoflavones do not naturally occur, i.e., in species other than legumes. Alternatively, introducing infection-inducible isoflavonoid biosynthesis into non-legumes qualitatively complements these plants' phytoalexin defenses against microbial pathogens, whereas over-expression of the isoflavonoid pathway in legumes quantitatively increases this defense response. Finally, modifying the extend of production of isoflavonoids in legume roots positively impacts nodulation efficiency and therefore plant yield.",SAMUEL ROBERTS NOBLE FOUND INC;;STEELE CHRISTOPHER L;;DIXON RICHARD A,STEELE CHRISTOPHER L;;DIXON RICHARD A,,https://lens.org/045-450-547-126-047,Patent Application,yes,2,9,7,8,5,C12N9/0077;;C07K2319/00;;C12N15/8242;;C12N15/8243;;C12N15/8261;;C12N15/8279;;Y02A40/146,C12N9/02;;C12N15/53;;C12N15/82,,11,9,059-011-946-503-122;;163-472-490-948-263;;004-526-766-441-136;;056-323-284-003-826;;138-835-193-112-420;;137-080-525-194-284;;070-527-153-985-104;;049-414-985-018-203;;001-906-076-969-393,9349273;;10.1023/a:1005821801228;;10.1007/bf00033879;;12232298;;10.1104/pp.105.4.1427;;pmc159476;;10.1016/s0014-5793(98)00781-9;;9708921;;10.1034/j.1399-3054.1995.930225.x;;10.1007/978-1-4615-4689-4_6;;10.1104/pp.121.3.821;;pmc59444;;10557230;;10.1006/abbi.1999.1238;;10375412;;10.1038/72671;;10657130,"SIMINSZKY B. ET AL.: ""Cytochrome P450 monooxygenase CYP93C1p from soybean; AC AF022462"", EBI DATABASE, 8 January 1998 (1998-01-08), XP002143672;;COLLIVER S P ET AL: ""Differential modification of flavonoid and isoflavonoid biosynthesis with an antisense chalcone synthase construct in transgenic Lotus corniculatus."", PLANT MOLECULAR BIOLOGY, vol. 35, no. 4, 1997, pages 509 - 522, XP002143673, ISSN: 0167-4412;;PAIVA N L ET AL: ""REGULATION OF ISOFLAVONOID METABOLISM IN ALFALFA"", PLANT CELL, TISSUE AND ORGAN CULTURE,XX,KLUWER ACADEMIC PUBLISHERS, vol. 38, no. 2/03, 1994, pages 213 - 220, XP000571330, ISSN: 0167-6857;;OTANI K. ET AL.: ""Licodione synthase, a cytochrome P-450 monooxygenase catalyzing 2-Hydroxylation of 5-Deoxyflavanone in cultured Glycyrrhiza achinata L. cells"", PLANT PHYSIOLOGY, vol. 105, 1994, pages 1427 - 1432, XP002143674;;AKASHI T. ET AL.: ""Identification of a cytochrome P450 cDNA encoding (2S)-flavanone 2-hydroxylase of licorice (Glycyrrhiza echinata L.; Fabaceae) which represents licodione synthase and flavone synthase"", FEBS LETTERS, vol. 431, 1998, pages 287 - 290, XP002927621;;DIXON RICHARD A ET AL: ""The isoflavonoid phytoalexin pathway: From enzymes to genes to transcription factors."", PHYSIOLOGIA PLANTARUM, vol. 93, no. 2, 1995, pages 385 - 392, XP000925614, ISSN: 0031-9317;;DIXON, R. A. ET AL: ""Molecular controls for isoflavonoid biosynthesis in relation to plant and human health"", 1999, PHYTOCHEMICALS IN HUMAN HEALTH PROTECTION, NUTRITION, AND PLANT DEFENSE, (1999) PP. 133-159. 99 REF. PUBLISHER: KLUWER ACADEMIC/PLENUM PUBLISHERS. NEW YORK ISBN: 0-306-46203-6, XP000925618;;AKASHI TOMOYOSHI ET AL: ""Cloning and functional expression of a cytochrome P450 cDNA encoding 2-hydroxyisoflavanone synthase involved in biosynthesis of the isoflavonoid skeleton in licorice."", PLANT PHYSIOLOGY (ROCKVILLE), vol. 121, no. 3, November 1999 (1999-11-01), pages 821 - 828, XP002143675, ISSN: 0032-0889;;STEELE CHRISTOPHER L ET AL: ""Molecular characterization of the enzyme catalyzing the aryl migration reaction of isoflavonoid biosynthesis in soybean."", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 367, no. 1, 1 July 1999 (1999-07-01), pages 146 - 150, XP000925681, ISSN: 0003-9861;;JUNG WOOSUK ET AL: ""Identification and expression of isoflavone synthase, the key enzyme for biosynthesis of isoflavones in legumes."", NATURE BIOTECHNOLOGY, vol. 18, no. 2, February 2000 (2000-02-01), pages 208 - 212, XP002143676, ISSN: 1087-0156;;See also references of EP 1161540A1",PATENTED
317,NZ,A,NZ 513992 A,058-582-251-551-657,2004-03-26,2004,NZ 51399200 A,2000-03-08,US 12326799 P;;US 0005915 W,1999-03-08,Genetic manipulation of isoflavonoids,,SAMUEL ROBERTS NOBLE FOUND INC,STEELE CHRISTOPHER L;;DIXON RICHARD A,,https://lens.org/058-582-251-551-657,Patent Application,no,0,0,7,8,0,C12N9/0077;;C07K2319/00;;C12N15/8242;;C12N15/8243;;C12N15/8261;;C12N15/8279;;Y02A40/146,C12N9/02;;C12N15/53;;C12N15/82,,0,0,,,,PENDING
318,HU,B,HU 202111 B,059-106-560-005-034,1991-02-28,1991,HU 103089 A,1989-03-03,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,PROCESS FOR PRODUCING PHARMACEUTICAL COMPOSITIONS CONTAINING (R)-(E)-4--(3-PHOSPHONO-2-PROPENYL)-2-PIPERAZINE-CARBOXYLIC ACID AS ACTIVE COMPONENT,,SANDOZ AG,DIXON KEITH ARNOLD;;GRAY JULIAN A,,https://lens.org/059-106-560-005-034,Granted Patent,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
319,US,B1,US 6213767 B1,071-313-685-267-528,2001-04-10,2001,US 37772199 A,1999-08-19,US 37772199 A,1999-08-19,"Individual dose adhesive delivery system, orthodontic appliance system and method of providing and using same","Individual orthodontic bracket doses of bracket adhesive are dispensed onto a flat resilient card and enclosed under a vapor proof cover sealed to the card. The cover is peeled off at chairside and individual orthodontic brackets pick up the individual doses of adhesive by a wiping of the adhesive doses by the orthodontist as the brackets are mounted on a patient's teeth. The card deforms to conform to the curvature of the edge of the appliance to cleanly transfer all of the adhesive of a dose from the card to the appliance base. On dose of adhesive is preferably provided for each tooth of a patient receiving a full set of orthodontic appliances. The individual doses are preferably divided into a bead of a basic dose with two small fractional supplemental dose beads to provide the orthodontist with the option of increasing the amount of adhesive on a given appliance. UV curable adhesive is dispensed onto the card as a single continuous bead while two part chemically curable adhesive is dispensed as a pattern of separate dots which do not combine until scooped up with the base of the appliance at the time of application. A sealed primer compartment is also provided on or with the card. Pads are provided on the card for mounting the appliances adjacent a corresponding adhesive dose. The appliances may be premounted by an appliance manufacturer and provided as a complete appliance system. Preferably, premounted appliances are provided on a separate card part that is connected to the adhesive bearing card at the time of use.",ORMCO CORP,DIXON DANIEL R;;ANDREIKO CRAIG A,ORMCO CORPORATION (1999-09-27),https://lens.org/071-313-685-267-528,Granted Patent,yes,7,93,1,3,0,A61C19/02;;A61C19/02;;A61C5/60;;A61C5/60;;A61C7/12;;A61C7/12;;A61C2202/01;;A61C2202/01,A61C5/06;;A61C7/12;;A61C19/02,433/9;;206/369;;401/129,0,0,,,,EXPIRED
320,AU,A,AU 1981/067867 A,081-764-915-567-792,1981-09-11,1981,AU 1981/067867 A,1981-02-18,US 12356280 A;;US 8100202 W,1980-02-22,THE SOLID PHASE ANTI-C3 ASSAY FOR DETECTION OF IMMUNE COMPLEXES,,SCRIPPS CLINIC RES,THEOFILOPOULOS A N;;DIXON F J,,https://lens.org/081-764-915-567-792,Patent Application,no,0,1,1,6,0,,,,0,0,,,,DISCONTINUED
321,US,B2,US 6663637 B2,129-730-672-826-095,2003-12-16,2003,US 3950902 A,2002-01-02,US 3950902 A;;US 25934901 P,2001-01-02,Vertebral distraction stabilizer,"
    This invention comprises a device and a method of maintaining distraction and providing tool guidance in the preparation of an intervertebral space for an implant. It provides a means for attaching a tube, to guide tools that will prepare the vertebra for accepting an implant. At any time during the procedure the tube may be removed to inspect or remove debris from the disc space and the vertebral end plates without disturbing the distraction. The system has multiple tube diameters which can be attached to a common flange to increase the dowel size during the procedure without redistracting. 
",DIXON ROBERT A;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/129-730-672-826-095,Granted Patent,yes,6,74,2,2,0,A61B17/025;;A61B17/1757;;A61B2017/0256;;A61B17/025;;A61B2017/0256;;A61B17/1757,A61B17/02;;A61B17/17,606/90;;606/99;;606/86,0,0,,,,EXPIRED
322,CN,A,CN 1512885 A,160-410-745-657-01X,2004-07-14,2004,CN 02810912 A,2002-05-29,SE 0101932 A,2001-05-31,Pharmaceutical combinations,本发明提供了新型的药物组合以及它们在抗血栓形成治疗中的应用。该组合包含式(I)的化合物或其可药用衍生物；以及另一种抗血栓形成剂或其可药用衍生物。,ASTRAZENECA AB,DIXON J;;HUMPHRIES R;;NICOL A,,https://lens.org/160-410-745-657-01X,Patent Application,no,0,4,28,28,0,A61K31/194;;A61K31/519;;A61K45/06;;A61P7/02;;A61P9/10;;A61K31/519;;A61K45/06;;A61K31/519;;A61K31/194,A61K45/00;;A61K31/194;;A61K31/519;;A61K31/616;;A61K38/55;;A61K45/06;;A61P7/02;;A61P9/10,,0,0,,,,EXPIRED
323,US,A,US 3419078 A,176-191-000-740-234,1968-12-31,1968,US 51033065 A,1965-11-29,US 51033065 A,1965-11-29,Pump anchors,,HARBISON FISCHER MFG CO,HARBISON DIXON T;;BURNS JAMES A,,https://lens.org/176-191-000-740-234,Granted Patent,no,5,1,1,1,0,E21B23/01;;E21B23/01,E21B23/01,166/138,0,0,,,,EXPIRED
324,WO,A3,WO 2005/042747 A3,012-959-054-140-291,2007-04-19,2007,US 2004/0035948 W,2004-10-28,US 51555903 P,2003-10-29,PLANT ISOFLAVONOID HYDROXYLASES AND METHODS OF USE THEREOF,"The invention provides plant isoflavonoid hydroxylase coding sequences. Also provided are constructs comprising these sequences, plants transformed therewith and methods of use thereof. In certain aspects of the invention, plants transformed with the nucleic acids are provided exhibiting improved pest and disease resistance. Plants provided by the invention may also exhibit improved nutritional qualities.",SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;LIU CHANG-JUN,DIXON RICHARD A;;LIU CHANG-JUN,,https://lens.org/012-959-054-140-291,Search Report,yes,1,0,8,8,0,C12N9/0073;;C12N9/0073,A23L19/00;;C12N15/53;;A01H5/00;;C12N9/02;;C12N15/82,,8,6,008-831-818-058-304;;040-238-080-165-869;;019-370-215-214-515;;006-713-586-398-958;;045-664-788-381-085;;010-860-681-994-410,10.1046/j.1365-313x.2003.01893.x;;14617078;;10.1016/0014-5793(87)80021-2;;10540749;;10.1271/bbb.63.1618;;9790908;;10.1006/bbrc.1998.9414;;10.1016/s0168-9452(00)00355-1;;11164575;;10773344;;10.1016/s0168-9452(00)00214-4,"LIU CHANG-JUN ET AL: ""Regiospecific hydroxylation of isoflavones by cytochrome P450 81E enzymes from Medicago truncatula."", PLANT JOURNAL, vol. 36, no. 4, November 2003 (2003-11-01), pages 471 - 484, XP002318604, ISSN: 0960-7412;;DATABASE UniProt [online] 1 May 1999 (1999-05-01), ""Cytochrome P450 (EC 1.14.14.1)."", XP002318606, retrieved from EBI accession no. UNIPROT:Q9ZRW6 Database accession no. Q9ZRW6;;HINDERER W ET AL: ""MICROSOMAL ISOFLAVONE 2' AND 3'-HYDROXYLASES FROM CHICKPEA CICER-ARIETINUM L. CELL SUSPENSIONS INDUCED FOR PTEROCARPAN PHYTOALEXIN FORMATION"", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 214, no. 1, 1987, pages 101 - 106, XP002139422, ISSN: 0014-5793;;DATABASE EMBL [online] 28 April 2001 (2001-04-28), ""EST509676 HOGA Medicago truncatula cDNA clone pHOGA-18N23 5' end, mRNA sequence."", XP002318607, retrieved from EBI accession no. EM_EST:BG648057 Database accession no. BG648057;;NAKAMURA K ET AL: ""INDUCTION OF ISOFLAVONOID AND RETROCHALCONE BRANCHES OF THE FLAVONOID PATHWAY IN CULTURED GLYCYRRHIZA ECHINATA CELLS TREATED WITH YEAST EXTRACT"", BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, JAPAN SOC. FOR BIOSCIENCE, BIOTECHNOLOGY AND AGROCHEM. TOKYO, JP, vol. 63, no. 9, 1999, pages 1618 - 1620, XP002927624, ISSN: 0916-8451;;AKASHI T ET AL: ""CYP81E1, A CYTOCHROME P450 CDNA OF LICORICE (GLYCYRRHIZA ECHINATA L.), ENCODES ISOFLAVONE 2'-HYDROXYLASE"", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 251, no. 1, 1998, pages 67 - 70, XP000914524, ISSN: 0006-291X;;SHIMADA NORIMOTO ET AL: ""Induction of isoflavonoid pathway in the model legume Lotus japonicus: Molecular characterization of enzymes involved in phytoalexin biosynthesis"", PLANT SCIENCE (SHANNON), vol. 160, no. 1, December 2000 (2000-12-01), pages 37 - 47, XP002330452, ISSN: 0168-9452;;OVERKAMP S ET AL: ""Cloning and characterization of eight cytochrome P450 cDNAs from chickpea (Cicer arietinum L.) cell suspension cultures"", PLANT SCIENCE, LIMERICK, IE, vol. 155, no. 1, June 2000 (2000-06-01), pages 101 - 108, XP002314013, ISSN: 0168-9452",PENDING
325,US,A,US 3925034 A,022-373-021-172-654,1975-12-09,1975,US 52994474 A,1974-12-05,US 52994474 A;;US 35973773 A,1973-05-14,RESIN BONDED GRINDING WHEEL CONTAINING GAS-FILLED THERMOPLASTIC RESIN BEADS AND METHOD OF MAKING IT,,RES ABRASIVE PRODUCTS INC,ANNA LEO A;;DIXON KENNETH C,,https://lens.org/022-373-021-172-654,Granted Patent,no,5,29,1,1,0,B24D3/32;;B24D3/32,B24D3/32,51/296,0,0,,,,EXPIRED
326,CA,A,CA 900613 A,027-395-733-141-353,1972-05-16,1972,CA 900613D A,,CA 900613T A,,IODIC ACID ACOUSTO-OPTIC DEVICES,,WESTERN ELECTRIC CO,DIXON RICHARD W;;PINNOW DOUGLAS A,,https://lens.org/027-395-733-141-353,Granted Patent,no,0,0,1,1,0,,G02F1/33,,0,0,,,,EXPIRED
327,CA,C,CA 2362440 C,027-866-332-192-836,2009-12-08,2009,CA 2362440 A,2000-03-08,US 12326799 P;;US 0005915 W,1999-03-08,GENETIC MANIPULATION OF ISOFLAVONOIDS,"Soybean and Medicago truncatula CYP93C genes have been isolated which encode a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone. Plants can now be genetically engineered to produce isoflavones that provide potential human health benefits and increas e disease resistance in plants. Isoflavones can now be produced in transgenic plants species in which isoflavones do not naturally occur, i.e., in species other than legumes. Alternatively, introducing infection-inducible isoflavonoid biosynthesis into non-legumes qualitatively complements these plants' phytoalexin defenses against microbial pathogens, whereas over-expression of the isoflavonoid pathway in legumes quantitatively increases this defense response. Finally, modifying the extend of production of isoflavonoids in legume roots positively impacts nodulation efficiency and therefore plant yield.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;STEELE CHRISTOPHER L,,https://lens.org/027-866-332-192-836,Granted Patent,no,0,0,7,8,5,C12N9/0077;;C07K2319/00;;C12N15/8242;;C12N15/8243;;C12N15/8261;;C12N15/8279;;Y02A40/146,C12N15/53;;A01H5/00;;A01H5/10;;A23L1/00;;C12N5/10;;C12N9/02;;C12N15/11;;C12N15/82,,0,0,,,,EXPIRED
328,AU,A1,AU 2013/287136 A1,079-606-161-171-568,2015-01-22,2015,AU 2013/287136 A,2013-06-20,US 201213541956 A;;US 2013/0046851 W,2012-07-05,Colpotomy cup-like structure and intrauterine manipulator including same,"A cup-like structure for engaging a cervix of a patient includes a rim, and includes a base defining an aperture through which one or more tubular members of a uterine manipulator may extend into the uterus. The cup-like structure is made from one or more of a polyphthalamide (PPA) material and a polyetheretherketone (PEEK) material. A uterine manipulator including a cup-like structure is also disclosed.",CLINICAL INNOVATIONS LLC,HORTON JEREMY C;;DIXON RICHARD A,,https://lens.org/079-606-161-171-568,Patent Application,no,0,0,10,10,0,A61B17/4241;;A61L29/06;;A61L29/126;;A61B18/1402;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L29/06;;A61L31/06;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L31/06;;A61L29/06,A61B17/42;;A61B1/303;;A61B17/3209;;A61L29/04;;A61M29/02,,0,0,,,,DISCONTINUED
329,US,A,US 5047908 A,114-184-391-821-626,1991-09-10,1991,US 61903090 A,1990-11-28,GB 8912941 A,1989-06-06,Lighting fittings,"A lighting fitting designed to operate either in the spotlight or flood mode has a reflector (7) extending forwardly of the lamp (1) and comprising a plurality of segments (8A, 8B) pivotable about respective axes (12) which are tangential to a circle centred on the longitudinal axis (X) of the reflector (7). Each segment comprises two longitudinally separate sections (8A, 8B) associated with arms (16) for pivoting them simultaneously but through different angles.",OSRAM LTD,DIXON ANGUS B;;PRICE WILFRED A,MURATA MANUFACTURING CO. LTD. 2-26-10 TENJIN NAGAOKAKYO-SHI KYOTO-FU 617 JAPAN (1990-12-19),https://lens.org/114-184-391-821-626,Granted Patent,yes,6,10,5,5,0,F21V7/09;;F21V7/16;;F21V17/02;;F21W2131/406;;F21V7/16;;F21W2131/406;;F21V17/02;;F21V7/09,F21S8/00;;F21V7/09;;F21V7/16;;F21V17/02,362/346,0,0,,,,EXPIRED
330,US,B2,US 10395769 B2,104-082-832-008-236,2019-08-27,2019,US 201615379572 A,2016-12-15,US 201615379572 A;;US 201562268016 P,2015-12-16,Patient care devices with local indication of correspondence and power line interconnectivity,"According to the present disclosure, a system includes a patient support device and a power line network for communicating data, such as patient identifying information. The patient support device locally indicates information about an assigned patient. A patient care apparatus is communicatively connected to the power line network to receive data and to provide a local indication of the data received. The local indication of the device and the apparatus includes respective lights that flash substantially synchronously.",HILL ROM SERVICES INC,RIBBLE DAVID L;;DIXON STEVEN A,HILL-ROM SERVICES INC (2016-01-02),https://lens.org/104-082-832-008-236,Granted Patent,yes,190,2,2,2,0,A61B90/90;;A61B90/90;;A61G7/05;;A61G7/05;;A61G2205/60;;A61G2205/60;;G16H40/63;;G16H40/63;;G08B5/38,G16H40/63;;A61B90/90;;A61G7/05;;G08B5/38,,4,0,,,"ST7540 FSK power line transceiver, 2006 STMicroelectronics, 43 pages.;;Maxim Integrated Powerline Digital Transceiver, Maxim Integrated Products, 2004, 28 pages.;;Maxim MAX2992 G3-PLC MAC/PHY Powerline Transceiver, 2 pages.;;Cypress Perform, Powerline Transceiver Data Sheet, Cypress Semiconductor Corporation, Oct. 20, 2009, 40 pages.",ACTIVE
331,US,A9,US 2006/0142765 A9,127-484-233-600-998,2006-06-29,2006,US 41901103 A,2003-04-18,US 41901103 A;;US 8333202 A;;US 3481501 A;;US 99685801 A;;US 97766301 A,2001-10-15,Vertebral implant for bone fixation or interbody use,"The present invention provides a biodegradable implant which can be used as fixation and/or interbody implants. The implant is formed of a biodegradable material and may be used as a cervical stabilizing system. The stabilizing system comprises a body constructed of a biodegradable, polymeric material, which when implanted within the body will maintain a predetermined structural integrity for at least a predetermined period of time while minimizing reactivity with adjacent tissues. In an embodiment of the invention, the stabilization system comprises a fixation member which includes apertures to allow selective coupling to bone segments by means of biodegradable screws. In another embodiment, the stabilization system includes a bone column implant which maintains space between at least two bone segments of a bone column. The body member is dimensioned to substantially maintain the distance, geometry and continuity between the at least two bone segments. The invention is also directed to a combination device comprising a fixation device along with an interbody implant and methods for using the stabilization system.",DIXON ROBERT A;;HACKMAN DONALD J,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30),https://lens.org/127-484-233-600-998,Amended Application,yes,55,103,2,10,0,A61B17/8052;;A61B17/8052;;A61B17/7059;;A61B17/7059;;A61B2017/00004;;A61B2017/00004;;A61F2/442;;A61F2/442;;A61F2/447;;A61F2/447;;A61F2002/2817;;A61F2002/2817;;A61F2002/30062;;A61F2002/30062;;A61F2002/30433;;A61F2002/30433;;A61F2002/30578;;A61F2002/30578;;A61F2002/30593;;A61F2002/30593;;A61F2002/30604;;A61F2002/30604;;A61F2210/0004;;A61F2210/0004;;A61F2220/0041;;A61F2220/0041,A61B17/56;;A61B17/00;;A61B17/70;;A61B17/80;;A61F2/00;;A61F2/02;;A61F2/28;;A61F2/30;;A61F2/44,606/69,0,0,,,,DISCONTINUED
332,CA,A,CA 522998 A,163-664-326-369-012,1956-03-20,1956,CA 522998D A,,CA 522998T A,,MANUFACTURE OF CELLULOSE,,INT PAPER CANADA,DIXON JULIAN A;;CHARLES FRANK R,,https://lens.org/163-664-326-369-012,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
333,AU,B2,AU 618325 B2,176-560-573-867-831,1991-12-19,1991,AU 1989/031164 A,1989-03-09,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS,,SANDOZ LTD,DIXON ARNOLD KEITH;;GRAY JULIAN A,,https://lens.org/176-560-573-867-831,Granted Patent,no,1,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
334,CA,A,CA 696439 A,187-132-122-035-911,1964-10-20,1964,CA 696439D A,,CA 696439T A,,MALTING OF BARLEY OR OTHER CEREALS,,ENZYMIC MALT COMPANY LTD;;DIXON MALT COMPANY LTD,COMRIE ALAN A D;;DIXON BERNARD,,https://lens.org/187-132-122-035-911,Granted Patent,no,0,0,1,1,0,C12C1/02;;C12C1/047,C12C1/02;;C12C1/047,,0,0,,,,EXPIRED
335,US,B2,US 6682530 B2,197-074-681-441-617,2004-01-27,2004,US 34096703 A,2003-01-13,US 34096703 A;;US 34818002 P,2002-01-14,Dynamized vertebral stabilizer using an outrigger implant,"
    A device and a method for stabilizing lumbar and thoracic vertebra or individual bones in human spine or bone column is provided for the purpose of fixing a vertebra or individual bone with respect to other vertebra or individual bones and with respect to other parts of the spinal or bone column. While providing spinal stabilization, the stabilizer allows axial load sharing or construct dynamized action. The device allows the vertebra or individual bones to be held in compression allowing subsidence along the plate axis or to be fixed with respect to the plate for rigid stabilization. The vertebra or individual bones will be prevented from distraction by a stop lock clamp. The device may be configured as a fully or partially rigid system. 
",DIXON ROBERT A;;HACKMAN DONALD J,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/197-074-681-441-617,Granted Patent,yes,5,124,2,2,0,A61B17/7007;;A61B17/701;;A61B17/7044;;A61B17/7058;;A61B17/7044;;A61B17/7007;;A61B17/7058;;A61B17/701,A61B17/70,606/61;;606/70,0,0,,,,EXPIRED
336,US,A,US 3269866 A,194-301-447-285-175,1966-08-30,1966,US 17650762 A,1962-02-28,US 17650762 A,1962-02-28,Low loss heat mounting system,,UNITED AIRCRAFT CORP,DIXON ROBERT W;;HORROCKS REX A,,https://lens.org/194-301-447-285-175,Granted Patent,no,1,4,3,3,0,H01M8/247;;Y02E60/50;;H01M8/247,H01M8/24,,0,0,,,,EXPIRED
337,IN,A,IN 3024KON2014 A,005-270-139-648-947,2015-05-08,2015,IN 3024KON2014 A,2014-12-23,US 201213541956 A;;US 2013/0046851 W,2012-07-05,COLPOTOMY CUP-LIKE STRUCTURE AND INTRAUTERINE MANIPULATOR INCLUDING SAME,"A cup-like structure for engaging a cervix of a patient includes a rim, and includes a base defining an aperture through which one or more tubular members of a uterine manipulator may extend into the uterus. The cup-like structure is made from one or more of a polyphthalamide (PPA) material and a polyetheretherketone (PEEK) material. A uterine manipulator including a cup-like structure is also disclosed.",CLINICAL INNOVATIONS LLC,HORTON JEREMY C;;DIXON RICHARD A,,https://lens.org/005-270-139-648-947,Patent Application,no,0,0,10,10,0,A61B17/4241;;A61L29/06;;A61L29/126;;A61B18/1402;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L29/06;;A61L31/06;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L31/06;;A61L29/06,A61B17/42;;A61M29/02,,0,0,,,,PENDING
338,EP,A1,EP 3029317 A1,023-120-216-435-005,2016-06-08,2016,EP 15198059 A,2015-12-04,US 201414561309 A,2014-12-05,METHOD AND APPARATUS FOR REDUCTION OF FATIGUE AND GUST LOADS ON WIND TURBINE BLADES,"An adjustable lift regulating device on an inboard portion of a wind turbine blade. The lift regulating device is activated to reduce lift on the inboard portion of the blade by causing flow separation on the suction side of the blade. To compensate for the lost lift, the blade pitch is increased to a running pitch that facilitates stalling on the outer portion of the blade in gusts. This provides passive reduction of fatigue and extreme loads from gusts while allowing full power production under non-gust conditions.",SIEMENS AG,DIXON KRISTIAN R;;MAYDA EDWARD A,"SIEMENS AKTIENGESELLSCHAFT (2017-08-30);;SIEMENS GAMESA RENEWABLE ENERGY A/S (2019-05-15);;SIEMENS GAMESA RENEWABLE ENERGY A/S, DK (2019-05-06)",https://lens.org/023-120-216-435-005,Patent Application,yes,3,9,3,7,0,F03D7/0224;;F03D7/0232;;F05B2240/31;;F05B2270/1095;;Y02E10/72,F03D7/02,,0,0,,,,ACTIVE
339,US,A,US 2540476 A,042-858-679-488-699,1951-02-06,1951,US 2598548 A,1948-05-08,US 2598548 A,1948-05-08,Method of separating dihalogenopyrazines,,AMERICAN CYANAMID CO,DIXON JAMES K;;MILLER ALEXANDER A,,https://lens.org/042-858-679-488-699,Granted Patent,no,0,0,1,1,0,C07D241/16;;C07D241/16,C07D241/16,,0,0,,,,EXPIRED
340,AU,A1,AU 2015/249751 A1,056-056-170-469-800,2016-11-10,2016,AU 2015/249751 A,2015-04-22,US 201461983325 P;;US 2015/0027099 W,2014-04-23,Methods of enhancing stem cell engraftment,"An effective amount of a composition comprising a stem cell, a stem cell engraftment enhancer, and a carrier fluid, for use in the treatment of an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease. A composition comprising PGI2-overexpressing human mesenchymal stem cells (PGI2-hMSCs), and a carrier fluid; wherein an effective amount of the composition is administered via a single treatment stream as an intramuscular injection to an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease, and wherein stem cell engraftment is enhanced in said individual by greater than about 200%, when compared to stem cell engraftment in an individual treated with a composition lacking the stem cell engraftment enhancer.",TEXAS HEART INST,LIU QI;;DIXON RICHARD A F,,https://lens.org/056-056-170-469-800,Patent Application,no,0,1,6,6,0,A61K35/12;;A61K35/34;;A61K35/36;;A61K45/06;;A61K35/28;;A61K31/5578;;A61P9/00;;A61K35/28;;A61K31/5578;;A61K35/34;;A61K45/06;;A61K35/36;;A61K35/12,A61K35/28;;A61K35/12;;A61K35/36;;A61P9/00,,0,0,,,,DISCONTINUED
341,US,A,US 3843517 A,060-679-825-998-187,1974-10-22,1974,US 9925370 A,1970-12-17,US 9925370 A;;US 151270 A,1970-01-08,METHODS FOR ELIMINATION OF OIL SLICKS,,GRACE W R & CO,MCKINNEY R;;DIXON A;;JORDAN R,W.R. GRACE & CO.-CONN (1988-05-25),https://lens.org/060-679-825-998-187,Granted Patent,no,0,50,4,6,0,C02F1/681;;C12N1/04;;C12N1/26;;Y10S435/875;;Y10S435/876;;Y10S210/922;;C12N1/26;;C12N1/04;;C02F1/681;;Y10S210/922;;Y10S435/876;;Y10S435/875,C02F1/68;;C12N1/04;;C12N1/26,210-011,0,0,,,,EXPIRED
342,US,A,US 814773 A,065-689-756-607-111,1906-03-13,1906,US 1904/0272194 A,1904-12-05,US 1904/0272194 A,1904-12-05,METHOD OF FEEDING GLASS.,,AUTOMATIC MACHINE GLASS COMPANY,DIXON HENRY L;;MARSH GEORGE A,,https://lens.org/065-689-756-607-111,Granted Patent,no,0,4,1,1,0,C03B7/08;;C03B7/08,,,0,0,,,,EXPIRED
343,AU,A,AU 1982/091439 A,064-388-877-253-924,1983-07-28,1983,AU 1982/091439 A,1982-12-13,US 34095282 A,1982-01-20,TRANSLATING AND POSITIONING A CATHETER,,SORENSON RESEARCH CO,WONDER TERRY M;;DIXON JOHN A,,https://lens.org/064-388-877-253-924,Patent Application,no,0,0,8,8,0,A61M25/0084;;A61B17/3478;;A61B2017/320084;;A61M2025/0089,A61M5/14;;A61B17/32;;A61B17/34;;A61M25/00,,0,0,,,,DISCONTINUED
344,US,A,US 4859403 A,133-153-648-196-924,1989-08-22,1989,US 10244487 A,1987-09-29,US 10244487 A,1987-09-29,Feedwater sparger restraint,"A restraint to enable temporary bracing and operation of a thermally cracked sparger nozzle mounted from a sparger manifold at the end of a pipe elbow is disclosed. The restraint includes a second and surrounding restraint elbow which is fitted over and captures the sparger elbow. The restraint elbow has a saddle surface baseplate communicated to the lower end which rest on the sparger manifold to form a substantially water tight base for the restraint. The nozzle end of the restraint elbow is fitted with a nozzle aperture plate for surrounding the outside of the sparger nozzle again in substantially water tight relation. The plate is mounted for movement on the end of the restraint elbow for conforming threading of the restraint at the plate over the sparger nozzle. The restraint can be rapidly mounted (in less than a minute), tack welded at the aperture and seat tensioning bold (in less than 4 minutes) and left in the reactor for a complete fuel cycle. With the restraint mounted, cracked and defective sparger nozzles are restrained in place while a replacement sparger is fabricated.",GEN ELECTRIC,DIXON ROBERT C;;DEAVER GERALD A,GENERAL ELECTRIC COMPANY A NY CORP (1987-09-23),https://lens.org/133-153-648-196-924,Granted Patent,yes,10,21,1,1,0,G21C13/032;;G21C15/14;;Y10T137/7036;;Y02E30/30;;Y10T137/7036;;G21C15/14;;G21C13/032;;Y02E30/30,G21C13/032;;G21C15/14,376/286;;376/352;;137/375;;138/99,0,0,,,,EXPIRED
345,US,A,US 4939129 A,124-074-658-292-184,1990-07-03,1990,US 32142289 A,1989-03-09,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,Uses of 4-(3-phosphono-2-propenyl)-2-pierazinecarboxylic acid,"The uses of piperazinecarboxylic acid in the treatment of disorders characterized by reduced drive and/or social withdrawal, sleep disturbances or migraine.",SANDOZ LTD,DIXON ARNOLD K;;GRAY JULIAN A,SANDOZ LTD. (AKA SANDOZ AG) A COMPANY OF THE SWISS CONFEDERATION (1989-02-27),https://lens.org/124-074-658-292-184,Granted Patent,yes,0,2,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,514/85,4,1,045-753-820-425-215,10.1016/0006-8993(88)90690-7;;2851364,"Chem. Abst. 109 211230 G (1988).;;Trends in Neuroscience, 10, pp. 8 13 (1987).;;Brain Research, 457, pp. 226 240 (1988).;;Neurology and Neurobiology, vol. 46, pp. 661 666 (1988).",EXPIRED
346,CA,A,CA 881479 A,179-315-656-086-782,1971-09-21,1971,CA 881479D A,,CA 881479T A,,PROCESS FOR MALTING GERMINATED GRAIN,,DIXON MALT COMPANY LTD;;ENZYMIC MALT COMPANY LTD,DIXON BERNARD;;COMRIE ALAN A D,,https://lens.org/179-315-656-086-782,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
347,PT,B,PT 89962 B,184-598-924-473-097,1994-05-31,1994,PT 8996289 A,1989-03-09,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,PROCESSO PARA A PREPARACAO DE NOVAS COMPOSICOES FARMACEUTICAS CONTENDO ACIDO 4--(3-FOSFONO-2-PROPENIL)-2-PIPERAZINOCARBOXILICO COMO SUBSTANCIA ACTIVA,,SANDOZ SA,DIXON ARNOLD KEITH;;GRAY JULIAN A,,https://lens.org/184-598-924-473-097,Granted Patent,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
348,EP,A3,EP 0740944 A3,030-411-916-435-931,1997-03-12,1997,EP 96302194 A,1996-03-28,US 43299895 A,1995-05-02,Pivot assisted defibrillator paddle retainer,"A retainer assembly for a defibrillator paddle has a resilient back plate. The back plate secures to a back wall in a pocket by a fastener positioned to allow pivotal movement of the back plate. The back plate has a bracket at its inner edge, retaining an edge of the base of the paddle. A lip extends forward from an outer edge of the back plate to overlie an outer edge of the paddle. The lip is within a tab section that deflects into a recess if a user exerts a sufficient outward pull on the handle.",HEWLETT PACKARD CO,ANDREWS JONATHAN N;;DIXON WILLIAM A,"HEWLETT-PACKARD COMPANY, A DELAWARE CORPORATION (2001-03-28);;AGILENT TECHNOLOGIES INC. A DELAWARE CORPORATION (2001-08-08);;KONINKLIJKE PHILIPS N.V., NL (2014-11-26);;AGILENT TECHNOLOGIES, INC. (A DELAWARE CORPORATION (2001-10-10);;AGILENT TECHNOLOGIES INC. (2001-08-01);;KONINKLIJKE PHILIPS ELECTRONICS N.V. (2003-08-06)",https://lens.org/030-411-916-435-931,Search Report,yes,5,0,8,8,0,A61N1/3904;;A61N1/3904;;B25H3/006;;B25H3/006,A61N1/39;;B25H3/00,,0,0,,,,EXPIRED
349,AU,A1,AU 2004/286279 A1,032-759-633-901-517,2005-05-12,2005,AU 2004/286279 A,2004-10-28,US 51555903 P;;US 2004/0035948 W,2003-10-29,Plant isoflavonoid hydroxylases and methods of use thereof,,THE SAMUEL ROBERTS NOBLE FOUNDATION INC,DIXON RICHARD A;;LIU CHANG-JUN,,https://lens.org/032-759-633-901-517,Patent Application,no,0,0,8,8,0,C12N9/0073;;C12N9/0073,A23L19/00;;C12N15/82;;C12N9/02,,0,0,,,,DISCONTINUED
350,WO,A1,WO 2007/092809 A1,046-224-331-792-068,2007-08-16,2007,US 2007/0061606 W,2007-02-05,US 76556206 P,2006-02-06,MATTRESS WITH PATIENT TRANSPORT APPARATUS INCORPORATED THEREIN,"A mattress having a storage compartment is provided. The storage compartment is used to hold items that are useful in the transport of a patient located on the mattress, such as a patient restraint that can be used to secure the patient to the mattress during transport.",HILL ROM CO INC;;WALKE JAMES L;;DIXON STEVEN A,WALKE JAMES L;;DIXON STEVEN A,,https://lens.org/046-224-331-792-068,Patent Application,yes,8,2,3,3,0,A61G1/00;;A61G1/044;;A61G1/048;;A61G7/015;;A61G7/0504;;A61G7/05769;;A61G7/0504;;A61G7/015;;A61G1/048;;A61G1/00;;A61G1/044;;A61G7/05769,A61G7/05,,0,0,,,,PENDING
351,CA,A,CA 664976 A,057-619-269-759-43X,1963-06-18,1963,CA 664976D A,,CA 664976T A,,BUOYANT ARTICLE TRANSPORTER,,MCLENNAN CHARLES A;;DIXON DOUGLAS G,DIXON DOUGLAS G;;MCLENNAN CHARLES A,,https://lens.org/057-619-269-759-43X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
352,EP,A1,EP 0371051 A1,044-720-204-975-419,1990-06-06,1990,EP 88906348 A,1988-06-09,US 7279687 A,1987-07-13,COMBINATION CATHETER AND DUCT CLAMP APPARATUS AND METHOD.,"L'appareil comprend un organe creux (12) présentant une surface de serrage sensiblement plane (14) à une extrémité et une organe de coulissement (32) ayant une surface de serrage sensiblement plane (16) à une extrémité qui peut être introduite de manière télescopique dans l'organe creux (12). Un ressort (34) maintient une pression de serrage constante entre les surfaces de serrage. La pince de serrage est idéale pour être utilisée pendant une cholangiographie au cours de laquelle on peut l'utiliser pour introduire un cathéter (48) dans le conduit cystique (54) et pour serrer le conduit cystique autour du cathéter. La pression de serrage établit un joint hermétique adéquat du conduit cystique et ne bouche pas le cathéter inséré. Des angles multiples de serrage confèrent à la pince une versatilité unique pendant l'opération chirurgicale. La pince de serrage étant construite avec un matériau transparent au rayonnement, elle peut être laissée en place pendant que l'on établit un cholangiogramme sans interférer avec le cholangiogramme achevé.",LAZARUS MEDICAL INNOVATIONS IN,LAZARUS HARRISON M;;FORD DIXON A,,https://lens.org/044-720-204-975-419,Patent Application,yes,0,0,6,6,0,A61B17/12;;A61B2017/00902;;Y10S128/26;;A61B17/12;;A61B2017/00902;;Y10S128/26,A61B17/00;;A61B17/12;;A61B19/00;;A61M25/00;;A61M25/02,,0,0,,,,DISCONTINUED
353,US,A1,US 2005/0150010 A1,054-358-665-502-204,2005-07-07,2005,US 7196405 A,2005-03-04,US 7196405 A;;US 92657101 A;;US 0013389 W;;US 13502699 P,1999-05-20,Isoflavonoid methylation enzyme,"Methods of genetically manipulating biology active 4′-O-methylated isoflavonoids have been found based upon the regiospecifity of isoflavone 7-OMT in vivo. Upon transformation and expression of an isoflavonoid O-methyltransferase gene, up-regulation of IOMT in the transgenic plants can be used to increase the accumulation of 4′-O-methylated isoflavonoid phytolalexins, providing for increased disease resistance to the plant. Similar methods can be used to increase accumulation of 4′-O-methylated isoflavonoid nutraceuticals in plants. For down-regulation of IOMT in plants that naturally make 4′O-isoflavonoid phytoalexins and 4′-O-methylated isoflavonoid nutraceuticals, IOMT gene sequences can be transformed in the antisense orientation.",DIXON RICHARD A.;;HE XIAN Z.,DIXON RICHARD A;;HE XIAN Z,NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/054-358-665-502-204,Patent Application,yes,1,3,3,10,5,C12N9/1007;;C12N15/8243;;C12N15/825;;C12N15/8282;;C12N15/8282;;C12N15/825;;C12N15/8243;;C12N9/1007,C12N9/10;;C12N15/29;;C12N15/54;;C12N15/82,800/284;;435/468;;435/193,0,0,,,,EXPIRED
354,US,A1,US 2002/0026191 A1,079-807-432-911-312,2002-02-28,2002,US 92306301 A,2001-08-06,US 92306301 A;;US 22447200 P,2000-08-10,Cam action vertebral spreader,"
   This invention comprises an apparatus and a method of spreading an intervertebral space to help guide tools that will prepare the vertebrae for accepting an implant. The spreader is a thin blade with cam surfaces forming a paddle on the proximal end, which spreads the vertebra when rotated 90 degrees about its axis. A stem between the paddle and a handle is notched to clear the vertebral protrusions so the vertebra will be distracted on the vertebral end plates. Since the spreader is in the center of the end plates, the centerline of the spreader shaft will coincide with the vertebral end plate centerline. The surgeon can monitor the spreading, stop and remove the spreader to make adjustments or to change the size of spreader as required at the time of the surgery. Once the vertebrae are distracted a tube may be placed over the handle and aligned with the vertebral end plates. 
",DIXON ROBERT A.;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/079-807-432-911-312,Patent Application,yes,7,16,2,2,0,A61B17/025;;A61B2017/0256;;A61B2017/2933;;A61B17/025;;A61B2017/2933;;A61B2017/0256,A61B17/02;;A61B17/28,606/57;;606/105,0,0,,,,EXPIRED
355,US,A,US 4697618 A,071-219-256-582-713,1987-10-06,1987,US 68929485 A,1985-01-07,US 68929485 A,1985-01-07,Container structure for dangerous material,"A container structure for a dangerous material. An inner container defines a chamber for receiving the dangerous material, an outer container surrounds the inner container, and a fluid chamber is disposed between the inner and outer containers. A body of non flammable liquid is disposed in and completely fills the fluid chamber, and the body of liquid is substantially confined in the fluid chamber. A vent space is disposed between the inner and outer containers in the area above the fluid chamber. The outer container has a bottom wall that is adapted to slidably engage a support surface so that the container structure can slide on the support surface in response to an external impact overcoming its inertia. The inner container is supported essentially by the body of liquid in the fluid chamber, and the body of liquid, being substantially confined in the fluid chamber, distributes impact forces applied to the outer container over a large area of the inner container, thus minimizing damage to the inner container in response to an external impact, and allowing the container structure to slide as a solid body on the support surface in response to an external impact that overcomes its inertia.",AMERICAN TANK & FABRICATING CO,YOUTT STANLEY A;;DIXON JOHN W,AMERICAN TANK AND FABRICATING CO. THE (1984-12-10),https://lens.org/071-219-256-582-713,Granted Patent,yes,15,29,2,2,0,B65D90/22;;B65D90/22;;Y10T137/1812;;Y10T137/1812;;Y10T137/86324;;Y10T137/86324;;Y10T137/86348;;Y10T137/86348,B65D90/22,137/587;;137/74;;137/590;;X220  1B;;220/18;;220/71;;X220 88R;;X220 89B;;220/428;;220/435,0,0,,,,EXPIRED
356,US,B2,US 8129592 B2,110-126-157-738-006,2012-03-06,2012,US 25995108 A,2008-10-28,US 25995108 A;;US 97619004 A;;US 51555903 P,2003-10-29,Plant isoflavonoid hydroxylases and methods of use thereof,"The invention provides plant isoflavonoid hydroxylase coding sequences. Also provided are constructs comprising these sequences, plants transformed therewith and methods of use thereof. In certain aspects of the invention, plants transformed with the nucleic acids are provided exhibiting improved pest and disease resistance. Plants provided by the invention may also exhibit improved nutritional qualities.",DIXON RICHARD A;;LIU CHANG-JUN;;SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;LIU CHANG-JUN,NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/110-126-157-738-006,Granted Patent,yes,9,0,8,8,21,C12N9/0073;;C12N9/0073,A23L19/00;;C12N15/29;;A01H5/00;;A01H5/10;;C12N9/02;;C12N15/52;;C12N15/82,800/301;;800/298;;536/23.6;;435/320.1;;435/419,46,31,030-560-996-409-192;;010-860-681-994-410;;084-079-299-563-31X;;030-800-960-815-367;;006-713-586-398-958;;029-444-788-587-249;;064-627-264-538-308;;111-423-948-356-968;;049-116-326-914-471;;016-260-898-220-124;;022-840-884-390-841;;053-522-357-177-636;;048-425-634-797-396;;030-730-200-090-470;;002-689-313-687-938;;040-238-080-165-869;;032-569-428-744-527;;079-620-757-564-531;;030-995-480-883-515;;009-730-205-489-885;;030-560-996-409-192;;008-831-818-058-304;;031-855-736-737-194;;021-790-234-568-506;;019-370-215-214-515;;010-860-681-994-410;;032-860-477-848-422;;045-664-788-381-085;;172-889-478-463-474;;023-730-405-857-029;;093-860-659-276-472,pmc137925;;12384577;;10.1073/pnas.212522099;;10773344;;10.1016/s0168-9452(00)00214-4;;10.1111/j.1432-1033.1994.tb18931.x;;8026495;;10.1007/978-1-4020-6754-9_1879;;9790908;;10.1006/bbrc.1998.9414;;10.1039/p19920000839;;10.1007/bf00232133;;24226376;;10.1016/0031-9422(95)00618-4;;10.1016/s0031-9422(00)95150-1;;12031439;;10.1016/s0031-9422(02)00116-4;;pmc1540287;;12644640;;10.1104/pp.102.017319;;10.1046/j.1364-3703.2002.00131.x;;20569344;;10.1016/b978-0-08-091283-7.00030-8;;10.1515/znc-1991-1-210;;10.2307/3871183;;11006341;;pmc149079;;10.1105/tpc.12.9.1689;;10.1016/0014-5793(87)80021-2;;10.1016/0003-9861(89)90514-6;;2505672;;10.1016/s0031-9422(00)90838-0;;11027686;;10.1074/jbc.m006277200;;pmc139479;;10.2307/3871525;;10.1105/tpc.010382;;11752378;;10.1105/tpc.13.12.2643;;pmc137925;;12384577;;10.1073/pnas.212522099;;10.1046/j.1365-313x.2003.01893.x;;14617078;;6649792;;10.1515/znc-1983-9-1007;;10.1016/s0176-1617(11)81242-3;;10540749;;10.1271/bbb.63.1618;;10773344;;10.1016/s0168-9452(00)00214-4;;10.1016/s0076-6879(96)72008-6;;8791762;;10.1016/s0168-9452(00)00355-1;;11164575;;11471948;;10.1023/a:1010339104206;;11413204;;10.1093/jexbot/52.357.681;;12166960;;10.1021/jf025549r,"Liu C. et al. PNAS, 2002, vol. 99, No. 22; pp. 14578-14583.;;Overkamp, S. et al. Plant Science (2000) vol. 155; pp. 101-108.;;Urban, P. et al. Eur. J. of Biochemistry (1994) vol. 222; pp. 843-850.;;Blast Basic Local Alignment Search Tool, Job Title: Icl|4054 (498 letters), dated Sep. 19, 2008.;;Blast Basic Local Alignment Search Tool, Job Title: Nucleotide Sequence (1560 letters), dated Sep. 19, 2008.;;GenPept Accession No. Q9XFX0, dated Nov. 28, 2006.;;GenPept Accession No. Q9ZRW6, dated Nov. 28, 2006.;;Akashi et al., ""CYP81E1, a Cytochrome P450 cDna of Licorice (Glycyrrhiza echinata L.) Encodes isoflavone 2'-hydroxylase,"" Biochemical and Biophysical Research Communications, 251:67-70, 1998.;;Bhandari et al., ""Biosynthesis of the A/B/C/D-ring system of the rotenoid amorphigenin by Amorpha fruticosa seedlings,"" J. Chem. Soc. Perkin Trans., 839-849, 1992.;;Choudhary et al., ""Stress responses in alfalfa (Medicago sativa L.) IV. Expression of defense gene constructs in electroporated suspension cell photoplasts,"" Plant Cell Rep., 9:42-46, 1990.;;Clemens et al., ""Cytochrome P450-dependant methylenedioxy bridge formation in Cicer Arietinum,"" Phytochemistry, 41:457-460, 1996.;;Clemens et al., ""Characterization of Cytochrome P450-dependent isoflavone hydroxylasas from chickpea,"" Phytochemistry, 32:653-657, 1993.;;Dewick, ""Isoflavonoids,"" The Flavonoids: Advances in Research Since 1986., Harborne (Ed.), London: Chapman and Hall, 117-238, 1993.;;Dixon et al., ""Molecules of Interest Genistein,"" Phytochemistry, 60:205-211, 2002.;;Dixon et al., ""Legume natural products: understanding and manipulating complex pathways for human and animal health,"" Plant Physiol., 131:878-885, 2003.;;Dixon et al., ""The phenylpropanoid pathway and plant defence-a genomics perspective,"" Mol. Plant Pathol., 3:371-390, 2002.;;Dixon, ""Isoflavonoids: biochemistry, molecular biology, and biological functions,"" Comprehensive Natural Products Chemistry, Barton et al. (ed), Elsevier, 1:773-823, 1999.;;GenBank Accession No. AB001379.;;GenBank Accession No. AB022732.;;GenBank Accession No. AB025016.;;GenBank Accession No. AJ012581.;;GenBank Accession No. AJ238439.;;GenBank Accession No. AY166658.;;GenBank Accession No. AY278227.;;GenBank Accession No. AY278229.;;Gunia et al., ""Elicitor induction of cytochrome P450 monooxygenases in cell suspension cultures of chickpea (Cicer arietinum L.) and their involvement in pterocarpan phytoalexin biosynthesis,"" Z. Naturforsch. 46:58-66, 1991.;;Hahn et al., ""ESTs from roots of Medicago truncatula treated with oligogalacturonides of DP 6-20,"" 2001, Accession No. BG648057.;;He et al., ""Genetic manipulation of isoflavone 7-O-methyltransferase enhances biosynthesis of 4'0-methylated isoflavonoid phytoalexins and disease resistance in alfalfa,"" Plant Cell, 12:1689-1702, 2000.;;Hinderer et al., ""Microsomal isoflavone 2'- and 3'-hydroxylases from chickpea (Cicer arietinum L.) cell suspensions induced for pterocarpan phytoalexin formation,"" Febs Letters, 214:101-106, 1987.;;Kochs et al., ""Phytoalexin synthesis in soybean: purification and reconstitution of cytochrome P450 3,9-dihydroxypterocarpan 6a-hydroxylase and separation from Cytochrome P450 cinnamate 4-hydroxylase,"" Arch. Biochem. Biophys., 273:543-553, 1989.;;Lambert et al., ""Production of rotenoids by heterotrophic and photomixotrophic cell cultures of tephrosia vogelii,"" Phytochemistry, 34:1515-1520, 1993.;;LatundeDada et al., ""Flavonoid 6-hydroxylase from soybean (Glycine max. L.), a novel plant P-450 monooxygenase,"" J. Biol. Chem., 276:1688-1695, 2001.;;Liu et al., ""Elicitor-induced association of isoflavone O-methyltransferase with endomembranes prevents the formation and 7-O-methylation of daidzein during isoflavonoid phytoalexin biosynthesis,"" Plant Cell, 13:2643-2658, 2001.;;Liu et al., ""Bottlenecks for metabolic engineering of isoflavone glycocojugates in Arabidopsis,"" Proc. Natl. Acad. Sci USA, 99:14578-14583, 2002.;;Liu et al., ""Regiospecific hydroxylation of isoflavones by ctyochrome P450 81E enzymes from medicago truncatula,"" The Plant Journal, 36:471-484, 2000.;;Mackenbrock et al., ""3'-Hydroxylation of 4'-Methoxyisoflavones by Fusarium oxysporum f. lycopersici,"" Z. Naturforsch. 38:708-710, 1983.;;Mackenbrock et al., ""Accumulation and metabolism of medicarpin and maackiain maolnylgucosides in elicited chickpea (Cicer arietinum L.) cell suspension cultures,"" J. Plant Physiol., 142:385-391, 1993.;;Mihaliak et al., ""Cytochrome P450 terpene hydroxylases,"" Meth. Plant Biochem., 9:261-279, 1993.;;Nakamura et al., ""Induction of isoflavonoid and retrochalcone branches of the flavonoid pathway in cultured Glycyrrhiza echinata cells treated with yeast extract,"" Biosci. Biotechnol. Biochem., 63:1618-1620, 1999.;;Overkamp et al., ""Cloning of two cicer arietinum L. cDNA's encoding Cytochrome P450's highly homologous Isoflavone 2'-Hydroxylase from licorice,"" Plant Physiol., 120:935, 1999.;;Overkamp et al., Cloning and characterization of eight cytochrome P450 cDNAs from chickpea (Cicer arietinum L.) cell suspension cultures, Plant Science, 155:101-108, 2000.;;Pompon et al., ""Yeast expression of animal and plant P450s in optimized redox environments,"" Meth. Enzymol., 272:51-64, 1996.;;Shimada et al., ""Induction of isoflavonoid pathway in the model legume Lotus japonicus: molecular characterization of enzymes involved in phytoalexin biosynthesis,"" Plant Science, 160:37-47, 2000.;;Simmonds et al., ""Effects of isoflavonoids from Cicer on larve of Heliocoverpa armigera,"" J. Chem. Ecol., 27:965-977, 2001.;;Tebayashi et al., ""Elicitor-induced changes in isoflavonoid metabolism in red clover roots,"" J. Exp. Bot., 52:681-668, 2001.;;Tolleson et al., ""Metabolism of Biochanin A and formononetin by human liver microsomes in vitro,"" J. Agric. Food Chem., 50:4783-4790, 2002.",ACTIVE
357,CH,A5,CH 643584 A5,122-825-341-330-455,1984-06-15,1984,CH 156079 A,1979-02-16,US 87885878 A,1978-02-17,BESCHICHTUNGSMASSE.,,WESTINGHOUSE ELECTRIC CORP,SATTLER FRANK A;;DIXON GEORGE D,,https://lens.org/122-825-341-330-455,Granted Patent,no,0,0,11,11,0,C08F283/01;;C08F299/0478;;C08G63/6854;;C09D167/00;;Y10T428/31681;;Y10T428/31681;;C08F299/0478;;C08G63/6854;;C08F283/01;;C09D167/00,C08F299/00;;C08F2/50;;C08F283/01;;C08F299/04;;C08G63/00;;C08G63/52;;C08G63/685;;C09D4/00;;C09D167/00,,0,0,,,,EXPIRED
358,CA,A,CA 181800 A,119-315-154-758-837,1918-01-29,1918,CA 181800D A,1917-04-13,CA 181800T A,1917-04-13,WRENCH,,DIXON ALBERT H;;HENSCHELL FERDINAND A,DIXON ALBERT H;;HENSCHELL FERDINAND A,,https://lens.org/119-315-154-758-837,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
359,BR,A,BR 8300243 A,131-655-020-380-950,1983-10-18,1983,BR 8300243 A,1983-01-19,US 34095282 A,1982-01-20,"MONTAGEM DE CATETER, MECANISMO DE PRISAO E PROCESSO PARA A INTRODUCAO DE UM CATETER DISTRIBUIDOR DE FLUIDO",,SORENSON RESEARCH CO,WONDER TERRY M;;DIXON JOHN A,,https://lens.org/131-655-020-380-950,Patent Application,no,0,0,8,8,0,A61M25/0084;;A61B17/3478;;A61B2017/320084;;A61M2025/0089,A61M5/14;;A61B17/32;;A61B17/34;;A61M25/00,,0,0,,,,DISCONTINUED
360,EP,A4,EP 2869772 A4,165-737-235-615-051,2016-01-20,2016,EP 13813766 A,2013-06-20,US 201213541956 A;;US 2013/0046851 W,2012-07-05,COLPOTOMY CUP-LIKE STRUCTURE AND INTRAUTERINE MANIPULATOR INCLUDING SAME,,CLINICAL INNOVATIONS LLC,HORTON JEREMY C;;DIXON RICHARD A,,https://lens.org/165-737-235-615-051,Search Report,no,1,0,10,10,0,A61B17/4241;;A61L29/06;;A61L29/126;;A61B18/1402;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L29/06;;A61L31/06;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L31/06;;A61L29/06,A61B17/42;;A61B1/303;;A61L29/06;;A61L29/12;;A61L31/06,,0,0,,,,DISCONTINUED
361,US,B2,US 6482003 B2,185-358-575-427-650,2002-11-19,2002,US 82514901 A,2001-04-03,US 82514901 A;;US 37772199 A,1999-08-19,Individual dose dental adhesive delivery system and method,"
    Individual doses of dental adhesive are dispensed onto a flat conformable card and enclosed under a cover sealed to the card. The cover is peeled off at chairside and individual doses of the adhesive are picked up by a wiping action of a dental tool or of an object to be bonded, such as, for example, by wiping action of an orthodontic bracket base over the adhesive bearing surface of the card. The card deforms to conform to the curvature of the edge of the appliance or object to cleanly transfer all of the adhesive of a dose from the card to the appliance base. 
",ORMCO CORP,DIXON DANIEL R;;ANDREIKO CRAIG A,ORMCO CORPORATION (2001-07-13),https://lens.org/185-358-575-427-650,Granted Patent,yes,8,26,2,3,0,A61C7/12;;A61C19/02;;A61C2202/01;;A61C5/60;;A61C7/12;;A61C19/02;;A61C2202/01;;A61C5/60,A61C5/06;;A61C7/12;;A61C19/02,433/9;;206/309;;401/129,0,0,,,,EXPIRED
362,CA,A,CA 823108 A,009-659-545-021-518,1969-09-16,1969,CA 823108D A,,CA 823108T A,,PREPARATION OF AMMONIUM PHOSPHATES,,ELECTRIC REDUCTION CO,DIXON JOHN T;;SMITH RAYMOND A,,https://lens.org/009-659-545-021-518,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
363,US,A,US 5554907 A,016-091-964-259-939,1996-09-10,1996,US 90462392 A,1992-06-26,US 90462392 A;;US 88063892 A,1992-05-08,Vehicle speed measurement apparatus,A vehicle speed monitoring system has a pair of parallel piezoelectric sensors or pressure transducers carried in closely spaced relation by a common elastomeric carrier such that the distance D between the sensors is maintained constant. A time measuring circuit connected to the sensors measures the time between peak voltages induced in the piezoelectric sensor transducers which is used to calculate and display vehicle speed. A weight is secured to or embedded in the carrier to cause the carrier to hug the roadway and be immune to lifting because of air currents and turbulence.,MITRON SYSTEMS CORP,DIXON DONALD A;;TYBURSKI ROBERT M,MITRON SYSTEMS CORPORATION A CORP. OF MD (1992-06-16);;MITRON SYSTEMS CORPORATION (1998-04-27),https://lens.org/016-091-964-259-939,Granted Patent,yes,25,60,1,1,0,G08G1/02;;G08G1/052;;Y10S310/80;;E01F9/529;;H10N30/302;;G08G1/052;;G08G1/02;;Y10S310/80;;E01F9/529;;H10N30/302,E01F9/529;;G08G1/02;;G08G1/052;;H01L41/113,310/339;;310/319;;310/800;;340/936;;340/933,1,0,,,"A Review of Current Traffic Sensor Technology , Robert M. Tyburski.",EXPIRED
364,US,A,US 1969260 A,029-306-944-773-882,1934-08-07,1934,US 69873633 A,1933-11-20,US 69873633 A,1933-11-20,Supporting fabrication for tents,,FRANCIS M COMPTON;;REED COMPTON,DIXON JOHN W;;FILER PAUL A,,https://lens.org/029-306-944-773-882,Granted Patent,no,0,6,1,1,0,E04H15/32;;E04H15/32,E04H15/32,,0,0,,,,EXPIRED
365,CA,A,CA 1127132 A,064-235-191-675-56X,1982-07-06,1982,CA 349787 A,1980-04-14,US 2941079 A,1979-04-12,VEHICLE SEAT BELT RETRACTOR MECHANISM,"A seat belt inhibitor system is designed to prevent a door mounted inertial seat belt retractor 14 from locking the seat belt webbing 13 whenever the door is opened. The retractor pendulum 31, sensitive to acceleration, moves the locking bar 28 upward locking the retractor and prevents the belt webbing from paying out. An electromagnet 36, when energized, attracts a leaf spring 37 extending from the locking bar inhibiting movement of the latter. System inhibiting is initiated by closing either a door latch switch 42 or a door release handle switch 41. At low accelerations (occurring while the door is being opened), the locking bar 28 is restrained by the electromagnet 36 through the leaf spring 37. If the system should fail such that the electromagnet was energized while the door is closed, high acceleration of the pendulum would force the locking bar up, locking the retractor. Deenergizing occurs normally whenever the door is closed.",FORD MOTOR CANADA,COLLINS ALFORD F;;DIXON BILL A,,https://lens.org/064-235-191-675-56X,Granted Patent,no,0,0,7,7,0,B60R22/41;;B60R22/41,B60R22/08;;B60R22/40;;B60R22/41;;B60R22/48,242-43.6,0,0,,,,EXPIRED
366,CA,A,CA 617134 A,069-250-344-309-26X,1961-03-28,1961,CA 617134D A,,CA 617134T A,,ROTARY MOWER,,JOHN DEERE PLOW CO,DIXON DAVID W;;NORTHCOTE JOHN A,,https://lens.org/069-250-344-309-26X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
367,AU,A1,AU 2005/265356 A1,064-225-573-826-328,2006-01-26,2006,AU 2005/265356 A,2005-07-11,US 58702004 P;;US 2005/0024470 W,2004-07-09,Genetic manipulation of condensed tannins,,SAMUEL ROBERTS NOBLE FOUND INC,SHARMA SHASHI B;;DIXON RICHARD A,,https://lens.org/064-225-573-826-328,Patent Application,no,0,0,9,9,0,C12N9/0004;;C12N9/0004;;C07K14/415;;C07K14/415;;C12N9/0093;;C12N9/0093;;C12N15/8223;;C12N15/8223;;C12N15/8234;;C12N15/8234;;C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,C12N15/82;;A01H5/00;;C12N15/29;;C12N15/52,,0,0,,,,INACTIVE
368,AU,A2,AU 2009/234210 A2,074-754-078-860-613,2010-12-16,2010,AU 2009/234210 A,2009-04-10,US 4430608 P;;US 2009/0040190 W,2008-04-11,Methods and compositions for accelerating the generation of regulatory Tcells ex vivo,,UNIV SOUTHERN CALIFORNIA,HORWITZ DAVID A;;GRAY J DIXON,,https://lens.org/074-754-078-860-613,Patent Application,no,0,0,9,9,0,A61K35/12;;C12N5/0636;;A61P37/06;;A61K2239/38;;A61K39/46433;;A61K39/4611;;A61K39/4621;;A61K2239/31;;C12N5/0636;;A61K35/12,A61K35/14;;A61K35/12;;A61P37/06;;C12N5/07;;C12N5/0783,,0,0,,,,DISCONTINUED
369,US,B2,US 6645207 B2,091-202-539-771-551,2003-11-11,2003,US 84695601 A,2001-05-01,US 84695601 A;;US 20242200 P,2000-05-08,Method and apparatus for dynamized spinal stabilization,"
    An improved device and a method for stabilizing lumbar vertebrae in a human spine for the purpose of fixing the vertebra with respect to other vertebra and with respect to other parts of the spinal column. This device comprises a plate, bone screws, bone screw clamp portion, spacers, and rigidizing stop locks. The bone screw clamps may be clamped firmly to the plate for a fully rigid system. Alternatively the screw clamp portions may be held apart, with clearance between them and the plate, which will allow for axial motion of the screw with respect to the plate for implant load sharing and dynamized motion. 
",DIXON ROBERT A.;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/091-202-539-771-551,Granted Patent,yes,15,306,2,2,0,A61B17/66;;A61B17/7007;;A61B17/701;;A61B17/7049;;A61B17/66;;A61B17/7007;;A61B17/7049;;A61B17/701,A61B17/66;;A61B17/70,606/61;;606/72,6,1,003-606-868-389-002,10703101;;10.1097/00007632-200002010-00008,"Patrick W. Hitchon, MD, et al., ""Biomechanical Studies of a Dynamized Anterior Thoracolumbar implant"" Spine, 2000, pp 306-309, vol. 25, No. 3, Lippincott Williams & Wilkins, Inc. Philadelphia, PA.;;Twinflex (R), Claris Surgical Technique, Spine Network Group of Companies (Brochure).;;Spinal Clip System OrthoTech Distributed by REO SpineLine Morgantown WV. (Brochure).;;Spinal Fixation System, Blackstone (TM) Medical Inc. Springfield, Massachusetts (Brochure).;;DOC Ventral Cervical Stabilization System, DePuy Acromed Co (Brochure).;;Solid Connection System (TM) Spinal System, Aesculap (R) Co South San Francisco, CA (Brochure).",EXPIRED
370,US,B2,US 10248988 B2,099-605-684-057-263,2019-04-02,2019,US 201514944029 A,2015-11-17,US 201514944029 A;;US 201462080874 P,2014-11-17,System and method for electronic manifesting in a distribution network,"System and method for providing electronic manifesting access for users of a distribution network. A distribution network may provide a user access point, such as by providing application programming interfaces. The access point may provide access the item tracking module upon receipt of valid credentials, such as a user's unique identifier. The access point may receive item information, generate an electronic manifest including the item information and the unique identifier, and allow for tracking the items on the electronic manifest.",UNITED STATES POSTAL SERVICE,DIXON ROBERT E;;SULLIVAN KELLEY A,UNITED STATES POSTAL SERVICE (2015-01-06),https://lens.org/099-605-684-057-263,Granted Patent,yes,9,0,4,4,0,G06Q10/0833;;G06Q30/0635;;G06Q10/0833;;G06Q30/0635;;B07C7/005,G06Q30/00;;B07C7/00;;G06Q10/08;;G06Q30/06,,1,0,,,"2011-A96886, Jan. 2011, Derwent, siegel et al.",ACTIVE
371,AU,A,AU 1988/019987 A,118-287-488-554-955,1989-02-13,1989,AU 1988/019987 A,1988-06-09,US 7279687 A,1987-07-13,COMBINATION CATHETER AND DUCT CLAMP APPARATUS AND METHOD,,LAZARUS MEDICAL INNOVATIONS INC,LAZARUS HARRISON M;;FORD DIXON A,,https://lens.org/118-287-488-554-955,Patent Application,no,0,0,6,6,0,A61B17/12;;A61B2017/00902;;Y10S128/26;;A61B17/12;;A61B2017/00902;;Y10S128/26,A61B17/00;;A61B17/12;;A61B19/00;;A61M25/00;;A61M25/02,,0,0,,,,DISCONTINUED
372,US,A1,US 2006/0251219 A1,141-657-186-129-928,2006-11-09,2006,US 12232705 A,2005-05-04,US 12232705 A,2005-05-04,Radiation attenuation system,"A radiation attenuation system for shielding from scatter radiation one or more portions of a patient that are not of primary interest to a particular radiological procedure (i.e., non-target areas, etc.). The radiation attenuation system may be configured to shield the head of a patient (such as the head of a pediatric patient), and/or any other portion of the patient that may benefit from being shielded from scatter radiation. The radiation attenuation system is preferably configured to conform to the contours of the patient. The radiation attenuation system may be a flexible member that can be reconfigured to accommodate patients of varying size.",WORLDWIDE INNOVATIONS & TECHNO,CADWALADER JOHN A;;DIXON G D,WORLDWIDE INNOVATIONS & TECHNOLOGIES INC (2005-07-29),https://lens.org/141-657-186-129-928,Patent Application,yes,11,22,4,4,0,A61B6/107;;G21F3/02;;G21K1/10;;A61B6/4423;;G21K1/10;;G21F3/02;;A61B6/107,H01J35/16,378/203,0,0,,,,INACTIVE
373,EP,B1,EP 3029317 B1,132-729-980-146-673,2019-01-30,2019,EP 15198059 A,2015-12-04,US 201414561309 A,2014-12-05,METHOD AND APPARATUS FOR REDUCTION OF FATIGUE AND GUST LOADS ON WIND TURBINE BLADES,,SIEMENS AG,DIXON KRISTIAN R;;MAYDA EDWARD A,"SIEMENS AKTIENGESELLSCHAFT (2017-08-30);;SIEMENS GAMESA RENEWABLE ENERGY A/S (2019-05-15);;SIEMENS GAMESA RENEWABLE ENERGY A/S, DK (2019-05-06)",https://lens.org/132-729-980-146-673,Granted Patent,yes,3,0,3,7,0,F03D7/0224;;F03D7/0232;;F05B2240/31;;F05B2270/1095;;Y02E10/72,F03D7/02,,0,0,,,,ACTIVE
374,IT,A0,IT 8947732 A0,138-784-285-656-313,1989-03-10,1989,IT 4773289 A,1989-03-10,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,"IMPIEGO DELL'ACIDO PIPERAZIN CARBOSSILICO E SUOI DERIVATI PER IL TRATTAMENTO DI RIDOTTO SPIRITO DI INIZIATIVA E/O RITROSIA SOCIALE, DISTURBI DI SONNO O EMICRANIA E SIMILI",,SANDOZ AG,ARNOLD KEITH DIXON;;JULIAN A GRAY,,https://lens.org/138-784-285-656-313,Patent Application,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
375,US,A,US 5227632 A,138-111-570-443-169,1993-07-13,1993,US 88805092 A,1992-05-22,US 88805092 A,1992-05-22,Optical radiation detector with wide field-of-view,"An optical radiation detector utilizes a unitary V-shaped or conical reflector element located within an internal cavity of an optically transmissive capped housing to provide a 180.degree. cylindrical swath or 2.pi. steradian hemispherical field-of-view in a compact package. Radiation from a central portion of the field-of-view received into the open top of the reflector is directed by internal reflective surfaces through an apex aperture onto a central sensing element. Radiation from peripheral points of the field-of-view received outside the open top is directed by external reflective surfaces outside the apex aperture onto outer sensing elements. Bandwidth filtering of the sensed radiation is provided either by selection of material for the cap, or by adding an optical filter plate between the reflector and sensing elements. The reflector is attached either to the undersurface of the cap top, or above the filter plate.",ELTEC INSTR INC,ARMSTRONG DOUGLAS S;;DIXON DEALMUS A,ELTEC INSTRUMENTS INC (1992-05-13),https://lens.org/138-111-570-443-169,Granted Patent,yes,5,35,1,1,0,G01J5/0018;;G01J5/0022;;G01J5/08;;G01J5/0806;;G01J5/0846;;G01J5/0893;;G08B13/193;;G08B17/12;;Y10S250/01;;G01J5/0808;;G01J5/07;;G08B13/193;;G01J5/0806;;G01J5/0846;;G01J5/0018;;G01J5/08;;G01J5/0893;;G08B17/12;;G01J5/0022;;Y10S250/01;;G01J5/07;;G01J5/0808,G01J5/08;;G08B13/193;;G08B17/12,250/353;;250/342;;250/349;;250/221;;359/840,0,0,,,,EXPIRED
376,EP,A4,EP 0371051 A4,158-251-095-713-093,1991-01-09,1991,EP 88906348 A,1988-06-09,US 7279687 A,1987-07-13,COMBINATION CATHETER AND DUCT CLAMP APPARATUS AND METHOD,,"LAZARUS MEDICAL INNOVATIONS, INC","LAZARUS, HARRISON, M.;;FORD, DIXON, A.",,https://lens.org/158-251-095-713-093,Search Report,no,2,0,6,6,0,A61B17/12;;A61B2017/00902;;Y10S128/26;;A61B17/12;;A61B2017/00902;;Y10S128/26,A61B17/00;;A61B17/12;;A61B19/00;;A61M25/00;;A61M25/02,,0,0,,,,DISCONTINUED
377,CA,A,CA 834133 A,151-143-377-663-60X,1970-02-10,1970,CA 834133D A,,CA 834133T A,,CEREAL MALTING METHOD,,DIXON MALT COMPANY LTD;;ENZYMIC MALT COMPANY LTD,DIXON BERNARD;;COMRIE ALAN A D,,https://lens.org/151-143-377-663-60X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
378,US,A,US 1244040 A,175-908-272-057-059,1917-10-23,1917,US 5321915 A,1915-09-30,US 5321915 A,1915-09-30,CARBURETER.,,DUZ MICAEL A;;WASHINGTON DIXON E,DUZ MICAEL A;;WASHINGTON DIXON E,,https://lens.org/175-908-272-057-059,Granted Patent,no,0,0,1,1,0,F02M19/035;;F02M19/035,,,0,0,,,,EXPIRED
379,US,A1,US 2002/0095158 A1,195-231-796-329-506,2002-07-18,2002,US 3481501 A,2001-12-27,US 3481501 A;;US 25991701 P,2001-01-05,Method utilizing chemical bonding to improve the bone screw fixation interface,"
   This invention relates to a method and materials in combination for bonding screws to a fixation plate or to a skeletal bone using chemical means. The chemicals include solvents, glues, or bonding agents, which act to improve the strength of bone screw to plate or the bone screw to skeletal bone interface. Interface refers to the contact area between the bone screw and either the plate or skeletal bone. The fixation device usually comprises a plate with bone screws implanted within the human skeleton. The bone screw maintains the plate in contact with the bone or maintains another structure such as a tendon in contact with the bony skeleton. The chemical bonding is in addition to or in place of a mechanical means to bond the bone screw to the fixation plate or to the skeletal bone. It provides for added strength to the bone screw interface with a plate or skeletal bone, reducing the probability of screw loosening and or migration. 
",DIXON ROBERT A.;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/195-231-796-329-506,Patent Application,yes,0,18,2,10,0,A61L24/06;;A61L24/06;;A61B17/7059;;A61B17/7059;;A61B17/80;;A61B17/80;;A61B17/866;;A61B17/866,A61B17/80;;A61L24/06,606/76;;623/23.62,0,0,,,,EXPIRED
380,US,A,US 3914358 A,001-862-530-990-466,1975-10-21,1975,US 42364173 A,1973-12-10,US 42364173 A,1973-12-10,Method of improving the finish of the bores of a reverse osmosis sand module,"A method of making a liquid purification module consists of (1) applying a finishing composition, comprising fine filler particles coated with a resinous material, to the interior circular cular bore walls of a membrane support module made of bonded, resin-coated coarse filler particles, to smooth irregularities in the bore walls, and then (2) drying the finishing composition to harden the finishing composition resinous material and bond it to the bore walls prior to applying semipermeable membranes inthe module bores.",WESTINGHOUSE ELECTRIC CORP,DIXON GEORGE D;;NELSON HUGH A,UCAR CARBON TECHNOLOGY CORPORATIONA CORP. OF DE (1989-12-20),https://lens.org/001-862-530-990-466,Granted Patent,no,12,23,1,1,0,B01D61/10;;B01D63/061;;B01D63/063;;B01D69/105;;B01D2313/146;;B01D61/10;;B01D63/063;;B01D63/061;;B01D69/105;;B01D2313/146,B29C44/00,264/41,0,0,,,,EXPIRED
381,WO,A8,WO 2006/010096 A8,027-639-464-487-61X,2006-12-07,2006,US 2005/0024470 W,2005-07-11,US 58702004 P,2004-07-09,GENETIC MANIPULATION OF CONDENSED TANNINS,The invention provides method and compositions for the modulation of condensed tannin production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of condensed tannins in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased condensed tannin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content. The invention may also be used to modify plant pigmentation.,SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;SHARMA SHASHI B,DIXON RICHARD A;;SHARMA SHASHI B,,https://lens.org/027-639-464-487-61X,Patent Application,no,0,0,9,9,0,C12N9/0004;;C12N9/0004;;C07K14/415;;C07K14/415;;C12N9/0093;;C12N9/0093;;C12N15/8223;;C12N15/8223;;C12N15/8234;;C12N15/8234;;C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,C12N15/82;;A01H5/00;;C12N15/29;;C12N15/52,,0,0,,,,PENDING
382,US,A,US 3715119 A,036-336-312-125-95X,1973-02-06,1973,US 3715119D A,1970-05-04,US 3428070 A,1970-05-04,AUTOMATIC ICE DISPENSER,An ice dispenser for automatically dispensing crushed ice fed from an ice bin to a delivery opening of the ice bin in response to actuation of a push-plate beneath the opening is described. Crushed ice is lifted from the ice bin by means of an ice-elevating mechanism in the form of an auger having an ice feeder disc at its lower end and a stationary auger tube within which the auger turns for elevating the ice. The auger and its feeder disc are driven at the bottom through a drive pin mechanism journalled in the bottom of the ice bin and releasably connectable with the drive pin mechanism to permit removal and disassembly of the ice-elevating mechanism for cleaning.,SHELLEY R;;SHELLEY G;;DIXON A,DIXON A;;SHELLEY G;;SHELLEY R,,https://lens.org/036-336-312-125-95X,Granted Patent,no,1,43,1,1,0,F25C5/20;;F25C5/20,F25C5/00,222-241,0,0,,,,EXPIRED
383,US,A,US 4571209 A,046-909-885-452-50X,1986-02-18,1986,US 49244283 A,1983-05-06,US 49244283 A,1983-05-06,Articulated toy figure,"An articulated toy figure, which does not require manual assembly of individual elements, is made by injection molding a frame using a first set of mold inserts. The frame includes elements that are joined together by breakable portions and that provide half hinges. The frame is left in the mold while the first set of inserts is replaced by a second set configured to produce completion elements around the frame. These completion elements span the individual elements of the frame and complete the half joints provided thereby. The frame elements, along with the completion elements molded around them, result in an automatically assembled figure produced by two molding operations. If desired, the figure can be painted before it is flexed to break the breakable portions of the frame in order to yield a fully mobile articulated toy figure.",MANNING PETER R;;DIXON A JOHN,MANNING PETER R;;DIXON A JOHN,,https://lens.org/046-909-885-452-50X,Granted Patent,yes,4,83,1,1,0,A63H9/00;;A63H9/00;;A63H3/46;;A63H3/46,A63H3/46;;A63H9/00,446/375;;446/376;;264/138;;264/242,0,0,,,,EXPIRED
384,WO,A1,WO 1996/005584 A1,046-907-316-077-78X,1996-02-22,1996,US 9509695 W,1995-08-11,US 28875594 A;;US 32076294 A,1994-08-11,LINEAR PRESSURE SENSOR,"A roadway sensor(10) is comprised of an elastomeric carrier having conductive properties. A sensor passage (11) formed in the carrier and a plurality of polytetrafluorethylene coated wire conductors (15') tightly fill the sensor passage (11). Signal output terminals connected to said carrier and said plurality of wires. The coating on said wire is selected from FEP or TFE polytetrafluorethylene. In a preferrred embodiment, the passage (11) is waterproof and in another embodiment, the sensor passage (11) has walls and means on the walls for preventing moisture from affecting signals induced in the coated wire conductors (15').",MITRON SYSTEMS CORP,DIXON DONALD A;;TYBURSKI ROBERT M,,https://lens.org/046-907-316-077-78X,Patent Application,yes,6,2,2,2,0,G08G1/02,G08G1/02,,0,0,,,,PENDING
385,EP,A1,EP 1183376 A1,053-173-489-497-903,2002-03-06,2002,EP 00932467 A,2000-05-15,US 0013389 W;;US 13502699 P,1999-05-20,ISOFLAVONOID METHYLATION ENZYME,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;HE XIAN Z,,https://lens.org/053-173-489-497-903,Patent Application,yes,0,0,7,10,0,A61P5/30;;A61P7/00;;A61P31/04;;A61P35/00;;A61P39/06;;C12N15/8282;;C12N9/1007;;C12N15/8243;;C12N15/825,A01H5/00;;A23L1/30;;A61K31/352;;A61K36/48;;A61P5/30;;A61P7/00;;A61P31/04;;A61P35/00;;A61P39/06;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/29;;C12N15/82;;C12P17/06,,1,0,,,See references of WO 0071736A1,DISCONTINUED
386,US,B2,US 7904979 B2,070-055-157-044-106,2011-03-15,2011,US 67118807 A,2007-02-05,US 67118807 A;;US 76556206 P,2006-02-06,Mattress with patient transport apparatus incorporated therein,"A mattress having a storage compartment is provided. The storage compartment is used to hold items that are useful in the transport of a patient located on the mattress, such as a patient restraint that can be used to secure the patient to the mattress during transport.",HILL ROM SERVICES INC,WALKE JAMES L;;DIXON STEVEN A,HILL-ROM SERVICES INC (2007-03-16),https://lens.org/070-055-157-044-106,Granted Patent,yes,47,5,3,3,0,A61G1/00;;A61G1/044;;A61G1/048;;A61G7/015;;A61G7/0504;;A61G7/05769;;A61G7/0504;;A61G7/015;;A61G1/048;;A61G1/00;;A61G1/044;;A61G7/05769,A61G7/10,5/706;;5/628;;5/625;;X  5 811 R,2,0,,,"Evacusled(TM), General Questions and Answers, http://www.evacusled.com/print-FAQ.htm, last visited Jan. 29, 2007. Date of original publication unknown.;;International Search Report for Application No. PCT/US2007/061606, Jun. 6, 2007, 11 pgs.",INACTIVE
387,US,B2,US 9689374 B2,095-600-769-965-780,2017-06-27,2017,US 201414561309 A,2014-12-05,US 201414561309 A;;US 201414164879 A;;US 2013/0064060 W,2013-10-09,Method and apparatus for reduction of fatigue and gust loads on wind turbine blades,"An adjustable lift regulating device ( 30, 32, 40, 50, 52, 56, 60, 68, 72, 76 ) on an inboard portion of a wind turbine blade ( 28 ). The lift regulating device is activated to reduce lift on the inboard portion of the blade by causing flow separation ( 41 ) on the suction side ( 22 ) of the blade. To compensate for the lost lift, the blade pitch is increased to a running pitch that facilitates stalling on the outer portion of the blade in gusts. This provides passive reduction of fatigue and extreme loads from gusts while allowing full power production under non-gust conditions.",SIEMENS AG,DIXON KRISTIAN R;;MAYDA EDWARD A,SIEMENS AKTIENGESELLSCHAFT (2014-12-19);;SIEMENS GAMESA RENEWABLE ENERGY A/S (2018-10-25);;SIEMENS WIND POWER A/S (2014-12-17);;SIEMENS ENERGY INC (2014-12-16),https://lens.org/095-600-769-965-780,Granted Patent,yes,34,6,2,7,0,F03D7/0224;;F03D7/0224;;F03D1/0633;;F03D1/0633;;F03D1/0675;;F03D7/0232;;F03D7/0232;;F05B2240/3052;;F05B2240/3062;;F05B2240/31;;F05B2240/31;;Y02E10/72;;Y02E10/72,F03D7/02;;F03D1/06,,0,0,,,,ACTIVE
388,US,B1,US 7038113 B1,096-261-524-444-285,2006-05-02,2006,US 93619001 A,2001-12-09,US 93619001 A;;US 12326799 P;;US 0005915 W,1999-03-08,Genetic manipulation of isoflavonoids,"Soybean and Medicago truncatula CYP93C genes have been isolated which encode a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone. Plants can now be genetically engineered to produce isoflavones that provide potential human health benefits and increase disease resistance in plants. Isoflavones can now be produced in transgenic plants species in which isoflavones do not naturally occur, i.e., in species other than legumes. Alternatively, introducing infection-inducible isoflavonoid biosynthesis into non-legumes qualitatively complements these plants phytoalexin defenses against microbial pathogens, whereas over-expression of the isoflavonoid pathway in legumes quantitatively increases this defense response. Finally, modifying the extend of production of isoflavonoids in legume roots positively impacts nodulation efficiency and therefore plant yield.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;STEELE CHRISTOPHER L,SAMUEL ROBERTS NOBLE FOUNDATION INC. THE (2001-09-06),https://lens.org/096-261-524-444-285,Granted Patent,yes,2,9,1,8,5,C12N9/0077;;C12N15/8243;;C12N15/825;;C12N15/8261;;Y02A40/146;;C12N9/0077;;C12N15/825;;C12N15/8243;;C12N15/8261;;Y02A40/146,C12N15/29;;A01H5/00;;A01H5/10;;C12N15/63;;C12N15/82,800/312;;800/278;;800/298,60,59,037-077-864-871-873;;008-831-818-058-304;;030-560-996-409-192;;070-914-008-321-23X;;056-323-284-003-826;;070-527-153-985-104;;087-327-323-440-555;;040-986-663-076-693;;009-452-351-189-736;;037-439-894-311-127;;019-027-340-670-167;;049-427-391-860-033;;059-011-946-503-122;;016-187-043-515-981;;042-904-125-018-841;;043-413-805-164-105;;138-835-193-112-420;;034-007-398-246-049;;137-080-525-194-284;;045-950-027-185-327;;033-840-455-588-074;;103-900-684-613-439;;095-404-749-938-170;;004-283-438-551-754;;014-560-833-522-836;;102-449-251-149-642;;161-371-929-951-982;;042-566-187-298-704;;001-906-076-969-393;;054-775-960-649-900;;089-544-742-570-358;;074-324-028-542-908;;076-650-562-664-397;;121-064-154-861-699;;036-072-457-855-80X;;094-195-650-610-197;;054-833-631-513-140;;075-881-463-404-698;;027-513-050-554-372;;031-757-758-717-523;;158-937-458-595-089;;085-724-849-689-60X;;004-287-010-679-616;;090-048-542-836-687;;004-526-766-441-136;;163-472-490-948-263;;026-723-082-172-191;;140-466-892-558-422;;037-077-864-871-873;;049-414-985-018-203;;062-942-989-195-944;;083-982-832-174-676;;034-854-035-104-911;;019-983-626-131-767;;024-318-307-995-497;;011-609-245-483-290;;021-019-896-868-242;;018-038-718-797-977;;034-749-442-126-080,pmc15582;;10.1073/pnas.96.4.1750;;9990096;;10.1046/j.1365-313x.2003.01893.x;;14617078;;pmc137925;;12384577;;10.1073/pnas.212522099;;1659780;;10.1093/ajcn/54.6.1093;;10.1016/s0014-5793(98)00781-9;;9708921;;10.1104/pp.121.3.821;;pmc59444;;10557230;;10.1016/s0021-9258(18)45614-1;;3106339;;10.1093/emboj/16.12.3675;;9218808;;pmc1169991;;9705203;;10.1006/abbi.1998.0783;;10.1016/0885-5765(87)90052-x;;10.1016/0168-9452(94)04051-6;;10.1046/j.1365-313x.1998.00343.x;;10069079;;9349273;;10.1023/a:1005821801228;;10.1021/jf00035a027;;10.1094/mpmi-6-665;;10.1105/tpc.7.7.1085;;10.2307/3870059;;12242399;;pmc160915;;10.1034/j.1399-3054.1995.930225.x;;10.1016/0031-9422(88)80666-6;;10.1007/978-1-4615-4689-4_6;;9278562;;10.1093/jn/127.9.1795;;16668024;;10.1104/pp.95.2.594;;pmc1077573;;10.1016/s0981-9428(98)80098-3;;10.1094/phyto-74-1312;;10.1016/0014-5793(84)80736-x;;10.1016/s0040-4020(01)86489-9;;10.1016/s0031-9422(98)00266-0;;2226805;;10.1016/0014-5793(90)80410-k;;17757866;;10.1126/science.227.4691.1229;;10.1038/72671;;10657130;;10.1016/s0176-1617(11)80851-5;;24226375;;10.1007/bf00232132;;10.1073/pnas.92.19.8990;;pmc41093;;7568058;;pmc45849;;8433985;;10.1073/pnas.90.4.1247;;10.1271/bbb.57.1353;;10.1073/pnas.85.22.8502;;pmc282486;;16593993;;3956488;;10.1111/j.1432-1033.1986.tb09492.x;;10.1515/znc-1987-0404;;16593884;;pmc299309;;10.1073/pnas.84.21.7428;;10.1016/0003-9861(81)90347-7;;6458246;;1673746;;10.1016/0140-6736(91)92867-2;;10.1094/phyto-75-235;;10.1046/j.1365-313x.1999.00636.x;;10652133;;8594308;;10.1016/0024-3205(95)02308-9;;10.1089/dna.1993.12.1;;7678494;;12232298;;10.1104/pp.105.4.1427;;pmc159476;;10.1007/bf00033879;;10.1046/j.1365-313x.1998.00085.x;;9681018;;10.1139/b73-310;;pmc15582;;10.1073/pnas.96.4.1750;;9990096;;10.1006/abbi.1999.1238;;10375412;;10.1016/0031-9422(94)00788-u;;pmc19702;;10.1073/pnas.95.6.3106;;9501223;;1734888;;10.1016/0006-291x(92)91816-9;;10.1126/science.7531365;;7531365;;10.1094/mpmi.1999.12.3.171;;10065555;;10.1146/annurev.phyto.27.1.143;;10.1146/annurev.py.27.090189.001043;;20214490;;10.1016/s0026-0495(97)90016-0;;9186308;;2500065;;10.1016/0003-9861(89)90199-9;;12228558;;10.1104/pp.108.4.1519;;pmc157531,"Siminszky B. et al. PNAS, Feb. 1999, vol. 96, pp. 1750-1755.;;Liu C. et al. The Plant Journal, 2003; vol. 36 pp. 471-484.;;Liu C. et al. PNAS, 2002, vol. 99, No. 22; pp. 14578-14583.;;Adlercreutz, et al., 1991, ""Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet,"" Am J Clin Nutr 54:1093-1100.;;Akashi, et al, 1998, ""Identification of a cytochrome P450 cDNA encoding (2S)-flavanone 2-hydroxylase of licorice (Glycyrrhiza echinata L.: Fabaceae) which represents licodione synthase and flavone synthase II,"" FEBS Letters 431: 287-290.;;Akashi, T., et al., 1999, ""Cloning and Functional Expression of a Cytochrome P450 cDNA Encoding 2-Hydroxyisoflavanone Synthase Involved in Biosynthesis of the Isoflavonoid Skeleton in Licorice,"" Plant Physiology, 121:821-828.;;Akiyama, et al., 1987, ""Genistein, a specific inhibitor of tyrosine-specific protein kinases,"" J Biol Chem 262: 5592-559.;;Angell, S. M. and D. C. Baulcombe, 1997, ""Consistent gene silencing in transgenic plants expressing a replicating potato virus X RNA,"" EMBO J 16:3675-3684.;;Arora, et al., 1998, ""Antioxidant activities of isoflavones and their biological metabolites in a lipsomal system,"" Arch Biochem Biophys 356: 133-141.;;Bhattacharyya, M. K. and E. W. B. Ward, 1987, ""Biosynthesis and metabolism of glyceollin I in soybean hypocotyls following wounding or inoculation with Phytophthora megasperma f. sp. glycinea,"" Physiol and Mol Plant Pathology 31: 387-405.;;Bourque, J.E., 1995, ""Antisense strategies for genetic manipulation in plants,"" Plant Science 105:125-149.;;Clough, S.J. and Bent, A.F., 1998, ""Floral dip: a simplified method for Agrobacterium-mediated transformation of Arabidopsis thaliana"", Plant J 16:735-74.;;Colliver, S.P., et al., 1997, ""Differential modification of flavonoid and isoflavonoid biosynthesis with an antisense chalcone synthase construct in trasgenic Lotus corniculatus,"" Plant Molecular Biology, 35: 509-522.;;Coward, et al., 1993, ""Genistein, daidzein, and their beta-glycoside conjugates: antitumor isoflavones in soybean foods from American and Asian diets,"" J Agricultural and Food Chemistry 41: 1961-1967.;;Dakora, et al., 1993, ""Common bean root exudates contain elevated levels of daidzein and coumestrol in response to Rhizobium inoculation,"" Mol Plant-Microbe Interact 6: 665-668.;;Dixon, R. A. and N. L. Paiva, 1995, ""Stress-induced phenylpropanoid metabolism,"" Plant Cell 7: 1085-1097.;;Dixon, R., et al., 1995, ""The isoflavonoid phytoalexin pathway: From enzymes to genes to transcription factors,"" Physiologia Plantarum, 93:385-392.;;Dixon, R.A., Blyden, E.R., Robbins, M.P., van Tunen, A.J. and Mol, J.N.M., 1988, ""Comparative biochemistry of chalcone isomerases."" Phytochemistry 27: 2801-2808.;;Dixon, R.A., et al., 1999 ""Molecular controls for isoflavonoid biosynthesis in relation to plant and human health,"" Phytochemicals in Human Health Protection, Nutrition and Plant Defense, Romeo, ed., Kluwer Academic/ Plenum Publishers, New York; pp. 133-159.;;Draper, et al., 1997, ""Phytoestrogens reduce bone loss and bone resorption in oophorectomized rats,"" J Nutr 127: 1795-1799.;;Graham, T.L., 1991, ""Flavonoid and isoflavonoid distribution in developing soybean seeding tissues and in seed and root exudates."" Plant Physiol 95: 594-603.;;Graham, T.L., 1998, ""Flavonoid and flavonol glycoside metabolism in Arabidopsis"". Plant Physiol Biochem 36: 135-144.;;Hadwiger, L. A. and D. M. Webster, 1984, ""Phytoelexin production in five cultivars of pea differentially resistant to three races of Pseudomonas syringae pv. pisi,"" Phytopathology 74: 1312-1314.;;Hagmann, M. and H. Grisebach, 1984, ""Enzymatic rearrangement of flavanone to isoflavone,"" FEBS Letters 175: 199-202.;;Hakamatsuka, et al., 1991, ""P-450-dependent oxidative rearrangement in isoflavone biosynthesis: reconstitution of P-450 and NADPH:P450 reductase,"" Tetrahedron 47: 5969-5978.;;Hakamatsuka, et al., 1998, ""Purification of 2-hydroxyisoflavanone dehydratase from the cell cultures of Pueraria lobata,"" Phytochemistry 49: 497-505.;;Hashim, et al., 1990, ""Reaction Mechanism of oxidative rearrangement of flavanone in isoflavone biosynthesis,"" FEBS Letters 271: 219-222.;;Horsch, et al., 1985, ""A simple and general method for transferring genes into plants,"" Science 227:1229-1231.;;Jung, W., et al., 2000, ""Identification and expession of isoflavone synthase, the key enzyme for biosynthesis of isoflavones in legumes,"" Nature Biotechnology 18: 206-212.;;Kape, et al., 1992, ""Legume root metabolites and VA-mycorrhiza development,"" J Plant Physiol 141: 54-60.;;Kessmann, et al., 1990, ""Stress responses in alfalfa (Medicago sativa L.) III. Induction of medicarpin and cytochrome P450 enzyme activities in elicitor-treated cell suspension cultures and protoplasts,"" Plant Cell Reports 9: 38-41.;;Keung, et al., 1995, ""Daidzin suppresses ethanol consumption by Syrian golden hamsters without blocking acetaldehyde metabolism,"" Proc Natl Acad Sci USA 92: 8990-8993.;;Keung, W. M. and B. L. Vallee, 1993, ""Daidzin: A potent, selective inhibitor of human mitochondrial aldehyde dehydrogenase,"" Proc Natl Acad Sci USA 90: 1247-1251.;;Kirikae, et al., 1993, ""Biosynthesis of a dibenzoylmethane, licodione, in cultured alfalfa cells induced by yeast extract,"" Biosci Biotech Biochem 57: 1353-1354.;;Klein, et al., 1988, ""Stable genetic transformation of intact Nicotiana cells by the particle bombardment process,"" Proc Natl Acad Sci USA 85:8502-8505.;;Kochs, G. and H. Grisebach, 1986, ""Enzymic synthesis of isoflavones,"" European J Biochem 155: 311-318.;;Kochs, G. and H. Grisebach, 1987, ""Induction and characterization of a NADPH-dependent flavone synthase from cell cultures of soybean,"" Z. Naturforsch 42C: 343-348.;;Kosslak, et al., 1987, ""Induction of Bradyrhizobium japonicum common nod genes by isoflavones isolated from Glycine max,"" Proc Natl Acad Sci USA 84: 7428-7432.;;Köster, J. and W. Barz, 1981, ""UDP-Glucose: isoflavone 7-O-glucosyltransferase from roots of chick pea (Cicer arietinum L.)."" Arch Biochem Biophys 212: 98-104.;;Lee, et al., 1991, ""Dietary effects on breast-cancer risk in Singapore,"" Lancet 337: 1197-1200.;;Long, et al., 1985, ""Further studies on the relationship between glyceollin accumulation and the resistance of soybean leaves to Pseudomonas syringae pv. glycinea,"" Phytopathology 75: 235-239.;;Martens, S. and G. Forkmann, ""Cloning and expression of flavone synthase II from Gerbera hybrids,"" Plant J 20: 616-618.;;Martin, et al., 1996, ""Interactions between phytoestrogens and human sex steroid binding protein,"" Life Sciences 58: 429-436.;;Nelson, et al. 1993. ""The P450 superfamily update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature,"" DNA Cell Biol 12:1.;;Otani, et al., 1994, ""Licodione synthase, a cytochrome P450 monooxygenase catalyzing 2-hydroxylation of 5-deoxyflavanone, in cultured Glycyrrhiza echinata L. cells,"" Plant Physiol 105: 1427-1432.;;Paiva, N. L. et al., 1994, ""Regulation of isoflavonoid metabolism in alfalfa,"" Plant Cell, Tissue and Organ Culture, 38: 213-220.;;Pauli, H. H. and T. M. Kutchan, 1998, ""Molecular cloning and functional heterologous expression of two alleles encoding (S)-N-methylcoclaurine 3'-hydroxylase (CYP80B1), a new methyl jasmonate-inducible cytochrome P-450-dependent mono-oxygenase of benzylisoquinoline alkaloid biosynthesis,"" The Plant J 13: 793-801.;;Rahe, J. E., 1973, ""Occurrence and levels of the phytoalexin phaseollin in relation to delimitation at sites of infection of Phaseolus vulgaris by Colletotrichum lindemuthianum,"" Canadian J Botany 51: 2423-2430.;;Sambrook, et al. 1989. Molecular Cloning. A Laboratory Manual, 2nd Ed, Cold Spring Harbor Laboratory Press, New York; pp. 7.2-7.87 and 9.2-9.62.;;Siminszky, B., Corbin, F.T., Ward, E.R., Fleischmann, T.J. and Dewey, R.E. , 1999, ""Expression of a soybean cytochrome P450 monooxygenase cDNA in yeast and tobacco enhances the metabolism of phenylurea herbicides."" Proc. Natl. Acad. Sci. USA 96: 1750-1755.;;Steele, C.L., et al., 1999, ""Molecular Characterization of the Enzyme Catalyzing the Aryl Migration Reaction of Isoflavonoid Biosynthesis in Soybean,"" Archives of Biochemistry and Biophysics, 367: 146-150.;;Tahara, S. and R. K. Ibrahim, 1995, ""Prenylated isoflavonoids-an update,"" Phytochemistry 38: 1073-1094.;;Tikkanen, et al., 1998, ""Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance,"" Proc Natl Acad Sci USA 95: 3106-3110.;;Tomonaga, et al., 1992, ""Isoflavonoids, genistein, PSI-tectorigenin, and orobol, increase cytoplasmic free calcium in isolated rat hepatocytes,"" Biochem Biophys Res Com 182: 894-899.;;Uckun, et al., 1995, ""Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases,"" Science 267: 886-891.;;van Buuren, M.L., I.E. Maldonado-Mendoza, A. T. Trieu, L.A. Blaylock, and M.J. Harrison, 1999, ""Novel genes induced during an arbuscular mycorrhizal (AM) symbiosis formed between Medicago truncatula and Glomus versiforme,"" Mol. Plant-Microbe Interact. 12, 171-181.;;VanEtten, et al., 1989, ""Phytoalexin detoxification: importance for pathogenicity and practical implications,"" An Rev Phytopathology 27: 143-164.;;Wagner, et al., 1997, ""Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys,"" Metabolism-Clinical and Experimental 46: 698-705.;;Welle, R. and Grisebach, H., 1989, ""Phytoalexin synthesis in soybean cells: elicitor induction of reductase involved in biosynthesis of 6'-deoxychalcone."" Arch Biochem Biophys 272: 97-102.;;Xie, et al., 1995, ""Rhizobial nodulation factors stimulate mycorrhizal colonization of nodulating and nonnodulating soybeans,"" Plant Physiology 108: 1519-1525.",EXPIRED
389,EP,A1,EP 0585598 A1,131-311-180-928-306,1994-03-09,1994,EP 93111950 A,1993-07-27,US 93875392 A,1992-09-01,Metal casting using a mold having attached risers.,"Apparatus and method for countergravity casting a melt (16) employs a particulate mass (20) disposed in a container about a mold (10) having a mold cavity (12), an ingate passage (14) communicated to the mold cavity (12) for supplying the melt (16) to the mold cavity (12), and a separate, preformed riser-forming member (22) connected to the mold (10) so as to communicate to an isolated and/or enlarged region (12a,b) of the mold cavity (12) needing additional melt supply during solidification in the mold. The mold ingate passage (14) and a source of the melt are communicated to conduct the melt through the ingate passage (14) to the mold cavity (12) to fill the mold cavity with the melt (16) and form a riser (70) of melt (16) in the particulate mass. The riser of melt provides a source of additional melt for supply, as necessary, to the isolated and/or enlarged region (12a,b) during solidification of the melt (16) in the mold cavity (12) to accommodate melt shrinkage thereat.",GEN MOTORS CORP,CHANDLEY GEORGE DIXON;;REDEMSKE JOHN A,,https://lens.org/131-311-180-928-306,Patent Application,yes,7,0,9,9,0,B22C9/08;;B22D18/06;;B22D18/06;;B22C9/08,B22C9/04;;B22C9/08;;B22D18/06,,0,0,,,,EXPIRED
390,CN,A,CN 102066557 A,133-757-873-640-128,2011-05-18,2011,CN 200980123083 A,2009-04-10,US 2009/0040190 W;;US 4430608 P,2008-04-11,Methods and compositions for accelerating the generation of regulatory T cells,"The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation of T cells into suppressor cells, and agents that are histone deacetylase inhibitors. The invention also encompasses compositions of regulatory T cells generated by cultuhng non-regulatory T cells with a regulatory composition as well as the use of such regulatory T cells in the treatment of autoimmune diseases and aberrant immune responses.",UNIV SOUTHERN CALIFORNIA,HORWITZ DAVID A;;DIXON GRAY J,,https://lens.org/133-757-873-640-128,Patent Application,no,0,2,9,9,0,A61K35/12;;C12N5/0636;;A61P37/06;;A61K2239/38;;A61K39/46433;;A61K39/4611;;A61K39/4621;;A61K2239/31;;C12N5/0636;;A61K35/12,A61K35/12;;A61K35/14;;A61P37/06;;C12N5/0783,,0,0,,,,DISCONTINUED
391,AR,A1,AR 030390 A1,130-364-270-626-97X,2003-08-20,2003,AR P000102477 A,2000-05-22,US 13502699 P,1999-05-20,ENZIMA ISOFLAVONOIDE PARA METILACION,"Se describen métodos para manipular genéticamente isoflavonoides 4'-O-metilados biologicamente activos que se han encontrado con base en el carácter regioespecífico de 7-OMT de isoflavona in vivo. Después de la transformacion y expresion de un gen de O-metiltransferasa de isoflavonoide, la sobre-regulacion de IOMT en las plantas transgénicas puede ser utilizada para elevar la acumulacion de fitoalexinas de isoflavonoide 4'-O-metiladas, proveyendo una resistencia de enfermedad incrementada a la planta. Se pueden utilizar métodos similares para incrementar la acumulacion de nutracéuticos de isoflavonoide 4' ûO- metilado en plantas. Para la sub-regulacion de IOMT en plantas que naturalmente hacen fitoalexinas 4-O-isoflavonoide y nutracéuticos de isoflavonoide 4'-O-metilados, las secuencias de gen IOMT pueden ser transformadas en la orientacion antisentido.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;HE XIAN Z,,https://lens.org/130-364-270-626-97X,Patent Application,no,0,0,7,10,0,A61P5/30;;A61P7/00;;A61P31/04;;A61P35/00;;A61P39/06;;C12N15/8282;;C12N9/1007;;C12N15/8243;;C12N15/825,A01H5/00;;A23L1/30;;A61K31/352;;A61K36/48;;A61P5/30;;A61P7/00;;A61P31/04;;A61P35/00;;A61P39/06;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/29;;C12N15/82;;C12P17/06,,0,0,,,,DISCONTINUED
392,DK,T3,DK 3029317 T3,137-968-925-265-813,2019-05-06,2019,DK 15198059 T,2015-12-04,US 201414561309 A,2014-12-05,Fremgangsmåde og indretning til reduktion af udmatning og vindstødsbelastninger på vindmøllevinger,,SIEMENS AG,DIXON KRISTIAN R;;MAYDA EDWARD A,,https://lens.org/137-968-925-265-813,Granted Patent,no,0,0,3,7,0,F03D7/0224;;F03D7/0232;;F05B2240/31;;F05B2270/1095;;Y02E10/72,F03D7/02,,0,0,,,,ACTIVE
393,US,A1,US 2002/0120271 A1,147-531-784-815-826,2002-08-29,2002,US 8333202 A,2002-02-25,US 8333202 A;;US 27178201 P,2001-02-27,Method and device for using extended interference fit screw shanks for spinal stabilization,"
   A device and a method for stabilizing vertebrae in a human spine for the purpose of fixing one vertebra with respect to other vertebrae and with respect to other parts of the spinal column. This device comprises bone screws that clamp to a plate to maintain the plate in contact with the vertebrae. The device may be fabricated from non-metals, metal, alloys, or composite materials. A tapered screw head is pulled into the plate with the taper extending through the plate into the underlying bone. Extending the taper into the bone moves the screw thread stress raiser into an area of lesser deflection. This strengthens the fixation by increasing the rigidity and reducing the risk of screw breakage. Extending the taper into the underlying bone has also been shown to strengthen the taper lock. 
",DIXON ROBERT A.;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/147-531-784-815-826,Patent Application,yes,12,14,2,10,0,A61B17/8052;;A61B17/8052;;A61B17/1728;;A61B17/1728;;A61B17/1757;;A61B17/1757;;A61B17/7059;;A61B17/7059;;A61B17/8057;;A61B17/8057,A61B17/17;;A61B17/70;;A61B17/80,606/61,0,0,,,,EXPIRED
394,AU,B2,AU 2005/265356 B2,151-778-862-579-654,2010-10-07,2010,AU 2005/265356 A,2005-07-11,US 58702004 P;;US 2005/0024470 W,2004-07-09,Genetic manipulation of condensed tannins,,THE SAMUEL ROBERTS NOBLE FOUNDATION INC,SHARMA SHASHI B;;DIXON RICHARD A,,https://lens.org/151-778-862-579-654,Granted Patent,no,4,0,9,9,0,C07K14/415;;C12N9/0004;;C12N9/0093;;C12N15/8223;;C12N15/8234;;C12N15/8243;;C12N15/825;;C12N9/0004;;C12N15/8243;;C12N15/8234;;C07K14/415;;C12N15/8223;;C12N9/0093;;C12N15/825,A01H5/00;;C12N15/29;;C12N15/52;;C12N15/82,,1,1,006-470-893-916-774,pmc139454;;10.2307/3871430;;10.1105/tpc.13.9.2099;;11549766;;10.1105/tpc.010098,"Nesi N. et al. The Plant Cell, 2001, vol. 13, pp. 2099-2114.",INACTIVE
395,EP,A1,EP 3099929 A1,154-267-404-109-668,2016-12-07,2016,EP 15703681 A,2015-01-27,US 201414164879 A;;US 2015/0012979 W,2014-01-27,DUAL PURPOSE SLAT-SPOILER FOR WIND TURBINE BLADE,,SIEMENS AG,DIXON KRISTIAN R;;MAYDA EDWARD A,SIEMENS AKTIENGESELLSCHAFT (2017-08-30),https://lens.org/154-267-404-109-668,Patent Application,yes,0,0,4,4,0,F03D7/022;;F03D7/0256;;F03D7/0232;;Y02E10/72;;F05B2240/3052;;F05B2240/305;;F03D7/0256;;F03D7/022;;Y02E10/72;;F03D7/0232,F03D7/02,,0,0,,,,DISCONTINUED
396,US,A1,US 2016/0140493 A1,162-428-340-449-843,2016-05-19,2016,US 201514944029 A,2015-11-17,US 201514944029 A;;US 201462080874 P,2014-11-17,SYSTEM AND METHOD FOR ELECTRONIC MANIFESTING IN A DISTRIBUTION NETWORK,"System and method for providing electronic manifesting access for users of a distribution network. A distribution network may provide a user access point, such as by providing application programming interfaces. The access point may provide access the item tracking module upon receipt of valid credentials, such as a user's unique identifier. The access point may receive item information, generate an electronic manifest including the item information and the unique identifier, and allow for tracking the items on the electronic manifest.",US POSTAL SERVICE,DIXON ROBERT E;;SULLIVAN KELLEY A,UNITED STATES POSTAL SERVICE (2015-01-06),https://lens.org/162-428-340-449-843,Patent Application,yes,0,8,4,4,0,G06Q10/0833;;G06Q30/0635;;G06Q10/0833;;G06Q30/0635;;B07C7/005,G06Q10/08;;G06Q30/06,,0,0,,,,ACTIVE
397,CA,A,CA 550257 A,056-601-217-694-791,1957-12-17,1957,CA 550257D A,,CA 550257T A,,MANUFACTURE OF CELLULOSE,,INT PAPER CANADA,CHARLES FRANK R;;DIXON JULIAN A,,https://lens.org/056-601-217-694-791,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
398,US,A1,US 2002/0082603 A1,080-601-321-844-69X,2002-06-27,2002,US 99685801 A,2001-11-20,US 99685801 A;;US 25267600 P,2000-11-22,Method and device utilizing tapered screw shanks for spinal stabilization,"
   A method and a device are provided for stabilizing vertebrae in a human spine for the purpose of fixing one vertebra with respect to other vertebrae and with respect to other parts of the spinal column. This device comprises a plate and bone screws fabricated from metals. The bone screw maintains the plate in contact with the vertebrae. A tapered screw head is pulled into a machined tapered hole, locking the screw to the plate. The taper is configured to be self-locking preventing the screw from backing out. The taper may be within the fixed structure of the plate, or within an insert placed into the plate. 
",DIXON ROBERT A.;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/080-601-321-844-69X,Patent Application,yes,0,73,2,10,0,A61B17/7059;;A61B17/8047;;A61B17/8052;;A61B17/8057;;A61B17/8052;;A61B17/8057;;A61B17/7059;;A61B17/8047,A61B17/70;;A61B17/80,606/69,0,0,,,,EXPIRED
399,US,A,US 2710861 A,070-878-010-091-618,1955-06-14,1955,US 24279951 A,1951-08-20,US 24279951 A,1951-08-20,Treatment of cellulose with the reaction product of primary aliphatic amines and ethylene oxide,,INT PAPER CANADA,CHARLES FRANK R;;DIXON JULIAN A,,https://lens.org/070-878-010-091-618,Granted Patent,no,5,19,1,1,0,D01F2/10;;D01F2/08;;D01F2/10,D01F2/08;;D01F2/10,,0,0,,,,EXPIRED
400,BR,A2,BR 112015000014 A2,070-094-413-948-81X,2017-06-27,2017,BR 112015000014 A,2013-06-20,US 2013/0046851 W;;US 201213541956 A,2012-07-05,estrutura em forma de copo de colpotomía e manipulador intrauterino que inclui a mesma,"relatório descritivo da patente de invenção para ""estrutura em forma de copo de colpotomia e manipulador intrauterino que inclui a mesma"". reivindicação de prioridade [001] este pedido de patente reivindica o benefício do pedido de patente u.s. no. de série 13/541,956, depositado em 5 de julho de 2012, para "" estrutura em forma de copo de colpotomia e manipulador intrauterino que inclui a mesma."" campo técnico [002] a presente invenção refre-se à instrumentação médica para manipular a posição de um útero para uma melhor visualização e acesso cirúrgico, e mais especificamente, a uma estrutura em forma de copo para se encaixar no colo do útero de uma paciente e um manipulador uterino equipado com a estrutura em forma de copo. antecedentes [003] manipuladores uterinos, os quais incluem manipuladores intrauterinos, são comumente usados por médicos para todas as laparoscopias que envolvem os órgãos pélvicos femininos (útero, trompas, ovários) quando existe um útero, visto que a cirurgia efetuada sem o uso de um manipulador uterino é mais perigosa e pode ser mais demorada. exemplos of procedimentos laparoscópicos nos quais um manipulador uterino possui utilidade substancial incluem: ligações de trompas para esterilização; laparoscopias diagnósticas para a avaliação de dor pélvica e infertilidade; tratamento de endometriose; remoção de cicatrizes pélvicas (adesões) envolvendo o útero, trompas de falópio e ovários; tratamento de gravidez ectópica; remoção de fibroides uterinos; remoção de cistos ovarianos; remoção de ovários; reparo das trompas; histerectomia laparoscópica; reparo laparoscópico do intestino pélvico ou da bexiga; amostragem de gânglios linfáticos da pélvis; ""amarração"" da bexiga para impedir a perda de urina; e biópsia de massas pélvicas. os manipuladores intrauterinos também são empregados como condutos para a distribuição de contraste dentro do útero quando o médico quer obter uma imagem do útero (histerossalpingografia). um manipulador do estado da técnica 12, conforme mostrado na fig. 1, e conforme oferecido pelo depositante da presente invenção como o manipulador uterino clearview(r), é um instrumento 12 que inclui uma porção distal 14 acoplada a um elemento rígido 16, tal como uma haste de inserção. o instrumento 12 é inserido através da vagina e se prende de um modo fixo ao útero enquanto a porção do instrumento 12, a qual inclui um cabo 18 com um mecanismo de controle 20 em si, se projeta a partir da vagina. o instrumento 12 pode incluir um tampão vaginal (não mostrado) para vedar a cavidade de uma abdominal paciente com dióxido de carbono (co2). o instrumento 12 pode ser mantido no lugar em parte por uma estrutura em forma de copo 22 projetada para se encaixar no colo do útero da paciente. de maneira mais específica, a estrutura em forma de copo 22 possui um aro 24 dimensionado para envelopar o fórnice anterior e posterior. uma base 26 da estrutura em forma de copo 22 toca o colo do útero e possui uma abertura alinhada com a cervical o que permite que uma seção de ponta 28 se estenda através da mesma e para dentro do útero. a seção de ponta 28 pode incluir um balão 30, uma ponta flexível 32 e um ou mais tubos 34, 36 os quais permitem ao médico inflar o balão 30 para injetar contraste dentro do útero através de um orifício 37, ou ambos. a seção de ponta 28 pode ser dimensionada para entrar no útero através da cervical sem nenhuma ou com a mínima dilatação do colo do útero. [004] uma vez dentro do útero, o balão 30 pode ser inflado para se encaixar na parede interna do útero de modo que o útero não seja traumaticamente preso entre a seção de ponta 28 e a estrutura em forma de copo 22 do instrumento 12. a estrutura em forma de copo 22 é comumente chamada de "" copo de colpotomia,"" e tal terminologia, bem como o termo ""copo,"" pode ser usada aqui por conveniência e não como limitação do modelo ou configuração da estrutura mencionada. assim que o útero é preso entre a seção de ponta 28 e a estrutura em forma de copo 22, a manipulação do útero é efetuada girando-se a porção distal 14 em torno de um ponto de pivô 38 próximo da estrutura em forma de copo 22. de maneira típica, o instrumento 12 é inserido em uma orientação na qual a rotação da porção distal 14 em torno do ponto de pivô 38 ocorre de frente para trás em relação às partes anterior e posterior da paciente. a rotação da porção distal 14 pode ser manipulada pelo mecanismo de controle 20, o qual, conforme descrito, é um botão giratório 40 localizado sobre ou perto do cabo 18. de tal modo que o instrumento 12 permite ao médico manipular a orientação do útero conforme desejado. por exemplo, se o médico quiser mudar o útero para uma posição antevertida, ele pode girar o botão 40 em uma direção horária. para mudar o útero para uma posição retrovertida, o médico pode girar o botão 40 em uma direção anti-horária. a rotação lateral (da esquerda para a direita) do útero também pode ser efetuada manipulando-se o elemento rígido 16 ou orientando-se o instrumento 12 durante a inserção na qual a rotação da porção distal 14 em torno do ponto de pivô 38 ocorre lateralmente em relação à paciente. [005] a estrutura em forma de copo 22 pode incluir uma protuberância circumferencial 42 que se estende radialmente para fora que se estende a partir da mesma sobre ou perto do aro 24. quando a estrutura em forma de copo 22 tiver se encaixado no colo do útero conforme previamente descrito, o médico pode localizar visualmente a protuberância 42 por meio da identificação de uma deformação correspondente na superfície externa dos fórnices vaginais. nos procedimentos laparoscópicos, o médico vê o útero a partir de uma câmera montada sobre um trocarte, inserida na cavidade abdominal através da parede abdominal. durante um procedimento de colpotomia, o médico usa um escalpelo para fazer uma incisão nos fórnices vaginais sobre ou perto da protuberância 42. desse modo, a protuberância 42 ou outra porção da estrutura em forma de copo 22, tal como o aro 24, pode atuar como um apoio ou uma ""trava de apoio"" para o escalpelo. vários tipos de escalpelos são comumente usados em procedimentos de colpotomia, o que inclui escalpelos eletrocirúrgicos (por exemplo, escalpelos que usam uma radiofrequência que oscila a corrente elétrica), escalpelos harmônicos (por exemplo, escalpelos ultrassônicos) e escalpelos a laser (por exemplo, lasers co2 ou yag) e são do conhecimento de pessoas versadas na técnica. [006] a maior desvantagem das estruturas convencionais em forma de copo 22 atualmente disponíveis é que os copos devem ser fabricados para acomodar o uso de um ou dois, porém, não todos os tipos de escalpelo: eletrocirúrgico, harmônico ou a laser. por exemplo, copos de metal são comumente usados com escalpelos harmônicos porque os materiais de metal possuem uma alta temperatura de fusão e podem suportar as intensas cargas térmicas geradas pela vibração de alta frequência na ordem de 55,500 khz empregadas pelos escalpelos harmônicos. no entanto, os copos de metal não podem ser usados com escalpelos eletrocirúrgicos porque um copo de metal eletricamente condutivo irá, dentre outras coisas, encurtar um escalpelo eletrocirúrgico se o escalpelo contatar o copo. de maneira similar, os copos de metal talvez não sejam indicados para o uso com escalpelos a laser devido a uma absorção térmica inadequada a partir do contato com o feixe de laser, particularmente com o feixe de potênca relativamente alta de um laser de co2. por outro lado, copos eletricamente isolantes, tais como copos plásticos ou poliméricos, são comumente usados com escalpelos eletrocirúrgicos porque eles não apresentam ameaça à funcionalidade eletrônica de tais escalpelos se o escalpelo contatar o copo; no entanto, copos plásticos ou poliméricos convencionais não podem ser usados com escalpelos harmônicos porque o copo irá, dentre outras coisas, empenar, derreter (frequentemente com beiras dentadas derretidas), queimar, de desfazer em fragmentos nocivos de particulado e/ou emitir gases indesejáveis se usado com os mesmos. problemas similares surgem com o uso de copos plásticos ou poliméricos convencionais em conjunção com escalpelos a laser. foi descoberto que copos cerâmicos também apresentam deficiências quando usados com escalpelos harmônicos. enquanto materiais cerâmicos podem ter altas temperaturas de fusão, geralmente benéficas para o uso com dispositivos de corte intensificados pelo calor, um material cerâmico inadequado apresenta o risco de fraturar um escalpelo harmônico ou ser fraturado caso o escalpelo contate o copo, produzindo particulados nocivos que podem ser dolorosos e causar o risco de infecção para a paciente. [007] visto que vários tamanhos de copos de colpotomia devem estar disponíveis para uso, múltiplos copos de diferentes tamanhos são comumente fornecidos. como os materiais de copos convencionais para colpotomia, conforme notado acima, não são adequados para uso com ambos os escalpelos eletrocirúrgicos e harmônicos, é necessário um número ainda maior de múltiplos copos, dois de cada tamanho feitos de diferentes materiais, respectivamente adequados para uso com cada tipo de escalpelo. consequentemente, existe uma duplicação indesejável de copos. descrição [008] este sumário é provido para introduzir a seleção de conceitos de uma forma simplificada. esses conceitos são descritos em mais detalhes na descrição detalhada das modalidades da presente invenção logo abaixo. este sumário não está destinado a identificar as características chave ou essenciais do assunto reivindicado nem deve ser usado para limitar o escopo do assunto reivindicado. [009] em vista das deficiências mencionadas acima no atual estado de ofertas de copo de colpotomia, os inventores idealizaram um copo de colpotomia para uso com um manipulador uterino e que pode ser usado com escalpelos eletrocirúrgicos, harmônicos e a laser. tal copo de colpotomia pode reduzir os custos e oferecer aos médicos um número maior de opções durante a seleção de instrumentação para executar uma laparoscopia uterina. com a crescente pressão para a contenção de despesas no tratamento médico e a crescente popularidade da mudança de procedimentos laparoscópicos ginecológicos para clínicas ambulatoriais e consultórios ginecológicos, o potencial para um copo de colpotomia mais versátil é muito atrativo para a área médica. [0010] em algumas modalidades, a presente invenção inclui um conjunto de manipulador intrauterino que inclui uma porção distal em comunicação com um cabo. a porção distal inclui um balão para encaixar a parte interna da parede uterina da paciente. a porção distal também inclui uma estrutura em forma de copo para se encaixar no colo do útero da paciente. a estrutura em forma de copo inclui um aro e uma base que define uma abertura através da qual um ou mais elementos tubulares podem se estender. a base está localizada próxima do balão. a estrutura em forma de copo consiste essencialmente em um material de poliftalamida (ppa) ou um material de poliéter-éter-cetona (peek). [0011] em modalidades adicionais, a presente invenção inclui uma estrutura em forma de copo para se encaixar no colo do útero de uma paciente e inclui um aro configurado para circundar pelo menos a porção dos fórnices vaginais anterior e posterior da paciente. a estrutura em forma de copo também inclui uma base com uma abertura definida. pelo menos um elemento dentre o aro e a base consiste essencialmente em um dentre um material de poliftalamida (ppa) ou um material de poliéter-éter-cetona (peek). breve descrição dos desenhos [0012] embora o relatório descritivo seja concluído com as reivindicações que apontam de maneira particular e reivindicam distintivamente o que é considerado como as modalidades da invenção, as vantagens das modalidades da invenção podem ser mais prontamente apuradas a partir da descrição de determinados exemplos das modalidades da invenção quando lidas em conjunção com os desenhos em anexo, nos quais: [0013] a fig. 1 é uma vista lateral de um manipulador uterino que possui uma estrutura em forma de copo para se encaixar no colo do útero de uma paciente; [0014] a fig. 2 é uma vista em perspectiva da estrutura em forma de copo para uso com um manipulador uterino; [0015] a fig. 3 é uma vista lateral da estrutura em forma de copo da fig. 2; [0016] a fig. 4 é uma vista superior da estrutura em forma de copo das figs. 2 e 3; e [0017] a fig. 5 é uma vista transversal da estrutura em forma de copo da fig. 4 tirada ao longo da linha de seção 5-5. modo(s) para executar a invenção [0018] as ilustrações apresentadas aqui não são as vistas reais de nenhum instrumento, estrutura ou dispositivo particular, elas são meramente representações idealizadas usadas para descrever as modalidades da invenção. [0019] conforme usado aqui, os termos ""copo"" e ""copo de colpotomia"" significam e incluem qualquer estrutura em forma de copo, configurada para se encaixar e envelopar pelo menos uma porção de colo do útero e a qual pode ser geralmente dimensionada para corresponder ao formato de um colo do útero, e não estão limitados ao uso em nenhum tipo específico de procedimento médico. [0020] conforme usado aqui para descrever um comportamento ou característica observada ou inerente, de uma estrutura em forma de copo ou de um material usado em um copo de colpotomia (conforme definido aqui), o termo ""substancialmente não"" significa que a estrutura em forma de copo ou o material não apresenta o comportamento mencionado ou não possui a característica mencionada até o ponto ou grau de tornar a estrutura em forma de copo ou material indesejado para uso, respectivamente como um copo de colpotomia ou em um copo de colpotomia. [0021] a título de exemplo não limitante, quando se refere a uma estrutura em forma de copo, o termo ""substancialmente não disassocia fragmentos de particulado"" significa que a estrutura em forma de copo não disassocia fragmentos de particulado até o ponto ou grau de tornar a estrutura em forma de copo indesejada para uso como um copo de colpotomia. [0022] a título de outro exemplo não limitante, quando refere-se a uma estrutura em forma de copo, o termo ""substancialmente não derrete ou queima"" significa que a estrutura em forma de copo não derrete ou queima até o ponto ou grau de tornar a estrutura em forma de copo indesejada para uso como um copo de colpotomia. [0023] a título de mais outro exemplo não limitante, quando refere-se a uma estrutura em forma de copo, o termo ""substancialmente não forma beiras dentadas derretidas"" significa que a estrutura em forma de copo não forma beiras dentadas derretidas até o ponto ou grau de tornar a estrutura em forma de copo indesejada para uso como um copo de colpotomia. [0024] a título de um exemplo não limitante adicional, quando se refere a uma estrutura em forma de copo, o termo ""substancialmente não emite fumaça ou gás"" significa que a estrutura em forma de copo não emite fumaça ou gás até o ponto ou grau de tornar a estrutura em forma de copo indesejada para uso como um copo de colpotomia. [0025] as figs. de 2 a 5 ilustram um copo 100 para uso com um manipulador uterino, tal como, a título de exemplo não limitante, o manipulador 12 da fig. 1. o copo 100 também pode ser usado com manipuladores uterinos de modelo similar e diferente, o que inclui sem limitação aqueles descritos na patente dos estados unidos no. 5,643,311 depositada em 1 de julho de 1997 de smith et al., e na patente dos estados unidos no. 5,487,377, depositada em 30 de janeiro de 1996 de smith et al., sendo ambas atribuídas ao depositante da presente invenção. o copo 100 pode incluir uma parede cilíndrica 102 que se estende entre uma base 104 localizada em uma extremidade proximal 106 do copo 100 e um aro 108 localizado em uma extremidade distal 110 do copo 100. a parede cilíndrica 102 inclui uma superfície externa 112 e uma superfície interna 114. o aro 108 é dimensionado para circundar ou pelo menos substancialmente envelopar os fórnices vaginais anterior e posterior e o mesmo pode se estender de forma contínua ou não contínua em torno da periferia da extremidade distal 110 do copo 100. o aro 108 pode ser biselado e/ou polido, conforme descrito, para reduzir a quantidade de tensão aplicada sobre o fórnice pelo copo 100. a base 104 está configurada para tocar o colo do útero e a mesma define uma abertura central 116 formada no mesmo através da qual um eixo geométrico longitudinal l 5 do copo 100 se estende, conforme ilustrado nas figs. 4 e 5, respectivamente. a abertura 116 está configurada para se alinhar substancialmente com a cervical quando o copo 100 se encaixar no colo do útero. a abertura 116 possui um diâmetro suficiente para permitir a extensão através de si de uma seção de ponta de um manipulador uterino, tal como a seção de ponta 28 do manipulador 12 da fig. 1. conforme descrito previamente, a seção de ponta 28 pode incluir uma ponta flexível 32, um balão 30 para inflar ese encaixar na parede interna do útero e um orifício 37 para injetar contraste dentro do útero. a seção de ponta 28 também pode incluir um ou mais tubos 34, 36 que possuem lúmens para enviar respectivamente fluido e contraste para o balão 30 e orifício 37. [0026] novamente com referência à fig. 2, a base 104 inclui uma estrutura de montagem 118 para acoplar o copo 100 a outro componente de um conjunto de manipulador, tal como o elemento rígido 16 mostrado na fig. 1. conforme mostrado na fig. 2, o copo 100 pode incluir uma protuberância circunferencial 120 que se estende radialmente localizada sobre a superfície externa 112 da parede cilíndrica 102 próxima do aro 108. a protuberância 120 pode ser biselada e/ou polidoa para reduzir a quantidade de tensão aplicada pela protuberância 120 ao útero. conforme previamente descrito, a protuberância 120 está configurada para permitir que um médico localize visualmente o aro 108 quando o colo do útero for suficientemente encaixado pelo copo 100. na maioria das modalidades, o colo do útero é suficientemente encaixado pelo copo 100 quando a base 104 do copo 100 toca o colo do útero. sendo assim, o médico pode fazer uma incisão usando um escalpelo eletrocirúrgico ou harmônico, conforme descrito acima, nos fórnices vaginais próxima de uma porção da protuberância 120. [0027] um copo 100, conforme descrito acima e de acordo com uma ou mais modalidades da invenção, é formado a partir de um material substancialmente com isolamento elétrico que possui uma temperatura de fusão suficientemente alta para suportar substancialmente as intensas cargas térmicas aplicadas por um escalpelo harmônico sem substancialmente envergar, queimar, derreter, produzir beiras dentadas derretidas, emitir gases indesejáveis a partir do mesmo, se quebrar ou dissociar fragmentos nocivos de particulado, ou fraturar o escalpelo. [0028] pelo menos nove materiais potenciais para o copo 100 foram testados pelos inventores: (1) polietileno de alta densidade (hdpe); (2) policarbonato; (3) politerimida (pei), de maneira específica, pei da marca ultem(r); (4) tereftalato de polibutileno enchido com trinta por cento de vidro (30% gf pbt), de maneira específica, 30% gf pbt da marca valox(r); (5) liga de óxido de polifenileno /polistireno (po/os), de maneira específica, po/os da marca noryl(r); (6) poliftalamida enchida com trinta por cento de vidro (30% gf pa), de maneira específica, a-l 133 hs nt pa da marca amodel(r); (7) poliftalamida (ppa) sem nenhum vidro, de maneira específica, at-1002 hs nt pa da marca amodel(r); (8) poliéter-éter-cetona (peek), de maneira específica, peek da marca peek-optima(r); e (9) poliftalamida enchida com quarenta e cinco por cento de vidro (45% gf pa), de maneira específica, a-1145 hs nt pa da marca amodel(r). deve ser compreendido que a porcentagem de vidro em determinados de materiais de teste mencionados acima (por exemplo, materiais (4), (6) e (9)) representa uma porcentagem de volume de vidro enchido. os resultados de teste são apresentados aqui nas tabelas de 1 a 9. as amostras de material foram repetidamente testadas sob exposição tanto a um escalpelo harmônico quanto a um escalpelo a laser com co2 simulado em relação a uma variedade de parâmetros, o que inclui a área cortada e o tempo de corte. o escalpelo harmônico usado foi um da marca ethicon, escalpelo harmônico do modelo ultracision(r). o escalpelo a laser com co2 simulado usado foi um soldador a laser de co2. algumas das amostras de material foram providas na forma de uma placa de amostra, enquanto outras amostras de material foram providas na forma de um copo de colpotomia comercialmente disponível. para cada teste executado, o tempo de corte normalizado foi calculado para ajustar as diferenças nos tipos de amostras de materiais testados. os testes não foram conduzidos com um escalpelo eletrocirúrgico, pois os materiais em questão compreendem um material eletricamente insolante aprovado. para cada material testado, as características comportamentais resultantes foram observadas durante e depois da exposição ao escalpelo a laser e ao escalpelo harmônico. deve ser compreendido que é geralmente desejável que o material de teste suporte durações mais longas de exposição aos escapelos harmônicos e eletrocirúrgicos do que seria normalmente observado durante um procedimento cirúrgico antes da exibição de características nocivas, tal como aquelas descritas acima. quanto mais o material suporta exposição aos dispositivos de corte, mais tempo o médico pode ter para fazer uma incisão cuidadosa e precisa na parede uterina. [0029] a tabela 1 provê os dados do resultado de teste para polietileno de alta densidade (hdpe). duas execuções de teste foram conduzidas no hdpe, com uma área cortada média de 1,155 centímetros quadrados (cm ) (0,179 polegada ao quadrado (in )) e um tempo de corte médio de 25,85 segundos (s), o que resulta em um tempo de corte normalizado of 22,384 segundos por centímetro quadrado (s/cm2) (144.413 segundos por polegada ao quadrado (s/in2)). foi observado que quando o hdpe material de teste foi exposto ao escalpelo harmônico, o hdpe apresentou uma qualidade ""fibrosa"" indesejada. tabela 1: polietileno de alta densidade (hdpe) teste no. área cortada (cm1) tempo de corte (s) tempo normalizado (s/cm2) 1 1,155 (0,179 in2) 26,8 23,207 (149,721 s/in2) 2 1,155 (0,179 in2) 24,9 21,561 (139,106 s/in2) média 1,155 (0,179 in2) 25,85 22,384 (144,413 s/in2) [0030] quando exposto ao escalpelo a laser, o hdpe (um material translúcido) não foi afetado e foi observado que o feixe de laser passou através do material. [0031] a tabela 2 provê os dados do resultado de teste para policarbonato. cinco execuções de teste foram conduzidas no policarbonato, com uma área cortada média de 0,168 centímetro quadrado (cm2) (0,026 polegada ao quadrado (in2)) e um tempo de corte médio de 4,60 segundos (s), o que resulta em um tempo de corte normalizado de 27,411 segundos por centímetro quadrado (s/cm2) (176,846 segundos por polegada ao quadrado (s/in2)). foi observado que quando o material de teste de policarbonato foi exposto ao escalpelo harmônico, indesejadas beiras dentadas e derretidas foram formadas no policarbonato, embora não tão severas quanto aquelas formadas na polieterimida (pei), conforme discutido abaixo. teste no. área cortada (cm2) tempo de corte (s) tempo normalizado (s/cm2) 1 0,168 (0,026 in2) 4,53 27,006 (174,231 s/in2) 2 0,168 (0,026 in2) 4,78 28,496 (183,846 s/in2) 3 0,168 (0,026 in2) 4,81 28,675(185,000 s/in2) 4 0,168 (0,026 in2) 4,34 25,873 (166,923 s/in2) 5 0,168 (0,026 in2) 4,53 27,006 (174,231 s/in2) média 0,168 (0,026 in2) 4,60 27,411 (176,846 s/in2) tabela 2: policarbonato [0032] quando exposto ao escalpelo a laser, o policarbonato apresentou derretimento limitado. a cor da amostra fez com que fosse difícil determinar se havia ocorrido alguma queimadura no policarbonato em função da exposição ao escalpelo a laser. [0033] a tabela 3 provê os dados do resultado de teste para polieterimida (pei). cinco execuções de teste foram conduzidas no pei, com uma área cortada média de 0,323 centímetros quadrados (cm2) (0,05 polegada ao quadrado (in2)) e um tempo de corte médio de 11,00 segundos (s), o que resulta em um tempo de corte normalizado de 34,100 segundos por centímetro quadrado (s/cm2) (220,000 segundos por polegada ao quadrado (s/in2)). foi observado que quando o material de teste de pei foi exposto ao escalpelo harmônico, severas beiras dentadas e derretidas se formaram no pei. de maneira adicional, particulados visíveis, comparavelmente dimensionados ao tamanho de grãos de areia, foram observados como um resultado do corte. teste no. área cortada (cm2) tempo de corte (s) tempo normalizado (s/cm2) 1 0,323 (0,050 in2) 11,91 36,921 (238,200 s/in2) 2 0,323 (0,050 in2) 10,85 33,635 (217,000 s/in2) 3 0,323 (0,050 in2) 11,09 34,379 (221,800 s/in2) 4 0,323 (0,050 in2) 10,87 33,697 (217,400 s/in2) 5 0,323 (0,050 in2) 10,28 31,868 (205,600 s/in2) média 0,323 (0,050 in2) 11,00 34,100 (220,000 s/in2) tabela 3: polieterimida (pei) [0034] quando exposto ao escalpelo a laser, foi observado que o feixe de laser não penetrou no pei a um grau significativo, todavia, queimaduras foram imediatamente observadas (mais severas do que em outros materiais testados). [0035] a tabela 4 provê os dados do resultado de teste para um tereftalato de polibutileno enchido com trinta por cento de vidro (30% gf pbt). cinco execuções de teste foram conduzidas no gf pbt a 30%, com uma área cortada média de 0,155 centímetros quadrados (cm2) (0,024 polegada ao quadrado (in2)) e um tempo de corte médio de 5,45 segundos (s), o que resulta em um tempo de corte normalizado de 35,211 segundos por centímetro quadrado (s/cm2) (227,167 segundos por polegada ao quadrado (s/in2)). embora nenhum particulado tenha sido observado quando o material de teste de gf pbt a 30% foi exposto ao escalpelo harmônico, ocorreram queimaduras em adição à liberação desfavorável de gás. teste no. área cortada (cm2) tempo de corte (s) tempo normalizado (s/cm2) 1 0,155 (0,024 in2) 5,88 37,975 (245,000 s/in2) 2 0,155 (0,024 in2) 5,63 36,360 (234,583 s/in2) 3 0,155 (0,024 in2) 5,34 34,488 (222,500 s/in2) 4 0,155 (0,024 in2) 5,25 33,906 (218,750 s/in2) 5 0,155 (0,024 in2) 5,16 33,325 (215,000 s/in2) média 0,155 (0,024 in2) 5,45 35,211 (227,167 s/in2) tabela 4: tereftalato de polibutileno (pbt) [0036] quando exposto ao escalpelo a laser, uma rápida queimadura foi observada, mesmo quando cortes mais rápidos foram feitos pelo laser, apesar de o feixe de laser não ter penetrado tão profundamente no material em comparação com outros materiais testados. [0037] a tabela 5 provê os dados do resultado de teste para a liga de óxido de polifenileno/polistireno (po/os). cinco execuções de teste foram conduzidas no po/os, com uma área cortada média de 0,265 centímetros quadrados (cm2) (0,041 polegada ao quadrado (in2)) e um tempo de corte médio de 12,23 segundos (s), o que resulta em um tempo de corte normalizado de 46,251 segundos por centímetro quadrado (s/cm2) (298,390 segundos por polegada ao quadrado (s/in2)). beiras dentadas derretidas foram formadas quando o material de teste po/os foi exposto ao escalpelo harmônico, embora menos severas do que aquelas formadas na polieterimida (pei) mencionada acima. além disso, particulados foram observados resultantes da exposição ao escalpelo harmônico, porém, menores do que os particulados observados no pei. teste no. área cortada (cm2) tempo de corte (s) tempo normalizado (s/cm2) 1 0,265 (0,041 in2) 11,62 43,929 (283,415 s/in2) 2 0,265 (0,041 in2) 12,43 46,992 (303,171 s/in2) 3 0,265 (0,041 in2) 12,63 47,748 (308,049 s/in2) 4 0,265 (0,041 in2) 12,59 47,596 (307,073 s/in2) 5 0,265 (0,041 in2) 11,9 44,988 (290,244 s/in2) média 0,265 (0,041 in2) 12,23 46,251 (298,390 s/in2) tabela 5: óxido de polifenileno (ppo/os) [0038] quando exposto ao escalpelo a laser, o po/os derreteu de forma imediata e intensa. foi também observado que o po/os permitiu a formação de queimaduras quando o feixe de laser pôde parar em um único local, embora a carbonização tenho sido mínima e o feixe de laser tenha parado no mesmo local por um tempo significativamente mais longo para queimar o po/os do que para queimar outros materiais testados. [0039] a tabela 6 provê os dados do resultado de teste para uma poliftalamida enchida com trinta por cento de vidro (30% gf pa). cinco execuções de teste foram conduzidas na 30% gf pa, com uma área cortada média de 0,174 centímetros quadrados (cm2) (0,027 polegada ao quadrado (in2)) e um tempo de corte médio de 8,07 segundos (s), o que resulta em um tempo de corte normalizado de 5 47,239 segundos por centímetro quadrado (s/cm2) (304,765 segundos por polegada ao quadrado (s/in2)). foi observado que quando o material 30% gf pa de teste foi exposto ao escalpelo harmônico, queimaduras no material e fumaça emanando do mesmo foram observadas, em adição a um forte cheiro de plástico queimado durante os testes de corte. no entanto, com uma quantidade mínima de",CLINICAL INNOVATIONS LLC,JEREMY C HORTON;;RICHARD A DIXON,,https://lens.org/070-094-413-948-81X,Patent Application,no,0,0,10,10,0,A61B17/4241;;A61L29/06;;A61L29/126;;A61B18/1402;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L29/06;;A61L31/06;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L31/06;;A61L29/06,A61B1/303;;A61B17/3209;;A61B17/42;;A61L29/04;;A61M29/02,,0,0,,,,DISCONTINUED
401,WO,A1,WO 2006/071322 A1,118-327-136-646-091,2006-07-06,2006,US 2005/0035645 W,2005-09-30,US 2255304 A,2004-12-23,LASER GONIOMETER FOR MEASURING THE ANGLE OF A SURFACE,A goniometer for measuring an angle of a surface of an object is provided. The goniometer includes a frame with an engagement element configured for engaging the object. A laser generator is carried by the frame and is configured for emitting a laser beam onto the surface of the object when the object engages the engagement element. The goniometer further includes a scale carried by the frame. The laser beam is reflected from the object towards the scale and the scale is configured for indicating an angle of the surface of the object onto which the laser beam is directed when emitted by the laser generator. The object may be a creping blade and the goniometer may be used in order to measure the grind angle of the creping blade.,KIMBERLY CLARK CO;;DIXON SCTOTT A;;BURCHAM KIM G,DIXON SCTOTT A;;BURCHAM KIM G,,https://lens.org/118-327-136-646-091,Patent Application,yes,2,1,2,2,0,G01B11/26;;G01B11/26;;G01B9/10;;G01B9/10,G01B9/10;;G01B11/26;;G01C9/00,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 009, no. 037 (P - 335) 16 February 1985 (1985-02-16)",PENDING
402,US,A,US 4229659 A,128-696-842-731-759,1980-10-21,1980,US 96180778 A,1978-11-17,US 96180778 A,1978-11-17,Oxidizer burn through detector with majority voting network,"A system for detecting oxidizer burn through comprising a network of three ndependent photodetectors and their associated circuitry connected to a two-out-of-three majority voting network. When a fire occurs, the photodiodes will produce a response. If two or three signals are received by the voting network, an output signal is produced which can be used to dump oxidizer, activate alarms, close valves, activate damage control systems, etc. Two types of detection techniques are possible: (1) spectral line detection which incorporates an optical pass filter before each photodetector which limits the detector so that it responds only to a wavelength of light produced by a particular burning metal-oxidizer combination, and (2) intensity change detection which incorporates comparison circuitry after the photodetectors which compares detected light levels to ambient light levels.",US NAVY,VASELICH RAYMOND A;;DIXON JR JOHN,,https://lens.org/128-696-842-731-759,Granted Patent,yes,3,4,1,1,0,G08B17/12;;G08B17/12,G08B17/12,250/554,0,0,,,,EXPIRED
403,US,A,US 746034 A,133-940-704-694-446,1903-12-08,1903,US 1903/0154333 A,1903-04-25,US 1903/0154333 A,1903-04-25,SPRING-BED.,,CRAWFORD EPHRAIM A;;DIXON JONAS F,CRAWFORD EPHRAIM A;;DIXON JONAS F,,https://lens.org/133-940-704-694-446,Granted Patent,no,0,0,1,1,0,A47C23/0522;;A47C23/0522,,,0,0,,,,EXPIRED
404,MX,A,MX 149688 A,141-442-746-980-967,1983-12-13,1983,MX 17663979 A,1979-02-16,US 87885878 A,1978-02-17,COMPOSICION MEJORADA DE RECUBRIMIENTO,,WESTINGHOUSE ELECTRIC CORP,SATTLER FRANK A;;DIXON GEORGE D,,https://lens.org/141-442-746-980-967,Granted Patent,no,0,0,11,11,0,C08F283/01;;C08F299/0478;;C08G63/6854;;C09D167/00;;Y10T428/31681;;Y10T428/31681;;C08F299/0478;;C08G63/6854;;C08F283/01;;C09D167/00,C08F2/50;;C08F299/00;;C08F283/01;;C08F299/04;;C08G63/00;;C08G63/52;;C08G63/685;;C09D4/00;;C09D167/00,79-3,0,0,,,,EXPIRED
405,CA,A1,CA 2946747 A1,147-481-844-654-794,2015-10-29,2015,CA 2946747 A,2015-04-22,US 201461983325 P;;US 2015/0027099 W,2014-04-23,METHODS OF ENHANCING STEM CELL ENGRAFTMENT,"An effective amount of a composition comprising a stem cell, a stem cell engraftment enhancer, and a carrier fluid, for use in the treatment of an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease. A composition comprising PGI2-overexpressing human mesenchymal stem cells (PGI2-hMSCs), and a carrier fluid; wherein an effective amount of the composition is administered via a single treatment stream as an intramuscular injection to an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease, and wherein stem cell engraftment is enhanced in said individual by greater than about 200%, when compared to stem cell engraftment in an individual treated with a composition lacking the stem cell engraftment enhancer.",TEXAS HEART INST,LIU QI;;DIXON RICHARD A F,,https://lens.org/147-481-844-654-794,Patent Application,no,0,0,6,6,0,A61K35/12;;A61K35/34;;A61K35/36;;A61K45/06;;A61K35/28;;A61K31/5578;;A61P9/00;;A61K35/28;;A61K31/5578;;A61K35/34;;A61K45/06;;A61K35/36;;A61K35/12,A61K35/28;;A61K35/12;;A61K35/36;;A61P9/00,,0,0,,,,DISCONTINUED
406,AU,A1,AU 2009/234210 A1,170-677-245-198-764,2009-10-15,2009,AU 2009/234210 A,2009-04-10,US 4430608 P;;US 2009/0040190 W,2008-04-11,Methods and compositions for accelerating the generation of regulatory Tcells ex vivo,,UNIV SOUTHERN CALIFORNIA,HORWITZ DAVID A;;GRAY J DIXON,,https://lens.org/170-677-245-198-764,Patent Application,no,0,0,9,9,0,A61K35/12;;C12N5/0636;;A61P37/06;;A61K2239/38;;A61K39/46433;;A61K39/4611;;A61K39/4621;;A61K2239/31;;C12N5/0636;;A61K35/12,A61K35/14;;A61K35/12;;A61P37/06;;C12N5/07;;C12N5/0783,,0,0,,,,DISCONTINUED
407,WO,A3,WO 2006/010096 A3,164-553-222-923-431,2006-10-12,2006,US 2005/0024470 W,2005-07-11,US 58702004 P,2004-07-09,GENETIC MANIPULATION OF CONDENSED TANNINS,The invention provides method and compositions for the modulation of condensed tannin production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of condensed tannins in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased condensed tannin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content. The invention may also be used to modify plant pigmentation.,SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;SHARMA SHASHI B,DIXON RICHARD A;;SHARMA SHASHI B,,https://lens.org/164-553-222-923-431,Search Report,yes,1,0,9,9,0,C12N9/0004;;C12N9/0004;;C07K14/415;;C07K14/415;;C12N9/0093;;C12N9/0093;;C12N15/8223;;C12N15/8223;;C12N15/8234;;C12N15/8234;;C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,C12N15/82;;A01H5/00;;C12N15/29;;C12N15/52,,5,4,006-470-893-916-774;;021-053-676-958-106;;044-560-896-492-580;;053-728-441-408-680,pmc139454;;10.2307/3871430;;10.1105/tpc.13.9.2099;;11549766;;10.1105/tpc.010098;;10.1111/j.1365-313x.2004.02138.x;;15255866;;10.1016/s0031-9422(03)00377-7;;12943753;;10.1111/j.1365-313x.2005.02510.x;;16167896,"NESI N ET AL: ""The Arabidopsis TT2 gene encodes an R2R3 MYB domain protein that acts as a key determinant for proanthocyanidin accumulation in developing seed"", September 2001, PLANT CELL, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, US, PAGES 2099-2114, ISSN: 1040-4651, XP002982938;;DATABASE Geneseq [online] 1 July 2004 (2004-07-01), ""Thalecress transcription factor cDNA #223."", XP002363656, retrieved from EBI accession no. GSN:ADO02032 Database accession no. ADO02032;;BAUDRY A ET AL: ""TT2, TT8, and TTG1 synergistically specify the expression of BANYULS and proanthocyanidin biosynthesis in Arabidopsis thaliana"", 15 June 2004, PLANT JOURNAL, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, PAGES 366-380, ISSN: 0960-7412, XP002982940;;MARLES M A S ET AL: ""New perspectives on proanthocyanidin biochemistry and molecular regulation"", January 2004, PHYTOCHEMISTRY, PERGAMON PRESS, GB, PAGES 367-383, ISSN: 0031-9422, XP004448652;;SHARMA SHASHI B ET AL: ""Metabolic engineering of proanthocyanidins by ectopic expression of transcription factors in Arabidopsis thaliana"", 16 August 2005, PLANT JOURNAL, VOL. 44, NR. 1, PAGES 62-75, ISSN: 0960-7412, XP002363652",PENDING
408,EP,B1,EP 0585598 B1,015-782-138-917-289,1999-04-21,1999,EP 93111950 A,1993-07-27,US 93875392 A,1992-09-01,Metal casting using a mold having attached risers,,GEN MOTORS CORP,CHANDLEY GEORGE DIXON;;REDEMSKE JOHN A,,https://lens.org/015-782-138-917-289,Granted Patent,yes,7,2,9,9,0,B22C9/08;;B22D18/06;;B22D18/06;;B22C9/08,B22C9/04;;B22C9/08;;B22D18/06,,0,0,,,,EXPIRED
409,EP,A2,EP 2281031 A2,017-357-413-152-07X,2011-02-09,2011,EP 09729610 A,2009-04-10,US 2009/0040190 W;;US 4430608 P,2008-04-11,METHODS AND COMPOSITIONS FOR ACCELERATING THE GENERATION OF REGULATORY TCELLS EX VIVO,,UNIV SOUTHERN CALIFORNIA,HORWITZ DAVID A;;GRAY J DIXON,,https://lens.org/017-357-413-152-07X,Patent Application,yes,0,1,9,9,0,A61K35/12;;C12N5/0636;;A61P37/06;;A61K2239/38;;A61K39/46433;;A61K39/4611;;A61K39/4621;;A61K2239/31;;C12N5/0636;;A61K35/12,C12N5/07;;A61K35/12;;A61K35/14;;A61P37/06;;C12N5/0783,,0,0,,,,DISCONTINUED
410,US,A,US 814774 A,030-830-495-727-114,1906-03-13,1906,US 1905/0249437 A,1905-03-10,US 1905/0249437 A,1905-03-10,APPARATUS FOR SHEARING GLASS.,,AUTOMATIC MACHINE GLASS COMPANY,DIXON HENRY L;;MARSH GEORGE A,,https://lens.org/030-830-495-727-114,Granted Patent,no,0,3,1,1,0,B26F3/004;;B26F3/004;;Y10T83/364;;Y10T83/364,,,0,0,,,,EXPIRED
411,EP,A1,EP 2869772 A1,056-018-346-878-994,2015-05-13,2015,EP 13813766 A,2013-06-20,US 201213541956 A;;US 2013/0046851 W,2012-07-05,COLPOTOMY CUP-LIKE STRUCTURE AND INTRAUTERINE MANIPULATOR INCLUDING SAME,,CLINICAL INNOVATIONS LLC,HORTON JEREMY C;;DIXON RICHARD A,,https://lens.org/056-018-346-878-994,Patent Application,yes,0,0,10,10,0,A61B17/4241;;A61L29/06;;A61L29/126;;A61B18/1402;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L29/06;;A61L31/06;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L31/06;;A61L29/06,A61B17/42;;A61B1/303;;A61L29/06;;A61L29/12;;A61L31/06,,0,0,,,,DISCONTINUED
412,CA,A,CA 827072 A,066-119-776-715-656,1969-11-11,1969,CA 827072D A,,CA 827072T A,,LIQUID FERTILIZERS,,ELECTRIC REDUCTION CO,DIXON JOHN T;;SMITH RAYMOND A,,https://lens.org/066-119-776-715-656,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
413,WO,A1,WO 2015/053768 A1,078-115-121-324-440,2015-04-16,2015,US 2013/0064060 W,2013-10-09,US 2013/0064060 W,2013-10-09,HINGED VORTEX GENERATOR FOR EXCESS WIND LOAD REDUCTION ON WIND TURBINE,"A vortex generator (VG) (42, 64, 80, 82, 84) mounted via a mounting plate (44, 92) to a wind turbine blade (22, 98). The VG airfoil (46) may be pivotally attached to the mounting plate by a spring hinge (48, 85) that causes the VG airfoil to passively deflect downstream in excess wind conditions to reduce lift on the blade above a predetermined wind speed. A blade pitch controller (99) sets a positive angle of attack on an outboard portion of the blade above the predetermined wind speed that compensates for lift reduction from deflection of VGs on an inboard portion of the blade. The spring hinge may provide a pivot axis (57) parallel to the suction side of the blade or normal (85) to it. A pivot limiter (58, 93/94) may hold the VG in an operating position against a spring preload, overcome by the predetermined wind speed.",SIEMENS AG;;DIXON KRISTIAN R;;MAYDA EDWARD A,DIXON KRISTIAN R;;MAYDA EDWARD A,,https://lens.org/078-115-121-324-440,Patent Application,yes,5,19,2,7,0,F03D7/0224;;F03D1/0675;;F05B2240/31;;F05B2260/502;;Y02E10/72;;F05B2240/3062,F03D7/02;;F03D1/06,,0,0,,,,PENDING
414,US,S,US D0403083 S,065-656-068-413-937,1998-12-22,1998,US 7834697 F,1997-10-22,US 7834697 F,1997-10-22,Roof structure,,AMERICAS DRIVE IN TRUST,POELVOORDE RAYMOND M;;DIXON PETER A,AMERICA'S DRIVE-IN CORP (2003-11-13);;AMERICA'S DRIVE-IN BRAND PROPERTIES LLC (2006-12-20);;AMERICA'S DRIVE-IN HOLDING INC (2006-12-20);;AMERICA'S DRIVE-IN TRUST (1997-10-21),https://lens.org/065-656-068-413-937,Design Right,yes,4,1,1,1,0,,,D25/56;;2502,0,0,,,,EXPIRED
415,US,A,US 2827290 A,063-300-337-609-277,1958-03-18,1958,US 45640254 A,1954-09-16,US 45640254 A,1954-09-16,Vacuum feed,,ROYAL MCBEE CORP,DIXON FREDERICK A;;ANDERSON WILLIAM M,,https://lens.org/063-300-337-609-277,Granted Patent,no,6,12,1,1,0,G06K13/107;;G06K13/107,G06K13/107,,0,0,,,,EXPIRED
416,US,A1,US 2006/0123508 A1,090-287-049-294-798,2006-06-08,2006,US 17906405 A,2005-07-11,US 17906405 A;;US 58702004 P,2004-07-09,Genetic manipulation of condensed tannins,The invention provides method and compositions for the modulation of condensed tannin production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of condensed tannins in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased condensed tannin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content. The invention may also be used to modify plant pigmentation.,SAMUEL ROBERTS NOBEL FOUNDATIO,DIXON RICHARD A;;SHARMA SHASHI B,NOBLE RESEARCH INSTITUTE LLC (2017-05-01);;SAMUEL ROBERTS NOBLE FOUNDATION THE (2005-10-18),https://lens.org/090-287-049-294-798,Patent Application,yes,3,13,9,9,0,C12N9/0004;;C12N9/0004;;C07K14/415;;C07K14/415;;C12N9/0093;;C12N9/0093;;C12N15/8223;;C12N15/8223;;C12N15/8234;;C12N15/8234;;C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,A01H1/00;;C07H21/04;;C12N5/04;;C12N15/82,800/278;;435/419;;435/468;;536/23.2,0,0,,,,ACTIVE
417,WO,A3,WO 2009/126877 A3,103-290-760-445-532,2009-12-03,2009,US 2009/0040190 W,2009-04-10,US 4430608 P,2008-04-11,METHODS AND COMPOSITIONS FOR ACCELERATING THE GENERATION OF REGULATORY TCELLS EX VIVO,"The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation of T cells into suppressor cells, and agents that are histone deacetylase inhibitors. The invention also encompasses compositions of regulatory T cells generated by cultuhng non-regulatory T cells with a regulatory composition as well as the use of such regulatory T cells in the treatment of autoimmune diseases and aberrant immune responses.",UNIV SOUTHERN CALIFORNIA;;HORWITZ DAVID A;;GRAY J DIXON,HORWITZ DAVID A;;GRAY J DIXON,,https://lens.org/103-290-760-445-532,Search Report,yes,1,0,9,9,0,A61K35/12;;C12N5/0636;;A61P37/06;;A61K2239/38;;A61K39/46433;;A61K39/4611;;A61K39/4621;;A61K2239/31;;C12N5/0636;;A61K35/12,A61K35/12;;A61K35/14;;A61P37/06;;C12N5/0783,,8,7,067-262-506-942-478;;080-594-097-184-427;;038-208-760-083-876;;006-710-477-907-764;;080-042-642-567-840;;078-838-569-854-182;;138-274-728-849-051,pmc3731994;;19109157;;10.4049/jimmunol.182.1.259;;18395858;;10.1002/eji.200738109;;10.1038/nm1652;;17922010;;17785809;;10.4049/jimmunol.179.6.3724;;17694575;;10.1002/eji.200737594;;16645171;;pmc1895505;;10.1182/blood-2006-02-004747;;17161354;;10.1016/j.intimp.2006.07.019,"FLOESS STEFAN ET AL: ""EPIGENETIC CONTROL OF THE FOXP3 LOCUS IN REGULATORY T CELLS"", PLOS BIOLOGY, PUBLIC LIBRARY OF SCIENCE, US, vol. 5, no. 2, 1 February 2007 (2007-02-01), pages 169 - 178, XP008079507, ISSN: 1544-9173;;LAL GIRDHARI ET AL: ""Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 JAN 2009, vol. 182, no. 1, 1 January 2009 (2009-01-01), pages 259 - 273, XP002538141, ISSN: 1550-6606;;HORWITZ DAVID A ET AL: ""Critical role of IL-2 and TGF-beta in generation, function and stabilization of Foxp3+CD4+ Treg."", EUROPEAN JOURNAL OF IMMUNOLOGY APR 2008, vol. 38, no. 4, April 2008 (2008-04-01), pages 912 - 915, XP002538142, ISSN: 0014-2980;;TAO RAN ET AL: ""Deacetylase inhibition promotes the generation and function of regulatory T cells."", NATURE MEDICINE NOV 2007, vol. 13, no. 11, November 2007 (2007-11-01), pages 1299 - 1307, XP002538143, ISSN: 1078-8956;;KANG SEUNG G ET AL: ""Vitamin a metabolites induce gut-homing FoxP3(+) regulatory T cells"", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 179, no. 6, 1 September 2007 (2007-09-01), pages 3724 - 3733, XP002503703, ISSN: 0022-1767;;BARON UDO ET AL: ""DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells"", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 37, no. 9, 1 September 2007 (2007-09-01), pages 2378 - 2389, XP002503237, ISSN: 0014-2980;;ZORN EMMANUEL ET AL: ""IL-2 REGULATES FOXP3 EXPRESSION IN HUMAN CD4(+)CD25(+) REGULATORY T CELLS THROUGH A STAT-DEPENDENT MECHANISM AND INDUCES THE EXPANSION OF THESE CELLS IN VIVO"", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 5, 1 September 2006 (2006-09-01), pages 1571 - 1579, XP008079309, ISSN: 0006-4971;;MELONI F ET AL: ""Peripheral CD4+ CD25+ Treg cell expansion in lung transplant recipients is not affected by calcineurin inhibitors"", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 13-14, 20 December 2006 (2006-12-20), pages 2002 - 2010, XP024976983, ISSN: 1567-5769, [retrieved on 20061220]",PENDING
418,US,A,US 4235455 A,154-689-217-437-359,1980-11-25,1980,US 2941079 A,1979-04-12,US 2941079 A,1979-04-12,Vehicle seat belt retractor mechanism,"A seat belt inhibitor system is designed to prevent door mounted inertial seat belt retractor 14 from locking the seat belt webbing 13 whenever the door is opened. The retractor pendulum 31, sensitive to acceleration, moves the locking bar 28 upward locking the retractor and prevents the belt webbing from paying out. An electromagnet 36, when energized, attracts a leaf spring 37 extending from the locking bar inhibiting movement of the latter. System inhibiting is initiated by closing either a door latch switch 42 or a door release handle switch 41. At low accelerations (occurring while the door is being opened), the locking bar 28 is restrained by the electromagnet 36 through the leaf spring 37. If the system should fail such that the electromagnet was energized while the door is closed, high acceleration of the pendulum would force the locking bar up, locking the retractor. Deenergizing occurs normally whenever the door is closed.",FORD MOTOR CO,COLLINS ALFORD F;;DIXON BILL A,,https://lens.org/154-689-217-437-359,Granted Patent,yes,5,17,7,7,0,B60R22/41;;B60R22/41,B60R22/08;;B60R22/40;;B60R22/41;;B60R22/48,280/803,0,0,,,,EXPIRED
419,WO,A2,WO 2005/042747 A2,159-067-909-030-088,2005-05-12,2005,US 2004/0035948 W,2004-10-28,US 51555903 P,2003-10-29,PLANT ISOFLAVONOID HYDROXYLASES AND METHODS OF USE THEREOF,"The invention provides plant isoflavonoid hydroxylase coding sequences. Also provided are constructs comprising these sequences, plants transformed therewith and methods of use thereof. In certain aspects of the invention, plants transformed with the nucleic acids are provided exhibiting improved pest and disease resistance. Plants provided by the invention may also exhibit improved nutritional qualities.",SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;LIU CHANG-JUN,DIXON RICHARD A;;LIU CHANG-JUN,,https://lens.org/159-067-909-030-088,Patent Application,yes,0,1,8,8,21,C12N9/0073;;C12N9/0073,A23L19/00;;C12N9/02;;C12N15/82,,0,0,,,,PENDING
420,US,A,US 3485720 A,188-869-869-948-797,1969-12-23,1969,US 3485720D A,1969-12-22,GB 130266 A,1966-01-11,MALTING OF BARLEY OR OTHER CEREALS,,ENZYMIC MALT CO LTD;;DIXON MALT CO LTD,DIXON BERNARD;;COMRIE ALAN A D,,https://lens.org/188-869-869-948-797,Granted Patent,no,2,0,2,8,0,C12C1/02;;C12C1/047;;C12C1/047;;C12C1/02,,195/70,0,0,,,,EXPIRED
421,CA,A1,CA 2721088 A1,195-478-107-286-892,2009-10-15,2009,CA 2721088 A,2009-04-10,US 4430608 P;;US 2009/0040190 W,2008-04-11,METHODS AND COMPOSITIONS FOR ACCELERATING THE GENERATION OF REGULATORY T CELLS EX VIVO,"The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation of T cells into suppressor cells, and agents that are histone deacetylase inhibitors. The invention also encompasses compositions of regulatory T cells generated by cultuhng non-regulatory T cells with a regulatory composition as well as the use of such regulatory T cells in the treatment of autoimmune diseases and aberrant immune responses.",UNIV SOUTHERN CALIFORNIA,HORWITZ DAVID A;;GRAY J DIXON,,https://lens.org/195-478-107-286-892,Patent Application,no,0,0,9,9,0,A61K35/12;;C12N5/0636;;A61P37/06;;A61K2239/38;;A61K39/46433;;A61K39/4611;;A61K39/4621;;A61K2239/31;;C12N5/0636;;A61K35/12,C12N5/0783;;A61K35/12;;A61K35/14;;A61P37/06;;C12N15/00,,0,0,,,,DISCONTINUED
422,US,A,US 1327056 A,004-922-396-267-146,1920-01-06,1920,US 26170118 A,1918-11-08,US 26170118 A,1918-11-08,Game,,MASON CHARLES P;;DIXON RUSSELL A,MASON CHARLES P;;DIXON RUSSELL A,,https://lens.org/004-922-396-267-146,Granted Patent,no,0,0,1,1,0,A63F3/00075;;A63F3/00075,A63F3/00,,0,0,,,,EXPIRED
423,CA,C,CA 2100831 C,010-632-120-589-795,2000-02-01,2000,CA 2100831 A,1993-07-19,US 93875392 A,1992-09-01,METAL CASTING USING A MOLD HAVING ATTACHED RISERS,"Apparatus and method for countergravity casting a melt employs a particulate mass disposed in a container about a mold having a mold cavity, an ingate passage communicated to the mold cavity for supplying the melt to the mold cavity, and a separate, preformed riser forming member connected to the mold so as to communicate to an isolated and/or enlarged region of the mold cavity needing additional melt supply during solidification in the mold. The mold ingate passage and a source of the melt are communicated to conduct the melt through the ingate passage to the mold cavity to fill the mold cavity with the melt and form a riser of melt in the particulate mass. The riser of melt provides a source of additional melt for supply, as necessary, to the isolated and/or enlarged region during solidification of the melt in the mold cavity to accommodate melt shrinkage thereat.",,CHANDLEY GEORGE DIXON;;REDEMSKE JOHN A,,https://lens.org/010-632-120-589-795,Granted Patent,no,0,0,9,9,0,B22C9/08;;B22D18/06;;B22D18/06;;B22C9/08,B22C9/04;;B22C9/08;;B22D18/06,,0,0,,,,EXPIRED
424,CA,A,CA 7767 A,032-488-833-205-557,1877-08-11,1877,CA 7767D A,,CA 7767T A,,APPARATUS FOR RECOVERING WASTE ALKALIES,,DIXON JOHN W;;FISHER JOHN A,DIXON JOHN W;;FISHER JOHN A,,https://lens.org/032-488-833-205-557,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
425,US,A,US 684046 A,033-322-093-802-941,1901-10-08,1901,US 1901/0042349 A,1901-01-07,US 1901/0042349 A,1901-01-07,OVEREDGE STITCHING-MACHINE.,,REECE BUTTONHOLE MACHINE COMPANY,DAHL CHARLES A;;DIXON WILLIAM W,,https://lens.org/033-322-093-802-941,Granted Patent,no,0,0,1,1,0,D05B73/12;;D05B73/12,,,0,0,,,,EXPIRED
426,US,A1,US 2009/0257988 A1,055-359-670-117-491,2009-10-15,2009,US 42194109 A,2009-04-10,US 42194109 A;;US 4430608 P,2008-04-11,METHODS AND COMPOSITIONS FOR ACCELERATING THE GENERATION OF REGULATORY T CELLS EX VIVO,"The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation of T cells into suppressor cells, and agents that are histone deacetylase inhibitors. The invention also encompasses compositions of regulatory T cells generated by culturing non-regulatory T cells with a regulatory composition as well as the use of such regulatory T cells in the treatment of autoimmune diseases and aberrant immune responses.",USC STEVENS HUGHES CT,HORWITZ DAVID A;;GRAY J DIXON,UNIVERSITY OF SOUTHERN CALIFORNIA (2009-05-25),https://lens.org/055-359-670-117-491,Patent Application,yes,4,13,9,9,0,A61K35/12;;C12N5/0636;;A61P37/06;;A61K2239/38;;A61K39/46433;;A61K39/4611;;A61K39/4621;;A61K2239/31;;C12N5/0636;;A61K35/12,A61K35/12;;C12N5/02;;C12N5/0783,424/93.7;;435/375,2,2,125-198-826-325-522;;043-681-853-335-707,10.1038/icb.2008.106;;19172156;;10.4049/jimmunol.172.9.5149;;15100250;;10.3410/f.1009117.211510,"Wang et al., 2009, Imm. Cell. Biol. Vol. 87: 195-202;;Fantini et al., 2001, J. Immunol. Vol. 172: 5149-5153",DISCONTINUED
427,US,A1,US 2008/0085313 A1,070-412-471-910-749,2008-04-10,2008,US 80405207 A,2007-05-15,US 80405207 A;;US 80072106 P,2006-05-15,Methods and compositions for treatment of sleep apnea,"Provided herein are methods of treatment of sleep apnea by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof to a patient in need of the treatment.",GIVEN BRUCE D;;DIXON RICHARD A,GIVEN BRUCE D;;DIXON RICHARD A,ENCYSIVE PHARMACEUTICALS INC (2007-12-07),https://lens.org/070-412-471-910-749,Patent Application,yes,1,10,6,6,0,A61K9/0019;;A61K9/19;;A61K9/2018;;A61K9/2054;;A61K31/422;;A61P11/00;;A61P25/00;;A61K31/422;;A61K9/0019;;A61K9/2054;;A61K9/19;;A61K9/2018,A61K9/30;;A61K31/42;;A61P11/00,424/475;;514/380,0,0,,,,DISCONTINUED
428,EP,A2,EP 1766031 A2,074-674-034-371-033,2007-03-28,2007,EP 05773590 A,2005-07-11,US 2005/0024470 W;;US 58702004 P,2004-07-09,GENETIC MANIPULATION OF CONDENSED TANNINS,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;SHARMA SHASHI B,,https://lens.org/074-674-034-371-033,Patent Application,yes,0,0,9,9,0,C12N9/0004;;C12N9/0004;;C07K14/415;;C07K14/415;;C12N9/0093;;C12N9/0093;;C12N15/8223;;C12N15/8223;;C12N15/8234;;C12N15/8234;;C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,C12N15/82;;A01H5/00;;C12N15/29;;C12N15/52,,1,0,,,See references of WO 2006010096A3,DISCONTINUED
429,CA,A,CA 1259268 A,079-381-242-775-094,1989-09-12,1989,CA 498647 A,1985-12-24,US 68929485 A,1985-01-07,CONTAINER STRUCTURE FOR DANGEROUS MATERIAL,"A container structure for a dangerous material. An inner container defines a chamber for receiving the dangerous material, an outer container surrounds the inner container, and a fluid chamber is disposed between the inner and outer containers. A body of non flammable liquid is disposed in and completely fills the fluid chamber, and the body of liquid is substantially confined in the fluid chamber. A vent space is disposed between the inner and outer containers in the area above the fluid chamber. The outer container has a bottom wall that is adapted to slidably engage a support surface so that the container structure can slide on the support surface in response to an external impact overcoming its inertia. The inner container is supported essentially by the body of liquid in the fluid chamber, and the body of liquid, being substantially confined in the fluid chamber, distributes impact forces applied to the outer container over a large area of the inner container, thus minimizing damage to the inner container in response to an external impact, and allowing the container structure to slide as a solid body on the support surface in response to an external impact that overcomes its inertia.",AMERICAN TANK & FABRICATING CO,YOUTT STANLEY A;;DIXON JOHN W,,https://lens.org/079-381-242-775-094,Granted Patent,no,0,0,2,2,0,B65D90/22;;B65D90/22;;Y10T137/1812;;Y10T137/1812;;Y10T137/86324;;Y10T137/86324;;Y10T137/86348;;Y10T137/86348,B65D90/22,190-38,0,0,,,,EXPIRED
430,CA,A,CA 827071 A,098-197-323-678-068,1969-11-11,1969,CA 827071D A,,CA 827071T A,,LIQUID FERTILIZERS,,ELECTRIC REDUCTION CO,DIXON JOHN T;;SMITH RAYMOND A,,https://lens.org/098-197-323-678-068,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
431,ZA,B,ZA 708672 B,117-842-780-184-000,1971-10-27,1971,ZA 708672 A,1970-12-28,US 151270 A,1970-01-08,METHODS AND PRODUCTS FOR ELIMINATION OF OIL SLICKS,,GRACE W R & CO,MCKINNEY R;;DIXON A;;JORDAN R,,https://lens.org/117-842-780-184-000,Granted Patent,no,0,0,2,6,0,C12N1/04;;C02F1/681;;C12N1/26,C02F1/68;;C12N1/04;;C12N1/26,,0,0,,,,EXPIRED
432,WO,A2,WO 2009/126877 A2,111-068-178-265-272,2009-10-15,2009,US 2009/0040190 W,2009-04-10,US 4430608 P,2008-04-11,METHODS AND COMPOSITIONS FOR ACCELERATING THE GENERATION OF REGULATORY TCELLS EX VIVO,"The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation of T cells into suppressor cells, and agents that are histone deacetylase inhibitors. The invention also encompasses compositions of regulatory T cells generated by cultuhng non-regulatory T cells with a regulatory composition as well as the use of such regulatory T cells in the treatment of autoimmune diseases and aberrant immune responses.",UNIV SOUTHERN CALIFORNIA;;HORWITZ DAVID A;;GRAY J DIXON,HORWITZ DAVID A;;GRAY J DIXON,,https://lens.org/111-068-178-265-272,Patent Application,yes,0,4,9,9,0,A61K35/12;;C12N5/0636;;A61P37/06;;A61K2239/38;;A61K39/46433;;A61K39/4611;;A61K39/4621;;A61K2239/31;;C12N5/0636;;A61K35/12,A61K35/12;;A61K35/14;;A61P37/06;;C12N5/0783,,1,1,056-460-105-212-624,18676178;;10.1016/j.it.2008.06.005,"HORWITZ ET AL., TRENDS IMMUNOL., vol. 29, no. 9, 2008, pages 429 - 35",PENDING
433,CA,A,CA 563193 A,109-177-111-799-676,1958-09-09,1958,CA 563193D A,,CA 563193T A,,MODIFIED REGENERATED CELLULOSE BY THE ADDITION OF POLYOXYETHYLENE ESTERS,,INT PAPER CANADA,DIXON JULIAN A;;SAXTON WILLIAM R,,https://lens.org/109-177-111-799-676,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
434,AU,A,AU 2000/037287 A,125-366-868-697-949,2000-09-28,2000,AU 2000/037287 A,2000-03-08,US 12326799 P;;US 0005915 W,1999-03-08,Genetic manipulation of isoflavonoids,,SAMUEL ROBERTS NOBLE FOUNDATION INC,STEELE CHRISTOPHER L;;DIXON RICHARD A,,https://lens.org/125-366-868-697-949,Patent Application,no,0,0,7,8,0,C12N9/0077;;C07K2319/00;;C12N15/8242;;C12N15/8243;;C12N15/8261;;C12N15/8279;;Y02A40/146,C12N9/02;;C12N15/53;;C12N15/82,,0,0,,,,EXPIRED
435,DE,D1,DE 69632935 D1,130-693-878-139-595,2004-08-26,2004,DE 69632935 T,1996-03-28,US 43299895 A,1995-05-02,Halteelement mit drehbarem Teil und Defibrillator mit solchem Halteelement,,KONINKL PHILIPS ELECTRONICS NV,ANDREWS JONATHAN N;;DIXON WILLIAM A,,https://lens.org/130-693-878-139-595,Granted Patent,no,0,0,8,8,0,A61N1/3904;;A61N1/3904;;B25H3/006;;B25H3/006,A61N1/39;;B25H3/00,,0,0,,,,EXPIRED
436,US,A,US 653928 A,144-338-784-585-297,1900-07-17,1900,US 1899/0716061 A,1899-05-08,US 1899/0716061 A,1899-05-08,TOBACCO-CUTTING MACHINE.,,DIXON GEORGE A;;HOWARD JOHN W,DIXON GEORGE A;;HOWARD JOHN W,,https://lens.org/144-338-784-585-297,Granted Patent,no,0,4,1,1,0,B26F1/36;;B26F1/36;;Y10T83/8785;;Y10T83/8785,,,0,0,,,,EXPIRED
437,CA,A,CA 805639 A,137-194-820-109-738,1969-02-04,1969,CA 805639D A,,CA 805639T A,,PROCESS FOR THE TREATMENT OF MALT,,DIXON MALT COMPANY LTD;;ENZYMIC MALT COMPANY LTD,COMRIE ALAN A D;;DIXON BERNARD,,https://lens.org/137-194-820-109-738,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
438,US,A1,US 2007/0180625 A1,155-455-716-743-494,2007-08-09,2007,US 67118807 A,2007-02-05,US 67118807 A;;US 76556206 P,2006-02-06,MATTRESS WITH PATIENT TRANSPORT APPARATUS INCORPORATED THEREIN,"A mattress having a storage compartment is provided. The storage compartment is used to hold items that are useful in the transport of a patient located on the mattress, such as a patient restraint that can be used to secure the patient to the mattress during transport.",WALKE JAMES L;;DIXON STEVEN A,WALKE JAMES L;;DIXON STEVEN A,HILL-ROM SERVICES INC (2007-03-16),https://lens.org/155-455-716-743-494,Patent Application,yes,13,24,3,3,0,A61G1/00;;A61G1/044;;A61G1/048;;A61G7/015;;A61G7/0504;;A61G7/05769;;A61G7/0504;;A61G7/015;;A61G1/048;;A61G1/00;;A61G1/044;;A61G7/05769,A61G1/013;;A61G1/00,5/706;;5/626;;5/627,0,0,,,,INACTIVE
439,CA,A1,CA 2097666 A1,156-122-311-393-001,1994-04-27,1994,CA 2097666 A,1993-06-03,US 96669792 A,1992-10-26,SLAT FOR A WINDOW BLIND,"SLAT FOR A WINDOW BLIND A slat for a vertical blind is disclosed. The slat comprises a backing, an end piece, and a decorative insert. The side flange is disposed along each side edge of the backing, and extends inwardly over a front side of the backing. An end flange is similarly integrally connected to the end piece and extends inwardly over an end edge of the backing. An opaque strip is disposed along each side flange, and an opaque strip is disposed along the end flange. A decorative insert is held against the backing by the flanges.",RYDEN LEE N;;DIXON JOHN A,RYDEN LEE N;;DIXON JOHN A,,https://lens.org/156-122-311-393-001,Patent Application,no,0,0,2,2,0,E06B9/386;;Y10S160/90;;E06B9/386;;Y10S160/90,E06B9/386,,0,0,,,,DISCONTINUED
440,WO,A2,WO 2006/010096 A2,167-097-421-085-752,2006-01-26,2006,US 2005/0024470 W,2005-07-11,US 58702004 P,2004-07-09,GENETIC MANIPULATION OF CONDENSED TANNINS,The invention provides method and compositions for the modulation of condensed tannin production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of condensed tannins in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased condensed tannin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content. The invention may also be used to modify plant pigmentation.,SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;SHARMA SHASHI B,DIXON RICHARD A;;SHARMA SHASHI B,,https://lens.org/167-097-421-085-752,Patent Application,yes,0,11,9,9,79,C12N9/0004;;C12N9/0004;;C07K14/415;;C07K14/415;;C12N9/0093;;C12N9/0093;;C12N15/8223;;C12N15/8223;;C12N15/8234;;C12N15/8234;;C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,C12N15/82;;A01H5/00;;C12N15/29;;C12N15/52,,0,0,,,,PENDING
441,CN,A,CN 104661605 A,194-167-727-363-823,2015-05-27,2015,CN 201380035994 A,2013-06-20,US 2013/0046851 W;;US 201213541956 A,2012-07-05,Colpotomy cup-like structure and intrauterine manipulator including same,"A cup-like structure for engaging a cervix of a patient includes a rim, and includes a base defining an aperture through which one or more tubular members of a uterine manipulator may extend into the uterus. The cup-like structure is made from one or more of a polyphthalamide (PPA) material and a polyetheretherketone (PEEK) material. A uterine manipulator including a cup-like structure is also disclosed.",CLINICAL INNOVATIONS LLC,HORTON JEREMY C;;DIXON RICHARD A,,https://lens.org/194-167-727-363-823,Patent Application,no,7,0,10,10,0,A61B17/4241;;A61L29/06;;A61L29/126;;A61B18/1402;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L29/06;;A61L31/06;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L31/06;;A61L29/06,A61B17/42;;A61B1/303;;A61B17/3209;;A61L29/04;;A61M29/02,,0,0,,,,DISCONTINUED
442,AU,A,AU 1989/031164 A,017-275-992-816-256,1989-09-14,1989,AU 1989/031164 A,1989-03-09,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS,,SANDOZ LTD,DIXON ARNOLD KEITH;;GRAY JULIAN A,,https://lens.org/017-275-992-816-256,Patent Application,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
443,US,B2,US 6695845 B2,019-961-230-219-132,2004-02-24,2004,US 97766301 A,2001-10-15,US 97766301 A;;US 24069700 P,2000-10-16,Method and apparatus utilizing interference fit screw shanks for nonmetallic spinal stabilization,"
    A device and a method for stabilizing cervical vertebrae in a human spine for the purpose of fixing one vertebra with respect to other vertebrae and with respect to other parts of the spinal column. This device comprises a plate and bone screws fabricated from non-metals. The bone screws maintain the plate in contact with the vertebrae. An interference fit screw head is pulled into a hole in the plate and into a machined hole in the vertebral bone, locking the screw to the plate and locking the screw to the bone. This locking reduces the screw bending within the plate and within the bone. The screw thread runout is threaded below the screw/bone interference fit area, protecting the runout stress raisers from bending and shear stresses. The interference fit is configured to create sufficient friction to eliminate the screw from backing out. 
",DIXON ROBERT A;;HACKMAN DONALD J,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/019-961-230-219-132,Granted Patent,yes,29,112,2,10,0,A61B17/1728;;A61B17/7059;;A61B17/8052;;A61B17/8057;;A61B17/1757;;Y10S606/907;;Y10S606/908;;Y10S606/91;;A61B17/8052;;A61B17/7059;;A61B17/8057;;A61B17/1728;;Y10S606/91;;Y10S606/908;;A61B17/1757;;Y10S606/907,A61B17/17;;A61B17/70;;A61B17/80,606/70;;606/61,1,0,,,"Macro Pore Resorbable Technology Insructional Guide, 2000, MacroPore Inc., San Diego California, (brochure).",EXPIRED
444,DE,D1,DE 69324537 D1,047-264-612-432-133,1999-05-27,1999,DE 69324537 T,1993-07-27,US 93875392 A,1992-09-01,Metallguss unter Verwendung einer mit Speisern versehenen Form,,GEN MOTORS CORP,CHANDLEY GEORGE DIXON;;REDEMSKE JOHN A,,https://lens.org/047-264-612-432-133,Granted Patent,no,0,0,9,9,0,B22C9/08;;B22D18/06;;B22D18/06;;B22C9/08,B22C9/04;;B22C9/08;;B22D18/06,,0,0,,,,EXPIRED
445,WO,A1,WO 2015/164506 A1,045-758-283-750-321,2015-10-29,2015,US 2015/0027099 W,2015-04-22,US 201461983325 P;;US 2015/0027099 W,2014-04-23,METHODS OF ENHANCING STEM CELL ENGRAFTMENT,"An effective amount of a composition comprising a stem cell, a stem cell engraftment enhancer, and a carrier fluid, for use in the treatment of an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease. A composition comprising PGI2-overexpressing human mesenchymal stem cells (PGI2-hMSCs), and a carrier fluid; wherein an effective amount of the composition is administered via a single treatment stream as an intramuscular injection to an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease, and wherein stem cell engraftment is enhanced in said individual by greater than about 200%, when compared to stem cell engraftment in an individual treated with a composition lacking the stem cell engraftment enhancer.",TEXAS HEART INST;;LIU QI;;DIXON RICHARD A F,LIU QI;;DIXON RICHARD A F,,https://lens.org/045-758-283-750-321,Patent Application,yes,2,3,6,6,2,A61K35/12;;A61K35/34;;A61K35/36;;A61K45/06;;A61K35/28;;A61K31/5578;;A61P9/00;;A61K35/28;;A61K31/5578;;A61K35/34;;A61K45/06;;A61K35/36;;A61K35/12,A61K35/28;;A61K35/12;;A61K35/36;;A61P9/00,,4,3,013-140-748-070-532;;019-568-385-522-522;;029-192-771-843-359,pmc3292628;;21938725;;10.1002/jcp.23035;;10.1016/j.atherosclerosis.2009.02.023;;19344900;;pmc3392764;;22575029;;10.1186/scrt108,"LIU, Q ET AL.: ""Engineered endothelial progenitor cells that overexpress prostacyclin protect vascular cells"", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 227, no. 7, 2012, pages 2907 - 2916, XP055233532;;ISHII, M. ET AL.: ""Mesenchymal stem cell -based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia"", ATHEROSCLEROSIS, vol. 206, no. 1, 2009, pages 109 - 118, XP026519542, DOI: doi:10.1016/j.atherosclerosis.2009.02.023;;BERNSTEIN, H. S. ET AL.: ""Strategies for enrichment and selection of stem cell -derived tissue precursors"", STEM CELL RESEARCH & THERAPY, vol. 3, 2012, pages 1 - 14, XP055233534;;See also references of EP 3134096A4",PENDING
446,WO,A1,WO 2014/007999 A1,049-262-625-101-126,2014-01-09,2014,US 2013/0046851 W,2013-06-20,US 201213541956 A,2012-07-05,COLPOTOMY CUP-LIKE STRUCTURE AND INTRAUTERINE MANIPULATOR INCLUDING SAME,"A cup-like structure for engaging a cervix of a patient includes a rim, and includes a base defining an aperture through which one or more tubular members of a uterine manipulator may extend into the uterus. The cup-like structure is made from one or more of a polyphthalamide (PPA) material and a polyetheretherketone (PEEK) material. A uterine manipulator including a cup-like structure is also disclosed.",CLINICAL INNOVATIONS LLC;;HORTON JEREMY C;;DIXON RICHARD A,HORTON JEREMY C;;DIXON RICHARD A,,https://lens.org/049-262-625-101-126,Patent Application,no,3,0,10,10,0,A61B17/4241;;A61L29/06;;A61L29/126;;A61B18/1402;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L29/06;;A61L31/06;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L31/06;;A61L29/06,A61B1/303;;A61B17/42;;A61B17/3209;;A61L29/04;;A61M29/02,,2,1,103-282-158-935-029,10.1177/0892705706059738,"PINI, N. ET AL.: ""Perspectives for reactive molding of PPA as matrix for high-performance composite materials"", JOURNAL OF THERMOPLASTIC COMPOSITE MATERIALS, vol. 19, no. 2, 2006, pages 207 - 216, XP009124455;;HARPER, C. A., HANDBOOK OF PLASTICS, ELASTOMERS, & COMPOSITES 063-9785336068, vol. 4, 2002, pages 51, 52, XP008175685",PENDING
447,GR,B,GR 77879 B,092-216-190-503-178,1984-09-25,1984,GR 830170234 A,1983-01-11,US 34095282 A,1982-01-20,GR 77879 B,,SORENSON RESEARCH CO,WONDER TERRY M;;DIXON JOHN A,,https://lens.org/092-216-190-503-178,Granted Patent,no,0,0,8,8,0,A61M25/0084;;A61B17/3478;;A61B2017/320084;;A61M2025/0089,A61M5/14;;A61B17/32;;A61B17/34;;A61M25/00,,0,0,,,,EXPIRED
448,US,A1,US 2002/0045897 A1,088-628-192-883-764,2002-04-18,2002,US 97766301 A,2001-10-15,US 97766301 A;;US 24069700 P,2000-10-16,Method and apparatus utilizing interference fit screw shanks for nonmetallic spinal stabilization,"
   A device and a method for stabilizing cervical vertebrae in a human spine for the purpose of fixing one vertebra with respect to other vertebrae and with respect to other parts of the spinal column. This device comprises a plate and bone screws fabricated from nonmetals. The bone screws maintain the plate in contact with the vertebrae. An interference fit screw head is pulled into a hole in the plate and into a machined hole in the vertebral bone, locking the screw to the plate and locking the screw to the bone. This locking reduces the screw bending within the plate and within the bone. The screw thread runout is threaded below the screw/bone interference fit area, protecting the runout stress raisers from bending and shear stresses. The interference fit is configured to create sufficient friction to eliminate the screw from backing out. 
",DIXON ROBERT A.;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/088-628-192-883-764,Patent Application,yes,0,88,2,10,0,A61B17/1728;;A61B17/7059;;A61B17/8052;;A61B17/8057;;A61B17/1757;;Y10S606/907;;Y10S606/908;;Y10S606/91;;A61B17/8052;;A61B17/7059;;A61B17/8057;;A61B17/1728;;Y10S606/91;;Y10S606/908;;A61B17/1757;;Y10S606/907,A61B17/17;;A61B17/70;;A61B17/80,606/61;;606/69,0,0,,,,EXPIRED
449,US,S,US D0497993 S,121-235-645-785-575,2004-11-02,2004,US 18680403 F,2003-07-22,US 18680403 F,2003-07-22,Bioabsorbable structural interbody vertebral implant,,DIXON ROBERT A.;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/121-235-645-785-575,Design Right,no,0,16,1,1,0,,,D24/155,0,0,,,,EXPIRED
450,US,A1,US 2017/0049822 A1,112-061-450-134-269,2017-02-23,2017,US 201515305717 A,2015-04-22,US 201515305717 A;;US 201461983325 P;;US 2015/0027099 W,2014-04-23,METHODS OF ENHANCING STEM CELL ENGRAFTMENT,"An effective amount of a composition comprising a stem cell, a stem cell engraftment enhancer, and a carrier fluid, for use in the treatment of an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease. A composition comprising PGI2-overexpressing human mesenchymal stem cells (PGI2-hMSCs), and a carrier fluid; wherein an effective amount of the composition is administered via a single treatment stream as an intramuscular injection to an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease, and wherein stem cell engraftment is enhanced in said individual by greater than about 200%, when compared to stem cell engraftment in an individual treated with a composition lacking the stem cell engraftment enhancer.",TEXAS HEART INST,LIU QI;;DIXON RICHARD A F,TEXAS HEART INSTITUTE (2016-12-02),https://lens.org/112-061-450-134-269,Patent Application,yes,0,0,6,6,2,A61K35/12;;A61K35/34;;A61K35/36;;A61K45/06;;A61K35/28;;A61K31/5578;;A61P9/00;;A61K35/28;;A61K31/5578;;A61K35/34;;A61K45/06;;A61K35/36;;A61K35/12,A61K35/28;;A61K31/5578,,0,0,,,,DISCONTINUED
451,CA,A,CA 202565 A,130-115-447-986-886,1920-08-03,1920,CA 202565D A,,CA 202565T A,,PLIERS,,LYNCH DIXON F;;LYNCH MARSHALL A,LYNCH DIXON F;;LYNCH MARSHALL A,,https://lens.org/130-115-447-986-886,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
452,US,A,US 4272364 A,140-261-346-172-427,1981-06-09,1981,US 13305080 A,1980-03-24,US 13305080 A,1980-03-24,Frother for coal flotation,"Use of 4,4-dimethyl-1-pentanol as a froth flotation agent for coal recovery processes.",CALGON CORP,DIXON KENNETH W;;HOFFSTADT FREDERICK A,CALGON CORPORATION (1994-06-20);;BETZ LABORATORIES INC. A CORP. OF PA (1987-08-01);;STOCKHAUSEN INC. A CORP. OF NC (1991-11-06),https://lens.org/140-261-346-172-427,Granted Patent,yes,8,6,1,1,0,B03B9/005;;B03B9/005;;B03D1/008;;B03D1/008;;B03D1/02;;B03D1/02;;B03D2201/04;;B03D2201/04;;B03D2203/08;;B03D2203/08,B03B9/00;;B03D1/008;;B03D1/02,209/166,1,0,,,"Chem. Abst. 68, 1968, 4716g.",EXPIRED
453,US,A,US 5269361 A,128-569-596-966-71X,1993-12-14,1993,US 96669792 A,1992-10-26,US 96669792 A,1992-10-26,Slat for a window blind,"A slat for a vertical blind is disclosed. The slat comprises a backing, an end piece, and a decorative insert. The side flange is disposed along each side edge of the backing, and extends inwardly over a front side of the backing. An end flange is similarly integrally connected to the end piece and extends inwardly over an end edge of the backing. An opaque strip is disposed along each side flange, and an opaque strip is disposed along the end flange. A decorative insert is held against the backing by the flanges.",DIXON JOHN;;RYDEN LEE,RYDEN LEE N;;DIXON JOHN A,RYDEN LEE (1992-11-10);;DIXON JOHN (1992-11-10),https://lens.org/128-569-596-966-71X,Granted Patent,yes,8,20,2,2,0,E06B9/386;;Y10S160/90;;E06B9/386;;Y10S160/90,E06B9/386,160/236;;160/900,0,0,,,,EXPIRED
454,US,A1,US 2015/0098820 A1,175-217-270-697-105,2015-04-09,2015,US 201414561309 A,2014-12-05,US 201414561309 A;;US 201414164879 A;;US 2013/0064060 W,2013-10-09,METHOD AND APPARATUS FOR REDUCTION OF FATIGUE AND GUST LOADS ON WIND TURBINE BLADES,"An adjustable lift regulating device ( 30, 32, 40, 50, 52, 56, 60, 68, 72, 76 ) on an inboard portion of a wind turbine blade ( 28 ). The lift regulating device is activated to reduce lift on the inboard portion of the blade by causing flow separation ( 41 ) on the suction side ( 22 ) of the blade. To compensate for the lost lift, the blade pitch is increased to a running pitch that facilitates stalling on the outer portion of the blade in gusts. This provides passive reduction of fatigue and extreme loads from gusts while allowing full power production under non-gust conditions.",SIEMENS AKTIENGESELLCHAFT,DIXON KRISTIAN R;;MAYDA EDWARD A,SIEMENS AKTIENGESELLSCHAFT (2014-12-19);;SIEMENS GAMESA RENEWABLE ENERGY A/S (2018-10-25);;SIEMENS WIND POWER A/S (2014-12-17);;SIEMENS ENERGY INC (2014-12-16),https://lens.org/175-217-270-697-105,Patent Application,yes,6,18,2,7,0,F03D7/0224;;F03D7/0224;;F03D1/0633;;F03D1/0633;;F03D1/0675;;F03D7/0232;;F03D7/0232;;F05B2240/3052;;F05B2240/3062;;F05B2240/31;;F05B2240/31;;Y02E10/72;;Y02E10/72,F03D7/02,416/1;;416/23,0,0,,,,ACTIVE
455,WO,A2,WO 2007/027240 A2,174-845-479-804-03X,2007-03-08,2007,US 2006/0017111 W,2006-05-03,US 12232705 A,2005-05-04,RADIATION ATTENUATION SYSTEM,"A radiation attenuation system for shielding from scatter radiation one or more portions of a patient that are not of primary interest to a particular radiological procedure (i.e., non-target areas, etc.). The radiation attenuation system may be configured to shield the head of a patient (such as the head of a pediatric patient), and/or any other portion of the patient that may benefit from being shielded from scatter radiation. The radiation attenuation system is preferably configured to conform to the contours of the patient. The radiation attenuation system may be a flexible member that can be reconfigured to accommodate patients of varying size.",WORLDWIDE INNOVATIONS & TECHNO;;CADWALADER JOHN A;;DIXON DAVID G,CADWALADER JOHN A;;DIXON DAVID G,,https://lens.org/174-845-479-804-03X,Patent Application,yes,0,0,4,4,0,A61B6/107;;G21F3/02;;G21K1/10;;A61B6/4423;;G21K1/10;;G21F3/02;;A61B6/107,H01J35/16,,0,0,,,,PENDING
456,EP,A2,EP 0740944 A2,168-873-541-616-39X,1996-11-06,1996,EP 96302194 A,1996-03-28,US 43299895 A,1995-05-02,Pivot assisted retainer assembly and defibrillator comprising same,"A retainer assembly for a defibrillator paddle has a resilient back plate. The back plate secures to a back wall in a pocket by a fastener positioned to allow pivotal movement of the back plate. The back plate has a bracket at its inner edge, retaining an edge of the base of the paddle. A lip extends forward from an outer edge of the back plate to overlie an outer edge of the paddle. The lip is within a tab section that deflects into a recess if a user exerts a sufficient outward pull on the handle.",HEWLETT PACKARD CO,ANDREWS JONATHAN N;;DIXON WILLIAM A,"HEWLETT-PACKARD COMPANY, A DELAWARE CORPORATION (2001-03-28);;AGILENT TECHNOLOGIES INC. A DELAWARE CORPORATION (2001-08-08);;KONINKLIJKE PHILIPS N.V., NL (2014-11-26);;AGILENT TECHNOLOGIES, INC. (A DELAWARE CORPORATION (2001-10-10);;AGILENT TECHNOLOGIES INC. (2001-08-01);;KONINKLIJKE PHILIPS ELECTRONICS N.V. (2003-08-06)",https://lens.org/168-873-541-616-39X,Patent Application,yes,0,0,8,8,0,A61N1/3904;;A61N1/3904;;B25H3/006;;B25H3/006,A61N1/39;;B25H3/00,,0,0,,,,EXPIRED
457,DK,D0,DK 118189 D0,177-225-367-738-797,1989-03-10,1989,DK 118189 A,1989-03-10,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,ANVENDELSE AF PIPERAZINDERIVAT,,SANDOZ AG,DIXON ARNOLD KEITH;;GRAY JULIAN A,,https://lens.org/177-225-367-738-797,Patent Application,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,DISCONTINUED
458,US,A1,US 2002/0107519 A1,182-210-769-210-871,2002-08-08,2002,US 6770002 A,2002-02-05,US 6770002 A;;US 26646201 P,2001-02-05,Dual spreader flange-tube vertebral stabilizer,"
   This invention comprises a device and a method of maintaining spinal exposure, distraction, alignment and temporary fixation. Additionally provided for, is tooling guidance for the preparation of an intervertebral space for an implant. The device provides a means for attaching a tube or other attachment to guide tools that will prepare the vertebrae for accepting an implant. At any time during the procedure the attachment may be removed to inspect or remove debris from the disc space and the vertebral end plates without disturbing the distraction and temporary fixation. 
",DIXON ROBERT A.;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,,https://lens.org/182-210-769-210-871,Patent Application,yes,4,191,1,1,0,A61B17/1757;;A61B17/1757,A61B17/17,606/61,0,0,,,,DISCONTINUED
459,AU,B2,AU 780464 B2,022-669-517-295-01X,2005-03-24,2005,AU 2000/050187 A,2000-05-15,US 13502699 P;;US 0013389 W,1999-05-20,Isoflavonoid methylation enzyme,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;HE XIAN Z,,https://lens.org/022-669-517-295-01X,Granted Patent,no,0,0,7,10,0,A61P5/30;;A61P7/00;;A61P31/04;;A61P35/00;;A61P39/06;;C12N15/8282;;C12N9/1007;;C12N15/8243;;C12N15/825,A01H5/00;;A23L1/30;;A61K31/352;;A61K36/48;;A61P5/30;;A61P7/00;;A61P31/04;;A61P35/00;;A61P39/06;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/29;;C12N15/82;;C12P17/06,,0,0,,,,EXPIRED
460,US,A1,US 2006/0089090 A1,008-337-529-284-280,2006-04-27,2006,US 97021404 A,2004-10-21,US 97021404 A,2004-10-21,High pressure cleaning and decontamination system,"Abrasive cleaning and decontamination methods and systems are disclosed. The methods and systems use a high pressure liquefied gas, such as carbon dioxide, which produces insignificant quantities of secondary waste. These principles of the invention exploit the properties of the relatively high triple point of CO 2 in order to first pressurize it to 35,000 to 60,000 PSI from a pressurized liquid. In the pressurized state, such a fluid can be at or above room temperature, allowing for transport over long distances in a flexible high pressure hose. At a point of use, a heat exchanger may subsequently chill the liquid, so that after expansion through a small high pressure orifice, a significant fraction of the liquid is converted to solid phase crystals exiting at high velocity to effectively clean and decontaminate. For more aggressive cleaning, abrasive particles and/or small diameter solid CO 2 pellets can be entrained into the high pressure CO 2 slipstream.",ROBOTICS SA,JOHNSON SAMUEL A;;DIXON JOSEPH E,KURION INC (2014-02-05);;S.A. ROBOTICS (2004-10-19);;SPECIAL APPLICATIONS TECHNOLOGY INC (2010-02-26);;SPECIAL APPLICATION ROBOTICS INC (2008-05-07),https://lens.org/008-337-529-284-280,Patent Application,yes,7,9,2,2,0,B24C1/003;;B24C3/06;;B24C1/003;;B24C3/06,B24B1/00;;B24C1/00;;B24C3/00,451/40;;451/75,0,0,,,,INACTIVE
461,CA,A,CA 823109 A,014-871-369-656-766,1969-09-16,1969,CA 823109D A,,CA 823109T A,,PREPARATION OF AMMONIUM PHOSPHATES,,ELECTRIC REDUCTION CO,DIXON JOHN T;;SMITH RAYMOND A,,https://lens.org/014-871-369-656-766,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
462,CA,A,CA 6152 A,061-905-502-910-549,1876-05-23,1876,CA 6152D A,,CA 6152T A,,PROCESS FOR TREATING COPPER PYRITES AND OTHER ORES OF COPPER,,COBLEY THOMAS H;;DIXON JOSEPH A,COBLEY THOMAS H;;DIXON JOSEPH A,,https://lens.org/061-905-502-910-549,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
463,US,A,US 4792330 A,114-514-768-901-503,1988-12-20,1988,US 7279687 A,1987-07-13,US 7279687 A,1987-07-13,Combination catheter and duct clamp apparatus and method,"A combination catheter and duct clamp apparatus and method. The apparatus includes a hollow member with a substantially planar clamping surface at one end and a sliding member with a substantially planar clamping surface at one end which is telescopically slidable within the hollow member. A spring maintains an essentially constant clamping pressure between the clamping surfaces. The clamp is ideally suited for use during cholangiography where it may be used for inserting a catheter within the cystic duct and for thereafter clamping the cystic duct around the catheter. The clamping pressure provides an adequate seal of the cystic duct and does not occlude the inserted catheter. Multiple clamping angles give the clamp unique versatility during the surgical procedure. Being constructed out of a radiolucent material, the clamp may be left in place while a cholangiogram is taken without interfering with the completed cholangiogram.",LAZARUS MEDICAL INNOVATIONS IN,LAZARUS HARRISON M;;FORD DIXON A,LAZARUS MEDICAL INNOVATIONS INC. A CORP. OF UTAH (1987-07-01),https://lens.org/114-514-768-901-503,Granted Patent,yes,22,94,6,6,0,A61B17/12;;A61B2017/00902;;Y10S128/26;;A61B17/12;;A61B2017/00902;;Y10S128/26,A61B17/12;;A61B17/00;;A61B19/00;;A61M25/00;;A61M25/02,604/174;;128/346;;X128DIG 26,8,6,127-363-507-063-915;;104-933-223-565-179;;010-177-166-451-650;;017-764-605-851-957;;038-885-635-324-480;;026-560-583-806-881,103451;;10.1016/0002-9610(79)90006-0;;454163;;10.1001/archsurg.1979.01370300103023;;7425836;;10.1001/archsurg.1980.01380100060014;;2421422;;6740471;;453480;;10.1016/0002-9610(79)90106-5,"Padula et al., A New Clamp for Rapid Vascular Anastomosis, Surgery, vol. 57, 6, 6/1975, pp. 819 822.;;Skillings, John C. et al., Cost Effectiveness of Operative Cholangiography, The American Journal of Surgery, pp. 26 31 (vol. 137, 1979).;;Taufic, Mansur, A Safe and Secure Technique of Cystic Duct Catherterization, Archives of Surgery, vol. 114, pp. 749 751 (Jun. 1979).;;Pagana, Timothy J., et al., Indications and Accuracy of Operative Cholangiography, Archives of Surgery, vol. 115, pp. 1214 1215 (Oct. 1980).;;Kitahama, Akio, et al., Routine Intraoperative Cholangiogram, Surgery, Gynecology & Obstetrics, vol. 162, pp. 317 322 (1986).;;Intraoperative Cholangiography: Now Obligatory , Surgical Capsule & Comment, p. 11 (Fall 1986).;;Hampson, L.G., et al., A Simple Method for Catheter Fixation of the Cystic Duct Cholangiography, Surgery, Gynecology & Obstetrics, vol. 159, p. 83, 1984.;;Berci, George, et al., Improved Cannula for Operative (Cystic Duct) Cholangiography, The American Journal of Surgery, vol. 137, pp. 826 828, Jun. 1979.",EXPIRED
464,EP,A1,EP 1161540 A1,130-004-595-756-255,2001-12-12,2001,EP 00916134 A,2000-03-08,US 0005915 W;;US 12326799 P,1999-03-08,GENETIC MANIPULATION OF ISOFLAVONOIDS,,SAMUEL ROBERTS NOBLE FOUND INC,STEELE CHRISTOPHER L;;DIXON RICHARD A,,https://lens.org/130-004-595-756-255,Patent Application,yes,1,0,7,8,0,C12N9/0077;;C07K2319/00;;C12N15/8242;;C12N15/8243;;C12N15/8261;;C12N15/8279;;Y02A40/146,C12N9/02;;C12N15/53;;C12N15/82,,2,0,,,"DATABASE EMBL [online] 1 April 1999 (1999-04-01), AKASHI ET AL.: ""Glycyrrhiza echinata CYP Ge-8 mRNA for cytochorme P450, complete CDS"", Database accession no. AB023636;;See also references of WO 0053771A1",DISCONTINUED
465,IT,B,IT 1232818 B,128-341-163-766-586,1992-03-05,1992,IT 4773289 A,1989-03-10,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,"IMPIEGO DELL'ACIDO PIPERAZIN CARBOSSILICO E SUOI DERIVATI PER IL TRATTAMENTO DI RIDOTTO SPIRITO DI INIZIATIVA E/O RITROSIA SOCIALE, DISTURBI DI SONNO O EMICRANIA E SIMILI",,SANDOZ AG,DIXON ARNOLD KEITH;;GRAY JULIAN A,,https://lens.org/128-341-163-766-586,Granted Patent,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
466,CA,A,CA 905639 A,158-155-179-303-593,1972-07-25,1972,CA 905639D A,,CA 905639T A,,PHOSPHATE COMPOSITIONS,,ELECTRIC REDUCTION CO,DIXON JOHN T;;SMITH RAYMOND A,,https://lens.org/158-155-179-303-593,Granted Patent,no,0,0,1,1,0,,C01B25/32,,0,0,,,,EXPIRED
467,US,B1,US 6217762 B1,161-999-034-591-342,2001-04-17,2001,US 28005199 A,1999-03-29,US 28005199 A,1999-03-29,Specially adapted oil filter casing,"An internal combustion engine oil filter casing specially adapted for engagement by a standard hand tool and to an oil filter employing such a casing to assist an operator in removing the oil filter from an engine block. The casing comprises a generally tubular body and different structures that are rigidly affixed to the tubular body for engaging the tool to assist the operator in removing the oil filter from the engine block. The tubular body has a first end, a second end, and a sidewall extending between the first and second ends. The first end includes a closed top and the second end includes a threaded aperture. The structures that are rigidly affixed to the tubular body for engaging the tool may be a strap, a plurality of fins, a fin having a hole, or a cylindrical sidewall extending outward from the first end of the tubular body having a groove or opposing holes.",ROONEY JEFFREY G.;;DIXON ROBERT A.,ROONEY JEFFREY G;;DIXON ROBERT A,,https://lens.org/161-999-034-591-342,Granted Patent,yes,21,25,1,1,0,B01D27/08;;B01D2201/24;;Y10S210/17;;B01D27/08;;B01D2201/24;;Y10S210/17,B01D27/08,210/232;;210/443;;X210DIG  17,0,0,,,,EXPIRED
468,WO,A1,WO 1989/000405 A1,010-925-778-981-581,1989-01-26,1989,US 8801956 W,1988-06-09,US 7279687 A,1987-07-13,COMBINATION CATHETER AND DUCT CLAMP APPARATUS AND METHOD,"The apparatus includes a hollow member (12) with a substantially planar clamping surface (14) at one end and a sliding member (32) with a substantially planar clamping surface (16) at one end which is telescopically slidable within the hollow member (12). A spring (34) maintains an essentially constant clamping pressure between the clamping surfaces. The clamp is ideally suited for use during cholangiography where it may be used for inserting a catheter (48) within the cystic duct (54) and for thereafter clamping the cystic duct around the catheter. The clamping pressure provides an adequate seal of the cystic duct and does not occlude the inserted catheter. Multiple clamping angles give the clamp unique versatility during the surgical procedure. Being constructed out of a radiolucent material, the clamp may be left in place while a cholangiogram is taken without interfering with the completed cholangiogram.",LAZARUS MEDICAL INNOVATIONS IN,LAZARUS HARRISON M;;FORD DIXON A,,https://lens.org/010-925-778-981-581,Patent Application,yes,10,0,6,6,0,A61B17/12;;A61B2017/00902;;Y10S128/26;;A61B17/12;;A61B2017/00902;;Y10S128/26,A61B17/12;;A61B17/00;;A61B19/00;;A61M25/00;;A61M25/02,,0,0,,,,PENDING
469,US,B1,US 6878859 B1,029-349-570-445-621,2005-04-12,2005,US 92657101 A,2001-11-28,US 92657101 A;;US 13502699 P;;US 0013389 W,1999-05-20,Isoflavonoid methylation enzyme,"Methods of genetically manipulating biologically active 4′-O-methylated isoflavonoids have been found based upon the regiospecifity of isoflavone 7-OMT in vivo. Upon transformation and expression of an isoflavonoid O-methyltransferase gene, up-regulation of IOMT in the transgenic plants can be used to increase the accumulation of 4′-O-methylated isoflavonoid phytolalexins, providing for increased disease resistance to the plant. Similar methods can be used to increase accumulation of 4′-O-methylated isoflavonoid nutraceuticals in plants. For down-regulation of IOMT in plants that naturally make 4′-O-isoflavonoid phytoalexins and 4′-O-methylated isoflavonoid nutraceuticals, IOMT gene sequences can be transformed in the antisense orientation.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;HE XIAN Z,NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/029-349-570-445-621,Granted Patent,yes,3,4,3,10,5,C12N9/1007;;C12N15/8243;;C12N15/825;;C12N15/8282;;C12N15/8282;;C12N15/825;;C12N15/8243;;C12N9/1007,C12N9/10;;C12N15/29;;C12N15/54;;C12N15/82,800/279;;278/298,59,55,008-120-631-983-38X;;070-914-008-321-23X;;012-544-595-835-438;;028-056-276-490-709;;040-986-663-076-693;;010-214-063-649-840;;037-439-894-311-127;;019-027-340-670-167;;045-870-011-974-882;;048-884-231-380-863;;104-586-507-621-730;;159-599-470-754-246;;048-425-634-797-396;;061-037-398-447-63X;;043-413-805-164-105;;071-551-288-641-153;;047-802-453-136-120;;050-857-911-966-735;;116-984-034-376-470;;005-198-454-419-972;;095-404-749-938-170;;014-560-833-522-836;;102-449-251-149-642;;010-635-987-157-26X;;075-809-971-728-078;;011-670-242-525-259;;042-566-187-298-704;;070-803-686-771-828;;143-147-057-242-468;;097-066-123-319-638;;054-150-480-227-565;;001-906-076-969-393;;089-544-742-570-358;;072-985-352-165-177;;036-072-457-855-80X;;094-195-650-610-197;;035-134-085-004-573;;031-757-758-717-523;;140-864-469-916-361;;158-937-458-595-089;;055-090-138-911-307;;066-337-522-311-649;;077-580-667-120-981;;163-472-490-948-263;;140-466-892-558-422;;030-257-753-926-660;;013-043-410-189-072;;144-745-219-737-532;;049-414-985-018-203;;044-347-068-901-534;;005-025-673-594-96X;;071-677-336-342-646;;092-944-718-518-390;;065-822-480-588-377;;024-855-853-923-988,9812895;;10.1126/science.282.5392.1315;;1659780;;10.1093/ajcn/54.6.1093;;9187225;;10.3109/07853899709113696;;pmc1075288;;16664813;;10.1104/pp.81.1.86;;10.1093/emboj/16.12.3675;;9218808;;pmc1169991;;10.1046/j.1365-313x.1998.00099.x;;9681028;;10.1016/0885-5765(87)90052-x;;10.1016/0168-9452(94)04051-6;;1932694;;10.1007/bf00028736;;pmc1062311;;16667295;;10.1104/pp.92.2.440;;10.1016/s0031-9422(00)84267-3;;10.1016/s0031-9422(00)84266-1;;10.1016/b978-0-08-091283-7.00030-8;;9781295;;10.1007/978-1-4615-5335-9_5;;10.1105/tpc.7.7.1085;;10.2307/3870059;;12242399;;pmc160915;;2239449;;10.1016/s0065-2660(08)60527-1;;2030957;;pmc333874;;10.1093/nar/19.6.1349;;10205892;;10.1046/j.1365-313x.1999.00379.x;;10.1007/bf00041401;;9002616;;10.1006/abbi.1997.0554;;9514654;;10.1094/phyto-74-1312;;10.1016/s0040-4020(01)86489-9;;10.1016/s0031-9422(98)00266-0;;9484461;;10.1023/a:1005938121453;;8951042;;10.1006/abbi.1996.0539;;10.1016/0048-4059(72)90012-4;;17757866;;10.1126/science.227.4691.1229;;10.1016/s0031-9422(00)81789-6;;10.1023/a:1005939803300;;9484457;;10.1515/znc-1983-3-407;;10.1023/a:1006035210889;;9687070;;10.1038/72671;;10657130;;24226375;;10.1007/bf00232132;;10.1099/00221287-130-10-2605;;10.1073/pnas.85.22.8502;;pmc282486;;16593993;;3956488;;10.1111/j.1432-1033.1986.tb09492.x;;1369021;;10.1038/nbt1192-1436;;1673746;;10.1016/0140-6736(91)92867-2;;10692459;;10.1074/jbc.275.9.6537;;10.1094/phyto-75-235;;12228391;;pmc157182;;10.1104/pp.107.3.679;;10.1016/0048-4059(82)90008-x;;10.1111/j.1399-3054.1962.tb08052.x;;10.1007/bf00033879;;10.1139/b73-310;;10.1105/tpc.2.10.987;;2136629;;pmc159947;;10.2307/3869238;;7910406;;pmc43777;;10.1073/pnas.91.10.4323;;62660;;10.1016/0160-9327(76)90004-1;;10.1006/abbi.1999.1238;;10375412;;10.1002/(sici)1096-9888(199605)31:5<472::aid-jms318>3.0.co;2-e;;8799289;;10.1016/0168-9452(90)90117-7;;10.1105/tpc.6.9.1191;;10.2307/3869817;;pmc160512;;12244269;;10.1016/s0031-9422(00)85668-x;;8242641;;9823337,"He, X.Z. and Dixon, R.A.; GenBank accession No. AF023481 see also Plant Physiology, 1997, vol. 115, p. 1289.*;;Broun P. et al. Science vol. 282; Nov. 13, 1998, pp. 1315-1317.*;;Adlercreutz, et al. 1991. ""Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet,"" Am J Clin Nutr 54: 1093-1100.;;Adlercreutz, H. and W. Mazur. 1997. ""Phyto-estrogens and western diseases,"" Ann Med 29: 95-120.;;An, G. 1986. ""Development of plant promoter expression vectors and their use for analysis of differential activity of nopaline synthase promoter is transformed tobacco cells,"" Plant Physiol 81: 86-91.;;Angell, S.M. and D.C. Baulcombe. 1997. ""Consistent gene silencing in transgenic plants expressing a replicating potato virus X RNA,"" EMBO J 16: 3675-3684.;;Barnes, et al. 1990. ""Soybeans inhibit mammary tumors in models of breast cancer."" In M.W. Puriza, eds, Mutagenes and Carcinogens in the Diet, Wiley-Liss, Inc, New York, pp 239-253.;;Batard, et al. 1998. ""Molecular cloning and functional expression in yeast of CYP76B1, a xenobiotic-inducible 7-ethoxycoumarin O-de-ethylase from Helianthus tuberosus,"" Plant J 14: 111-120.;;Bhattacharyya, M.K. and E.W. Ward. 1987. ""Biosynthesis and metabolism of glyceollin I in soybean hypocotyls following wounding or inoculation with Phytophthora megasperma f. sp. Glycinea,"" Physiol Mol Plant Pathol 31:387-405.;;Bourque, J. E. 1995. ""Antisense strategies for genetic manipulations in plants,"" Plant Sci 105: 125-149.;;Bugos, et al. 1991. ""cDNA cloning, sequence analysis and seasonal expression of lignin-bispecific caffeic acid/5-hydroxyferulic acid O-methyltransferase of aspen,"" Plant Mol Biol 17: 1203-1215.;;Dalkin, et al. 1990. ""Stress responses in alfalfa (Medicago sativa L.) I. Elicitor-induction of phenylpropanoid biosynthesis and hydrolytic enzymes in cell suspension cultures,"" Plant Physiol 92: 440-446.;;Dewick, P.M. and M. Martin. 1979. ""Biosynthesis of pterocarpan, isoflavan and coumestan metabolites of Medicago sativa : chalcone, isoflavone and isoflavanone precursors,"" Phytochemistry 18: 597-602.;;Dewick, P.M. and Martin, M. 1979. ""Biosynthesis of pterocarpan and isoflavan phytoalexins in Medicago sativa: the biochemical interconversion of pterocarpans and 2'-hydroxyisoflavans,"" Phytochemistry 18: 591-596.;;Dixon, et al. 1999. ""Molecular controls for isoflavonoid biosynthesis in relation to plant and human health,"" Recent Advances in Phytochemistry 33: 133-160.;;Dixon, R.A. 1999. ""Isoflavonoids: biochemistry, molecular biology and biological functions."" In U. Sankawa, eds, Comprehensive Natural Products Chemistry, Elsevier, pp 773-823.;;Dixon, et al. 1998. ""Prospects for the metabolic engineering of bioactive flavonoids and related phenylpropanoid compounds,"" Adv Exp Med and Biolog 439:55-66.;;Dixon, R.A. and N.L. Paiva. 1995. ""Stress-induced phenylpropanoid metabolism,"" Plant Cell 7: 1085-1097.;;Dixon, R.A., and M.J. Harrison. 1990. ""Activation, structure and organization of genes involved in microbial defense in plants,"" Adv Genet 28: 165-234.;;Edwards, et al. 1991. ""A simple and rapid method for the preparation of plant genomic DNA for PCR analysis,"" Nucleic Acids Res 19: 1349.;;Frick, S., Kutchan, T.M. 1999. ""Molecular cloning and functional expression of O-methyltransferases common to isoquinoline alkaloid and phenylpropanoid biosynthesis,"" Plant J 17: 329-339.;;Gauthier, et al. 1996. ""cDNA cloning and characterization of a 3'/5'-O-methyltransferase for partially methylated flavonols from Chrysosplenium americanum,"" Plant Mol Biol 32: 1163-1169.;;Gauthier, et al. 1998. ""Characterization of two cDNA clones which encode O-methyltransferases for the methylation of both flavonoid and phenylpropanoid compounds,"" Arch Biochem Biophys 351: 243-249.;;Hadwiger, L.A. and D.M. Webster. 1984. ""Phytoalexin production in five cultivars of pea differentially resistance to three races of Pseudomonas syringae pv. Pisi,"" Phytopathology 74: 1312-1314.;;Hakamatsuka, et al. 1991. ""P-450-dependent oxidative rearrangement in isoflavone biosynthesis: reconstitution of P-450 and NADPH:P450 reductase"", Tetrahedron 47: 5969-5978.;;Hakamatsuka, et al. 1998. ""Purification of 2-hydroxyisoflavanone dehydratase from the cell cultures of Pueraria lobata,"" Phytochemistry 49: 497-505.;;He, et al. 1998. ""Stress responses in alfalfa (Medicago sativa L.) XXII. cDNA cloning and characterization of an elicitor-inducible isoflavone 7-O-methyltransferase,"" Plant Mol Biol 36: 43-54.;;He, X-Z and R.A. Dixon. 1996. ""Affinity chromatography, substrate/product specificity and amino acid sequence analysis of an isoflavone O-methyltransferase from alfalfa (Medicago sativa L.),"" Arch Biochem Biophys 336: 121-129.;;Higgins, V.J. 1972. ""Role of the phytoalexin medicarpin in three leaf spot diseases of alfalfa,"" Physiol Plant Pathol 2: 289-300.;;Horsch, B. et al. 1985. ""A simple and general method for transferring genes into plants,"" Science 227: 1229-1231.;;Ibrahim, et al. 1987. ""Enzymology and compartmentation of polymethylated flavonol glucosides in Chrysasplenium americamum,"" Phytochemistry 26: 1237-1245.;;Ibrahim, et al. 1998: ""Plant O-methyltransferases: molecular analysis, common signature and classification,"" Plant Mol Biol 36: 1-10.;;Ingham, et al. 1983. ""Fungitoxic isoflavones from Lupinus albus and other Lupinus species,"" Zeitschrift fur Naturforschung, C38: 194-200.;;Joshi, C.P. and V.L. Chiang. 1998. ""Conserved sequence motifs in plant S-adenosyl-L-methionine-dependent methyltransferases,"" Plant Mol Biol 37: 663-674.;;Jung, et al. 2000. ""Identification and expression of isoflavone synthase: the key enzyme for biosynthesis of isoflavones in legumes,"" Nature Biotechnology 18:208-212.;;Kessmann, et al. 1990. ""Stress responses in alfalfa (Medicago sativa L.) III. Induction of medicarpin and cytochrome P450 enzyme activities in elicitor-treated cell suspension cultures and protoplasts,"" Plant Cell Rep 9: 38-41.;;Kistler, H.C. and H.D. VanEtten. 1984. ""Regulation of pisatin demethylation in Nectria haematococca and its influence on pisatin tolerance and virulence,"" J Gen Micro 130: 2605-2613.;;Klein, et al. 1988. ""Stable genetic transformation of intact Nicotiana cells by the particle bombardment process,"" Proc Natl Acad Sci USA 85: 8502-8505.;;Kochs, G. and H. Grisebach. 1986. ""Enzymatic synthesis of isoflavones,"" Eur J Biochem 155: 311-318.;;Lamb, et al. 1992. ""Emerging strategies for enhancing crop resistance to microbial pathogens,"" Bio/technology 10: 1436-1445.;;Lee, et al. 1991. ""Dietary effects on breast-cancer risk in Singapore,"" Lancet 337: 1197-1200.;;Li, et al. 2000. ""5-Hydroxyconiferyl aldehyde modulates enzymatic methylation for syringyl monolignol formation, a new view of monolignol biosynthesis in angiosperms,"" J Biol Chem 275: 6537-6545.;;Long, et al. 1985. ""Further studies on the relationship between glycollin accumulation and the resistance of soybean leaves to Pseudomonas syringae pv. Glycinea,"" Phytopathology 75: 235-239.;;Matzke, M.A. and A.J. M. Matzke. 1995. ""How and why do plants inactivate homologous (trans)genes?"" Plant Physiol 107: 679-685.;;Moesta, P. and H. Grisebach. 1982. ""L-2-Aminooxy-3-phenylpropionic acid inhibits phytoalexin accumulation in soybean with concomitant loss of resistance against Phytophthora megasperma f. sp. Glycinea,"" Physiol Plant Pathol 21: 65-70.;;Murashige, T. and Skoog, F. 1962, ""A revised media for rapid growth and bioassay with tobacco tissue culture,"" Physiol Plant 15:473-497.;;Paiva, et al. 1994. ""Regulation of isoflavonoid metabolism in alfalfa,"" Plant Cell, Tissue and Organ Cult 38: 213-220.;;Rahe, J.E. 1973. ""Occurrence and levels of the phytoalex in phasecollin in relation to delimination at sites of infection of Phaseolus vulgaris by Colletotrichum lindemuthianum,"" Can J Botany 51: 2423-2430.;;Restrepo, et al. 1990. ""Nuclear transport of plant polyviral proteins,"" Plant Cell 2: 987-998.;;Sambrook, et al. 1989. Molecular Cloning A Laboratory Manual (2nd Ed), Cold Spring Harbor Laboratory Press, New York: pp. 1.53-1.110.;;Shorrosh, et al. 1994. ""Molecular cloning, characterization and elicitation of acetyl-CoA carboxylase in alfalfa,"" Proc Natl Acad Sci USA 91:4323-4327.;;Shutt, D.A. 1976. ""The effects of plant oestrogens on animal reproduction,"" Endeavour 75: 110-113.;;Steele et al. 1999. ""Molecular characterization of the enzyme catalyzing the aryl migration reaction of isoflavonoid biosynthesis in soybean,"" Arch Biochem Biophys 367: 146-150.;;Summer, et al. 1996. ""High-performance liquid chromatography/continuous-flow liquid secondary ion mass spectrometry of flavonoid glucosides in leguminous plant extracts,"" J. Mass Spectrom 31:472-485.;;Thomas, et al. 1990. ""Selection of interspecific somatic hybrids of Medicago by using Agrobacterium-transformed tissue,"" Plant Sci 69: 189-198.;;VanEtten, et al. 1994. ""Two classes of plant antibiotics: phytoalexins versus phytoanticipins,"" The Plant Cell 6:1191-1192.;;Wong, E. and C.M. Francis. 1968. ""Flavonoids in genotypes of Trifolium subterraneum-II. Mutants of the Geraldton variety,"" Phytochemistry 7: 2131-2137.;;Yanagihara, et al. 1993. ""Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract,"" Cancer Res 53: 5815-5821.;;Zhou-Jin-Rong, et al. 1998. ""Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis,"" Cancer Res 58: 5231-5238.",EXPIRED
470,US,A1,US 2002/0087163 A1,075-116-898-082-212,2002-07-04,2002,US 3950902 A,2002-01-02,US 3950902 A;;US 25934901 P,2001-01-02,Vertebral distraction stabilizer,"
   This invention comprises a device and a method of maintaining distraction and providing tool guidance in the preparation of an intervertebral space for an implant. It provides a means for attaching a tube, to guide tools that will prepare the vertebra for accepting an implant. At any time during the procedure the tube may be removed to inspect or remove debris from the disc space and the vertebral end plates without disturbing the distraction. The system has multiple tube diameters which can be attached to a common flange to increase the dowel size during the procedure without redistracting. 
",DIXON ROBERT A.;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/075-116-898-082-212,Patent Application,yes,0,77,2,2,0,A61B17/025;;A61B17/1757;;A61B2017/0256;;A61B17/025;;A61B2017/0256;;A61B17/1757,A61B17/02;;A61B17/17,606 9,0,0,,,,EXPIRED
471,EP,A1,EP 2860393 A1,078-541-576-267-018,2015-04-15,2015,EP 14181279 A,2014-08-18,US 201314048106 A,2013-10-08,Reverse flow load mitigation device for a wind turbine blade,"A reverse wind load mitigation device (30) is provided for a wind turbine blade (20). The device (30) comprises a hinge member (32) attachable to a trailing edge (26) of a wind turbine blade (20). The separated flow inducer (34) is associated with the hinge member (32) and is configured to pivot about or with the hinge member (32) toward at least one of the surfaces (40, 42) in response to wind (45) traveling from a direction of the trailing edge (28). The separated flow inducer (34) is effective to induce flow separation (50) over at least one of the surfaces (40, 42).
",SIEMENS AG,DIXON KRISTIAN R;;MAYDA EDWARD A,,https://lens.org/078-541-576-267-018,Patent Application,yes,13,1,2,2,0,F03D1/0633;;F03D1/0641;;F05B2240/31;;F03D7/0232;;Y02E10/72;;F05B2240/3052;;F03D1/0675;;F03D7/0232;;F03D7/04;;F05B2240/31;;F03D1/0633;;F03D1/0641;;Y02E10/72;;F03D1/0675,F03D7/02;;F03D1/06,,0,0,,,,DISCONTINUED
472,CA,A1,CA 2373751 A1,136-891-302-118-287,2000-11-30,2000,CA 2373751 A,2000-05-15,US 13502699 P;;US 0013389 W,1999-05-20,ISOFLAVONOID METHYLATION ENZYME,"Methods of genetically manipulating biologically active 4'-O-methylated isoflavonoids have been found based upon the regiospecifity of isoflavone 7- OMT in vivo. Upon transformation and expression of an isoflavonoid O- methyltransferase gene, up-regulation of IOMT in the transgenic plants can b e used to increase the accumulation of 4'-O-methylated isoflavonoid phytolalexins, providing for increased disease resistance to the plant. Similar methods can be used to increase accumulation of 4'-O-methylated isoflavonoid nutraceuticals in plants. For down-regulation of IOMT in plants that naturally make 4'O-isoflavonoid phytoalexins and 4'-O- methylated isoflavonoid nutraceuticals, IOMT gene sequences can be transform ed in the antisense orientation.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;HE XIAN Z,,https://lens.org/136-891-302-118-287,Patent Application,no,0,0,7,10,0,A61P5/30;;A61P7/00;;A61P31/04;;A61P35/00;;A61P39/06;;C12N15/8282;;C12N9/1007;;C12N15/8243;;C12N15/825,A01H5/00;;A23L1/30;;A61K31/352;;A61K36/48;;A61P5/30;;A61P7/00;;A61P31/04;;A61P35/00;;A61P39/06;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/29;;C12N15/82;;C12P17/06,,0,0,,,,DISCONTINUED
473,EP,A4,EP 3134096 A4,127-087-944-177-357,2018-01-10,2018,EP 15783392 A,2015-04-22,US 201461983325 P;;US 2015/0027099 W,2014-04-23,METHODS OF ENHANCING STEM CELL ENGRAFTMENT,,TEXAS HEART INST,LIU QI;;DIXON RICHARD A F,,https://lens.org/127-087-944-177-357,Search Report,no,2,0,6,6,0,A61K35/12;;A61K35/34;;A61K35/36;;A61K45/06;;A61K35/28;;A61K31/5578;;A61P9/00;;A61K35/28;;A61K31/5578;;A61K35/34;;A61K45/06;;A61K35/36;;A61K35/12,A61K35/28;;A61K31/5578;;A61K35/12;;A61K35/36;;A61P9/00,,1,0,,,See also references of WO 2015164506A1,DISCONTINUED
474,AU,A,AU 2000/050187 A,162-579-045-195-607,2000-12-12,2000,AU 2000/050187 A,2000-05-15,US 13502699 P;;US 0013389 W,1999-05-20,Isoflavonoid methylation enzyme,,SAMUEL ROBERTS NOBLE FOUNDATION INC,DIXON RICHARD A;;HE XIAN Z,,https://lens.org/162-579-045-195-607,Patent Application,no,0,0,7,10,0,A61P5/30;;A61P7/00;;A61P31/04;;A61P35/00;;A61P39/06;;C12N15/8282;;C12N9/1007;;C12N15/8243;;C12N15/825,A01H5/00;;A23L1/30;;A61K31/352;;A61K36/48;;A61P5/30;;A61P7/00;;A61P31/04;;A61P35/00;;A61P39/06;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/29;;C12N15/82;;C12P17/06,,0,0,,,,EXPIRED
475,US,A1,US 2004/0210218 A1,176-236-676-543-480,2004-10-21,2004,US 41901103 A,2003-04-18,US 41901103 A;;US 8333202 A;;US 3481501 A;;US 99685801 A;;US 97766301 A,2001-10-15,Vertebral implant for bone fixation or interbody use,"
   The present invention provides a biodegradable implant which can be used as fixation and/or interbody implants. The implant is formed of a biodegradable material and may be used as a cervical stabilizing system. The stabilizing system comprises a body constructed of a biodegradable, polymeric material, which when implanted within the body will maintain a predetermined structural integrity for at least a predetermined period of time while minimizing reactivity with adjacent tissues. In an embodiment of the invention, the stabilization system comprises a fixation member which includes apertures to allow selective coupling to bone segments by means of biodegradable screws. In another embodiment, the stabilization system includes a bone column implant which maintains space between at least two bone segments of a bone column. The body member is dimensioned to substantially maintain the distance, geometry and continuity between the at least two bone segments. The invention is also directed to a combination device comprising a fixation device along with an interbody implant and methods for using the stabilization system. 
",DIXON ROBERT A.;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,,https://lens.org/176-236-676-543-480,Patent Application,yes,55,53,2,10,0,A61B17/8052;;A61B17/8052;;A61B17/7059;;A61B17/7059;;A61B2017/00004;;A61B2017/00004;;A61F2/442;;A61F2/442;;A61F2/447;;A61F2/447;;A61F2002/2817;;A61F2002/2817;;A61F2002/30062;;A61F2002/30062;;A61F2002/30433;;A61F2002/30433;;A61F2002/30578;;A61F2002/30578;;A61F2002/30593;;A61F2002/30593;;A61F2002/30604;;A61F2002/30604;;A61F2210/0004;;A61F2210/0004;;A61F2220/0041;;A61F2220/0041,A61B17/00;;A61B17/70;;A61B17/80;;A61F2/00;;A61F2/02;;A61F2/28;;A61F2/30;;A61F2/44,606/69,0,0,,,,DISCONTINUED
476,US,B2,US 7667214 B2,183-103-620-468-949,2010-02-23,2010,US 12232705 A,2005-05-04,US 12232705 A,2005-05-04,Radiation attenuation system,"A radiation attenuation system for shielding from scatter radiation one or more portions of a patient that are not of primary interest to a particular radiological procedure (i.e., non-target areas, etc.). The radiation attenuation system may be configured to shield the head of a patient (such as the head of a pediatric patient), and/or any other portion of the patient that may benefit from being shielded from scatter radiation. The radiation attenuation system is preferably configured to conform to the contours of the patient. The radiation attenuation system may be a flexible member that can be reconfigured to accommodate patients of varying size.",WORLDWIDE INNOVATIONS & TECHNO,CADWALADER JOHN A;;DIXON G DAVID,WORLDWIDE INNOVATIONS & TECHNOLOGIES INC (2005-07-29),https://lens.org/183-103-620-468-949,Granted Patent,yes,11,4,4,4,0,A61B6/107;;G21F3/02;;G21K1/10;;A61B6/4423;;G21K1/10;;G21F3/02;;A61B6/107,G21F3/00,250/515.1;;250/517.1;;250/519.1,0,0,,,,INACTIVE
477,FR,A1,FR 2628322 A1,000-526-569-128-663,1989-09-15,1989,FR 8903014 A,1989-03-05,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,NOUVELLES UTILISATIONS THERAPEUTIQUES DE L'ACIDE 4-(3-PHOSPHONO-2-PROPENYL)-PIPERAZINE-2-CARBOXYLIQUE,"<P>La présente invention a pour objet l'utilisation de l'acide [R-(E)] -4- (3-phosphono-2-propényl) -pipérazine-2-carboxylique dans le traitement des troubles caractérisés par une pulsion psycho-motrice réduite et/ou un retrait social, des troubles du sommeil ou de la migraine.</P>",SANDOZ SA,DIXON ARNOLD KEITH;;GRAY JULIAN A,,https://lens.org/000-526-569-128-663,Patent Application,no,1,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
478,US,A,US 3110277 A,020-126-107-629-490,1963-11-12,1963,US 79977959 A,1959-03-16,US 79977959 A,1959-03-16,Chill ring,,CROSE UNITED CORP,DIXON WILLIS O;;CUNNINGHAM JOSEPH A,,https://lens.org/020-126-107-629-490,Granted Patent,no,9,30,1,1,0,B23K9/035;;B23K9/035,B23K9/035,,0,0,,,,EXPIRED
479,US,B2,US 6709438 B2,032-809-956-334-353,2004-03-23,2004,US 92306301 A,2001-08-06,US 92306301 A;;US 22447200 P,2000-08-10,Cam action vertebral spreader,"
    This invention comprises an apparatus and a method of spreading an intervertebral space to help guide tools that will prepare the vertebrae for accepting an implant. The spreader is a thin blade with cam surfaces forming a paddle on the proximal end, which spreads the vertebra when rotated 90 degrees about its axis. A stem between the paddle and a handle is notched to clear the vertebral protrusions so the vertebra will be distracted on the vertebral end plates. Since the spreader is in the center of the end plates, the centerline of the spreader shaft will coincide with the vertebral end plate centerline. The surgeon can monitor the spreading, stop and remove the spreader to make adjustments or to change the size of spreader as required at the time of the surgery. Once the vertebrae are distracted a tube may be placed over the handle and aligned with the vertebral end plates. 
",DIXON ROBERT A;;HACKMAN DONALD J,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/032-809-956-334-353,Granted Patent,yes,11,38,2,2,0,A61B17/025;;A61B2017/0256;;A61B2017/2933;;A61B17/025;;A61B2017/2933;;A61B2017/0256,A61B17/02;;A61B17/28,606/90,1,0,,,"PRECISION-GRAFT (TM), MEDTRONIC SOFAMOR DANEK, MEMPHIS TN (brochure).",EXPIRED
480,US,A,US 4718620 A,047-231-716-261-315,1988-01-12,1988,US 66070884 A,1984-10-15,US 66070884 A,1984-10-15,Terraced channels for reducing afterbody drag,A fluid flow control for reducing the drag associated with an upswept afterbody includes a pair of ridges forming substantially symmetric flow channels arranged in an approximately helical fashion on either side of the afterbody so as to intersect at approximately the centerline of the undersurface. Each ridge has a generally rearward pitch so that the flow channels form a substantially V-shaped configuration rearwardly. The flow channels cross the local fluid flow streamlines at an optimum angle for producing a strong vortex core along the channel length with the vortex rotating in a direction counter to that normally found in the wake of conventional upswept afterbodies.,BRADEN JOHN A;;DIXON CHARLES J,BRADEN JOHN A;;DIXON CHARLES J,LOCKHEED CORPORATION (1984-10-09),https://lens.org/047-231-716-261-315,Granted Patent,yes,5,54,1,1,0,B64C23/06;;B64C23/06;;Y02T50/10;;Y02T50/10,B64C23/06,244/130;;244/199;;244/200,0,0,,,,EXPIRED
481,US,A1,US 2001/0037111 A1,059-623-928-786-015,2001-11-01,2001,US 84695601 A,2001-05-01,US 84695601 A;;US 20242200 P,2000-05-08,Method and apparatus for dynamized spinal stabilization,"
   An improved device and a method for stabilizing lumbar vertebrae in a human spine for the purpose of fixing the vertebra with respect to other vertebra and with respect to other parts of the spinal column. This device comprises a plate, bone screws, bone screw clamp portion, spacers, and rigidizing stop locks. The bone screw clamps may be clamped firmly to the plate for a fully rigid system. Alternatively the screw clamp portions s may be held apart, with clearance between them and the plate, which will allow for axial motion of the screw with respect to the plate for implant load sharing and dynamized motion. 
",DIXON ROBERT A.;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/059-623-928-786-015,Patent Application,yes,0,132,2,2,0,A61B17/66;;A61B17/7007;;A61B17/701;;A61B17/7049;;A61B17/66;;A61B17/7007;;A61B17/7049;;A61B17/701,A61B17/66;;A61B17/70,606/61,0,0,,,,EXPIRED
482,US,S,US D0256588 S,104-711-888-794-407,1980-08-26,1980,US 94896278 F,1978-10-05,US 94896278 F,1978-10-05,Cylinder mounting device for electronic scanner used in photographic,,MAHIQUES ROBERT J;;DIXON ROBERT A,MAHIQUES ROBERT J;;DIXON ROBERT A,,https://lens.org/104-711-888-794-407,Design Right,yes,3,0,1,1,0,,,D16/32;;D1603,0,0,,,,EXPIRED
483,DE,T2,DE 69324537 T2,121-634-653-039-677,1999-10-14,1999,DE 69324537 T,1993-07-27,US 93875392 A,1992-09-01,Metallguss unter Verwendung einer mit Speisern versehenen Form,,GEN MOTORS CORP,CHANDLEY GEORGE DIXON;;REDEMSKE JOHN A,,https://lens.org/121-634-653-039-677,Granted Patent,no,0,1,9,9,0,B22C9/08;;B22D18/06;;B22D18/06;;B22C9/08,B22C9/04;;B22C9/08;;B22D18/06,,0,0,,,,EXPIRED
484,US,B2,US 6656181 B2,131-956-208-702-850,2003-12-02,2003,US 99685801 A,2001-11-20,US 99685801 A;;US 25267600 P,2000-11-22,Method and device utilizing tapered screw shanks for spinal stabilization,"
    A method and a device are provided for stabilizing vertebrae in a human spine for the purpose of fixing one vertebra with respect to other vertebrae and with respect to other parts of the spinal column. This device comprises a plate and bone screws fabricated from metals. The bone screw maintains the plate in contact with the vertebrae. A tapered screw head is pulled into a machined tapered hole, locking the screw to the plate. The taper is configured to be self-locking preventing the screw from backing out. The taper may be within the fixed structure of the plate, or within an insert placed into the plate. 
",DIXON ROBERT A;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/131-956-208-702-850,Granted Patent,yes,36,137,2,10,0,A61B17/7059;;A61B17/8047;;A61B17/8052;;A61B17/8057;;A61B17/8052;;A61B17/8057;;A61B17/7059;;A61B17/8047,A61B17/70;;A61B17/80,606/69,0,0,,,,EXPIRED
485,US,A1,US 2015/0211487 A1,133-869-675-615-956,2015-07-30,2015,US 201414164879 A,2014-01-27,US 201414164879 A,2014-01-27,DUAL PURPOSE SLAT-SPOILER FOR WIND TURBINE BLADE,"An aerodynamic slat ( 30 ) mounted over a forward suction side ( 40 ) of a wind turbine blade ( 22 ) and a mechanism ( 51 A-F) that closes or reduces a gap ( 31 ) between slat and blade. The slat may pivot to reduce the gap, or the gap may be reduced by a device such as an extendable gate ( 58 ), or butterfly plate ( 59 ), or damper plate ( 60 ). Control logic ( 64 ) activates an actuator ( 70 ) of the mechanism to close or reduce the gap when wind conditions meet or exceed a predetermined criterion such as a rated wind condition. This reduces wind loading on the blade by separating airflow ( 53 ) over the suction side of the blade downstream of the slat. The blades can then maintain a higher angle of attack during rated wind conditions than in the prior art, allowing them to stall in gusts sooner to limit peak aerodynamic loads.",SIEMENS AG,DIXON KRISTIAN R;;MAYDA EDWARD A,SIEMENS AKTIENGESELLSCHAFT (2014-08-22);;SIEMENS WIND POWER A/S (2014-06-12);;SIEMENS ENERGY INC (2014-02-03),https://lens.org/133-869-675-615-956,Patent Application,yes,13,8,4,4,0,F03D7/0232;;F03D7/0232;;F03D7/022;;F03D7/022;;F03D7/0256;;F03D7/0256;;F05B2240/305;;F05B2240/3052;;Y02E10/72;;Y02E10/72,F03D7/02,,1,0,,,"Benson, Tom; Aerodynamic Center, Beginner's Guide to Aeronautics, NASA, 2002",DISCONTINUED
486,US,A,US 5690684 A,130-436-446-827-864,1997-11-25,1997,US 43299895 A,1995-05-02,US 43299895 A,1995-05-02,Pivot assisted defibrillator paddle retainer,"A retainer assembly for a defibrillator paddle has a resilient back plate. The back plate secures to a back wall in a pocket by a fastener positioned to allow pivotal movement of the back plate. The back plate has a bracket at its inner edge, retaining an edge of the base of the paddle. A lip extends forward from an outer edge of the back plate to overlie an outer edge of the paddle. The lip is within a tab section that deflects into a recess if a user exerts a sufficient outward pull on the handle.",HEWLETT PACKARD CO,ANDREWS JONATHAN N;;DIXON WILLIAM A,HEWLETT-PACKARD COMPANY (1995-04-26);;HEWLETT-PACKARD COMPANY A DELAWARE CORPORATION (1998-05-20);;AGILENT TECHNOLOGIES INC (1999-11-01);;KONINKLIJKE PHILIPS ELECTRONICS N.V (2001-08-01),https://lens.org/130-436-446-827-864,Granted Patent,yes,8,11,8,8,0,A61N1/3904;;A61N1/3904;;B25H3/006;;B25H3/006,A61N1/39;;B25H3/00,607/5;;D24/167;;D24/168;;248/316.5;;248/222.51,0,0,,,,EXPIRED
487,US,A1,US 2007/0232671 A1,149-025-719-714-923,2007-10-04,2007,US 71749707 A,2007-03-12,US 71749707 A;;US 78185306 P,2006-03-13,Methods and compositions for treatment of diastolic heart failure,"Provided herein are methods of treatment of diastolic heart failure (DHF) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof.",GIVEN BRUCE D;;DIXON RICHARD A,GIVEN BRUCE D;;DIXON RICHARD A,ENCYSIVE PHARMACEUTICALS INC (2007-05-14),https://lens.org/149-025-719-714-923,Patent Application,yes,85,1,13,13,0,A61K9/0019;;A61K9/1623;;A61K9/2054;;A61K9/2095;;A61K9/2866;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61K31/194;;A61K31/401;;A61K9/19;;A61K31/357;;A61K31/194;;A61K31/506;;A61K31/401;;A61K31/501;;A61K9/0019;;A61K9/1623;;A61K9/2095;;A61K9/2866;;A61K9/2054;;A61K31/357;;A61K31/42,A61K31/42,514/378,0,0,,,,DISCONTINUED
488,US,A,US 3195643 A,167-327-341-129-787,1965-07-20,1965,US 25729663 A,1963-02-08,US 25729663 A,1963-02-08,Pump anchors with slips and packer,,HARBISON FISCHER MFG CO,HARBISON DIXON T;;BURNS JAMES A,,https://lens.org/167-327-341-129-787,Granted Patent,no,5,6,1,1,0,E21B23/01;;E21B23/01,E21B23/01,,0,0,,,,EXPIRED
489,US,B2,US 7104991 B2,179-611-519-909-590,2006-09-12,2006,US 8333202 A,2002-02-25,US 8333202 A;;US 27178201 P,2001-02-27,Method and device for using extended interference fit screw shanks for spinal stabilization,"A device and a method for stabilizing vertebrae in a human spine for the purpose of fixing one vertebra with respect to other vertebrae and with respect to other parts of the spinal column. This device comprises bone screws that clamp to a plate to maintain the plate in contact with the vertebrae. The device may be fabricated from non-metals, metal, alloys, or composite materials. A tapered screw head is pulled into the plate with the taper extending through the plate into the underlying bone. Extending the taper into the bone moves the screw thread stress raiser into an area of lesser deflection. This strengthens the fixation by increasing the rigidity and reducing the risk of screw breakage. Extending the taper into the underlying bone has also been shown to strengthen the taper lock.",DIXON ROBERT A;;HACKMAN DONALD J,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/179-611-519-909-590,Granted Patent,yes,12,27,2,10,0,A61B17/8052;;A61B17/8052;;A61B17/1728;;A61B17/1728;;A61B17/1757;;A61B17/1757;;A61B17/7059;;A61B17/7059;;A61B17/8057;;A61B17/8057,A61B17/70;;A61B17/17;;A61B17/80,606/61;;606/69;;606/73,0,0,,,,EXPIRED
490,US,A1,US 2017/0177816 A1,170-593-409-476-508,2017-06-22,2017,US 201615379572 A,2016-12-15,US 201615379572 A;;US 201562268016 P,2015-12-16,PATIENT CARE DEVICES WITH LOCAL INDICATION OF CORRESPONDENCE AND POWER LINE INTERCONNECTIVITY,"According to the present disclosure, a system includes a patient support device and a power line network for communicating data, such as patient identifying information. The patient support device locally indicates information about an assigned patient. A patient care apparatus is communicatively connected to the power line network to receive data and to provide a local indication of the data received. The local indication of the device and the apparatus includes respective lights that flash substantially synchronously.",HILL ROM SERVICES INC,RIBBLE DAVID L;;DIXON STEVEN A,HILL-ROM SERVICES INC (2016-01-02),https://lens.org/170-593-409-476-508,Patent Application,yes,4,6,2,2,0,G16H40/63;;A61G7/05;;A61B90/90;;A61G2205/60;;A61G7/05;;G08B5/38;;A61B90/90;;A61G2205/60;;G16H40/63,G06F19/00;;A61B90/90;;A61G7/05;;G08B5/38,,0,0,,,,ACTIVE
491,CA,A1,CA 2362440 A1,188-322-558-236-208,2000-09-14,2000,CA 2362440 A,2000-03-08,US 12326799 P;;US 0005915 W,1999-03-08,GENETIC MANIPULATION OF ISOFLAVONOIDS,"Soybean and Medicago truncatula CYP93C genes have been isolated which encode a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone. Plants can now be genetically engineered to produce isoflavones that provide potential human health benefi ts and increase disease resistance in plants. Isoflavones can now be produced i n transgenic plants species in which isoflavones do not naturally occur, i.e., in species other than legumes. Alternatively, introducing infection-inducibl e isoflavonoid biosynthesis into non-legumes qualitatively complements these plants' phytoalexin defenses against microbial pathogens, whereas over- expression of the isoflavonoid pathway in legumes quantitatively increases this defense response. Finally, modifying the extend of production of isoflavonoids in legume roots positively impacts nodulation efficiency and therefore plant yield.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;STEELE CHRISTOPHER L,,https://lens.org/188-322-558-236-208,Patent Application,no,0,0,7,8,5,C12N9/0077;;C07K2319/00;;C12N15/8242;;C12N15/8243;;C12N15/8261;;C12N15/8279;;Y02A40/146,C12N9/02;;C12N15/53;;C12N15/82,,0,0,,,,EXPIRED
492,US,A,US 2815631 A,194-499-439-731-282,1957-12-10,1957,US 45345354 A,1954-09-01,US 45345354 A,1954-09-01,Rotary mower,,JOHN DEERE PLOW COMPANY,NORTHCOTE JOHN A;;DIXON DAVID W,,https://lens.org/194-499-439-731-282,Granted Patent,no,10,23,1,2,0,A01D34/63;;A01D34/8355;;A01D34/63;;A01D34/8355,A01D34/63;;A01D34/835,,0,0,,,,EXPIRED
493,EP,A2,EP 1720986 A2,018-111-207-772-864,2006-11-15,2006,EP 04810095 A,2004-10-28,US 2004/0035948 W;;US 51555903 P,2003-10-29,PLANT ISOFLAVONOID HYDROXYLASES AND METHODS OF USE THEREOF,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;LIU CHANG-JUN,,https://lens.org/018-111-207-772-864,Patent Application,yes,0,0,8,8,0,C12N9/0073;;C12N9/0073,A23L19/00;;C12N15/53;;A01H5/00;;C12N9/02;;C12N15/82,,1,0,,,See references of WO 2005042747A3,DISCONTINUED
494,DK,A,DK 118189 A,018-385-326-086-910,1989-09-12,1989,DK 118189 A,1989-03-10,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,ANVENDELSE AF PIPERAZINDERIVAT,,SANDOZ AG,DIXON ARNOLD KEITH;;GRAY JULIAN A,,https://lens.org/018-385-326-086-910,Patent Application,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,DISCONTINUED
495,HU,A,HU T52383 A,009-988-607-701-541,1990-07-28,1990,HU 103089 A,1989-03-03,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,PROCESS FOR PRODUCING PHARMACEUTICAL COMPOSITIONS COMPRISING (R)-(E)-4-(3-PHOSPHONO-2-PROPENYL)-2-PIPERAZINECARBOXYLIC ACID AS ACTIVE INGREDIENT,,SANDOZ AG,DIXON KEITH ARNOLD;;GRAY JULIAN A,,https://lens.org/009-988-607-701-541,Unknown,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
496,US,A1,US 2001/0055741 A1,032-988-838-278-190,2001-12-27,2001,US 82514901 A,2001-04-03,US 82514901 A;;US 37772199 A,1999-08-19,Individual dose dental adhesive delivery system and method,"
   Individual doses of dental adhesive are dispensed onto a flat conformable card and enclosed under a cover sealed to the card. The cover is peeled off at chairside and individual doses of the adhesive are picked up by a wiping action of a dental tool or of an object to be bonded, such as, for example, by wiping action of an orthodontic bracket base over the adhesive bearing surface of the card. The card deforms to conform to the curvature of the edge of the appliance or object to cleanly transfer all of the adhesive of a dose from the card to the appliance base. 
",DIXON DANIEL R.;;ANDREIKO CRAIG A.,DIXON DANIEL R;;ANDREIKO CRAIG A,ORMCO CORPORATION (2001-07-13),https://lens.org/032-988-838-278-190,Patent Application,yes,0,22,2,3,0,A61C7/12;;A61C19/02;;A61C2202/01;;A61C5/60;;A61C7/12;;A61C19/02;;A61C2202/01;;A61C5/60,A61C5/06;;A61C7/12;;A61C19/02,433/9;;206/369,0,0,,,,EXPIRED
497,EP,A1,EP 3134096 A1,049-007-826-031-12X,2017-03-01,2017,EP 15783392 A,2015-04-22,US 201461983325 P;;US 2015/0027099 W,2014-04-23,METHODS OF ENHANCING STEM CELL ENGRAFTMENT,,TEXAS HEART INST,LIU QI;;DIXON RICHARD A F,,https://lens.org/049-007-826-031-12X,Patent Application,yes,0,0,6,6,2,A61K35/12;;A61K35/34;;A61K35/36;;A61K45/06;;A61K35/28;;A61K31/5578;;A61P9/00;;A61K35/28;;A61K31/5578;;A61K35/34;;A61K45/06;;A61K35/36;;A61K35/12,A61K35/28;;A61K35/12;;A61K35/36;;A61P9/00,,0,0,,,,DISCONTINUED
498,US,A,US 2818269 A,070-250-768-929-628,1957-12-31,1957,US 53815855 A,1955-10-03,US 53815855 A,1955-10-03,Adjustable wheel assembly for farm implement,,JOHN DEERE PLOW COMPANY,NORTHCOTE JOHN A;;DIXON DAVID W,,https://lens.org/070-250-768-929-628,Granted Patent,no,2,34,1,1,0,A01D34/63;;A01D34/63;;A01B63/16;;A01B63/16;;A01B63/22;;A01B63/22;;A01D67/00;;A01D67/00,A01B63/16;;A01B63/22;;A01D34/63;;A01D67/00,,0,0,,,,EXPIRED
499,PT,A,PT 89962 A,075-448-814-958-426,1989-11-10,1989,PT 8996289 A,1989-03-09,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,PROCESSO PARA A PREPARACAO DE NOVAS COMPOSICOES FARMACEUTICAS CONTENDO ACIDO 4--(3-FOSFONO-2-PROPENIL)-2-PIPERAZINOCARBOXILICO COMO SUBSTANCIA ACTIVA,,SANDOZ SA,DIXON ARNOLD KEITH;;GRAY JULIAN A,,https://lens.org/075-448-814-958-426,Patent Application,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
500,AU,A,AU 1995/036248 A,076-653-989-142-858,1996-03-07,1996,AU 1995/036248 A,1995-08-11,US 28875594 A;;US 32076294 A;;US 9509695 W,1994-08-11,Linear pressure sensor,,MITRON SYSTEMS CORP,DIXON DONALD A;;TYBURSKI ROBERT M,,https://lens.org/076-653-989-142-858,Patent Application,no,0,0,2,2,0,G08G1/02,G08G1/02,,0,0,,,,PENDING
501,GB,A,GB 2216417 A,083-842-883-680-89X,1989-10-11,1989,GB 8905180 A,1989-03-07,GB 8805875 A;;GB 8820344 A;;GB 8819192 A,1988-03-11,New uses of 4-(3-phosphono-2-propenyl)-2-piperazinecarboxylic acid,"The compound of formula I <IMAGE> or a hydrate thereof or pharmaceutically acceptable salt thereof is useful in the treatment of disorders characterised by reduced drive and/or social withdrawal, sleep disturbances or migraine.",SANDOZ LTD,DIXON ARNOLD KEITH;;GRAY JULIAN A,,https://lens.org/083-842-883-680-89X,Patent Application,no,2,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,A5B BHA           BHA2;;A5B B180          BHA2;;A5B B28Y          BHA2;;A5B B281          BHA2;;U1S S2415;;U1S S2417;;U1S S2418,0,0,,,,EXPIRED
502,US,A1,US 2019/0251617 A1,090-896-921-116-737,2019-08-15,2019,US 201916353953 A,2019-03-14,US 201916353953 A;;US 201514944029 A;;US 201462080874 P,2014-11-17,SYSTEM AND METHOD FOR ELECTRONIC MANIFESTING IN A DISTRIBUTION NETWORK,"System and method for providing electronic manifesting access for users of a distribution network. A distribution network may provide a user access point, such as by providing application programming interfaces. The access point may provide access the item tracking module upon receipt of valid credentials, such as a user's unique identifier. The access point may receive item information, generate an electronic manifest including the item information and the unique identifier, and allow for tracking the items on the electronic manifest.",UNITED STATES POSTAL SERVICE,DIXON ROBERT E;;SULLIVAN KELLEY A,UNITED STATES POSTAL SERVICE (2015-01-06),https://lens.org/090-896-921-116-737,Patent Application,yes,0,0,4,4,0,G06Q10/0833;;G06Q30/0635;;G06Q10/0833;;G06Q30/0635;;B07C7/005,G06Q30/06;;G06Q10/08,,0,0,,,,ACTIVE
503,US,A,US 4252398 A,082-187-464-532-986,1981-02-24,1981,US 3187279 A,1979-04-20,US 3187279 A,1979-04-20,Electric power meter,"A method and means for preventing reversal of the orientation of an electric utility meter in its base socket. A first tab is attached to the rear face of the meter and a second tab is attached to the front face of the base such that a conflict between the two tabs develops if reversed assembly of the meter and socket base is attempted. In one embodiment of the invention, the first tab, consisting of a short metal rod, is welded to a vertical edge of one of the meter plugs and the second tab, consisting of a metal sleeve, is mounted to the base socket receptacle which is diagonally opposite to the receptacle in which the tabbed plug normally fits.",MISSISSIPPI POWER AND LIGHT CO,AVARA TEDDY W;;DIXON JAMES A,,https://lens.org/082-187-464-532-986,Granted Patent,yes,6,1,1,1,0,G01R11/24;;G01R11/24;;G01R11/02;;G01R11/02;;G01R11/04;;G01R11/04,G01R11/02;;G01R11/04;;G01R11/24,339184M,0,0,,,,EXPIRED
504,DE,A1,DE 3011624 A1,096-769-012-732-774,1980-10-30,1980,DE 3011624 A,1980-03-26,US 2941079 A,1979-04-12,AUFROLLEINRICHTUNG FUER EINEN PASSIVEN SICHERHEITSGURT IN EINEM KRAFTFAHRZEUG,,FORD WERKE AG,COLLINS ALFORD F;;DIXON BILL A,,https://lens.org/096-769-012-732-774,Patent Application,no,0,6,7,7,0,B60R22/41;;B60R22/41,B60R22/08;;B60R22/40;;B60R22/41;;B60R22/48,,0,0,,,,DISCONTINUED
505,US,A,US 686031 A,106-976-035-769-986,1901-11-05,1901,US 1901/0064383 A,1901-06-13,US 1901/0064383 A,1901-06-13,SEAM FOR SEWED ARTICLES.,,REECE BUTTONHOLE MACHINE COMPANY,DAHL CHARLES A;;DIXON WILLIAM W,,https://lens.org/106-976-035-769-986,Granted Patent,no,0,0,1,1,0,D05B93/00;;D05B93/00,,,0,0,,,,EXPIRED
506,US,A1,US 2014/0012305 A1,118-389-953-291-60X,2014-01-09,2014,US 201213541956 A,2012-07-05,US 201213541956 A,2012-07-05,COLPOTOMY CUP-LIKE STRUCTURE AND INTRAUTERINE MANIPULATOR INCLUDING SAME,"A cup-like structure for engaging a cervix of a patient includes a rim, and includes a base defining an aperture through which one or more tubular members of a uterine manipulator may extend into the uterus. The cup-like structure is made from one or more of a polyphthalamide (PPA) material and a polyetheretherketone (PEEK) material. A uterine manipulator including a cup-like structure is also disclosed.",HORTON JEREMY C;;DIXON RICHARD A;;CLINICAL INNOVATIONS LLC,HORTON JEREMY C;;DIXON RICHARD A,CLINICAL INNOVATIONS LLC (2012-07-02),https://lens.org/118-389-953-291-60X,Patent Application,yes,21,24,10,10,0,A61B17/4241;;A61L29/06;;A61L29/126;;A61B18/1402;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L29/06;;A61L31/06;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L31/06;;A61L29/06,A61M29/00,606/193,1,1,103-282-158-935-029,10.1177/0892705706059738,"Pini et al., Perspectives for Reactive Molding of PPA as Matrix for High-performance Composite Materials"", March 2006, Journal of Thermoplastic Composite Materials, Volume 19, pages 207-216",DISCONTINUED
507,US,A,US 2926479 A,138-465-624-961-147,1960-03-01,1960,US 69868557 A,1957-11-25,US 69868557 A;;US 45345354 A,1954-09-01,Rotary mower,,JOHN DEERE PLOW COMPANY,NORTHCOTE JOHN A;;DIXON DAVID W,,https://lens.org/138-465-624-961-147,Granted Patent,no,5,2,1,2,0,A01D34/63;;A01D34/63,A01D34/63,,0,0,,,,EXPIRED
508,WO,A1,WO 2015/113011 A1,139-543-441-456-006,2015-07-30,2015,US 2015/0012979 W,2015-01-27,US 201414164879 A,2014-01-27,DUAL PURPOSE SLAT-SPOILER FOR WIND TURBINE BLADE,"An aerodynamic slat (30) mounted over a forward suction side (40) of a wind turbine blade (22) and a mechanism (51A-F) that closes or reduces a gap (31) between slat and blade. The slat may pivot to reduce the gap, or the gap may be reduced by a device such as an extendable gate (58), or butterfly plate (59), or damper plate (60). Control logic (64) activates an actuator (70) of the mechanism to close or reduce the gap when wind conditions meet or exceed a predetermined criterion such as a rated wind condition. This reduces wind loading on the blade by separating airflow (53) over the suction side of the blade downstream of the slat. The blades can then maintain a higher angle of attack during rated wind conditions than in the prior art, allowing them to stall in gusts sooner to limit peak aerodynamic loads.",SIEMENS AG;;SIEMENS ENERGY INC,DIXON KRISTIAN R;;MAYDA EDWARD A,,https://lens.org/139-543-441-456-006,Patent Application,yes,10,0,4,4,0,F03D7/022;;F03D7/0256;;F03D7/0232;;Y02E10/72;;F05B2240/3052;;F05B2240/305;;F03D7/0256;;F03D7/022;;Y02E10/72;;F03D7/0232,F03D7/02,,0,0,,,,PENDING
509,US,A,US 4154896 A,136-903-411-798-141,1979-05-15,1979,US 87885878 A,1978-02-17,US 87885878 A,1978-02-17,Photosensitive solventless oil free low viscosity coating composition,"A photosensitive, solventless, low viscosity, oil free coating composition is made by admixing: (A) about 40 wt.% to about 90 wt.% of an alkyd component, consisting essentially of a polyhydric alcohol and a dibasic aromatic and aliphatic acid mixture with (B) about 10 wt.% to about 60 wt.% of an acrylate monomer and (C) an effective amount of a photoinitiator; the composition characterized by having a viscosity of up to about 2,000 cps. at 25.degree. C., and being capable of forming an ultraviolet radiation cured, hard, pin hole free film, having a thickness of under about 5 mils.",WESTINGHOUSE ELECTRIC CORP,DIXON GEORGE D;;SATTLER FRANK A,RANBAR ELECTRICAL MATERIALS INC (1995-07-31),https://lens.org/136-903-411-798-141,Granted Patent,yes,11,8,11,11,0,C08F283/01;;C08F299/0478;;C08G63/6854;;C09D167/00;;Y10T428/31681;;Y10T428/31681;;C08F299/0478;;C08G63/6854;;C08F283/01;;C09D167/00,C08F2/50;;C08F299/00;;C08F283/01;;C08F299/04;;C08G63/00;;C08G63/52;;C08G63/685;;C09D4/00;;C09D167/00,428/458,0,0,,,,EXPIRED
510,EP,A1,EP 0086338 A1,173-508-915-403-205,1983-08-24,1983,EP 83100329 A,1983-01-15,US 34095282 A,1982-01-20,Method and apparatus for translating and positioning a catheter.,"A catheter assembly (10), includes a flexible inner catheter tube (11) which is telescopically translatable through a shorter, outer sheath tube (12). The inner catheter tube (11) has an injection needle (19) projection from its distal end (13) which is retracted into the open distal end (14) of the sheath tube (12) as the sheath tube traverses the endoscope or other tubular passage. Upon reaching the desired location, the needle (19) and the distal end (13) of the inner catheter tube (11) are projected from the distal end (14) of the sheath (12) by applying an axial force to the catheter tube at a location beyond the proximal end (17) of the sheath (12). A positional locking mechanism includes an elastomeric washer (30) which concentrically slidably engages the catheter tube (11) at a location beyond the proximal end (17) of the sheath (12). The washer (30) is selectively axially compressed between two locking members (25, 21) which are disposed about the sheath (12) and catheter tube (11), respectively. The washer (30) is radially constricted so that the axial compression produces a radial compression which results in a gripping action on the catheter tube (11).",SORENSON RESEARCH CO,WONDER TERRY M;;DIXON JOHN A,,https://lens.org/173-508-915-403-205,Patent Application,yes,8,51,8,8,0,A61M25/0084;;A61B17/3478;;A61B2017/320084;;A61M2025/0089,A61M5/14;;A61B17/32;;A61B17/34;;A61M25/00,,0,0,,,,DISCONTINUED
511,US,S,US D0458372 S,186-338-263-980-121,2002-06-04,2002,US 13159400 F,2000-10-25,US 13159400 F,2000-10-25,Combination disc cutter and spinal vertebral spreader,,DIXON ROBERT A;;HACKMAN DONALD J,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/186-338-263-980-121,Design Right,no,0,2,1,1,0,,,D24/147,0,0,,,,EXPIRED
512,US,B2,US 6666870 B2,191-172-039-330-400,2003-12-23,2003,US 3481501 A,2001-12-27,US 3481501 A;;US 25991701 P,2001-01-05,Method utilizing chemical bonding to improve the bone screw fixation interface,"
    This invention relates to a method and materials in combination for bonding screws to a fixation plate or to a skeletal bone using chemical means. The chemicals include solvents, glues, or bonding agents, which act to improve the strength of bone screw to plate or the bone screw to skeletal bone interface. Interface refers to the contact area between the bone screw and either the plate or skeletal bone. The fixation device usually comprises a plate with bone screws implanted within the human skeleton. The bone screw maintains the plate in contact with the bone or maintains another structure such as a tendon in contact with the bony skeleton. The chemical bonding is in addition to or in place of a mechanical means to bond the bone screw to the fixation plate or to the skeletal bone. It provides for added strength to the bone screw interface with a plate or skeletal bone, reducing the probability of screw loosening and or migration. 
",DIXON ROBERT A;;HACKMAN DONALD J.,DIXON ROBERT A;;HACKMAN DONALD J,ALTUS PARTNERS LLC (2011-04-04);;VERTEBRON INC (2009-04-14);;CARDO MEDICAL INC (2009-09-30);;SPECIALIST PROPERTIES LLC (2009-01-26),https://lens.org/191-172-039-330-400,Granted Patent,yes,14,29,2,10,0,A61L24/06;;A61L24/06;;A61B17/7059;;A61B17/7059;;A61B17/80;;A61B17/80;;A61B17/866;;A61B17/866,A61B17/80;;A61L24/06,606/76;;606/69;;606/73,3,0,,,"Patrick J. Courtney and Christopher Verosky Advances in Cyanoacrylates Technology for Device Assembly.;;Medical Device & Diagnostic Industry Magazine Sep. 1999, pp. 1, 4, 5, 7, 9 of 14.;;Canon Communications.",EXPIRED
513,CA,A,CA 1145676 A,003-484-739-730-531,1983-05-03,1983,CA 352417 A,1980-05-21,US 4165679 A;;US 14229780 A,1979-05-23,CONDITIONING SHAMPOO WITH SATURATED FATTY ACIDS,"A conditioning shampoo containing as the conditioning agent about 1-3% of a saturated, straight chain fatty acid having from about 14 to about 18 carbon atoms, together with about 10-26% synthetic anionic surfactant and the balance water. The novel feature is the fatty acid conditioner.",PROCTER & GAMBLE,DIXON THOMAS J;;UCHTMAN VERNON A,,https://lens.org/003-484-739-730-531,Granted Patent,no,0,0,3,8,0,,C11D1/37,167-304,0,0,,,,EXPIRED
514,CA,A1,CA 2877304 A1,001-036-384-507-266,2014-01-09,2014,CA 2877304 A,2013-06-20,US 201213541956 A;;US 2013/0046851 W,2012-07-05,COLPOTOMY CUP-LIKE STRUCTURE AND INTRAUTERINE MANIPULATOR INCLUDING SAME,"A cup-like structure for engaging a cervix of a patient includes a rim, and includes a base defining an aperture through which one or more tubular members of a uterine manipulator may extend into the uterus. The cup-like structure is made from one or more of a polyphthalamide (PPA) material and a polyetheretherketone (PEEK) material. A uterine manipulator including a cup-like structure is also disclosed.",CLINICAL INNOVATIONS LLC,HORTON JEREMY C;;DIXON RICHARD A,,https://lens.org/001-036-384-507-266,Patent Application,no,0,0,10,10,0,A61B17/4241;;A61L29/06;;A61L29/126;;A61B18/1402;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L29/06;;A61L31/06;;A61B17/4241;;A61L29/126;;A61B18/1402;;A61L31/06;;A61L29/06,A61B17/42;;A61B1/303;;A61B17/3209;;A61L29/04;;A61M29/02,,0,0,,,,DISCONTINUED
515,GB,B,GB 2216417 B,054-127-424-910-743,1991-12-11,1991,GB 8905180 A,1989-03-07,GB 8805875 A;;GB 8820344 A;;GB 8819192 A,1988-03-11,NEW USES OF 4-(3-PHOSPHONO-2-PROPENYL)-2-PIPERAZINECARBOXYLIC ACID,,SANDOZ LTD,DIXON ARNOLD KEITH;;GRAY JULIAN A,,https://lens.org/054-127-424-910-743,Granted Patent,no,2,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,A5B BHA           BHA2;;A5B B180          BHA2;;A5B B28Y          BHA2;;A5B B281          BHA2;;U1S S2415;;U1S S2417;;U1S S2418,0,0,,,,EXPIRED
516,US,A1,US 2014/0236611 A1,064-413-491-750-145,2014-08-21,2014,US 201414179782 A,2014-02-13,US 201414179782 A;;US 201361765923 P,2013-02-18,PROXIMITY TRACKING SYSTEMS AND METHOD,"Systems and methods to track proximity of articles, locations and people are disclosed herein. Radio frequency tags are configured to communicate proximity of articles, locations and people over time.",HILL ROM SERVICES INC;;HILL ROM SERVICES INC,RIBBLE DAVID L;;DIXON STEVEN A,HILL-ROM SERVICES INC (2014-02-17),https://lens.org/064-413-491-750-145,Patent Application,yes,1,23,1,1,0,G16H40/20;;G16H40/20,G06F19/00,705/2;;340/539.13,0,0,,,,DISCONTINUED
517,NZ,A,NZ 552453 A,063-169-328-470-751,2009-09-25,2009,NZ 55245305 A,2005-07-11,US 58702004 P;;US 2005/0024470 W,2004-07-09,Genetic manipulation of condensed tannins,"Provided is a transgenic plant transformed with a first selected DNA encoding TT2 and a second selected DNA encoding a BAN polypeptide, wherein the plant expresses the first selected DNA encoding TT2 and exhibits increased condensed tannin biosynthesis relative to a second plant that differs from the transgenic plant only in that the first selected DNA is absent. Further provided are methods of producing said plants and methods of producing human food using said plants.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;SHARMA SHASHI B,,https://lens.org/063-169-328-470-751,Patent Application,no,0,0,9,9,0,C12N9/0004;;C12N9/0004;;C07K14/415;;C07K14/415;;C12N9/0093;;C12N9/0093;;C12N15/8223;;C12N15/8223;;C12N15/8234;;C12N15/8234;;C12N15/8243;;C12N15/8243;;C12N15/825;;C12N15/825,A01H5/00;;C12N15/29;;C12N15/52;;C12N15/82,,0,0,,,,PENDING
518,US,S,US D0253887 S,065-515-022-971-416,1980-01-08,1980,US 81145777 F,1977-06-28,US 81145777 F,1977-06-28,Panel for an electronic module,,TURNER JAMES F;;DIXON GARY A,TURNER JAMES F;;DIXON GARY A,,https://lens.org/065-515-022-971-416,Design Right,yes,6,0,1,1,0,,,D13/35;;D1303,0,0,,,,EXPIRED
519,AU,B2,AU 776161 B2,071-749-836-724-771,2004-08-26,2004,AU 2000/037287 A,2000-03-08,US 12326799 P;;US 0005915 W,1999-03-08,Genetic manipulation of isoflavonoids,,SAMUEL ROBERTS NOBLE FOUND INC,STEELE CHRISTOPHER L;;DIXON RICHARD A,,https://lens.org/071-749-836-724-771,Granted Patent,no,1,0,7,8,0,C12N9/0077;;C07K2319/00;;C12N15/8242;;C12N15/8243;;C12N15/8261;;C12N15/8279;;Y02A40/146,C12N9/02;;C12N15/53;;C12N15/82,,0,0,,,,EXPIRED
520,JP,A,JP 2015157750 A,084-689-619-638-869,2015-09-03,2015,JP 2015048475 A,2015-03-11,GB 0918228 A,2009-10-19,HEATABLE WINDOW GLASS,"PROBLEM TO BE SOLVED: To provide a heatable window glass.SOLUTION: Provided is a heatable window glass 3 including a window glass material pane 4, at least one high-resistance bus bar 12a or 12b, and at least one low-resistance bus bar 16a or 16b, disposed on the pane 4, and in which the high-resistance bus bar 12a,12b and low-resistance bus bar 16a,16b can be electrically connected to a resistance-heating element 6a,6b for heating the window glass 3, the high-resistance bus bar 12a,12b has a per unit length predetermined resistance of 0.25 to 0.04 Ω/m, and the high-resistance bus bar 12a,12b and low-resistance bus bar 16a,16b can independently be electrically connected to a power source.",PILKINGTON GROUP LTD,JONATHAN BARCLAY DIXON;;CHAMBERLAIN MARK A,,https://lens.org/084-689-619-638-869,Patent Application,no,4,4,12,12,0,B32B17/10091;;B32B17/10091;;B32B17/10385;;B32B17/10385;;H05B3/84;;H05B3/84;;H05B2203/016;;H05B2203/016;;H05B2203/031;;H05B2203/031,C03C17/06;;B60S1/58;;C03C27/12,,0,0,,,,ACTIVE
521,US,A1,US 2019/0017060 A1,081-193-087-658-958,2019-01-17,2019,US 201816037042 A,2018-07-17,US 201816037042 A;;US 201762533356 P,2017-07-17,MANIPULATION OF PROANTHOCYANIDIN (PA) COMPOSITION BY AFFECTING ANTHOCYANIDIN SYNTHASE (ANS) AND LEUCOANTHOCYANIDIN DIOXYGENASE (LDOX),"Using methods described in preferred embodiments, the composition of proanthocyanidins (PAs) in plants can be modified to produce plants that produce PAs with specific selections of catechin or epicatechin starter units, as well as specific selections of catechin or epicatechin extension units. Reduction or elimination of expression of the leucoanthocyanidin dioxygenase (ldox) gene or the anthocyanidin synthase (ans) gene, or both, is implemented in preferred embodiments to produce modified plants having modified PA content.",UNIV NORTH TEXAS,DIXON RICHARD A;;JUN JI HYUNG,UNIVERSITY OF NORTH TEXAS (2018-08-02),https://lens.org/081-193-087-658-958,Patent Application,yes,0,1,1,1,14,C12N9/0071;;C12N15/8243;;C12N15/8243;;C12N9/0071,C12N15/82,,0,0,,,,DISCONTINUED
522,CN,A,CN 105917116 A,090-178-708-016-60X,2016-08-31,2016,CN 201580006051 A,2015-01-27,US 201414164879 A;;US 2015/0012979 W,2014-01-27,DUAL PURPOSE SLAT-SPOILER FOR WIND TURBINE BLADE,"An aerodynamic slat (30) mounted over a forward suction side (40) of a wind turbine blade (22) and a mechanism (51A-F) that closes or reduces a gap (31) between slat and blade. The slat may pivot to reduce the gap, or the gap may be reduced by a device such as an extendable gate (58), or butterfly plate (59), or damper plate (60). Control logic (64) activates an actuator (70) of the mechanism to close or reduce the gap when wind conditions meet or exceed a predetermined criterion such as a rated wind condition. This reduces wind loading on the blade by separating airflow (53) over the suction side of the blade downstream of the slat. The blades can then maintain a higher angle of attack during rated wind conditions than in the prior art, allowing them to stall in gusts sooner to limit peak aerodynamic loads.",SIEMENS AG,DIXON KRISTIAN R;;MAYDA EDWARD A?,,https://lens.org/090-178-708-016-60X,Patent Application,no,4,3,4,4,0,F03D7/0232;;F03D7/0232;;F03D7/022;;F03D7/022;;F03D7/0256;;F03D7/0256;;F05B2240/305;;F05B2240/3052;;Y02E10/72;;Y02E10/72,F03D7/02,,0,0,,,,DISCONTINUED
523,EP,A1,EP 3055556 A1,099-131-480-320-03X,2016-08-17,2016,EP 13780029 A,2013-10-09,US 2013/0064060 W,2013-10-09,HINGED VORTEX GENERATOR FOR EXCESS WIND LOAD REDUCTION ON WIND TURBINE,,SIEMENS AG,DIXON KRISTIAN R;;MAYDA EDWARD A,SIEMENS AKTIENGESELLSCHAFT (2017-08-30);;SIEMENS GAMESA RENEWABLE ENERGY A/S (2019-05-15),https://lens.org/099-131-480-320-03X,Patent Application,yes,0,2,2,7,0,F03D7/0224;;F03D1/0675;;F05B2240/31;;F05B2260/502;;Y02E10/72;;F05B2240/3062,F03D7/02;;F03D1/06,,0,0,,,,DISCONTINUED
524,DE,A1,DE 2905533 A1,104-596-448-585-969,1979-08-30,1979,DE 2905533 A,1979-02-14,US 87885878 A,1978-02-17,FOTOEMPFINDLICHE BESCHICHTUNG,,WESTINGHOUSE ELECTRIC CORP,SATTLER FRANK A;;DIXON GEORGE D,,https://lens.org/104-596-448-585-969,Patent Application,no,3,0,11,11,0,C08F283/01;;C08F299/0478;;C08G63/6854;;C09D167/00;;Y10T428/31681;;Y10T428/31681;;C08F299/0478;;C08G63/6854;;C08F283/01;;C09D167/00,C08F299/00;;C08F2/50;;C08F283/01;;C08F299/04;;C08G63/00;;C08G63/52;;C08G63/685;;C09D4/00;;C09D167/00,,0,0,,,,DISCONTINUED
525,CA,A,CA 740509 A,109-415-406-808-905,1966-08-09,1966,CA 740509D A,,CA 740509T A,,LOW LOSS HEAT MOUNTING SYSTEM,,UNITED AIRCRAFT CORP,DIXON ROBERT W;;HORROCKS REX A,,https://lens.org/109-415-406-808-905,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
526,US,B2,US 11113750 B2,121-035-641-385-359,2021-09-07,2021,US 201916353953 A,2019-03-14,US 201916353953 A;;US 201514944029 A;;US 201462080874 P,2014-11-17,System and method for electronic manifesting in a distribution network,"System and method for providing electronic manifesting access for users of a distribution network. A distribution network may provide a user access point, such as by providing application programming interfaces. The access point may provide access the item tracking module upon receipt of valid credentials, such as a user's unique identifier. The access point may receive item information, generate an electronic manifest including the item information and the unique identifier, and allow for tracking the items on the electronic manifest.",UNITED STATES POSTAL SERVICE,DIXON ROBERT E;;SULLIVAN KELLEY A,UNITED STATES POSTAL SERVICE (2015-01-06),https://lens.org/121-035-641-385-359,Granted Patent,yes,13,0,4,4,0,G06Q10/0833;;G06Q30/0635;;G06Q10/0833;;G06Q30/0635;;B07C7/005,G06Q30/06;;B07C7/00;;G06Q10/08,,0,0,,,,ACTIVE
527,WO,A1,WO 2000/071736 A1,159-213-803-700-20X,2000-11-30,2000,US 0013389 W,2000-05-15,US 13502699 P,1999-05-20,ISOFLAVONOID METHYLATION ENZYME,"Methods of genetically manipulating biologically active 4'-O-methylated isoflavonoids have been found based upon the regiospecifity of isoflavone 7-OMT in vivo. Upon transformation and expression of an isoflavonoid O-methyltransferase gene, up-regulation of IOMT in the transgenic plants can be used to increase the accumulation of 4'-O-methylated isoflavonoid phytolalexins, providing for increased disease resistance to the plant. Similar methods can be used to increase accumulation of 4'-O-methylated isoflavonoid nutraceuticals in plants. For down-regulation of IOMT in plants that naturally make 4'O-isoflavonoid phytoalexins and 4'-O-methylated isoflavonoid nutraceuticals, IOMT gene sequences can be transformed in the antisense orientation.",SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;HE XIAN Z,DIXON RICHARD A;;HE XIAN Z,,https://lens.org/159-213-803-700-20X,Patent Application,yes,3,4,7,10,5,A61P5/30;;A61P7/00;;A61P31/04;;A61P35/00;;A61P39/06;;C12N15/8282;;C12N9/1007;;C12N15/8243;;C12N15/825,A01H5/00;;A23L1/30;;A61K31/352;;A61K36/48;;A61P5/30;;A61P7/00;;A61P31/04;;A61P35/00;;A61P39/06;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/29;;C12N15/82;;C12P17/06,,4,4,010-635-987-157-26X;;010-635-987-157-26X;;061-037-398-447-63X;;137-080-525-194-284,9484461;;10.1023/a:1005938121453;;9484461;;10.1023/a:1005938121453;;9781295;;10.1007/978-1-4615-5335-9_5;;10.1007/978-1-4615-4689-4_6,"HE XIAN-ZHI ET AL: ""Stress responses in alfalfa (Medicago sativa L). XXII. cDNA cloning and characterization of an elicitor-inducible isoflavone 7-0-methyltransferase"", PLANT MOLECULAR BIOLOGY,NL,NIJHOFF PUBLISHERS, DORDRECHT, vol. 36, no. 1, 1 January 1998 (1998-01-01), pages 43 - 54, XP002139377, ISSN: 0167-4412;;DATABASE EMBL SEQUENCE LIBRARY 5 November 1997 (1997-11-05), HE, X., ET AL.: ""Stress responses in alfalfa (Medicago sativa L). XXII. cDNA cloning and characterization of an elicitor-inducible isoflavone 7-0-methyltransferase"", XP002148151;;DIXON R A ET AL: ""PROSPECTS FOR THE METABOLIC ENGINEERING OF BIOACTIVE FLAVONOIDS AND RELATED PHENYLPROPANOID COMPOUNDS"", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY,SPRING ST., NY,US, vol. 439, 1998, pages 55 - 66, XP000929350, ISSN: 0065-2598;;DIXON, R.A. ET AL.: ""molecular controls for isoflavonoid biosynthesis in relation to plant and human health"", PHYTOCHEMICALS IN HUMAN HEALTH PROTECTION, NUTRITION, AND PLANT DEFENCE: KLUWER ACADEMIC/PLENUM PUBLISHERS. EDITED BY J.T. ROMEO. NEW YORK ISBN: 0-306-46203-6, September 1999 (1999-09-01), pages 133 - 159, XP000925618",PATENTED
528,US,A,US 896631 A,177-487-942-868-513,1908-08-18,1908,US 1904/0203631 A,1904-04-18,US 1904/0203631 A,1904-04-18,METHOD OF SHAPING GLASS.,,DIXON HENRY L;;MARSH GEORGE A,DIXON HENRY L;;MARSH GEORGE A,,https://lens.org/177-487-942-868-513,Granted Patent,no,0,3,1,1,0,C03B7/08;;C03B7/08,,,0,0,,,,EXPIRED
529,CA,A,CA 509205 A,199-490-690-548-112,1955-01-18,1955,CA 509205D A,,CA 509205T A,,METHOD OF ISOLATING DIHALOGENOPYRAZINES,,AMERICAN CYANAMID CO,DIXON JAMES K;;MILLER ALEXANDER A,,https://lens.org/199-490-690-548-112,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
530,US,B2,US 7317717 B2,081-395-715-732-035,2008-01-08,2008,US 83202804 A,2004-04-26,US 83202804 A,2004-04-26,Integrated wireline and wireless end-to-end virtual private networking,"An end-to-end virtual private networking system transports network packets securely through a public data network. A mobile device comprises an application client and a wireless roaming client managing data transfer from the mobile device to the public data network via one of a plurality of predetermined wireless links. A roaming gateway is located in a data center and is coupled to the public data network for tracking the plurality of predetermined wireless links and for managing data transfer from the public data network to the mobile device via one of the plurality of predetermined wireless links. An enterprise server is provided in a private enterprise for exchanging network packets with the application client in the mobile device. A CPE-VPN router in the private enterprise network is coupled to the enterprise server and to the public data network. A VPN router located in the data center is coupled to the roaming gateway and to the public data network, wherein the VPN router and the CPE-VPN router establish a VPN tunnel therebetween via the public data network. The CPE-VPN router transports the network packets between the enterprise server and the VPN tunnel. The VPN router transports the network packets between the roaming gateway and the VPN tunnel.",SPRINT COMMUNICATIONS CO,PANKAJAKSHAN BEJOY;;ZAMORA PEDRO A;;DIXON MATHEW A,T-MOBILE INNOVATIONS LLC (2021-03-03);;SPRINT COMMUNICATIONS COMPANY LP (2004-04-22),https://lens.org/081-395-715-732-035,Granted Patent,yes,6,34,4,4,0,H04L12/66;;H04L12/66;;H04L12/5692;;H04L12/5692;;H04L63/0272;;H04L63/0272;;H04W12/03;;H04W12/03;;H04W24/00;;H04W24/00;;H04W88/16;;H04W88/16;;H04W92/02;;H04W92/02,H04L12/66;;H04L12/28;;H04L12/56;;H04L29/06;;H04W12/00;;H04W24/00;;H04W88/16;;H04W92/02,370/352;;370/401;;726/15,1,0,,,"PADCOM, Inc., Total Roam Technical Overview, Mar. 25, 2004, pp. 1-39.",ACTIVE
531,US,A1,US 2020/0101696 A1,086-613-353-682-337,2020-04-02,2020,US 201916256825 A,2019-01-24,US 201916256825 A;;US 201862737687 P,2018-09-27,PLUGGING ANODIC OXIDES FOR INCREASED CORROSION RESISTANCE,"This application relates to an enclosure for a portable electronic device. The enclosure includes a metal substrate and a dehydrated anodized layer overlaying the metal substrate. The dehydrated anodized layer includes pores having openings that extend from an external surface of the dehydrated anodized layer and towards the metal substrate, and a metal oxide material that plugs the openings of the pores, where a concentration of the metal oxide material is between about 3 wt % to about 10 wt %.",APPLE INC,CURRAN JAMES A;;LI HOISHUN;;DIXON NATHANIEL A,APPLE INC (2019-01-15),https://lens.org/086-613-353-682-337,Patent Application,yes,0,0,4,4,0,H05K5/00;;C25D11/02;;B32B1/00;;B32B15/043;;B32B3/30;;B32B2307/20;;B32B2307/714;;B32B2311/24;;B32B2307/752;;B32B5/145;;B32B5/147;;B32B15/04;;B32B15/20;;Y10T428/24273;;Y10T428/24331;;B32B2307/7265;;Y10T428/249956;;B32B2307/40;;B32B33/00;;Y10T428/24942;;B32B2457/00;;Y10T428/24339;;B32B2307/402;;C25D11/18;;C25D11/243;;C25D11/16;;C25D11/14;;H05K5/04;;H05K5/0243;;C25D11/02,B32B15/04;;B32B3/30,,0,0,,,,ACTIVE
532,US,A1,US 2018/0207143 A1,106-271-641-230-833,2018-07-26,2018,US 201715412622 A,2017-01-23,US 201715412622 A,2017-01-23,Aqueous Suspensions Of Oximes For Autoinjectors,"The present invention is directed at aqueous suspensions of oxime compounds, such as 2-pyridine aldoxime methyl chloride (2-PAM Cl) for autoinjectors. The suspensions are able to provide 600 mg of 2-PAM Cl in one relatively small dose of less than or equal to 1.0 mL, and are particularly useful for placement in relatively small size autoinjectors.",SOUTHWEST RES INST,DIXON HONG;;MCDONOUGH JOSEPH A;;CABELL LARRY A,SOUTHWEST RESEARCH INSTITUTE (2017-03-27),https://lens.org/106-271-641-230-833,Patent Application,yes,0,0,2,2,0,A61K31/4425;;A61K31/46;;A61K9/0024;;A61K47/10;;A61K9/10;;A61K31/44;;A61K31/439;;A61M5/32;;A61M5/3287;;A61M5/20;;A61M5/3157;;A61M2005/2026;;A61K31/4425;;A61K9/0024;;A61K47/10;;A61K31/46;;A61K9/10,A61K31/44;;A61K31/439;;A61M5/20;;A61M5/315;;A61M5/32,,0,0,,,,ACTIVE
533,WO,A3,WO 2005/109800 A3,192-109-514-963-640,2007-07-12,2007,US 2005/0011933 W,2005-04-08,US 83202804 A,2004-04-26,INTEGRATED WIRELINE AND WIRELESS END-TO-END VIRTUAL PRIVATE NETWORKING,"An end-to-end virtual private networking system transports network packets securely through a public data network. A mobile device comprises an application client and a wireless roaming client managing data transfer from the mobile device to the public data network via one of a plurality of predetermined wireless links. A roaming gateway is located in a data center and is coupled to the public data network for tracking the plurality of predetermined wireless links and for managing data transfer from the public data network to the mobile device via one of the plurality of predetermined wireless links. An enterprise server is provided in a private enterprise for exchanging network packets with the application client in the mobile device. A CPE-VPN router in the private enterprise network is coupled to the enterprise server and to the public data network. A VPN router located in the data center is coupled to the roaming gateway and to the public data network, wherein the VPN router and the CPE-VPN router establish a VPN tunnel therebetween via the public data network. The CPE VPN router transports the network packets between the enterprise server and the VPN tunnel. The VPN router transports the network packets between the roaming gateway and the VPN tunnel.",SPRINT COMMUNICATIONS CO;;PANKAJAKSHAN BEJOY;;ZAMORA PEDRO A;;DIXON MATHEW A,PANKAJAKSHAN BEJOY;;ZAMORA PEDRO A;;DIXON MATHEW A,,https://lens.org/192-109-514-963-640,Search Report,yes,2,0,4,4,0,H04L12/66;;H04L12/66;;H04L12/5692;;H04L12/5692;;H04L63/0272;;H04L63/0272;;H04W12/03;;H04W12/03;;H04W24/00;;H04W24/00;;H04W88/16;;H04W88/16;;H04W92/02;;H04W92/02,H04L12/28;;G06F15/16;;H04L12/56;;H04L12/66;;H04L29/06;;H04W12/00;;H04W24/00;;H04W88/16;;H04W92/02,,0,0,,,,PENDING
534,US,B2,US 11312107 B2,099-968-951-331-128,2022-04-26,2022,US 201916256825 A,2019-01-24,US 201916256825 A;;US 201862737687 P,2018-09-27,Plugging anodic oxides for increased corrosion resistance,"This application relates to an enclosure for a portable electronic device. The enclosure includes a metal substrate and a dehydrated anodized layer overlaying the metal substrate. The dehydrated anodized layer includes pores having openings that extend from an external surface of the dehydrated anodized layer and towards the metal substrate, and a metal oxide material that plugs the openings of the pores, where a concentration of the metal oxide material is between about 3 wt % to about 10 wt %.",APPLE INC,CURRAN JAMES A;;LI HOISHUN;;DIXON NATHANIEL A,APPLE INC (2019-01-15),https://lens.org/099-968-951-331-128,Granted Patent,yes,159,0,4,4,0,H05K5/00;;C25D11/02;;B32B1/00;;B32B15/043;;B32B3/30;;B32B2307/20;;B32B2307/714;;B32B2311/24;;B32B2307/752;;B32B5/145;;B32B5/147;;B32B15/04;;B32B15/20;;Y10T428/24273;;Y10T428/24331;;B32B2307/7265;;Y10T428/249956;;B32B2307/40;;B32B33/00;;Y10T428/24942;;B32B2457/00;;Y10T428/24339;;B32B2307/402;;C25D11/18;;C25D11/243;;C25D11/16;;C25D11/14;;H05K5/04;;H05K5/0243;;C25D11/02,B32B3/30;;B32B5/14;;B32B15/04;;B32B15/20;;B32B33/00;;C25D11/02;;C25D11/14;;C25D11/16;;C25D11/18;;C25D11/24;;H05K5/02;;H05K5/04,,26,17,127-426-072-399-625;;009-820-897-272-781;;039-434-806-466-410;;024-536-830-627-07X;;125-705-903-977-203;;146-223-749-806-288;;025-345-005-726-769;;051-434-012-797-765;;169-279-663-368-667;;021-829-649-437-474;;004-277-583-501-920;;059-736-372-910-949;;016-464-005-667-266;;052-688-741-694-199;;004-429-529-586-820;;050-623-202-090-345;;014-875-080-362-407,10.1038/218707a0;;10.1149/1.2401679;;10.1016/s0026-0576(01)80002-7;;10.1149/1.1393301;;10.1149/1.2163811;;10.1016/j.surfcoat.2005.03.019;;10.1007/978-0-387-92263-8_2;;10.1179/174329409x409459;;10.4028/www.scientific.net/amr.337.77;;10.5402/2012/323676;;10.1016/j.surfcoat.2012.05.023;;10.1016/j.apsusc.2013.07.047;;10.1016/j.surfcoat.2012.05.071;;10.4028/www.scientific.net/amm.577.11;;10.1016/j.corsci.2015.03.021;;28465572;;pmc5430995;;10.1038/s41598-017-01549-y;;10.1016/j.ejpe.2017.07.014,"Machine Translation of AT262714B, Jun. 1968 (Year: 1968).;;Alwitt, The Growth of Hydrous Oxide Films on Aluminum, 1974, Journal of The Electrochemical Society, vol. 121 (Year: 1974).;;Machine Translation of JP11229185A, Aug. 1999 (Year: 1999).;;Hao et al., Sealing processes of anodic coatings—Past, present, and future, Dec. 2000, Metal Finishing, vol. 98, Issue 12, pp. 8-18 (Year: 2000).;;González et al., Postsealing Changes in Porous Aluminum Oxide Films Obtained in Sulfuric Acid Solutions, 2000, Journal of The Electrochemical Society, vol. 147, No. 3 (Year: 2000).;;Krokidis et al., Theoretical Study of the Dehydration Process of Boehmite to γ-Alumina, May 2001, J. Phys. Chem. B, vol. 105, No. 22, pp. 5121-5130 (Year: 2001).;;Ventura et al., Sealing Method for Anodizing Aluminium and Hard Anodizing and Test For Seal Quality of Aluminium, 2004 (Year: 2004).;;López et al., Comparison by SEM, TEM, and EIS of Hydrothermally Sealed and Cold Sealed Aluminum Anodic Oxides, Jan. 2006, Journal of The Electrochemical Society, vol. 153, No. 3 (Year: 2006).;;Bartolomé et al., Changes in the specific surface area of porous aluminium oxide films during sealing, Apr. 2006, Surface and Coatings Technology, vol. 200, Issues 14-15, pp. 4530-4537 (Year: 2006).;;Machine Translation of DE102007057777A1, Jun. 2009 (Year: 2009).;;Machine Translation of KR20100089197A, Aug. 2010 (Year: 2010).;;Ono et al., Sealing Mechanism of Anodic Porous Oxide Films Formed on Aluminum in Lithium Hydroxide Solution, Sep. 2010, Proceedings of the 12th International Conference on Aluminum Alloys, (Year: 2010).;;Takahashi et al., Anodic Oxide Films on Aluminum: Their Significance for Corrosion Protection and Micro- and Nano-Technologies, Jan. 2010, Modern Aspects of Series Editors: Electrochemistry, No. 46: Progress in Corrosion Science and Engineering I (Year: 2010).;;Liu et al., Abstract for “Study on corrosion resistance properties of hydrothermal sealed arc sprayed aluminium coating”, Aug. 2010, Surface Engineering, vol. 26, No. 6 (Year: 2010).;;Zhou et al., Abstract for “Influence of Technological Parameter on Boehmite Sol Sealing Anodized Al 2024 Alloy”, Sep. 2011, Advanced Materials Research, vol. 337, pp. 77-80 (Year: 2011).;;Franco et al., Porous Layer Characterization of Anodized and Black-Anodized Aluminium by Electrochemical Studies, Dec. 2012, International Scholarly Research Notices, vol. 2012 (Year: 2012).;;Hakimizad et al., A comparative study of corrosion performance of sealed anodized layers of conventionally colored and interference-colored aluminium, Jun. 2012, Surface and Coatings Technology, vol. 206, Issue 22, pp. 4628-4633 (Year: 2012).;;Lee et al., Effects of residual water in the pores of aluminum anodic oxide layers prior to sealing on corrosion resistance, Oct. 2013, Applied Surface Science, vol. 283, pp. 941-946 (Year: 2013).;;Machine Translation of JP2014136832A, Jul. 2014 (Year: 2014).;;Lee et al., Cr2O3 sealing of anodized aluminum alloy by heat treatment, Mar. 2014, Surface and Coatings Technology, vol. 243, pp. 34-38 (Year: 2014).;;Liu et al., Abstract for “Preparation and Effect of Heat Treatment Temperature on the Crystal Phase of Anodic Aluminum Oxide Films” Jul. 2014, Applied Mechanics and Materials, vol. 577 (Year: 2014).;;Machine Translation of CN105297104A, Feb. 2016 (Year: 2016).;;Machine Translation of CN105937046A, Sep. 2016 (Year: 2016).;;Hu et al., Effect of sealing on the morphology of anodized aluminum oxide, Aug. 2016, Corrosion Science, vol. 97, pp. 17-24 (Year: 2016).;;Wu et al., Novel anodic oxide film with selfsealing layer showing excellent corrosion resistance, May 2017, Scientific Reports, vol. 7 (Year: 2017).;;Abdel-Salam et al., “Characterization of the hard anodizing layers formed on 2014-T3 Al alloy, in sulphuric acid electrolyte containing sodium lignin sulphonate,” Egyptian Journal of Petroleum, Aug. 9, 2017 <https://doi.org/10.1016/j.ejpe.2017.07.014>, 8 pages.",ACTIVE
535,US,A1,US 2005/0237982 A1,170-058-682-696-144,2005-10-27,2005,US 83202804 A,2004-04-26,US 83202804 A,2004-04-26,Integrated wireline and wireless end-to-end virtual private networking,"An end-to-end virtual private networking system transports network packets securely through a public data network. A mobile device comprises an application client and a wireless roaming client managing data transfer from the mobile device to the public data network via one of a plurality of predetermined wireless links. A roaming gateway is located in a data center and is coupled to the public data network for tracking the plurality of predetermined wireless links and for managing data transfer from the public data network to the mobile device via one of the plurality of predetermined wireless links. An enterprise server is provided in a private enterprise for exchanging network packets with the application client in the mobile device. A CPE-VPN router in the private enterprise network is coupled to the enterprise server and to the public data network. A VPN router located in the data center is coupled to the roaming gateway and to the public data network, wherein the VPN router and the CPE-VPN router establish a VPN tunnel therebetween via the public data network. The CPE-VPN router transports the network packets between the enterprise server and the VPN tunnel. The VPN router transports the network packets between the roaming gateway and the VPN tunnel.",PANKAJAKSHAN BEJOY;;ZAMORA PEDRO A;;DIXON MATHEW A,PANKAJAKSHAN BEJOY;;ZAMORA PEDRO A;;DIXON MATHEW A,T-MOBILE INNOVATIONS LLC (2021-03-03);;SPRINT COMMUNICATIONS COMPANY LP (2004-04-22),https://lens.org/170-058-682-696-144,Patent Application,yes,5,30,4,4,0,H04L12/66;;H04L12/66;;H04L12/5692;;H04L12/5692;;H04L63/0272;;H04L63/0272;;H04W12/03;;H04W12/03;;H04W24/00;;H04W24/00;;H04W88/16;;H04W88/16;;H04W92/02;;H04W92/02,H04L12/28;;H04L12/56;;H04L12/66;;H04L29/06;;H04W12/00;;H04W24/00;;H04W88/16;;H04W92/02,370/338;;370/352,0,0,,,,ACTIVE
536,US,B2,US 10117859 B2,053-902-714-579-348,2018-11-06,2018,US 201615193254 A,2016-06-27,US 201615193254 A,2016-06-27,Dosage suspensions of active pharmaceutical ingredients,Methods for preparing suspensions of active pharmaceutical ingredients for ensuing drug delivery. The suspension may include a mixture of a relatively low dosage API and a relatively high dosage API or a mixture of an API with a suitable excipient.,SOUTHWEST RES INST,DIXON HONG;;CABELL LARRY A;;MCDONOUGH JOSEPH A,SOUTHWEST RESEARCH INSTITUTE (2016-07-11),https://lens.org/053-902-714-579-348,Granted Patent,yes,6,0,2,2,0,A61K45/06;;A61K9/10;;A61K47/44;;A61K9/14;;A61K31/46;;A61K31/444;;A61K31/444;;A61K31/5375;;A61K31/439;;A61K9/14;;A61K47/44;;A61K31/46;;A61K9/10;;A61K45/06,A61K31/444;;A61K31/439;;A61K31/5375,,1,1,043-017-411-520-037,10.1016/j.ijpharm.2014.10.011;;25305380,"Santovena, A., et al “Study of Quality and Stability of Ursodeoxycholic Acid Formulations for Oral Pediatric Administration”, International Journal of Pharmaceutics 477 (2014) pp. 32-38.",ACTIVE
537,CN,A,CN 110958790 A,051-440-004-430-198,2020-04-03,2020,CN 201910459794 A,2019-05-30,US 201862737687 P;;US 201916256825 A,2018-09-27,PLUGGING ANODIC OXIDES FOR INCREASED CORROSION RESISTANCE,"The disclosure relates to plugging anodic oxides for increased corrosion resistance. This application relates to an enclosure for a portable electronic device. The enclosure includes a metal substrateand a dehydrated anodized layer overlaying the metal substrate. The dehydrated anodized layer includes pores having openings that extend from an external surface of the dehydrated anodized layer andtowards the metal substrate, and a metal oxide material that plugs the openings of the pores, where a concentration of the metal oxide material is between about 3 wt % to about 10 wt %.",APPLE INC,CURRAN JAMES A;;LI HOISHUN;;DIXON NATHANIEL A,,https://lens.org/051-440-004-430-198,Patent Application,no,22,1,4,4,0,H05K5/00;;C25D11/02;;B32B1/00;;B32B15/043;;B32B3/30;;B32B2307/20;;B32B2307/714;;B32B2311/24;;B32B2307/752;;B32B5/145;;B32B5/147;;B32B15/04;;B32B15/20;;Y10T428/24273;;Y10T428/24331;;B32B2307/7265;;Y10T428/249956;;B32B2307/40;;B32B33/00;;Y10T428/24942;;B32B2457/00;;Y10T428/24339;;B32B2307/402;;C25D11/18;;C25D11/243;;C25D11/16;;C25D11/14;;H05K5/04;;H05K5/0243;;C25D11/02,H05K5/00;;C25D11/02,,0,0,,,,ACTIVE
538,US,B2,US 10350200 B2,157-973-616-284-617,2019-07-16,2019,US 201715412622 A,2017-01-23,US 201715412622 A,2017-01-23,Aqueous suspensions of oximes for autoinjectors,"The present invention is directed at aqueous suspensions of oxime compounds, such as 2-pyridine aldoxime methyl chloride (2-PAM Cl) for autoinjectors. The suspensions are able to provide 600 mg of 2-PAM Cl in one relatively small dose of less than or equal to 1.0 mL, and are particularly useful for placement in relatively small size autoinjectors.",SOUTHWEST RES INST,DIXON HONG;;MCDONOUGH JOSEPH A;;CABELL LARRY A,SOUTHWEST RESEARCH INSTITUTE (2017-03-27),https://lens.org/157-973-616-284-617,Granted Patent,yes,16,0,2,2,0,A61K31/4425;;A61K31/46;;A61K9/0024;;A61K47/10;;A61K9/10;;A61K31/44;;A61K31/439;;A61M5/32;;A61M5/3287;;A61M5/20;;A61M5/3157;;A61M2005/2026;;A61K31/4425;;A61K9/0024;;A61K47/10;;A61K31/46;;A61K9/10,A61K31/44;;A61K31/439;;A61M5/20;;A61M5/315;;A61M5/32,,28,19,114-242-728-907-242;;021-692-258-954-082;;063-744-309-561-840;;103-746-044-229-145;;052-331-592-234-540;;098-484-038-361-784;;064-811-078-805-580;;094-729-426-663-693;;021-692-258-954-082;;118-693-076-468-966;;135-080-023-398-620;;026-926-623-362-503;;018-836-597-525-866;;091-245-849-136-06X;;073-591-942-773-185;;026-609-720-347-736;;007-546-909-269-87X;;005-060-294-901-732;;001-178-949-154-765,10.1002/jat.1143;;16583462;;10.1002/jps.2600780905;;2585264;;10.7748/ns.29.4.52.e9183;;25249123;;10.1002/jps.2600710926;;7131276;;10.1016/j.jcrysgro.2004.05.084;;10.1177/1091581813490204;;23929446;;10.31482/mmsl.2014.004;;23929445;;10.1177/1091581813489314;;10.1002/jps.2600780905;;2585264;;10.1016/j.saa.2011.01.012;;21324730;;10.1001/dmp.2011.86;;22125290;;10.14429/dsj.62.1130;;10.1002/dta.327;;21953823;;25276588;;10.9745/ghsp-d-14-00043;;pmc4168628;;4420469;;10.1002/cpt1974164711;;10.1016/j.fluid.2009.08.006;;20383314;;pmc2850219;;10.1111/j.1742-7843.2005.pto_97108.x;;15943759;;10.14429/dsj.62.2317;;10.1016/j.porgcoat.2011.08.001,"The Product Description of Pralidoxime Chloride Injection from Meridian Medical Technologies (downloaded Aug. 25, 2017 from: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=2520.;;G.A. Petroianu, S. M. Nurulain, N. Nagelkerke, M. A. H. Al-Sultan, K. Kuça and J. Kassa. Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: survival in rats exposed to the organophosphate paraoxon. J. Appl. Toxicol. 2006; 26: 262-268.;;Karl E. Friedl, Charles J. Hannan Jr ., Paul w. Schadler and Willis H. Jacob. Journal of Pharmaceutical Sciences, vol. 78, No. 9, pp. 728-731, 1989. (Year: 1989).;;S. Ogston-Tuck, Intramuscular injection technique: an evidence-based approach. Nursing Standard, 29, 4, 52-59, 2014. (Year: 2014).;;Robert I. Ellin. “Stability of Concentrated Aqueous Solutions of Pralidoxime Chloride.” Journal of Pharmaceutical Sciences vol. 71, No. 9, Sep. 1982, pp. 1057-1059 (Year: 1982).;;Choi, B. S., et al: “Stabilizing NaCl Particles with Cd2+ in a Saturated Solution During ex situ PSD Measurement”; Journal of Crystal Growth 269, May 23, 2004 (9 pgs).;;Clark, A. P.-Z, et al: “Good Manufacturing Practice: Manufacturing of a Nerve Agent Antidote Nanoparticle Suspension”; International Journal of Toxicology 32 (Supplement 2), 2013, (pp. 5S-17S).;;Clark A. P.-Z, et al: “Non-Newtonian Suspension Formulations for Improved Stability and Delivery of Autoinjectable CBRN Countermeasures”; Military Medical Science Letters 2014, vol. 83, Apr. 7, 2014, pp. 18-27.;;Dixon, H., et al; “MMB4 DMS Nanoparticle Suspension Formulation With Enhanced Stability for the Treatment of Nerve Agent Intoxication”; International Journal of Toxicology 32 (Supplement 2), 2013, pp. 18S-29S.;;Friedl, K. E., et al; “Atropine Absorption after Intramuscular Administration with 2-Pralidoxime Chloride by Two Automatic Injector Devices”; Journal of Pharmaceutical Sciences, vol. 78, No. 9, Sep. 1989, pp. 728-731.;;Grosev, V.M., et al; “Vibrational Analysis of 1-methyl-pyridinium-2-aldoxime and 1-methyl-pyridinium-4-aldoxime cations”; Spectrochimica ACTA Part A: Molecular & Biomolecular Spectroscopy, vol. 78A, Issue 5, May 2011, pp. 1376-1379.;;Hoffman, M.D., R.S., et al; “Preparing for Chemical Terrorism: A Study of the Stability of Expired Pralidoxime (2-PAM)”, Disaster Medicine and Public Health Preparedness, vol. 6, No. 1, 2012, pp. 20-25, American Medical Association, USA.;;Jain, N., et al; “Development and Evaluation of Combined Drug Formulation for Autoject-injector, for Emergency Application in Organophosphate Poisoning”; Defence Science Journal vol. 62, No. 2, Mar. 13, 2012, pp. 105-111.;;John, H., et al; “Review of UV Spectroscopic, Chromatographic, and Electrophoretic Methods for the Cholinesterase Reactivating Antidote Pralidoxime (2-PAM)”, Drug Test Analysis, vol. 4, 2012, pp. 179-193.;;Kumar, P., et al: “Shelf Life Studies of Pralidoxime Chloride Solution in Autoinjector Cartridges Stored at Room Temperature”; Current Trends in Biotechnology and Pharmacy vol. 2, 2008, (9 pgs).;;Mcalister, PhD, D.R.; “Gamma Ray Attenuation Properties of Common Shielding Materials”, Jan. 3, 2013, (14 pgs); PG Research Foundation Inc., Lisle Illinois USA.;;Mullany, L.C., et al; “Cumulative Effects of Heat Exposure and Storage Conditions of Oxytocin-in-Uniject in Rural Ghana: Implications for Scale Up”; Global Health: Science and Practice vol. 2, No. 3, 2014, pp. 285-294.;;O'Donnell, K.; “Mean Kinetic Temperature Storage vs. Shipping and the Vagaries of Regulatory Requirements”; Contract Pharma Times, Advanced Degrees, Jul./Aug. 2008, vol. 40, No. 10 (pp. 26-28).;;Sidell, M.D., F.R.; Modification by Diluents of Effects of Intramuscular Atropine on Heart Rate in Man; Clinical Pharmacology and Therapeutics, May 21, 1974, vol. 16, No. 4 (pp. 711-715).;;Smith, P.E.; “The Effect of Urea on the Morphology of NaCl Crystals: A Combined Theoretical and Simulation Study”; (author manuscript), National Institutes of Health Public Access, Fluid Phase Equilibrium (final edited published form), Mar. 25, 2010; , 290(1-2): pp. 36-42.;;Svendsen, O., et al; “Intramuscular Injection of Hypertonic Saline: In vitro and in vivo Muscle Tissue Toxicity and Spinal Neurone c-fos Expression”; Basic & Clinical Pharmacology & Toxicology, 2005, vol. 97 (pp. 52-57).;;VanHavre, W., et al; 2-[(Hydroxyimino)methyl]-1-methylpyridinium Chloride, ACTA Cryst. B38, 1982, pp. 2516-2518.;;Vijayaraghavan, R.; “Autoinjector Device for Rapid Administration of Live Saving Drugs in Emergency Situations,”; Defence Science Journal, vol. 62, No. 5, Sep. 2012 ( pp. 307-314).;;Zand, R.Z., et al; “The Corrosion Resistance of 316L Stainless Steel Coated With a Silane Hybrid Nanocomposite Coating”; Progress in Organic Coatings, Vo. 72, Aug. 2011, pp. 709-715.;;Nikipedia, Cottonseed Oil, <<https://en.wikipedia.org/wiki/Cottonseed_oil>> (accessed Feb. 7, 2017).;;BD Pharmaceuticals; “Auto-Disable Injection System”; <<http://www.bd.com/pharmaceuticals/products/auto-disable.asp>> (accessed Feb. 7, 2017).;;PATH: Uniject Injection System; “The Radically Simple Uniject™ Injection System Rethinking the Needle to Extend the Reach of Contraception, Medicines, and Vaccines”; <<http://www.path.org/projects/uniject.php >> (accessed Feb. 2, 2017—9 pgs).;;VAISALA/ Application Note, Cold Chain Compliance; “USP Guidance Chapters for Temperature-Controlled Supply Chains” <<http://www.vaisala.com/Vaisala%20Documents/Application%20notes/Application%20Note_Cold%20Chain%20Compliance%20USP.pdf>>; (accessed Feb. 7, 2017, 2 pgs).",ACTIVE
539,WO,A2,WO 2005/109800 A2,170-225-142-102-187,2005-11-17,2005,US 2005/0011933 W,2005-04-08,US 83202804 A,2004-04-26,INTEGRATED WIRELINE AND WIRELESS END-TO-END VIRTUAL PRIVATE NETWORKING,"An end-to-end virtual private networking system transports network packets securely through a public data network. A mobile device comprises an application client and a wireless roaming client managing data transfer from the mobile device to the public data network via one of a plurality of predetermined wireless links. A roaming gateway is located in a data center and is coupled to the public data network for tracking the plurality of predetermined wireless links and for managing data transfer from the public data network to the mobile device via one of the plurality of predetermined wireless links. An enterprise server is provided in a private enterprise for exchanging network packets with the application client in the mobile device. A CPE-VPN router in the private enterprise network is coupled to the enterprise server and to the public data network. A VPN router located in the data center is coupled to the roaming gateway and to the public data network, wherein the VPN router and the CPE-VPN router establish a VPN tunnel therebetween via the public data network. The CPE VPN router transports the network packets between the enterprise server and the VPN tunnel. The VPN router transports the network packets between the roaming gateway and the VPN tunnel.",SPRINT COMMUNICATIONS CO;;PANKAJAKSHAN BEJOY;;ZAMORA PEDRO A;;DIXON MATHEW A,PANKAJAKSHAN BEJOY;;ZAMORA PEDRO A;;DIXON MATHEW A,,https://lens.org/170-225-142-102-187,Patent Application,yes,0,3,4,4,0,H04L12/66;;H04L12/66;;H04L12/5692;;H04L12/5692;;H04L63/0272;;H04L63/0272;;H04W12/03;;H04W12/03;;H04W24/00;;H04W24/00;;H04W88/16;;H04W88/16;;H04W92/02;;H04W92/02,H04L12/28;;H04L12/56;;H04L12/66;;H04L29/06;;H04W12/00;;H04W24/00;;H04W88/16;;H04W92/02,,0,0,,,,PENDING
540,US,B2,US 9028873 B2,090-259-370-739-812,2015-05-12,2015,US 70209510 A,2010-02-08,US 70209510 A,2010-02-08,Nanoparticles for drug delivery to the central nervous system,"The present disclosure relates to compositions and methods for producing nanoparticles to provide relatively more rapid delivery of such particles across the blood-brain barrier. The nanoparticles may be formed from bis-quaternary pyridinium-aldoxime salts that may also be of a specific polymorphic structure and which may be formed in either hydrophobic or hydrophilic type liquid media. In addition, the nanoparticle for transport across the blood-brain barrier may comprise a polymeric resin encapsulating a bis-quaternary pyridinium-2-aldoxime salt.",MCDONOUGH JOSEPH A;;DIXON HONG;;CABELL LARRY A;;SOUTHWEST RES INST,MCDONOUGH JOSEPH A;;DIXON HONG;;CABELL LARRY A,SOUTHWEST RESEARCH INSTITUTE (2010-02-11),https://lens.org/090-259-370-739-812,Granted Patent,yes,73,1,2,2,0,A61K31/444;;A61K31/444;;A61K9/5021;;A61K9/5021;;A61K9/5115;;A61K9/5115;;A61P25/00;;Y10S977/773;;Y10S977/773;;Y10S977/906;;Y10S977/906;;Y10T428/2982;;Y10T428/2982,A61K9/14;;A61K9/50;;A61K9/51;;A61K31/444;;A61P25/00;;B32B5/00,424/489;;428/402;;514/332;;977/773;;977/906,93,54,020-649-853-103-071;;010-365-910-651-844;;044-124-157-368-542;;150-154-596-880-505;;129-785-372-749-268;;065-745-366-158-377;;020-711-788-338-222;;022-124-730-878-417;;045-064-651-203-57X;;013-460-526-508-781;;067-396-135-255-110;;026-377-215-887-811;;016-994-665-735-437;;046-776-116-900-21X;;130-099-343-741-14X;;028-317-930-994-008;;102-430-547-461-862;;009-042-394-096-263;;027-537-795-950-560;;032-382-262-966-161;;103-835-505-738-861;;039-472-959-626-478;;039-210-843-240-370;;108-779-808-821-249;;069-267-496-570-740;;011-367-293-495-262;;005-740-409-518-178;;125-954-371-954-752;;150-154-596-880-505;;043-633-374-263-578;;080-122-871-425-598;;030-023-524-915-675;;015-875-458-563-830;;071-195-716-275-252;;110-234-105-014-063;;058-971-233-291-643;;090-343-887-082-448;;060-549-919-189-73X;;080-127-572-157-768;;021-991-833-069-160;;020-317-537-639-586;;044-172-026-673-906;;037-114-652-426-030;;035-320-259-635-279;;047-382-068-025-143;;033-105-832-073-199;;054-766-749-738-639;;035-230-547-171-641;;104-715-357-676-493;;000-560-546-318-818;;038-074-861-608-626;;053-903-911-051-176;;002-679-196-036-124;;063-421-470-582-430,10.1042/bj0750363;;14402133;;pmc1204433;;16092078;;10.1002/jat.1084;;10.1016/j.jpba.2009.01.015;;19217737;;12164380;;10.1080/10611860290031877;;10213373;;10.1023/a:1018829920158;;10.18388/abp.2007_3232;;17713603;;17265683;;19075873;;10.2174/187221107779814104;;10.1039/b401644k;;10.1016/j.ijpharm.2004.07.035;;15607268;;15869447;;10.1089/cbr.2005.20.141;;17509234;;10.1179/016164107x187017;;10.1016/j.ejpb.2009.09.003;;19755158;;10.1080/10611860903112842;;19694610;;19537130;;19285109;;10.1016/j.jconrel.2009.03.002;;10.1016/j.ejpb.2008.08.021;;18805484;;10.1016/j.toxlet.2008.01.020;;18374523;;10.1177/030089160809400220;;18564616;;10.1016/j.ijpharm.2006.10.021;;17110063;;16980278;;10.1080/02652040600788080;;16608736;;10.1080/10611860600636135;;10.1080/10611860500411043;;16390814;;10.1016/j.bbrc.2005.02.019;;15737630;;10.1016/j.ics.2005.02.014;;10.1166/jnn.2003.077;;15503433;;12669961;;10.1023/a:1022604120952;;10.2174/1568015023357950;;12164380;;10.1080/10611860290031877;;10.1016/s0378-4274(01)00456-8;;11751017;;10.1016/s0169-409x(00)00122-8;;11251246;;10886334;;10.1046/j.1460-9568.2000.00078.x;;10.3109/07420529909016944;;10584177;;18154426;;08111/aim.0015;;10.14429/dsj.58.1660;;10.3121/cmr.2007.701;;pmc1855336;;17456837;;10.1007/bf03033389;;17449453;;pmc1112762;;10.1136/bmj.316.7134.789;;9549442;;10.1007/bf00808599;;10.3987/r-1986-07-1883;;10518158;;10.1176/ajp.156.10.1500;;8094968;;10.1177/096032719301200101;;10.1002/9780470060032.ch15;;13523283;;7488679;;10.1021/bi701002f;;17900152;;3713965;;10.1021/cr950066q;;11848856;;10.1016/j.tox.2004.07.019;;15590116;;10.1016/j.tox.2006.04.030;;16720069;;10.1016/0378-5173(96)04511-5;;10.1358/mf.1998.20.3.485666;;9646283;;10.1016/j.minpro.2004.07.025;;10.1002/jps.1168.abs;;11782895;;10.1002/jps.1168,"Hobbiger, Biochemical Journal, 75, 1960.;;Kuca, Journal of Applied Toxicology, 25, 2005.;;Gao, International Journal of Pharmaceutics, 310, 2006.;;Macauley, Journal of Phamraceutical and Biomedical Analysis, 49, 2009.;;Bagryanskaya, Russion Chemical Bulletin, International Edition, 50, 11, 2001.;;Kreuter, Journal of Drug Targeting, 10, 4, 2002.;;Wu, Pharmaceutical Research, 16, 3, 1999.;;Liu, Biomaterial, 29, 2008.;;Radic, et al., ""Evaluation of HI-6 oxime: potential use in protection of human acetylcholinesterase inhibited by antineoplastic drug irinotecan and its cyto/genotoxicity in vitro,"" Acta Biochimica Polonica vol. 54 No. Mar. 2007, 583-593, Aug. 23, 2007.;;Stojiljkovic, et al., ""Pryidinum Oximes: Rationale for their Selection as casual Antidotes against Organophosphate Poisonings and current solutions for auto-injectors,"" Arh Hig Toksikol 2006, 57:435-443.;;Praetorius, et al., ""Engineered Nanoparticles in Cancer Therapy,"" Recent Patents on Drug Delivery & Formation 2007,vol. 1 No. 1, pp. 37-51.;;Biosante Pharmaceuticals, ""Hormone Therapy-A Multi-Billion Dollar Market,"" Investor Fact Sheet Sep. 2007; www.biosantepharma.com; (2 pages).;;T.Welzel, et al., ""Transfection of Cells With Custom-made Calcium Phosphate Nanoparticles Coated With DNA""; The Royal Society of Chemistry 2004; J. Mater. Chem. 2004, 14, pp. 2213-2217.;;S. Bisht, et al., ""pDNA Loaded Calcium Phosphate Nanoparticles: Highly Efficient Non-Viral Vector for Gene Delivery""; International Journal of Pharmaceutics 288 (2005), pp. 157-168.;;T.Liu, et al., ""Calcium Phosphate Nanoparticles as a Novel Nonviral Vector for Efficient Transfection of DNA in Cancer Gene Therapy""; Cancer Biotherapy & Radiopharmaceuticls, vol. 20, No. 2, 2005, pp. 141-150.;;A. Brioschi, et al, ""Solid Lipid Nanoparticles: Could They Help . . .""; Neurological Research 2007, vol. 29, Apr. 2007; pp. 324-330.;;M. Nahar, et al, ""Functional Polymeric Nanoparticles: An Efficient . . . ""; Critical Reviews (TM) In Therapeutic Drug Carrier Systems, 23(4):259-318 (2006); Begell House Inc., http://begellhouse.com; downloaded Sep. 18, 2009 from IP 129.162.1.41 by Celia Frausto.;;Gelperina, et al., ""Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters,"" European Journal of Pharmaceutics and Biopharmaceutics (2009) doi:10.1016/j.ejpb.2009.09.003.;;Kurakhmaeva, et al, ""Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles,"" Journal of Drug Targeting, 2009; 17(8): 564-574.;;Hekmatara, et al., ""Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects,"" Clinical Neuropathology, vol. 28-No. Mar. 2009 (153-164).;;Zensi, et al., ""Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones,"" Journal of Controlled Release 137 (2009) 78-86.;;Ulbrich, et al., ""Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB),"" European Journal of Pharmaceutics and Biopharmaceutics 71 (2009) 251-256.;;Pereverzeva, et al., ""Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats,"" Toxicology Letters 178 (2008) 9-19.;;Kreuter, et al., ""Use of nanoparticles for cerebral cancer,"" Tumori: 9-4: 271-277, 2008.;;Kreuter, ""Nanoparticles-a historical perspective,"" International Journal of Pharmaceutics 331 (2007) 1-10.;;Petri, et al., ""Mechanism of Action and Surfactant Influence During Chemotherapy of Brain Tumour Using Doxorubicin-Loaded Poly(butyl Cyanoacrylate) Nanoparticles,"" NSTI-Nanotech 2007, vol. 2, 2007, p. 386-389.;;Ambruosi, et al., ""Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model,"" Journal of Microencapsulation, Aug. 2006; 23(5): 582-592.;;Ambruosi, et al., ""Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats,"" Journal of Drug Testing, Feb. 2006; 14(2): 97-105.;;Ambruosi, et al., ""Body distribution of polysorbate-80 and doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats,"" Journal of Drug Targeting, Dec. 2005; 13(10): 535-542.;;Schuller et al., ""Degradation of microvascular brain endothelial cell beta-catenin after co-culture with activated neutrophils from patients undergoing cardiac surgery with prolonged cardiopulmonary bypass,"" Biochemical and Biophysical Research Communications 329 (2005) 616-623.;;Kreuter, ""Application of nanoparticles for the delivery of drugs to the brain,"" International Congress Series 1277 (2005) 85-94.;;Kreuter, ""Influence of the Surface Properties on Nanoparticle-Mediated Transport of Drugs to the Brain,"" Journal of Nanoscience and Nanotechnology, 2004, vol. 4, No. 5; p. 484-488.;;Kreuter, ""Direct Evidence that Polysorbate-80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles,"" Pharmaceutical Research, vol. 20, No. 3, Mar. 2003; p. 409-416.;;Kreuter, ""Transport of Drugs Across the Blood-Brain Barrier by Nanoparticles,"" Curr. Med. Chem.-Central Nervous System Agents, 2002, 2, 241-249.;;Kreuter, et al.""Apolipoprotein-medicated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier,"" Journal of Drug Testing, 2002 vol. 10 (4), pp. 317-325.;;Gelperina, et al., ""Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrykate) nanoparticles in healthy rats and rats with intracranial glioblastoma,"" Toxicology Letters 126 (2002) 131-141.;;Kreuter, ""Nanoparticulate systems for brain delivery of drugs,"" Advanced Drug Delivery Reviews 47 (2001) 65-81.;;Ramge, et al., ""Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells,"" European Journal of Neuroscience, vol. 12, pp. 1931-1940 (2000).;;Ramge, et al., ""Circadian Phase-dependent Antinociceptive Reaction in Mice and the Tail-flick Test after Intravenous Injection of Dalargin-Loaded Nanoparticles,"" Chronobiology International, 16(6), 767-777 (1999).;;Alyautdin, et al., ""Drug delivery to brain by nanoparticles,"" (2003) eksperimental'naya i Klinicheskaya Farmakologiya, 66 (2), pp. 65-68.;;Balali-Mood Md Phd, et al., ""Neurotoxic Disorders of Organophosphorous Compounds and Their Managements,"" Arch Iranian Med 2008; 11 (1): 65-89.;;Kuca, et al., ""Preparation of Oxime HI-6 (Dichloride and Dimethanesulphonate)- Antidote against Nerve Agents,"" Defense Science Journal, vol. 58, No. 3, May 2008, pp. 399-404.;;Antonijevic et al., ""Unequal Efficacy of Pyridinium Oximes in Acute Organophosphate Poisoning,"" Clinical Medicine & Research, vol. 5, No. 1: 71-82, 2007.;;Chambers, et al., ""Development of a broad-spectrum Oxime for the treatment of nerve agent toxicity,"", 2006.;;Kuca, et al., ""In Vitro Reactivation Potency of Acetylcholinesterase Reactivators-K074 and K075-to Reactivate Tabun-inhibited Human Brain Cholinesterases,"" Neurotoxicity Research, 2007, vol. 11(2), pp. 101-106.;;Dennison, et al. ""Corticosteroids in rheumatoid arthritis,"" British Medical Journal vol. 316, pp. 789-790 (1998).;;KENAGOG® CREAMSTriamcinolone Acetonide Cream USPO.025%, 0.1 %,0.5% (Online) http://dai1ymed.n1m.nih.gOYdai1ymed/fda/fdaDrugXsl.cfm?id=1872&type=disp1ay; retrieved Jun. 21, 208 (8 pages).;;D. Farcasiu, et al. ""Evaluation of hydrogen bonding by C-13NMR"" Catalysis Letters 31 (1995) 351-358.;;Chemistry and Industry; Applied Chemistry; Nigel Freestone; Nov. 7, 2005 (4 pgs).;;Chemistry and Industry; New Drug Delivery Systems; Alexander T. Florence; Dec. 20, 1993 (7 pgs).;;Advanstar Communications, Inc.; Pharmaceutical Technology; Vivek Kharb; Meenakshi Bhatia; Harish Dureja; Deepak Kaushik; Feb. 1, 2006 (11 pgs).;;Advanstar Communications, Inc.; Pharmaceutical Technology Europe; Magdalene Radtke; Eliana B. Souto; Rainer H. Muller; Apr. 1, 2005 (4 pgs).;;International Search Report and Written Opinion dated Nov. 23, 2009 issued in related International Patent Application No. PCT/US0959386.;;U.S. Office Action dated Dec. 9, 2010 issued in related U.S. Appl. No. 11/555,995.;;U.S. Office Action dated Mar. 11, 2011 issued in related U.S. Appl. No. 12/245,450.;;U.S. Office Action dated May 25, 2011 issued in related U.S. Appl. No. 12/192,400.;;Munavalli, et al; Preparation and Properties of Methylenebispyridinium Derivatives; Heterocycles 1986, vol. 24. No. 7; pp. 1883-1892.;;U.S. Office Action dated Jun. 22, 2011 issued in related U.S. Appl. No. 12/047,988.;;U.S. Office Action dated Aug. 15, 2011 issued in related U.S. Appl. No. 11/555,995.;;Luo, et al., ""Development of a broad-spectrum Oxime for the treatment of nerve agent toxicity,"" Conference paper, Division of Biochemistry, Walter Reed Army Institute of Research, Silver Spring, MD 20910, Report Date: Nov. 2006 Report No. A376184. Available at http://www.dtic.mil/cgi-bin/GetTRDoc?Location=U2&doc=GetTRDoc.pdf&AD=ADA481673, retrieved on Mar. 9, 2011.;;Alyautdin, et al, ""Drug delivery to brain by nanoparticles,"" (2003) eksperimental'naya i Klinicheskaya Farmakologiya, 66 (2), pp. 65-68. English language Abstract can be found on p. 68, final paragraph.;;Digiovanni, Jr., M.D., Cleto, Domestic Terrorism With Chemical or Biological Agents: Psychiatric Aspects, Am J Psychiatry, Oct. 1999, pp. 1500-1505, vol. 156:10.;;D'Mello, G.D., Behavioural Toxicity of Anticholinesterases in Humans and Animals-A Review, Human & Experimental Toxicology, 1993, pp. 3-7, vol. 12.;;Eyer, et al., Oximes-Chapter 15, Chemical Warfare Agents: Toxicology and Treatment, 2007, pp. 305-329, 2nd Edition.;;Garcia, et al., Sensitive and Rapid Blood and Tissue HPLC Oxime Assay and Pharmacokinetics of MMB-4 in Guinea Pigs and African Green Monkeys, 2006.;;International Search Report and Written Opinion dated Jul. 17, 2009 issued in PCT Patent Application No. PCT/US09/35539, 8 pages.;;International Search Report and Written Opinion dated Oct. 6, 2009 issued in PCT Patent Application No. PCT/US09/52457, 9 pages.;;Jager, et al., Toxicity of Diacetyl Monoxime and of Pyridine-2-Aldoxime Methiodide in Man, Bull John Hopkins Hosp., 1958, pp. 203-211, vol. 102.;;Jamal, Goran A., Long term neurotoxic effects of organophosphate compounds, Adverse Drug React. Toxicol. Rev, 1995, pp. 85-99, vol. 14(2).;;Luo, et al., An In Vitro Comparative Study on the Reactivation of Nerve Agent-Inhibited Guinea Pig and Human Acetylcholinesterases by Oximes, Biochemistry, 2009, pp. 11771-11779, vol. 46.;;Marrs et al., Chemical Warfare Agents: Toxicology and Treatment Second Edition, 2007, pp all. Table of contents attached electronically, physical book mailed to USPTO Oct. 8, 2010.;;McDonough, et al., Behavioral Correlates of Soman-Induced Neuropathology: Deficits in DRL Acquisition, Neurobehavioral Toxicology and Teratology, 1986, pp. 179-187, vol. 8.;;U.S. Office Action dated Jun. 25, 2008 issued in U.S. Appl. No. 11/555,995, 23 pages.;;U.S. Office Action dated Nov. 28, 2008 issued in U.S. Appl. No. 11/555,995, 23 pages.;;Giulian et al, ""Short Communication"", Optical and Quantum Electronics, vol. 9, pp. 263-264; 1977.;;Patani et al, ""Bioisosterism: A Rational Approach in Drug Design"", (Chemical Reviews, vol. 96, No. 8, pp. 3147-3176; 1996.;;U.S. Office Action dated Nov. 1, 2011 issued in related U.S. Appl. No. 11/555,995.;;European Supplementary Search Report-mailing date Sep. 27, 2011, issued in related European Appln. No. 09718843.7.;;Sevelova et al, ""Antidotal Treatment of GF-agent intoxication in mice with bispyridinium Oximes"", Toxicology, vol. 207, No. 1, pp. 1-6, 2005.;;Aurbek et al, ""Analysis of Inhibition, Reactivation and Aging Kinetics of Highly Toxic Organophosphorus Compounds with Human and Pig Acetylcholinesterase"", Toxicology, vol. 224, No. 1-2. pp. 91-99, 2006.;;Office Action dated Dec. 29, 2011 issued in related U.S. Appl. No. 12/047,988.;;Office Action dated Nov. 29, 2011 issued in related U.S. Appl. No. 12/245,450.;;Office Action dated Jan. 26, 2012 issued in related U.S. Appl. No. 12/192,400.;;Thiermann, ""HI 6 dimethanesulfonate has better dissolution properties than HI 6 dichloride for application in dry/wet autoinjectors,"" International Journal of Pharmaceutics vol. 137, Issue 2, Jun. 28, 1996, pp. 167-176.;;European Search Report dated Oct. 31, 2011 issued in related European Patent Application No. 09807064.2.;;Office Action dated May 20, 2014 issued in related U.S. Appl. No. 11/555,995 (15 pgs).;;Office Action dated Sep. 14, 2012 issued in related U.S. Appl. No. 12/047,988 (15 pgs).;;Office Action dated Oct. 11, 2012 issued in related U.S. Appl. No. 12/192,400 (28 pgs).;;Office Action dated Oct. 19, 2012 issued in related European Patent Application No. 09 718 843.7 (4 pgs).;;Office Action dated Jan. 20, 2013 issued in related Israel Patent Application No. 208084 (3 pgs.).;;J.C. Chaumeil, ""Micronization: A Method of Improving the Bioavailability of Poorly Soluble Drugs"", Methods and Findings in Experimental and Clinical Pharmacology, Apr. 1998, vol. 20, No. 3, pp. 211-215.;;W.S. Choi, et al, ""Amorphous Ultrafine Particle Preparation for Improvement of Bioavailability of Insoluble Drugs: Grinding Characteristics of Fine Grinding Mills""; International Journal of Mineral Processing, vol. 74, Supplement 1, Dec. 10, 2004, pp. S165-S172.;;R.C. Garner et al, ""Comparison of the Absorption of Micronized (Daflon 500 mg) and Nonmicronized 14C-Diosmin Tablets After Oral Administration to Healthy Volunteers by Accelerator Mass Spectrometry and Liquid Scintillation Counting""; Journal of Pharmaceutical Sciences, Jan. 2002, vol. 91, Issue 1, pp. 32-40.",ACTIVE
541,US,A1,US 2017/0368042 A1,064-360-702-365-962,2017-12-28,2017,US 201615193254 A,2016-06-27,US 201615193254 A,2016-06-27,Dosage Suspensions Of Active Pharmaceutical Ingredients,Methods for preparing suspensions of active pharmaceutical ingredients for ensuing drug delivery. The suspension may include a mixture of a relatively low dosage API and a relatively high dosage API or a mixture of an API with a suitable excipient.,SOUTHWEST RES INST,DIXON HONG;;CABELL LARRY A;;MCDONOUGH JOSEPH A,SOUTHWEST RESEARCH INSTITUTE (2016-07-11),https://lens.org/064-360-702-365-962,Patent Application,yes,0,0,2,2,0,A61K45/06;;A61K9/10;;A61K47/44;;A61K9/14;;A61K31/46;;A61K31/444;;A61K31/444;;A61K31/5375;;A61K31/439;;A61K9/14;;A61K47/44;;A61K31/46;;A61K9/10;;A61K45/06,A61K31/444;;A61K31/439;;A61K31/5375,,0,0,,,,ACTIVE
542,US,A1,US 2011/0195125 A1,079-350-137-227-684,2011-08-11,2011,US 70209510 A,2010-02-08,US 70209510 A,2010-02-08,Nanoparticles For Drug Delivery To The Central Nervous System,"The present disclosure relates to compositions and methods for producing nanoparticles to provide relatively more rapid delivery of such particles across the blood-brain barrier. The nanoparticles may be formed from bis-quaternary pyridinium-aldoxime salts that may also be of a specific polymorphic structure and which may be formed in either hydrophobic or hydrophilic type liquid media. In addition, the nanoparticle for transport across the blood-brain barrier may comprise a polymeric resin encapsulating a bis-quaternary pyridinium-2-aldoxime salt of the formula:",SOUTHWEST RES INST,MCDONOUGH JOSEPH A;;DIXON HONG;;CABELL LARRY A,SOUTHWEST RESEARCH INSTITUTE (2010-02-11),https://lens.org/079-350-137-227-684,Patent Application,yes,61,5,2,2,0,A61K31/444;;A61K31/444;;A61K9/5021;;A61K9/5021;;A61K9/5115;;A61K9/5115;;A61P25/00;;Y10S977/773;;Y10S977/773;;Y10S977/906;;Y10S977/906;;Y10T428/2982;;Y10T428/2982,A61K9/14;;A61K31/444;;A61P25/00;;B32B5/00,424/489;;514/332;;428/402;;977/773;;977/906,8,5,020-649-853-103-071;;010-365-910-651-844;;044-124-157-368-542;;150-154-596-880-505;;129-785-372-749-268,10.1042/bj0750363;;14402133;;pmc1204433;;16092078;;10.1002/jat.1084;;10.1016/j.jpba.2009.01.015;;19217737;;12164380;;10.1080/10611860290031877;;10213373;;10.1023/a:1018829920158,"Hobbiger, Biochemical Journal, 75, 1960;;Kuca, Journal of Applied Toxicology, 25, 2005;;Gao, International Journal of Pharmaceutics, 310, 2006.;;Macauley, Journal of Phamraceutical and Biomedical Analysis, 49, 2009;;Bagryanskaya, Russion Chemical Bulletin, International Edition, 50, 11, 2001.;;Kreuter, Journal of Drug Targeting, 10, 4, 2002.;;Wu, Pharmaceutical Research, 16, 3, 1999.;;Liu, Biomaterial, 29, 2008.",ACTIVE
543,AU,A,AU 1994/060801 A,038-806-088-907-055,1994-08-15,1994,AU 1994/060801 A,1993-12-28,US 9312600 W;;US 99970692 A,1992-12-31,Antisense molecules directed against a fibroflast growth factor receptor gene family,,TEXAS BIOTECHNOLOGY CORP,DENNER LARRY A;;REGE AJAY A;;DIXON RICHARD A F,,https://lens.org/038-806-088-907-055,Patent Application,no,0,0,4,4,0,A61K31/70;;C07H21/00;;C12N15/1138;;C12N2310/31;;C12N2310/315,C07H21/00;;C12N15/113,,0,0,,,,PENDING
544,WO,A1,WO 1994/015645 A1,109-354-471-362-974,1994-07-21,1994,US 9312603 W,1993-12-28,US 99971092 A,1992-12-31,ANTISENSE MOLECULES DIRECTED AGAINST GENES OF THE RAF ONCOGENE FAMILY,"The present invention is directed to a polynucleotide, of about 10 to about 50 nucleic acid bases in length, which hybridizes to the gene encoding raf. The present invention is also directed to a pharmaceutical composition comprising the above polynucleotide dissolved or dispersed in a physiologically tolerable diluent. The present invention is further directed to a process for inhibiting vascular smooth muscle cell proliferation, a process for treating vascular smooth muscle cell proliferation, and process for treating a disease state involving smooth muscle cell proliferation. These processes comprise contacting the vascular smooth muscle cells or administering to a host mammal in need of such treatment, an effective amount of a polynucleotide of about 10 to about 50 nucleic acid bases in length, said polynucleotide hybridizing to the gene for raf.",TEXAS BIOTECHNOLOGY CORP,DENNER LARRY A;;REGE AJAY A;;DIXON RICHARD A F,,https://lens.org/109-354-471-362-974,Patent Application,yes,0,28,2,2,0,C12N15/1135;;C07H21/00;;C12N2310/315;;C12N2310/321,C07H21/00;;C12N15/113,,4,4,016-006-083-080-390;;071-256-417-025-583;;048-907-112-707-295;;045-339-665-441-034,1680858;;10.1016/s0021-9258(18)55250-9;;10.1016/0006-291x(92)92378-b;;1384482;;1881900;;10.1073/pnas.88.17.7595;;pmc52348;;10.1093/nar/14.2.1009;;3003687;;pmc339479,"THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 266, No. 27, issued 25 September 1991, CHIANG et al., ""Antisense Oligonucleotides Inhibit Intercellular Adhesion Molecule 1 Expression by Two Distinct Mechanisms"", pages 18162-12171.;;BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 188, No. 1, issued 15 October 1992, DUFF et al., ""Angiotensin II Stimulates the pp44 and pp42 Mitogen-Activated Protein Kinases in Cultured Rat Aortic Smooth Muscle Cells"", pages 257-264.;;PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Vol. 88, issued September 1991, AGRAWAL et al., ""Pharmacokinetics, Biodistribution, and Stability of Oligodeoxynucleotide Phosphorothioates in Mice"", pages 7595-7599.;;NUCLEIC ACIDS RESEARCH, Vol. 14, No. 2, issued 1986, BONNER et al., ""The Complete Coding Sequence of the Human raf Oncogene and the Corresponding Structure of the c-raf-1 Gene"", pages 1009-1015.",PENDING
545,EP,A1,EP 0677055 A1,175-173-207-262-510,1995-10-18,1995,EP 94907109 A,1993-12-28,US 9312600 W;;US 99970692 A,1992-12-31,ANTISENSE MOLECULES DIRECTED AGAINST A FIBROFLAST GROWTH FACTOR RECEPTOR GENE FAMILY.,,TEXAS BIOTECHNOLOGY CORP,DENNER LARRY A;;REGE AJAY A;;DIXON RICHARD A F,,https://lens.org/175-173-207-262-510,Patent Application,yes,0,0,4,4,0,A61K31/70;;C07H21/00;;C12N15/1138;;C12N2310/31;;C12N2310/315,C07H21/00;;C12N15/113,,1,0,,,See references of WO 9415945A1,DISCONTINUED
546,WO,A1,WO 1994/015945 A1,060-201-841-477-143,1994-07-21,1994,US 9312600 W,1993-12-28,US 99970692 A,1992-12-31,ANTISENSE MOLECULES DIRECTED AGAINST A FIBROFLAST GROWTH FACTOR RECEPTOR GENE FAMILY,"The present invention is directed to a polynucleotide of about 10 to about 50 nucleic acid bases in length, which polynucleotide hybridizes to the gene encoding fibroblast growth factor receptor. The present invention is also directed to a pharmaceutical composition comprising the above polynucleotide dissolved or dispersed in a physiologically tolerable diluent. The present invention is further directed to a process for inhibiting vascular smooth muscle cell proliferation (figs. 1 and 2), a process for treating vascular smooth muscle cell proliferation (figs. 3 and 4), and a process for treating a disease state involving vascular smooth muscle cell proliferation (figs. 3 and 4), all of which processes comprise contacting vascular smooth muscle cells or administering an effective amount of a polynucleotide of about 10 to about 50 nucleic acid bases in length, said polynucleotide hybridizing to the gene for fibroblast growth factor receptor.",TEXAS BIOTECHNOLOGY CORP,DENNER LARRY A;;REGE AJAY A;;DIXON RICHARD A F,,https://lens.org/060-201-841-477-143,Patent Application,yes,2,8,4,4,0,A61K31/70;;C07H21/00;;C12N15/1138;;C12N2310/31;;C12N2310/315,C07H21/00;;C12N15/113,,2,2,054-389-174-631-070;;010-311-187-141-875,pmc50963;;1847508;;10.1073/pnas.88.4.1095;;2172978;;pmc54916;;10.1073/pnas.87.20.8180,"Proceedings of the National Academy of Sciences, Volume 88, No. 4, issued 15 February 1991, C. KEEGAN et al., ""Isolation of an Additional Member of the Fibroblast Growth Factor Receptor Family, FGFR"", pages 1095-1099, especially page 1096.;;Proceedings of the National Academy of Sciences, Volume 87, No. 20, issued October 1990, E. HOUSSAINT et al., ""Related Fibroblast Growth Factor Receptor Genes Exist in the Human Genome"", pages 8180-8185, especially page 8180.",PENDING
547,CA,A1,CA 2152903 A1,095-429-258-343-94X,1994-07-21,1994,CA 2152903 A,1993-12-28,US 99970692 A,1992-12-31,ANTISENSE MOLECULES DIRECTED AGAINST A FIBROBLAST GROWTH FACTOR RECEPTOR GENE FAMILY,"The present invention is directed to a polynucleotide of about 10 to about 50 nucleic acid bases in length, which polynucleotide hybridizes to the gene encoding fibroblast growth factor receptor. The present invention is also directed to a pharmaceutical composition comprising the above polynucleotide dissolved or dispersed in a physiologically tolerable diluent. The present invention is further directed to a process for inhibiting vascular smooth muscle cell proliferation (figs. 1 and 2), a process for treating vascular smooth muscle cell proliferation (figs. 3 and 4), and a process for treating a disease state involving vascular smooth muscle cell proliferation (figs. 3 and 4), all of which processes comprise contacting vascular smooth muscle cells or administering an effective amount of a polynucleotide of about 10 to about 50 nucleic acid bases in length, said polynucleotide hybridizing to the gene for fibroblast growth factor receptor. I",TEXAS BIOTECHNOLOGY CORP,DENNER LARRY A;;REGE AJAY A;;DIXON RICHARD A F,,https://lens.org/095-429-258-343-94X,Patent Application,no,0,0,4,4,0,A61K31/70;;C07H21/00;;C12N15/1138;;C12N2310/31;;C12N2310/315,C07H21/00;;C12N15/113,,0,0,,,,DISCONTINUED
548,AU,A,AU 1994/059610 A,085-056-402-830-389,1994-08-15,1994,AU 1994/059610 A,1993-12-28,US 9312602 W;;US 99970892 A,1992-12-31,Antisense molecules directed against a platelet derived growth factor receptor related gene,,TEXAS BIOTECHNOLOGY CORP,DENNER LARRY A;;REGE AJAY A;;DIXON RICHARD A F,,https://lens.org/085-056-402-830-389,Patent Application,no,0,0,2,2,0,C12N15/1138;;C07H21/00;;C12N2310/315,C07H21/00;;C12N15/113,,0,0,,,,PENDING
549,AU,A,AU 1994/060802 A,132-929-772-891-886,1994-08-15,1994,AU 1994/060802 A,1993-12-28,US 9312603 W;;US 99971092 A,1992-12-31,Antisense molecules directed against genes of the (raf) oncogene family,,TEXAS BIOTECHNOLOGY CORP,DENNER LARRY A;;REGE AJAY A;;DIXON RICHARD A F,,https://lens.org/132-929-772-891-886,Patent Application,no,0,1,2,2,0,C12N15/1135;;C07H21/00;;C12N2310/315;;C12N2310/321,C07H21/00;;C12N15/113,,0,0,,,,PENDING
550,WO,A1,WO 1994/015943 A1,172-233-531-640-627,1994-07-21,1994,US 9312602 W,1993-12-28,US 99970892 A,1992-12-31,ANTISENSE MOLECULES DIRECTED AGAINST A PLATELET DERIVED GROWTH FACTOR RECEPTOR RELATED GENE,"The present invention is directed to a polynucleotide of about 10 to about 50 nucleic acid bases in length, which polynucleotide hybridizes to the platelet derived growth factor receptor related gene. The present invention is also directed to a pharmaceutical composition comprising the above polynucleotide dissolved or dispersed in a physiologically tolerable diluent. The present invention is further directed to a process for inhibiting vascular smooth muscle cell proliferation and to a process for treating vascular smooth muscle cell proliferation that comprises contacting the vascular smooth muscle cells with, or administering to a host mammal in need of such treatment an effective amount of a polynucleotide of about 10 to about 50 nucleic acid bases in length, said polynucleotide hybridizing to the platelet derived growth factor receptor related gene.",TEXAS BIOTECHNOLOGY CORP,DENNER LARRY A;;REGE AJAY A;;DIXON RICHARD A F,,https://lens.org/172-233-531-640-627,Patent Application,yes,1,5,2,2,0,C12N15/1138;;C07H21/00;;C12N2310/315,C07H21/00;;C12N15/113,,5,4,022-671-955-301-419;;048-569-969-195-496;;082-766-954-183-893;;077-083-286-836-858,2452645;;10.1161/01.cir.86.2.538;;1353419;;3020426;;10.1038/323226a0;;2558722;;10.1021/bi00450a039,"ANTICANCER DRUG DES., Vol. 2, No. 4, issued March 1988, C. PAOLETTI, ""Anti-Sense Oligonucleotide as potential Antitumour Agents: Prospective Views and Preliminary Results"", pages 325-31.;;CHEMICAL REVIEWS, Vol. 90, No. 4, issued June 1990, E. UHLMANN et al., ""Antisense Oligonucleotides: a New Therapeutic Principle"", pages 544-579.;;CIRCULATION, Vol. 86, No. 2, issued August 1992, E. SPEIR et al., ""Inhibition of Smooth Muscle Cell Proliferation by an Antisense Oligodeoxynucleotide Targeting the Messenger RNA Encoding Proliferating Cell Nuclear Antigen"", pages 538-547.;;NATURE, Vol. 323, issued 18 September 1986, T. YARDEN et al., ""Structure of the Receptor for Platelet-Derived Growth Factor Helps Define a Family of Closely Related Growth Factor Receptors"", pages 226-232.;;BIOCHEMISTRY, Vol. 28, issued 1989, C.-Y. WANG et al., ""Highly Efficient DNA Delivery Mediated by pH-Sensitive Immunoliposomes"", pages 9508-9514.",PENDING
551,US,A,US 4771462 A,013-625-424-450-147,1988-09-13,1988,US 1601187 A,1987-02-18,US 1601187 A,1987-02-18,Communication port encryption/decryption method and apparatus,"There is provided herein an apparatus and method of encryption/decryption which incorporates a microprocessor into security devices. A first such device is connected to the communication port of the accessing remote terminal, and a second such security device is connected to the communication port of the computer to which access is sought. This microprocessor is programmed to encode and decode all signals directed through the communication port of the computer terminal. The system incorporates a programmed ROM associated with the sending computer terminal containing tables of characters and a programmed ROM associated with the receiving computer terminal containing a complementary image of the tables programmed into the sending station. When data is transmitted by the sending computer terminal it is processed by the sending encryption device. The character code that is generated by the remote terminal is used as an address to access the ROM of the sending encryption device. The character in that memory location is then retrieved and transmitted in place of the original clear data. When the transmitted encrypted code is received, the microprocessor associated with the receiving device uses the received code as an address location and retrieves the character contained within that address location and thereby reclaims the clear data.",HANNAN FORREST A;;DIXON DALE A;;OSTRANDER LINDA L,HANNAN FORREST A;;DIXON DALE A;;OSTRANDER LINDA L,SECURITY TWO INC. SCHAUMBURG ILLINOIS (1987-02-16),https://lens.org/013-625-424-450-147,Granted Patent,yes,5,26,3,3,0,H04L9/0662;;H04L9/0662,H04L9/22,380/44;;380/48;;380/50,0,0,,,,EXPIRED
552,US,A,US 2344687 A,140-979-968-028-369,1944-03-21,1944,US 30197239 A,1939-10-30,US 30197239 A,1939-10-30,Pump plunger,,FISCHER CHARLES A;;HARBISON DIXON T;;MERCER CHARLES A,FISCHER CHARLES A;;HARBISON DIXON T;;MERCER CHARLES A,,https://lens.org/140-979-968-028-369,Granted Patent,no,0,15,1,1,0,F04B53/126;;F04B53/126;;F16J9/28;;F16J9/28;;Y10T29/4987;;Y10T29/4987;;Y10T29/49876;;Y10T29/49876,F04B53/12;;F16J9/28,,0,0,,,,EXPIRED
553,AU,A,AU 1988/014204 A,163-529-956-881-65X,1988-09-14,1988,AU 1988/014204 A,1988-02-12,US 1601187 A,1987-02-18,COMMUNICATION PORT ENCRYPTION/DECRYPTION METHOD AND APPARATUS,,SECURITY TWO INC,HANNAN FORREST A;;DIXON DALE A;;OSTRANDER LINDA L,,https://lens.org/163-529-956-881-65X,Patent Application,no,0,0,3,3,0,H04L9/0662;;H04L9/0662,H04L9/22,,0,0,,,,DISCONTINUED
554,CN,A,CN 1430539 A,102-215-613-539-655,2003-07-16,2003,CN 01810072 A,2001-05-25,AU PQ779900 A,2000-05-26,Hot rolling thin strip,"Thin steel strip is passed through a pinch roll stand comprising pinch rolls to a rolling mill comprising a pair of work rolls and upper and lower backing rolls. Strip passes through the bite between the work rolls and strip squeezing forces are applied between the work rolls to reduce the thickness of the strip. The pinch rolls apply tension to the strip passing to the work rolls. In order to minimize generation of crimping defects in the strip, the tension applied by the pinch rolls is high enough to ensure no part of the strip entering the work rolls is in longitudinal compression such as to exceed the buckling stress of the strip. The applied tension is sufficiently low as to produce no more than 1% strip elongation through creep. The strip may be hot rolled by the work rolls at a temperature in the range of 700° C.-1200° C.",CASTRIP LLC,ZIEGELAAR JOHN A;;LOPEN MICHAEL A;;DIXON ANDREW E,,https://lens.org/102-215-613-539-655,Patent Application,no,0,3,23,25,0,B21B1/26;;B21B1/463;;B21B37/28;;B21B37/48;;B21B37/56;;B21B39/006;;B21B39/08;;B21B45/008;;B21B2001/225;;B21B2265/04;;B21B2265/08;;Y10T29/49991;;Y02P70/10;;B21B1/40;;Y10T29/49991;;B21B37/28;;B21B2265/04;;B21B1/463;;B21B39/08;;B21B2265/08;;B21B45/008;;B21B2001/225;;B21B1/26;;B21B37/48;;B21B37/56;;B21B39/006;;Y02P70/10,B21B1/22;;B21B1/26;;B21B1/46;;B21B37/28;;B21B37/48;;B21B37/56;;B21B39/00;;B21B39/08;;B21B45/00;;B22D11/06;;B22D11/12,,0,0,,,,EXPIRED
555,US,A,US 4153691 A,149-008-276-047-230,1979-05-08,1979,US 76942877 A,1977-02-17,GB 671676 A,1976-02-20,Analgesic and anti-inflammatory compositions,"A pharmaceutical composition having analgesic, anti-pyretic and anti-inflammatory activity and administration thereof in oral dosage form, comprising 2-(carbamoyl)phenyl-2-acetoxybenzoate as active ingredient and procedure for preparing such active ingredient. One or more pharmaceutically acceptable oral carriers are mixed with the active ingredient for oral administration in various dosage forms. The disadvantages of acetyl salicyclic acid and salicylamide are avoided.",BEECHAM GROUP LTD,DAVIS ADRIAN F;;DIXON GORDON J A,,https://lens.org/149-008-276-047-230,Granted Patent,yes,0,1,36,38,0,A61K31/60;;A61P25/04;;A61P29/00;;A61K31/60,A61K31/60;;A61P25/04;;A61P29/00;;C07C67/00;;C07C231/00;;C07C235/46,424/230,3,1,031-520-016-072-185,13412809,"grollman, Pharmacology & Therapeutics, 6th ed. (1965), pp. 166-175.;;S. Pasquino, Boll. Chem. Farm, 1957, 96, pp. 47-50.;;Anschiitz et al., Ann. (1924), 439, 1, pp. 5-7.",EXPIRED
556,US,B1,US 6289744 B1,174-466-243-858-621,2001-09-18,2001,US 54316600 A,2000-04-05,US 54316600 A;;US 16925498 A;;US 6235297 P,1997-10-15,Torsion tester,"A torsion tester incorporates a microprocessor based data acquisition/control package and special tooling. The tooling makes calibration of the tester very easy. The combination of the tooling and control package permits acquisition, storage and transfer of test data that is accurate, absolute and repeatable. In addition, torsion tester provides a zeroing pin and a zeroing slot on opposing tooling members for calibration. Further, the torsion tester provides an interchangably mounted load cell.",LARSON SYSTEMS INC,LARSON DAVID A;;DIXON JR WILLIAM R,,https://lens.org/174-466-243-858-621,Granted Patent,yes,5,15,2,2,0,G01N3/00;;G01N3/00;;G01N2203/0021;;G01N2203/0021;;G01N2203/021;;G01N2203/021;;G01N2203/0292;;G01N2203/0292,G01N3/00,73/847,0,0,,,,EXPIRED
557,CA,A1,CA 2670096 A1,168-960-190-134-545,2008-05-29,2008,CA 2670096 A,2007-11-21,US 86676406 P;;US 2007/0085344 W,2006-11-21,BIOFUEL PRODUCTION METHODS AND COMPOSITIONS,"The invention provides methods for increasing the level of fermentable ca rbohydrates in a biofuel crop plant such as alfalfa or switchgrass, by modif ication of the lignin biosynthetic pathway. Also provided are plants prepare d by the methods of the invention. Methods for processing plant tissue and f or producing ethanol by utilizing such plants are also provided.",SAMUEL ROBERTS NOBLE FOUND INC,WANG ZENGYU;;CHEN FANG;;DIXON RICHARD A,,https://lens.org/168-960-190-134-545,Patent Application,no,0,0,5,5,10,C12N15/8245;;C12N15/8245;;C12N15/8255;;C12N15/8255;;Y02E50/10;;Y02E50/10,C12N15/82;;A01H5/00,,0,0,,,,DISCONTINUED
558,WO,A1,WO 1988/006388 A1,176-708-687-999-582,1988-08-25,1988,US 8800426 W,1988-02-12,US 1601187 A,1987-02-18,COMMUNICATION PORT ENCRYPTION/DECRYPTION METHOD AND APPARATUS,"The system incorporates a programmed ROM (U16) associated with the sending computer terminal (A) containing tables of characters and a programmed ROM (U16) associated with the receiving computer terminal (B) containing a complementary image of the tables programmed into the sending station. When data is transmitted by the sending computer terminal (A) it is processed by the sending encryption device (U4). The character code that is generated by the remote terminal is used as an address to access the ROM (U16) of the sending encryption device. When the transmitted encrypted code is received, the microprocessor (U4) associated with the receiving device (B) uses the received code as an address location and retrieves the character contained within the address location and thereby reclaims the clear data.",SECURITY TWO INC,HANNAN FORREST A;;DIXON DALE A;;OSTRANDER LINDA L,,https://lens.org/176-708-687-999-582,Patent Application,yes,5,2,3,3,0,H04L9/0662;;H04L9/0662,H04L9/22,H4P PDCSX         PDCSX,0,0,,,,PENDING
559,US,B2,US 6980976 B2,021-079-075-441-158,2005-12-27,2005,US 92889401 A,2001-08-13,US 92889401 A,2001-08-13,Combined database index of unstructured and structured columns,"A database management system and method provides access to a data table having structured data and unstructured data. A user interface allows a user to issue instructions to the database management system such as to build an index based on the structured and unstructured data and to search the data table. An indexing logic generates an index structure by combining the structured and unstructured data. With this index structure, a single query can contain search conditions from both the structured data and the unstructured data. In this manner, efficiency for searching the data table for combined structured and unstructured conditions is improved.",ORACLE INT CORP,ALPHA SHAMIM A;;KAMINAGA GARRETT;;DIXON PAUL,ORACLE INTERNATIONAL CORPORATION (OIC) (2003-10-30);;ORACLE CORPORATION (2001-12-19),https://lens.org/021-079-075-441-158,Granted Patent,yes,8,65,2,2,0,G06F16/2228;;G06F16/316;;G06F16/316;;Y10S707/99931;;Y10S707/99933;;Y10S707/99943;;G06F16/2228,G06F7/00;;G06F17/30,707/1;;707/3;;707/100;;707/102,0,0,,,,EXPIRED
560,CA,A1,CA 2337096 A1,060-153-518-376-226,2000-01-27,2000,CA 2337096 A,1999-07-14,US 9269698 P;;US 9912374 W,1998-07-14,"CONSTITUTIVE DISEASE RESISTANCE GENE (CDR1), AND METHODS OF USE THEREOF","Substantially purified CDR1 polypeptide, isolated polynucleotides encoding CDR1 polypeptide, vectors containing CDR1, host cells expressing CDR1, and antibodies which bind to CDR1 are all provided. The invention also provides a method of producing a genetically modified plant characterized as having increased disease resistance as compared to wild-type plants. A method is al so provided for identifying novel disease resistance genes by probing a nucleic acid library with at least a fragment of a polynucleotide encoding CDR1, and selecting those clones that hybridize with the fragment.",SALK INST FOR BIOLOGICAL STUDI,XIA YIJI;;DIXON RICHARD A;;LAMB CHRISTOPHER,,https://lens.org/060-153-518-376-226,Patent Application,no,0,0,9,9,3,C07K14/415;;C12N9/63;;C07K14/415;;C12N9/50;;C12N9/63;;C12N15/8281;;C12N15/8281,C07K14/415;;C12N9/50;;C12N15/29;;C12N15/82,,0,0,,,,DISCONTINUED
561,CA,A1,CA 2057391 A1,090-954-064-953-903,1992-06-19,1992,CA 2057391 A,1991-12-17,GB 9027424 A;;GB 9027425 A;;GB 9113596 A,1990-12-18,SEROTONIN ANTAGONISTS,"3,7-disubstituted indole derivatives of formula I (I) wherein R1, R2, n, X, Y and Z are as defined in the description, are useful for the treatment of psychiatric disorders.",DIXON ARNOLD K;;GIGER RUDOLF K A,DIXON ARNOLD K;;GIGER RUDOLF K A,,https://lens.org/090-954-064-953-903,Patent Application,no,0,0,35,42,0,C07D451/12;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/26;;A61P43/00;;A61K31/405;;C07D451/12,A61K31/435;;A61K31/40;;A61K31/46;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/26;;A61P43/00;;C07D209/32;;C07D233/54;;C07D401/12;;C07D403/12;;C07D451/02;;C07D451/04;;C07D451/12;;C07D451/14;;C07D453/02;;C07D471/04;;C07D471/08;;C07D487/08,,0,0,,,,DISCONTINUED
562,WO,A3,WO 2008/064289 A3,088-542-909-156-867,2008-11-06,2008,US 2007/0085344 W,2007-11-21,US 86676406 P,2006-11-21,BIOFUEL PRODUCTION METHODS AND COMPOSITIONS,"The invention provides methods for increasing the level of fermentable carbohydrates in a biofuel crop plant such as alfalfa or switchgrass, by modification of the lignin biosynthetic pathway. Also provided are plants prepared by the methods of the invention. Methods for processing plant tissue and for producing ethanol by utilizing such plants are also provided.",SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;CHEN FANG;;WANG ZENGYU,DIXON RICHARD A;;CHEN FANG;;WANG ZENGYU,,https://lens.org/088-542-909-156-867,Search Report,yes,1,0,5,5,10,C12N15/8245;;C12N15/8245;;C12N15/8255;;C12N15/8255;;Y02E50/10;;Y02E50/10,C12N15/82;;A01H5/00,,13,9,032-802-996-819-548;;009-568-658-490-747;;036-455-388-275-446;;085-168-531-128-752;;092-026-802-374-892;;020-577-919-065-531;;033-354-698-623-379;;067-609-810-409-045;;056-760-206-406-932,16701991;;10.1016/j.copbio.2006.05.003;;10.1111/j.1365-313x.2006.02857.x;;16972868;;16421107;;10.1074/jbc.m511598200;;10.1385/abab:130:1:427;;16915659;;10.1007/s001220200015;;12579437;;10.1038/nbt1316;;17572667;;17621299;;10.1038/nbt0707-746;;10.1016/j.copbio.2008.02.014;;18403196;;10.1016/j.plantsci.2007.11.009,"STICKLEN ET AL: ""Plant genetic engineering to improve biomass characteristics for biofuels"", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 17, no. 3, 1 June 2006 (2006-06-01), pages 315 - 319, XP005495090, ISSN: 0958-1669;;DIXON R A ET AL: ""Expanding the utility of alfalfa."", IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL, vol. 42, no. Suppl. S, April 2006 (2006-04-01), & MEETING OF THE SOCIETY-FOR-IN-VITRO-BIOLOGY; MINNEAPOLIS, MN, USA; JUNE 03 -07, 2006, pages 15A, XP002485061, ISSN: 1071-2690;;CHEN FANG ET AL: ""Multi-site genetic modulation of monolignol biosynthesis suggests new routes for formation of syringyl lignin and wall-bound ferulic acid in alfalfa (Medicago sativa L.)"", PLANT JOURNAL, vol. 48, no. 1, October 2006 (2006-10-01), pages 113 - 124, XP002485062, ISSN: 0960-7412;;RALPH JOHN ET AL: ""Effects of coumarate 3-hydroxylase down-regulation on lignin structure"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 13, March 2006 (2006-03-01), pages 8843 - 8853, XP002485063, ISSN: 0021-9258;;DAVISON, B.H., ET AL.: ""Variation of S7G Ratio and Lignin content in a Populus family influences the reease of Xylose by dilute acid hydrolysis"", APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, vol. 129, 2005, Humana Press Inc., pages 129 - 132, XP002485064;;NAKASHIMA, J., ET AL.: ""Down-regulation of key enzymes in the monolignol pathway: effects on lignin composistion in specific cell types of alfalfa (Medicago sativa L.)"", PHYTOCHEMICAL SOCIETY OF NORTH AMERICA, July 2006 (2006-07-01), 2006 PSNA Annual Meeting , july 8th-12th, 2006, Oxford , Mississippi, XP002485065;;CASLER M D ET AL: ""Genetic modification of lignin concentration affects fitness of perennial herbaceous plants"", THEORETICAL AND APPLIED GENETICS, vol. 104, no. 1, January 2002 (2002-01-01), pages 127 - 131, XP002485066, ISSN: 0040-5752;;DATABASE EMBL [online] 20 February 2005 (2005-02-20), TOBIAS, C.M., ET AL.: ""4810_C02_E04 Switchgrass stem cDNA library Panicum virgatum cDNA clone 4810_C02_E04 5', mRNA sequence."", XP002485070, retrieved from EBI accession no. EMBL:DN143567 Database accession no. DN143567;;DATABASE EMBL [online] 25 September 2003 (2003-09-25), ""SCSGST3121B05.g ST3 Saccharum officinarum cDNA clone SCSGST3121B05 5', mRNA sequence."", XP002485071, retrieved from EBI accession no. EMBL:CA186689 Database accession no. CA186689;;CHEN FANG ET AL: ""Lignin modification improves fermentable sugar yields for biofuel production"", NATURE BIOTECHNOLOGY, vol. 25, no. 7, July 2007 (2007-07-01), pages 759 - 761, XP002485067, ISSN: 1087-0156;;CHAPPLE, C., ET AL.: ""loosening lignin's grip on biofuel production"", NATURE BIOTECHNOLOGY, vol. 25, no. 7, July 2007 (2007-07-01), pages 746 - 748, XP002485068;;WENG J K ET AL: ""Emerging strategies of lignin engineering and degradation for cellulosic biofuel production"", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 19, no. 2, 1 April 2008 (2008-04-01), pages 166 - 172, XP022620669, ISSN: 0958-1669, [retrieved on 20080409];;GRESSEL JONATHAN: ""Transgenics are imperative for biofuel crops"", PLANT SCIENCE (OXFORD), vol. 174, no. 3, March 2008 (2008-03-01), pages 246 - 263, XP002485069, ISSN: 0168-9452",PENDING
563,US,A1,US 2009/0004268 A1,155-220-390-774-445,2009-01-01,2009,US 4727108 A,2008-03-12,US 4727108 A;;US 91801507 P,2007-03-13,Methods and Compositions for Treatment of an Interstitial Lung Disease,"Provided herein are methods of treatment of an interstitial lung disease (ILD) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof.",GIVEN BRUCE D;;DIXON RICHARD A F,GIVEN BRUCE D;;DIXON RICHARD A F,,https://lens.org/155-220-390-774-445,Patent Application,yes,3,1,2,2,0,A61K31/42;;A61K31/42;;A61P11/00,A61K9/20;;A61K9/28;;A61K31/42;;A61P11/00,424/465;;514/380;;424/474,0,0,,,,DISCONTINUED
564,US,A,US 3993500 A,160-268-434-653-965,1976-11-23,1976,US 64816376 A,1976-01-12,US 64816376 A;;US 64825376 A;;US 67359676 A,1976-01-12,Reduced charge montmorillonite pigment for sensitizing record material,"A reduced charge montmorillonite pigment useful as a colorformer in record material, especially pressure-sensitive carbonless copying record systems. The pigment is produced by replacing exchangeable cations of a selected dioctahedral montmorillonite crude clay (exemplified by certain bentonite clays) with a predetermined amount of lithium ions, mildly heating the lithium-exchanged montmorillonite to collapse irreversibly the montmorillonite structure, and grinding the heat-treated material to pigment-size particles, the grinding preferably being carried out in a fluid energy mill. When the pigment particles are coated on paper, the coated sheets produce stabilized intense images when printed with a solution of crystal violet lactone (CVL) dye precursor and thus may be used in record material with CVL without employing secondary slow acting dyes such as benzoyl leuco methylene blue. The sheets are also useful with other colorless or substantially colorless dye precursors.",ENGELHARD MIN & CHEM,ISAAC PETER A H;;OULTON T DIXON,ENGLEHARD CORPORATION A CORP. OF DE (1981-05-18),https://lens.org/160-268-434-653-965,Granted Patent,yes,4,15,9,13,0,B41M5/1555;;C01P2002/72;;C01P2004/41;;C01P2004/50;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2004/80;;C01P2006/12;;C01P2006/60;;C01P2006/80;;C01P2006/82;;C09C1/42;;Y10S428/914;;Y10T428/259;;Y10T428/259;;C09C1/42;;C01P2004/61;;B41M5/1555;;C01P2004/51;;C01P2004/50;;C01P2006/82;;C01P2004/80;;C01P2006/12;;C01P2004/41;;C01P2006/80;;C01P2006/60;;C01P2002/72;;C01P2004/62;;Y10S428/914,B41M5/155;;C09C1/42,106288B,0,0,,,,EXPIRED
565,MX,A,MX 2008011842 A,199-289-083-819-107,2008-10-02,2008,MX 2008011842 A,2007-03-12,US 78185306 P;;US 2007/0006336 W,2006-03-13,METHODS AND COMPOSITIONS FOR TREATMENT OF DIASTOLIC HEART FAILURE.,"Provided herein are methods of treatment of diastolic heart failure (DHF) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof.",ENCYSIVE PHARMACEUTICALS INC,GIVEN BRUCE D;;DIXON RICHARD A F,,https://lens.org/199-289-083-819-107,Patent Application,no,0,0,13,13,0,A61K9/0019;;A61K9/1623;;A61K9/2054;;A61K9/2095;;A61K9/2866;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61K31/194;;A61K31/401;;A61K9/19;;A61K31/357;;A61K31/194;;A61K31/506;;A61K31/401;;A61K31/501;;A61K9/0019;;A61K9/1623;;A61K9/2095;;A61K9/2866;;A61K9/2054;;A61K31/357;;A61K31/42,A61K9/20;;A61K9/19;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61K38/07;;A61K38/12;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08,,0,0,,,,DISCONTINUED
566,US,B1,US 6316697 B1,004-093-241-339-453,2001-11-13,2001,US 35333299 A,1999-07-14,US 35333299 A;;US 9269698 P,1998-07-14,Constitutive disease resistance(CDR1) gene and methods of use thereof,"Substantially purified CDR1 polypeptide, isolated polynucleotides encoding CDR1 polypeptide, vectors containing CDR1, host cells expressing CDR1, and antibodies which bind to CDR1 are all provided. The invention also provides a method of producing a genetically modified plant characterized as having increased disease resistance as compared to wild-type plants. A method is also provided for identifying novel disease resistance genes by probing a nucleic acid library with at least a fragment of a polynucleotide encoding CDR1, and selecting those clones that hybridize with the fragment.",NOBLE FOUNDATION INC;;SALK INST FOR BIOLOGICAL STUDI,DIXON RICHARD A;;XIA YIJI;;LAMB CHRISTOPHER,SALK INSTITUTE FOR BIOLOGICAL STUDIES THE (1999-12-17);;NOBLE FOUNDATION INC. THE (2000-11-20),https://lens.org/004-093-241-339-453,Granted Patent,yes,2,0,9,9,3,C07K14/415;;C12N9/63;;C07K14/415;;C12N9/50;;C12N9/63;;C12N15/8281;;C12N15/8281,C07K14/415;;C12N9/50;;C12N15/29;;C12N15/82,800/279;;800/295;;800/287;;800/278;;435/69.1;;435/320.1;;435/252.2;;435/468;;435/419;;536/23.1;;536/23.6;;536/24.1,2,1,157-182-940-978-855,8955630;;10.1016/s0378-1119(96)00327-7,"Dixon et al., ""Metabolic engineering: prospects for crop improvement through the genetic manipulation of phenylpropanoid biosynthesis and defense responses-a review,"" Gene, 179:61-71 (1996).;;Dixon et al., ""Engineering Disease Resistance in Plants: An Overview,"" Molecular Methods in Plant Pathology, Sing, Rudra P. et al. (eds). pp. 249-270 (1995).",EXPIRED
567,US,A1,US 2011/0269939 A1,014-799-370-673-56X,2011-11-03,2011,US 67346908 A,2008-08-15,US 67346908 A;;US 96526007 P;;US 2008/0073366 W,2007-08-17,NEW APPROACH FOR DESIGNING DIABETES DRUGS,"The present technology relates to the fields of crystallography, biochemistry, and drug design. In particular, methods and compositions for screening, identifying and designing compounds that interact with human mitoNEET.",UNIV CALIFORNIA,JENNINGS PATRICIA A;;DIXON JACK;;NECHUSHTAI RACHEL,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2007-08-24),https://lens.org/014-799-370-673-56X,Patent Application,yes,1,0,4,4,0,C07K14/705;;C07K2299/00;;C07K14/705;;C07K2299/00,C07K14/47;;G01J3/00;;G06G7/60,530/350;;356/300;;703/11,0,0,,,,INACTIVE
568,EP,A2,EP 1097239 A2,022-941-514-725-926,2001-05-09,2001,EP 99935290 A,1999-07-14,US 9912374 W;;US 9269698 P,1998-07-14,"CONSTITUTIVE DISEASE RESISTANCE GENE (CDR1), AND METHODS OF USE THEREOF",,SALK INST FOR BIOLOGICAL STUDI,DIXON RICHARD A;;XIA YIJI;;LAMB CHRISTOPHER,,https://lens.org/022-941-514-725-926,Patent Application,yes,0,0,9,9,3,C07K14/415;;C12N9/63;;C07K14/415;;C12N9/50;;C12N9/63;;C12N15/8281;;C12N15/8281,C07K14/415;;C12N9/50;;C12N15/29;;C12N15/82,,1,0,,,See references of WO 0004040A3,DISCONTINUED
569,AU,B2,AU 2010/273587 B2,034-075-711-023-816,2014-07-10,2014,AU 2010/273587 A,2010-07-12,US 22512609 P;;US 2010/0041717 W,2009-07-13,Plants with modified lignin content and methods for production thereof,"The invention provides methods for decreasing lignin content and for increasing the level of fermentable carbohydrates in plants by down-regulation of the NST transcription factor. Nucleic acid constructs for down-regulation of NST are described. Transgenic plants are provided that comprise reduced lignin content. Plants described herein may be used, for example, as improved biofuel feedstock and as highly digestible forage crops. Methods for processing plant tissue and for producing ethanol by utilizing such plants are also provided.",THE SAMUEL ROBERTS NOBLE FOUNDATION INC,ZHAO QIAO;;CHEN FANG;;DIXON RICHARD A,,https://lens.org/034-075-711-023-816,Granted Patent,no,4,0,8,8,0,C07K14/415;;C07K14/415;;C12N15/8255;;C12N15/8255;;D21C5/00;;D21C5/00;;D21H23/00;;D21H23/00,C12N15/82;;A01H5/00,,2,2,027-615-569-962-310;;017-196-717-690-067,10.1007/s00425-007-0498-y;;17333250;;pmc1820955;;17237351;;10.1105/tpc.106.047043,"ZHONG, R. ET AL., Planta, 2007, vol. 225, no.6, pp1603-1611.;;MITSUDA, N. ET AL.,The Plant Cell, 2007, vol. 19, pp270-280.",INACTIVE
570,WO,A3,WO 2000/004040 A3,036-176-852-590-019,2000-04-20,2000,US 9912374 W,1999-07-14,US 9269698 P,1998-07-14,"CONSTITUTIVE DISEASE RESISTANCE GENE (CDR1), AND METHODS OF USE THEREOF","Substantially purified CDR1 polypeptide, isolated polynucleotides encoding CDR1 polypeptide, vectors containing CDR1, host cells expressing CDR1, and antibodies which bind to CDR1 are all provided. The invention also provides a method of producing a genetically modified plant characterized as having increased disease resistance as compared to wild-type plants. A method is also provided for identifying novel disease resistance genes by probing a nucleic acid library with at least a fragment of a polynucleotide encoding CDR1, and selecting those clones that hybridize with the fragment.",SALK INST FOR BIOLOGICAL STUDI;;DIXON RICHARD A;;XIA YIJI;;LAMB CHRISTOPHER,DIXON RICHARD A;;XIA YIJI;;LAMB CHRISTOPHER,,https://lens.org/036-176-852-590-019,Search Report,yes,2,0,9,9,0,C07K14/415;;C12N9/63;;C07K14/415;;C12N9/50;;C12N9/63;;C12N15/8281;;C12N15/8281,C07K14/415;;C12N9/50;;C12N15/29;;C12N15/82,,2,1,157-182-940-978-855,8955630;;10.1016/s0378-1119(96)00327-7,"DIXON R A, PAIVA N L, BHATTACHARYYA M K: ""ENGINEERING DISEASE RESISTANCE IN PLANTS: AN OVERVIEW"", MOLECULAR METHODS IN PLANT PATHOLOGY, XX, XX, 1 January 1995 (1995-01-01), XX, pages 249 - 270, XP002924133;;DIXON R.A. ET AL: ""Methabolic engineering: Prospects for crop improvement through the genetic manipulation of phenylpropanoid biosynthesis and defense responses - a review"", GENE, vol. 179, no. 1, 1996, pages 61 - 71, XP002924132",PENDING
571,DE,A1,DE 2701056 A1,048-884-025-649-42X,1977-07-21,1977,DE 2701056 A,1977-01-12,US 64816376 A;;US 64825376 A;;US 67359676 A,1976-01-12,"SENSIBILISIERUNGSPIGMENT FUER AUFZEICHNUNGSMATERIALIEN, VERFAHREN ZU SEINER HERSTELLUNG UND AUFZEICHNUNGSMATERIAL, WORIN ES ENTHALTEN IST",,ENGELHARD MIN & CHEM,ISAAC PETER A H;;OULTON THOMAS DIXON,,https://lens.org/048-884-025-649-42X,Patent Application,no,0,1,9,13,0,B41M5/1555;;C01P2002/72;;C01P2004/41;;C01P2004/50;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2004/80;;C01P2006/12;;C01P2006/60;;C01P2006/80;;C01P2006/82;;C09C1/42;;Y10S428/914;;Y10T428/259;;Y10T428/259;;C09C1/42;;C01P2004/61;;B41M5/1555;;C01P2004/51;;C01P2004/50;;C01P2006/82;;C01P2004/80;;C01P2006/12;;C01P2004/41;;C01P2006/80;;C01P2006/60;;C01P2002/72;;C01P2004/62;;Y10S428/914,B41M5/155;;C09C1/42,,0,0,,,,EXPIRED
572,US,A,US 2912344 A,071-994-438-562-956,1959-11-10,1959,US 68963557 A,1957-10-11,US 68963557 A;;US 83892159 A,1957-10-11,Pressure-sensitive transfer element for placing smudge-resistant marks,,COLUMBIA RIBBON CARBON MFG,NEWMAN DOUGLAS A;;DIXON HAROLD F E,,https://lens.org/071-994-438-562-956,Granted Patent,no,3,15,2,2,0,B41M5/10;;H01F41/16;;Y10S428/914;;Y10S428/90;;Y10T428/24983;;Y10T428/28;;Y10T428/2848;;Y10T428/31804;;Y10T428/24983;;Y10T428/28;;Y10T428/2848;;Y10T428/31804;;H01F41/16;;B41M5/10;;Y10S428/914;;Y10S428/90,B41M5/10;;H01F41/16,,0,0,,,,EXPIRED
573,EP,A2,EP 1996162 A2,112-281-311-513-773,2008-12-03,2008,EP 07752997 A,2007-03-12,US 2007/0006336 W;;US 78185306 P,2006-03-13,METHODS AND COMPOSITIONS FOR TREATMENT OF DIASTOLIC HEART FAILURE,,ENCYSIVE PHARMACEUTICALS INC,GIVEN BRUCE D;;DIXON RICHARD A F,,https://lens.org/112-281-311-513-773,Patent Application,yes,0,0,13,13,0,A61K9/0019;;A61K9/1623;;A61K9/2054;;A61K9/2095;;A61K9/2866;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61K31/194;;A61K31/401;;A61K9/19;;A61K31/357;;A61K31/194;;A61K31/506;;A61K31/401;;A61K31/501;;A61K9/0019;;A61K9/1623;;A61K9/2095;;A61K9/2866;;A61K9/2054;;A61K31/357;;A61K31/42,A61K9/19;;A61K9/20;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61K38/07;;A61K38/12;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08,,0,0,,,,DISCONTINUED
574,SK,B6,SK 278597 B6,131-779-666-110-057,1997-11-05,1997,SK 381591 A,1991-12-16,GB 9027425 A;;GB 9027424 A;;GB 9113596 A,1990-12-18,"3,7-DISUBSTITUTED INDOLE DERIVATIVES, PROCESS FOR PRODUCING THEM PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE","This patent describes the derivatives closed to 3,7-disubstituted indole with a general formula (I), where the symbol R1 means alkyl with 1 up 4 carbon atoms, R2 is alkyl with 1 up to 3 carbon atoms, together with a production of them and their application as pharmaceutical compositions and pharmaceutical means contained in these compounds.",DIXON ARNOLD K.;;GIGER RUDOLF K. A.,DIXON ARNOLD K;;GIGER RUDOLF K A,,https://lens.org/131-779-666-110-057,Granted Patent,no,0,0,35,42,0,C07D451/12;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/26;;A61P43/00;;A61K31/405;;C07D451/12,A61K31/40;;A61K31/46;;A61P25/00;;A61P25/18;;A61K31/435;;A61P25/20;;A61P25/24;;A61P25/26;;A61P43/00;;C07D209/32;;C07D233/54;;C07D401/12;;C07D403/12;;C07D451/02;;C07D451/04;;C07D451/12;;C07D451/14;;C07D453/02;;C07D471/04;;C07D471/08;;C07D487/08,,0,0,,,,EXPIRED
575,US,A1,US 2012/0322122 A1,019-934-834-817-48X,2012-12-20,2012,US 201213462583 A,2012-05-02,US 201213462583 A;;US 201161483460 P,2011-05-06,COMPOSITIONS AND METHODS FOR IMPROVED PLANT FEEDSTOCK,"The invention provides methods for modifying lignin content and composition in plants and achieving associated benefits therefrom involving altered expression of newly discovered MYB4 transcription factors. Nucleic acid constructs for modifying MYB4 transcription factor expression are described. By over-expressing the identified MYB4 transcription factors, for example, an accompanying decrease in lignin content may be achieved. Plants are provided by the invention comprising such modifications, as are methods for their preparation and use.",SHEN HUI;;CHEN FANG;;DIXON RICHARD A,SHEN HUI;;CHEN FANG;;DIXON RICHARD A,NOBLE RESEARCH INSTITUTE LLC (2012-05-14),https://lens.org/019-934-834-817-48X,Patent Application,yes,2,15,2,2,192,C12N15/8243;;C12N15/8255;;C12N15/8261;;C07K2319/21;;Y02A40/146;;C07K14/415;;Y02E50/30;;C12N15/8243;;C12N15/8255;;C12N15/8261;;C07K2319/21;;Y02A40/146;;Y02E50/30;;C07K14/415,C12N15/29;;A01H5/00;;C12N5/10;;C12N15/82;;C12P7/14,435/162;;435/320.1;;800/298;;435/419;;800/320;;800/320.1;;800/312;;800/320.2;;800/314;;800/315;;800/306;;800/320.3;;536/23.6;;800/278;;800/284;;800/285;;800/286,4,3,091-569-698-846-961;;084-254-913-213-762;;047-723-672-768-544,14675440;;10.1046/j.1365-313x.2003.01916.x;;21988539;;10.1111/j.1469-8137.2011.03922.x;;pmc305818;;10.1093/emboj/19.22.6150;;11080161,"Patzlaff et al, 2003, The Plant J., 36:743-754;;Shen et al, 2012, New Phytologist, 193:121-136;;Lucas et al, GenBank accession no. FE635325 published 10 March 2008;;Jin et al, 2000, Embo, 19:6150-6161",ACTIVE
576,EP,A1,EP 0829160 A1,039-217-708-026-330,1998-03-18,1998,EP 97914010 A,1997-03-27,CA 9700204 W;;US 1433596 P,1996-03-29,MULTIMEDIA DOCUMENT CONFERENCING SYSTEM,,NORTHERN TELECOM LTD,CRADDOCK A JULIAN;;DIXON FRED;;NG CHARLES,NORTEL NETWORKS LIMITED (2000-09-27);;NORTEL NETWORKS CORPORATION (1999-07-14),https://lens.org/039-217-708-026-330,Patent Application,yes,0,2,4,4,0,H04L12/1827;;H04M3/567;;H04M7/12;;H04M2203/5009;;H04M2203/5063,H04N7/15;;H04L12/18;;H04M3/56;;H04M7/12,,1,0,,,See references of WO 9737484A1,DISCONTINUED
577,EP,A1,EP 2314288 A1,050-869-329-837-485,2011-04-27,2011,EP 10011358 A,1998-12-14,EP 04004843 A;;EP 98963170 A;;US 6951097 P;;US 16335198 A,1997-12-15,Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate,"The present invention relates to a composition for topical application of methylphenidate, comprising methylphenidate in a flexible finite system and a non-functional acrylic polymer.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A;;KANIOS DAVID,,https://lens.org/050-869-329-837-485,Patent Application,yes,10,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K31/435;;A61K9/70;;A61K31/445;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,1,0,,,"GEBLER H, KINDL G: ""Pharmazie für die Praxis"", 1990, GEORG THIEME VERLAG, Stuttgart, ISBN: 3-13-730701-5, pages: 175 - 176, XP002628340",EXPIRED
578,US,A1,US 2013/0324575 A1,071-060-367-642-465,2013-12-05,2013,US 201313962464 A,2013-08-08,US 201313962464 A;;US 201113071048 A;;US 98115410 A;;US 81219807 A;;US 37862906 A;;US 2451301 A;;US 61862600 A;;US 16335198 A;;US 6951097 P,1997-12-15,COMPOSITIONS AND METHOD FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",MANTELLE JUAN;;DIXON TERESE A;;KANIOS DAVID;;NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A;;KANIOS DAVID,,https://lens.org/071-060-367-642-465,Patent Application,yes,2,10,7,65,0,A61K9/7061;;A61K9/7069;;A61K31/445;;A61K31/4458;;A61P25/00;;A61K31/445;;A61K9/7061;;A61K9/7069;;A61K31/4458;;A61K47/32,A61K31/4458;;A61K9/70,514/317,2,0,,,generic daytrana [online] retrieved from: http://www.drugs.com/availability/generic-daytrana.html?printable=1 on 2/14/14; 3 pages.;;Sharma et al. (IJDDR 2011; 3(3):70-84).,DISCONTINUED
579,BR,A2,BR PI0708879 A2,078-329-887-418-487,2011-06-14,2011,BR PI0708879 A,2007-03-12,US 78185306 P;;US 2007/0006336 W,2006-03-13,peocessos e composiÇÕes para o tratamento de insufiÊncia cardÍaca diastàlica,"PROCESSOS E COMPOSIÇÕES PARA O TRATAMENTO DE INSUFICIÊNCIA CARDÍACA DIASTàLICA. A presente invenção refere-se a processos de tratamento de insuficiência cardíaca diastólica (DHF) por administração de um antagonista a endotelina, tal como sitaxsentan ou um sal farmaceuticamente aceitável do mesmo.",ENCYSIVE PHARMACEUTICALS,GIVEN BRUCE D;;DIXON RICHARD A F,,https://lens.org/078-329-887-418-487,Patent Application,no,0,0,13,13,0,A61K9/0019;;A61K9/1623;;A61K9/2054;;A61K9/2095;;A61K9/2866;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61K31/194;;A61K31/401;;A61K9/19;;A61K31/357;;A61K31/194;;A61K31/506;;A61K31/401;;A61K31/501;;A61K9/0019;;A61K9/1623;;A61K9/2095;;A61K9/2866;;A61K9/2054;;A61K31/357;;A61K31/42,A61K9/19;;A61K9/20;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61K38/07;;A61K38/12;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08,,0,0,,,,DISCONTINUED
580,US,A1,US 2014/0179739 A1,103-771-160-162-122,2014-06-26,2014,US 201414192260 A,2014-02-27,US 201414192260 A;;US 201313962464 A;;US 201113071048 A;;US 98115410 A;;US 81219807 A;;US 37862906 A;;US 2451301 A;;US 61862600 A;;US 16335198 A;;US 6951097 P,1997-12-15,COMPOSITIONS AND METHOD FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",MANTELLE JUAN;;DIXON TERESE A;;KANIOS DAVID;;NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A;;KANIOS DAVID,,https://lens.org/103-771-160-162-122,Patent Application,yes,0,6,7,65,0,A61K9/7061;;A61K9/7069;;A61K31/445;;A61K31/4458;;A61P25/00;;A61K31/445;;A61K9/7061;;A61K9/7069;;A61K31/4458;;A61K47/32,A61K47/32;;A61K9/70;;A61K31/4458,514/317,1,0,,,polyacrylate [online] retrieved on 10/1/14 from: http://www.britannica.com/EBchecked/topic/1551195/polyacrylate.,DISCONTINUED
581,US,A,US 5543426 A,153-456-794-862-837,1996-08-06,1996,US 42655895 A,1995-04-21,US 42655895 A;;GB 9027424 A;;GB 9027425 A;;GB 9113596 A;;US 16322493 A;;US 80981591 A,1990-12-18,"Use of certain 3,7-disubstituted indole compounds for treating depression or cognitive disorders","3,7-disubstituted indole derivatives of formula I ##STR1## wherein R.sub.1, R.sub.2, n, X, Y and Z are as defined in the description, are useful for the treatment of psychiatric disorders.",SANDOZ LTD,DIXON ARNOLD K;;GIGER RUDOLF K A,NOVARTIS AG (1997-01-06),https://lens.org/153-456-794-862-837,Granted Patent,yes,24,45,35,42,0,C07D451/12;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/26;;A61P43/00;;A61K31/405;;C07D451/12,A61K31/40;;A61K31/435;;A61K31/46;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/26;;A61P43/00;;C07D209/32;;C07D233/54;;C07D401/12;;C07D403/12;;C07D451/02;;C07D451/04;;C07D451/12;;C07D451/14;;C07D453/02;;C07D471/04;;C07D471/08;;C07D487/08,514/410,2,2,046-510-776-719-59X;;020-593-225-662-286,2855746;;2533904,"Mol. Toxicol., vol. 1, pp. 341 350 (1987).;;Eur. J. Cancer Clin. Oncol., vol. 25, Suppl. 1, pp. S75 S77 (1989).",EXPIRED
582,CA,A,CA 1070054 A,175-724-977-981-042,1980-01-22,1980,CA 264910 A,1976-11-04,US 64816376 A;;US 64825376 A;;US 67359576 A;;US 67359676 A,1976-01-12,REDUCED CHARGE MONTMORILLONITE PIGMENT AND USE IN RECORD RIAL,"A sheet coated with a reduced charge montmorillonite pigment for use in record material, especially pressure-sensitive carbonless copying systems. The pigment is produced by replacing exchangeable cations of a substantially dioctahedral montmorillonite(exemplified by certain bentonite clays) with a preselected quantity of lithium ions, mildly heating the lithium-exchanged montmorillonite to collapse irreversibly the montmorillonite structure, and grinding the heat-treated material to pigment-size particles. The sheets produce stabilized intense images when printed with a solution of crystal violet lactone (CVL) dye precursor and thus may be used with CVL without employing secondary slow acting dyes such as benzoyl leuco methylene blue. The sheets are also useful with other colorless or substantially colorless dye precursors.",ENGELHARD MIN & CHEM,ISAAC PETER A H;;OULTON T DIXON,,https://lens.org/175-724-977-981-042,Granted Patent,no,0,0,2,13,0,B41M5/1555;;B41M5/1555;;C01P2002/72;;C01P2002/72;;C01P2004/41;;C01P2004/41;;C01P2004/50;;C01P2004/50;;C01P2004/51;;C01P2004/51;;C01P2004/61;;C01P2004/61;;C01P2004/62;;C01P2004/62;;C01P2004/80;;C01P2004/80;;C01P2006/12;;C01P2006/12;;C01P2006/60;;C01P2006/60;;C01P2006/80;;C01P2006/80;;C01P2006/82;;C01P2006/82;;C09C1/42;;C09C1/42;;Y10S428/914;;Y10S428/914;;Y10T428/259;;Y10T428/259,B41M5/155;;C09C1/42,6-194,0,0,,,,EXPIRED
583,US,A,US 4047738 A,174-304-584-350-947,1977-09-13,1977,US 67359576 A,1976-04-05,US 67359576 A;;US 64816376 A;;US 64825376 A;;US 67359676 A,1976-01-12,Record sheets sensitized with reduced charge montmorillonite pigment,"A sheet coated with a reduced charge montmorillonite pigment for use in record material, especially pressure-sensitive carbonless copying systems. The pigment is produced by replacing exchangeable cations of a substantially dioctahedral montmorillonite (exemplified by certain bentonite clays) with lithium ions, mildly heating the lithium-exchanged montmorillonite to collapse irreversibly the montmorillonite structure, and grinding the heat-treated material to pigment-size particles. The sheets produce stabilized intense images when printed with a solution of crystal violet lactone (CVL) dye precursor and thus may be used with CVL without employing secondary slow acting dyes such as benzoyl leuco methylene blue. The sheets are also useful with other colorless or substantially colorless dye precursors.",ENGELHARD MIN & CHEM,ISAAC PETER A H;;OULTON T DIXON,PHIBRO CORPORATION (1983-03-28);;ENGLEHARD CORPORATION A CORP. OF DE (1981-05-18),https://lens.org/174-304-584-350-947,Granted Patent,yes,6,10,2,13,0,B41M5/1555;;B41M5/1555;;C01P2002/72;;C01P2002/72;;C01P2004/41;;C01P2004/41;;C01P2004/50;;C01P2004/50;;C01P2004/51;;C01P2004/51;;C01P2004/61;;C01P2004/61;;C01P2004/62;;C01P2004/62;;C01P2004/80;;C01P2004/80;;C01P2006/12;;C01P2006/12;;C01P2006/60;;C01P2006/60;;C01P2006/80;;C01P2006/80;;C01P2006/82;;C01P2006/82;;C09C1/42;;C09C1/42;;Y10S428/914;;Y10S428/914;;Y10T428/259;;Y10T428/259,B41M5/155;;C09C1/42,282/27.5,0,0,,,,EXPIRED
584,WO,A1,WO 2008/112241 A1,075-319-468-631-373,2008-09-18,2008,US 2008/0003250 W,2008-03-12,US 91801507 P,2007-03-13,METHODS AN COMPOSITIONS FOR TREATMENT OF AN INTERSTITIAL LUNG DISEASE,"Provided herein are methods of treatment of an interstitial lung disease (ILD) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof.",ENCYSIVE PHARMACEUTICALS INC;;GIVEN BRUCE D;;DIXON RICHARD A F,GIVEN BRUCE D;;DIXON RICHARD A F,,https://lens.org/075-319-468-631-373,Patent Application,yes,2,0,2,2,0,A61K31/42;;A61K31/42;;A61P11/00,A61K31/42;;A61P11/00,,1,1,023-599-662-626-722,10.1016/s0025-6196(11)61030-6;;10.4065/82.3.342;;17352370,"RYU JAY H ET AL: ""Pulmonary hypertension in patients with interstitial lung diseases"", MAYO CLINIC PROCEEDINGS, vol. 82, no. 3, March 2007 (2007-03-01), pages 342 - 350, XP002484182, ISSN: 0025-6196",PENDING
585,US,A,US 3062676 A,105-324-546-623-022,1962-11-06,1962,US 83892059 A,1959-09-09,US 83892059 A;;DE C0021381 A,1959-09-09,Smudge-resistant pressure-sensitive transfer element for placing smudgeresistant marks,,COLUMBIA RIBBON & CARBON,NEWMAN DOUGLAS A;;DIXON HAROLD F E,,https://lens.org/105-324-546-623-022,Granted Patent,no,2,10,2,2,0,B41M5/10;;B41M5/10;;H01F41/16;;H01F41/16;;Y10T428/2848;;Y10T428/2848;;Y10T428/2883;;Y10T428/2883,B41M5/10;;H01F41/16,,0,0,,,,EXPIRED
586,US,A,US 2022276 A,125-334-653-005-873,1935-11-26,1935,US 64091832 A,1932-11-03,US 64091832 A,1932-11-03,Adhesive carbon paper,,COLUMBIA RIBBON & CARBON,DIXON HAROLD W A;;MOORE ROBSON S,,https://lens.org/125-334-653-005-873,Granted Patent,no,0,6,1,1,0,B41L1/16;;Y10T428/31848;;Y10T428/31848;;B41L1/16,B41L1/16,,0,0,,,,EXPIRED
587,AU,A,AU 1999/050800 A,125-930-875-345-225,2000-02-07,2000,AU 1999/050800 A,1999-07-14,US 9269698 P;;US 9912374 W,1998-07-14,"Constitutive disease resistance gene (cdr1), and methods of use thereof",,NOBLE FOUNDATION INC THE;;SALK INST FOR BIOLOGICAL STUDI,DIXON RICHARD A;;XIA YIJI;;LAMB CHRISTOPHER,,https://lens.org/125-930-875-345-225,Patent Application,no,0,0,9,9,0,C07K14/415;;C12N9/63;;C07K14/415;;C12N9/50;;C12N9/63;;C12N15/8281;;C12N15/8281,C07K14/415;;C12N9/50;;C12N15/29;;C12N15/82,,0,0,,,,DISCONTINUED
588,CN,A,CN 1085233 A,159-473-913-873-84X,1994-04-13,1994,CN 93102507 A,1993-02-04,US 83072792 A,1992-02-04,Decorative floor coverings having the appearance of ceramic title and compositions and methods for making same,,CONGOLEUM CORP,SHALOV ALLEN A;;MORSELANDER EUGENE;;DIXON RONALD,,https://lens.org/159-473-913-873-84X,Patent Application,no,0,0,10,10,0,B05D1/28;;B29C70/603;;B29L2031/722;;B29L2031/732;;C08L27/06;;C08L33/06;;C08L33/10;;C08L61/28;;C08L2205/02;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/0055;;C08K5/10;;D06N3/00;;C08L27/04;;D06N7/0055;;C08L2205/02;;D06N3/06;;B05D1/28;;D06N3/08;;C08L27/06;;B29L2031/732;;B29C70/603;;B29L2031/722;;C08L33/10;;C08L33/06;;C08L61/28;;C09D127/06,B05D1/28;;B29C70/60;;C08L27/06;;C08L33/04;;C08L33/06;;C08L33/10;;C08L61/28;;C08L101/00;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/00,,0,0,,,,DISCONTINUED
589,US,A1,US 2003/0033275 A1,081-578-353-749-180,2003-02-13,2003,US 92889401 A,2001-08-13,US 92889401 A,2001-08-13,Combined database index of unstructured and structured columns,"
   A database management system and method provides access to a data table having structured data and unstructured data. A user interface allows a user to issue instructions to the database management system such as to build an index based on the structured and unstructured data and to search the data table. An indexing logic generates an index structure by combining the structured and unstructured data. With this index structure, a single query can contain search conditions from both the structured data and the unstructured data. In this manner, efficiency for searching the data table for combined structured and unstructured conditions is improved. 
",ALPHA SHAMIM A.;;KAMINAGA GARRETT;;DIXON PAUL,ALPHA SHAMIM A;;KAMINAGA GARRETT;;DIXON PAUL,ORACLE INTERNATIONAL CORPORATION (OIC) (2003-10-30);;ORACLE CORPORATION (2001-12-19),https://lens.org/081-578-353-749-180,Patent Application,yes,8,93,2,2,0,G06F16/2228;;G06F16/316;;G06F16/316;;Y10S707/99931;;Y10S707/99933;;Y10S707/99943;;G06F16/2228,G06F7/00;;G06F17/30,707/1,0,0,,,,EXPIRED
590,US,A1,US 2022/0154199 A1,109-324-627-530-464,2022-05-19,2022,US 202117528375 A,2021-11-17,US 202117528375 A;;US 202063114834 P,2020-11-17,RECOMBINANT LAC POLYNUCLEOTIDES AND USES THEREOF TO INCREASE PRODUCTION OF C-LIGNIN IN PLANTS,"The disclosure provides recombinant LAC polynucleotides encoding a laccase (LAC) polypeptide capable of polymerizing caffeyl alcohol, vectors and cells including the recombinant LAC polynucleotide. The disclosure also provides transgenic plants including cells having the recombinant LAC polynucleotide of the present disclosure and methods of increasing production of C-lignin in a plant.",UNIV NORTH TEXAS,DIXON RICHARD A;;CHEN FANG;;ZHUO CHUNLIU,UNIVERSITY OF NORTH TEXAS (2021-11-29),https://lens.org/109-324-627-530-464,Patent Application,yes,1,0,1,1,3,C12N15/8218;;C12N15/8255;;C12N9/0061;;C12N15/8218;;C12N15/8255,C12N15/82,,6,6,003-282-804-610-240;;055-600-108-234-20X;;021-317-502-721-674;;019-744-004-287-101;;055-003-061-629-507;;053-274-000-747-851,33037146;;pmc7721330;;10.1105/tpc.20.00598;;10.1073/pnas.1120992109;;pmc3277123;;22307645;;10.1105/tpc.113.113142;;pmc3753385;;23903315;;22957702;;10.1111/tpj.12012;;10.1073/pnas.0403255101;;pmc438954;;15197260;;10.3389/fpls.2019.00435;;31024599;;pmc6463009,"Wang, X. et al. Substrate Specificity of LACCASE8 Facilitates Polymerization of Caffeyl Alcohol for C-Lignin Biosynthesis in the Seed Coat of Cleome hassleriana, 2020, The Plant Cell, Vol 32: 3825-3845 with Supplemental Data. (Year: 2020);;Chen F. et al. A polymer of caffeyl alcohol in plant seeds. 2012 Proceeding of the National Academies of Science. 109: 1772-1777. (Year: 2012);;Tobimatsu, Y. et al. Coexistance but independent biosynthesis of catechyl and quaiacy/syringyl lignin polymers in seed coats. 2012, Plant Cell 25: 2587-2600. (Year: 2012);;Chen F et al, Novel seed coat lignins in the Cactaceae: structure, distribution and implications for the evolution of lignin diversity, 2013, The Plant Journal, 73: 201-211. (Year: 2013);;Guo H et al, Protein tolerance to random amino acid change, 2004, Proceedings of the National Academies of Science, 101:9205-9210. (Year: 2004);;Li et al, 2019, Genome-Wide Identification and Characterization of Salvia miltiorrhiza Laccases Reveal Potential Targets for Salvianolic Acid B Biosynthesis, Frontiers in Plant Science, 10: 435 (Year: 2019)",PENDING
591,WO,A1,WO 1994/026957 A1,140-183-120-888-376,1994-11-24,1994,US 9403812 W,1994-04-07,US 6079693 A,1993-05-12,SEAMLESS HOLOGRAPHIC TRANSFER,"A method of making a die as shown in Fig. 3 and the die (18) itself for establishing through embossing or micro-embossing a seamless pattern (14), preferably a holographic pattern, on a decorative medium such as a metallized film is provided. A cylindrical embossing or micro-embossing die (18) is provided with a layer of an embossable material, preferably pure silver, a silver alloy or any other suitable embossable material. The cylindrical die (18) is an integral member in which a pattern (14) is recombined thereon by a step and repeat embossing or micro-embossing process as opposed to an intricate lathe-type machine turning operation, and can thus accept, carry and maintain complex patterns with the integrity required for producing a repeating holographic pattern.",TRANSFER PRINT FOILS INC,PARKER HARRY A;;ALLOCCO JOSEPH;;DIXON JOHN,,https://lens.org/140-183-120-888-376,Patent Application,yes,4,1,2,2,0,B44B5/028;;B44B5/028;;B23P15/24;;B23P15/24;;B29C59/002;;B29C59/002;;B29L2031/7224;;B29L2031/7224;;B44B5/009;;B44B5/009;;G03H1/028;;G03H1/028;;G03H2001/0296,B23P15/24;;B29C59/00;;B44B5/00;;B44B5/02,,0,0,,,,PENDING
592,US,A1,US 2011/0010790 A1,164-319-330-493-795,2011-01-13,2011,US 83458110 A,2010-07-12,US 83458110 A;;US 22512609 P,2009-07-13,PLANTS WITH MODIFIED LIGNIN CONTENT AND METHODS FOR PRODUCTION THEREOF,"The invention provides methods for decreasing lignin content and for increasing the level of fermentable carbohydrates in plants by down-regulation of the NST transcription factor. Nucleic acid constructs for down-regulation of NST are described. Transgenic plants are provided that comprise reduced lignin content. Plants described herein may be used, for example, as improved biofuel feedstock and as highly digestible forage crops. Methods for processing plant tissue and for producing ethanol by utilizing such plants are also provided.",SAMUEL ROBERTS NOBLE FOUND INC,ZHAO QIAO;;CHEN FANG;;DIXON RICHARD A,THE SAMUEL ROBERTS NOBLE FOUNDATION (2010-07-29);;NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/164-319-330-493-795,Patent Application,yes,5,11,8,8,6,C07K14/415;;C07K14/415;;C12N15/8255;;C12N15/8255;;D21C5/00;;D21C5/00;;D21H23/00;;D21H23/00,A01H5/00;;A01H5/02;;A01H5/04;;A01H5/10;;C07C29/74;;C12N5/04;;C12N15/85;;D21C5/00;;D21H23/00,800/263;;800/298;;800/320;;800/312;;435/410;;568/913;;435/320.1;;435/419;;426/635;;162/100;;162/1;;44/307,11,11,027-615-569-962-310;;101-379-692-204-048;;000-047-739-257-25X;;023-302-404-832-988;;098-829-195-772-799;;022-119-665-738-576;;006-181-967-002-57X;;109-190-670-672-272;;055-003-061-629-507;;020-577-919-065-531;;079-463-304-815-987,10.1007/s00425-007-0498-y;;17333250;;21883551;;10.1111/j.1365-313x.2011.04764.x;;10.1046/j.1365-313x.2001.00976.x;;11260498;;12624759;;10.1007/s00425-002-0922-2;;11202440;;10.1023/a:1026507517182;;17177787;;10.1111/j.1467-7652.2005.00159.x;;10.1073/pnas.182204199;;pmc129380;;12181491;;17770331;;10.1126/science.236.4806.1299;;10.1073/pnas.0403255101;;pmc438954;;15197260;;10.1038/nbt1316;;17572667;;pmc1077548;;10.1104/pp.95.2.426;;16668001,"Zhong, R., E. A. Richardson, Z-H. Ye. 2007. Two NAC domain transcription factors, SND1 and NST1, function redundantly in regulation of secondary wall synthesis in fibers of Arabidopsis. Planta. 225:1603-1611.;;Wang, H., Q. Zhao, F. Chen, M. Wang, and R. A. Dixon. 2011. NAC domain function and transcriptional control of a secondary cell wall master switch. Plant J. 68:1104-1114;;Thomas, C. L., L. Jones, D. C. Baulcombe, and A. J. Maule. 2001. Size constraints for targeting post-transciptional gene silencing and for RNA-directed methylation in Nicotiana benthamiana using a potato virus X vector. Plant J. 25(4):417-425.;;Olhoft, P.M., L.E. Flagel, C. M. Donovan, and D.A. Somers. 2003. Efficient soybean transformation using hygromycin B selection in the cotyledonary-node method. Planta. 216:723-735.;;Zhao, Z., T. Cai, L. Tagliani, M. Miller, N. Wang, H. Pang, M. Rudert, S. Schroeder, D. Hondred, J. Seltzer, and D. Pierce. 2000. Agrobacterium-mediated sorghum transformation. Plant Mol Biol. 44:789-798.;;Nykiforuk, C. L., J. G. Boothe, E. W. Murray, R. G. Keon, H. J. Goren, N. A. Markley, and M. M. Moloney. 2006. Transgenic expression and recovery of biologically active recombinant human insulin from Arabidopsis thaliana seeds. Plant Biotech. J. 4:77-85.;;Klahre, U., P. Crete, S. A. Leuenberger, V. A. Iglesias, and F. Meins Jr. 2002. High molecular weight RNAs and small interfering RNAs induce systemic posttranscriptional gene silencing in plants. PNAS. 99(18):11981-11986).;;Kay, R., A. Chan, M. Daly, and J. McPherson. 1987. Duplication of CaMV 35S promoter sequences creates a strong enhancer for plant genes. Science. 236(4806):1299-1302.;;Guo, H. H., J. Choe, and L. A. Loeb. 2004. Protein tolerance to random amino acid change. PNAS. 101(25):9205-9210.;;Chen, F., and R. A. Dixon. 2007. Lignin modification improves fermentable sugar yields for biofuel production. Nat. Biotech. 25(7):759-761.;;Gould, J., M. Devey, O. Hasegawa, E.C. Ulian, G. Peterson, and R.H. Smith. 1991. Transformation of Zea mays L. using Agrobacterium tumefaciens and the shoot apex. Plant Physiol. 95:426-434",ACTIVE
593,US,A1,US 2005/0210069 A1,179-682-633-811-51X,2005-09-22,2005,US 7021005 A,2005-03-03,AU 2004/901457 A,2004-03-18,Scalable object recognition architecture,"A method ( 500 ) of processing received objects in a rendering system ( 230 ) is disclosed. The rendering system ( 230 ) has a plurality of detection schemes ( 234 - 1 through 234 -N), with each detection scheme ( 234 - 1 through 234 -N) having an associated object group type. The method ( 500 ) determines ( 516 ) whether a detection scheme ( 234 ) which already has grouped objects exists. If such a detection scheme ( 234 ) does not exist and a previously received object has been stored, then the method ( 500 ) determines ( 536 ) in descending priority order whether one of the detection schemes ( 234 ) is operative to group the received object with the previously received object. If it is determined ( 526 ) that none of the detection schemes is operative to group the received object with the previously received object, then the previously received object is output ( 528 ) for rendering and the received object is stored ( 528 ). If it is determined ( 536 ) that one of the detection schemes is operative to group the received object with the previously received object, then the received object is grouped with the previously received object.",CANON KK,DENG DIXON D S;;MARTIN MICHAEL A,CANON KABUSHIKI KAISHA (2005-04-14),https://lens.org/179-682-633-811-51X,Patent Application,yes,10,2,2,4,0,G06F16/904;;G06F16/904,G06F7/00;;G06F17/30,707/104.1,0,0,,,,ACTIVE
594,US,A,US 5627231 A,000-555-746-213-344,1997-05-06,1997,US 28933594 A,1994-08-11,US 28933594 A;;US 83072792 A,1992-02-04,Decorative floor coverings having the appearance of ceramic tile and compositions and methods for making same,"Disclosed are compositions comprising plasticizer, first organic polymeric material fused or fusible in the plasticizer and second polymeric material not fusible in the plasticizer, said second polymeric material having a softening point temperature less than about the fusion temperature of the first polymeric material in the plasticizer. The first polymeric material preferably comprises vinyl resin and the second polymeric material preferably comprises acrylate polymers in particulate form. Also disclosed are methods for producing surface coverings comprising converting the liquid plastisols of the present invention to solid compositions under time and temperature conditions sufficient to enable softening, and preferably substantial softening and swelling, of the second polymeric material prior to fusion of the liquid composition.",CONGOLEUM CORP,SHALOV ALAN A;;MORSELANDER EUGENE;;DIXON RONALD,,https://lens.org/000-555-746-213-344,Granted Patent,yes,9,52,10,10,0,B05D1/28;;B29C70/603;;B29L2031/722;;B29L2031/732;;C08L27/06;;C08L33/06;;C08L33/10;;C08L61/28;;C08L2205/02;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/0055;;C08K5/10;;D06N3/00;;C08L27/04;;D06N7/0055;;C08L2205/02;;D06N3/06;;B05D1/28;;D06N3/08;;C08L27/06;;B29L2031/732;;B29C70/603;;B29L2031/722;;C08L33/10;;C08L33/06;;C08L61/28;;C09D127/06,B05D1/28;;B29C70/60;;C08L27/06;;C08L33/04;;C08L33/06;;C08L33/10;;C08L61/28;;C08L101/00;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/00,524/523;;524/284;;524/293;;524/294;;525/227;;525/239,0,0,,,,EXPIRED
595,US,A1,US 2006/0037484 A1,097-670-372-930-121,2006-02-23,2006,US 80150004 A,2004-08-23,US 80150004 A,2004-08-23,Container with sliding lid,A container for breath mints and the like includes a tray and lid. The lid may be retracted to define a dispensing slot of limited width for controlled dispensing. An internal shelf may be provided to facilitate dispensing. The lid and tray are configured to resist inelastic deformation during normal use.,DIXON KEITH A;;MCDOWELL ALLEN;;LIEBE THOMAS,DIXON KEITH A;;MCDOWELL ALLEN;;LIEBE THOMAS,WM. WRIGLEY JR. COMPANY (2005-08-10),https://lens.org/097-670-372-930-121,Patent Application,yes,39,14,1,1,0,A47J47/01;;A47J47/01;;B65D83/0409;;B65D83/0409;;B65D2583/0454;;B65D2583/0454,A47J43/18,99/426,0,0,,,,DISCONTINUED
596,WO,A1,WO 2012/061615 A1,113-238-275-785-343,2012-05-10,2012,US 2011/0059181 W,2011-11-03,US 40987110 P,2010-11-03,TRANSCRIPTION FACTORS FOR MODIFICATION OF LIGNIN CONTENT IN PLANTS,"The invention provides methods for modifying lignin, cellulose, xylan, and hemicellulose content in plants, and for achieving ectopic lignification and, for instance, secondary cell wall synthesis in pith cells, by altered regulation of a WRKY transcription factor. Nucleic acid constructs for altered WRKY-TF expression are described. Transgenic plants are provided that comprise modified pith cell walls, and lignin, cellulose, and hemicellulose content. Plants described herein may be used, for example, as improved biofuel feedstock and as highly digestible forage crops.",SAMUEL ROBERTS NOBLE FOUND INC;;WANG HUANZHONG;;CHEN FANG;;DIXON RICARD A,WANG HUANZHONG;;CHEN FANG;;DIXON RICARD A,,https://lens.org/113-238-275-785-343,Patent Application,yes,29,3,3,3,43,C07K14/415;;C07K14/415;;C12N15/8245;;C12N15/8245;;C12N15/8246;;C12N15/8246;;C12N15/8255;;C12N15/8255;;C12N15/8261;;C12N15/8261;;Y02A40/146;;Y02A40/146;;Y02E50/10;;Y02E50/10,C07K14/415;;A01H5/00;;C12N15/82,,144,113,064-728-414-823-343;;002-724-747-289-970;;022-971-245-406-739;;064-918-147-571-82X;;042-187-232-771-311;;013-327-223-989-239;;061-506-672-572-556;;085-931-117-294-284;;132-648-276-369-49X;;004-411-337-008-609;;067-482-345-489-67X;;055-937-073-493-546;;007-714-228-950-221;;085-046-344-390-610;;055-843-210-171-424;;033-640-692-920-900;;033-093-660-215-000;;004-451-549-165-67X;;100-074-254-185-613;;049-427-391-860-033;;076-199-387-718-752;;048-959-281-822-221;;065-915-996-629-822;;040-967-961-034-72X;;025-412-837-175-565;;042-631-221-753-714;;133-866-246-409-405;;055-584-682-905-277;;052-597-711-097-605;;054-771-305-892-797;;018-020-177-526-297;;073-498-212-436-367;;034-994-929-400-239;;073-236-401-605-529;;056-033-533-845-763;;044-160-688-806-618;;039-231-167-687-603;;086-465-821-806-694;;001-709-346-311-266;;056-957-854-103-39X;;085-998-712-480-096;;028-938-351-274-681;;004-453-997-751-807;;026-583-850-755-495;;013-320-975-332-107;;052-264-662-732-610;;022-883-455-634-414;;010-408-992-432-262;;056-585-155-715-771;;067-803-940-131-597;;002-647-886-462-407;;010-144-555-018-585;;064-790-473-449-272;;026-092-759-748-730;;037-985-467-569-463;;004-920-754-746-691;;015-322-811-120-978;;153-423-927-948-351;;033-748-163-412-876;;011-593-933-027-914;;034-312-125-538-67X;;019-617-293-031-409;;029-615-555-051-121;;017-791-667-521-420;;077-580-667-120-981;;050-725-947-833-964;;058-816-599-846-72X;;058-145-297-843-203;;060-909-037-461-654;;028-234-369-927-462;;062-077-633-121-107;;024-661-241-823-075;;126-549-551-821-479;;014-451-503-095-39X;;029-409-447-008-102;;001-116-986-308-061;;008-108-452-184-37X;;058-032-369-859-095;;036-433-596-884-038;;049-829-029-267-263;;109-433-846-675-703;;064-286-724-259-404;;101-153-001-620-420;;049-926-193-459-915;;032-884-899-824-515;;016-070-439-124-064;;071-726-576-416-905;;040-264-748-392-762;;017-119-626-419-598;;045-599-715-620-702;;027-306-014-726-278;;125-696-449-855-553;;005-025-673-594-96X;;106-863-310-321-051;;074-931-020-985-514;;008-606-268-179-142;;109-987-791-985-919;;027-648-422-776-362;;095-553-441-891-037;;050-833-363-642-337;;065-489-631-799-686;;002-289-321-628-900;;074-591-553-080-592;;125-318-010-578-336;;017-462-855-729-176;;081-432-894-050-290;;104-238-270-795-861;;029-940-225-165-635;;042-187-232-771-311;;095-234-496-972-741;;077-702-440-591-669;;156-451-973-121-31X;;049-202-096-491-506,10.1007/s11103-009-9563-1;;19902151;;10.1007/s11103-007-9244-x;;17960484;;10.1186/1471-2229-8-132;;pmc2628384;;19102779;;18251882;;10.1111/j.1399-3054.2007.00975.x;;20408998;;10.1016/s1360-1385(00)01600-9;;10785665;;21135241;;10.1073/pnas.1016436107;;pmc3009815;;10.3109/10520296909063335;;4181665;;11875555;;10.1038/415977a;;7866872;;10.1007/bf02824806;;10.1007/bf00226207;;24213060;;6298724;;pmc325720;;10.1093/nar/11.2.369;;16844685;;10.1074/jbc.m605903200;;2591372;;10.1002/j.1460-2075.1989.tb08605.x;;pmc401614;;10.1111/j.1365-313x.1992.00409.x;;8190073;;10.1007/bf00283878;;10.1101/gad.1.10.1183;;2828168;;pmc159853;;2535537;;10.1105/tpc.1.12.1175;;10.2307/3868915;;pmc305001;;10.1073/pnas.84.12.3962;;16593845;;10.1046/j.1365-313x.1998.00343.x;;10069079;;16667579;;10.1104/pp.93.3.1203;;pmc1062652;;pmc553667;;10.1002/j.1460-2075.1987.tb02537.x;;16453789;;pmc1062058;;16667089;;10.1104/pp.91.2.694;;1470919;;10.1126/science.1470919;;1334743;;pmc160236;;10.2307/3869493;;10.1105/tpc.4.12.1495;;15155505;;10.1136/bmj.328.7450.1245;;pmc416605;;10.1093/bioinformatics/19.2.204;;12538240;;16593869;;10.1073/pnas.84.16.5745;;pmc298939;;10.1002/j.1460-2075.1987.tb02636.x;;pmc553770;;16453801;;pmc150706;;10.1105/tpc.002022;;12119374;;9486653;;10.1038/35888;;3005872;;10.1038/319791a0;;15186087;;10.1021/jf035497l;;pmc159763;;2535505;;10.1105/tpc.1.3.301;;10.2307/3869010;;10.1016/0168-1656(94)90114-7;;7764447;;10.1007/3-540-49194-5_9;;10533436;;pmc102215;;10.1105/tpc.13.1.73;;11158530;;10.2307/3871154;;10.1007/bf00232571;;24221592;;10.1073/pnas.93.18.9975;;8790442;;pmc38540;;pmc20051;;10.1073/pnas.94.6.2122;;9122158;;10.2135/cropsci1999.0011183x003900010005x;;24192893;;10.1007/bf00233789;;8400127;;10.1007/bf00028980;;9291974;;10.1007/978-94-011-5794-0_20;;10.1023/a:1005847615493;;10429249;;10.1038/11758;;10.1007/bf00036971;;24271073;;10.1038/nbt0390-241;;1367421;;10.1093/nar/gng015;;pmc150247;;12582260;;10.1038/nbt0696-745;;9630983;;10.1007/s00425-004-1432-1;;15578215;;10.1007/bf00232262;;24227167;;24201341;;10.1007/bf00224152;;6313861;;10.1099/00221287-129-9-2703;;24192870;;10.1007/bf00233766;;19674407;;10.1111/j.1365-313x.2009.03989.x;;10.1007/bf03052266;;24277084;;10.1007/bf00014906;;10.1385/0-89603-321-x:95;;8563832;;16357033;;10.1093/bioinformatics/btk005;;10.1093/bfgp/3.1.68;;15163361;;10.1007/bf00330256;;10.1038/335454a0;;10.1007/bf00269069;;18576508;;10.1002/bit.260290610;;10.1111/j.1399-3054.1962.tb08052.x;;10.1023/a:1018497529493;;10.1038/313810a0;;3974711;;10.1016/0141-0229(95)00157-3;;10.1007/bf00028800;;8443339;;10.1126/science.234.4778.856;;17758108;;10.1093/nar/29.9.e45;;11328886;;pmc55695;;10.1007/bf00330257;;2579647;;10.1016/0006-291x(85)90321-3;;10.1016/s0304-3940(02)01423-4;;12618301;;pmc1283808;;10.1073/pnas.0505749102;;16263933;;10.1073/pnas.93.12.5888;;pmc39157;;8650188;;pmc2106263;;10.1083/jcb.17.1.208;;13986422;;10.1038/nbt936;;14758366;;8528414;;10.1385/0-89603-328-7:121;;8111034;;10.1007/bf00020170;;8528289;;10.1046/j.1365-313x.1995.08050777.x;;10.1104/pp.127.4.1466;;10.1104/pp.010820;;11743090;;pmc1540179;;10.1023/a:1018481805928;;9090064;;10.2135/cropsci2002.2080;;17789813;;10.1126/science.242.4877.419;;pmc170937;;10.1073/pnas.1530509100;;12883005;;10.1007/bf00427040;;2651890;;10.1016/s0960-8524(01)00212-7;;12058826;;358200;;10.1073/pnas.75.8.3737;;pmc392861;;10.1016/j.tplants.2005.03.009;;15882655;;10.1111/j.1365-313x.2008.03418.x;;18208518;;10.1016/s0021-9258(18)37783-4;;3045118;;10.1016/0168-9452(90)90117-7;;10.1007/bf00023932;;pmc553668;;10.1002/j.1460-2075.1987.tb02538.x;;16453790;;10.1007/s002990050220;;10.1046/j.1365-313x.1997.11061369.x;;10.1007/bf00018566;;1966275;;24194311;;10.1007/bf00232728;;10.1007/bf00273712;;24240741;;16667175;;pmc1062178;;10.1104/pp.91.4.1270;;10.1104/pp.91.4.1575;;pmc1062224;;16667219;;10.1073/pnas.84.19.6624;;pmc299135;;16578816;;10.1128/mcb.12.8.3399;;1630454;;10.1128/mcb.12.8.3399-3406.1992;;pmc364588;;10.1146/annurev.energy.24.1.189;;10.1111/j.1365-313x.2008.03533.x;;18445131;;11607079;;10.1073/pnas.87.11.4144;;pmc54064;;17791346;;10.1126/science.267.5195.240;;20408998;;pmc2590737;;10.1105/tpc.108.061325;;18952777;;24201873;;10.1007/bf00232809;;10.1105/tpc.108.063321;;19122102;;pmc2648072;;6405380;;pmc393536;;10.1073/pnas.80.4.1101,"GUILLAUMIE SABINE ET AL: ""The grapevine transcription factor WRKY2 influences the lignin pathway and xylem development in tobacco"", PLANT MOLECULAR BIOLOGY, vol. 72, no. 1-2, January 2010 (2010-01-01), pages 215 - 234, XP002666887, ISSN: 0167-4412;;ARCHANA K ET AL: ""Down-regulation of an abiotic stress related Nicotiana benthamiana WRKY transcription factor induces physiological abnormalities"", INDIAN JOURNAL OF BIOTECHNOLOGY, vol. 8, no. 1, January 2009 (2009-01-01), pages 53 - 60, XP002666888, ISSN: 0972-5849;;HAIHUA WANG ET AL: ""Overexpression of rice WRKY89 enhances ultraviolet B tolerance and disease resistance in rice plants"", PLANT MOLECULAR BIOLOGY, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 65, no. 6, 25 October 2007 (2007-10-25), pages 799 - 815, XP019556099, ISSN: 1573-5028, DOI: 10.1007/S11103-007-9244-X;;NAOUMKINA MARINA A ET AL: ""Elicitor-induced transcription factors for metabolic reprogramming of secondary metabolism in Medicago truncatula"", BMC PLANT BIOLOGY, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 1, 22 December 2008 (2008-12-22), pages 132, XP021048392, ISSN: 1471-2229, DOI: 10.1186/1471-2229-8-132;;MZID RIM ET AL: ""Overexpression of VvWRKY2 in tobacco enhances broad resistance to necrotrophic fungal pathogens"", PHYSIOLOGIA PLANTARUM, vol. 131, no. 3, November 2007 (2007-11-01), pages 434 - 447, XP002666889, ISSN: 0031-9317;;ZHAO QIAO ET AL: ""An NAC transcription factor orchestrates multiple features of cell wall development in Medicago truncatula"", PLANT JOURNAL, vol. 63, no. 1, July 2010 (2010-07-01), pages 100 - 114, XP002666890, ISSN: 0960-7412;;EULGEM THOMAS ET AL: ""The WRKY superfamily of plant transcription factors"", TRENDS IN PLANT SCIENCE, ELSEVIER SCIENCE, OXFORD, GB, vol. 5, no. 5, 1 May 2000 (2000-05-01), pages 199 - 206, XP002198997, ISSN: 1360-1385, DOI: 10.1016/S1360-1385(00)01600-9;;WANG HUANZHONG ET AL: ""Mutation of WRKY transcription factors initiates pith secondary wall formation and increases stem biomass in dicotyledonous plants"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 107, no. 51, December 2010 (2010-12-01), XP002666891, ISSN: 0027-8424;;WANG, H., AND DIXON, R.A.: ""On-Off switches for secondary cell wall biosynthesis"", MOLECULAR PLANT, 2 December 2011 (2011-12-02), pages 1 - 7, XP008147196;;WANG, H.: ""WRKY transcription factors control pith secondary wall formation and affect stem biomass production"", PLANT BIOLOGY 2011 ASPB MEETING / CONFERENCE; AMERICAN SOCIETY OF PLANT BIOLOGISTS, 6 August 2011 (2011-08-06) - 10 August 2011 (2011-08-10), XP002666892;;ABDULLAH ET AL., BIOTECHNOLOGY, vol. 4, 1986, pages 1087;;ALEXANDER, STAIN TECHNOL., vol. 44, 1969, pages 117 - 122;;ASAI ET AL., NATURE, vol. 415, 2002, pages 977;;BATES, MOL. BIOTECHNOL., vol. 2, 1994, pages 135 - 145;;BATTRAW ET AL., HEOR. APP. GENET., vol. 82, 1991, pages 161 - 168;;BENEDITO ET AL., PLANT.L., vol. 55, 2008, pages 504;;BEVAN ET AL., NUCLEIC ACIDS RESEARCH, vol. 11, 1983, pages 369 - 385;;BHATTACHARJEE ET AL., J. PLANT BIOCH. AND BIOTECH., vol. 6, 1997, pages 69 - 73;;BLAKE ET AL., J. BIOL. CHEM., vol. 281, 2006, pages 29321;;BOUCHEZ ET AL., EMBO JOURNAL, vol. 8, 1989, pages 4197 - 4204;;BOWER ET AL., PLANT JOURNAL, vol. 2, 1992, pages 409 - 416;;BUISING ET AL., MOL GEN GENET, vol. 243, 1994, pages 71 - 81;;CALLIS ET AL., GENES DEV., vol. 1, 1987, pages 1183 - 1200;;CANO-DELGADO ET AL., DEVEL., vol. 127, 2000, pages 3395;;CASA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 11212 - 11216;;CHANDLER ET AL., THE PLANT CELL, vol. 1, 1989, pages 1175 - 1183;;CHRISTOU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 3962 - 3966;;CHU ET AL., SCIENTIA SINICA, vol. 18, 1975, pages 659 - 668;;CLOUGH; BENT, PLANT J., vol. 16, 1998, pages 735;;CONKLING ET AL., PLANT PHYSIOL., vol. 93, 1990, pages 1203 - 1211;;DE BLOCK ET AL., EMBO JOURNAL, vol. 6, 1987, pages 2513 - 2518;;DE BLOCK ET AL., PLANT PHYSIOL., vol. 91, 1989, pages 694 - 701;;DELLAPORTA ET AL., CHROMOSOME STRUCTURE AND FUNCTION: IMPACT OF NEW CONCEPTS, 18TH STADLER GENETICS SYMPOSIUM, vol. 11, 1988, pages 263 - 282;;DEVANE ET AL., SCIENCE, vol. 258, 1992, pages 1946 - 1949;;D'HALLUIN ET AL., PLANT CELL, vol. 4, 1992, pages 1495 - 1505;;DIXON ET AL., REC ADV PHYTOCHEM., vol. 28, 1994, pages 153 - 178;;DOWNWARD, BMJ, vol. 328, no. 7450, 2004, pages 1245 - 1248;;DOZMOROV; CENTOLA, BIOINFORMATICS, vol. 19, 2003, pages 204;;DUFF; MURRAY, BIORESOURCE TECH., vol. 55, 1995, pages 1 - 33;;EBERT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 5745 - 5749;;ELLIS ET AL., EMBO JOURNAL, vol. 6, 1987, pages 3203 - 3208;;ELLIS ET AL., PLANT CELL, vol. 14, 2002, pages 1557;;FIRE ET AL., NATURE, vol. 391, 1998, pages 806 - 11;;FRALEY ET AL., BIO/TECHNOLOGY, vol. 3, 1985, pages 629 - 635;;FROMM ET AL., NATURE, vol. 319, 1986, pages 791 - 793;;FUKUSHIMA; HATFIELD, J. AGRIC. FOOD CHEM., vol. 52, 2004, pages 3713 - 3720;;GALLIE ET AL., THE PLANT CELL, vol. 1, 1989, pages 301 - 311;;GHOSH-BISWAS ET AL., J. BIOTECHNOL., vol. 32, 1994, pages 1 - 10;;GONG ET AL., ADV. BIOCHEM. ENGNG. BIOTECH., vol. 65, 1999, pages 207 - 241;;GUO ET AL., PLANT CELL, vol. 13, 2001, pages 73;;HAGIO ET AL., PLANT CELL REP., vol. 10, 1991, pages 260 - 264;;HAMILTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 9975 - 9979;;HASELOFF ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 2122 - 2127;;HATFIELD ET AL., CROP SCIENCE, vol. 39, 1999, pages 27 - 37;;HE ET AL., PLANT CELL REPORTS, vol. 14, no. 2-3, 1994, pages 192 - 196;;HENSGENS ET AL., PLANT MOL. BIOL., vol. 22, no. 6, 1993, pages 1101 - 1127;;HIEI ET AL., PLANT. MOL. BIOL., vol. 35, no. 1-2, 1997, pages 205 - 218;;HINCHEE ET AL., BIO/TECHNOL., vol. 6, 1988, pages 915 - 922;;HOU ET AL., PLANT PHYSIOLOGY, vol. 111, 1996, pages 166;;HU ET AL., NAT. BIOTECHNOL., vol. 17, 1999, pages 808 - 812;;HUDSPETH ET AL., PLANT MOL. BIOL, vol. 12, 1989, pages 579 - 589;;IKUTA ET AL., BIO/TECHNOL., vol. 8, 1990, pages 241 - 242;;IRIZARRY ET AL., NUCL. ACIDS RES., vol. 31, 2003, pages E15;;ISHIDA ET AL., NAT. BIOTECHNOL., vol. 14, 1996, pages 745 - 750;;JONES ET AL., PLANTA, vol. 221, 2005, pages 255 - 264;;KAEPPLER ET AL., PLANT CELL REPORTS, vol. 9, 1990, pages 415 - 418;;KAEPPLER ET AL., THEOR. APPL. GENET., vol. 84, 1992, pages 560 - 566;;KARIMI ET AL., TRENDS PL. SCI., vol. 7, 2002, pages 193;;KATZ ET AL., J. GEN. MICROBIOL., vol. 129, 1983, pages 2703 - 2714;;KLEE ET AL., BIO-TECHNOLOGY, vol. 3, 1985, pages 637 - 642;;KNITTEL ET AL., PLANT CELL REPORTS, vol. 14, 1994, pages 81 - 86;;KO ET AL., PLANT J., vol. 60, 2009, pages 649;;LAPIERRE ET AL., J. WOOD. CHEM. TECHNOL., vol. 5, 1985, pages 277;;LAPIERRE ET AL., RES. CHEM. INTERMED., vol. 21, 1995, pages 397 - 412;;LAWTON ET AL., PLANT MOL. BIOL., vol. 9, 1987, pages 315 - 324;;LAZZERI, METHODS MOL. BIOL., vol. 49, 1995, pages 95 - 106;;LEE ET AL., ADV. BIOCHEM. ENGNG. BIOTECH., vol. 65, 1999, pages 93 - 115;;LEE ET AL., KOREAN J. GENET., vol. 11, 1989, pages 65 - 72;;LEEK ET AL., BIOINFORMATICS, vol. 22, 2006, pages 507;;LEHNER ET AL., BRIEF FUNCT GENOMIC PROTEOMIC, vol. 3, 2004, pages 68 - 83;;LI ET AL., PNAS, vol. 98, 2001, pages 31;;LORZ ET AL., MOL GEN GENET, vol. 199, 1985, pages 178 - 182;;MARCOTTE ET AL., NATURE, vol. 335, 1988, pages 454;;MES-HARTREE ET AL., APPL. MICROBIOL. BIOTECHNOL., vol. 29, 1988, pages 462 - 468;;MORJANOFF; GRAY, BIOTECHNOL. BIOENG., vol. 29, 1987, pages 733 - 741;;MURAKAMI ET AL., MOL. GEN. GENET., vol. 205, 1986, pages 42 - 50;;MURASHIGE ET AL., PHYSIOL. PLANT, vol. 15, 1962, pages 473 - 497;;NAGATANI ET AL., BIOTECH. TECH., vol. 11, 1997, pages 471 - 473;;ODELL ET AL., NATURE, vol. 313, 1985, pages 810 - 812;;OGAWA ET AL., SCI. REP., vol. 13, 1973, pages 42 - 48;;OLSSON ET AL., ENZYME AND MICROB. TECHNOL., vol. 18, 1996, pages 312 - 331;;OMIRULLEH ET AL., PLANT MOL. BIOL., vol. 21, 1993, pages 415 - 428;;OW ET AL., SCIENCE, vol. 234, 1986, pages 856 - 859;;PATTATHIL ET AL., PL. PHYSIOL., vol. 153, 2010, pages 514;;PFAFFL, NUCLEIC ACIDS RES., vol. 29, 2001, pages E45;;POTRYKUS ET AL., MOL. GEN. GENET., vol. 199, 1985, pages 183 - 188;;PRASHER ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 126, no. 3, 1985, pages 1259 - 1268;;RAMAKERS ET AL., NEUROSCI LETT., vol. 339, 2003, pages 62 - 66;;REDDY ET AL., PROC. NAT. ACAD. SCI., vol. 102, 2005, pages 16573 - 16578;;REICHEL ET AL., PROC. NATL. ACAD. SCI, vol. 93, 1996, pages 5888 - 5893;;REYNOLDS, J. CELL BIOL., vol. 17, 1963, pages 208;;REYNOLDS, NAT. BIOTECHNOL., vol. 22, 2004, pages 326 - 330;;RHODES ET AL., METHODS MOL. BIOL., vol. 55, 1995, pages 121 - 131;;RICHARDS ET AL., PLANT CELL REP., vol. 20, 2001, pages 48 - 54;;RITALA ET AL., PLANT MOL. BIOL., vol. 24, no. 2, 1994, pages 317 - 325;;ROGERS ET AL., METHODS ENZYMOL., vol. 153, 1987, pages 253 - 277;;SAMBROOK ET AL.: ""Molecular Cloning-A Laboratory Manual(second edition),"", 1989, COLD SPRING HARBOUR LABORATORY PRESS;;SHEEN ET AL., PLANT JOURNAL, vol. 8, 1995, pages 777 - 784;;SHEEN ET AL., PL. PHYSIOL., vol. 127, 2001, pages 1466;;SINGSIT ET AL., TRANSGENIC RES., vol. 6, no. 2, 1997, pages 169 - 176;;SOMLEVA ET AL., CROP SCIENCE, vol. 42, 2002, pages 2080 - 2087;;STALKER ET AL., SCIENCE, vol. 242, 1988, pages 419 - 422;;STOREY ET AL., PNAS, vol. 100, 2003, pages 9440;;SULLIVAN ET AL., MOL. GEN. GENET., vol. 215, no. 3, 1989, pages 431 - 440;;SUN; CHENG, BIORESOURCE TECHNOL., vol. 83, 2002, pages 1 - 11;;SUTCLIFFE, PROC. NATL. ACAD. SCI., vol. 75, 1978, pages 3737 - 3741;;TADEGE ET AL., TRENDS PLANT SCI., vol. 10, 2005, pages 229 - 235;;TADEGE ET AL., PLANT J., vol. 54, 2008, pages 335 - 347;;THILLET ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 12500 - 12508;;THOMAS ET AL., PLANT SCI., vol. 69, 1990, pages 189 - 198;;THOMPSON ET AL., EUPHYTICA, vol. 85, 1995, pages 75 - 80;;THOMPSON ET AL., THE EMBO JOURNAL, vol. 6, no. 9, 1987, pages 2519 - 2523;;TIAN; SEQUIN; CHAREST, PLARZT CELL REP., vol. 16, 1997, pages 267 - 271;;TINGAY ET AL., THE PLANT JOURNAL, 1997, pages 1369 - 1376;;TOMES ET AL., PLANT. MOL. BIOL., vol. 14, no. 2, 1990, pages 261 - 268;;TORBET ET AL., CROP SCIENCE, vol. 38, no. 1, 1998, pages 226 - 231;;TORBET ET AL., PLANT CELL REPORTS, vol. 14, no. 10, 1995, pages 635 - 640;;TORIYAMA ET AL., THEOR APPL. GENET., vol. 73, 1986, pages 16;;TSUKADA ET AL., PLANT CELL PHYSIOL., vol. 30, no. 4, 1989, pages 599 - 604;;TWELL ET AL., PLANT PHYSIOL., vol. 91, 1989, pages 1270 - 1274;;UCHIMIYA ET AL., MOL. GEN. GENET., vol. 204, no. 204, 1986;;VASIL ET AL., PLANT PHYSIOL., vol. 91, 1989, pages 1575 - 1579;;WALKER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 6624 - 6628;;WANG ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 12, no. 8, 1992, pages 3399 - 3406;;WYMAN, ANNU. REV. ENERGY ENVIRON, vol. 24, 1999, pages 189 - 226;;YAMADA ET AL., PLANT CELL REP., vol. 4, 1986, pages 85;;YAMAGUCHI ET AL., PLANT J., vol. 55, 2008, pages 652;;YANG ET AL., PROC. NATL. ACAD. SCI., vol. 87, 1990, pages 4144 - 4148;;ZHANG ET AL., SCIENCE, vol. 267, 1995, pages 240 - 243;;ZHAO ET AL., PLANT J. PLANT JOURNAL, vol. 63, 2010, pages 100 - 114;;ZHONG ET AL., PLANT CELL, vol. 20, 2008, pages 2763 - 2782;;ZHOU ET AL., PLANT CELL REPORTS, vol. 12, 1993, pages 612 - 616;;ZHOU ET AL., PLANT CELL, vol. 21, 2009, pages 248;;ZUKOWSKY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 1101 - 1105",PENDING
597,US,A,US 5087283 A,138-488-712-157-601,1992-02-11,1992,US 45995590 A,1990-01-02,US 45995590 A,1990-01-02,Sympathetic ink for ink jet printer,"Sympathetic ink compositions particularly adapted for use with high speed, non-impact ink printing equipment are disclosed, together with methods of use and development thereof. The inks of the invention are water-based and include of from about 4-20% by weight of a water soluble transition metal salt (e.g., nickel sulfate), together with of from about 2-4.5%, by weight of n-butanol or 2-butanol. After application using, e.g., ink jet printing equipment, the resulting inked images are invisible to the naked eye, and can be selectively developed through use of color-forming developers such as dimethylglyoxime- or oxalic acid-type aqueous compositions.",DIXON MARVIN P;;WALKER JR HAYWOOD A,DIXON MARVIN P;;WALKER JR HAYWOOD A,,https://lens.org/138-488-712-157-601,Granted Patent,yes,16,15,1,1,0,C09D11/30;;C09D11/50;;C09D11/50;;C09D11/30,C09D11/00,106/21;;503/211;;503/213;;503/217;;503/219;;427/145;;427/150,0,0,,,,EXPIRED
598,WO,A2,WO 2000/004040 A2,145-683-427-004-240,2000-01-27,2000,US 9912374 W,1999-07-14,US 9269698 P,1998-07-14,"CONSTITUTIVE DISEASE RESISTANCE GENE (CDR1), AND METHODS OF USE THEREOF","Substantially purified CDR1 polypeptide, isolated polynucleotides encoding CDR1 polypeptide, vectors containing CDR1, host cells expressing CDR1, and antibodies which bind to CDR1 are all provided. The invention also provides a method of producing a genetically modified plant characterized as having increased disease resistance as compared to wild-type plants. A method is also provided for identifying novel disease resistance genes by probing a nucleic acid library with at least a fragment of a polynucleotide encoding CDR1, and selecting those clones that hybridize with the fragment.",SALK INST FOR BIOLOGICAL STUDI;;DIXON RICHARD A;;XIA YIJI;;LAMB CHRISTOPHER,DIXON RICHARD A;;XIA YIJI;;LAMB CHRISTOPHER,,https://lens.org/145-683-427-004-240,Patent Application,yes,0,5,9,9,0,C07K14/415;;C12N9/63;;C07K14/415;;C12N9/50;;C12N9/63;;C12N15/8281;;C12N15/8281,C07K14/415;;C12N9/50;;C12N15/29;;C12N15/82,,0,0,,,,PENDING
599,US,A,US 5272154 A,178-713-229-166-961,1993-12-21,1993,US 80981591 A,1991-12-18,GB 9027424 A;;GB 9027425 A;;GB 9113596 A,1990-12-18,"3,7 substituted indole and indazole compounds and pharmaceutical compositions containing them","3,7-disubstituted indole derivatives of formula I ##STR1## wherein R.sub.1, R.sub.2, n, X, Y and Z are as defined in the description are useful for the treatment of psychiatric disorders.",SANDOZ LTD,DIXON ARNOLD K;;GIGER RUDOLF K A,NOVARTIS AG (1992-01-17),https://lens.org/178-713-229-166-961,Granted Patent,yes,23,77,35,42,0,C07D451/12;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/26;;A61P43/00;;A61K31/405;;C07D451/12,A61K31/40;;A61K31/435;;A61K31/46;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/26;;A61P43/00;;C07D209/32;;C07D233/54;;C07D401/12;;C07D403/12;;C07D451/02;;C07D451/04;;C07D451/12;;C07D451/14;;C07D453/02;;C07D471/04;;C07D471/08;;C07D487/08,514/299;;546/112,3,2,046-510-776-719-59X;;020-593-225-662-286,2855746;;2533904,"Chemical Abstracts, vol. 112, No. 23, Abstract No. 216,686g, p. 519 (Jun. 4, 1990).;;Mol. Toxicol., vol. 1, pp. 341 350 (1987).;;Eur. J. Cancer Clin. Oncol., vol. 25, Suppl. 1, pp. S75 S77 (1989).",EXPIRED
600,AR,A1,AR 077312 A1,164-536-935-878-701,2011-08-17,2011,AR P100102532 A,2010-07-13,US 22512609 P,2009-07-13,PLANTAS CON CONTENIDO MODIFICADO DE LIGNINA Y METODOS PARA SU PRODUCCION,"Métodos para reducir el contenido de lignina y para aumentar el nivel de carbohidratos en plantas mediante la regulacion hacia abajo del NST. Se describen las construcciones de ácido nucleico para la regulacion hacia abajo de NST. Se ofrecen plantas transgénicas que comprenden bajo contenido de lignina. Las plantas aquí descriptas pueden utilizarse, por ejemplo, como materia prima mejorada para biocombustibles y como cosecha forrajera de fácil digestion. Se ofrecen también métodos para procesar tejidos vegetales y para producir etanol mediante el uso de dichas plantas.",SAMUEL ROBERTS NOBLE FOUND INC,ZHAO QIAO;;DIXON RICHARD A;;CHEN FANG,,https://lens.org/164-536-935-878-701,Patent Application,no,0,0,8,8,0,C07K14/415;;C07K14/415;;C12N15/8255;;C12N15/8255;;D21C5/00;;D21C5/00;;D21H23/00;;D21H23/00,,,0,0,,,,DISCONTINUED
601,US,A,US 5327825 A,154-696-152-564-415,1994-07-12,1994,US 6079693 A,1993-05-12,US 6079693 A,1993-05-12,Seamless holographic transfer,"A method of making a die and the die itself for establishing through embossing or micro-embossing a seamless pattern, preferably a holographic pattern, on a decorative medium such as a metallized film is provided. A cylindrical embossing or micro-embossing die is provided with a layer of an embossable material, preferably pure silver, a silver alloy or any other suitable embossable material. The cylindrical die is an integral member in which a pattern is recombined thereon by a step and repeat embossing or micro-embossing process as opposed an intricate lathe-type machine-turning operation, and can thus accept, carry and maintain complex patterns with the integrity required for producing a repeating holographic pattern.",TRANSFER PRINT FOILS INC,PARKER HARRY A;;ALLOCCO JOSEPH;;DIXON JOHN,TRANSFER PRINT FOILS INC (1993-05-11);;ILLINOIS TOOL WORKS INC (2001-05-21),https://lens.org/154-696-152-564-415,Granted Patent,yes,20,50,2,2,0,B44B5/028;;B44B5/028;;B23P15/24;;B23P15/24;;B29C59/002;;B29C59/002;;B29L2031/7224;;B29L2031/7224;;B44B5/009;;B44B5/009;;G03H1/028;;G03H1/028;;G03H2001/0296,B23P15/24;;B29C59/00;;B44B5/00;;B44B5/02,101/32;;101/28;;101/401.1;;205/69;;264/219;;264/293;;264/1.3;;264/226,0,0,,,,EXPIRED
602,CA,A1,CA 2221702 A1,014-038-736-789-633,1997-10-09,1997,CA 2221702 A,1997-03-27,US 1433596 P,1996-03-29,MULTIMEDIA DOCUMENT CONFERENCING SYSTEM,"A multimedia documents conferencing system (10), having a data communications network (12) coupled to which are a plurality of client stations (14), a meeting server (16) and a presentation server (18). The system is embodied by a client-server based collaborative application that allows users to share multimedia documents on any of PC, MAC or UNIX based hardware platforms. A ""meet me"" approach may be scaled to support a practically unlimited number of simultaneous users for sharing and accessing different multimedia documents at the same time. The client-server architecture allows centralized billing, secure document storage and secure document transmission, and centralized administration. Multiple clients may interface with the server or servers via a telecommunications network (13) and the data communications network which preferably is the Internet, whereby users at geographically dispersed locations are able to participate in a meeting session.",NORTHERN TELECOM LTD,CRADDOCK A JULIAN;;DIXON FRED;;NG CHARLES,,https://lens.org/014-038-736-789-633,Patent Application,no,0,0,4,4,0,H04L12/1827;;H04M3/567;;H04M7/12;;H04M2203/5009;;H04M2203/5063,H04N7/15;;H04L12/18;;H04M3/56;;H04M7/12,,0,0,,,,DISCONTINUED
603,US,B2,US 8350007 B2,073-792-058-095-038,2013-01-08,2013,US 67346908 A,2008-08-15,US 67346908 A;;US 96526007 P;;US 2008/0073366 W,2007-08-17,Crystal structure of human mitoNEET protein,"The present technology relates to the fields of crystallography, biochemistry, and drug design. In particular, methods and compositions for screening, identifying and designing compounds that interact with human mitoNEET.",UNIV CALIFORNIA;;YISSUM RES DEV COMPANY OF HEBREW UNIVERSITY OF JERUSALEM;;JENNINGS PATRICIA A;;DIXON JACK;;NECHUSHTAI RACHEL,JENNINGS PATRICIA A;;DIXON JACK;;NECHUSHTAI RACHEL,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2007-08-24),https://lens.org/073-792-058-095-038,Granted Patent,yes,4,0,4,4,2,C07K14/705;;C07K2299/00;;C07K14/705;;C07K2299/00,C07K1/00,530/350,99,91,025-004-775-772-002;;040-694-135-115-041;;046-250-525-927-062;;054-418-959-978-111;;136-362-513-209-900;;049-615-905-577-701;;051-453-609-262-222;;010-106-994-617-208;;007-372-385-403-558;;020-327-622-694-888;;029-805-728-671-829;;106-794-363-564-085;;080-093-159-926-516;;035-186-349-734-663;;052-792-690-107-299;;001-584-694-897-885;;088-446-192-951-280;;053-651-433-953-125;;013-457-952-690-195;;011-708-325-416-411;;022-878-775-990-77X;;066-626-412-120-463;;008-514-681-389-743;;011-433-553-533-281;;065-576-697-812-711;;040-792-071-848-084;;026-938-903-354-573;;089-012-326-129-953;;039-911-698-743-730;;072-811-843-484-578;;006-971-147-047-71X;;117-163-916-784-511;;002-415-125-938-076;;075-877-723-407-245;;029-742-983-481-795;;030-042-017-746-591;;067-828-763-495-007;;101-627-564-002-169;;050-672-300-487-304;;042-289-645-698-439;;007-386-582-715-443;;043-841-620-298-378;;009-831-068-358-645;;043-691-833-242-414;;034-140-988-373-243;;007-176-024-077-576;;081-456-147-284-436;;115-946-888-456-710;;020-080-430-516-209;;134-207-981-277-522;;057-302-335-774-991;;028-623-320-457-390;;047-418-399-653-541;;131-716-762-776-491;;046-072-043-619-455;;000-602-243-453-812;;018-749-275-581-309;;155-769-000-939-055;;022-456-014-485-330;;034-524-951-576-015;;069-450-943-413-364;;034-901-580-035-930;;040-418-840-605-862;;085-390-396-837-544;;024-955-074-670-57X;;046-651-652-259-674;;010-843-254-899-019;;019-874-433-737-372;;038-742-474-825-47X;;029-519-259-734-50X;;079-720-003-861-415;;098-440-566-122-993;;065-242-409-523-457;;030-311-480-120-390;;007-254-057-504-651;;088-289-190-397-777;;066-718-729-335-874;;064-406-626-054-484;;055-410-088-121-496;;006-539-454-986-562;;072-262-729-313-928;;037-296-962-721-801;;144-007-909-684-912;;113-970-420-130-341;;036-205-186-931-159;;004-832-604-490-862;;003-497-880-691-933;;020-981-245-189-312;;065-211-239-307-572;;078-648-453-215-373;;107-797-409-957-344,pmc540005;;10.1093/nar/gki051;;15608229;;10.1038/35000501;;10676951;;15254419;;10.4161/cbt.3.8.994;;10.1107/s0907444994003112;;15299374;;16873691;;10.2337/db06-0062;;593365;;0000593365;;10.1038/270449a0;;10.1021/bi035385n;;14622009;;10.1089/106652700750050943;;11108479;;10.1111/j.1432-1033.1988.tb13917.x;;3280310;;10.1038/326347a0;;3550471;;15855325;;10.2337/diabetes.54.5.1392;;10.1126/science.1853201;;1853201;;pmc508497;;10.1172/jci119839;;9389757;;10.1107/s002188988301078x;;16136080;;10.1038/nature03985;;15520168;;10.1158/0008-5472.can-04-2933;;16837529;;10.1093/bioinformatics/btl370;;10.1093/protein/2.5.335;;2928296;;10.1152/ajpendo.00424.2003;;14570702;;10.1517/13543784.15.3.205;;16503758;;16472781;;10.1016/j.bcp.2006.01.002;;10.1110/ps.0222402;;pmc2373747;;12441394;;10.1136/jmg.39.4.225;;11950848;;pmc1735082;;pmc151291;;10.1186/gb-2003-4-1-r7;;12540299;;10.1016/s0888-7543(02)00021-6;;12620386;;10.2210/pdb6rlx/pdb;;1656049;;10.1016/0022-2836(91)80196-2;;10.1016/0022-2836(91)90796-9;;15308542;;10.1093/bioinformatics/bth469;;pmc1458674;;10.1073/pnas.0601231103;;16585533;;10.1107/s0907444904019158;;15572765;;10.1107/s0021889800014655;;12112074;;10.1002/ana.10206;;15925327;;10.1016/j.bcp.2005.03.033;;12657796;;10.1107/s0907444903002245;;10.1016/s0021-9258(19)49563-x;;1639790;;10.1126/science.286.5439.531;;10521349;;10.1021/jm00145a002;;3892003;;10.1021/ja00192a003;;10.1021/ja00192a002;;10.1016/s0092-8674(00)81683-9;;10647931;;10.1093/brain/awh452;;15817521;;10.1002/jcp.1041340115;;3275678;;10.2337/diacare.15.8.1075;;1505314;;8578593;;10.1016/s0968-0004(00)89105-7;;10.1074/jbc.c700172200;;17905743;;10.1093/bioinformatics/18.suppl_1.s233;;12169552;;10.1021/ja031976p;;15080677;;10.1074/jbc.271.44.27659;;8910356;;pmc1166864;;3709525;;10.1002/j.1460-2075.1986.tb04287.x;;15608231;;10.1093/nar/gki072;;pmc540026;;10.1093/nar/gkh063;;pmc1236573;;16172383;;10.1073/pnas.0506517102;;10.1016/j.expneurol.2004.10.007;;15649489;;10.1038/nature03877;;15988478;;pmc1895599;;10469881;;1538716;;10.1021/bi0488606;;15449929;;016210596;;10.4049/jimmunol.175.8.4948;;16210596;;14726526;;10.1074/jbc.m305923200;;10.1021/ja00239a041;;1280165;;10.1016/0005-2728(92)90007-o;;7154081;;10.1016/0022-2836(82)90153-x;;10.1107/s0021889892009944;;10.1002/prot.340120105;;1313175;;10.1002/jcc.540130608;;10.1074/jbc.270.22.12953;;7768881;;10.1107/s0907444905039107;;16369093;;10.1016/0263-7855(92)80047-h;;1467330;;16527810;;10.1074/jbc.m600582200;;10.1016/j.bbamcr.2006.05.011;;16843540;;pmc1976232;;10.1073/pnas.0702426104;;17766439;;10.1021/ja0627388;;16910649;;12557186;;10.1002/prot.10286;;10.1002/prot.340100307;;1881879;;17135207;;10.1093/nar/gkl937;;pmc1751555;;10.1021/ar0301781;;15379587;;10.1107/s0909049502015170;;12409628;;10400537;;10.1126/science.284.5422.1948;;10.1002/prot.340110104;;1961699;;17401378;;10.1038/nchembio872;;10.1093/bioinformatics/btg290;;14594725;;1978340;;10.1098/rspb.1990.0077;;pmc1963346;;10.2210/pdb2qh7/pdb;;10.1073/pnas.0707189104;;17766440;;2206480;;10.1107/s0108767390002379;;10.1002/jcc.540060510;;10.1142/9789812799623_0044;;11928500;;15176478;;10.1023/b:nere.0000023608.29741.45;;10.1016/0263-7855(93)87001-l;;8394110;;14525934;;10.1101/gr.1680803;;pmc403728;;pmc483056;;10.1186/1742-2094-1-3;;15285799;;10.1038/8263;;10331874;;15908672;;10.1200/jco.2005.02.509,"Alfarano et al,. ""The Biomolecular Interaction Network Database and related tools 2005 update"", Nucleic acids research, 2005; 33: D418-424.;;Alizadeh et al., ""Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling"", Nature, 2000; 403: 503-511.;;Allen et al., Acta Oyst. B 1979; 35: 2331.;;Bachman et al., ""The PIK3CA gene is mutated with high frequency in human breast cancers"", Cancer Biol Ther., 2004; 3(8): 772-775.;;Bailey S., The CCP4 Suite Programs for protein crystallography, Acta Crystallogr D Biol Crystallogr. 1994; 50(Pt5): 760-763.;;Bandyopadhyay et al., ""Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects"", Diabetes, 2006; 55: 2277-2285.;;Bedarkar et al., ""Relaxin has conformational homology with insulin"", Nature, 1977; 270: 449-451.;;Beharry et al., ""Histidine ligand protonation and redox potential in the rieske dioxygenases: role of a conserved aspartate in anthranilate 1,2-dioxygenase"", Biochemistry, 2003, 42: 13625-13636.;;Ben-Dor et al., ""Tissue classification with gene expression profiles"", J Comput Biol., 2000; 7: 559-583.;;Blundell et al., ""18th Sir Hans Krebs lecture. Knowledge-based protein modelling and design"", Eur J Biochem, 1988; 172(3): 513-520.;;Blundell et al., ""Knowledge-based prediction of protein structures and the design of novel molecules"", Nature, 1987; 326(6111): 347-352.;;Bogacka et al., ""Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo"", Diabetes, 2005; 54: 1392-1399.;;Bowie et al., ""A method to identify protein sequences that fold into a known three-dimensional structure"", Science, 1991, 253: 164-170.;;Burant et al., ""Troglitazone Action Is Independent of Adipose Tissue"", J Clin Invest 1997; 100: 2900-2908.;;Busetta et al., ""DOCKER, an interactive program for simulating protein receptor and substrate interactions"", J Appl. Crystallogr., 1983; 16(4): 432-437.;;Calvano et al., ""A network-based analysis of systemic inflammation in humans"", Nature, 2005; 437(7061): 1032-1037.;;Campbell et al., ""Mutation of the PIK3CA gene in ovarian and breast cancer"", Cancer Res., 2004; 64: 7678-7681.;;Chang et al., ""LIBSVM : a library for support vector machines"", Software available at http://www.csie.ntu.edu.tw/~cjlin/libsvm (2001).;;Chen et al., ""Detecting functional modules in the yeast protein-protein interaction network"", Bioinformatics, 2006; 22(18): 2283-2290.;;Claessens et al., ""Modelling the polypeptide backbone with 'spare parts' from known protein structures"", Protein Eng, 1989, 2(5): 335-345.;;Colca et al., ""Identification of a novel mitochondrial protein (""mitoNEET"") cross-linked specifically by a thiazolidinedione photoprobe"", Am J Physio; Endocrinol. Metab., 2004, 286: E252-E260.;;Colca et al., ""What has prevented the expansion of insulin sensitizers?"", Expert Opin Investig Drugs, 2006; 15: 205-210.;;Colca, ""Insulin sensitizers may prevent metabolic inflammation"", Biochem Pharma., 2006, 72(2): 125-131.;;Cosper et al., ""Redox-dependent structural changes in archaeal and bacterial Rieske-type [2Fe-2S] clusters"", Prot. Sci. 2002, 11(12): 2969-2973.;;de Jong et al., ""Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility"", J Med Genet., 2002; 39: 225-242.;;DeLano et al., Abstr Pap Am Chem Soc. 2005; 230: U1371-U1372.;;Doniger et al., ""MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data"", Genome Biol. 2003; 4: R7.;;Dr{hacek over (a)}ghici et al., ""Global functional profiling of gene expression"", Genomics, 2003; 81(2): 98-104.;;Eigenbrot et al., X-ray structure of human relaxin at 1.5 A. Comparison to insulin and implications for receptor binding determinants, J Mol Biol., 1991; 221(1): 15-21.;;Ein-Dor et al., ""Outcome signature genes in breast cancer: is there a unique set?"" Bioinformatics. 2005; 21(2): 171-178.;;Ein-Dor et al., ""Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer"", Proc Natl Acad Sci USA. 2006; 103(15): 5923-5928.;;Emsley et al., ""Coot: model-building tools for molecular graphics"", Acta Crystallogr D Biol Crystallogr, 2004; 60(Pt 12 Pt 1): 2126-2132.;;Evans et al., ""CHOOCH: a program for deriving anomalous-scattering factors from X-ray fluorescence spectra"", J Appl Crystallogr. 2001; 34: 82-86.;;Feinstein et al., ""Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis."", Ann Neurol, 2002; 51(6): 694-702.;;Feinstein et al., ""Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?"", Biochem Pharma., 2005; 70(2): 177-188.;;Fish et al., ""Purification, crystallization and preliminary X-ray analysis of ferredoxin isolated from thermophilic cyanobacterium Mastigocladus laminosus."", Acta Crystallogr D Biol Crystallogr, 2003; 59(Pt 4): 734-6.;;Fu et al., ""Resonance Raman and magnetic circular dichroism studies of reduced [2Fe-2S] proteins"", J Bio Chem., 1992; 267(22): 15502-10.;;GO. Gene Ontology Consortium; http://www.geneontology.org/GO.consrtiumlist.shtml/, 2012.;;Goebel et al., ""An Approximation to the Distribution of Finite Sample Size Mutual Information Estimates"", In IEEE Internatioanl Conference on Communications, Seoul, Korea, 2005; 2: 1102-1106.;;Golub et al., ""Molecular classification of cancer: class discovery and class prediction by gene expression monitoring"", Science. 1999; 286(5439): 531-537.;;Goodford, ""A computational procedure for determining energetically favorable binding sites on biologically important macromolecules"" J Med Chem. 1985; 28(7): 849-57.;;Grootenhuis et al., Bull. Soc. Chim. Belg. 1992; 101: 661.;;Han et al., ""Fe2S2 protein resonance Raman spectra revisited: structural variations among adrenodoxin, ferredoxin, and red paramagnetic protein"", J. Am. Chem. Soc. 1989, 111(10), 3505-3511.;;Han et al., ""Vibrational spectra and normal mode analysis for [2Fe-2S] protein analogs using sulfur-34, iron-54 and deuterium substitution . . . "", J Am Chem Soc. 1989; 111(10): 3496-3504.;;Hanahan et al., ""The hallmarks of cancer"", Cell. 2000; 100(1): 57-70.;;Heneka et al., ""Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice."", Brain, 2005; 128(Pt 6): 1442-53.;;Hiragun et al., ""Preadipocyte differentiation in vitro: identification of a highly active adipogenic agent"", J Cell Physiol, 1988; 134(1): 124-30.;;Hofmann et al., ""New oral thiazolidinedione antidiabetic agents act as insulin-sensitizers"", Diabetes Care, 1992; 15(8): 1075-1078.;;Holm et al., ""Dali: a network tool for protein structure comparison"", Trends Biochem Sci. 1995; 20(11): 478-480.;;Hou et al., ""Crystallographic studies of human MitoNEET"", J Biol Chem, 2007; 282(46): 33242-6.;;Ideker et al., ""Discovering regulatory and signalling circuits in molecular interaction networks"", Bioinformatics, 2002; 18(Suppl 1): S233-240.;;Iwasaki et al., ""Characterization of the pH-dependent resonance Raman transitions of archaeal and bacterial Rieske [2Fe-2S] proteins"", J Am Chem Soc., 2004; 126(15): 4788-9.;;Iwasaki et al., ""Redox-linked ionization of sulredoxin, an archaeal Rieske-type [2Fe-2S] protein from Sulfolobus sp. strain 7"", J Biol Chem., 1996; 271(44): 27659-63.;;Jones et al., ""Using known substructures in protein model building and crystallography"", EMBO J, 1986, 5(4): 819-822.;;Joshi-Tope et al. ""Reactome: a knowledgebase of biological pathways"", Nucleic Acids Res. 2005; 33: D428-432.;;Kanehisa et al., ""The KEGG resource for deciphering the genome"", Nucleic Acids Res.,2004; 32: D277-280.;;Kang et al., ""Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway"", Proc Natl Acad Sci USA. 2005; 102: 13909-13914.;;Kiaei et al., ""Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis"", Experimental Neurology, 2005, 191(2): 331-336.;;Kim et al., ""A high-resolution map of active promoters in the human genome"", Nature, 2005; 436: 876-880.;;Kirkpatrick et al., ""Structure-based drug design: combinatorial chemistry and molecular modeling"", Comb Chem High Throughput Screen., 1999, 2: 211-221.;;Kletzien et al., ""Enhancement of adipocyte differentiation by an insulin-sensitizing agent."", Mol Pharmacol, 1992; 41(2): 393-8.;;Klingen et al., ""Negatively charged residues and hydrogen bonds tune the ligand histidine pKa values of Rieske iron-sulfur proteins"", Biochemistry. 2004; 43(39): 12383-12389.;;Klotz et al., ""Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients."", J Immunol., 2005; 175(8): 4948-55.;;Kounosu et al., ""Engineering a Three-cysteine, One-histidine Ligand Environment into a New Hyperthermophilic Archaeal Rieske-type [2Fe-2S] Ferredoxin from Sulfolobus solfataricus"", J Biol Chem., 2004; 279(13): 12519-12528.;;Kuila et al., ""Resonance Raman spectra of the [2Fe-2S] clusters of the Rieske protein from Thermus and phthalate dioxygenase from Pseudomonas"", J Am Chem Soc., 1987; 109(5): 1559-1561.;;Kuila et al., ""Resonance Raman studies of Rieske-type proteins,"" Biochimica et Biophysica Acta (BBA)-Bioenergetics, 1992, 1140(2): 175-183.;;Kuntz et al., ""A geometric approach to macromolecule-ligand interactions"", J Mol Biol., 1982, 161(2): 269-288.;;Laskowski et al., ""PROCHECK: A program to check the stereochemical quality of protein structures"", J. Appl. Crystallogr., 1993, 26(pt2): 283-291.;;Lawrence et al., ""CLIX: A search algorithm for finding novel ligands capable of binding proteins of known three-dimensional structure"", Proteins Struct Funct Genet. 1992; 12(1): 31-41.;;Leach et al., ""Conformational analysis of flexible ligands in macromolecular receptor"", J Comput Chem., 1992; 13(6): 730-748.;;Lehmann et al., ""An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)"", J Biol Chem, 1995, 270: 12953-12956.;;Leslie, AGW, ""The integration of macromolecular diffraction data"", Acta Crystallogr Section D., 2006; 62: 48-57.;;Lewis, Richard A., ""Automated site-directed drug design: a method for the generation of general three-dimensional molecular graphs,"" J Mol Graph. 1992, 10(3): 131-143.;;Li et al., ""Roles of the mammalian cytosolic cysteine desulfurase, ISCS, and scaffold protein, ISCU, in iron-sulfur cluster assembly"", J Biol Chem, 2006; 281(18): 12344-51.;;Lill et al., ""Mechanisms of iron-sulfur protein maturation in mitochondria, cytosol and nucleus of eukaryotes,"" Biochim Biophys Acta (BBA), 2006, 1763(7): 652-667.;;Lin et al., ""Crystal structure of human mitoNEET reveals distinct groups of iron sulfur proteins."", Proc Natl Acad Sci USA, 2007; 104(37): 14640-5.;;Lin et al., ""Rieske protein from Thermus thermophilus: 15N NMR titration study demonstrates the role of iron-ligated histidines in the pH dependence of the reduction potential"", J Amer Chem Soc., 2006; 128(33): 10672-3.;;Lovell et al., ""Structure validation by Calpha geometry: phi,psi and Cbeta deviation"", Proteins, 2003; 50(3): 437-50.;;Lüthy et al., ""Secondary structure-based profiles: use of structure-conserving scoring tables in searching protein sequence databases for structural similarities"", Proteins Struct. Funct. Genet., 1991, 10: 229-239.;;Mak et al., ""CellCircuits: a database of protein network models"", Nucleic Acids Res., 2007; 35: D538-545.;;Mansy et al., ""Iron-sulfur cluster biosynthesis: toward an understanding of cellular machinery and molecular mechanism"", Acc Chem Res, 2004; 37(9): 719-25.;;McPhillips et al., ""Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines"", J Synchrotron Radiat, 2002; 9(Pt 6): 401-6.;;Mendelsohn et al., ""Protein interaction methods-toward an endgame"", Science. 1999; 284(5422): 1948-1950.;;Miranker et al., Functionality Maps of Binding-sites-A Multiple Copy simultaneous Search Method. Proteins: Struct Funct Genet.1991; 11(1): 29-34.;;MSigDB. Molecular Signature Database; http://www.broadinstitute.org/gsea/msigdb/index.jsp, 2012.;;Netz et al., ""The Cfd1-Nbp35 complex acts as a scaffold for iron-sulfur protein assembly in the yeast cytosol."", Nat Chem Biol, 2007; 3(5): 278-86.;;Nikitin et al., ""Pathway studio-the analysis and navigation of molecular networks"", Bioinformatics. 2003; 19: 2155-2157.;;Online Mendelian Inheritance in Man, O.T. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), {Jun. 30, 2006}. http://www.ncbi.nlm.nih.gov/omim/.;;Overington et al., ""Tertiary structural constraints on protein evolutionary diversity: templates, key residues and structure prediction"", Proc Biol Sci., 1990; 241(1301): 132-145.;;Paddock, et al, MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone, Proc. Natl. Acad. Sci. U.S.A., 2007, vol. 104, pp. 14342-14347.;;Pähler et al., ""A probability representation for phase information from multiwavelength anomalous dispersion"", Acta Crystallogr. 1990; A 46( Pt 7): 537-540.;;Pattabiraman et al. ""Computer Graphics in Real-time Docking with Energy Calculation and Minimization"", J Comput Chem. 1985; 6: 432.;;Pavlidis et al., ""Exploring gene expression data with class scores"", Pac Symp Biocomput. 2002; 7: 474-485.;;Pavlidis et al., ""Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex"", Neurochem Res. 2004; 29(6): 1213-1222.;;Payne et al., ""Molecular recognition using a binary genetic search algorithm"", J Mol Graphics. 1993; 11(2): 74-91.;;Peri et al., ""Development of human protein reference database as an initial platform for approaching systems biology in humans"", Genome Res. 2003; 13(10): 2363-2371.;;Pershadsingh et al., ""Effect of pioglitazone treatment in a patient with secondary multiple sclerosis,"" J. Neuroinflammation, 2004; 1(1):3.;;Perrakis et al., ""Automated protein model building combined with iterative structure refinement."", Nat Struct Biol. 1999; 6(5): 458-463.;;Petricoin et al. ""Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy"", J Clin Oncol. 2005; 23: 3614-3621.",INACTIVE
604,US,A1,US 2012/0117691 A1,109-601-189-507-864,2012-05-10,2012,US 201113288677 A,2011-11-03,US 201113288677 A;;US 40987110 P,2010-11-03,TRANSCRIPTION FACTORS FOR MODIFICATION OF LIGNIN CONTENT IN PLANTS,"The invention provides methods for modifying lignin, cellulose, xylan, and hemicellulose content in plants, and for achieving ectopic lignification and, for instance, secondary cell wall synthesis in pith cells, by altered regulation of a WRKY transcription factor. Nucleic acid constructs for altered WRKY-TF expression are described. Transgenic plants are provided that comprise modified pith cell walls, and lignin, cellulose, and hemicellulose content. Plants described herein may be used, for example, as improved biofuel feedstock and as highly digestible forage crops.",WANG HUANZHONG;;CHEN FANG;;DIXON RICHARD A;;SAMUEL ROBERTS NOBLE FOUND INC,WANG HUANZHONG;;CHEN FANG;;DIXON RICHARD A,THE SAMUEL ROBERTS NOBLE FOUNDATION (2011-12-22);;NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/109-601-189-507-864,Patent Application,yes,0,4,3,3,43,C07K14/415;;C07K14/415;;C12N15/8245;;C12N15/8245;;C12N15/8246;;C12N15/8246;;C12N15/8255;;C12N15/8255;;C12N15/8261;;C12N15/8261;;Y02A40/146;;Y02A40/146;;Y02E50/10;;Y02E50/10,C12N15/82;;A01H5/00;;A23K1/00;;C10L1/00;;C12N5/10;;C12N15/113;;C12N15/29;;C12P7/10;;D21H11/00,800/284;;536/24.5;;536/23.6;;435/419;;800/298;;800/278;;435/165;;44/307;;426/635;;162/100,1,1,025-897-171-017-859,19420325;;pmc2719123;;10.1104/pp.109.138990,Pandey and Somssich 2009 Plant Physiology 150:1648-1655,ACTIVE
605,US,A1,US 2002/0108145 A1,120-308-242-959-84X,2002-08-08,2002,US 1635801 A,2001-10-30,US 1635801 A;;US 35333299 A;;US 9269698 P,1998-07-14,Constitutive disease resistance (CDR1) gene and methods of use thereof,"
   Substantially purified CDR1 polypeptide, isolated polynucleotides encoding CDR1 polypeptide, vectors containing CDR1, host cells expressing CDR1, and antibodies which bind to CDR1 are all provided. The invention also provides a method of producing a genetically modified plant characterized as having increased disease resistance as compared to wild-type plants. A method is also provided for identifying novel disease resistance genes by probing a nucleic acid library with at least a fragment of a polynucleotide encoding CDR1, and selecting those clones that hybridize with the fragment. 
",DIXON RICHARD A.;;XIA YIJI;;LAMB CHRISTOPHER,DIXON RICHARD A;;XIA YIJI;;LAMB CHRISTOPHER,,https://lens.org/120-308-242-959-84X,Patent Application,yes,7,0,9,9,3,C07K14/415;;C12N9/63;;C07K14/415;;C12N9/50;;C12N9/63;;C12N15/8281;;C12N15/8281,C07K14/415;;C12N9/50;;C12N15/29;;C12N15/82,800/279;;435/219;;X4352;;536/23.2,0,0,,,,DISCONTINUED
606,CA,A1,CA 2768133 A1,133-532-792-025-96X,2011-01-20,2011,CA 2768133 A,2010-07-12,US 22512609 P;;US 2010/0041717 W,2009-07-13,PLANTS WITH MODIFIED LIGNIN CONTENT AND METHODS FOR PRODUCTION THEREOF,"The invention provides methods for decreasing lignin content and for increasing the level of fermentable carbohydrates in plants by down-regulation of the NST transcription factor. Nucleic acid constructs for down-regulation of NST are described. Transgenic plants are provided that comprise reduced lignin content. Plants described herein may be used, for example, as improved biofuel feedstock and as highly digestible forage crops. Methods for processing plant tissue and for producing ethanol by utilizing such plants are also provided.",SAMUEL ROBERTS NOBLE FOUND INC,ZHAO QIAO;;CHEN FANG;;DIXON RICHARD A,,https://lens.org/133-532-792-025-96X,Patent Application,no,0,0,8,8,6,C07K14/415;;C07K14/415;;C12N15/8255;;C12N15/8255;;D21C5/00;;D21C5/00;;D21H23/00;;D21H23/00,A01H5/00,,0,0,,,,DISCONTINUED
607,WO,A2,WO 2007/133796 A2,134-736-095-857-366,2007-11-22,2007,US 2007/0011698 W,2007-05-15,US 80072106 P,2006-05-15,METHODS AND COMPOSITIONS FOR TREATMENT OF SLEEP APNEA,"Provided herein are methods of treatment of sleep apnea by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof to a patient in need of the treatment.",ENCYSIVE PHARMACEUTICALS INC;;DIXON RICHARD A F;;GIVEN BRUCE D,DIXON RICHARD A F;;GIVEN BRUCE D,,https://lens.org/134-736-095-857-366,Patent Application,yes,0,5,6,6,0,A61K9/0019;;A61K9/19;;A61K9/2018;;A61K9/2054;;A61K31/422;;A61P11/00;;A61P25/00;;A61K31/422;;A61K9/0019;;A61K9/2054;;A61K9/19;;A61K9/2018,,,0,0,,,,PENDING
608,CN,A,CN 1317054 A,002-605-820-158-60X,2001-10-10,2001,CN 99810840 A,1999-07-14,US 9269698 P,1998-07-14,Constitutive disease resistance gene (CDR1) and method of use thereof,,SALK INST OF BIOLOG STUDIES,DIXON R A;;YIJI XI;;LAMB C,,https://lens.org/002-605-820-158-60X,Patent Application,no,0,1,9,9,0,C07K14/415;;C12N9/63;;C07K14/415;;C12N9/50;;C12N9/63;;C12N15/8281;;C12N15/8281,C07K14/415;;C12N9/50;;C12N15/29;;C12N15/82,,0,0,,,,DISCONTINUED
609,US,A,US 4028133 A,071-279-888-368-920,1977-06-07,1977,US 67359676 A,1976-04-05,US 67359676 A;;US 64816376 A;;US 64825376 A,1976-01-12,Reduced charge montmorillonite pigment for sensitizing record material,"A reduced charge montmorillonite pigment useful as a color-former in record material, especially pressure-sensitive carbonless copying record systems. The pigment is produced by replacing exchangeable cations of a selected dioctahedral montmorillonite crude clay (exemplified by certain bentonite clays) with a predetermined amount of lithium ions, mildly heating the lithium-exchanged montmorillonite to collapse irreversibly the montmorillonite structure, and grinding the heat-treated material to pigment-size particles, the grinding preferably being carried out in a fluid energy mill. When the pigment particles are coated on paper, the coated sheets produce stabilized intense images when printed with a solution of crystal violet lactone (CVL) dye precursor and thus may be used in record material with CVL without employing secondary slow acting dyes such as benzoyl leuco methylene blue. The sheets are also useful with other colorless or substantially colorless dye precursors.",ENGELHARD MIN & CHEM,ISAAC PETER A H;;OULTON T DIXON,PHIBRO CORPORATION (1983-03-28);;ENGLEHARD CORPORATION A CORP. OF DE (1981-05-18),https://lens.org/071-279-888-368-920,Granted Patent,yes,4,2,9,13,0,B41M5/1555;;C01P2002/72;;C01P2004/41;;C01P2004/50;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2004/80;;C01P2006/12;;C01P2006/60;;C01P2006/80;;C01P2006/82;;C09C1/42;;Y10S428/914;;Y10T428/259;;Y10T428/259;;C09C1/42;;C01P2004/61;;B41M5/1555;;C01P2004/51;;C01P2004/50;;C01P2006/82;;C01P2004/80;;C01P2006/12;;C01P2004/41;;C01P2006/80;;C01P2006/60;;C01P2002/72;;C01P2004/62;;Y10S428/914,B41M5/155;;C09C1/42,106288B,0,0,,,,EXPIRED
610,HK,A1,HK 1156872 A1,083-797-946-442-646,2012-06-22,2012,HK 11111285 A,2011-10-20,US 6951097 P;;US 16335198 A,1997-12-15,COMPOSITIONS AND METHODS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,,NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A;;KANIOS DAVID,,https://lens.org/083-797-946-442-646,Patent Application,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K/;;A61K31/435;;A61K9/06;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,DISCONTINUED
611,NZ,A,NZ 209952 A,108-863-857-542-459,1988-08-30,1988,NZ 20995284 A,1984-10-23,GB 8328489 A;;GB 8328490 A;;GB 8332447 A;;GB 8332448 A;;GB 8332452 A;;GB 8401746 A;;GB 8401747 A;;GB 8401748 A;;GB 8401750 A,1983-10-25,AMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS,,FISONS PLC,DIXON J;;INCE F;;TINKER A C,,https://lens.org/108-863-857-542-459,Patent Application,no,0,0,21,42,0,C07C43/174;;C07C43/23;;C07C45/515;;C07C65/24;;C07C215/52;;C07C215/80;;C07C217/10;;C07C217/16;;C07C229/14;;C07C233/13;;C07C233/40;;C07C237/06;;C07C275/28;;C07C311/08;;C07C317/28;;C07C323/25;;C07D215/227;;C07D215/26;;C07D263/14;;C07D319/08;;C07C2601/12;;C07C2601/14;;C07C2602/08,A61K31/18;;C07C43/174;;C07C43/23;;C07C45/51;;C07C65/24;;C07C215/52;;C07C215/80;;C07C217/10;;C07C217/16;;C07C229/14;;C07C233/13;;C07C233/40;;C07C237/00;;C07C237/06;;C07C275/28;;C07C311/02;;C07C317/04;;C07C317/28;;C07C323/25;;C07C329/00;;C07D215/22;;C07D215/227;;C07D215/26;;C07D263/14;;C07D319/08,,0,0,,,,DISCONTINUED
612,CA,A,CA 751324 A,160-396-647-969-45X,1967-01-24,1967,CA 751324D A,,CA 751324T A,,METHOD OF PREPARING HECTOGRAPH MASTER SHEETS,,COLUMBIA RIBBON & CARBON,DIXON HAROLD F E;;NEWMAN DOUGLAS A,,https://lens.org/160-396-647-969-45X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
613,AU,A1,AU 2007/225139 A1,025-077-006-572-716,2007-09-20,2007,AU 2007/225139 A,2007-03-12,US 78185306 P;;US 2007/0006336 W,2006-03-13,Methods and compositions for treatment of diastolic heart failure,,ENCYSIVE PHARMACEUTICALS INC,GIVEN BRUCE D;;DIXON RICHARD A F,,https://lens.org/025-077-006-572-716,Patent Application,no,0,0,13,13,0,A61K9/0019;;A61K9/1623;;A61K9/2054;;A61K9/2095;;A61K9/2866;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61K31/194;;A61K31/401;;A61K9/19;;A61K31/357;;A61K31/194;;A61K31/506;;A61K31/401;;A61K31/501;;A61K9/0019;;A61K9/1623;;A61K9/2095;;A61K9/2866;;A61K9/2054;;A61K31/357;;A61K31/42,A61K9/19;;A61K9/20;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61K38/07;;A61K38/12;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08,,0,0,,,,DISCONTINUED
614,EP,A2,EP 2037912 A2,029-355-808-589-010,2009-03-25,2009,EP 07794914 A,2007-05-15,US 2007/0011698 W;;US 80072106 P,2006-05-15,METHODS AND COMPOSITIONS FOR TREATMENT OF SLEEP APNEA COMPRISING ADMINISTRATION OF AN ENDOTHELIN ANTAGONIST,,ENCYSIVE PHARMACEUTICALS INC,DIXON RICHARD A F;;GIVEN BRUCE D,,https://lens.org/029-355-808-589-010,Patent Application,yes,0,0,6,6,0,A61K9/0019;;A61K9/19;;A61K9/2018;;A61K9/2054;;A61K31/422;;A61P11/00;;A61P25/00;;A61K31/422;;A61K9/0019;;A61K9/2054;;A61K9/19;;A61K9/2018,A61K31/357;;A61K31/422;;A61K31/506;;A61K45/00;;A61P11/00,,0,0,,,,DISCONTINUED
615,PL,B1,PL 168230 B1,076-660-445-688-815,1996-01-31,1996,PL 29317492 A,1992-01-14,PL 29317492 A,1992-01-14,"METHOD OF OBTAINING 3,7-DISUBSTITUTED INDOLE DERIVATIVES",,SANDOZ AG,DIXON ARNOLD K;;GIGER RUDOLF K A,,https://lens.org/076-660-445-688-815,Granted Patent,no,0,0,2,2,0,,C07D403/12;;C07D451/02,,0,0,,,,EXPIRED
616,MY,A,MY 103844 A,112-461-249-732-622,1993-09-30,1993,MY PI19890291 A,1989-03-10,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,NEW USES OF 4-(3-PHOSPHONO-2-PROPENYL)-2-PIPERAZINE- CARBOXYLIC ACID.,"THE USES OF PIPERAZINECARBOXYLIC ACID IN THE TREATMENT OF DISORDERS CHARACTERISED BY REDUCED DRIVE AND/OR SOCIAL WITHDRAWAL, SLEEP DISTURBANCES OR MIGRAINE.",SANDOZ LTD,JULIAN A GRAY;;DR ARNOLD KEITH DIXON,,https://lens.org/112-461-249-732-622,Granted Patent,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
617,CA,A1,CA 2129025 A1,104-559-978-207-874,1993-08-05,1993,CA 2129025 A,1993-02-04,US 83072792 A,1992-02-04,DECORATIVE FLOOR COVERINGS HAVING THE APPEARANCE OF CERAMIC TILE AND COMPOSITIONS AND METHODS FOR MAKING SAME,"2129025 9315135 PCTABS00024 Disclosed are compositions comprising carrier, first organic polymeric material fused or fusible in said carrier and second polymeric material not fusible in said carrier, said second polymeric material having a softening point temperature which is less than about the fusion temperature of said first polymeric material in the plasticizer, and preferably within about the gelation temperature range of said first polymeric material in said carrier. It is preferred that the first polymeric material comprise vinyl resin and that the second polymeric material comprise polymer particles. Also disclosed are methods for producing surface coverings and surface covering compositions comprising converting the liquid compositions of the present invention to the solid compositions hereof under time and temperature conditions sufficient to enable softening, and preferably substantial softening and swelling, of the second polymeric material prior to fusion, and preferably during gelation, of the liquid composition.",CONGOLEUM CORP,MORSELANDER EUGENE;;DIXON RONALD;;SHALOV ALLEN A,,https://lens.org/104-559-978-207-874,Patent Application,no,0,0,10,10,0,B05D1/28;;B29C70/603;;B29L2031/722;;B29L2031/732;;C08L27/06;;C08L33/06;;C08L33/10;;C08L61/28;;C08L2205/02;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/0055;;C08K5/10;;D06N3/00;;C08L27/04;;D06N7/0055;;C08L2205/02;;D06N3/06;;B05D1/28;;D06N3/08;;C08L27/06;;B29L2031/732;;B29C70/603;;B29L2031/722;;C08L33/10;;C08L33/06;;C08L61/28;;C09D127/06,B05D1/28;;B29C70/60;;C08L27/06;;C08L33/04;;C08L33/06;;C08L33/10;;C08L61/28;;C08L101/00;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/00,,0,0,,,,DISCONTINUED
618,WO,A1,WO 2011/008698 A1,113-771-502-886-60X,2011-01-20,2011,US 2010/0041717 W,2010-07-12,US 22512609 P,2009-07-13,PLANTS WITH MODIFIED LIGNIN CONTENT AND METHODS FOR PRODUCTION THEREOF,"The invention provides methods for decreasing lignin content and for increasing the level of fermentable carbohydrates in plants by down-regulation of the NST transcription factor. Nucleic acid constructs for down-regulation of NST are described. Transgenic plants are provided that comprise reduced lignin content. Plants described herein may be used, for example, as improved biofuel feedstock and as highly digestible forage crops. Methods for processing plant tissue and for producing ethanol by utilizing such plants are also provided.",SAMUEL ROBERTS NOBLE FOUND INC;;ZHAO QIAO;;CHEN FANG;;DIXON RICHARD A,ZHAO QIAO;;CHEN FANG;;DIXON RICHARD A,,https://lens.org/113-771-502-886-60X,Patent Application,yes,3,1,8,8,6,C07K14/415;;C07K14/415;;C12N15/8255;;C12N15/8255;;D21C5/00;;D21C5/00;;D21H23/00;;D21H23/00,C12N15/82;;A01H5/00,,2,2,017-196-717-690-067;;027-615-569-962-310,pmc1820955;;17237351;;10.1105/tpc.106.047043;;10.1007/s00425-007-0498-y;;17333250,"MITSUDA ET AL.: ""NAC Transcription Factors, NST1 and NST3, Are Key Regulators of the Formation of Secondary Walls in Woody Tissues of Arabidopsis."", THE PLANT CELL., vol. 19, 2007, pages 270 - 280, XP003017400, DOI: doi:10.1105/tpc.106.047043;;ZHONG ET AL.: ""Two NAC domain transcription factors, SND1 and NST1, function redundantly in regulation of secondary wall synthesis in fibers of Arabidopsis."", PLANTA, vol. 225, 2007, pages 1603 - 1611, XP019517523, DOI: doi:10.1007/s00425-007-0498-y",PENDING
619,EP,A1,EP 0625170 A1,153-773-332-219-15X,1994-11-23,1994,EP 93904852 A,1993-02-04,US 9300947 W;;US 83072792 A,1992-02-04,DECORATIVE FLOOR COVERINGS HAVING THE APPEARANCE OF CERAMIC TILE AND COMPOSITIONS AND METHODS FOR MAKING SAME.,"L'invention concerne des compositions comprenant un support, un premier matériau polymère organique fusionné ou fusible dans ledit support ainsi qu'un second matériau polymère non fusible dans ledit support, ledit second matériau polymère présentant une température de ramollissement inférieure à environ la température de fusion dudit premier matériau polymère dans le plastifiant, et de préférence environ à l'intérieur de la plage de température de gélification dudit premier matériau polymère dans ledit support. Il est préférable que le premier matériau polymère comprenne une résine vinylique, et que le second matériau polymère comprenne des particules polymères. L'invention concerne également des procédés de production de revêtements de surface et de compositions de revêtements de surface consistant à transformer les compositions liquides de l'invention en conpositions solides dans des conditions de temps et de température suffisantes pour permettre le ramollissement, et de préférence un ramollissement ainsi qu'un gonflement substantiel, du second matériau polymère avant fusion, et de préférence pendant la gélification, de ladite composition liquide.",CONGOLEUM CORP,SHALOV ALLEN A;;MORSELANDER EUGENE;;DIXON RONALD,,https://lens.org/153-773-332-219-15X,Patent Application,yes,0,2,10,10,0,B05D1/28;;B29C70/603;;B29L2031/722;;B29L2031/732;;C08L27/06;;C08L33/06;;C08L33/10;;C08L61/28;;C08L2205/02;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/0055;;C08K5/10;;D06N3/00;;C08L27/04;;D06N7/0055;;C08L2205/02;;D06N3/06;;B05D1/28;;D06N3/08;;C08L27/06;;B29L2031/732;;B29C70/603;;B29L2031/722;;C08L33/10;;C08L33/06;;C08L61/28;;C09D127/06,B05D1/28;;B29C70/60;;C08L27/06;;C08L33/04;;C08L33/06;;C08L33/10;;C08L61/28;;C08L101/00;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/00,,0,0,,,,DISCONTINUED
620,FR,A1,FR 2337626 A1,049-218-619-193-599,1977-08-05,1977,FR 7700194 A,1977-01-05,US 64816376 A;;US 64825376 A;;US 67359676 A,1976-01-12,PIGMENT SENSIBILISANT POUR MATIERE D'ENREGISTREMENT,,ENGELHARD MIN & CHEM,ISAAC PETER A H;;OULTON THOMAS DIXON,,https://lens.org/049-218-619-193-599,Patent Application,no,4,0,9,13,0,B41M5/1555;;C01P2002/72;;C01P2004/41;;C01P2004/50;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2004/80;;C01P2006/12;;C01P2006/60;;C01P2006/80;;C01P2006/82;;C09C1/42;;Y10S428/914;;Y10T428/259;;Y10T428/259;;C09C1/42;;C01P2004/61;;B41M5/1555;;C01P2004/51;;C01P2004/50;;C01P2006/82;;C01P2004/80;;C01P2006/12;;C01P2004/41;;C01P2006/80;;C01P2006/60;;C01P2002/72;;C01P2004/62;;Y10S428/914,B41M5/155;;C09C1/42,,0,0,,,,DISCONTINUED
621,WO,A3,WO 1993/015135 A3,040-183-568-472-891,1993-09-30,1993,US 9300947 W,1993-02-04,US 83072792 A,1992-02-04,DECORATIVE FLOOR COVERINGS HAVING THE APPEARANCE OF CERAMIC TILE AND COMPOSITIONS AND METHODS FOR MAKING SAME,,CONGOLEUM CORP,SHALOV ALLEN A;;MORSELANDER EUGENE;;DIXON RONALD,,https://lens.org/040-183-568-472-891,Search Report,no,5,0,10,10,0,B05D1/28;;B29C70/603;;B29L2031/722;;B29L2031/732;;C08L27/06;;C08L33/06;;C08L33/10;;C08L61/28;;C08L2205/02;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/0055;;C08K5/10;;D06N3/00;;C08L27/04;;D06N7/0055;;C08L2205/02;;D06N3/06;;B05D1/28;;D06N3/08;;C08L27/06;;B29L2031/732;;B29C70/603;;B29L2031/722;;C08L33/10;;C08L33/06;;C08L61/28;;C09D127/06,B05D1/28;;B29C70/60;;C08L27/06;;C08L33/04;;C08L33/06;;C08L33/10;;C08L61/28;;C08L101/00;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/00,,0,0,,,,PENDING
622,US,A,US 4784876 A,163-883-754-782-858,1988-11-15,1988,US 14227687 A,1987-12-31,US 14227687 A;;US 94814986 A,1986-12-31,Sympathetic ink and developer system,"A sharp imaging, non-smearing system for latent imaging and subsequent visual development of printed text or the like is provided which can be used on a variety of substrates (e.g. paper, metal, cloth, synthetic resins) and is extremely stable and easy to use. The system involves first imaging a substrate with an invisible non-blurring, non-sublimating ink containing a dissociable nickel salt such as NiSO.sub.4, with subsequent application of a liquid developer containing a dispersed color precursor such as dimethylglyoxime which reacts with nickel ion to give a sharp, long lasting red color. The developer preferably includes an accelerator such as NaOH for accelerating the above reaction so as to make it virtually instantaneous. The system of the present invention can be used in a variety of contexts, such as in self-testing materials or novelty items.",LYNWOOD GRAPHICS INC,WALKER JR HAYWOOD A;;DIXON MARVIN P,LYNWOOD ENTERPRISES INC. BOX 432D ROUTE 1 LIBERTY MO A CORP. OF MO (1988-09-13),https://lens.org/163-883-754-782-858,Granted Patent,yes,12,12,1,2,0,B41M3/001;;B41M3/001,B41M3/00,B6C CSC           SC;;U1S S1205;;U1S S2271;;U1S S2301,2,0,,,"Chemical Abstract, vol. 104, No. 16, Abstract No. 141436z, Zinchuk et al., U.S.S.R., Patent No. 1176244, Aug. 30, 1985.;;Titas Simpaticas by P. L. DeAraujo Feio, Revista Da Sociedade Brasileira de Quimica, Boletin Cientifico, vol. XIV, Janeiro Marco de 1945, N. 1, Rio de Janeiro, Brazil.",EXPIRED
623,EP,B1,EP 2314288 B1,184-642-559-116-504,2013-12-11,2013,EP 10011358 A,1998-12-14,EP 04004843 A;;EP 98963170 A;;US 6951097 P;;US 16335198 A,1997-12-15,Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate,,NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A;;KANIOS DAVID,,https://lens.org/184-642-559-116-504,Granted Patent,yes,2,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K31/435;;A61K9/70;;A61K31/445;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,1,0,,,"Gebler H, Kindl G: ""Pharmazie für die Praxis"", 1990, Georg Thieme Verlag, Stuttgart, XP002628340, ISBN: 3-13-730701-5 pages 175-176, * page 176, left-hand column *",EXPIRED
624,US,A1,US 2012/0047600 A1,194-791-304-955-586,2012-02-23,2012,US 201113181284 A,2011-07-12,US 201113181284 A;;US 36355610 P,2010-07-12,CAFFEOYL COA REDUCTASE,"The invention provides methods for increasing lignin content in plants by expression of a cinnamoyl CoA reductase 2 (CCR2) coding sequence in the plant. Also provided are methods for reducing lignin content in a plant by down-regulation of CCR2 expression in the plant. Nucleic acid molecules for modulation of CCR2 expression and transgenic plants the same are also provided. Plants described herein may be used, for example, as improved biofuel feedstock and as highly digestible forage crops. Methods for processing plant tissue and for producing biofuels by utilizing such plants are also provided.",ZHOU RUI;;DIXON RICHARD A;;CHEN FANG,ZHOU RUI;;DIXON RICHARD A;;CHEN FANG,,https://lens.org/194-791-304-955-586,Patent Application,yes,0,2,1,1,73,A23K10/30;;A23K10/30;;A23K30/15;;A23K30/15;;C12N9/0008;;C12N9/0008;;C12N15/8242;;C12N15/8242;;C12N15/8255;;C12N15/8255;;D21C5/005;;D21C5/005;;D21C11/0007;;D21C11/0007;;D21H17/005;;D21H17/005;;Y02E50/30;;Y02E50/30;;Y02P20/145;;Y02P20/145,A01H1/06;;A01H5/00;;A01H5/02;;A01H5/06;;A01H5/10;;A23K1/00;;C01B3/32;;C07C29/74;;C07G99/00;;C08H7/00;;C12N5/10;;C12N9/10;;C12N15/54;;C12N15/63;;C12N15/82;;D01F9/12;;D21C5/00,800/278;;536/23.2;;435/320.1;;435/193;;800/298;;800/320.1;;800/317.4;;800/312;;800/320;;435/419;;530/500;;568/913;;44/307;;426/635;;X 48197  R;;162/96;;162/97;;162/99;;423/447.1,4,3,055-003-061-629-507;;003-360-320-963-032;;139-554-120-885-954,10.1073/pnas.0403255101;;pmc438954;;15197260;;11430991;;10.1016/s0031-9422(01)00053-x;;20876124;;10.1073/pnas.1012900107;;pmc2955080,Guo et al. 2004. Protein tolerance to random amino acid change. PNAS. 101(25):9205-9210.;;Lauvergeat et al. 2001. Two cinnamoyl-CoA reductase (CCR) genes from Arabidopsis thaliana are differentially expressed during development and in response to infection with pathogenic bacteria. Phytochemistry. 57:1187-1195.;;ENA (European Nucleotide Archive). 2009. RCOM_0470860. pg 1-2.;;Zhou et al. 2010. Distinct cinnamoyl CoA reductases involved in parallel routes to lignin in Medicago truncatula. PNAS. 107(41):17803-17808.,DISCONTINUED
625,US,B2,US 9045549 B2,104-168-116-388-933,2015-06-02,2015,US 201113288677 A,2011-11-03,US 201113288677 A;;US 40987110 P,2010-11-03,Transcription factors for modification of lignin content in plants,"The invention provides methods for modifying lignin, cellulose, xylan, and hemicellulose content in plants, and for achieving ectopic lignification and, for instance, secondary cell wall synthesis in pith cells, by altered regulation of a WRKY transcription factor. Nucleic acid constructs for altered WRKY-TF expression are described. Transgenic plants are provided that comprise modified pith cell walls, and lignin, cellulose, and hemicellulose content. Plants described herein may be used, for example, as improved biofuel feedstock and as highly digestible forage crops.",WANG HUANZHONG;;CHEN FANG;;DIXON RICHARD A;;SAMUEL ROBERTS NOBLE FOUND INC,WANG HUANZHONG;;CHEN FANG;;DIXON RICHARD A,THE SAMUEL ROBERTS NOBLE FOUNDATION (2011-12-22);;NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/104-168-116-388-933,Granted Patent,yes,3,1,3,3,43,C07K14/415;;C07K14/415;;C12N15/8245;;C12N15/8245;;C12N15/8246;;C12N15/8246;;C12N15/8255;;C12N15/8255;;C12N15/8261;;C12N15/8261;;Y02A40/146;;Y02A40/146;;Y02E50/10;;Y02E50/10,C12N15/82;;A01H5/04;;C07K14/415;;C12N15/09;;C12N15/63,,21,15,025-897-171-017-859;;073-610-837-609-368;;054-771-305-892-797;;013-327-223-989-239;;064-728-414-823-343;;037-985-467-569-463;;064-918-147-571-82X;;022-971-245-406-739;;061-506-672-572-556;;002-724-747-289-970;;101-379-692-204-048;;041-520-527-948-911;;007-735-774-039-227;;042-187-232-771-311;;095-234-496-972-741,19420325;;pmc2719123;;10.1104/pp.109.138990;;10887094;;10.1242/dev.127.15.3395;;pmc150706;;10.1105/tpc.002022;;12119374;;10.1016/s1360-1385(00)01600-9;;10785665;;10.1007/s11103-009-9563-1;;19902151;;19674407;;10.1111/j.1365-313x.2009.03989.x;;18251882;;10.1111/j.1399-3054.2007.00975.x;;10.1186/1471-2229-8-132;;pmc2628384;;19102779;;21135241;;10.1073/pnas.1016436107;;pmc3009815;;10.1007/s11103-007-9244-x;;17960484;;21883551;;10.1111/j.1365-313x.2011.04764.x;;10.1093/mp/ssr098;;22138968;;20660755;;10.1073/pnas.1009170107;;pmc2922545;;20408998;;pmc2590737;;10.1105/tpc.108.061325;;18952777,"Pandey and Somssich 2009 Plant Physiology 150:1648-1655.;;Archana K et al., ""Down-regulation of an abiotic stress related Nicotiana benthamiana WRKY transcription factor induces physiological abnormalities,"" Indian Journal of Biotechnology, 8(1):53-60, Jan. 2009.;;Caño-Delgado Al et al., ""The eli1 mutation reveals a link between cell expansion and secondary cell wall formation in Arabidopsis thaliana ,"" Development, 127(15):3395-405, Aug. 2000.;;Ellis C et al., ""The Arabidopsis mutant cev1 links cell wall signaling to jasmonate and ethylene responses,"" Plant Cell., 14(7):1557-66, Jul. 2002.;;Eulgem T et al., ""The WRKY superfamily of plant transcription factors,"" Trends in Plant Science, 5(5):199-206, May 2000.;;Guillaumie S et al., ""The grapevine transcription factor WRKY2 influences the lignin pathway and xylem development in tobacco,"" Plant Molecular Biology, 72(1-2):215-234, Jan. 2010.;;Ko JH et al., ""Ectopic expression of MYB46 identifies transcriptional regulatory genes involved in secondary wall biosynthesis in Arabidopsis,"" Plant J., 60(4):649-65, Nov. 2009.;;Mzid Rim et al: ""Overexpression of VvWRKY2 in tobacco enhances broad resistance to necrotrophic fungal pathogens,"" Physiologia Plantarum, 131(3):434-447, November.;;Naoumkina Marina A et al., ""Elicitor-induced transcription factors for metabolic reprogramming of secondary metabolism in Medicago truncatula,"" BMC Plant Biology, Biomed Central, 8(1), Dec. 22, 2008, London, GB.;;Wang H et al., ""Mutation of WRKY transcription factors initiates pith secondary wall formation and increases stem biomass in dicotyledonous plants,"" PNAS (U.S.A.), 107(51): 22338-22343, Dec. 2010.;;Wang H et al., ""Overexpression of rice WRKY89 enhances ultraviolet B tolerance and disease resistance in rice plants,"" Plant Molecular Biology, 65(6):799-815, Oct. 25 2007, Kluwer Academic Publishers, Dordrecht, NL.;;Wang H et al., ""NAC domain function and transcriptional control of a secondary cell wall master switch,"" Plant J., 68(6):1104-1114, Dec. 2011.;;Wang HZ, Dixon RA, ""On-off switches for secondary cell wall biosynthesis,"".Mol Plant, 5(2):297-303, Mar. 2012.;;Wang, H., ""WRKY transcription factors control pith secondary wall formation and affect stem biomass production,"" Abstract; Plant Biology 2011 ASPB Meeting / Conference; American Society of Plant Biologists, 10, Aug. 6, 2011.;;Zhao Q et al., ""Syringyl lignin biosynthesis is directly regulated by a secondary cell wall master switch,"" Proc Natl Acad Sci U S A, 107(32):14496-501, Aug. 10, 2010.;;Zhao Qiao et al., ""An NAC transcription factor orchestrates multiple features of cell wall development in Medicago truncatula,"" Plant Journal, 63(1): 100-114, Jul. 2010.;;Zhong R et al., ""A battery of transcription factors involved in the regulation of secondary cell wall biosynthesis in Arabidopsis,"" Plant Cell, (10):2763-82, Oct. 20, 2008.;;GenBank Accession No. HM622066; Wang et al.;;GenBank Accession No. IMGA|AC202489-11.1; .;;GenBank Accession No. ABY84655.1, dated Feb. 3, 2008.;;GenBank Accession No. CBI16682.3, dated Jun. 8, 2010.",ACTIVE
626,US,B2,US 8901371 B2,129-282-635-271-696,2014-12-02,2014,US 201213462583 A,2012-05-02,US 201213462583 A;;US 201161483460 P,2011-05-06,Compositions and methods for improved plant feedstock,"The invention provides methods for modifying lignin content and composition in plants and achieving associated benefits therefrom involving altered expression of newly discovered MYB4 transcription factors. Nucleic acid constructs for modifying MYB4 transcription factor expression are described. By over-expressing the identified MYB4 transcription factors, for example, an accompanying decrease in lignin content may be achieved. Plants are provided by the invention comprising such modifications, as are methods for their preparation and use.",SHEN HUI;;CHEN FANG;;DIXON RICHARD A;;SAMUEL ROBERTS NOBLE FOUND INC,SHEN HUI;;CHEN FANG;;DIXON RICHARD A,NOBLE RESEARCH INSTITUTE LLC (2012-05-14),https://lens.org/129-282-635-271-696,Granted Patent,yes,20,0,2,2,192,C12N15/8243;;C12N15/8255;;C12N15/8261;;C07K2319/21;;Y02A40/146;;C07K14/415;;Y02E50/30;;C12N15/8243;;C12N15/8255;;C12N15/8261;;C07K2319/21;;Y02A40/146;;Y02E50/30;;C07K14/415,C12N15/82;;A01H5/00;;C07K14/415;;C12N15/00,800/278;;435/320.1;;435/419;;800/298;;800/320;;800/284,48,32,091-569-698-846-961;;084-254-913-213-762;;047-723-672-768-544;;043-728-564-645-237;;029-936-550-209-716;;044-771-817-963-816;;018-356-283-473-212;;015-891-501-459-829;;009-284-177-648-350;;099-909-877-116-058;;041-176-204-971-674;;050-075-196-798-528;;037-202-166-498-020;;047-723-672-768-544;;032-394-849-710-542;;085-852-936-510-571;;017-196-717-690-067;;091-569-698-846-961;;037-165-456-140-107;;149-059-153-912-159;;036-789-848-455-182;;084-254-913-213-762;;118-169-461-622-180;;052-050-441-875-569;;023-063-822-814-277;;088-725-879-841-143;;061-506-672-572-556;;081-594-352-299-093;;001-414-081-635-899;;056-167-235-352-980;;051-801-565-083-203;;139-554-120-885-954,14675440;;10.1046/j.1365-313x.2003.01916.x;;21988539;;10.1111/j.1469-8137.2011.03922.x;;pmc305818;;10.1093/emboj/19.22.6150;;11080161;;10.1105/tpc.106.044495;;17237352;;pmc1820963;;18805909;;10.1093/jxb/ern234;;pmc2576632;;10.1021/pr800298s;;19053836;;10.1104/pp.105.067231;;16384897;;pmc1361319;;18424797;;10.1093/nar/gkn180;;pmc2447785;;pmc55100;;11607118;;10.1073/pnas.87.22.9057;;21070416;;10.1111/j.1365-313x.2010.04363.x;;16941210;;10.1007/s11103-006-9058-2;;10.1111/j.1365-313x.2006.02719.x;;16640595;;10.1111/j.1365-313x.2005.02480.x;;16098109;;pmc305818;;10.1093/emboj/19.22.6150;;11080161;;15604742;;10.1007/s11103-004-3354-5;;10.1016/j.plantsci.2007.08.007;;pmc1820955;;17237351;;10.1105/tpc.106.047043;;14675440;;10.1046/j.1365-313x.2003.01916.x;;10.1111/j.1365-313x.2004.02280.x;;15584962;;9628022;;10.1046/j.1365-313x.1998.00113.x;;10.1007/s12155-009-9058-6;;21988539;;10.1111/j.1469-8137.2011.03922.x;;10.1007/s11103-009-9473-2;;19238561;;10.1016/s1369-5266(00)00199-0;;11597504;;9490739;;10.2307/3870694;;pmc143979;;10.1105/tpc.10.2.135;;16049706;;10.1007/s00122-005-0030-3;;21135241;;10.1073/pnas.1016436107;;pmc3009815;;10.1631/jzus.b1000161;;20593511;;pmc2897016;;10.1105/tpc.106.048900;;pmc2174865;;17993626;;21227733;;10.1016/j.tplants.2010.12.005;;10.1016/j.tplants.2010.08.007;;20833576;;20876124;;10.1073/pnas.1012900107;;pmc2955080,"Patzlaff et al, 2003, The Plant J., 36:743-754.;;Shen et al, 2012, New Phytologist, 193:121-136.;;Lucas et al, Gen Bank accession No. FE635325 published Mar. 10, 2008.;;Jin et al, 2000, Embo, 19:6150-6161.;;Besseau et al.,""Flavonoid accumulation in Arabidopsis repressed in lignin synthesis affects auxin transport and plant growth,"" Plant Cell 19:148-162, 2007.;;Bomal et al., ""Involvement of Pinus taeda MYB1 and MYB8 in phenylpropanoid metabolism and secondary cell wall biogenesis: a comparative in planta analysis,"" J. Exp. Bot. 59:3925-3939, 2008.;;Bylesjo, et al., ""Integrated analysis of transcript, protein and metabolite data to study lignin biosynthesis in hybrid aspen,"" J. Proteome Res. 8(1):199-210, 2008.;;Deluc et al., ""Characterization of a grapevine R2R3-MYB transcription factor that regulates the phenylpropanoid pathway,"" Plant Physiol. 140:499-511, 2006.;;Dereeper et al.,"" Phylogeny. fr: robust phylogenetic analysis for the non-specialist,"" Nucleic Acids Res. (Web Server issue): W465-W469, Apr. 19, 2008.;;Elkind et al., ""Abnormal plant development and down regulation of phenylpropanoid biosynthesis in transgenic tobacco containing a heterologous phenylalanine ammonia-lyase gene,"" Proc. Natl. Acad. Sci. USA 87:9057-9061, 1990.;;Fornaléet al., "" ZmMYB31 directly represses maize lignin genes and redirects the phenylpropanoid metabolic flux,"" Plant J. 64(4):633-644, 2010.;;Fornaléet al., ""Down-regulation of the maize and Arabidopsis thaliana caffeic acid O- methyl-transferase genes by two new maize R2R3-MYB transcription factors,"" Plant Mol. Biol. 62: 809-823; 2006.;;Gális et al., ""A novel R2R3 MYB transcription factor NtMYBJS1 is a methyl jasmonate-dependent regulator of phenylpropanoid-conjugate biosynthesis in tobacco,"" Plant J. 46: 573-592; 2006.;;GenBank Accession No. JF299185, ""Panicum virgatum R2R3-MYB transcriptional factor PvMYB4a mRNA, complete cds,"" Dec. 12, 2011.;;GenBank Accession No. JF299186, ""Panicum virgatum R2R3-MYB transcriptional factor PvMYB4b mRNA, complete cds,"" Dec. 12, 2011.;;GenBank Accession No. JF299187, ""Panicum virgatum R2R3-MYB transcriptional factor PvMYB4c mRNA, complete cds,"" Dec. 12, 2011.;;GenBank Accession No. JF299188, ""Panicum virgatum R2R3-MYB transcriptional factor PvMYB4d mRNA, complete cds,"" Dec. 12, 2011.;;GenBank Accession No. JF299189, ""Panicum virgatum R2R3-MYB transcriptional factor PvMYB4e mRNA, partial cds,"" Dec. 12, 2011, Dec. 21, 2011.;;GenBank Accession No. NM-119665, ""Arabidopsis thaliana transcription factor MYB32 mRNA, complete cds,"" Jun. 5, 2013; accessed Jul. 29, 2013.;;GenBank Accession No. CAE09058, ""MYB transcription factor [Eucalyptus gunnii],"" accessed Aug. 27, 2009.;;GenBank Accession No. JQ0960, ""myb-related protein 308-garden snapdragon,"" accessed Feb. 2006.;;GenBank Accession No. AY519615, ""Arabidopsis thaliana MYB transcription factor (At4g38620) mRNA, complete cds,"" accessed Feb. 7, 2004.;;GenBank Accession No. JQ0957, ""myb-related protein 330-garden snapdragon,"" accessed Feb. 2006.;;GenBank Accession No. CAJ42204, ""transcription factor MYB42 [Zea mays],"" accessed Mar. 2, 2006.;;GenBank Accession No. CAJ42202, ""transcription factor MYB31 [Zea mays],"" accessed Mar. 2, 2006.;;GenBank Accession No. P81393, ""RecName: Full=Myb-related protein 308,"" accessed Jan. 2009.;;GenBank Accession No. P81395, ""RecName: Full=Myb-related protein 330,"" accessed Jan. 2009;;Goicoechea et al., "" EgMYB2, a new transcriptional activator from Eucalyptus xylem, regulates secondary cell wall formation and lignin biosynthesis,"" Plant J. 43:553-567; 2005.;;Jin et al., ""Transcriptional repression by AtMYB4 controls production of UV-protecting sunscreens in Arabidopsis,"" Embo J. 19:6150-6161; 2000.;;Karpinska at al.,""MYB transcription factors are differentially expressed and regulated during secondary vascular tissue development in hybrid aspen,"" Plant Mol. Biol. 56:255-270: 2004.;;Legay et al., ""Molecular characterization of EgMYB1, a putative transcriptional repressor of the lignin biosynthetic pathway,"" Plant Sci. 173: 542-549; 2007.;;Mitsuda et al., ""NAC transcription factors, NST1 and NST3, are key regulators of the formation of secondary walls in woody tissues of Arabidopsis,"" Plant Cell 19:270-280, 2007.;;Patzlaff et al.,""Charactensation of a pine MYB that regulates lignification,"" Plant J. 36:743-754; 2003.;;Preston at al.,""AtMYB32 is required for normal pollen development in Arabidopsis thaliana,"" Plant J. 40:979-995; 2004.;;Romero at al., ""More than 80 R2R3-MYB regulatory genes in the genome of Arabidopsis thaliana,"" Plant J. 14: 273-284;1998.;;Shen at al., ""Developmental control of lignification in stems of lowland switchgrass variety Alamo and the effects on saccharification efficiency,"" BioEnerg. Res. 2:233-245; 2009.;;Shen et al., ""Functional characterization of the switchgrass (Panicum virgatum) R283-MY8 transcription factor PvMYB4 for improvement of lignocellulosic feedstocks,"" New Phytologist, 193:121-136: 2012.;;Sonbol et al., ""The maize ZmMYB42 represses the phenylpropanoid pathway and affects the cell wall structure, composition and degradability in Arabidopsis thaliana,"" Plant Mol. Biol.70: 283-296, Feb. 24, 2009.;;Stracke et al., ""The R2R3-MYB gene family in Arabidopsis thaliana,"" Curr. Opin. Plant Biol. 4:447-456, 2001.;;Tamagnone et al., ""The AmMYB308 and AmMYB330 transcription factors from Antirrhinum regulate phenylpropanoid and lignin biosynthesis in transgenic tobacco,"" Plant Cell 10:135-154; 1998.;;Tobias et al.,"" Analysis of expressed sequence tags and the identification of associated short tandem repeats in switchgrass,"" Theor. Appl. Genet. 111:956-964; 2005.;;Tobias et al., ""Comparative genomics in switchgrass using 61,585 high-quality expressed sequence tags,"" Plant Genome 1:111-124; Nov. 2008.;;Wang et al., ""Mutation of WRKY transcription factors initiates pith secondary wall formation and increases stem biomass in dicotyledonous plants,"" Proc. Natl. Acad. Sci. USA early edition; pp. 1-6; 2010.;;Zhao et al., ""Over-expression of the AtGA2ox8 gene decreases the biomass accumulation and lignification in rapeseed (Brassica napus L.),"" J. Zhejiang Univ. Sci. B 11:471-481; 2010.;;Zhao et al., ""SAD2, an importin beta-like protein, is required for UV-B response in Arabidopsis by mediating MYB4 nuclear trafficking,"" Plant Cell 19:3805-3818; 2007.;;Zhao et al.,""Transcriptional networks for lignin biosynthesis: more complex than we thought?"" Trends Plant Sci. 16(4):227-233, 2011.;;Zhong et al.,""Evolutionary conservation of the transcriptional network regulating secondary cell wall biosynthesis,"" Trends Plant Sci. 15: 625-632; Nov. 2010.;;Zhou et al., ""Distinct cinnamoyl CoA reductases involved in parallel routes to lignin in Medicago truncatula."" Proc. Natl. Acad. Sci. USA 107: 17803-17808; Oct. 12, 2010.",ACTIVE
627,EP,A4,EP 0625170 A4,154-568-592-141-516,1996-06-05,1996,EP 93904852 A,1993-02-04,US 9300947 W;;US 83072792 A,1992-02-04,DECORATIVE FLOOR COVERINGS HAVING THE APPEARANCE OF CERAMIC TILE AND COMPOSITIONS AND METHODS FOR MAKING SAME.,,CONGOLEUM CORP,SHALOV ALLEN A;;MORSELANDER EUGENE;;DIXON RONALD,,https://lens.org/154-568-592-141-516,Search Report,no,10,0,10,10,0,B05D1/28;;B29C70/603;;B29L2031/722;;B29L2031/732;;C08L27/06;;C08L33/06;;C08L33/10;;C08L61/28;;C08L2205/02;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/0055;;C08K5/10;;D06N3/00;;C08L27/04;;D06N7/0055;;C08L2205/02;;D06N3/06;;B05D1/28;;D06N3/08;;C08L27/06;;B29L2031/732;;B29C70/603;;B29L2031/722;;C08L33/10;;C08L33/06;;C08L61/28;;C09D127/06,B05D1/28;;B29C70/60;;C08L27/06;;C08L33/04;;C08L33/06;;C08L33/10;;C08L61/28;;C08L101/00;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/00,,0,0,,,,DISCONTINUED
628,CA,A,CA 1099643 A,167-515-230-569-681,1981-04-21,1981,CA 272073 A,1977-02-18,GB 671676 A,1976-02-20,ANALGESIC COMPOUND,"Pharmaceutical compositions are disclosed having analgesic, antipyretic and anti-inflammatory activity, the compositions including 2(carbamoyl)phenyl-2-acetoxy benzoate, which compound is absorbed into the blood and there hydrolyzed to salicyl amide and acetyl salicylic acid. Preparation of the 2(carbamoyl)phenyl-2-benzoate is also disclosed.",BEECHAM GROUP LTD,DAVIS ADRIAN F;;DIXON GORDON J A,,https://lens.org/167-515-230-569-681,Granted Patent,no,0,0,36,38,0,A61K31/60;;A61P25/04;;A61P29/00;;A61K31/60,A61K31/60;;A61P25/04;;A61P29/00;;C07C67/00;;C07C231/00;;C07C235/46,167-254,0,0,,,,EXPIRED
629,WO,A3,WO 2007/133796 A3,172-276-153-566-625,2008-02-07,2008,US 2007/0011698 W,2007-05-15,US 80072106 P,2006-05-15,METHODS AND COMPOSITIONS FOR TREATMENT OF SLEEP APNEA COMPRISING ADMINISTRATION OF AN ENDOTHELIN ANTAGONIST,"Provided herein are methods of treatment of sleep apnea by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof to a patient in need of the treatment.",ENCYSIVE PHARMACEUTICALS INC;;DIXON RICHARD A F;;GIVEN BRUCE D,DIXON RICHARD A F;;GIVEN BRUCE D,,https://lens.org/172-276-153-566-625,Search Report,yes,4,0,6,6,0,A61K9/0019;;A61K9/19;;A61K9/2018;;A61K9/2054;;A61K31/422;;A61P11/00;;A61P25/00;;A61K31/422;;A61K9/0019;;A61K9/2054;;A61K9/19;;A61K9/2018,A61K31/422;;A61K31/357;;A61K31/506;;A61K45/00;;A61P11/00,,3,2,062-511-642-826-802;;027-112-217-849-870,10.1097/00004872-199917010-00010;;10100095;;10.1161/01.hyp.0000153794.52852.04;;15738350,"PHILLIPS BRADLEY G ET AL: ""Effects of obstructive sleep apnea on endothelin-1 and blood pressure"", JOURNAL OF HYPERTENSION, vol. 17, no. 1, January 1999 (1999-01-01), pages 61 - 66, XP009092132, ISSN: 0263-6352;;BRATZ IAN N ET AL: ""Attenuated ET-B Receptor Dependent Endothelial Responses Following Intermittent Hypoxia"", FASEB JOURNAL, vol. 18, no. 4-5, 2004, & FASEB MEETING ON EXPERIMENTAL BIOLOGY: TRANSLATING THE GENOME; WASHINGTON, DISTRICT OF COLUMBIA, USA; APRIL 17-21, 2004, pages Abst. 470.6 URL - http://ww, XP000902145, ISSN: 0892-6638;;ALLAHDADI KYAN J ET AL: ""Augmented endothelin vasoconstriction in intermittent hypoxia-induced hypertension."", HYPERTENSION APR 2005, vol. 45, no. 4, April 2005 (2005-04-01), pages 705 - 709, XP002458584, ISSN: 1524-4563",PENDING
630,US,A,US 2997821 A,015-225-837-215-321,1961-08-29,1961,US 74319958 A,1958-06-19,US 74319958 A,1958-06-19,Adapter for grinding planer knives,,DIXON GEORGE A;;MILLICK SR THEODORE F,DIXON GEORGE A;;MILLICK SR THEODORE F,,https://lens.org/015-225-837-215-321,Granted Patent,no,6,5,1,1,0,B24B3/38;;B24B3/38,B24B3/38,,0,0,,,,EXPIRED
631,AU,A1,AU 2010/273587 A1,008-264-132-189-061,2012-02-02,2012,AU 2010/273587 A,2010-07-12,US 22512609 P;;US 2010/0041717 W,2009-07-13,Plants with modified lignin content and methods for production thereof,"The invention provides methods for decreasing lignin content and for increasing the level of fermentable carbohydrates in plants by down-regulation of the NST transcription factor. Nucleic acid constructs for down-regulation of NST are described. Transgenic plants are provided that comprise reduced lignin content. Plants described herein may be used, for example, as improved biofuel feedstock and as highly digestible forage crops. Methods for processing plant tissue and for producing ethanol by utilizing such plants are also provided.",SAMUEL ROBERTS NOBLE FOUND INC,ZHAO QIAO;;CHEN FANG;;DIXON RICHARD A,,https://lens.org/008-264-132-189-061,Patent Application,no,0,0,8,8,0,C07K14/415;;C07K14/415;;C12N15/8255;;C12N15/8255;;D21C5/00;;D21C5/00;;D21H23/00;;D21H23/00,C12N15/82;;A01H5/00,,0,0,,,,INACTIVE
632,US,A1,US 2008/0274528 A1,017-875-848-511-06X,2008-11-06,2008,US 94421707 A,2007-11-21,US 94421707 A;;US 86676406 P,2006-11-21,BIOFUEL PRODUCTION METHODS AND COMPOSITIONS,"The invention provides methods for increasing the level of fermentable carbohydrates in a biofuel crop plant such as alfalfa or switchgrass, by modification of the lignin biosynthetic pathway. Also provided are plants prepared by the methods of the invention. Methods for processing plant tissue and for producing ethanol by utilizing such plants are also provided.",DIXON RICHARD A;;CHEN FANG;;WANG ZENGYU,DIXON RICHARD A;;CHEN FANG;;WANG ZENGYU,THE SAMUEL ROBERTS NOBLE FOUNDATION (2008-05-20);;NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/017-875-848-511-06X,Patent Application,yes,37,32,5,5,10,C12N15/8245;;C12N15/8245;;C12N15/8255;;C12N15/8255;;Y02E50/10;;Y02E50/10,C12P7/06;;A01H1/00;;A01H5/00;;C12N5/10;;C12N15/29;;C12N15/82,435/161;;800/320.1;;800/298;;435/410;;800/284;;800/263;;536/23.6,2,1,000-183-195-092-675,10.1016/j.biortech.2004.06.025;;15588770,"Vogel, 2001, Crit. Rev. Plant Sci., 20:15-49;;Mosier et al, 2005, Bioresource Tech., 96:673-686",ACTIVE
633,WO,A2,WO 2007/106494 A2,044-774-875-986-171,2007-09-20,2007,US 2007/0006336 W,2007-03-12,US 78185306 P,2006-03-13,METHODS AND COMPOSITIONS FOR TREATMENT OF DIASTOLIC HEART FAILURE,"Provided herein are methods of treatment of diastolic heart failure (DHF) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof.",ENCYSIVE PHARMACEUTICALS INC;;GIVEN BRUCE D;;DIXON RICHARD A F,GIVEN BRUCE D;;DIXON RICHARD A F,,https://lens.org/044-774-875-986-171,Patent Application,yes,0,1,13,13,0,A61K9/0019;;A61K9/1623;;A61K9/2054;;A61K9/2095;;A61K9/2866;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61K31/194;;A61K31/401;;A61K9/19;;A61K31/357;;A61K31/194;;A61K31/506;;A61K31/401;;A61K31/501;;A61K9/0019;;A61K9/1623;;A61K9/2095;;A61K9/2866;;A61K9/2054;;A61K31/357;;A61K31/42,A61K9/19;;A61K9/20;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61K38/07;;A61K38/12;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14,,0,0,,,,PENDING
634,US,A,US 3303900 A,075-473-373-257-257,1967-02-14,1967,US 36980164 A,1964-05-25,US 36980164 A,1964-05-25,Bore control device,,DRILCO OIL TOOLS INC,KLOESEL JR JOSEPH A;;DIXON JAMES W,,https://lens.org/075-473-373-257-257,Granted Patent,no,5,22,1,1,0,E21B10/18;;E21B10/30;;E21B17/1057;;E21B10/18;;E21B10/30;;E21B17/1057,E21B10/18;;E21B10/30,,0,0,,,,EXPIRED
635,WO,A3,WO 2007/106494 A3,076-096-864-601-417,2007-12-27,2007,US 2007/0006336 W,2007-03-12,US 78185306 P,2006-03-13,METHODS AND COMPOSITIONS FOR TREATMENT OF DIASTOLIC HEART FAILURE,"Provided herein are methods of treatment of diastolic heart failure (DHF) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof.",ENCYSIVE PHARMACEUTICALS INC;;GIVEN BRUCE D;;DIXON RICHARD A F,GIVEN BRUCE D;;DIXON RICHARD A F,,https://lens.org/076-096-864-601-417,Search Report,yes,11,0,13,13,0,A61K9/0019;;A61K9/1623;;A61K9/2054;;A61K9/2095;;A61K9/2866;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61K31/194;;A61K31/401;;A61K9/19;;A61K31/357;;A61K31/194;;A61K31/506;;A61K31/401;;A61K31/501;;A61K9/0019;;A61K9/1623;;A61K9/2095;;A61K9/2866;;A61K9/2054;;A61K31/357;;A61K31/42,A61K9/19;;A61K9/20;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61K38/07;;A61K38/12;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08,,0,0,,,,PENDING
636,ES,T3,ES 2452517 T3,080-022-659-685-052,2014-04-01,2014,ES 10011358 T,1998-12-14,US 6951097 P;;US 16335198 A,1997-12-15,Composiciones y métodos para el tratamiento del trastorno de déficit de atención y del trastorno de déficit de atención e hiperactividad con metilfenidato,"Una composición para la administración por vía tópica de metilfenidato, que comprende el metilfenidato en un sistema finito y flexible, en donde el sistema comprende metilfenidato en una cantidad suficiente para permitir una tasa de suministro de desde aproximadamente 0,5 mg/24 horas hasta aproximadamente 100 mg/24 horas, con el fin de conseguir una dosis terapéuticamente efectiva en un paciente y en donde la composición comprende un polímero acrílico seleccionado entre el conjunto que se compone de polímeros acrílicos sin funcionalidades, polímeros acrílicos con funciones hidroxi y polímeros acrílicos con mínimas funcionalidades de carácter ácido, y en donde el polímero acrílico con mínimas funcionalidades de carácter ácido es un polímero acrílico que tiene no más de aproximadamente 5 % en peso de monómeros funcionales de carácter ácido, basado en el peso del polímero acrílico.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A;;KANIOS DAVID,,https://lens.org/080-022-659-685-052,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/06;;A61K31/435;;A61K9/70;;A61K31/445;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
637,CA,C,CA 1310831 C,098-906-524-867-120,1992-12-01,1992,CA 575944 A,1988-08-29,CA 575944 A;;US 94814986 A,1986-12-31,SYMPATHETIC INK AND DEVELOPER SYSTEM,"SYMPATHETIC INK AND DEVELOPER SYSTEM A sharp imaging, non-smearing system for latent imaging and subsequent visual development of printed text or the like is provided which can be used on a variety of substrates (e.g. paper, metal, cloth, synthetic resins) and is extremely stable and easy to use. The system involves first imaging a substrate with an invisible non-blur-ring, non-sublimating ink containing a dissociable nickel salt such as NiSO4, with subsequent application of a liquid developer containing a dispersed color precursor such as dimethylglyoxime which reacts with nickel ion to give a sharp, long lasting red color. The developer preferably includes an accelerator such as NaOH for accelerating the above reaction so as to make it virtually instantaneous. The system of the present invention can be used in a variety of contexts, such as in self-testing materials or novelty items.",LYNWOOD GRAPHICS LTD,WALKER HAYWOOD A JR;;DIXON MARVIN P,,https://lens.org/098-906-524-867-120,Granted Patent,no,0,0,1,2,0,,B41M3/12;;B41M5/00,D40420009    M,0,0,,,,EXPIRED
638,US,A,US 2053325 A,106-839-420-402-485,1936-09-08,1936,US 62032232 A,1932-07-01,US 62032232 A,1932-07-01,Light mixing apparatus,,HOLOPHANE CO INC,DOREY WILLIAM A;;DIXON JR HENRY M,,https://lens.org/106-839-420-402-485,Granted Patent,no,0,2,3,3,0,F21V13/02;;F21V13/02;;F21V7/005;;F21V7/005;;F21V7/09;;F21V7/09;;F21Y2103/00;;F21Y2103/00;;F21Y2113/00;;F21Y2113/00,F21V3/00;;F21V5/02;;F21V7/00;;F21V7/08;;F21V13/02,,0,0,,,,EXPIRED
639,CN,A,CN 1373660 A,132-596-370-589-083,2002-10-09,2002,CN 00809801 A,2000-07-05,US 14429299 P,1999-07-16,Method for treating chronic pain using MEK inhibitors,,WARNER LAMBERT CO,DIXON A;;LEE K;;PINNOCK R D,,https://lens.org/132-596-370-589-083,Patent Application,no,0,0,18,18,0,A61K31/00;;A61K31/166;;A61K31/192;;A61P13/12;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/04;;A61P25/32;;A61P29/00;;A61P3/02;;A61P31/12;;A61P31/18;;A61P31/22;;A61P43/00;;A61P5/14;;A61K31/166,C07D333/20;;A61K31/00;;A61K31/166;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/196;;A61K31/198;;A61K31/245;;A61K31/341;;A61K31/351;;A61K31/381;;A61K31/40;;A61K31/41;;A61K31/4409;;A61K31/4453;;A61K31/4458;;A61K31/451;;A61K31/495;;A61K31/5375;;A61P3/02;;A61P5/14;;A61P13/12;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/04;;A61P25/32;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P43/00;;C07D211/14;;C07D211/22;;C07D213/40;;C07D257/04;;C07D307/42;;C07D309/12,,0,0,,,,DISCONTINUED
640,US,B1,US 6348211 B1,144-463-606-392-081,2002-02-19,2002,US 61862600 A,2000-07-18,US 61862600 A;;US 16335198 A;;US 6951097 P,1997-12-15,Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate,"
    The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours. 
",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A;;KANIOS DAVID,,https://lens.org/144-463-606-392-081,Granted Patent,yes,11,55,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,424/448;;424/449,2,2,046-579-110-156-28X;;064-231-427-175-505,10.1002/bdd.2510100206;;2706316;;10.1097/00004583-198201000-00005;;7096827,"Patrick (1989.) ""The absorption of sustained-released methylphenidate formulations compared to an immediate-release formulation."" Biopharmaceutics & Drug Disposition 10: 165-171.;;Gualtieri et al., (1989) ""Clinical Studies of Methylphenidate Serum Levels in Children and Adults."" Journal of the American Academy of Child Psychiatry, 21: 19-26.",EXPIRED
641,US,A,US 6094980 A,024-848-037-897-464,2000-08-01,2000,US 16925498 A,1998-10-09,US 16925498 A,1998-10-09,Torsion spring tester,"A torsion spring tester incorporates a microprocessor based data acquisition/control package and special tooling. The tooling makes calibration of the tester very easy. The combination of the tooling and control package permits acquisition, storage and transfer of test data that is accurate, absolute and repeatable.",LARSON SYSTEMS INC,LARSON DAVID A;;DIXON JR WILLIAM R,LARSON SYSTEMS INC (1998-10-08),https://lens.org/024-848-037-897-464,Granted Patent,yes,4,22,2,2,0,G01N3/00;;G01N3/00;;G01N2203/0021;;G01N2203/0021;;G01N2203/021;;G01N2203/021;;G01N2203/0292;;G01N2203/0292,G01N3/00,73/161,3,0,,,"Improve the Performance of Your Torsion Springs with s SRAMA Torque Testing Machine , on or about Oct., 1998.;;Digital Torsion Spring Test System by Link Engineering Company, on or about 1990.;;Digital Torsion Spring Testers by Carlson Electronic, The Carlson Company, pp. 5 6, on or about 1990.",EXPIRED
642,US,A1,US 2013/0164381 A1,108-159-086-477-193,2013-06-27,2013,US 201313752246 A,2013-01-28,US 201313752246 A;;US 88633410 A,2010-09-20,Nanoparticle-Based Targeted Drug Delivery For In Vivo Bone Loss Mitigation,"The present invention is directed to nanoparticle-based targeted drug delivery system for treatment of bone-loss. An enantiomeric phenothiazine is formulated into an in-vivo nanoparticle delivery system which may contain bone-targeting functionality. The nanoparticle formulations and their associated influence on whole bone porosity may now also be evaluated utilizing nuclear magnetic resonance (NMR) and relaxation time profiles, and in particular, median T 2 relaxation times.",SOUTHWEST RES INST;;SOUTHWEST RES INST,DIXON HONG;;NI QINGWEN;;MCDONOUGH JOSEPH A,SOUTHWEST RESEARCH INSTITUTE (2013-07-12),https://lens.org/108-159-086-477-193,Patent Application,yes,4,1,2,2,0,A61K31/5415;;A61K31/5415;;A61K9/5153;;A61K9/5153;;A61P19/08;;B82Y5/00;;B82Y5/00;;Y10T428/2982;;Y10T428/2982,A61K9/14,424/497;;514/226.2,1,1,019-750-767-805-158,22973097;;10.2147/ijn.s32830;;pmc3433327,"Liu et al (2012). ""Polymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-active targeting ligand for doxorubicin."" International Journal of Nanomedicine, 7: 4749-4767.",DISCONTINUED
643,US,A1,US 2012/0070503 A1,131-698-448-847-953,2012-03-22,2012,US 88633410 A,2010-09-20,US 88633410 A,2010-09-20,Nanoparticle-Based Targeted Drug Delivery For In Vivo Bone Loss Mitigation,"The present invention is directed to nanoparticle-based targeted drug delivery system for treatment of bone-loss. An enantiomeric phenothiazine is formulated into an in-vivo nanoparticle delivery system which may contain bone-targeting functionality. The nanoparticle formulations and their associated influence on whole bone porosity may now also be evaluated utilizing nuclear magnetic resonance (NMR) and relaxation time profiles, and in particular, median T 2 relaxation times.",DIXON HONG;;NI QINGWEN;;MCDONOUGH JOSEPH A;;SOUTHWEST RES INST,DIXON HONG;;NI QINGWEN;;MCDONOUGH JOSEPH A,SOUTHWEST RESEARCH INSTITUTE (2010-10-12),https://lens.org/131-698-448-847-953,Patent Application,yes,3,2,2,2,0,A61K31/5415;;A61K31/5415;;A61K9/5153;;A61K9/5153;;A61P19/08;;B82Y5/00;;B82Y5/00;;Y10T428/2982;;Y10T428/2982,A61K9/50;;A61K31/5415;;A61P19/08;;B82Y5/00,424/497;;424/490;;514/226.2;;428/402;;977/773;;977/906,1,1,081-026-637-080-84X,10.1200/jco.2005.04.063;;15659502,"Kempf-Bielack et al., Journal of Clinical Oncology, 23 (3) 559-568, 2005",DISCONTINUED
644,CA,A,CA 733759 A,136-275-807-178-665,1966-05-10,1966,CA 733759D A,,CA 733759T A,,THERMOGRAPHIC DUPLICATING PROCESS,,COLUMBIA RIBBON & CARBON,NEWMAN DOUGLAS A;;DIXON HAROLD F E,,https://lens.org/136-275-807-178-665,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
645,US,A,US 3185087 A,198-317-716-547-56X,1965-05-25,1965,US 22377662 A,1962-09-14,US 22377662 A;;US 5775660 A,1960-09-22,Thermographic duplicating process,,COLUMBIA RIBBON & CARBON,NEWMAN DOUGLAS A;;DIXON HAROLD F E,INTERNATIONAL BUSINESS MACHINES CORPORATION (1981-11-02),https://lens.org/198-317-716-547-56X,Granted Patent,no,3,2,5,5,0,B41M5/04;;B41M5/04,B41M5/04,,0,0,,,,EXPIRED
646,WO,A2,WO 2008/064289 A2,025-480-979-877-698,2008-05-29,2008,US 2007/0085344 W,2007-11-21,US 86676406 P,2006-11-21,BIOFUEL PRODUCTION METHODS AND COMPOSITIONS,"The invention provides methods for increasing the level of fermentable carbohydrates in a biofuel crop plant such as alfalfa or switchgrass, by modification of the lignin biosynthetic pathway. Also provided are plants prepared by the methods of the invention. Methods for processing plant tissue and for producing ethanol by utilizing such plants are also provided.",SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;CHEN FANG;;WANG ZENGYU,DIXON RICHARD A;;CHEN FANG;;WANG ZENGYU,,https://lens.org/025-480-979-877-698,Patent Application,yes,0,50,5,5,10,C12N15/8245;;C12N15/8245;;C12N15/8255;;C12N15/8255;;Y02E50/10;;Y02E50/10,C12N15/82,,0,0,,,,PENDING
647,WO,A1,WO 1997/037484 A1,079-096-833-928-344,1997-10-09,1997,CA 9700204 W,1997-03-27,US 1433596 P,1996-03-29,MULTIMEDIA DOCUMENT CONFERENCING SYSTEM,"A multimedia documents conferencing system (10), having a data communications network (12) coupled to which are a plurality of client stations (14), a meeting server (16) and a presentation server (18). The system is embodied by a client-server based collaborative application that allows users to share multimedia documents on any of PC, MAC or UNIX based hardware platforms. A 'meet me' approach may be scaled to support a practically unlimited number of simultaneous users for sharing and accessing different multimedia documents at the same time. The client-server architecture allows centralized billing, secure document storage and secure document transmission, and centralized administration. Multiple clients may interface with the server or servers via a telecommunications network (13) and the data communications network which preferably is the Internet, whereby users at geographically dispersed locations are able to participate in a meeting session.",NORTHERN TELECOM LTD,CRADDOCK A JULIAN;;DIXON FRED;;NG CHARLES,,https://lens.org/079-096-833-928-344,Patent Application,yes,2,18,4,4,0,H04L12/1827;;H04M3/567;;H04M7/12;;H04M2203/5009;;H04M2203/5063,H04N7/15;;H04L12/18;;H04M3/56;;H04M7/12,,7,5,043-703-763-682-849;;051-249-615-390-775;;052-008-109-293-71X;;017-332-545-109-689;;057-792-497-958-122,10.1016/0169-7552(95)00078-x;;10.1016/0169-7552(90)90074-3;;10.1016/0140-3664(94)90013-2;;10.1016/0169-7552(95)00092-4;;10.1007/3-540-58759-4,"CRONJAEGER S ET AL: ""FUNCTIONAL COMPONENTS FOR MULTIMEDIA SERVICES"", PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON COMMUNICATIONS (ICC), GENEVA, MAY 23 - 26, 1993, vol. 3 OF 3, 23 May 1993 (1993-05-23), INSTITUTE OF ELECTRICAL AND ELECTRONICS ENGINEERS, pages 1563 - 1568, XP000448397;;NENTWIG L., MANHART S., SANDKUHL K.: ""Hotline and consulting in a metropolitan area network: the HotCon approach to integrated services."", COMPUTER NETWORKS AND ISDN SYSTEMS, vol. 28, no. 4, February 1996 (1996-02-01), pages 481 - 490, XP002037465;;LUBICH H P: ""MULTIMETH, A COLLABORATIVE EDITING AND CONFERENCING PROJECT"", COMPUTER NETWORKS AND ISDN SYSTEMS, vol. 19, no. 3 - 05, 1 November 1990 (1990-11-01), pages 215 - 223, XP000160601;;GOOPEEL CHUNG ET AL: ""DYNAMIC PARTICIPATION IN A COMPUTER-BASED CONFERENCING SYSTEM"", COMPUTER COMMUNICATIONS, vol. 17, no. 1, 1 January 1994 (1994-01-01), pages 7 - 16, XP000415042;;FRIVOLT T J , LANG R E , FONG M W: ""Extending WWW for synchronous collaboration"", COMPUTER NETWORK AND ISDN SYSTEMS, vol. 28, no. 1-2, December 1995 (1995-12-01), pages 69 - 75, XP002037466;;""COLLABORATIVE MULTIMEDIA ANNOTATION USING A CENTRALIZED DOCUMENT SERVER"", IBM TECHNICAL DISCLOSURE BULLETIN, vol. 38, no. 9, 1 September 1995 (1995-09-01), pages 425, XP000540317;;RIEXINGER D ET AL: ""INTEGRATION OF EXISTING APPLICATIONS INTO A CONFERENCE SYSTEM"", MULTIMEDIA TRANSPORT AND TELESERVICES. INTERNATIONAL COST 237 WORKS PROCEEDINGS, VIENNA, NOV. 13 - 15, 1994, 13 November 1994 (1994-11-13), HUTCHISON D;DANTHINE A; LEOPOLD H; COULSON G (EDS ), pages 346 - 355, XP000585312",PENDING
648,CA,A1,CA 2646438 A1,092-287-814-313-11X,2007-09-20,2007,CA 2646438 A,2007-03-12,US 78185306 P;;US 2007/0006336 W,2006-03-13,METHODS AND COMPOSITIONS FOR TREATMENT OF DIASTOLIC HEART FAILURE,,ENCYSIVE PHARMACEUTICALS INC,GIVEN BRUCE D;;DIXON RICHARD A F,,https://lens.org/092-287-814-313-11X,Patent Application,no,0,0,13,13,0,A61K9/0019;;A61K9/1623;;A61K9/2054;;A61K9/2095;;A61K9/2866;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61K31/194;;A61K31/401;;A61K9/19;;A61K31/357;;A61K31/194;;A61K31/506;;A61K31/401;;A61K31/501;;A61K9/0019;;A61K9/1623;;A61K9/2095;;A61K9/2866;;A61K9/2054;;A61K31/357;;A61K31/42,A61K9/19;;A61K9/20;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61K38/07;;A61K38/12;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08,,0,0,,,,DISCONTINUED
649,MX,A,MX 9300647 A,134-465-694-398-69X,1994-07-29,1994,MX 9300647 A,1993-02-04,US 83072792 A,1992-02-04,CUBIERTAS DECORATIVAS PARA PISOS QUE TIENEN LA APARIENCIA DE LOZETA DE CERAMICA Y COMPOSICIONES Y MEETODOS PARA HACERLAS.,"Se describen composiciones que comprenden un vehículo, un primer material polimérico orgánico fundido o fusible en dicho vehículo y un segundo material polimérico no fusible en dicho vehículo, el segundo material polimérico teniendo una temperatura de punto de ablandamiento que es menor que aproximadamente la temperatura de fusión del primer material polimérico en el plastificador, y preferiblemente dentro de aproximadamente la escala de temperatura de gelificación de dicho primer material polimérico en el vehículo.",CONGOLEUM CORP,SHALOV ALLEN A;;MORSELANDER EUGENE;;DIXON RONALD,,https://lens.org/134-465-694-398-69X,Patent Application,no,0,0,10,10,0,B05D1/28;;B29C70/603;;B29L2031/722;;B29L2031/732;;C08L27/06;;C08L33/06;;C08L33/10;;C08L61/28;;C08L2205/02;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/0055;;C08K5/10;;D06N3/00;;C08L27/04;;D06N7/0055;;C08L2205/02;;D06N3/06;;B05D1/28;;D06N3/08;;C08L27/06;;B29L2031/732;;B29C70/603;;B29L2031/722;;C08L33/10;;C08L33/06;;C08L61/28;;C09D127/06,B05D1/28;;B29C70/60;;C08L27/06;;C08L33/04;;C08L33/06;;C08L33/10;;C08L61/28;;C08L101/00;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/00,,0,0,,,,PENDING
650,KR,A,KR 20080104149 A,136-193-701-990-381,2008-12-01,2008,KR 20087022436 A,2008-09-12,US 78185306 P,2006-03-13,METHODS AND COMPOSITIONS FOR TREATMENT OF DIASTOLIC HEART FAILURE,"Provided herein are methods of treatment of diastolic heart failure (DHF) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof. ® KIPO & WIPO 2009",ENCYSIVE PHARMACEUTICALS INC,GIVEN BRUCE D;;DIXON RICHARD A F,,https://lens.org/136-193-701-990-381,Patent Application,no,0,0,13,13,0,A61K9/0019;;A61K9/1623;;A61K9/2054;;A61K9/2095;;A61K9/2866;;A61K31/194;;A61K31/357;;A61K31/401;;A61K31/42;;A61K31/501;;A61K31/506;;A61P9/00;;A61P9/02;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61K31/194;;A61K31/401;;A61K9/19;;A61K31/357;;A61K31/194;;A61K31/506;;A61K31/401;;A61K31/501;;A61K9/0019;;A61K9/1623;;A61K9/2095;;A61K9/2866;;A61K9/2054;;A61K31/357;;A61K31/42,A61K31/194;;A61K9/19;;A61K31/357;;A61K31/401,,0,0,,,,DISCONTINUED
651,US,B1,US 6210705 B1,188-677-673-899-034,2001-04-03,2001,US 16335198 A,1998-09-30,US 16335198 A;;US 6951097 P,1997-12-15,Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate,"The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.",NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A;;KANIOS DAVID,NOVEN PHARMACEUTICALS NC (1998-12-11);;NOVEN PHARMACEUTICALS INC (2002-07-10),https://lens.org/188-677-673-899-034,Granted Patent,yes,11,111,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,424/448;;424/449,2,2,046-579-110-156-28X;;064-231-427-175-505,10.1002/bdd.2510100206;;2706316;;10.1097/00004583-198201000-00005;;7096827,"Patrick 1989. ""The Absorption of Sustained-Release Methylphenidate Formulations Compared To An Immediate-Release Formulation."" Biopharmaceutics &Drug Disposition 10: 165-171.;;C. Gualtieri, et al., ""Clinical Studies of Methylphenidate Serum Levels in Children and Adults"", Jnl. of the Am. Academy of Child Psychiatry, 21, 1:19-26, 1982,, pp. 19-26.",EXPIRED
652,US,A,US 3017297 A,024-423-690-196-114,1962-01-16,1962,US 83892159 A,1959-09-09,US 83892159 A;;US 68963557 A,1957-10-11,Smudge-resistant pressure-sensitive transfer sheet and method of making,,COLUMBIA RIBBON CARBON MFG,NEWMAN DOUGLAS A;;DIXON HAROLD F E,,https://lens.org/024-423-690-196-114,Granted Patent,no,4,6,2,2,0,B41M5/10;;H01F41/16;;Y10S428/914;;Y10S428/90;;Y10T428/24983;;Y10T428/28;;Y10T428/2848;;Y10T428/31804;;Y10T428/24983;;Y10T428/28;;Y10T428/2848;;Y10T428/31804;;H01F41/16;;B41M5/10;;Y10S428/914;;Y10S428/90,B41M5/10;;H01F41/16,,0,0,,,,EXPIRED
653,WO,A9,WO 2000/004040 A9,075-016-798-427-772,2001-06-28,2001,US 9912374 W,1999-07-14,US 9269698 P,1998-07-14,"CONSTITUTIVE DISEASE RESISTANCE GENE (CDR1), AND METHODS OF USE THEREOF","Substantially purified CDR1 polypeptide, isolated polynucleotides encoding CDR1 polypeptide, vectors containing CDR1, host cells expressing CDR1, and antibodies which bind to CDR1 are all provided. The invention also provides a method of producing a genetically modified plant characterized as having increased disease resistance as compared to wild-type plants. A method is also provided for identifying novel disease resistance genes by probing a nucleic acid library with at least a fragment of a polynucleotide encoding CDR1, and selecting those clones that hybridize with the fragment.",SALK INST FOR BIOLOGICAL STUDI;;DIXON RICHARD A;;XIA YIJI;;LAMB CHRISTOPHER,DIXON RICHARD A;;XIA YIJI;;LAMB CHRISTOPHER,,https://lens.org/075-016-798-427-772,Patent Application,no,0,0,9,9,0,C07K14/415;;C12N9/63;;C07K14/415;;C12N9/50;;C12N9/63;;C12N15/8281;;C12N15/8281,C07K14/415;;C12N9/50;;C12N15/29;;C12N15/82,,0,0,,,,PENDING
654,NZ,A,NZ 597561 A,114-658-249-210-746,2013-06-28,2013,NZ 59756110 A,2010-07-12,US 22512609 P;;US 2010/0041717 W,2009-07-13,PLANTS WITH MODIFIED LIGNIN CONTENT AND METHODS FOR PRODUCTION THEREOF,"597561 PLANTS WITH MODIFIED LIGNIN CONTENT AND METHODS FOR PRODUCTION THEREOF Provided is a plant comprising a down-regulated NST transcription factor wherein the plant exhibits reduced lignin content, wherein the plant comprises a mutated NST coding sequence or a DNA molecule capable of expressing a nucleic acid sequence complementary to all or a portion of a NST coding sequence, and wherein the NST coding sequence comprises at least 80% sequence identity to a specified DNA sequence. Further provided are products derived using the transformed plants methods of increasing drought tolerance of plants using the sequences.",SAMUEL ROBERTS NOBLE FOUND INC,ZHAO QIAO;;CHEN FANG;;DIXON RICHARD A,,https://lens.org/114-658-249-210-746,Patent Application,no,0,0,8,8,0,C07K14/415;;C07K14/415;;C12N15/8255;;C12N15/8255;;D21C5/00;;D21C5/00;;D21H23/00;;D21H23/00,C12N15/82;;A01H5/00,,0,0,,,,PENDING
655,US,A,US 4040648 A,117-090-635-714-58X,1977-08-09,1977,US 64825376 A,1976-01-12,US 64825376 A;;US 64816376 A;;US 67359676 A,1976-01-12,Record sheets sensitized with reduced charge montmorillonite pigment,"A sheet coated with a reduced charge montmorillonite pigment for use in record material, especially pressure-sensitive carbonless copying systems. The pigment is produced by replacing exchangeable cations of a dioctahedral montmorillonite (exemplified by certain bentonite clays) with lithium ions, mildly heating the lithium-exchanged montmorillonite to collapse irreversibly the montmorillonite structure, and grinding the heat-treated material to pigment-size particles. The sheets produce stabilized intense images when printed with a solution of crystal violet lactone (CVL) dye precursor and thus may be used with CVL without employing secondary slow acting dyes such as benzoyl leuco methylene blue. The sheets are also useful with other colorless or substantially colorless dye precursors.",ENGELHARD MIN & CHEM,ISAAC PETER A H;;OULTON T DIXON,PHIBRO CORPORATION (1983-03-28);;ENGLEHARD CORPORATION A CORP. OF DE (1981-05-18),https://lens.org/117-090-635-714-58X,Granted Patent,yes,6,2,9,13,0,B41M5/1555;;C01P2002/72;;C01P2004/41;;C01P2004/50;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2004/80;;C01P2006/12;;C01P2006/60;;C01P2006/80;;C01P2006/82;;C09C1/42;;Y10S428/914;;Y10T428/259;;Y10T428/259;;C09C1/42;;C01P2004/61;;B41M5/1555;;C01P2004/51;;C01P2004/50;;C01P2006/82;;C01P2004/80;;C01P2006/12;;C01P2004/41;;C01P2006/80;;C01P2006/60;;C01P2002/72;;C01P2004/62;;Y10S428/914,B41M5/155;;C09C1/42,282/27.5,0,0,,,,EXPIRED
656,WO,A2,WO 1993/015135 A2,134-374-693-953-504,1993-08-05,1993,US 9300947 W,1993-02-04,US 83072792 A,1992-02-04,DECORATIVE FLOOR COVERINGS HAVING THE APPEARANCE OF CERAMIC TILE AND COMPOSITIONS AND METHODS FOR MAKING SAME,"Compositions comprising carrier, first organic polymeric material fused or fusible in said carrier and second polymeric material not fusible in said carrier, said second polymeric material having a softening point temperature which is less than about the fusion temperature of said first polymeric material in the plasticizer. It is preferred that the first polymeric material comprise vinyl resin and that the second polymeric material comprise polymer particles. The Figure (2) shows a resinous polymer sheet (10) comprising a base layer (11) comprising a relatively flat sheet backing (12). Optionally, but preferably, overlying (12) is an intermediate resinous layer (13). An ink composition (18) is deposited on the surface of the intermediate resinous layer (13). Layer (19) of composition is supplied over layer (18) of printing ink. An additional layer (20) of synthetic organic material, like vinyl and urethane polymers, is applied over decorative layer (19).",CONGOLEUM CORP,SHALOV ALLEN A;;MORSELANDER EUGENE;;DIXON RONALD,,https://lens.org/134-374-693-953-504,Patent Application,yes,0,3,10,10,0,B05D1/28;;B29C70/603;;B29L2031/722;;B29L2031/732;;C08L27/06;;C08L33/06;;C08L33/10;;C08L61/28;;C08L2205/02;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/0055;;C08K5/10;;D06N3/00;;C08L27/04;;D06N7/0055;;C08L2205/02;;D06N3/06;;B05D1/28;;D06N3/08;;C08L27/06;;B29L2031/732;;B29C70/603;;B29L2031/722;;C08L33/10;;C08L33/06;;C08L61/28;;C09D127/06,B05D1/28;;B29C70/60;;C08L27/06;;C08L33/04;;C08L33/06;;C08L33/10;;C08L61/28;;C08L101/00;;C09D127/06;;D06N3/06;;D06N3/08;;D06N7/00,,0,0,,,,PENDING
657,US,B2,US 8796509 B2,156-651-480-914-836,2014-08-05,2014,US 83458110 A,2010-07-12,US 83458110 A;;US 22512609 P,2009-07-13,Plants with modified lignin content and methods for production thereof,"The invention provides methods for decreasing lignin content and for increasing the level of fermentable carbohydrates in plants by down-regulation of the NST transcription factor. Nucleic acid constructs for down-regulation of NST are described. Transgenic plants are provided that comprise reduced lignin content. Plants described herein may be used, for example, as improved biofuel feedstock and as highly digestible forage crops. Methods for processing plant tissue and for producing ethanol by utilizing such plants are also provided.",ZHAO QIAO;;CHEN FANG;;DIXON RICHARD A;;SAMUEL ROBERTS NOBLE FOUND INC,ZHAO QIAO;;CHEN FANG;;DIXON RICHARD A,THE SAMUEL ROBERTS NOBLE FOUNDATION (2010-07-29);;NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/156-651-480-914-836,Granted Patent,yes,5,0,8,8,9,C07K14/415;;C07K14/415;;C12N15/8255;;C12N15/8255;;D21C5/00;;D21C5/00;;D21H23/00;;D21H23/00,A01H5/00;;A01H1/00;;A01H5/10;;C07H21/00;;C07H21/04;;C12N15/82;;C12N15/87,800/295;;800/284;;800/285;;800/286;;800/298;;435/468;;536/22.1;;536/24.5,16,16,027-615-569-962-310;;101-379-692-204-048;;000-047-739-257-25X;;023-302-404-832-988;;098-829-195-772-799;;022-119-665-738-576;;006-181-967-002-57X;;109-190-670-672-272;;055-003-061-629-507;;020-577-919-065-531;;079-463-304-815-987;;017-196-717-690-067;;045-599-715-620-702;;027-306-014-726-278;;095-234-496-972-741;;027-615-569-962-310,10.1007/s00425-007-0498-y;;17333250;;21883551;;10.1111/j.1365-313x.2011.04764.x;;10.1046/j.1365-313x.2001.00976.x;;11260498;;12624759;;10.1007/s00425-002-0922-2;;11202440;;10.1023/a:1026507517182;;17177787;;10.1111/j.1467-7652.2005.00159.x;;10.1073/pnas.182204199;;pmc129380;;12181491;;17770331;;10.1126/science.236.4806.1299;;10.1073/pnas.0403255101;;pmc438954;;15197260;;10.1038/nbt1316;;17572667;;pmc1077548;;10.1104/pp.95.2.426;;16668001;;pmc1820955;;17237351;;10.1105/tpc.106.047043;;10.1016/j.tplants.2005.03.009;;15882655;;10.1111/j.1365-313x.2008.03418.x;;18208518;;pmc2590737;;10.1105/tpc.108.061325;;18952777;;10.1007/s00425-007-0498-y;;17333250,"Zhong, R., E.A. Richardson, Z-H. Ye. 2007. Two NAC domain transcription factors, SND1 and NST1, function redundantly in regulation of secondary wall synthesis in fibers of Arabidopsis. Planta. 225:1603-1611.;;Wang, H., Q. Zhao, F. Chen, M. Wang, and R. A. Dixon. 2011. NAC domain function and transcriptional control of a secondary cell wall master switch. Plant J. 68:1104-1114.;;Thomas, C. L., L. Jones, D. C. Baulcombe, and A. J. Maule. 2001. Size constriants for targeting post-transcriptional gene silencing and for RNA-directed methylation in Nicotiana benthamiana using a potato virus X vector. Plant J. 25(4):417-425.;;Olhoft, P.M., L.E. Flagel, C. M. Donovan, and D.A. Somers. 2003. Efficient soybean transformation using hygromycin B selection in the cotyledonary-node method. Planta. 216:723-735.;;Zhao, Z., T. Cai, L. Tagliani, M. Miller, N. Wang, H. Pang, M. Rudert, S. Schroeder, D. Hondred, J. Seltzer, and D. Pierce. 2000. Agrobacterium-mediated sorghum transformation. Plant Mol Biol. 44:789-798.;;Nykiforuk, C. L., J. G. Boothe, E. W. Murray, R. G. Keon, H. J. Goren, N. A. Markley, and M. M. Moloney. 2006. Transgenic expression and recovery of biologically active recombinant human insulin from Arabidopsis thaliana seeds. Plant Biotech. J. 4:77-85.;;Klahre, U., P. Crete, S. A. Leuenberger, V. A. Iglesias, and F. Meins Jr. 2002. High molecular weight RNAs and small interfering RNAs induce systemic posttranscriptional gene silencing in plants. PNAS. 99(18):11981-11986).;;Kay, R., A. Chan, M. Daly, and J. McPherson. 1987. Duplication of CaMV 35S promoter sequences creates a strong enhancer for plant genes. Science. 236(4806):1299-1302.;;Guo, H. H., J. Choe, and L. A. Loeb. 2004. Protein tolerance to random amino acid change. PNAS. 101(25):9205-9210.;;Chen, F., and R. A. Dixon. 2007. Lignin modification improves fermentable sugar yields for biofuel production. Nat. Biotech. 25(7):759-761.;;Gould, J., M. Devey, O. Hasegawa, E.C. Ulian, G. Peterson, and R.H. Smith. 1991. Transformation of Zea mays L. using Agrobacterium tumefaciens and the shoot apex. Plant Physiol. 95:426-434.;;Mitsuda et al., ""NAC transcription factors, NST1 and NST3, are key regulators of the formation of secondary walls in woody tissues of arabidopsis,"" The Plant Cell, 19:270-280, 2007.;;Tadege et al., ""Insertional mutagenesis: a Swiss army knife for functional genomics of M. truncatula,"" Trends Plant Sci., 10:229-235, 2005.;;Tadege et al., ""Large-scale insertional mutagenesis using the Tnt1 retrotransposon in the model legume M. truncatula truncatula,"" Plant J., 54:335-347, 2008.;;Zhong et al., ""A battery of transcription factors involved in the regulation of secondary cell wall biosynthesis in arabidopsis,"" The Plant Cell, 20:2763-2782, 2008.;;Zhong et al., ""Two NAC domain transcription factors, SND1 and NST1, function redundantly in regulation of secondary wall synthesis in fibers of arabidopsis,"" Planta, 225:1603-1611, 2007.",ACTIVE
658,US,B2,US 9309528 B2,181-174-605-678-038,2016-04-12,2016,US 94421707 A,2007-11-21,US 94421707 A;;US 86676406 P,2006-11-21,Biofuel production methods and compositions,"The invention provides methods for increasing the level of fermentable carbohydrates in a biofuel crop plant such as alfalfa or switchgrass, by modification of the lignin biosynthetic pathway. Also provided are plants prepared by the methods of the invention. Methods for processing plant tissue and for producing ethanol by utilizing such plants are also provided.",DIXON RICHARD A;;CHEN FANG;;WANG ZENGYU;;SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;CHEN FANG;;WANG ZENGYU,THE SAMUEL ROBERTS NOBLE FOUNDATION (2008-05-20);;NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/181-174-605-678-038,Granted Patent,yes,40,1,5,5,10,C12N15/8245;;C12N15/8245;;C12N15/8255;;C12N15/8255;;Y02E50/10;;Y02E50/10,A01H5/00;;A01H5/10;;C12N15/82;;C12P7/06,,71,53,029-409-447-008-102;;000-183-195-092-675;;058-012-914-815-39X;;031-132-193-330-865;;060-435-151-785-714;;064-020-317-605-308;;078-927-467-320-053;;009-568-658-490-747;;085-168-531-128-752;;021-831-087-698-826;;031-271-028-591-463;;157-182-940-978-855;;053-628-300-009-637;;060-178-055-146-889;;037-459-624-301-496;;044-160-688-806-618;;016-686-242-147-938;;019-568-606-038-655;;067-999-241-399-305;;018-667-643-178-785;;074-892-027-920-511;;122-319-270-282-844;;055-350-423-950-581;;101-055-519-489-966;;088-801-202-079-144;;103-681-277-448-950;;073-093-137-316-588;;080-460-585-508-028;;142-927-301-440-29X;;058-145-297-843-203;;092-736-530-463-774;;040-874-788-299-624;;036-455-388-275-446;;029-409-447-008-102;;095-632-990-350-570;;000-830-989-125-916;;142-495-803-547-445;;049-926-193-459-915;;032-802-996-819-548;;040-264-748-392-762;;002-379-420-271-205;;064-056-558-088-49X;;057-061-926-898-481;;083-000-996-514-985;;017-462-855-729-176;;092-026-802-374-892;;033-354-698-623-379;;020-577-919-065-531;;056-760-206-406-932;;067-609-810-409-045;;118-133-181-801-147;;025-622-930-909-434;;029-227-844-003-412,pmc1283808;;10.1073/pnas.0505749102;;16263933;;10.1016/j.biortech.2004.06.025;;15588770;;10.1080/10409230391036757;;10.1080/10409230390242443;;14551235;;10.2135/cropsci1988.0011183x002800030026x;;10.1146/annurev.arplant.47.1.445;;15012297;;10.2135/cropsci1987.0011183x002700050021x;;10.1023/a:1004176714883;;10.1111/j.1365-313x.2006.02857.x;;16972868;;10.1385/abab:130:1:427;;16915659;;pmc160898;;10.2307/3870052;;10.1105/tpc.7.7.987;;7640530;;15012210;;10.1146/annurev.arplant.50.1.245;;8955630;;10.1016/s0378-1119(96)00327-7;;10.2172/985404;;10.1016/0960-8524(95)00122-0;;10.1016/s0960-8524(97)81606-9;;10.1007/3-540-49194-5_9;;10533436;;10.2135/cropsci1992.0011183x003200030046x;;15255476;;10.1016/j.crvi.2004.02.009;;10.1021/jf970029v;;10.1023/a:1012278106147;;11708655;;10.1016/j.biombioe.2004.09.002;;pmc490038;;10.1105/tpc.020297;;15161961;;8582870;;10.2527/1995.7392774x;;10.2527/jas1986.6261703x;;3733564;;10.1007/3-540-49194-5_5;;10322202;;10.1016/s1369-5266(99)80030-2;;10.1016/j.copbio.2005.08.009;;16154338;;10.1016/s0961-9534(97)10066-6;;10.2134/agronj2001.934896x;;10.1016/0141-0229(95)00157-3;;10.1038/nbt0602-607;;12042866;;10.1007/s11053-005-4679-8;;16421107;;10.1074/jbc.m511598200;;pmc1283808;;10.1073/pnas.0505749102;;16263933;;10.1007/s002990000274;;30759912;;10322194;;10.1016/s1369-5266(99)80029-6;;10.1038/11678;;10429234;;10.2135/cropsci2002.2080;;16701991;;10.1016/j.copbio.2006.05.003;;10.1016/s0960-8524(01)00212-7;;12058826;;8119592;;10.1007/bf01435039;;10.1038/nbt0406-395;;16601716;;10.2172/777678;;10.1016/0378-1127(91)90133-g;;10.1146/annurev.energy.24.1.189;;10.1007/s001220200015;;12579437;;17621299;;10.1038/nbt0707-746;;10.1038/nbt1316;;17572667;;10.1016/j.plantsci.2007.11.009;;10.1016/j.copbio.2008.02.014;;18403196;;10.1016/s0735-2689(98)00360-8;;10.1002/(sici)1097-0010(19990501)79:6<922::aid-jsfa307>3.0.co;2-9;;10.1007/bf01974090,"Reddy et al 2005 PNAS, 102:16573-16578, provided by Applicant.;;Vogel, 2001, Crit. Rev. Plant Sci., 20:15-49.;;Mosier et al, 2005, Bioresource Tech., 96:673-686.;;""2006 Awards,"" Plant Feedstocks Genomics for Bioenergy, U.S. Department of Energy Office of Science, genomics.energy.gov., Press Release, Aug. 9, 2006.;;""Foundation wins grant for research,"" The Oklahoman, Nov. 22, 2005.;;""USDA awards $12.6 million for biomass research and development,"" State News Service, Oct. 6, 2005.;;Anderson et al., Development of Biotechnological Resources for Biofuels-Project Proposal, U.S. Department of Agriculture, cris.csrees.usda.gov/cgi-bin/starfinder/22651/crisassist.txt, undated.;;Badger, ""Ethanol from cellulose: a general review,"" In: Trends in New Crops and New Uses, Janick et al. Eds., ASHS Press, Alexandria, VA, 2002.;;Baucher et al., ""Lignin: genetic engineering and impact on pulping,"" Crit. Rev. Biochem Mol. Biol., 38(4):305-350, 2003.;;Buxon et al., ""Lignin constituents and cell-wall digestibility of grass and legume stems,"" Crop Sci., 28:553-558, 1988.;;Carpita, ""Structure and biogenesis of the cell walls of grasses,"" Annu. Rev. Plant Physiol. Plant Mol. Biol., 47-445-476, 1996.;;Casler, ""In vitro digestibility of dry matter and cell wall constituents of smooth bromegrass forage,"" Crop Sci., 27:931-934, 1987.;;Chen et al., ""Biotechnology in trees: towards improved paper pulping by lignin engineering,"" Euphytica, 118:185-195, 2001.;;Chen et al., ""Multi-site genetic modulation of monolignol biosynthesis suggests new routes for formation of syringyl lignin and wall-bound ferulic acid in alfalfa(Medicago sativa L.),"" The Plant Journal, 48(1):113-124, 2006.;;Comis, ""Scientists study feasibility of switchgrass for energy production,"" U.S. Department of Agriculture, Mar. 10, 2006.;;Davison et al., ""Variation of S/G ratio and lignin content in a populus family influences the release of xylose by dilute acid hydrolysis,"" In: Applied Biochemistry and Biotechnology, Humana Press, pp. 427-435, 2006.;;Delmer et al., ""Cellulose biosynthesis,"" The Plant Cell, 7:987-1000, 1995.;;Delmer, ""Cellulose biosynthesis: exciting times for a difficult field of study,"" Annu. Rev. Plant Physiol. Plant Mol. Biol., 50:245-276, 1999.;;Dixon et al., ""Metabolic engineering: prospects for crop improvement through the genetic manipulation of phenylpropanoid biosynthesis and defense responses-a review,"" Gene 179:6171, 1996.;;Dixon et al., ""Systematic modification of monolignol pathway gene expression for improved lignocellulose utilization,"" Plant Feedstocks Genomics for Bioenergy, U.S. Department of Energy Office of Science, genomics.energy.gov., undated.;;Duff et al., ""Bioconversion of forest products industry waste cellulosics to fuel ethanol: a review,"" Bioresource Technology, 55(1):1-33, 1996.;;Esteghlalian et al., ""Modeling and optimization of the dilute-sulfuric-acid pretreatment of corn stover, poplar and switchgrass,"" Bioresource Technology, 59:129-136, 1997.;;GenBank Database Accession No. AF153824, Jul. 1, 2001.;;Gong et al., ""Ethanol production from renewable resources,"" Advances in Biochemical Engineering/Biotechnology, 65:207-241, 1999.;;Grabber et al., ""Digestion kinetics of parenchyma and sclerenchyma cell walls isolated from orchardgrass and switchgrass,"" Crop Sci., 32:806-810, 1992.;;Grabber et al., ""Genetic and molecular basis of grass cell-wall degradability. I. Lignin-cell wall matrix interactions,"" C.R. Biologies, 327:455-465, 2004.;;Grabber et al., ""p-hydroxyphenyl, guaiacyl, and syringyl lignins have similar inhibitory effects on wall degradability,"" J. Agric. Food Chem., 45:2530-2532, 1997.;;Guo et al., ""Improvement of in-rumen digestibility of alfalfa forage by genetic manipulation of lignin O-methyltransferases,"" Transgenic Res., 10:457-464, 2001.;;Hamelinck et al., ""Ethanol from lignocellulosic biomass: techno-economic performance in short-, middle- and long-term,"" Biomass & Bioenergy, 28:384-410, 2005.;;Hoffmann et al., ""Silencing of hydroxycinnanioyl-coenzyme a shikimate/quinate hydroxycinnamoyltransferase affects phenylpropanoid biosynthesis,"" The Plant Cell, 16:1446-1465, 2004.;;Jung et al., ""Characteristics of plant cell walls affecting intake and digestibility of forages by ruminants,"" J. Anim. Sci. 73:2774-2790, 1995.;;Jung et al., ""Genetic manipulation of cell walls-Identification of cell wall traits that can be manipulated to improve forage digestibility,"" U.S. Dairy Forage Research Center, 1996 Informational Conference with Dairy and Forage Industries, 1996.;;Jung et al., ""Influence of lignin on digestibility of forage cell wall material,"" J. Anim. Sci., 62:1703-1712, 1986.;;Lara, ""Nation taking a closer look at fossil fuel alternatives,"" Southwest Farm Press, Nov. 3, 2005.;;Lee et al., ""Dilute-acid hydrolysis of lignocellulosic biomass,"" Advances in Biochemical Engineering/Biotechnology, 65:93-115, 1999.;;Lewin, ""Switchgrass: the super plant saviour?-President touts alternative fuel ingredient, but when will it be ready,"" Good Morning America, ABCNews.com, Feb. 1, 2006.;;Lewis, ""A 20th century roller coaster ride: a short account of lignification,"" Current Opinion in Plant Biology, 2:153-162, 1999.;;Lynd et al., ""Consolidated bioprocessing of cellulosic biomass: an update,"" Current Opinion in Biotechnology, 16:577-583, 2005.;;McLaughlin et al., ""Evaluating environmental consequences of producing herbaceous crops for bioenergy,"" Biomass and Bioenergy, 14(4):317-324, 1998.;;McLaughlin et al., ""Evaluating physical, chemical, and energetic properties of perennial grasses as biofuels,"" Proc. Bioenergy '96, The Seventh National Bioenergy Conference: Partnerships to Develop and Apply Biomass Technologies, Nashville, Tennessee, Sep. 15-20, 1996.;;Muir et al., ""Biomass production of 'alamo' switchgrass in response to nitrogen, phosphorus, and row spacing,"" Agron. J., 93:896-901, 2001.;;Olsson et al., ""Fermentation of lignocellulosic hydrolysates for ethanol production,"" Enzyme and Microbial Technology, 18:312-331, 1996.;;Pilate et al., ""Field and pulping performances of transgenic trees with altered lignification,"" Nature Biotechnology, 20:607-612, 2002.;;Pimentel et al., ""Ethanol production using corn, switchgrass, and wood; Biodiesel production using soybean and sunflower,"" Natural Resources Research, 14(1):65-75, 2005.;;Ralph et al., ""Effects of coumarate 3-hydroxylase down-regulation on lignin structure,"" J. Biol. Chem., 281(13):8843-8853, 2006.;;Reddy et al., ""Targeted down-regulation of cytochrome P450 enzymes for forage quality improvement in alfalfa (Medicago sativa L.),"" Proc. Nat. Acad. Sci., 102(46):16573-16578, 2005.;;Richards et al., ""Construction of a GFP-BAR plasmid and its use for switchgrass transformation,"" Plant Cell Reports, 20:48-54, 2001.;;Sederoff et al., ""Unexpected variation in lignin,"" Current Opinion in Plant Biology, 2:145-152, 1999.;;Sederoff, ""Building better trees with antisense,"" Nature Biotechnology, 17:750-751, 1999.;;Shadle et al., ""Effects of Down-regulation HCT on lignin in alfalfa,"" Phytochemical Society of North America Annual Meeting, Oxford, MS, Jul. 8-12, 2006.;;Somleva et al., ""Agrobacterium-mediated genetic transformation of switchgrass,"" Crop Sci., 42:2080-2087, 2002.;;Sticklen, ""Plant genetic engineering to improve biomass characteristics for biofuels,"" Current Opinion in Biotechnology, 17:315-319, 2006.;;Sun et al., ""hydrolysis of lignocellulosic materials for ethanol production: a review,"" Bioresource Technology, 83:1-11, 2002.;;Tabe et al., ""Genetic engineering of grain and pasture legumes for improved nutritive value,"" Genetica, 90:181-200, 1993.;;Talukder, ""Low-lignin wood-a case study,"" Nature Biotechnology, 24(4):395-396, 2006.;;Vogel et al., ""Genetic improvement of switchgrass and other herbaceous plants for use as biomass fuel feedstock-Final Report,"" U.S. Department of Energy, Office of Fuels Development, Bioenergy Feedstock Development Program, Environmental Sciences Division, Oak Ridge National Laboratory, Oak Ridge Tennessee, 2000.;;Whetten et al., ""Genetic engineering of wood,"" Forest Ecology and Management, 43:301-316, 1991.;;Wilson et al., ""Genetics and properties of cellulases,"" Advances in Biochemical Engineering/Biotechnology, 65:1-21, 1999.;;Wyman, ""Biomass ethanol: technical progress, opportunities, and commercial challenges,"" Annu. Rev. Energy Environ., 24:189-226, 1999.;;Casler et al., ""Genetic modification of lignin concentration affects fitness of perennial herbaceous plants,"" Theor Appl Genet, 104:127-131, 2002.;;Chapple et al., ""Loosening lignin's grip on biofuel production,"" Nature Biotechnology, 25(7):746-748, 2007.;;Chen et al., ""Lignin modification improves fermentable sugar yields for biofuel production,"" Nature Biotechnology, 25(7):759-761, 2007.;;Dixon et al., ""Expanding the utility of Alfalfa,"" In Vitro Cellular & Developmental Biology Animal, 42(Suppl. S.):15A, 2006.;;EMBL Database Accession No. CA186689, dated Sep. 25, 2003.;;EMBL Database Accession No. DN143567, dated Feb. 20, 2005.;;Gressel et al., ""Transgenics are imperative for biofuel crops,"" Plant Science, 174:246-263, 2008.;;Nakashima et al., Down-regulation of key enzymes in the monolignol pathway effects on lignin composition in specific cell types of alfalfa (Medicago sativa L.), Phytochemical Society of North America, 2006 PSNA Annual Meeting, Oxford, Mississippi, Jul. 8-12, 2006.;;Weng et al., ""Emerging strategies of lignin engineering and degradation for cellulosic biofuel production,"" Current Opinion in Biotechnology, 19:166-172, 2008.;;Baucher, M.D. et al. Biosynthesis and genetic engineering of lignin, Crit. Rev. Plant. Sci. 17:125-197, 1998.;;Jung, H.G. et al. Impact of lignin composition on cell-wall degradability in an Arabidopsis mutant. J. Sci. Food Agric. 79:922-928, 1999.;;Ni, W. et al. Reduced lignin in transgenic plants containing a caffeic acid O-methyltransferase antisense gene. Transgenic Res. 3:120-126, 1994.",ACTIVE
659,HK,A1,HK 1210431 A1,064-932-168-942-395,2016-04-22,2016,HK 15111290 A,2011-12-19,US 10947408 P,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,,ABLYNX NV,FERNANDEZ JASON E E;;DIXON DANIEL A A;;PAULSON ANDREA,,https://lens.org/064-932-168-942-395,Patent Application,no,0,0,44,44,0,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K/;;A61P/,,0,0,,,,PENDING
660,US,B1,US 6274230 B1,008-821-817-536-379,2001-08-14,2001,US 34027899 A,1999-06-25,US 34027899 A,1999-06-25,Articles of composite construction and method of producing patterns thereon,A process for producing sharp surface visible patterns on composite articles formed of resin coated reinforcing strands employs a liquid uncured resin having a coloring component therein to produce an opaque resin of light color to mask the color of the reinforcing strands. An absorbent surface veil is applied to the surface of the article before curing the resin to produce an absorbent opaque surface layer of light color into which a pattern of contrasting color is then transferred by sublimating an ink or dye pattern from a pattern carrier into the opaque resin impregnated surface layer and veil. Articles ready for application of the surface pattern thereto by sublimation may be produced using pultrusion or hand lay-up methods. Distribution of the surface pattern partially or entirely through the thickness of the surface layer results in an article having a surface in which the pattern remains sharply visible despite surface wear.,EASTON JAMES D INC,SARRELONGUE DIDIER;;ROWSELL EDWIN A;;DIXON PHILIP A;;YAN PETER,JAS. D. EASTON INC (1999-06-15);;EASTON TECHNICAL PRODUCTS INC (2006-03-16),https://lens.org/008-821-817-536-379,Granted Patent,yes,5,34,1,1,0,B29C67/0007;;B29C70/525;;B32B17/067;;Y10T428/2925;;Y10T428/2936;;Y10T428/2933;;Y10T428/249947;;Y10T428/249929;;Y10T428/249952;;Y10T428/249945;;Y10T428/249928;;Y10T428/249943;;Y10T428/2925;;Y10T428/2936;;Y10T428/2933;;Y10T428/249947;;Y10T428/249929;;Y10T428/249952;;Y10T428/249945;;Y10T428/249928;;Y10T428/249943;;B32B17/067;;B29C67/0007;;B29C70/525,B29C67/00;;B29C70/52;;B32B17/12,428/293.7;;428/293.4;;428/298.4;;428/299.1;;428/299.11;;428/299.7;;428/301.4;;428/371;;428/375;;428/377,0,0,,,,EXPIRED
661,CN,B,CN 102271707 B,018-765-791-680-899,2015-04-08,2015,CN 200980153163 A,2009-10-29,US 2009/0062611 W;;US 10947408 P,2008-10-29,Formulations of single domain antigen binding molecules,,ABLINKS N V,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,ABLYNX N. V. (2012-05-17),https://lens.org/018-765-791-680-899,Granted Patent,no,0,0,44,44,0,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K39/395;;A61K9/00;;A61K9/19;;A61P1/00;;A61P1/04;;A61P17/06;;A61P19/02;;A61P19/08;;A61P29/00;;A61P37/02;;G06F19/00;;G06Q90/00,,0,0,,,,ACTIVE
662,WO,A2,WO 2010/077422 A2,038-895-663-168-971,2010-07-08,2010,US 2009/0062611 W,2009-10-29,US 10947408 P,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,"The invention relates to formulations of single domain antigen binding molecules, e.g. , nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g. , as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g. , TNF-associated disorders, are also disclosed.",WYETH LLC;;FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,,https://lens.org/038-895-663-168-971,Patent Application,yes,0,61,44,44,10,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,,,0,0,,,,PENDING
663,YU,A,YU 30691 A,047-734-411-295-703,1994-01-20,1994,YU 30691 A,1991-02-20,US 48211890 A,1990-02-20,HERBICIDI NA BAZI 6-ARIL-2-SUPSTITUISANE BENZOEVE KISELINE,"HERBICIDI NA BAZI 6-ARIL-2-SUPSTITUISANE BENZOEVE KISELINE, jedinjenje formule: u kojoj su: A O, S, ili -N-R2 u kojoj je R2 vodonik, alkil, -C(O)-NH2 ili -C(O)alkil; B je -CH-, -CR4-ili -N-; R i R1 su nezavisno alkil, alkoksi, haloalkoksi, halogen ili alkilamino; i R4 je vodonik, alkil, fenil, nitro, cijano, amino, alkoksikarbonil ili halogen; M je vodonik, alkil, alkenil, alkinil, fenilalkil, haloalkil, cijanoalkil, alkiltioalkil, dialkilaminoalkil, alkilsulfonilalkil, alkoksiak-robonilalkil, karboksialkil, di (alkoksikarbonil) alkil, dialkilaminokarbonilalkil, dialkilidenamino, alkiltioalkilidenamino, opciono alkil supstituisani amonijum, opciono hidroksialkil supstituisani amonijum, katjon alkalnog ili zemnoalkalnog metala, ili fenil koji je opciono supstituisan sa nitro, halo, alkil, haloalkil ili alkoksi; i Q je gde su X, Y i P nezavisno vodonik, halogen, nižialkil, nižialkoksi, niži haloalkil, niži alkiltio, niži alkilsulfonil, alkilsulfonilamino, alkilsul-foniloksi, arisulfoniloksi, di(arilsulfonil)amino, benzilamino, alkilkarbonilamino, aminokarbonilamino, alkoksikarbonil, alkilkar-boniloksi, alkilsulfonilamino, fenilsulfonilamino, soli naznačenih jedinjenjasa kiselinama, niži alkenil, niži alkinil, niži alkeniloksi, niži alkiniloksi, cijano, nitro ili amino, ili X i Y zajednički formiraju C1 do C3 alkilendioksi-heterociklični prsten; ili aromatični heterocikl koji je izabran do tiofena, furana, pirola, pirazola, izoksazola, izotiazola, imidazola, oksazola, tiazola, oksadiazola, tiadiazola, tri-azola, tetrazola, piridina, pirimidina, pirazina, piridazina i triazina.",FMC CORP,MUGUGESAN N;;DIXON J A;;BARNES K O,,https://lens.org/047-734-411-295-703,Patent Application,no,0,0,9,35,0,A01N43/54;;A01N43/66;;C07D239/60;;C07D251/34;;C07D401/12;;C07D409/12,A01N43/54;;A01N43/66;;C07D239/60;;C07D251/34;;C07D401/12;;C07D409/12,,0,0,,,,PENDING
664,US,A1,US 2010/0137213 A1,057-173-183-554-501,2010-06-03,2010,US 60855309 A,2009-10-29,US 60855309 A;;US 10947408 P,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,"The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.",WYETH CORP,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,ABLYNX N.V (2011-11-18);;WYETH LLC (2009-12-18),https://lens.org/057-173-183-554-501,Patent Application,yes,3,47,44,44,10,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K38/16;;C12P21/06;;G01N11/00;;G06Q90/00,514/12;;435/69.1;;73/53.01;;705/500,0,0,,,,INACTIVE
665,WO,A1,WO 2008/094325 A1,081-723-977-776-978,2008-08-07,2008,US 2007/0082852 W,2007-10-29,US 88730707 P;;US 68117507 A,2007-01-30,OPEN SYSTEM ACCOUNT REMOTE VALIDATION FOR ACCESS,"At each of a plurality of point of sale terminals (POS) of a transit system, for each of a plurality of riders, where each rider seeks access into a facility of the transit facility by using a payment device issued by an issuer in a payment system, data is read from the payment device. The data can include an identifier for an account issued by an issuer. For each such access, a communication including the account is addressed to a network address of a system remote from the payment processing system and remote from each of POS terminals. A response to the communication is received that includes information as to the validation of the access based upon the account being on a list keep by remote system. When the received information contains the validation of the access, the rider is permitted access to the facility of the transit system and the payment device is unchanged for the fare of the access to the facility of the transit system.",VISA USA INC;;HAMMAD AYMAN A;;DIXON PHIL;;EL-AWADY KHALID,HAMMAD AYMAN A;;DIXON PHIL;;EL-AWADY KHALID,,https://lens.org/081-723-977-776-978,Patent Application,yes,2,0,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/14;;G06Q20/36;;G07B15/02,,0,0,,,,PENDING
666,AU,A1,AU 2009/285705 A1,083-847-389-061-973,2010-03-04,2010,AU 2009/285705 A,2009-08-27,US 9300608 P;;US 2009/0055188 W,2008-08-29,Epicatechin glucosyltransferase,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;PANG YONGZHEN;;PEEL GREGORY J,,https://lens.org/083-847-389-061-973,Patent Application,no,0,1,6,6,0,C12N15/8243;;C12N15/8243;;C12N9/1051;;C12N9/1051,C07K14/415;;A01H5/00;;A61K38/45;;C12N9/10;;C12N15/82,,0,0,,,,INACTIVE
667,US,A1,US 2007/0163700 A1,098-600-434-494-357,2007-07-19,2007,US 70452007 A,2007-03-23,US 70452007 A;;GB 0003713 A;;GB 0004245 A;;GB 0018404 A;;GB 0101372 A;;US 20406102 A;;GB 0100647 W,2000-02-17,Fabrication of hoses or other elongated articles,"Armouring tape ( 102 ) for wrapping around a hose ( 300 ) during its fabrication by a hose-wrapping machine ( 200; 400 ). The tape ( 102 ) is coiled into a roll ( 100 ) having a hollow core ( 109 ) from which the tape ( 102 ) is unwound to be wrapped onto the hose ( 300 ). Th hose-wrapping machine ( 200; 400 ) rotatably mounts the roll ( 100 ) with the hose ( 300 ) passing through the roll core ( 109 ), the roll axis ( 108 ) being skewed to the hose axis ( 304 ) by the helix angle at which the tape ( 102 ) is to be wrapped onto and along the hose ( 300 ). The hose ( 300 ) is moved longitudinally through the longitudinally static roll ( 100 ) and at the same time, the roll ( 100 ) is rotated around the longitudinal axis ( 304 ) of the non-rotating hose ( 300 ). The armouring tape ( 102 ) unwinds from the inside ( 109 ) of the roll onto and along the hose ( 300 ) so as to wrap the hose ( 300 ) with a uniform helix of armouring tape ( 102 ). The use of a tape ( 102 ) containing an elastomer-enbedded array of armouring cables ( 104 ) enables armouring wires and elastomer layers to be applied without a stabilising layer of fabric, and greatly simplifies setting-up of machinery for hose fabrication. The use of a tape roll ( 100 ) which can be unwound from its inside ( 109 ) enables hoses to be wrapped without having to orbit rolls that are very large and heavy.",DIXON-ROCHE KEITH;;BOURGEOIS LUC JULIEN P A,DIXON-ROCHE KEITH;;BOURGEOIS LUC JULIEN P A,,https://lens.org/098-600-434-494-357,Patent Application,yes,7,0,19,23,0,B29C53/582;;B29C53/68;;B29C53/8016;;B29C63/0021;;B29C63/105;;B29C2053/8025;;B29L2023/005;;B32B1/08;;B32B37/00;;B65H81/08;;F16L11/081;;F16L11/24;;B29C48/09;;B29C48/10;;B29C48/0018;;B29C48/151;;B29C48/156;;B29C48/21;;Y10T428/2913;;Y10T428/2913;;B32B2305/08;;B32B27/06;;B32B25/04;;B32B2597/00;;B32B1/08;;F16L11/24;;B29C63/0021;;B29C53/8016;;B29C63/105;;B29C53/68;;B65H81/08;;B29C2053/8025;;B29C53/582;;B29L2023/005;;F16L11/081;;B32B37/00;;B29C48/09;;B29C48/21;;B29C48/156;;B29C48/151;;B29C48/0018;;B29C48/10,B65H81/00;;A61M39/00;;B29C48/09;;B29C48/10;;B29C48/151;;B29C48/156;;B29C48/21;;B29C53/58;;B29C53/68;;B29C53/80;;B29C63/10;;B32B1/08;;B65H81/08;;F16L11/08;;F16L11/24,156/184;;428/364,0,0,,,,DISCONTINUED
668,DE,T2,DE 69822199 T2,096-548-448-709-63X,2005-02-17,2005,DE 69822199 T,1998-12-14,US 6951097 P;;US 16335198 A;;US 9826560 W,1997-12-15,ARZNEIMITTEL UND VERFAHREN ZUR BEHANDLUNG VON AUFMERKSAMKEITSSTÖRUNGEN UND AUFMERKSAMKEITS-/HYPERAKTIVITÄTSSTÖRUNGEN MIT METHYLPHENIDAT,,NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A;;KANIOS DAVID P,,https://lens.org/096-548-448-709-63X,Granted Patent,no,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,0,0,,,,EXPIRED
669,EP,A4,EP 2255448 A4,096-396-050-007-208,2012-05-30,2012,EP 09714157 A,2009-02-25,US 2009/0035172 W;;US 3107208 P,2008-02-25,VEHICLE SECURITY AND MONITORING SYSTEM,,RECOVERY SYSTEMS HOLDINGS LLC,BEVACQUA KURT;;OSMAN MARK A;;DIXON STEVEN C,,https://lens.org/096-396-050-007-208,Search Report,no,4,0,7,7,0,B60R25/102;;B60R25/33;;B60R2025/1016;;B60R2325/205;;G01S5/0027;;H04W8/24;;H04W64/00;;H04W12/126;;B60R25/33;;G01S5/0027;;B60R2025/1016;;H04W64/00;;B60R25/102;;B60R2325/205;;H04W8/24;;H04W12/126,H04B1/38;;B60R25/10;;G01S5/02;;G08G1/123;;H04B17/00;;H04W64/00,,0,0,,,,DISCONTINUED
670,US,B2,US 9993552 B2,114-964-235-017-799,2018-06-12,2018,US 201615041690 A,2016-02-11,US 201615041690 A;;US 60855309 A;;US 10947408 P,2008-10-29,Formulations of single domain antigen binding molecules,"The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.",ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,ABLYNX N.V (2011-11-18);;WYETH LLC (2009-12-18),https://lens.org/114-964-235-017-799,Granted Patent,yes,179,1,44,44,10,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,C07K16/00;;A61K9/00;;A61K9/16;;A61K9/19;;A61K39/00;;A61K39/395;;A61K47/10;;A61K47/26;;C07K1/00;;C07K16/18;;C07K16/24;;C12P21/08;;G01N33/15;;G06Q99/00,,117,103,010-540-999-593-024;;056-201-471-905-934;;028-862-168-091-90X;;090-754-759-154-175;;045-375-597-992-763;;014-221-462-042-262;;005-585-893-014-176;;090-202-835-731-435;;002-688-704-634-679;;178-753-379-974-063;;065-832-213-953-842;;085-597-883-496-167;;015-058-913-193-123;;049-134-753-209-354;;002-664-741-683-318;;021-281-191-729-211;;091-234-354-982-068;;029-611-134-469-353;;039-508-259-975-855;;078-227-590-332-589;;142-625-978-671-635;;028-677-787-189-119;;096-246-275-104-11X;;107-893-263-643-528;;048-980-207-062-312;;167-193-534-403-139;;030-063-586-948-460;;084-724-411-649-711;;043-796-369-932-016;;139-162-774-140-879;;002-236-302-730-599;;181-848-098-428-701;;085-277-440-303-853;;064-136-916-388-59X;;034-598-659-452-885;;064-312-847-804-27X;;050-959-366-576-084;;092-986-814-359-292;;029-366-136-077-007;;047-697-041-421-417;;047-697-041-421-417;;125-439-449-787-91X;;075-144-617-501-360;;024-160-272-335-60X;;005-602-212-993-893;;028-948-486-931-641;;104-212-297-137-759;;088-505-020-666-376;;020-026-345-586-213;;002-422-273-022-428;;062-353-036-290-103;;008-561-023-298-876;;072-677-789-622-276;;024-042-191-114-154;;051-207-145-128-792;;016-841-733-546-324;;059-116-449-512-23X;;030-607-398-087-475;;023-676-781-371-861;;002-584-557-858-587;;129-021-293-134-556;;026-164-216-541-151;;032-728-154-591-070;;038-140-492-359-304;;042-709-342-743-632;;037-245-807-598-049;;015-573-402-710-703;;071-953-263-224-312;;013-389-204-869-42X;;011-689-670-898-65X;;008-920-774-642-932;;056-891-153-615-422;;115-568-540-673-612;;083-665-446-968-989;;027-477-313-726-928;;001-930-950-214-65X;;051-875-809-608-013;;004-149-017-447-708;;134-602-023-001-741;;069-917-507-345-672;;078-075-414-981-82X;;014-998-780-825-054;;037-316-452-701-945;;026-553-967-491-457;;069-778-338-173-349;;055-933-943-437-663;;088-581-950-418-154;;003-707-911-471-072;;055-286-836-842-470;;005-648-278-768-326;;092-023-577-402-127;;021-641-900-032-887;;022-375-749-274-329;;002-308-039-268-236;;082-830-103-052-514;;025-930-820-482-18X;;003-653-620-396-243;;074-817-300-512-106;;088-267-117-025-726;;121-076-763-383-141;;038-371-868-499-013;;015-692-072-798-109;;011-068-199-883-509,10.1385/1-59259-816-1:067;;15173609;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1023/a:1015825027737;;2052513;;10.1016/s0014-5793(97)01062-4;;9323027;;10.1021/bc00028a007;;7948099;;11787799;;10.1023/a:1012278022349;;7535159;;10.1385/0-89603-274-4:11;;10.1016/j.jmb.2005.02.063;;15826665;;17107777;;10.1016/j.ejpb.2006.09.009;;10.1002/jps.21989;;19918982;;10.1093/protein/6.4.441;;8332602;;12052713;;10.1016/s0169-409x(02)00026-1;;10.1016/0022-2836(87)90412-8;;3681981;;10.1016/0022-2836(92)90224-8;;1404389;;12069157;;10.1023/a:1015396825274;;8124728;;7516563;;10.1016/s0923-2494(94)80039-1;;7779254;;10.1016/0167-5699(95)80166-9;;10.1002/ijc.10212;;11920600;;16839640;;10.1007/978-0-387-76643-0_8;;10.1016/j.addr.2006.03.011;;10.1038/nbt0595-475;;9634788;;pmc4310817;;10.1016/j.ejmech.2014.08.064;;25193298;;10.1074/jbc.m102107200;;11342547;;10.1016/s0016-5085(99)70005-3;;10220494;;2521350;;11053416;;10.1074/jbc.m007734200;;10.1080/02648725.2001.10648017;;11530694;;10702907;;10.1016/s0168-1656(99)00228-x;;10.1002/0471142727.mb1111s37;;10.1002/bit.20729;;16206278;;10.4236/abb.2013.44a011;;25635232;;pmc4307952;;10.1038/ng0594-13;;8075633;;12866935;;10.1208/ps050208;;pmc2751516;;15870065;;10.1074/jbc.m503963200;;10.1074/jbc.m707078200;;17932041;;10.1038/363446a0;;8502296;;10.1002/bit.21080;;16897740;;11163394;;10.1016/s0161-5890(00)00081-x;;10.1016/j.vetmic.2008.04.030;;18534789;;10.1016/j.vetmic.2008.04.030;;18534789;;10.1038/nrd1033;;12612647;;10.1002/jps.22812;;22083792;;10.1016/j.jchromb.2006.09.030;;17030158;;10.1038/nbt0797-632;;9219264;;9035132;;10.1038/nbt0297-125;;10.4049/jimmunol.148.5.1547;;1531669;;10722953;;10.1016/s0378-5173(99)00458-5;;25291284;;10.1016/0167-5699(83)90123-8;;10.1093/protein/gzl031;;16868004;;10.1006/cyto.2001.0936;;11741351;;10.1016/0161-5890(93)90044-c;;8413328;;17134947;;10.1016/j.jchromb.2006.10.033;;17828753;;10.1002/jps.21170;;pmc1573213;;11861313;;10.1038/sj.bjp.0704549;;8276795;;10.1016/s0021-9258(17)42334-9;;7711105;;10.1021/bc00031a006;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1126/science.3929380;;3929380;;11526908;;10.1016/s1389-0352(01)00021-6;;10.1002/(sici)1099-1352(199903/04)12:2<131::aid-jmr454>3.0.co;2-m;;10398404;;10.1002/(sici)1099-1352(199903/04)12:2<131::aid-jmr454>3.3.co;2-d;;3382986;;10.1093/bioinformatics/4.1.11;;10.1016/0022-2836(70)90057-4;;5420325;;9194169;;10.1093/protein/10.4.435;;10.1093/protein/1.2.107;;3507693;;10.1006/prep.1997.0767;;9325133;;6343768;;10.1016/0076-6879(83)92004-9;;7951745;;10.1385/0-89603-268-x:461;;10648925;;10.1016/s0022-1759(99)00138-6;;421339;;10.1111/j.1365-2222.1979.tb01527.x;;10.4049/jimmunol.154.12.6437;;7759880;;12052709;;10.1016/s0169-409x(02)00022-4;;14507303;;10.1046/j.1365-3083.2003.01320.x;;10.1097/00005344-199404000-00025;;7516023;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1593/tlo.13253;;23908681;;pmc3730013;;8118028;;10.1182/blood.v83.5.1244.1244;;3087891;;10.1002/ijc.2910380120;;913410;;10.1111/j.1432-1033.1977.tb11760.x;;10.1021/bc010003g;;11562193;;4001944;;10.1126/science.4001944;;10.1110/ps.8.7.1423;;pmc2144376;;10422830;;10.1016/s0022-1759(99)00211-2;;10675758;;10.1016/0076-6879(90)82008-p;;2314256;;16199666;;pmc2253229;;10.1110/ps.051709505;;10.1038/314452a0;;3920533;;10.4049/jimmunol.164.3.1432;;10640759;;10.1016/s0022-1759(02)00027-3;;12009207;;10.1016/0021-9673(92)85453-z;;1618986;;10.1073/pnas.80.23.7308;;6316357;;pmc390044;;1404388;;10.1016/0022-2836(92)90223-7;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;1675655;;10.4049/jimmunol.147.1.60;;10.1016/s0021-9258(17)43463-6;;6319407;;11585004;;10.1517/14656566.2.6.1015;;12052707;;10.1016/s0169-409x(02)00020-0;;10967427;;10.1016/s0378-5173(00)00423-3;;10.1038/341544a0;;2677748;;10.1023/a:1005554900286;;11258548;;pmc4263261;;25220475;;10.1002/jcc.23728;;10.1093/protein/gzg093;;14600206;;17097246;;10.1016/j.ijpharm.2006.09.015;;pmc3985794;;24803864;;10.1021/ct401058w,"Zhang et al., Applications of Modulated Differential Scanning Calorimetry in Polymer Studies. China Acad J. Electronic Publishing House. 2004;341-348.;;Zhou, Determining Protein Half-Lives. Methods in Molecular Biology, vol. 284: Signal Transduction Protocols. Edited by: R.C. Dickson. Humana Press Inc., Totowa, NJ. 2004:67-77.;;PCT/IB2011/053007, Feb. 23, 2012, International Search Report and Written Opinion.;;PCT/US2007/022256, Jun. 27, 2008, International Search Report.;;PCT/US2007/022256, Apr. 22, 2009, International Preliminary Report on Patentability.;;Altschul et al., Basic local alignment search tool. J Mol Biol. Oct. 5, 1990;215(3):403-10.;;Altschul et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. Sep. 1, 1997;25(17):3389-402.;;Arakawa et al., Protein—solvent interactions in pharmaceutical formulations. Pharm Res. Mar. 1991;8(3):285-91.;;Arbabi Ghahroudi et al., Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. Febs Lett. Sep. 15, 1997;414(3):521-6.;;Benhar et al., Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization. Bioconjug Chem. Jul.-Aug. 1994;5(4):321-6.;;Birch et al., Monoclonal antibodies. Principles and Applications. 1st ed. 1995:237-247.;;Blank et al., Expanded bed adsorption in the purification of monoclonal antibodies: a comparison of process alternatives. Bioseparation. 2001;10(1-3):65-71.;;Bollag, Ion-exchange chromatography. Methods Mol Biol. 1994;36:11-22.;;Bond et al., A structure-based database of antibody variable domain diversity. J Mol Biol. May 6, 2005;348(3):699-709.;;Capelle et al., High throughput screening of protein formulation stability: practical considerations. Eur J Pharm Biopharm. Feb. 2007;65(2):131-48. Epub Sep. 29, 2006.;;Carpenter et al., Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci. May 2010;99(5):2200-8. doi: 10.1002/jps.21989.;;Cedergren et al., Mutational analysis of the interaction between staphylococcal protein A and human IgG1. Protein Eng. Jun. 1993;6(4):441-8.;;Chapman, PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev. Jun. 17, 2002;54(4):531-45.;;Chothia et al., Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol. Aug. 20, 1987;196(4):901-17.;;Chothia et al., Structural repertoire of the human VH segments. J Mol Biol. Oct. 5, 1992;227(3):799-817.;;Chuang et al., Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res. May 2002;19(5):569-77.;;Cleland et al., The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-77.;;Colman et al., Effects of amino acid sequence changes on antibody-antigen interactions. Res Immunol. Jan. 1994;145(1):33-6.;;Connelly, Fully human domain antibody therapeutics: the best of both worlds. Innovations in Pharmaceutical Technol. 2005;:42-5.;;Cook et al., The human immunoglobulin VH repertoire. Immunol Today. May 1995;16(5):237-42.;;Cortez-Retamozo et al., Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer. Mar. 20, 2002;98(3):456-62.;;Daugherty et al., Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev. Aug. 7, 2006;58(5-6):686-706. Epub May 22, 2006.;;Davies et al., Antibody VH domains as small recognition units. Biotechnology (N Y). May 1995;13(5):475-9.;;Decherchi et al., Implicit solvent methods for free energy estimation. Eur J Med Chem. Feb. 16, 2015;91C:27-42. doi: 10.1016/j.ejmech.2014.08.064. Epub Aug. 25, 2014.;;Desmyter et al., Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem. Jul. 13, 2001;276(28):26285-90. Epub May 7, 2001.;;D'Haens et al., Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. May 1999;116(5):1029-34.;;Eliasson et al., Differential IgG-binding characteristics of staphylococcal protein A, streptococcal protein G, and a chimeric protein AG. J Immunol. Jan. 15, 1989;142(2):575-81.;;Els Conrath et al., Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem. Mar. 9, 2001;276(10):7346-50. Epub Oct. 25, 2000.;;Fahrner et al., Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol Genet Eng Rev. 2001;18:301-27.;;Frenken et al., Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol. Feb. 28, 2000;78(1):11-21.;;Fuller et al., Purification of monoclonal antibodies. Curr Protoc Mol Biol. May 2001;Chapter 11:Unit11.11. doi: 10.1002/0471142727.mb1111s37.;;Ghose et al., Antibody variable region interactions with Protein A: implications for the development of generic purification processes. Biotechnol Bioeng. Dec. 20, 2005;92(6):665-73.;;Gil et al., Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments. Adv Biosci Biotechnol. Apr. 2013;4(4a):73-84.;;Gokarn et al., Excipients for Protein Drugs. Ashok et al., (Eds.) 2006. Chapter 17:291-331.;;Green et al., Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet. May 1994;7(1):13-21.;;Gupta et al., Development of a Multidose Formulation for a Humanized Monoclonal Antibody Using Experimental Design Techniques. AAPSPharm Sci. 2003;5:article 8, p. 1-9.;;Hagihara et al., Cellular quality control screening to identify amino acid pairs for substituting the disulfide bonds in immunoglobulin fold domains. J Biol Chem. Jul. 1, 2005;280(26):24752-8. Epub May 3, 2005.;;Hagihara et al., Stabilization of an immunoglobulin fold domain by an engineered disulfide bond at the buried hydrophobic region. J Biol Chem. Dec. 14, 2007;282(50):36489-95. Epub Oct. 11, 2007.;;Hamers-Casterman et al., Naturally occurring antibodies devoid of light chains. Nature. Jun. 3, 1993;363(6428):446-8.;;Harinarayan et al., An exclusion mechanism in ion exchange chromatography. Biotechnol Bioeng. Dec. 5, 2006;95(5):775-87.;;Harmsen et al., Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol Immunol. Aug. 2000;37(10):579-90.;;Harmsen et al., Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease. Vet Microbiol. Mar. 10, 2007;120(3-4):193-206. Epub Oct. 28, 2006.;;Harmsen et al., Passive immunization of pigs with bispecific llama single-domain antibody fragments against foot-and-mouth disease and porcine immunoglobulin. Vet Microbiol. Nov. 25, 2008;132(1-2):56-64. Epub Apr. 30, 2008.;;Harris et al., Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. Mar. 2003;2(3):214-21.;;Hasemann et al., Immunoglobulins: Structure and Function, in William E. Paul, ed. Fundamental Immunology, Second Ed. 1989;209:210-18.;;Hawe et al., Forced Degradation of Therapeutic Proteins. J. Pharm Sci. Mar. 2012. 101(3):895-913.;;Hober et al., Protein A chromatography for antibody purification. J Chromatogr B Analyt Technol Biomed Life Sci. Mar. 15, 2007;848(1):40-7. Epub Oct. 9, 2006.;;Holliger et al., Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotechnol. Jul. 1997;15(7):632-6.;;Hoogenboom, Mix and match: building manifold binding sites. Nat Biotechnol. Feb. 1997;15(2):125-6.;;Kostelny et al., Formation of a bispecific antibody by the use of leucine zippers. J Immunol. Mar. 1, 1992;148(5):1547-53.;;Koumenis et al., Modulating pharmacokinetics of an anti-interleukin-8 F(ab′)(2) by amine-specific PEGylation with preserved bioactivity. Int J Pharm. Mar. 30, 2000;198(1):83-95.;;Kozbor et al., The production of monoclonal antibodies from human lymphocytes. Immunology Today. 1983;4:72-79.;;Krinner et al., A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration. Protein Eng Des Sel. Oct. 2006;19(10):461-70. Epub Jul. 25, 2006.;;Leong et al., Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation. Cytokine Nov. 7, 2001;16(3):106-19.;;Ljungberg et al., The interaction between different domains of staphylococcal protein A and human polyclonal IgG, IgA, IgM and F(ab′)2: separation of affinity from specificity. Mol Immunol. Oct. 1993;30(14):1279-85.;;Low et al., Future of antibody purification. J Chromatogr B Analyt Technol Biomed Life Sci. Mar. 15, 2007;848(1):48-63. Epub Nov. 28, 2006.;;Lu et al., Effect of PEGylation on the solution conformation of antibody fragments. J Pharm Sci. Jun. 2008;97(6):2062-79.;;MacEwan, TNF ligands and receptors—a matter of life and death. Br J Pharmacol. Feb. 2002;135(4):855-75.;;Mallender et al., Construction, expression, and activity of a bivalent bispecific single-chain antibody. J Biol Chem. Jan. 7, 1994;269(1):199-206.;;Martin, Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Ed.: Duebel, Kontermann, Springer-Verlag, Heidelberg). Chapter 3. 2010. 33-51.;;Monfardini et al., A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjugate Chem. Jan. 1, 1995;6(1):62-69.;;Morrison et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A. Nov. 1984;81(21):6851-5.;;Morrison, Transfectomas provide novel chimeric antibodies. Science. Sep. 20, 1985;229(4719):1202-7.;;Muyldermans et al., Single domain camel antibodies: current status. J Biotechnol. Jun. 2001:74(4):277-302.;;Muyldermans et al., Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. J Mol Recognit. Mar.-Apr. 1999;12(2):131-40.;;Myers et al., Optimal alignments in linear space. CABIOS. 1989;4:11-7.;;Needleman et al., A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol. Mar. 1970;48(3):443-53.;;Nieba et al., Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng. Apr. 1997;10(4):435-44.;;Nilsson et al., A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. Feb.-Mar. 1987;1(2):107-13.;;Nilsson et al., Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins. Protein Expr Purif. Oct. 1997;11(1):1-16.;;O'Donnell et al., A high capacity strong cation exchange resin for the chromatographic purification of monoclonal antibodies and other proteins. PREP. 2007;:1-13.;;Oi et al., Chimeric Antibodies. BioTechniques. 1986;4:214.;;Olsson et al., Human—human monoclonal antibody-producing hybridomas: technical aspects. Methods Enzymol. 1983;92:3-16.;;Paul, Fundamental Immunology, 3rd Edition, under the heading “Fv Structure and Diversity in Three Dimensions.” 1993;:292-5.;;Pikal, Freeze drying of proteins part II: formulation selection. Biopharm. 1990;3(9):26-30.;;Reen et al., Enzyme-linked immunosorbent assay (ELISA). Methods Mol Biol. 1994;32:461-6.;;Riechmann et al., Single domain antibodies: comparison of camel VH and camelised human VH domains. J Immunol Methods. Dec. 10, 1999;231(1-2):25-38.;;Ring et al., Anaphylactoid reactions to infusions of plasma protein and human serum albumin. Role of aggregated proteins and of stabilizers added during production. Clin Allergy. Jan. 1979;9(1):89-97. Abstract only.;;Roben et al., VH3 family antibodies bind domain D of staphylococcal protein A. J Immunol. Jun. 15, 1995;154(12):6437-45.;;Roberts et al., Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. Jun. 17, 2002;54(4):459-76.;;Roguin et al., Monoclonal antibodies inducing conformational change on the antigen molecule. Scandinavian Journal of Immunology. 2003;58:387-94.;;Rote et al., Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis. J Cardiovasc Pharmacol. Apr. 1994;23(4):681-9.;;Rudikoff et al., Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.;;Rutkoski et al., Human ribonuclease with a pendant poly(ethylene glycol) inhibits tumor growth in mice. Transl Oncol. Aug. 1, 2013;6(4):392-7. Print Aug. 2013 Erratum in: Transl Oncol. 2013;6:5.;;Saelman et al., Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood. Mar. 1, 1994;83(5):1244-50.;;Scheurich et al., Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines. Int J Cancer. Jul. 15, 1986;38(1):127-33.;;Shumway et al., XM-ONE[reg] Part 1: The challenges of flow cytometric crossmatching (fcxm) with endotheliallmonocyte. American Society for Histocompatibility and Immunogenetics. Poster Session.2009. Abstract 60-P.;;Sjodahl et al., Structural studies on the four repetitive Fc-binding regions in protein A from Staphylococcus aureus. Eur J Biochem. Sep. 1977;78(2):471-90.;;Smith et al., Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem. Sep.-Oct. 2001;12(5):750-6.;;Smith, Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. Jun. 14, 1985;228(4705):1315-7.;;Starovasnik et al., Antibody variable region binding by Staphylococcal protein A: thermodynamic analysis and location of the Fv binding site on E-domain. Protein Sci. Jul. 1999;8(7):1423-31.;;Steindl et al., A simple method to quantify staphylococcal protein A in the presence of human or animal IgG in various samples. J Immunol Methods. Feb. 21, 2000;235(1-2):61-9.;;Stoscheck, Quantitation of protein. Methods Enzymol. 1990;182:50-68.;;Streltsov et al., Structure of a shark IgNAR antibody variable domain and modeling of an early-developmental isotype. Protein Sci. Nov. 2005;14(11):2901-9. Epub Sep. 30, 2005.;;Takeda et al., Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences. Nature. Apr. 4-10, 1985;314(6010):452-4.;;Tamura et al., Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J Immunol. Feb. 1, 2000;164(3):1432-41.;;Tanha et al., Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties. J Immunol Methods. May 1, 2002;263(1-2):97-109.;;Tarditi et al., Selective high-performance liquid chromatographic purification of bispecific monoclonal antibodies. J Chromatogr. May 22, 1992;599(1-2):13-20.;;Teng et al., Construction and testing of mouse—human heteromyelomas for human monoclonal antibody production. Proc Natl Acad Sci U S A. Dec. 1983;80(23):7308-12.;;Tomlinson et al., The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol. Oct. 5, 1992;227(3):776-98.;;Tomlinson et al., The structural repertoire of the human V kappa domain. EMBO J. Sep. 15, 1995;14(18):4628-38.;;Tutt et al., Trispecific F(ab′)3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. J Immunol. Jul. 1, 1991;147(1):60-9.;;Uhlén et al., Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications. J Biol Chem. Feb. 10, 1984;259(3):1695-702.;;Valle et al., Infliximab. Expert Opin Pharmacother. Jun. 2001;2(6):1015-25.;;Veronese et al., Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev. Jun. 17, 2002;54(4):453-6.;;Wang, Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. Aug. 10, 2000;203(1-2):1-60.;;Ward et al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. Oct. 12, 1989;341(6242):544-6.;;Worledge et al., Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats. Digestive Diseases and Sciences. Dec. 2000;45(12):2298-305.;;Yamagishi et al., A new set of atomic radii for accurate estimation of solvation free energy by Poisson-Boltzmann solvent model. J Comput Chem. Nov. 5, 2014;35(29):2132-9. doi: 10.1002/jcc.23728. Epub Sep. 15, 2014.;;Yang et al., Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng. Oct. 2003;16(10):761-70.;;Yang et al., Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation. Int J Pharm. Feb. 22, 2007;331(1):123-32. Epub Sep. 17, 2006.;;Zhou et al., Variational Implicit Solvation with Poisson-Boltzmann Theory. J Chem Theory Comput. Apr. 8, 2014;10(4):1454-1467. Epub Feb. 21, 2014.",ACTIVE
671,WO,A3,WO 2008/134372 A3,140-609-631-118-256,2009-03-19,2009,US 2008/0061301 W,2008-04-23,US 91427907 P,2007-04-26,PRODUCTION OF PROANTHOCYANIDINS TO IMPROVE FORAGE QUALITY,"The invention provides method and compositions for the modulation of anthocyanin and proanthocyanidin production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of anthocyanins and proanthocyanidins in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased proanthocyanidin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content. The invention may also be used to modify plant pigmentation, and for nutraceutical and food colorant production.",SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;MODOLO LUZIA V;;PEEL GREGORY,DIXON RICHARD A;;MODOLO LUZIA V;;PEEL GREGORY,,https://lens.org/140-609-631-118-256,Search Report,yes,5,0,8,8,0,A23V2002/00;;C07K14/415;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K20/121;;A23K50/10;;A23L5/43;;A23L33/105;;C07K14/415;;A23V2002/00;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K50/10;;A23K20/121;;A23L5/43;;A23L33/105,C12N15/82;;A01H5/00;;A23K10/32;;A23L1/00,,3,2,092-613-692-992-396;;135-926-819-985-421,10.1093/jxb/54.381.239;;10.1093/jxb/erg022;;12493851;;10.1111/j.1365-313x.2006.02655.x;;16507081,"ROBBINS MARK PASKE ET AL: ""Sn, a maize bHLH gene, modulates anthocyanin and condensed tannin pathways in Lotus corniculatus."", JOURNAL OF EXPERIMENTAL BOTANY, vol. 54, no. 381, January 2003 (2003-01-01), pages 239 - 248, XP002492558, ISSN: 0022-0957;;XIE D-Y ET AL: ""Metabolic engineering of proanthocyanidins through co-expression of anthocyanidin reductase and the PAP1 MYB transcription factor"", PLANT JOURNAL, BLACKWELL SCIENCE, OXFORD, GB, vol. 45, 1 January 2006 (2006-01-01), pages 895 - 907, XP003012516, ISSN: 1365-313X;;DATABASE EMBL [online] 23 November 2005 (2005-11-23), ""Medicago truncatula chromosome 7 clone mth2-16i6, complete sequence."", XP002492559, retrieved from EBI accession no. EMBL:AC172742 Database accession no. AC172742",PENDING
672,DE,T2,DE 60203408 T2,167-515-945-585-677,2006-04-13,2006,DE 60203408 T,2002-10-04,US 32733701 P;;US 0233230 W,2001-10-05,VERFAHREN ZUR HERSTELLUNG VON BAUMATERIALIEN AUS ROHEN LACKSCHLÄMMEN,"A process for producing building materials, such as asphalt, cement, concrete, mortar, or plaster board from liquid paint sludge containing water and paint solids produced from overspray in commercial paint booth operations. The preferred embodiment comprises adding the liquid paint sludge as the hydrating agent directly to the building material mix.",DU PONT,MATHESON R;;DIXON M;;MOORE R;;FISCHER A,"E.I. DU PONT DE NEMOURS AND CO., WILMINGTON, DEL., (2005-06-02)",https://lens.org/167-515-945-585-677,Granted Patent,no,0,0,17,18,0,C04B18/0418;;C04B22/002;;C04B22/0046;;C04B26/26;;C04B28/04;;C04B28/14;;C04B2111/00586;;C04B2111/0075;;C08J11/00;;C08L95/005;;Y02W30/91;;C04B18/04;;C04B22/0046;;C04B28/14;;C04B22/002;;C04B28/04;;C08J11/00;;C04B18/0418;;C04B26/26;;C04B2111/00586;;C08L95/005;;C04B2111/0075;;Y02W30/91,C04B18/04;;C04B28/02;;C04B18/30;;C04B22/00;;C04B28/10;;C04B28/16;;C08J11/00;;C08L95/00,,0,0,,,,EXPIRED
673,WO,A8,WO 2004/024079 A8,175-735-636-285-894,2005-03-17,2005,US 0328454 W,2003-09-10,US 40944702 P,2002-09-10,METHODS AND COMPOSITIONS FOR PRODUCTION OF FLAVONOID AND ISOFLAVONOID NUTRACEUTICALS,The invention provides method and compositions for the modulation of flavanone and/or isoflavone production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of isoflavones in particular in plants may be used to increase the nutritional value of food plants for both human and animal consumption. The invention overcomes limitations of the prior art which prevented accumulation of high levels of isoflavones in plants.,SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;LIU CHANG-JUN;;DEAVOURS BETTINA,DIXON RICHARD A;;LIU CHANG-JUN;;DEAVOURS BETTINA,,https://lens.org/175-735-636-285-894,Patent Application,no,0,0,10,10,0,C12N9/0071;;C12N9/0077;;C12N15/8243;;C12N15/825;;C12N9/0071;;C12N15/825;;C12N15/8243;;C12N9/0077,A01H1/00;;C12N9/02;;C12N9/90;;C12N15/82,,0,0,,,,PENDING
674,WO,A2,WO 2004/024079 A2,171-996-401-791-047,2004-03-25,2004,US 0328454 W,2003-09-10,US 40944702 P,2002-09-10,METHODS AND COMPOSITIONS FOR PRODUCTION OF FLAVONOID AND ISOFLAVONOID NUTRACEUTICALS,The invention provides method and compositions for the modulation of flavanone and/or isoflavone production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of isoflavones in particular in plants may be used to increase the nutritional value of food plants for both human and animal consumption. The invention overcomes limitations of the prior art which prevented accumulation of high levels of isoflavones in plants.,SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;LIU CHANG-JUN;;DEAVOURS BETTINA,DIXON RICHARD A;;LIU CHANG-JUN;;DEAVOURS BETTINA,,https://lens.org/171-996-401-791-047,Patent Application,yes,0,77,10,10,0,C12N9/0071;;C12N9/0077;;C12N15/8243;;C12N15/825;;C12N9/0071;;C12N15/825;;C12N15/8243;;C12N9/0077,A01H1/00;;C12N9/02;;C12N9/90;;C12N15/82,,0,0,,,,PENDING
675,WO,A2,WO 2003/071861 A2,035-007-953-771-288,2003-09-04,2003,US 0306397 W,2003-02-27,US 8771402 A,2002-02-28,VANILLIN BIOSYNTHETIC PATHWAY ENZYME FROM VANILLA PLANIFOLIA,Novel compositions and methods for improving vanillin production in cultured Vanilla planifolia and in intact plants are provided. Transgenic cells and plants having improved vanillin production are also provided. Isolated 4-hydroxybenzaldehyde synthase enzyme and nucleic acids encoding the enzyme are further provided.,DAVID MICHAEL & CO INC;;HAVKIN-FRENKEL DAPHNA;;PODSTOLSKI ANDRZEJ;;DIXON RICHARD A,HAVKIN-FRENKEL DAPHNA;;PODSTOLSKI ANDRZEJ;;DIXON RICHARD A,,https://lens.org/035-007-953-771-288,Patent Application,yes,0,0,5,5,0,C07C2/32;;C07C2531/22;;C07D213/53;;C07F15/02;;C07F15/025;;C08F10/00;;C12N5/04;;C12N9/00;;C12N9/0006;;C12N9/0077;;C12N15/8207;;C12N15/8243;;C12P7/24;;A01H4/002;;C08F10/00;;C12N9/0077;;C12N5/04;;C07C2531/22;;C07F15/02;;C07F15/025;;C12P7/24;;C12N9/0006;;C12N9/00;;C07C2/32;;C07D213/53;;C12N15/8243;;C12N15/8207;;A01H4/002,A01H4/00;;C07C2/32;;C07D213/53;;C07F15/02;;C08F10/00;;C12N5/04;;C12N9/00;;C12N9/02;;C12N9/04;;C12N15/29;;C12N15/82;;C12P7/24,,0,0,,,,PENDING
676,CA,A1,CA 2676619 A1,084-344-295-249-555,2008-08-07,2008,CA 2676619 A,2007-10-29,US 88730707 P;;US 68117907 A;;US 2007/0082898 W,2007-01-30,PROCESSING TRANSACTIONS OF DIFFERENT PAYMENT DEVICES OF THE SAME ISSUER ACCOUNT,"Each portable payment device associated with a single account within a pa yment processing system is distinguished using track data. The track data fr om the portable payment device is read at each of a plurality of merchant po int of sale terminals (POS). Rather than relying on the PAN alone, a merchan t may utilizes the track data, or a proxy thereof, as the unique identifier for the portable payment device. The merchant may then process transactions involving the portable payment device based on the unique identifier. For ex ample, in the transit environment the transit fare for each rider with diffe rent portable payment devices but the same account can be calculated using t he unique identifier, such as the full track data read from both tracks of t he corresponding portable payment devices.",VISA USA INC,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,,https://lens.org/084-344-295-249-555,Patent Application,no,0,0,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/14;;G06Q20/36;;G07B15/02,,0,0,,,,DISCONTINUED
677,US,B2,US 7880059 B2,097-621-922-497-393,2011-02-01,2011,US 10833208 A,2008-04-23,US 10833208 A;;US 91427907 P,2007-04-26,Production of proanthocyanidins to improve forage quality,"The invention provides method and compositions for the modulation of anthocyanin and proanthocyanidin production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of anthocyanins and proanthocyanidins in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased proanthocyanidin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content. The invention may also be used to modify plant pigmentation, and for nutraceutical and food colorant production.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;MODOLO LUZIA V;;PEEL GREGORY,NOBLE RESEARCH INSTITUTE LLC (2008-07-24),https://lens.org/097-621-922-497-393,Granted Patent,yes,13,3,8,8,98,A23V2002/00;;C07K14/415;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K20/121;;A23K50/10;;A23L5/43;;A23L33/105;;C07K14/415;;A23V2002/00;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K50/10;;A23K20/121;;A23L5/43;;A23L33/105,A01H5/00;;A23K10/32;;C07H21/04;;C12N5/14;;C12N15/63,800/295;;800/298;;435/419;;435/320.1;;536/23.1;;536/23.6,43,34,116-651-492-139-16X;;043-592-224-847-318;;108-195-965-075-252;;055-003-061-629-507;;058-449-969-249-120;;016-265-697-674-181;;027-655-982-060-35X;;192-467-365-170-240;;040-075-166-049-478;;014-921-916-579-046;;015-279-533-554-483;;127-437-090-611-785;;023-953-046-860-282;;018-356-283-473-212;;011-806-609-814-883;;112-180-797-410-316;;004-357-768-192-802;;010-163-151-302-348;;002-485-351-554-971;;030-560-996-409-192;;072-530-999-385-794;;037-600-532-041-631;;131-737-655-070-816;;030-338-985-732-077;;008-845-970-093-611;;027-655-982-060-35X;;053-728-441-408-680;;006-191-344-749-449;;048-681-233-820-623;;052-761-919-214-841;;135-926-819-985-421;;128-543-873-632-887;;015-010-359-455-866;;092-613-692-992-396,11572990;;pmc58748;;10.1073/pnas.201411298;;11395776;;10.1038/35079635;;9767075;;10.1016/s0167-4781(98)00119-5;;10.1073/pnas.0403255101;;pmc438954;;15197260;;pmc2280042;;15044734;;10.1110/ps.03484604;;10.1021/bi00489a001;;2271534;;10.1104/pp.103.025361;;pmc167084;;12857826;;10.1007/978-1-4684-6831-1;;10.1046/j.1365-313x.2001.01154.x;;11722774;;10.1007/s00425-004-1424-1;;15578217;;pmc102225;;10.2307/3871236;;11148285;;10.1105/tpc.12.12.2383;;10.1071/pp99115;;10.1105/tpc.13.4.853;;10.2307/3871345;;11283341;;pmc135529;;10.1104/pp.105.067231;;16384897;;pmc1361319;;15720617;;10.1111/j.1469-8137.2004.01217.x;;10.1002/(sici)1097-0010(199605)71:1<103::aid-jsfa554>3.0.co;2-8;;14675436;;10.1046/j.1365-313x.2003.01943.x;;10.1021/jf00028a012;;10.1007/978-1-4615-3476-1_55;;1417702;;pmc137925;;12384577;;10.1073/pnas.212522099;;pmc167162;;12897245;;10.1105/tpc.012963;;10.1007/bf00029615;;17437063;;10.1007/s11103-007-9167-6;;10.1105/tpc.105.035154;;pmc1276023;;16243908;;10.1105/tpc.11.8.1433;;pmc144295;;10.2307/3870973;;10449578;;10.1104/pp.103.025361;;pmc167084;;12857826;;10.1111/j.1365-313x.2005.02510.x;;16167896;;10.2307/2446026;;10.1074/jbc.m302783200;;12788945;;10.1111/j.1365-313x.2005.02371.x;;15807784;;10.1111/j.1365-313x.2006.02655.x;;16507081;;16153412;;10.1016/j.phytochem.2005.01.008;;10.1126/science.1078540;;12532018;;10.1093/jxb/54.381.239;;10.1093/jxb/erg022;;12493851,"Yang et al. (PNAS, 98:11438-11443, 2001; abstract; pp. 11442-11443).;;McConnell et al. (Nature, 411:709-713, 2001).;;Chan et al. (Biochimica et Biophysica Acta, 1442:1-19, 1998).;;Guo et al. (PNAS, 101: 9205-9210, 2004).;;Keskin et al. (Protein Science, 13:1043-1055, 2004).;;Wells, Biochemistry 29:8509-8517, 1990.;;Lin et al. (NCBI, GenBank, Sequence Accession No. AC152405; Published Mar. 21, 2006).;;Ray et al. (Plant Physiol., 132:1448-1463; Published 2003).;;Ngo et al., (The Protein Folding Problem and Tertiary Structure Prediction, K. Merz., and S. Le Grand (eds.) pp. 492-495, 1994).;;Thornton et al. (Nature structural Biology, structural genomics supplement, Nov. 2000).;;Aharoni et al., ""The strawberry FaMYB1 transcription factor suppresses anthocyanin and flavonol accumulation in transgenic tobacco,"" Plant J., 28(3):319-332, 2001.;;Aziz et al., ""Trascriptome analysis of alfalfa glandular trichomes,"" Planta, 221:28-38, 2005.;;Borevitz et al., ""Activation tagging identifies a conserved MYB regulator of phenylpropanoid biosysnthesis,"" Plant Cell, 12:2383-2393, 2000.;;de Majnik et al., ""Anthocyanin regulatory gene expression in transgenic white clover can result in an altered pattern of pigmentation,"" Aust. J. Plant Physiol., 27:659-667, 2000.;;Debeaujon et al., ""The Transparent Testa 12 gene of Arabidopsis encodes a multidrug secondary transporter-like protein required for flavonoid sequestration in vacuoles of the seed coat endothelium,"" Plant Cell, 13:853-871, 2001.;;Deluc et al., ""Characterization of a grapevine R2R3-MYB transcription factor that regulates the phenylpropanoid pathway1,"" Plant Physiology, 140:499-511, 2006.;;Dixon et al., ""Tansley review-Proanthocyanidins-a final frontier in flavonoid research,"" New Phytologist, 165:9-28, 2005.;;GenBank Accession No. AC135317, dated Apr. 26, 2008.;;GenBank Accession No. AC152405, dated Aug. 24, 2007.;;GenBank Accession No. AC172742, dated Mar. 24, 2007.;;GenBank Accession No. AF325123, dated Feb. 7, 2001.;;GenBank Accession No. CT573509, dated Feb. 6, 2006.;;GenPept Accession No. AAG25927, dated Oct. 25, 2000.;;Jackson et al., ""The extractable and bound condensed tannin content of leaves from tropical tree, shrub and forage legumes,"" J. Sci. Food Agric., 71:103-110, 1996.;;Kitamura et al., ""Transparent Testa 19 is involved in the accumulation of both anthocyanins and proanthocyanidins in Arabidopsis,"" Plant J., 37:104-114, 2004.;;Koupai-Abyazani et al., ""Purification and characterization of a proanthocyanidin polymer from seed of alfalfa (Medicago sativa),"" J. Agric. Food Chem., 41:565-569, 1993.;;Lees, ""Condensed tannins in some forage legumes: their role in the prevention of ruminant pasture bloat,"" Basic Life Sci., 59:915-934, 1992.;;Liu et al., ""Bottlnecks for metabolic engineering of isoflavone glycoconjugates in Arabidopsis,"" Proc. Natl. Acad. Sci. USA, 99:14578-14583, 2002.;;Mathews et al., ""Activation tagging in tomato identifies a transcriptional regulator of anthocyaninbiosynthesis, modification, and transport,"" Plant Cell, 15:1689-1703, 2003.;;McKhann et al., ""Isolation of chalcone synthase and chalcone isomerase cDNAs from alfalfa (Medicago sativa L.): highest transcript levels occur in young roots and root tips,"" Plant Mol. Biol, 24(5):767-777, 1994.;;Modolo et al., ""A functional genomics approach to (iso)flavonoid glycosylation in the model legume Medicago truncatula,"" Plant Mol. Biol., 64:499-518, 2007.;;Pourcel et al., ""Transparent Testa 10 encodes a laccase-like enzyme involved in oxidative polymerization of flavonoids in Arabidopsis seed coat,"" Plant Cell, 17:2966-2980, 2005.;;Quattrocchio et al., ""Molecular analysis of the anthocyanin2 gene of petunia and its role in the evolution of flower color,"" Plant Cell, 11:1433-1444, 1999.;;Ray et al., ""Expression of anthocyanins and proanthocyanidins after transformation of alfalfa with maize Lc1,2,"" Plant Physiology, 132:1448-1463, 2003.;;Sharma et al., ""Metabolic engineering of proanthocyanidins by ectopic expression of transcription factors in Arabidopsis thaliana,"" Plant J., 44:62-75, 2005.;;Skadhauge et al., ""Leucocyanidin reductase activity and accumulation of proanthocyanidins in developing legume tissues,"" American J. of Bot., 84:494, Abstract, 1997.;;Tanner et al., ""Proanthocyanidin biosynthesis in plants: purification of legume leucoanthocyanidin reductase and molecular cloning of its cDNA,"" J. Biol. Chem., 278:31647-31656, 2003.;;TIGR Clone TC105632, undated.;;Tohge et al., ""Functional genomics by integrated analysis of metabolome and transcriptome of Arabidopsis plants overexpressing a MYB transcription factor,"" Plant J., 42:218-235, 2005.;;Xie et al., ""Metabolic engineering of proanthocyanidins through co-expression of anthocyanidin reductase and the PAP1 MYB transcription factor,"" Plant J., 45:895-907, 2006.;;Xie et al., ""Proanthocyanidin biosynthesis-still more questions than answers,"" Phytochemistry, 66:2126-2143, 2005.;;Xie et al., ""Role of anthocyanidin reductase, encoded by Banyuls in plant flavonoid biosynthesis,"" Science, 299:396-399, 2003.;;Robbins et al., ""Sn, a maize bHLH gene, modulates anthocyanin and condensed tannin pathways in Lotus corniculatus,"" J. of Exper. Bot., 54(381):239-248, 2003.",ACTIVE
678,US,A1,US 2008/0179394 A1,114-211-290-957-816,2008-07-31,2008,US 68117507 A,2007-03-01,US 68117507 A;;US 88730707 P,2007-01-30,OPEN SYSTEM ACCOUNT REMOTE VALIDATION FOR ACCESS,"At each of a plurality of point of sale terminals (POS) of a transit system, for each of a plurality of riders, where each rider seeks access into a facility of the transit facility by using a payment device issued by an issuer in a payment system, data is read from the payment device. The data can include an identifier for an account issued by an issuer. For each such access, a communication including the account is addressed to a network address of a system remote from the payment processing system and remote from each of POS terminals. A response to the communication is received that includes information as to the validation of the access based upon the account being on a list keep by remote system. When the received information contains the validation of the access, the rider is permitted access to the facility of the transit system and the payment device is unchanged for the fare of the access to the facility of the transit system.",DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,VISA U.S.A. INC (2007-05-11),https://lens.org/114-211-290-957-816,Patent Application,yes,45,101,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06K5/00;;G06Q20/36;;G06Q20/14;;G07B15/02,235/380,0,0,,,,ACTIVE
679,US,A1,US 2015/0154602 A1,122-896-570-066-756,2015-06-04,2015,US 201514611061 A,2015-01-30,US 201514611061 A;;US 201213564625 A;;US 68117907 A;;US 88730707 P,2007-01-30,PROCESSING TRANSACTIONS OF DIFFERENT PAYMENT DEVICES OF THE SAME ISSUER ACCOUNT,"Each portable payment device associated with a single account within a payment processing system is distinguished using track data. The track data from the portable payment device is read at each of a plurality of merchant point of sale terminals (POS). Rather than relying on the PAN alone, a merchant may utilizes the track data, or a proxy thereof, as the unique identifier for the portable payment device. The merchant may then process transactions involving the portable payment device based on the unique identifier. For example, in the transit environment the transit fare for each rider with different portable payment devices but the same account can be calculated using the unique identifier, such as the full track data read from both tracks of the corresponding portable payment devices.",DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,VISA U.S.A. INC (2007-05-11),https://lens.org/122-896-570-066-756,Patent Application,yes,1,1,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/14;;G06Q20/20;;G06Q20/40;;G06Q20/36;;G07B15/02,,0,0,,,,ACTIVE
680,EP,A2,EP 2140011 A2,143-678-462-742-522,2010-01-06,2010,EP 08746680 A,2008-04-23,US 2008/0061301 W;;US 91427907 P,2007-04-26,PRODUCTION OF PROANTHOCYANIDINS TO IMPROVE FORAGE QUALITY,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;MODOLO LUZIA V;;PEEL GREGORY,,https://lens.org/143-678-462-742-522,Patent Application,yes,0,0,8,8,0,A23V2002/00;;C07K14/415;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K20/121;;A23K50/10;;A23L5/43;;A23L33/105;;C07K14/415;;A23V2002/00;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K50/10;;A23K20/121;;A23L5/43;;A23L33/105,C12N15/82;;A01H5/00;;A23K10/32;;A23L1/00,,0,0,,,,DISCONTINUED
681,KR,A,KR 20130105749 A,141-469-169-120-085,2013-09-25,2013,KR 20137022657 A,2009-10-29,US 10947408 P;;US 2009/0062611 W,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,,ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,,https://lens.org/141-469-169-120-085,Patent Application,no,1,1,44,44,20,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/19;;A61K39/395;;A61P35/00;;G06F19/00,,0,0,,,,ACTIVE
682,AU,A,AU 1999/044349 A,149-364-546-019-178,1999-12-30,1999,AU 1999/044349 A,1999-06-11,US 9610198 A;;US 9913158 W,1998-06-11,Collaborative object architecture,,PLACEWARE INC,CURTIS PAVEL;;DIXON MICHAEL D;;NICHOLS DAVID A,,https://lens.org/149-364-546-019-178,Patent Application,no,0,0,8,8,0,H04L67/10;;H04L69/329;;H04L67/131;;H04L69/329;;H04L67/10;;H04L9/40;;H04L67/01;;H04L67/131,G06F15/16;;G06F9/46;;H04L29/06;;H04L29/08,,0,0,,,,DISCONTINUED
683,BR,A2,BR PI0721202 A2,155-278-543-233-765,2014-03-18,2014,BR PI0721202 A,2007-10-29,US 88730707 P;;US 68117407 A;;US 2007/0082842 W,2007-01-30,MÉTODO,,VISA USA INC,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,,https://lens.org/155-278-543-233-765,Patent Application,no,0,0,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/14;;G07B15/00;;G06Q20/36;;G07B15/02,,0,0,,,,DISCONTINUED
684,CA,A1,CA 2233426 A1,178-136-570-573-192,1998-09-28,1998,CA 2233426 A,1998-03-27,US 4211897 P,1997-03-28,NURSERY CRATE,"A nursery crate including a pallet-like bottom, sides of spaced-apart upright st rips of wood veneer or sawn lumber and connected shelf-support cleats of sawn lumber, an d shelves with wood slats of veneer or sawn lumber fastened to sawn lumber battens. The sides o f the crate are wirebound with lengths of wire encircling the sides and connected at their ends. The crate sides form an open grid or lattice admitting light, air and water. The shelves may be confi gured to retain flats of plants nested in openings or for the passage through openings of light, air a nd water.",STAPLING MACHINES CO L L C,BRODIE ROBERT A;;DIXON DAVID D;;KUFTA RICHARD,,https://lens.org/178-136-570-573-192,Patent Application,no,0,1,1,1,0,,A01G9/02;;A47B47/04,,0,0,,,,DISCONTINUED
685,US,A,US 5094634 A,185-071-026-321-046,1992-03-10,1992,US 68453291 A,1991-04-11,US 68453291 A,1991-04-11,Electrical connector employing terminal pins,"An electrical connector includes a housing having at least one through hole. A terminal pin is inserted into the through hole and includes an enlarged retention portion and an enlarged stabilizing portion spaced longitudinally of the pin from the enlarged retention portion. Both the retention portion and the stabilizing portion are located in the through hole and at least the enlarged retention portion is sized to establish an interference fit with the housing within the hole. The enlarged retention portion is located adjacent a mid-point of the through hole, and the enlarged stabilizing portion is located adjacent one end of the through hole.",MOLEX INC,DIXON DANIEL A;;LEE HSIN;;LOPATA JOHN E,MOLEX INCORPORATED 2222 WELLINGTON COURT LISLE IL 60532 A CORP OF DE (1991-04-10),https://lens.org/185-071-026-321-046,Granted Patent,yes,12,43,1,1,0,H01R12/58;;H01R12/58,H01R13/40,H2E EDAK          EDAK,0,0,,,,EXPIRED
686,EP,A4,EP 3265125 A4,193-646-231-276-250,2018-11-07,2018,EP 16759606 A,2016-03-04,US 201562128462 P;;US 2016/0020980 W,2015-03-04,ANTIBODY THERAPEUTICS THAT BIND CD47,,SORRENTO THERAPEUTICS INC,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,YUHAN CORPORATION (2024-01-17),https://lens.org/193-646-231-276-250,Search Report,no,4,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;A61K39/395,,2,2,066-756-238-112-737;;115-916-015-721-506,25721088;;pmc4886734;;10.1016/j.canlet.2015.02.036;;14985099;;10.1016/j.bbrc.2004.01.128,"XIAO ZHENYU ET AL: ""Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma"", CANCER LETTERS, NEW YORK, NY, US, vol. 360, no. 2, 23 February 2015 (2015-02-23), pages 302 - 309, XP029203894, ISSN: 0304-3835, DOI: 10.1016/J.CANLET.2015.02.036;;KIKUCHI Y ET AL: ""A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cells"", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 315, no. 4, 19 March 2004 (2004-03-19), pages 912 - 918, XP004491573, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2004.01.128",PENDING
687,US,A1,US 2010/0238535 A1,199-698-960-981-622,2010-09-23,2010,US 40795009 A,2009-03-20,US 40795009 A,2009-03-20,ELECTROCHROMIC THIN-FILM MATERIAL,"One exemplary embodiment of an electrochromic thin-film material comprises a metal-chalcogen compound; and/or a mixture or solid solution of one or more metal-rich metal-chalcogen compounds and/or lithium. One or more of the metals comprise Ti, Zr, Hf, V, Nb, Ta, Cr, Mo, W, Mn, Sb, or Bi, or combinations thereof; and one or more of the chalcogens comprise O, S, Se, or Te, or combinations thereof.",WANG ZHONGCHUN;;NGUYEN PAUL P;;DIXON JEREMY A,WANG ZHONGCHUN;;NGUYEN PAUL P;;DIXON JEREMY A,VIEW INC (2009-03-18),https://lens.org/199-698-960-981-622,Patent Application,yes,7,6,5,5,0,C09K9/00;;C09K9/00,G02F1/153;;C09K9/00,359/275;;252/583,0,0,,,,INACTIVE
688,EP,A2,EP 1555870 A2,028-895-769-671-935,2005-07-27,2005,EP 03752235 A,2003-09-10,US 0328454 W;;US 40944702 P,2002-09-10,METHODS AND COMPOSITIONS FOR PRODUCTION OF FLAVONOID AND ISOFLAVONOID NUTRACEUTICALS,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;LIU CHANG-JUN;;DEAVOURS BETTINA,,https://lens.org/028-895-769-671-935,Patent Application,yes,0,0,10,10,14,C12N9/0071;;C12N9/0077;;C12N15/8243;;C12N15/825;;C12N9/0071;;C12N15/825;;C12N15/8243;;C12N9/0077,A01H1/00;;C12N9/02;;C12N9/90;;C12N15/82,,0,0,,,,DISCONTINUED
689,AU,A1,AU 2003/270537 A1,033-434-376-199-632,2004-04-30,2004,AU 2003/270537 A,2003-09-10,US 40944702 P;;US 0328454 W,2002-09-10,METHODS AND COMPOSITIONS FOR PRODUCTION OF FLAVONOID AND ISOFLAVONOID NUTRACEUTICALS,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;LIU CHANG-JUN;;DEAVOURS BETTINA,,https://lens.org/033-434-376-199-632,Patent Application,no,0,0,10,10,0,C12N9/0071;;C12N9/0077;;C12N15/8243;;C12N15/825;;C12N9/0071;;C12N15/825;;C12N15/8243;;C12N9/0077,A01H1/00;;C12N9/02;;C12N9/90;;C12N15/82,,0,0,,,,EXPIRED
690,CA,A1,CA 2978594 A1,044-315-668-155-911,2016-09-09,2016,CA 2978594 A,2016-03-04,US 201562128462 P;;US 2016/0020980 W,2015-03-04,ANTIBODY THERAPEUTICS THAT BIND CD47,"There is disclosed compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, there is disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.",SORRENTO THERAPEUTICS INC,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,,https://lens.org/044-315-668-155-911,Patent Application,no,0,0,34,34,32,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;C07K16/18;;C07K16/30,,0,0,,,,PENDING
691,US,B2,US 10035855 B2,065-454-749-732-890,2018-07-31,2018,US 201615061771 A,2016-03-04,US 201615061771 A;;US 201562128462 P,2015-03-04,Antibody therapeutics that bind CD47,"There is disclosed compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, there is disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.",SORRENTO THERAPEUTICS INC,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,YUHAN CORPORATION (2023-11-02);;SORRENTO THERAPEUTICS INC (2017-04-07),https://lens.org/065-454-749-732-890,Granted Patent,yes,0,4,34,34,32,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,A61K39/395;;C07K16/28;;C07K16/30,,12,11,027-477-313-726-928;;095-334-545-560-259;;014-113-432-888-031;;045-942-104-775-903;;051-707-000-800-833;;001-779-867-387-972;;013-142-717-038-23X;;045-872-081-200-101;;008-841-048-374-253;;037-732-210-958-572;;093-507-762-980-276,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1006/jmbi.1996.0548;;8876650;;12218124;;10.4049/jimmunol.169.6.3076;;12850000;;10.1016/s0006-291x(03)01131-8;;12079396;;10.1016/s0022-2836(02)00264-4;;10.1006/jmbi.1999.3192;;10543973;;10556035;;10.1006/jmbi.1999.3141;;pmc297746;;10.1073/pnas.86.15.5938;;2762305;;10.2210/pdb3hfm/pdb;;11451948;;10.1074/jbc.m102367200;;10.1146/annurev.med.52.1.125;;11160771;;10.1002/9783527609628,"Rudikoff et al. (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979).;;MacCallum et al. J. Mol. Biol. (1996) 262, 732-745.;;Pascalis et al. (The Journal of Immunology (2002) 169, 3076-3084).;;Casset et al. (BBRC 2003, 307:198-205).;;Vajdos et al. (J. Mol. Biol. (2002) 320, 415-428).;;Chen et al. (J. Mol. Bio. (1999) 293, 865-881).;;Wu et al. (J. Mol. Biol. (1999) 294, 151-162).;;Padlan et al. (PNAS 1989, 86:5938-5942).;;Lamminmaki et al. (JBC 2001, 276:36687-36694).;;White et al. (2001, Ann. Rev. Med., 2001, 52:125-145).;;Meibohm (Pharmacokinetics and Pharmacodynamics of Biotech Drugs, Wiley-VHC, 2006, chapter 3, p. 45-91).;;International Search Report for PCT/US2016/020980, published Sep. 9, 2016, 5 pages.",ACTIVE
692,MX,A,MX 2017011329 A,058-636-818-439-078,2018-06-06,2018,MX 2017011329 A,2016-03-04,US 201562128462 P;;US 2016/0020980 W,2015-03-04,ANTIBODY THERAPEUTICS THAT BIND CD47.,"There is disclosed compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, there is disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.",SORRENTO THERAPEUTICS INC,BARBARA A SWANSON;;JOHN DIXON GRAY;;HEYUE ZHOU,,https://lens.org/058-636-818-439-078,Patent Application,no,0,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,A61K39/395;;C07K16/18;;C07K16/28,,0,0,,,,PENDING
693,AR,A1,AR 103868 A1,065-898-307-716-073,2017-06-07,2017,AR P160100592 A,2016-03-04,US 201562128462 P,2015-03-04,ANTICUERPOS ANTI-CD47 COMO AGENTES TERAPÉUTICOS,"Reivindicación 1: Un anticuerpo anti-CD47 completamente humano aislado de una clase de IgG que se une a un epitope CD47, donde dicho anticuerpo comprende una secuencia del dominio variable de la cadena pesada que es por lo menos un 95% idéntica a una secuencia de aminoácidos seleccionada del grupo que consiste en la SEQ ID Nº 1, la SEQ ID Nº 7, la SEQ ID Nº 9, la SEQ ID Nº 10, la SEQ ID Nº 11, la SEQ ID Nº 12, la SEQ ID Nº 13, la SEQ ID Nº 14, la SEQ ID Nº 16, la SEQ ID Nº 17, la SEQ ID Nº 18, la SEQ ID Nº 22, la SEQ ID Nº 24 y la SEQ ID Nº 32; y una secuencia del dominio variable de la cadena liviana que es por lo menos un 95% idéntica a la secuencia de aminoácidos seleccionada del grupo que consiste en la SEQ ID Nº 2, la SEQ ID Nº 4, la SEQ ID Nº 5, la SEQ ID Nº 6, la SEQ ID Nº 8, la SEQ ID Nº 15, la SEQ ID Nº 19, la SEQ ID Nº 20, la SEQ ID Nº 21, la SEQ ID Nº 23, la SEQ ID Nº 25, la SEQ ID Nº 26, la SEQ ID Nº 27, la SEQ ID Nº 28, la SEQ ID Nº 29 y la SEQ ID Nº 30. Reivindicación 10: Un método de tratamiento de cáncer o una enfermedad fibrótica, donde dicho método comprende administrar una cantidad eficaz de un anticuerpo anti-CD47 o un fragmento de anticuerpo, de cualquiera de las reivindicaciones 1 a 9, a un sujeto que lo necesita. Reivindicación 14: Una composición farmacéutica que comprende el anticuerpo anti-CD47, o un fragmento de anticuerpo, de cualquiera de las reivindicaciones 1 a 9 ó 13, y un vehículo farmacéuticamente aceptable. Reivindicación 15: Un método de tratamiento de cáncer o una enfermedad fibrótica en un sujeto humano que lo necesita, que comprende administrar una cantidad eficaz del anticuerpo anti-CD47, o un fragmento de unión al antígeno del mismo, de cualquiera de las reivindicaciones 1 a 9 ó 13 al sujeto, de manera tal que el cáncer o la enfermedad fibrótica sea tratada.",SORRENTO THERAPEUTICS INC,HEYUE ZHOU;;JOHN DIXON GRAY;;BARBARA A SWANSON,,https://lens.org/065-898-307-716-073,Patent Application,no,0,1,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;A61K39/395;;A61P35/00,,0,0,,,,PENDING
694,NZ,A,NZ 591217 A,096-339-923-406-873,2011-12-22,2011,NZ 59121709 A,2009-08-27,US 9300608 P;;US 2009/0055188 W,2008-08-29,EPICATECHIN GLUCOSYLTRANSFERASE,"Disclosed is the polypeptide sequence SEQ ID NO: 1 which is the uridine diphosphate gylcosyltransferase, UGT72L1, from the legume Medicago truncatula. The glycosyltransferase has high activity for glucosylation of (-)-epitcatechin, significant activity with (-)-epigallacatechin and weak activity with (+)-catechin and cyanidin. The nucleic acid sequence encoding SEQ ID NO: 1 is used to construct expression vectors to transform plants and is expressed in the plants to increase the proanthocyanidin biosynthesis. The expression of SEQ ID NO: 1 can increase the nutritional value of food plants for both human and animal consumption. Increased proanthocyanidin content also reduces the potential bloat in animals fed certain forage plants low in condensed tannin content.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;PANG YONGZHEN;;PEEL GREGORY J,,https://lens.org/096-339-923-406-873,Patent Application,no,0,0,6,6,0,C12N15/8243;;C12N15/8243;;C12N9/1051;;C12N9/1051,C12N9/10;;A01H5/00;;A61K38/45;;C07K14/415;;C12N15/82,,0,0,,,,DISCONTINUED
695,AU,B2,AU 2008/245794 B2,150-623-597-390-996,2011-12-01,2011,AU 2008/245794 A,2008-04-23,US 91427907 P;;US 2008/0061301 W,2007-04-26,Production of proanthocyanidins to improve forage quality,"The invention provides method and compositions for the modulation of anthocyanin and proanthocyanidin production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of anthocyanins and proanthocyanidins in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased proanthocyanidin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content. The invention may also be used to modify plant pigmentation, and for nutraceutical and food colorant production.",THE SAMUEL ROBERTS NOBLE FOUNDATION INC,GREGORY PEEL;;MODOLO LUZIA V;;DIXON RICHARD A,,https://lens.org/150-623-597-390-996,Granted Patent,no,1,0,8,8,0,A23V2002/00;;C07K14/415;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K20/121;;A23K50/10;;A23L5/43;;A23L33/105;;C07K14/415;;A23V2002/00;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K50/10;;A23K20/121;;A23L5/43;;A23L33/105,A01H5/00;;A23K10/32;;A23L1/00;;C12N15/82,,1,0,,,"GenBank Accession AC152405, 21 March 2006",INACTIVE
696,US,B2,US 8448852 B2,174-805-142-612-933,2013-05-28,2013,US 68117507 A,2007-03-01,US 68117507 A;;US 88730707 P,2007-01-30,Open system account remote validation for access,"At each of a plurality of point of sale terminals (POS) of a transit system, for each of a plurality of riders, each seeking access to a facility of the transit system by using a payment device issued by an issuer in a payment system, data is read from the payment device, where the data includes an identifier for an account issued by an issuer. For each such access, a communication including the identifier is addressed to a network address of a system remote from the payment processing system and each of POS terminals. A response to the communication is received including information regarding whether access is granted based upon the identifier being on a list keep by the remote system. If access is granted, the rider is permitted access to the facility and the payment device is unchanged for the fare.",DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID;;VISA USA INC,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,VISA U.S.A. INC (2007-05-11),https://lens.org/174-805-142-612-933,Granted Patent,yes,48,22,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/36;;G06K5/00;;G07B15/02;;G06Q20/14,235/380;;235/375,9,0,,,"English Translation of Japanese Publication 2004-48193, Masanao, et al.;;International Search Report and Written Opinion corresponding to the PCT application No. PCT/US07/82852, date of mailing Apr. 18, 2008, 6 pages total.;;Examiner's Report for IP Australian application AU2007345583 (Nov. 17, 2011).;;International Search report for application PCT/US07/82842 (Apr. 1, 2008).;;International Search report for application PCT/US07/82887 (May 7, 2008).;;International Search report for application PCT/US07/82898 (May 7, 2008).;;International Search report for application PCT/US07/82903 (Aug. 8, 2008).;;Nationamaster.com http://www.statemaster.com/encyclopedia/Mybi. Retrieved online May 10, 2010. @ 2003-2005.;;Office Action mailed Jun. 5, 2012 in U.S. Appl. No. 12/883,919, 17 pages.",ACTIVE
697,CA,A1,CA 2738243 A1,179-623-885-158-879,2010-07-08,2010,CA 2738243 A,2009-10-29,US 10947408 P;;US 2009/0062611 W,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,"The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated dis-orders, are also disclosed.",WYETH LLC,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,,https://lens.org/179-623-885-158-879,Patent Application,no,0,0,44,44,10,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/19;;A61K9/00;;A61K39/395;;A61P35/00;;G06F19/00,,0,0,,,,ACTIVE
698,NZ,A,NZ 580217 A,170-074-631-183-832,2011-07-29,2011,NZ 58021708 A,2008-04-23,US 91427907 P;;US 2008/0061301 W,2007-04-26,PRODUCTION OF PROANTHOCYANIDINS TO IMPROVE FORAGE QUALITY,"Disclosed are methods and compositions for the modulation of anthocyanin and proanthocyanidin production in plants using LAP polypeptides. The specification discloses sequences for these polypeptides, and their use to transform plants, particularly food and forage crops.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;MODOLO LUZIA V;;PEEL GREGORY,,https://lens.org/170-074-631-183-832,Patent Application,no,0,0,8,8,0,A23V2002/00;;C07K14/415;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K20/121;;A23K50/10;;A23L5/43;;A23L33/105;;C07K14/415;;A23V2002/00;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K50/10;;A23K20/121;;A23L5/43;;A23L33/105,C12N15/82;;A01H5/00;;A23K10/32;;A23L1/00,,0,0,,,,DISCONTINUED
699,WO,A2,WO 1996/015239 A2,182-418-927-492-011,1996-05-23,1996,US 9514149 W,1995-11-01,US 33912994 A,1994-11-14,ISOFLAVONE REDUCTASE PROMOTER,The invention relates to a promoter and associated control elements derived from the isoflavone reductase gene. The upstream activating region and portions thereof have been characterized as to their ability to control the transcription of operably linked foreign structural genes in legumes as well as in plants which lack the isoflavonoid pathway.,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;PAIVA NANCY L;;OOMMEN ABRAHAM,,https://lens.org/182-418-927-492-011,Patent Application,no,0,7,9,9,1,C12N9/001;;C12N15/8239;;C12N9/001;;C12N15/8239,C12N5/10;;C12N9/02;;C12N15/00;;A01H5/00;;C12N15/09;;C12N15/82;;C12R1/91,,0,0,,,,PENDING
700,CA,A1,CA 2676396 A1,180-461-929-746-573,2008-08-07,2008,CA 2676396 A,2007-10-29,US 88730707 P;;US 68117407 A;;US 2007/0082842 W,2007-01-30,DELAYED TRANSIT FARE ASSESSMENT,"At each of a plurality of point of sale terminals (POS) of a merchant, fo r each of a plurality of consumers, where each consumer seeks to conduct a t ransaction with the merchant for a good or service at a cost by using a paym ent device issued by an issuer in a payment system, data is read from a paym ent device. The data can include an identifier for an account issued by an i ssuer. Information is stored for each transaction and the consumer is permit ted to receive the good or service from the merchant. After the consumer has received the good or service, a batch of the transaction are processed to d erive there from the respective costs that are assessable to the respective accounts, where the merchant can be a transit system, the consumer a rider t hereon, and the transaction can be access to a facility thereof.",VISA USA INC,EL-AWADY KHALID;;HAMMAD AYMAN A;;DIXON PHIL,,https://lens.org/180-461-929-746-573,Patent Application,no,0,2,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/14;;G06Q20/36;;G07B15/02,,0,0,,,,DISCONTINUED
701,AU,A1,AU 2003/213674 A1,191-280-559-576-314,2003-09-09,2003,AU 2003/213674 A,2003-02-27,US 8771402 A;;US 0306397 W,2002-02-28,VANILLIN BIOSYNTHETIC PATHWAY ENZYME FROM VANILLA PLANIFOLIA,,DAVID MICHAEL AND CO INC,DIXON RICHARD A;;HAVKIN-FRENKEL DAPHNA;;PODSTOLSKI ANDRZEJ,,https://lens.org/191-280-559-576-314,Patent Application,no,0,0,5,5,0,C07C2/32;;C07C2531/22;;C07D213/53;;C07F15/02;;C07F15/025;;C08F10/00;;C12N5/04;;C12N9/00;;C12N9/0006;;C12N9/0077;;C12N15/8207;;C12N15/8243;;C12P7/24;;A01H4/002;;C08F10/00;;C12N9/0077;;C12N5/04;;C07C2531/22;;C07F15/02;;C07F15/025;;C12P7/24;;C12N9/0006;;C12N9/00;;C07C2/32;;C07D213/53;;C12N15/8243;;C12N15/8207;;A01H4/002,A01H4/00;;C07C2/32;;C07D213/53;;C07F15/02;;C08F10/00;;C12N5/04;;C12N9/00;;C12N9/02;;C12N9/04;;C12N15/29;;C12N15/82;;C12P7/24,,0,0,,,,DISCONTINUED
702,EP,A1,EP 0981623 A1,185-113-419-402-245,2000-03-01,2000,EP 98922292 A,1998-05-14,US 9809863 W;;US 4647597 P,1997-05-14,GENE ENCODING FOR SYSTEMIC ACQUIRED RESISTANCE IN ARABIDOPSIS,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;CAMERON ROBIN;;LAMB CHRISTOPHER J,,https://lens.org/185-113-419-402-245,Patent Application,yes,0,0,7,7,0,C07K14/415;;C12N15/8281,C07K14/415;;C07K16/16;;C12N5/10;;C12N15/09;;C12N15/29;;A01H5/00;;C12N15/82,,0,0,,,,DISCONTINUED
703,US,B2,US 9256875 B2,000-444-482-078-043,2016-02-09,2016,US 201514611061 A,2015-01-30,US 201514611061 A;;US 201213564625 A;;US 68117907 A;;US 88730707 P,2007-01-30,Processing transactions of different payment devices of the same issuer account,"Each portable payment device associated with a single account within a payment processing system is distinguished using track data. The track data from the portable payment device is read at each of a plurality of merchant point of sale terminals (POS). Rather than relying on the PAN alone, a merchant may utilizes the track data, or a proxy thereof, as the unique identifier for the portable payment device. The merchant may then process transactions involving the portable payment device based on the unique identifier. For example, in the transit environment the transit fare for each rider with different portable payment devices but the same account can be calculated using the unique identifier, such as the full track data read from both tracks of the corresponding portable payment devices.",DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID;;VISA USA INC,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,VISA U.S.A. INC (2007-05-11),https://lens.org/000-444-482-078-043,Granted Patent,yes,94,9,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06K5/00;;G06Q20/02;;G06Q20/14;;G06Q20/04;;G06Q20/08;;G06Q20/20;;G06Q20/32;;G06Q20/34;;G06Q20/36;;G06Q20/38;;G06Q20/40;;G07B15/00;;G07B15/02,,56,0,,,"ISO/I EC 7812 Standard. [online] Jan. 27, 2007. Retrieved from the Internet: <URL:en.wikipedia.org/w/index.php?title=IS0/1 EC 7812&oldid= 1 03608433.;;MYBI [online] NATIONMASTER.COM 2003-2005. Retrieved from the Internet: , 2 pages.;;U.S. Appl. No. 11/681,174, ""Final Office Action"", Oct. 19, 2009, 22 pages.;;U.S. Appl. No. 11/681,174, ""Final Office Action"", Mar. 14, 2011, 9 pages.;;U.S. Appl. No. 11/681,174, ""Non-Final Office Action"", Aug. 13, 2014, 14 pages.;;U.S. Appl. No. 11/681,174, ""Non-Final Office Action"", Nov. 21, 2008, 22 pages.;;U.S. Appl. No. 11/681,174, ""Non-Final Office Action"", May 14, 2010, 23 pages.;;U.S. Appl. No. 11/681,175, ""Final Office Action"", Jun. 29, 2010, 13 Pages.;;U.S. Appl. No. 11/681,175, ""Non-Final Office Action"", Dec. 24. 2009, 13 Pages.;;U.S. Appl. No. 11/681,175, ""Non-Final Office Action"", Aug. 19, 2011, 14 Pages.;;U.S. Appl. No. 11/681,175, ""Non-Final Office Action"", Jan. 14, 2011, 15 Pages.;;U.S. Appl. No. 11/681,175, ""Notice of Allowance"", Mar. 27, 2012, 8 pages.;;U.S. Appl. No. 11/681,175, ""Notice of Allowance"", Jan. 28, 2013, 9 pages.;;U.S. Appl. No. 11/681,176, ""Final Office Action"", Apr. 19, 2011, 13 pages.;;U.S. Appl. No. 11/681,176, ""Final Office Action"", Mar. 7, 2012, 16 pages.;;U.S. Appl. No. 11/681,176, ""Non-Final Office Action"", Oct. 13, 2010, 13 pages.;;U.S. Appl. No. 11/681,176, ""Non-Final Office Action"", Nov. 2, 2011, 14 pages.;;U.S. Appl. No. 11/681,176, ""Notice of Allowability"", Jan. 18, 2013, 15 pages.;;U.S. Appl. No. 11/681,176, ""Notice of Allowability"", Jan. 9, 2013, 15 pages.;;U.S. Appl. No. 11/681,176, ""Notice of Allowance"", Nov. 27, 2012, 18 pages.;;U.S. Appl. No. 11/681,179, ""Final Office Action"", Jul. 21, 2010, 20 pages.;;U.S. Appl. No. 11/681,179, ""Non-Final Office Action"", Jun. 4, 2009, 15 pages.;;U.S. Appl. No. 11/681,179, ""Non-Final Office Action"", May 5, 2011, 20 pages.;;U.S. Appl. No. 11/681,179, ""Notice of Allowance"", Jan. 6, 2012, 9 pages.;;U.S. Appl. No. 11/681,179, ""Supplemental Notice of Allowance"", May 3, 2012, 7 pages.;;U.S. Appl. No. 11/713,307, ""Non-Final Office Action"", Sep. 9, 2009, 17 Pages.;;U.S. Appl. No. 11/713,307, ""Notice of Allowance"", Jun. 1, 2010, 10 Pages.;;U.S. Appl. No. 12/883,919, ""Non-Final Office Action"", Jun. 5, 2012, 17 pages.;;U.S. Appl. No. 12/883,919, ""Notice of Allowance"", Nov. 29, 2012, 16 pages.;;U.S. Appl. No. 13/564,625, ""Final Office Action"", Jul. 25, 2013, 13 pages.;;U.S. Appl. No. 13/564,625, ""Non-Final Office Action"", Dec. 19, 2012, 13 pages.;;U.S. Appl. No. 13/564,625, ""Non-Final Office Action"", Mar. 24, 2014, 13 pages.;;U.S. Appl. No. 13/564,625, ""Notice of Allowance"", Oct. 31, 2014, 8 Pages.;;U.S. Appl. No. 13/776,421, ""Final Office Action"", Mar. 6, 2014, 12 pages.;;U.S. Appl. No. 13/776,421, ""Non-Final Office Action"", Jun. 12, 2014, 10 pages.;;U.S. Appl. No. 13/776,421, ""Non-Final office action"", Nov. 18, 2013, 12 pages.;;U.S. Appl. No. 13/776,421, ""Non-Final Office Action"", Jan. 7, 2015, 5 pages.;;U.S. Appl. No. 13/872,637, ""Non Final Office Action"", Oct. 10, 2013, 6 pages.;;U.S. Appl. No. 13/872,637, ""Notice of Allowance"", Dec. 16, 2013, 11 pages.;;U.S. Appl. No. 13/564,625, ""Non-Final Office Action"", Jul. 25, 2013, 13 pages.;;AU2007345583, ""First Examiner Report"", Nov. 17, 2011, 2 pages.;;KR10-2008-7017975, ""Office Action"", Nov. 13, 2013, 8 pages.;;KR10-2009-7017975, ""Notice of Allowance"", Jan. 14, 2015, 5 pages.;;KR10-2009-7017975, ""Office Action"", Sep. 10, 2014, 3 pages.;;KR10-2009-7017980, ""Office Action"", Nov. 30, 2013, 3 pages.;;KR10-2009-7017982, ""Office Action"", Sep. 10, 2014, 6 pages.;;KR10-2009-7017982, ""Office Action"", Feb. 12, 2015, 7 pages.;;PCT/US2007/082842, ""International Preliminary Report on Patentability"", Aug. 4, 2009, 5 pages.;;PCT/US2007/082842, ""International Search Report and Written Opinion"", Apr. 1, 2008, 5 pages.;;PCT/US2007/082852 ""International Search Report and Written Opinion"", Apr. 18, 2008, 6 pages.;;PCT/US2007/082887, ""International Search Report and Written Opinion"", May 7, 2008, 7 pages.;;PCT/US2007/082898, ""International Preliminary Report on Patentability"", Aug. 4, 2009, 6 pages.;;PCT/US2007/082898, ""International Search Report and Written Opinion"", May 7, 2008, 6 pages.;;PCT/US2007/082903, ""International Preliminary Report on Patentability"", Aug. 4, 2009, 6 pages.;;PCT/US2007/082903, ""International Search Report and Written Opinion"", Aug. 20, 2008, 6 pages.;;Office Action mailed Jun. 12, 2015 in U.S. Appl. No. 11/681,174, 21 pages.",ACTIVE
704,WO,A1,WO 1995/022805 A1,013-062-654-733-461,1995-08-24,1995,US 9409448 W,1994-08-19,US 19721894 A;;US 25080194 A,1994-02-16,CREDIT CARD WITH MAGNIFYING LENS,"A financial transaction card adapted for use in reading externally stored information including a substantially non-foldable, substantially rectangular rigid base and machine-readable information carried on the base. The rigid base comprises a magnifying lens.",FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/013-062-654-733-461,Patent Application,yes,1,1,5,54,0,G06K19/041,G06K19/04,,0,0,,,,PENDING
705,CA,A1,CA 2162893 A1,046-250-396-167-959,1995-08-24,1995,CA 2162893 A,1994-08-19,US 19721894 A;;US 25080194 A;;US 9409448 W,1994-02-16,CREDIT CARD WITH MAGNIFYING LENS,"A financial transaction card adapted for use in reading externally stored information including a substantially non-foldable, substantially rectangular rigid base and machine-readable information carried on the base. The rigid base comprises a magnifying lens.",FINKELSTEIN ALAN,BOEDE ROBERT H;;DIXON DONALD A;;FINKELSTEIN ALAN,,https://lens.org/046-250-396-167-959,Patent Application,no,0,0,5,54,0,G06K19/041,G06K19/04,,0,0,,,,EXPIRED
706,WO,A1,WO 1993/016445 A1,062-885-983-721-431,1993-08-19,1993,US 9301176 W,1993-02-09,US 83449092 A,1992-02-12,CREDIT CARD WITH MAGNIFYING LENS,A credit card (10) includes an integral magnifying lens (24) positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip (14) and the embossed indicia (12) associated with the card is not impaired. The magnifying lens (24) incorporates a fresnel-type contour lens (36) mounted in a window (25) provided in the credit card base.,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/062-885-983-721-431,Patent Application,yes,8,5,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,G2J JVAX          JVAX;;U1S S2271,0,0,,,,PATENTED
707,WO,A3,WO 2010/077422 A3,090-765-980-188-829,2010-11-18,2010,US 2009/0062611 W,2009-10-29,US 10947408 P,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,"The invention relates to formulations of single domain antigen binding molecules, e.g. , nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g. , as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g. , TNF-associated disorders, are also disclosed.",WYETH LLC;;FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,,https://lens.org/090-765-980-188-829,Search Report,yes,4,0,44,44,0,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/19;;A61K9/00;;A61K39/395;;A61P35/00;;G06F19/00,,1,1,015-692-072-798-109,17097246;;10.1016/j.ijpharm.2006.09.015,"YANG ET AL: ""Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: Preparation and in vitro evaluation"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL LNKD- DOI:10.1016/J.IJPHARM.2006.09.015, vol. 331, no. 1, 31 January 2007 (2007-01-31), pages 123 - 132, XP005867347, ISSN: 0378-5173",PENDING
708,EP,A1,EP 4104821 A1,120-577-054-111-716,2022-12-21,2022,EP 22174073 A,2009-10-29,US 10947408 P;;EP 15189934 A;;EP 09748625 A;;US 2009/0062611 W,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,"The invention relates to formulations of single domain antigen binding molecules, e.g. nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g. bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.",ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,,https://lens.org/120-577-054-111-716,Patent Application,yes,80,0,44,44,10,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/19;;A61K9/00;;A61K39/395;;A61P35/00,,31,20,091-234-354-982-068;;090-754-759-154-175;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;069-778-338-173-349;;050-959-366-576-084;;022-375-749-274-329;;104-212-297-137-759;;023-676-781-371-861;;085-277-440-303-853;;055-933-943-437-663;;005-648-278-768-326;;020-026-345-586-213;;092-023-577-402-127;;039-508-259-975-855;;002-664-741-683-318;;021-641-900-032-887;;125-439-449-787-91X;;038-371-868-499-013,8124728;;10.1023/a:1015825027737;;2052513;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;16199666;;pmc2253229;;10.1110/ps.051709505;;10.1038/363446a0;;8502296;;1675655;;10.4049/jimmunol.147.1.60;;10.4049/jimmunol.148.5.1547;;1531669;;10.1126/science.3929380;;3929380;;10.1038/ng0594-13;;8075633;;10.1038/314452a0;;3920533;;10.1073/pnas.80.23.7308;;6316357;;pmc390044;;25291284;;10.1016/0167-5699(83)90123-8;;1404388;;10.1016/0022-2836(92)90223-7;;7779254;;10.1016/0167-5699(95)80166-9;;10.1016/0022-2836(92)90224-8;;1404389;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;10.1038/nrd1033;;12612647;;10.1093/protein/gzg093;;14600206,"CLELAND ET AL., CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, vol. 10, no. 4, 1993, pages 307 - 377;;PIKAL, M, BIOPHANN, vol. 3, no. 9, 1990, pages 26 - 30;;ARAKAWA ET AL., PHARM. RES., vol. 8, no. 3, 1991, pages 285 - 291;;NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;E. MEYERSW. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17;;ALTSCHUL, J. MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402;;STRELTSOV, PROTEIN SCI., vol. 14, 2005, pages 2901 - 2909;;HAMERS-CASTERMAN, C. ET AL., NATURE, vol. 363, 1993, pages 446 - 448;;HASEMANN AND J. DONALD CAPRA: ""Fundamental Immunology"", vol. 209, 1989, article "" Immunoglobulins: Structure and Function"", pages: 210 - 218;;TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60 - 69;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;MORRISON, SCIENCE, vol. 229, 1985, pages 1202 - 1207;;GREEN, NATURE GENETICS, vol. 7, 1994, pages 13 - 21;;MORRISON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1985, pages 6851;;TAKEDA ET AL., NATURE, vol. 314, 1985, pages 452;;BIOTECHNIQUES, vol. 4, 1986, pages 214;;TENG ET AL., PROC. NATL. ACAD. SET U.S.A., vol. 80, 1983, pages 7308 - 7312;;KOZBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 7279;;OLSSON ET AL., METH. ENZYMOL., vol. 92, 1982, pages 3 - 16;;TOMLINSON ET AL., J. MOL. BIOL., vol. 227, 1992, pages 776 - 798;;COOK, G. P., IMMUNOL. TODAY, vol. 16, no. 5, 1995, pages 237 - 242;;CHOTHIA, D. ET AL., J. MOL. BIOL., vol. 227, pages 799 - 817;;TOMLINSON ET AL., EMBOJ, vol. 14, 1995, pages 4628 - 4638;;""Current Protocols in Molecular Biology"", 1990;;""Remington's Pharmaceutical Sciences"", 1980, MACK PUBLISHING CO.;;CHAPMAN, NAT. BIOTECHNOL., vol. 54, 2002, pages 531 - 545;;VERONESEHARRIS, ADV. DRUG DELIV., vol. 54, 2003, pages 453 - 456;;HARRISCHESS, NAT. REV. DRUG. DISCOV, vol. 2, 2003;;YANG ET AL., PROTEIN ENGINEERING, vol. 16, no. 10, 2003, pages 761 - 770;;GUPTA ET AL., AAPS PHARM. SCI., vol. 8, 2003, pages 1 - 9",PENDING
709,CN,A,CN 107921121 A,123-391-253-381-616,2018-04-17,2018,CN 201680024600 A,2016-03-04,US 201562128462 P;;US 2016/0020980 W,2015-03-04,ANTIBODY THERAPEUTICS THAT BIND CD47,"The invention discloses compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, there is disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.",SORRENTO THERAPEUTICS INC,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,,https://lens.org/123-391-253-381-616,Patent Application,no,6,1,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,A61K39/395;;C07K16/18;;C07K16/28,,2,2,115-916-015-721-506;;066-756-238-112-737,14985099;;10.1016/j.bbrc.2004.01.128;;25721088;;pmc4886734;;10.1016/j.canlet.2015.02.036,"KIKUCHI Y ET AL.: ""A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cells"", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》;;XIAO XHENYU ET AL.: ""Antibosy mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma"", 《CANCER LETTERS》",ACTIVE
710,AU,B2,AU 699496 B2,150-123-694-596-653,1998-12-03,1998,AU 1995/039727 A,1995-11-01,US 33912994 A;;US 9514149 W,1994-11-14,Isoflavone reductase promoter,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;PAIVA NANCY L;;OOMMEN ABRAHAM,,https://lens.org/150-123-694-596-653,Granted Patent,no,0,0,9,9,0,C12N9/001;;C12N15/8239;;C12N9/001;;C12N15/8239,A01H5/00;;C12N5/10;;C12N9/02;;C12N15/00;;C12N15/09;;C12N15/82;;C12R1/91,,0,0,,,,EXPIRED
711,US,A1,US 2010/0064387 A1,193-856-823-710-01X,2010-03-11,2010,US 54924809 A,2009-08-27,US 54924809 A;;US 9300608 P,2008-08-29,EPICATECHIN GLUCOSYLTRANSFERASE,"The invention provides methods and compositions for the modulation of epicatechin glucosyltransferase activity in plants. Increased expression of epicatechin glucosides, and ultimately anthocyanins and proanthocyanidins, in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased proanthocyanidin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;PANG YONGZHEN;;PEEL GREGORY J,THE SAMUEL ROBERTS NOBLE FOUNDATION (2009-09-02);;NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/193-856-823-710-01X,Patent Application,yes,2,1,6,6,66,C12N15/8243;;C12N15/8243;;C12N9/1051;;C12N9/1051,A01H1/00;;A01H5/00;;C07H21/00;;C12N5/04;;C12N9/10;;C12N15/74,800/278;;536/23.1;;435/320.1;;435/193;;800/295;;800/298;;435/419,2,2,055-003-061-629-507;;123-127-395-374-005,10.1073/pnas.0403255101;;pmc438954;;15197260;;pmc2544603;;10.1073/pnas.0805954105;;18772380,"Guo et al., 2004, Protein tolerance to random amino acid change, PNAS 101(25):9205-9210.;;Pang et al, A transcript profiling approach reveals an epicatechin-specific glycosyltransferas expressed in the seed coat of Medicago truncatula, 2008, PNAS 105:14210-14215",ACTIVE
712,US,A1,US 2016/0263220 A1,199-566-066-730-55X,2016-09-15,2016,US 201615041690 A,2016-02-11,US 201615041690 A;;US 60855309 A;;US 10947408 P,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,"The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.",ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,ABLYNX N.V (2011-11-18);;WYETH LLC (2009-12-18),https://lens.org/199-566-066-730-55X,Patent Application,yes,1,4,44,44,10,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K39/395;;A61K9/00;;A61K9/16;;A61K9/19;;C07K16/18;;C07K16/24;;G01N33/15,,0,0,,,,ACTIVE
713,BR,A,BR 9305870 A,008-533-739-455-656,1997-08-19,1997,BR 9305870 A,1993-02-09,US 83449092 A;;US 9301176 W,1992-02-12,Cartão para transações financeiras de uso individual cartão de crédito e cartão que contém informações armazenadas externamente ao cartão,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,BOEDE ROBERT H;;DIXON DONALD A;;FINKELSTEIN ALAN,,https://lens.org/008-533-739-455-656,Patent Application,no,0,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,DISCONTINUED
714,WO,A1,WO 2008/094324 A1,029-308-408-296-022,2008-08-07,2008,US 2007/0082842 W,2007-10-29,US 88730707 P;;US 68117407 A,2007-01-30,DELAYED TRANSIT FARE ASSESSMENT,"At each of a plurality of point of sale terminals (POS) of a merchant, for each of a plurality of consumers, where each consumer seeks to conduct a transaction with the merchant for a good or service at a cost by using a payment device issued by an issuer in a payment system, data is read from a payment device. The data can include an identifier for an account issued by an issuer. Information is stored for each transaction and the consumer is permitted to receive the good or service from the merchant. After the consumer has received the good or service, a batch of the transaction are processed to derive there from the respective costs that are assessable to the respective accounts, where the merchant can be a transit system, the consumer a rider thereon, and the transaction can be access to a facility thereof.",VISA USA INC;;DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,,https://lens.org/029-308-408-296-022,Patent Application,yes,5,1,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/36;;G06Q20/14;;G07B15/02,,0,0,,,,PENDING
715,JP,A,JP 2015091844 A,031-395-149-234-512,2015-05-14,2015,JP 2014262998 A,2014-12-25,US 10947408 P,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,"PROBLEM TO BE SOLVED: To provide a single domain antigen binding molecule (SDAB) for particularly subcutaneous administration to treat or prevent TNF-associated disorders and the like, which is stable for long-term storage and delivery, particularly to provide formulations of TNF-binding nanobody molecules.SOLUTION: The invention provides a formulation contains a) an SDAB molecule comprising one or more single domain molecules, wherein at least one single domain molecule binds to a human serum albumin (HSA), the concentration is about 0.1 mg/mL to about 350 mg/mL, and a single domain molecule bound to e.g., at least one, preferably two tumor necrosis factors α are comprised; (b) a freeze-dried protective agent; and (c) histidine buffer solution with a concentration of about 5 mM to about 50 mM so that the pH of a formulation is about 5.0-7.5.",ABLYNX NV,JASON E FERNANDEZ;;DANIEL A DIXON;;ANDREA PAULSON,,https://lens.org/031-395-149-234-512,Patent Application,no,7,0,44,44,10,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K39/395;;A61K9/08;;A61K47/02;;A61K47/10;;A61K47/18;;A61K47/22;;A61K47/26;;A61K47/34;;A61P1/00;;A61P3/10;;A61P5/00;;A61P9/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P37/02;;A61P37/06;;A61P37/08,,1,0,,,"""UNDERSTANDING NANOBODIES"", アブリンクス社ホームページ, [2015/11/13検索], JPN6015046835, ISSN: 0003200104",ACTIVE
716,US,A,US 5750399 A,045-434-661-318-245,1998-05-12,1998,US 33912994 A,1994-11-14,US 33912994 A,1994-11-14,Isoflavone reductase promoter,The invention relates to a promoter and associated control elements derived from the isoflavone reductase gene. The upstream activating region and portions thereof have been characterized as to their ability to control the transcription of operably linked foreign structural genes in legumes as well as in plants which lack the isoflavonoid pathway.,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;PAIVA NANCY L;;OOMMEN ABRAHAM,SAMUEL ROBERTS NOBLE FOUNDATION INC. THE (1995-02-13),https://lens.org/045-434-661-318-245,Granted Patent,yes,1,20,9,9,1,C12N9/001;;C12N15/8239;;C12N9/001;;C12N15/8239,C12N5/10;;C12N9/02;;C12N15/00;;C12N15/09;;A01H5/00;;C12N15/82;;C12R1/91,435/419;;435/172.3;;435/189;;435/320.1;;536/23.2;;536/23.6;;536/24.1;;800/205,39,37,163-472-490-948-263;;011-007-941-039-179;;008-962-487-026-235;;096-145-153-924-643;;037-345-842-626-912;;073-012-114-277-304;;078-993-209-042-412;;029-727-195-335-396;;044-608-223-081-058;;071-551-288-641-153;;077-929-348-534-879;;010-489-871-119-461;;107-127-454-132-808;;015-906-607-993-21X;;050-117-844-928-785;;013-652-342-029-678;;065-929-544-495-189;;041-887-373-948-054;;009-083-455-089-27X;;130-701-103-467-718;;014-294-400-140-526;;003-474-525-636-946;;028-540-007-072-706;;018-203-650-301-504;;017-181-299-596-454;;022-630-949-392-94X;;039-298-796-880-058;;102-862-868-293-328;;050-157-730-588-897;;056-222-825-326-204;;044-109-537-504-280;;047-204-724-955-524;;099-667-217-717-81X;;120-924-541-109-262;;033-472-458-125-722;;012-907-360-890-280;;023-609-811-432-945,10.1007/bf00033879;;17835349;;10.1126/science.244.4901.174;;3469655;;pmc304345;;10.1073/pnas.84.4.980;;6791577;;10.1146/annurev.bi.50.070181.002025;;8208857;;10.1104/pp.103.1.41;;pmc158944;;10.1046/j.1365-313x.1993.04010125.x;;8220470;;1600949;;pmc556698;;10.1002/j.1460-2075.1992.tb05290.x;;10.2307/3869509;;10.1105/tpc.4.11.1371;;1477553;;pmc160225;;6353887;;10.1002/9780470123010.ch1;;2239449;;10.1016/s0065-2660(08)60527-1;;2050114;;pmc452848;;10.1002/j.1460-2075.1991.tb07701.x;;pmc160226;;10.2307/3869510;;1477554;;10.1105/tpc.4.11.1383;;pmc160058;;10.1105/tpc.3.9.893;;10.2307/3869153;;12324622;;10.1073/pnas.88.6.2515;;2006188;;pmc51263;;10.1086/297074;;10.1126/science.241.4863.346;;17734864;;10.1002/j.1460-2075.1987.tb02730.x;;pmc553867;;3327686;;10.1104/pp.94.1.227;;pmc1077214;;16667691;;2643475;;10.1016/0092-8674(89)90894-5;;10.1073/pnas.86.23.9284;;2594769;;pmc298479;;10.1016/0966-842x(93)90088-9;;8143136;;pmc50099;;1409628;;10.1073/pnas.89.19.9230;;10.1002/j.1460-2075.1989.tb03554.x;;pmc401003;;2767049;;10.2307/3869592;;pmc160266;;10.1105/tpc.5.3.241;;8467221;;pmc159873;;10.2307/3868928;;10.1105/tpc.2.2.163;;2136633;;2152131;;10.2307/3869320;;pmc159934;;10.1105/tpc.2.9.837;;17839183;;10.1126/science.263.5144.221;;1912490;;10.1007/bf00037051;;10.1006/abbi.1994.1338;;8037464;;7378947;;10.1139/m80-092;;pmc159916;;2136636;;10.2307/3869125;;10.1105/tpc.2.7.619;;10.1007/bf00020507;;24272801;;10.1094/mpmi-3-381;;10.1007/bf00042344;;8292775;;1915347;;10.1111/j.1432-1033.1991.tb16241.x;;10.1016/b978-0-12-675407-0.50010-5;;10.1046/j.1365-313x.1993.03060805.x;;8401613;;10.1111/j.1365-313x.1993.00805.x,"Oommen, et al., Analysis of genomic clone for isoflavone reductase a defense response gene from alfalfa, J Cell Biochem , Suppl 0, 46 Part F, p. 220, abstract Y222 (1992).;;Paiva, et al., Regulation of isoflavonoid metabolism is alfalfa, Plant Cell Tissue and Organ Culture 38:213 220 (1994).;;Benfey, PN and Chua, NH, Regulated genes in transgenic plants, Science 244:174 181 (1989).;;Binns, et al., Cell division promoting activity of naturally occurring dehydrodiconiferyl glucosides: do cell wall components control cell division Proc Natl Acad Sci USA 84:980 984 (1987).;;Breathnach, U and Chambon, P, Organization and expression of eukaryotic split genes coding for proteins, Annu Rev Biochem 50:349 383 (1981).;;Burnett, et al., Expression of a 3 hydroxy 3 methylglutaryl coenzyme A reductase gene from Camptotheca acuminata is differentially regulated by wounding and methyl jasmonate, Plant Physiol 103:41 48 (1993).;;da Costa e Silva, et al., BPF 1, a pathogen induced DNA binding protein involved in the plant defense response, Plant J 4:125 135 (1993).;;Dickey, et al., Light regulatory sequences are located within the 5 portion of the Fed 1 message sequence, EMBO J 11:2311 2317 (1992).;;Dietrich, et al., Downstream DNA sequences are required to activate a gene expressed in the root cortex of embryos and seedlings, Plant Cell 4:1371 1382 (1992).;;Dixon, et al., Phytoalexins: enzymology and molecular biology, Adv Enzymol Related Areas Mol Biol 55:1 135 (1983).;;Dixon, RA and Harrison, MJ, Activation, structure and organization of genes involved in microbial defense in plants, Adv Genetics 28:165 234 (1990).;;Douglas, et al., Exonic sequences are required for elicitor and light activation of a plant defense gene, but promoter sequences are sufficient for tissue specific expression, EMBO J 10:1767 1775 (1991).;;Drews, et al., Regional and cell specific gene expression patterns during petal developments, Plant Cell 4:1383 1404 (1992).;;Fritze, et al., Developmental and UV light regulation of the snapdragon chalcone synthase promoter, Plant Cell 3:893 905 (1991).;;Harrison, et al., Characterization of a nuclear protein that binds to three elements within the silencer region of a bean chalcone synthase gene promoter, Proc Natl Acad Sci USA 88:2515 2519 (1991).;;Hirsch, et al., Bacterial induced changes in plant form and function, Int J Plant Sci 153:S171 S181 (1992).;;Jacobs, M. and Rubery, PH, Naturally occurring auxin transport regulators, Science 241:346 349 (1988).;;Jefferson, et al., GUS fusions: glucuronidase as a sensitive and versatile gene fusion marker in higher plants, EMBO J 6:3901 3907 (1987).;;Kessman, et al., Stress responses in alfalfa ( Medicago sativa L.) V. Constitutive and elicitor induced accumulation of isoflavonoid conjugates in cell suspension cultures, Plant Physiology 94:227 232 (1990).;;Lamb, et al., Signals and transduction mechanisms for activation of plant defenses against microbial attack, Cell 56:215 224 (1989).;;Liang, et al., Developmental and environmental regulation of a phenylalanine ammonia lyase glucuronidase gene fusion in transgenic tobacco plants, Proc Natl Acad Sci USA 86:9284 9288 (1989).;;Lindsay, et al., eds., Microbial recognition and activation of plant defense systems, Trends Microbiol 1:181 187 (1993).;;Loake, et al., Combination of H box CCTACC(N) 7 CT and G box CACGTG cis elements is necessary for feedforward stimulation of a chalcone synthase promoter by the phenylpropanoid pathway intermediate p coumaric acid, Proc Natl Acad Sci USA 89:9230 9234 (1992).;;Lois, et al., A phenylalanine ammonia lyase gene from parsley; structure, regulation and identification of elicitor and light responsive cis acting elements, EMBO J. 8:1641 1648 (1989).;;Mason, et al., Identification of a methyl jasmonate responsive domain in the soybean vspB promoter, Plant Cell 5:241 251 (1993).;;McElroy, et al., Isolation of an efficient actin promoter for use in rice transformation, Plant Cell 2:163 171 (1990).;;Ohl, et al., Functional properties of a phenylalanine ammonia lyase promoter from Arabidopsis, Plant Cell 2:837 848 (1990).;;Oppermann, et al., Root knot nematode directed expression of plant root specific gene, Science 263:221 223 (1994).;;Paiva, et al., Stress responses in alfalfa ( Medicago sativa L.) 11. Molecular cloning and expression of alfalfa isoflavone reductase, a key enzyme of isoflavonoid phytoalexin biosynthesis, Plant Mol Biol 17:653 667 (1991).;;Paiva, et al., Molecular cloning of isoflavone reductase from pea ( Pisum sativum L.): evidence for a 3R isoflavanone intermediate in ( ) pisatin biosynthesis, Archives Biochem Biophys 312:501 510 (1994).;;Pankhurst, CE and Biggs, DR, Sensitivity of Rhizobium to selected isoflavonoids, Can J Microbiol 26:542 545 (1980).;;Schmid, et al., Developmental and environmental regulation of a bean chalcone synthase promoter in transgenic tobacco, Plant Cell 2:619 631 (1990).;;Somssich, et al., Differential early activation of defense related genes in elicitor treated parsley cells, Plant Mol Biol 12:227 234 (1989).;;Stermer, et al., Infection and stress activation of bean chalcone synthase promoters in transgenic tobacco, Mol Plant Microbe Interact 3:381 388 (1990).;;Sullivan, et al., Post transcriptional regulation of nuclear encoded genes in higher plants: the roles of mRNA stability and translation, Plant Mol Biol 23:1091 1104 (1993).;;Tiemann, et al., Pterocarpan phytoalexin biosynthesis in elicitor challenged chickpea ( Cicer arietinum L.) cell cultures: purification, characterization and cDNA cloning of NADPH: isoflavone oxidoreductase, Eur J Biochem 200:751 757 (1991).;;Wiermann, R., Secondary plant products and cell and tissue differentiation, In The Biochemistry of Plants , P.K. Stumpf and E.E. Conn, eds., New York, Academic Press, 7:85 116 (1981).;;Yu, et al., Purification and biochemical characterization of proteins which bind to the H box cis element implicated in transcriptional activation of plant defense genes, Plant J 3:805 816 (1993).;;Oomen et al. 1992. J. Cell. Biochem. Suppl. 16F:220 Oommen.",EXPIRED
717,CA,A1,CA 2204131 A1,052-268-367-681-775,1996-05-23,1996,CA 2204131 A,1995-11-01,US 33912994 A,1994-11-14,ISOFLAVONE REDUCTASE PROMOTER,The invention relates to a promoter and associated control elements derived from the isoflavone reductase gene. The upstream activating region and portions thereof have been characterized as to their ability to control the transcription of operably linked foreign structural genes in legumes as well as in plants which lack the isoflavonoid pathway.,SAMUEL ROBERTS NOBLE FOUND INC,OOMMEN ABRAHAM;;PAIVA NANCY L;;DIXON RICHARD A,,https://lens.org/052-268-367-681-775,Patent Application,no,0,0,9,9,0,C12N9/001;;C12N15/8239;;C12N9/001;;C12N15/8239,A01H5/00;;C12N5/10;;C12N9/02;;C12N15/00;;C12N15/09;;C12N15/82;;C12R1/91,,0,0,,,,DISCONTINUED
718,EP,A1,EP 2255448 A1,056-001-911-510-471,2010-12-01,2010,EP 09714157 A,2009-02-25,US 2009/0035172 W;;US 3107208 P,2008-02-25,VEHICLE SECURITY AND MONITORING SYSTEM,,RECOVERY SYSTEMS HOLDINGS LLC,BEVACQUA KURT;;OSMAN MARK A;;DIXON STEVEN C,,https://lens.org/056-001-911-510-471,Patent Application,yes,0,0,7,7,0,B60R25/102;;B60R25/33;;B60R2025/1016;;B60R2325/205;;G01S5/0027;;H04W8/24;;H04W64/00;;H04W12/126;;B60R25/33;;G01S5/0027;;B60R2025/1016;;H04W64/00;;B60R25/102;;B60R2325/205;;H04W8/24;;H04W12/126,B60R25/10;;H04B1/38;;G01S5/02;;G08G1/123;;H04B17/00;;H04W64/00,,0,0,,,,DISCONTINUED
719,TW,B,TW I719966 B,094-227-635-449-028,2021-03-01,2021,TW 105106782 A,2016-03-04,US 201562128462 P,2015-03-04,Antibody therapeutics that bind cd47,,SORRENTO THERAPEUTICS INC,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,,https://lens.org/094-227-635-449-028,Granted Patent,no,2,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,,,0,0,,,,ACTIVE
720,US,B2,US 8840114 B2,097-138-303-763-509,2014-09-23,2014,US 201213420100 A,2012-03-14,GB 201105182 A,2011-03-29,Assembly comprising a rotatable component,"An assembly, for example in a gas turbine engine, includes a rotatable component supported by a bearing in a support structure. A sealing arrangement includes a non-rotating sealing ring which makes sealing contact with sealing features on the rotatable component. The non-rotating sealing ring is radially displaceable with respect to the support structure by means of ribs which engage axially facing support faces of the support structure. The non-rotating sealing ring is radially located by an outer, non-rotating, race of the bearing, by means of a locating surface on a locating body of the non-rotating sealing ring. As a result of this arrangement, the running clearance at the sealing arrangement can be maintained, despite radial displacement of the rotatable component with respect to the support structure, and despite thermal and mechanical deflections of the support structure.",DIXON JEFFREY A;;UDALL KENNETH F;;NICHOLSON RICHARD;;ROLLS ROYCE PLC,DIXON JEFFREY A;;UDALL KENNETH F;;NICHOLSON RICHARD,ROLLS-ROYCE PLC (2012-02-22),https://lens.org/097-138-303-763-509,Granted Patent,yes,9,5,5,5,0,F01D25/183;;F01D25/183;;F01D11/04;;F01D11/04;;F05D2240/55;;F05D2240/55,F16J15/447;;F01D11/04;;F01D25/18,277/412,1,0,,,"British Search Report dated Jul. 22, 2011 issued in British Patent Application No. 1105182.8.",INACTIVE
721,MX,B,MX 345226 B,080-580-595-716-054,2017-01-20,2017,MX 2011004557 A,2009-10-29,US 10947408 P;;US 2009/0062611 W,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES.,"The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.",ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,ABLYNX N.V. (2012-07-09),https://lens.org/080-580-595-716-054,Granted Patent,no,0,0,44,44,0,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K39/395;;A61K9/00;;A61K9/19;;A61P35/00;;G06F19/00,,0,0,,,,ACTIVE
722,CA,C,CA 2129355 C,089-155-573-755-677,1999-08-10,1999,CA 2129355 A,1993-02-09,US 83449092 A;;US 9301176 W,1992-02-12,CREDIT CARD WITH MAGNIFYING LENS,A credit card (10) includes an integral magnifying lens (24) positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip (14) and the embossed indicia (12) associated with the card is not impaired. The magnifying tens (24) incorporates a fresnel-type contour lens (36) mounted in a window (25) provided in the credit card base.,,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/089-155-573-755-677,Granted Patent,no,0,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,EXPIRED
723,US,B2,US 9393304 B2,095-569-807-212-972,2016-07-19,2016,US 60855309 A,2009-10-29,US 60855309 A;;US 10947408 P,2008-10-29,Formulations of single domain antigen binding molecules,"The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.",FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA;;ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,ABLYNX N.V (2011-11-18);;WYETH LLC (2009-12-18),https://lens.org/095-569-807-212-972,Granted Patent,yes,101,6,44,44,10,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,C12P21/08;;A61K9/00;;A61K9/19;;A61K39/395;;A61K47/10;;A61K47/26;;C07K16/00;;G06Q99/00,,102,88,027-477-313-726-928;;029-611-134-469-353;;002-688-704-634-679;;072-677-789-622-276;;015-692-072-798-109;;056-201-471-905-934;;028-862-168-091-90X;;090-754-759-154-175;;045-375-597-992-763;;014-221-462-042-262;;005-585-893-014-176;;090-202-835-731-435;;178-753-379-974-063;;065-832-213-953-842;;085-597-883-496-167;;015-058-913-193-123;;049-134-753-209-354;;002-664-741-683-318;;021-281-191-729-211;;091-234-354-982-068;;030-063-586-948-460;;039-508-259-975-855;;078-227-590-332-589;;142-625-978-671-635;;028-677-787-189-119;;096-246-275-104-11X;;107-893-263-643-528;;048-980-207-062-312;;084-724-411-649-711;;043-796-369-932-016;;002-236-302-730-599;;181-848-098-428-701;;085-277-440-303-853;;064-136-916-388-59X;;034-598-659-452-885;;064-312-847-804-27X;;050-959-366-576-084;;092-986-814-359-292;;029-366-136-077-007;;047-697-041-421-417;;047-697-041-421-417;;125-439-449-787-91X;;075-144-617-501-360;;024-160-272-335-60X;;005-602-212-993-893;;028-948-486-931-641;;104-212-297-137-759;;020-026-345-586-213;;008-561-023-298-876;;024-042-191-114-154;;051-207-145-128-792;;016-841-733-546-324;;026-164-216-541-151;;030-607-398-087-475;;023-676-781-371-861;;002-584-557-858-587;;129-021-293-134-556;;032-728-154-591-070;;038-140-492-359-304;;042-709-342-743-632;;037-245-807-598-049;;015-573-402-710-703;;071-953-263-224-312;;013-389-204-869-42X;;011-689-670-898-65X;;008-920-774-642-932;;056-891-153-615-422;;115-568-540-673-612;;083-665-446-968-989;;001-930-950-214-65X;;051-875-809-608-013;;004-149-017-447-708;;134-602-023-001-741;;069-917-507-345-672;;078-075-414-981-82X;;014-998-780-825-054;;037-316-452-701-945;;026-553-967-491-457;;069-778-338-173-349;;055-933-943-437-663;;088-581-950-418-154;;003-707-911-471-072;;055-286-836-842-470;;005-648-278-768-326;;092-023-577-402-127;;021-641-900-032-887;;022-375-749-274-329;;002-308-039-268-236,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1016/j.jmb.2005.02.063;;15826665;;17134947;;10.1016/j.jchromb.2006.10.033;;17097246;;10.1016/j.ijpharm.2006.09.015;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1023/a:1015825027737;;2052513;;10.1016/s0014-5793(97)01062-4;;9323027;;10.1021/bc00028a007;;7948099;;11787799;;10.1023/a:1012278022349;;7535159;;10.1385/0-89603-274-4:11;;17107777;;10.1016/j.ejpb.2006.09.009;;10.1002/jps.21989;;19918982;;10.1093/protein/6.4.441;;8332602;;12052713;;10.1016/s0169-409x(02)00026-1;;10.1016/0022-2836(87)90412-8;;3681981;;10.1016/0022-2836(92)90224-8;;1404389;;12069157;;10.1023/a:1015396825274;;8124728;;11053416;;10.1074/jbc.m007734200;;7779254;;10.1016/0167-5699(95)80166-9;;10.1002/ijc.10212;;11920600;;16839640;;10.1007/978-0-387-76643-0_8;;10.1016/j.addr.2006.03.011;;10.1038/nbt0595-475;;9634788;;pmc4310817;;10.1016/j.ejmech.2014.08.064;;25193298;;10.1074/jbc.m102107200;;11342547;;10.1016/s0016-5085(99)70005-3;;10220494;;10.1080/02648725.2001.10648017;;11530694;;10702907;;10.1016/s0168-1656(99)00228-x;;10.1002/bit.20729;;16206278;;10.4236/abb.2013.44a011;;25635232;;pmc4307952;;10.1038/ng0594-13;;8075633;;12866935;;10.1208/ps050208;;pmc2751516;;15870065;;10.1074/jbc.m503963200;;10.1074/jbc.m707078200;;17932041;;10.1038/363446a0;;8502296;;10.1002/bit.21080;;16897740;;11163394;;10.1016/s0161-5890(00)00081-x;;10.1016/j.vetmic.2008.04.030;;18534789;;10.1016/j.vetmic.2008.04.030;;18534789;;10.1038/nrd1033;;12612647;;10.1002/jps.22812;;22083792;;10.1016/j.jchromb.2006.09.030;;17030158;;10.1038/nbt0797-632;;9219264;;9035132;;10.1038/nbt0297-125;;10.4049/jimmunol.148.5.1547;;1531669;;25291284;;10.1016/0167-5699(83)90123-8;;10.1016/0161-5890(93)90044-c;;8413328;;17828753;;10.1002/jps.21170;;pmc1573213;;11861313;;10.1038/sj.bjp.0704549;;8276795;;10.1016/s0021-9258(17)42334-9;;3382986;;10.1093/bioinformatics/4.1.11;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1126/science.3929380;;3929380;;11526908;;10.1016/s1389-0352(01)00021-6;;10.1002/(sici)1099-1352(199903/04)12:2<131::aid-jmr454>3.0.co;2-m;;10398404;;10.1002/(sici)1099-1352(199903/04)12:2<131::aid-jmr454>3.3.co;2-d;;10.1016/0022-2836(70)90057-4;;5420325;;9194169;;10.1093/protein/10.4.435;;10.1093/protein/1.2.107;;3507693;;10.1006/prep.1997.0767;;9325133;;6343768;;10.1016/0076-6879(83)92004-9;;7951745;;10.1385/0-89603-268-x:461;;10648925;;10.1016/s0022-1759(99)00138-6;;421339;;10.1111/j.1365-2222.1979.tb01527.x;;10.4049/jimmunol.154.12.6437;;7759880;;12052709;;10.1016/s0169-409x(02)00022-4;;14507303;;10.1046/j.1365-3083.2003.01320.x;;10.1097/00005344-199404000-00025;;7516023;;10.1593/tlo.13253;;23908681;;pmc3730013;;8118028;;10.1182/blood.v83.5.1244.1244;;3087891;;10.1002/ijc.2910380120;;913410;;10.1111/j.1432-1033.1977.tb11760.x;;10.1021/bc010003g;;11562193;;4001944;;10.1126/science.4001944;;10.1110/ps.8.7.1423;;pmc2144376;;10422830;;10.1016/s0022-1759(99)00211-2;;10675758;;10.1016/0076-6879(90)82008-p;;2314256;;16199666;;pmc2253229;;10.1110/ps.051709505;;10.1038/314452a0;;3920533;;10.4049/jimmunol.164.3.1432;;10640759;;10.1016/s0022-1759(02)00027-3;;12009207;;10.1016/0021-9673(92)85453-z;;1618986;;10.1073/pnas.80.23.7308;;6316357;;pmc390044;;1404388;;10.1016/0022-2836(92)90223-7;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;1675655;;10.4049/jimmunol.147.1.60;;10.1016/s0021-9258(17)43463-6;;6319407,"Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295, under the heading ""Fv Structure and Diversity in Three Dimensions"".;;Rudikoff et al Proc. Natl. Acad. Sci.USA, 79(6):1979-1983, Mar. 1982.;;Colman P. M. Research in Immunology, 145:33-36, 1994.;;International Search Report and Written Opinion in related International Application PCT/US09/062651, dated Mar. 26, 2010 (21 pgs.).;;Bond et al., ""A structure-based database of antibody variable domain diversity"", Journal of Molecular Biology, London, GB, vol. 348, No. 3, p. 702, May 6, 2005.;;Low et al., ""Future of antibody purification"", Journal of Chromatography B: Biomedical Sciences & Applns, Elsevier, Amsterdam, NL, vol. 848, No. 1, pp. 48-63, Mar. 12, 2007.;;International Search Report and Written Opinion for PCT/US09/062611, dated Oct. 1, 2010, 14 pages.;;Yang et al., ""Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation"", International Journal of Pharmaceutics, 331 (2007), pp. 123-132.;;[No Author Listed], ICH Harmonised tripartite guideline. Q5C. Nov. 30, 1995. 10 pages.;;Altschul et al., Basic local alignment search tool. J Mol Biol. Oct. 5, 1990;215(3):403-10.;;Altschul et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. Sep. 1, 1997;25(17):3389-402.;;Arakawa et al., Protein-solvent interactions in pharmaceutical formulations. Pharm Res. Mar. 1991;8(3):285-91.;;Arbabi Ghahroudi et al., Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. Sep. 15, 1997;414(3):521-6.;;Benhar et al., Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization. Bioconjug Chem. Jul.-Aug. 1994;5(4):321-6.;;Birch et al., Monoclonal antibodies. Principles and Applications. 1st ed. 1995:237-247.;;Blank et al., Expanded bed adsorption in the purification of monoclonal antibodies: a comparison of process alternatives. Bioseparation. 2001;10(1-3):65-71.;;Bollag, Ion-exchange chromatography. Methods Mol Biol. 1994;36:11-22.;;Capelle et al., High throughput screening of protein formulation stability: practical considerations. Eur J Pharm Biopharm. Feb. 2007;65(2):131-48. Epub Sep. 29, 2006.;;Carpenter et al., Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci. May 2010;99(5):2200-8. doi: 10.1002/jps.21989.;;Cedergren et al., Mutational analysis of the interaction between staphylococcal protein A and human IgG1. Protein Eng. Jun. 1993;6(4):441-8.;;Chapman, PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev. Jun. 17, 2002;54(4):531-45.;;Chothia et al., Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol. Aug. 20, 1987;196(4):901-17.;;Chothia et al., Structural repertoire of the human VH segments. J Mol Biol. Oct. 5, 1992;227(3):799-817.;;Chuang et al., Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res. May 2002;19(5):569-77.;;Cleland et al., The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-77.;;Connelly, Fully human domain antibody therapeutics: the best of both worlds. Innovations in Pharmaceutical Technol. 2005;:42-5.;;Conrath et al., Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem. Mar. 9, 2001;276(10):7346-50. Epub Oct. 25, 2000.;;Cook et al., The human immunoglobulin VH repertoire. Immunol Today. May 1995;16(5):237-42.;;Cortez-Retamozo et al., Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer. Mar. 20, 2002;98(3):456-62.;;Daugherty et al., Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev. Aug. 7, 2006;58(5-6):686-706. Epub May 22, 2006.;;Davies et al., Antibody VH domains as small recognition units. Biotechnology (N Y). May 1995;13(5):475-9.;;Decherchi et al., Implicit solvent methods for free energy estimation. Eur J Med Chem. Feb. 16, 2015;91C:27-42. doi: 10.1016/j.ejmech.2014.08.064. Epub Aug. 25, 2014.;;Desmyter et al., Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem. Jul. 13, 2001;276(28):26285-90. Epub May 7, 2001.;;D'Haens et al., Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. May 1999;116(5):1029-34.;;Fahrner et al., Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol Genet Eng Rev. 2001;18:301-27.;;Frenken et al., Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol. Feb. 28, 2000;78(1):11-21.;;Fuller et al., Purification of monoclonal antibodies. Curr Protoc Mol Biol. 1997. Unit 11.11.1-11.11.5. Suppl 37.;;Ghose et al., Antibody variable region interactions with Protein A: implications for the development of generic purification processes. Biotechnol Bioeng. Dec. 20, 2005;92(6):665-73.;;Gil et al., Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments. Adv Biosci Biotechnol. Apr. 2013;4(4a):73-84.;;Gokarn et al., Excipients for Protein Drugs. Ashok et al., (Eds.) 2006. Chapter 17:291-331.;;Green et al., Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet. May 1994;7(1):13-21.;;Gupta et al., Development of a Multidose Formulation for a Humanized Monoclonal Antibody Using Experimental Design Techniques. AAPSPharm Sci. 5:article 8, p. 1-9.;;Hagihara et al., Cellular quality control screening to identify amino acid pairs for substituting the disulfide bonds in immunoglobulin fold domains. J Biol Chem. Jul. 1, 2005;280(26):24752-8. Epub May 3, 2005.;;Hagihara et al., Stabilization of an immunoglobulin fold domain by an engineered disulfide bond at the buried hydrophobic region. J Biol Chem. Dec. 14, 2007;282(50):36489-95. Epub Oct. 11, 2007.;;Hamers-Casterman et al., Naturally occurring antibodies devoid of light chains. Nature. Jun. 3, 1993;363(6428):446-8.;;Harinarayan et al., An exclusion mechanism in ion exchange chromatography. Biotechnol Bioeng. Dec. 5, 2006;95(5):775-87.;;Harmsen et al., Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol Immunol. Aug. 2000;37(10):579-90.;;Harmsen et al., Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease. Vet Microbiol. Mar. 10, 2007;120(3-4):193-206. Epub Oct. 28, 2006.;;Harmsen et al., Passive immunization of pigs with bispecific llama single-domain antibody fragments against foot-and-mouth disease and porcine immunoglobulin. Vet Microbiol. Nov. 25, 2008;132(1-2):56-64. Epub Apr. 30, 2008.;;Harris et al., Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. Mar. 2003;2(3):214-21.;;Hasemann et al., Immunoglobulins: Structure and Function, in William E. Paul, ed. Fundamental Immunology, Second Ed. 1989;209:210-18.;;Hawe et al., Forced Degradation of Therapeutic Proteins. J. Pharm Sci. Mar. 2012. 101(3):895-913.;;Hober et al., Protein A chromatography for antibody purification. J Chromatogr B Analyt Technol Biomed Life Sci. Mar. 15, 2007;848(1):40-7. Epub Oct. 9, 2006.;;Holliger et al., Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotechnol. Jul. 1997;15(7):632-6.;;Hoogenboom, Mix and match: building manifold binding sites. Nat Biotechnol. Feb. 1997;15(2):125-6.;;Kostelny et al., Formation of a bispecific antibody by the use of leucine zippers. J Immunol. Mar. 1, 1992;148(5):1547-53.;;Kozbor et al., The production of monoclonal antibodies from human lymphocytes. Immunology Today. 1983;4:72-79.;;Ljungberg et al., The interaction between different domains of staphylococcal protein A and human polyclonal IgG, IgA, IgM and F(ab')2: separation of affinity from specificity. Mol Immunol. Oct. 1993;30(14):1279-85.;;Lu et al., Effect of PEGylation on the solution conformation of antibody fragments. J Pharm Sci. Jun. 2008;97(6):2062-79.;;MacEwan, TNF ligands and receptors-a matter of life and death. Br J Pharmacol. Feb. 2002;135(4):855-75.;;Mallender et al., Construction, expression, and activity of a bivalent bispecific single-chain antibody. J Biol Chem. Jan. 7, 1994;269(1):199-206.;;Martin, Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Eds.: Kontermann and Duebel, Springer-Verlag, Heidelberg). Chapter 3. 2010. 33-51.;;Myers et al., Optimal alignments in linear space. CABIOS. 1989;4:11-7.;;Morrison et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A. Nov. 1984;81(21):6851-5.;;Morrison, Transfectomas provide novel chimeric antibodies. Science. Sep. 20, 1985;229(4719):1202-7.;;Muyldermans et al., Single domain camel antibodies: current status. J Biotechnol. Jun. 2001;74(4):277-302.;;Muyldermans et al., Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. J Mol Recognit. Mar.-Apr. 1999;12(2):131-40.;;Needleman et al., A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol. Mar. 1970;48(3):443-53.;;Nieba et al., Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng. Apr. 1997;10(4):435-44.;;Nilsson et al., A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. Feb.-Mar. 1987;1(2):107-13.;;Nilsson et al., Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins. Protein Expr Purif. Oct. 1997;11(1):1-16.;;O'Donnell et al., A high capacity strong cation exchange resin for the chromatographic purification of monoclonal antibodies and other proteins. PREP. 2007;1-13.;;Oi et al., Chimeric antibodies. BioTechniques. 1986;4(3):214-21.;;Olsson et al., Human-human monoclonal antibody-producing hybridomas: technical aspects. Methods Enzymol. 1983;92:3-16.;;Pikal, Freeze-drying of proteins. Part II:formulation selection. BioPharm. 1990;3(9):26-30.;;Reen, Enzyme-linked immunosorbent assay (ELISA). Methods Mol Biol. 1994;32:461-6. Chapter 47.;;Riechmann et al., Single domain antibodies: comparison of camel VH and camelised human VH domains. J Immunol Methods. Dec. 10, 1999;231(1-2):25-38.;;Ring et al., Anaphylactoid reactions to infusions of plasma protein and human serum albumin. Role of aggregated proteins and of stabilizers added during production. Clin Allergy. Jan. 1979;9(1):89-97. Abstract only.;;Roben et al., VH3 family antibodies bind domain D of staphylococcal protein A. J Immunol. Jun. 15, 1995;154(12):6437-45.;;Roberts et al., Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. Jun. 17, 2002;54(4):459-76.;;Roguin et al., Monoclonal antibodies inducing conformational change on the antigen molecule. Scandinavian Journal of Immunology. 2003;58:387-94.;;Rote et al., Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis. J Cardiovasc Pharmacol. Apr. 1994;23(4):681-9.;;Rutkoski et al., Human ribonuclease with a pendant poly(ethylene glycol) inhibits tumor growth in mice. Transl Oncol. Aug. 1, 2013;6(4):392-7. Print Aug. 2013 Erratum in: Transl Oncol. 2013;6:5.;;Saelman et al., Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood. Mar. 1, 1994;83(5):1244-50.;;Scheurich et al., Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines. Int J Cancer. Jul. 15, 1986;38(1):127-33.;;Shumway et al., XM-ONE[reg] Part 1: The challenges of flow cytometric crossmatching (fcxm) with endothelial/monocyte. American Society for Histocompatibility and Immunogentics. Poster Session.2009. Abstract 60-P.;;Sjödahl, Structural studies on the four repetitive Fc-binding regions in protein A from Staphylococcus aureus. Eur J Biochem. Sep. 1977;78(2):471-90.;;Smith et al., Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem. Sep.-Oct. 2001;12(5):750-6.;;Smith, Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. Jun. 14, 1985;228(4705):1315-7.;;Starovasnik et al., Antibody variable region binding by Staphylococcal protein A: thermodynamic analysis and location of the Fv binding site on E-domain. Protein Sci. Jul. 1999;8(7):1423-31.;;Steindl et al., A simple method to quantify staphylococcal protein A in the presence of human or animal IgG in various samples. J Immunol Methods. Feb. 21, 2000;235(1-2):61-9.;;Stoscheck, Quantitation of protein. Methods Enzymol. 1990;182:50-68.;;Streltsov et al., Structure of a shark IgNAR antibody variable domain and modeling of an early-developmental isotype. Protein Sci. Nov. 2005;14(11):2901-9. Epub Sep. 30, 2005.;;Takeda et al., Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences. Nature. Apr. 4-10, 1985;314(6010):452-4.;;Tamura et al., Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J Immunol. Feb. 1, 2000;164(3):1432-41.;;Tanha et al., Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties. J Immunol Methods. May 1, 2002;263(1-2):97-109.;;Tarditi et al., Selective high-performance liquid chromatographic purification of bispecific monoclonal antibodies. J Chromatogr. May 22, 1992;599(1-2):13-20.;;Teng et al., Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production. Proc Natl Acad Sci U S A. Dec. 1983;80(23):7308-12.;;Tomlinson et al., The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol. Oct. 5, 1992;227(3):776-98.;;Tomlinson et al., the structural repertoire of the human V kappa domain. EMBO J. Sep. 15, 1995;14(18):4628-38.;;Tutt et al., Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. J Immunol. Jul. 1, 1991;147(1):60-9.;;Uhlén et al., Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications. J Biol Chem. Feb. 10, 1984;259(3):1695-702.",INACTIVE
724,US,A1,US 2018/0099059 A1,094-478-523-505-597,2018-04-12,2018,US 201715729164 A,2017-10-10,US 201715729164 A;;US 201662405364 P,2016-10-07,METHODS AND APPARATUS FOR CELL TRACKING AND MOLECULAR IMAGING,A composition for cell tracking and molecular imaging containing perfluorocarbon (“PFC”) droplets having a liquid PFC core enclosed within a stabilizing shell and embedded with solid nanoparticles. The solid nanoparticles act as nucleating agents for reducing the activation pressure of the liquid PFC core required to transition the liquid PFC core to a gaseous microbubble thereby permitting the use of more body-temperature stable longer chain PFCs in the liquid PFC core. The improved stability of the PFC droplets with a reduced or limited increase in the activation pressure required due to the nucleating nanoparticles improves the efficacy of using the PFC droplets as phase-change contrast agents.,HOSSACK JOHN A;;DIXON ADAM JOSEPH;;LU EDWIN,HOSSACK JOHN A;;DIXON ADAM JOSEPH;;LU EDWIN,UNIVERSITY OF VIRGINIA PATENT FOUNDATION (2018-10-03);;UNIVERSITY OF VIRGINIA (2018-09-25),https://lens.org/094-478-523-505-597,Patent Application,yes,0,2,1,1,0,A61K49/223;;A61K49/223;;A61K49/225;;A61K49/225;;A61K49/227;;A61K49/227,A61K49/22,,0,0,,,,DISCONTINUED
725,US,A1,US 2018/0353604 A1,111-778-960-585-205,2018-12-13,2018,US 201815969896 A,2018-05-03,US 201815969896 A;;US 201615041690 A;;US 60855309 A;;US 10947408 P,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,"The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.",ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,ABLYNX N.V (2011-11-18);;WYETH LLC (2009-12-18),https://lens.org/111-778-960-585-205,Patent Application,yes,3,1,44,44,10,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K39/395;;A61K9/00;;A61K9/16;;A61K9/19;;A61K39/00;;A61K47/10;;A61K47/26;;C07K16/18;;C07K16/24;;G01N33/15;;G06Q99/00,,0,0,,,,DISCONTINUED
726,US,A1,US 2012/0296710 A1,114-877-828-168-810,2012-11-22,2012,US 201213564625 A,2012-08-01,US 201213564625 A;;US 68117907 A;;US 88730707 P,2007-01-30,PROCESSING TRANSACTIONS OF DIFFERENT PAYMENT DEVICES OF THE SAME ISSUER ACCOUNT,"Each portable payment device associated with a single account within a payment processing system is distinguished using track data. The track data from the portable payment device is read at each of a plurality of merchant point of sale terminals (POS). Rather than relying on the PAN alone, a merchant may utilizes the track data, or a proxy thereof, as the unique identifier for the portable payment device. The merchant may then process transactions involving the portable payment device based on the unique identifier. For example, in the transit environment the transit fare for each rider with different portable payment devices but the same account can be calculated using the unique identifier, such as the full track data read from both tracks of the corresponding portable payment devices",DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,,https://lens.org/114-877-828-168-810,Patent Application,yes,6,25,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/36;;G06Q20/14;;G07B15/02;;G06Q20/20,705/13;;705/17,1,0,,,"ISO/IEC 7812 Standard, en.wikipedia.org/w/index.php?title=ISO/IEC_7812&oldid=103608433, 1/27/2007",ACTIVE
727,US,B2,US 8610599 B2,126-652-675-545-424,2013-12-17,2013,US 201213372317 A,2012-02-13,US 201213372317 A;;US 39294209 A;;US 3107208 P,2008-02-25,Vehicle security and monitoring system,"A vehicle monitoring system includes a communication subsystem configured to provide two-way wireless communication, and a controller mounted in a vehicle and configured to receive data indicative of a location of the vehicle and to control the communication subsystem to transmit the data indicative of the vehicle location toward a remote communication center and receive operational information transmitted from the remote communication center. The controller receives a mode change command included in the operational information and in response changes operating mode between an authorization mode, in which the controller transmits an alert signal to the remote communication center, and a tracking mode, in which the controller transmits the data indicative of vehicle location continuously at predetermined intervals regardless of the authorization signal.",BEVACQUA KURT;;OSMAN MARK A;;DIXON STEVEN C;;RECOVERY SYSTEMS HOLDINGS LLC,BEVACQUA KURT;;OSMAN MARK A;;DIXON STEVEN C,RECOVERY SYSTEMS HOLDINGS LLC (2009-08-14),https://lens.org/126-652-675-545-424,Granted Patent,yes,63,1,7,7,0,B60R25/102;;B60R25/33;;B60R2025/1016;;B60R2325/205;;G01S5/0027;;H04W8/24;;H04W64/00;;H04W12/126;;B60R25/33;;G01S5/0027;;B60R2025/1016;;H04W64/00;;B60R25/102;;B60R2325/205;;H04W8/24;;H04W12/126,B60R25/10;;G08G1/123,340/989;;340/426.1;;340/686.1,1,0,,,"Supplementary European Search Report for EP Application No. 09714157 dated Apr. 20, 2012, 5 pages.",INACTIVE
728,EP,A1,EP 1309246 A1,128-342-549-484-199,2003-05-14,2003,EP 00954084 A,2000-08-15,US 0022354 W,2000-08-15,MINERAL-ENHANCED BAKERY PRODUCTS,,MALDONADO ALFONSO;;EDGE JOE DIXON;;MARQUEZ JOAQUIM A,MALDONADO ALFONSO;;EDGE JOE DIXON;;MARQUEZ JOAQUIM A,,https://lens.org/128-342-549-484-199,Patent Application,yes,0,0,5,5,0,A21D2/18;;A21D2/02;;A21D10/00;;A21D13/02;;A23L7/198,A21D2/02;;A21D2/18;;A21D10/00;;A21D13/02;;A23L7/10,,1,0,,,See references of WO 0213626A1,DISCONTINUED
729,NZ,A,NZ 296033 A,151-238-892-683-033,1999-02-25,1999,NZ 29603395 A,1995-11-01,US 33912994 A;;US 9514149 W,1994-11-14,ISOFLAVONE REDUCTASE (IFR) PROMOTER AND VECTORS THEREOF TO PUT INTO PLANTS THAT LACK THE ISOFLAVONOID PATHWAY,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;PAIVA NANCY L;;OOMMEN ABRAHAM,,https://lens.org/151-238-892-683-033,Patent Application,no,0,0,9,9,0,C12N9/001;;C12N15/8239;;C12N9/001;;C12N15/8239,A01H5/00;;C12N5/10;;C12N9/02;;C12N15/00;;C12N15/09;;C12N15/82;;C12R1/91,,0,0,,,,DISCONTINUED
730,US,A1,US 2006/0288450 A1,177-864-622-725-469,2006-12-21,2006,US 17659405 A,2005-07-07,US 17659405 A;;US 58589204 P,2004-07-07,Plant N-acylethanolamine binding proteins,"The invention provides plant binding proteins of N-acylethanolamines. Also provided are constructs comprising coding sequences for the binding proteins, plants transformed therewith and methods of use thereof. The invention allows the modification of plant signaling by N-acylethanolamines. Such modification may be used to produce plants that are improved with respect to growth, seed germination, pathogen response and stress tolerance.",SAMUEL ROBERTS NOBLE FOUND INC,CHAPMAN KENT D;;TRIPATHY SWATI;;DIXON RICHARD A,THE SAMUEL ROBERTS NOBLE FOUNDATION INC (2008-04-02);;THE UNIVERSITY OF NORTH TEXAS (2008-04-03);;SAMUEL ROBERTS NOBLE FOUNDATION (2005-10-19),https://lens.org/177-864-622-725-469,Patent Application,yes,2,1,7,7,52,C07K14/415;;C12N15/8261;;C12N15/8279;;Y02A40/146;;C12N15/8279;;C07K14/415;;C12N15/8261;;Y02A40/146,C07H21/04;;A01H5/00;;C07K14/415;;C12N5/04;;C12N5/10;;C12N9/10;;C12N15/82;;C12P21/06,800/281;;435/69.1;;435/193;;435/468;;435/419;;530/370;;536/23.6,0,0,,,,DISCONTINUED
731,EP,A1,EP 0792356 A1,175-706-378-688-611,1997-09-03,1997,EP 95937698 A,1995-11-01,US 9514149 W;;US 33912994 A,1994-11-14,ISOFLAVONE REDUCTASE PROMOTER,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;PAIVA NANCY L;;OOMMEN ABRAHAM,,https://lens.org/175-706-378-688-611,Patent Application,yes,0,0,9,9,0,C12N9/001;;C12N15/8239;;C12N9/001;;C12N15/8239,A01H5/00;;C12N5/10;;C12N9/02;;C12N15/00;;C12N15/09;;C12N15/82;;C12R1/91,,0,0,,,,DISCONTINUED
732,US,A1,US 2003/0070188 A1,184-685-887-691-460,2003-04-10,2003,US 8771402 A,2002-02-28,US 8771402 A;;US 46257600 A;;US 5260697 P;;US 27241501 P,1997-07-15,Vanillin biosynthetic pathway enzyme from Vanilla planifolia,"
    Novel compositions and methods for improving vanillin production in cultured Vanilla planifolia and in intact plants are provided. Transgenic cells and plants having improved vanillin production are also provided. Isolated 4-hydroxybenzaldehyde synthase enzyme and nucleic acids encoding the enzyme are further provided. 
",HAVKIN-FRENKEL DAPHNA;;PODSTOLSKI ANDRZEJ;;DIXON RICHARD A.,HAVKIN-FRENKEL DAPHNA;;PODSTOLSKI ANDRZEJ;;DIXON RICHARD A,DAVID MICHAEL & CO. INC (2002-06-04),https://lens.org/184-685-887-691-460,Patent Application,yes,0,27,5,5,25,C07C2/32;;C07C2531/22;;C07D213/53;;C07F15/02;;C07F15/025;;C08F10/00;;C12N5/04;;C12N9/00;;C12N9/0006;;C12N9/0077;;C12N15/8207;;C12N15/8243;;C12P7/24;;A01H4/002;;C08F10/00;;C12N9/0077;;C12N5/04;;C07C2531/22;;C07F15/02;;C07F15/025;;C12P7/24;;C12N9/0006;;C12N9/00;;C07C2/32;;C07D213/53;;C12N15/8243;;C12N15/8207;;A01H4/002,A01H4/00;;C07C2/32;;C07D213/53;;C07F15/02;;C08F10/00;;C12N5/04;;C12N9/00;;C12N9/02;;C12N9/04;;C12N15/29;;C12N15/82;;C12P7/24,800/278;;435/147,0,0,,,,DISCONTINUED
733,DE,D1,DE 69834177 D1,018-469-066-769-712,2006-05-24,2006,DE 69834177 T,1998-04-22,US 85885997 A;;US 9807991 W,1997-05-19,BIOZIDES PUDER MIT VERZÖGERTER FREISETZUNG,"A powder for sustained release of a gas including a hydrophilic core, a hydrophobic layer on an outer surface of the hydrophilic core, and particles in contact with the hydrophobic layer. The hydrophobic layer contains an acid releasing agent. The particles contain an anhydrous material capable of binding with water. The core, the particles, and the hydrophobic layer are substantially free of water, and the core is capable of generating and releasing a gas after hydrolysis of the acid releasing agent.",BERNARD TECHNOLOGIES INC;;SOUTHWEST RES INST SAN ANTONIO,WELLINGHOFF T;;BARENBERG A;;DIXON HONG;;KAMPA J,"SOUTHWEST RESEARCH INSTITUTE, SAN ANTONIO, TEX., U (2006-06-29);;MICROACTIVE CORP., RENO, NEV., US (2006-06-29)",https://lens.org/018-469-066-769-712,Granted Patent,no,0,0,13,13,0,A01N25/18;;A01N59/00;;A01N59/02;;Y02A50/30;;A01N59/00;;A01N25/18;;A01N59/02;;Y02A50/30,A01N25/12;;A01N59/08;;A01N25/14;;A01N25/18;;A01N25/22;;A01N25/26;;A01N59/00;;A01N59/02;;A61K9/14;;A61K9/16;;A61K9/50,,0,0,,,,EXPIRED
734,US,A,US 4416873 A,025-120-785-465-960,1983-11-22,1983,US 44911782 A,1982-12-13,US 44911782 A;;US 38340482 A,1982-06-01,Combined allantoin-hydrolyzed animal protein skin preparation,"A stable form of allantoin is provided which takes the form of a combined allantoin-hydrolyzed animal protein product which may be employed in the form of a hydroalcoholic solution, such as a cologne, after-shave lotion or skin toner, containing at least about 0.5% by weight allantoin which remains in solution, without crystallizing out, over extended periods of time. Methods for increasing the stability of allantoin and for forming a stable form of allantoin are also provided.",RITZ GROUP LTD CHARLES,PUCHALSKI EUGENE;;DONAHUE FRANCES A;;DIXON RICHARD P,YVES SAINT LAURENT PARFUMS CORP (1987-12-29);;CRG-YSL INC (1987-08-04);;CHARLES OF THE RITZ GROUP LTD. FORMERLY KNOWN AS CRG ACQUISITION CORP. INC (1987-08-04);;CRG HOLDING INC (1987-08-21),https://lens.org/025-120-785-465-960,Granted Patent,yes,2,65,1,10,0,A23J3/04;;A23J3/04;;A61K8/4946;;A61K8/4946;;A61K8/65;;A61K8/65;;A61Q19/00;;A61Q19/00;;A61Q19/002;;A61Q19/002;;C07D233/88;;C07D233/88,A23J3/00;;A61K8/49;;A61K8/65;;A61Q19/00;;C07D233/88,424/177;;X260112R;;260/123.7;;424/63;;424/69;;424/70;;424/73;;424/167;;424/168;;424/170,4,0,,,"`Allantoin`, Brochures I and II, Schuylkil Chemical Co., Philadelphia, PA.;;DL-Panthenol-Product Data, Roche.;;Proteins in Cosmetics & Toiletries, Johnson, D & CL, Jun. 1980, pp. 36-38.;;Croda 77-Crotein Specifications Sheets, pp. 23-24.",EXPIRED
735,WO,A3,WO 2003/071861 A3,075-893-862-274-382,2003-12-11,2003,US 0306397 W,2003-02-27,US 8771402 A,2002-02-28,VANILLIN BIOSYNTHETIC PATHWAY ENZYME FROM VANILLA PLANIFOLIA,Novel compositions and methods for improving vanillin production in cultured Vanilla planifolia and in intact plants are provided. Transgenic cells and plants having improved vanillin production are also provided. Isolated 4-hydroxybenzaldehyde synthase enzyme and nucleic acids encoding the enzyme are further provided.,DAVID MICHAEL & CO INC;;HAVKIN-FRENKEL DAPHNA;;PODSTOLSKI ANDRZEJ;;DIXON RICHARD A,HAVKIN-FRENKEL DAPHNA;;PODSTOLSKI ANDRZEJ;;DIXON RICHARD A,,https://lens.org/075-893-862-274-382,Search Report,yes,2,0,5,5,0,C07C2/32;;C07C2531/22;;C07D213/53;;C07F15/02;;C07F15/025;;C08F10/00;;C12N5/04;;C12N9/00;;C12N9/0006;;C12N9/0077;;C12N15/8207;;C12N15/8243;;C12P7/24;;A01H4/002;;C08F10/00;;C12N9/0077;;C12N5/04;;C07C2531/22;;C07F15/02;;C07F15/025;;C12P7/24;;C12N9/0006;;C12N9/00;;C07C2/32;;C07D213/53;;C12N15/8243;;C12N15/8207;;A01H4/002,A01H4/00;;C07C2/32;;C07D213/53;;C07F15/02;;C08F10/00;;C12N5/04;;C12N9/00;;C12N9/02;;C12N9/04;;C12N15/29;;C12N15/82;;C12P7/24,,0,0,,,,PENDING
736,WO,A2,WO 2005/033309 A2,078-985-519-262-998,2005-04-14,2005,US 2004/0032365 W,2004-09-30,US 50736203 P,2003-09-30,PLANT PROMOTERS AND METHODS OF USE THEREOF,"The current invention provides plant promoter sequences. Compositions comprising these promoter sequence are described, as are plants transformed with such compositions. Further provided are methods for the expression of transgenes in plants comprising the use of these sequences. The methods of the invention include the direct creation of transgenic plants with the promoters by genetic transformation, as well as by plant breeding methods. The sequences of the invention represent valuable new tools for the creation of transgenic plants, preferably having one or more added beneficial characteristics.",SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;WANG LIANGJIANG;;MAY GREGORY D,DIXON RICHARD A;;WANG LIANGJIANG;;MAY GREGORY D,,https://lens.org/078-985-519-262-998,Patent Application,yes,0,0,3,3,26,C07K14/415;;C07K14/415;;C12N15/8216;;C12N15/8216,A01H1/00;;C07K14/415;;C12N15/82;;C12Q1/68,,0,0,,,,PENDING
737,JP,A,JP 2021121635 A,137-754-933-210-78X,2021-08-26,2021,JP 2021089081 A,2021-05-27,JP 2021000870 A;;US 201562128462 P,2015-03-04,ANTIBODY THERAPEUTICS THAT BIND CD47,"To provide antibody therapeutics that bind CD47.SOLUTION: Disclosed herein are compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, disclosed herein are fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further disclosed are nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.SELECTED DRAWING: Figure 1",SORRENTO THERAPEUTICS INC,BARBARA A SWANSON;;JOHN DIXON GRAY;;ZHOU HEYUE,,https://lens.org/137-754-933-210-78X,Patent Application,no,2,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;A61K39/395;;A61P1/04;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P15/00;;A61P19/02;;A61P25/00;;A61P35/00;;A61P35/02;;A61P43/00,,0,0,,,,DISCONTINUED
738,US,B1,US 6338086 B1,142-115-112-488-039,2002-01-08,2002,US 9610198 A,1998-06-11,US 9610198 A,1998-06-11,Collaborative object architecture,"
    A collaborative object architecture with one or more of the following technologies: 1) lightweight asynchronous messaging; 2) collaborative objects; 3) optimistic concurrency control; and 4) transparent object serialization. Lightweight asynchronous messaging allows highly responsive interactivity and natural interactions with minimal network loads. Collaborative objects allow ubiquitous sharing and provides each user with the same copy of the shared object. Optimistic concurrency control allows full-duplex group editing and natural interactions. Transparent object serialization provides real world persistence and support for asynchronous changes. Thus, combination of these technologies provides a collaborative object architecture with several advantages over the prior art. 
",PLACEWARE INC,CURTIS PAVEL;;DIXON MICHAEL D;;NICHOLS DAVID A,MICROSOFT PLACEWARE LLC (2004-12-31);;MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2004-12-31);;PLACEWARE INC (1998-06-09),https://lens.org/142-115-112-488-039,Granted Patent,yes,30,142,8,8,0,H04L67/10;;H04L69/329;;H04L67/131;;H04L69/329;;H04L67/10;;H04L9/40;;H04L67/01;;H04L67/131,G06F9/46;;G06F15/16;;H04L29/06;;H04L29/08,709/218;;709/203;;709/205,23,11,003-151-043-621-702;;112-092-412-118-147;;080-598-297-253-86X;;019-632-085-861-286;;099-686-035-357-570;;178-985-160-423-649;;138-216-553-453-163;;018-251-206-857-879;;101-961-216-892-365;;192-805-530-979-844;;150-474-101-853-613,10.1145/74334.74347;;10.1145/192426.192454;;10.1109/cmpcon.1994.282924;;10.1145/217279.215128;;10.1145/192593.192629;;10.1145/120782.120790;;10.1145/67544.66963;;10.1145/67449.67456;;10.1002/j.1538-7305.1984.tb00056.x;;10.1002/spe.4380171105;;10.1145/143457.143460,"Sun Microsystems, Inc., ""Java Card 2.0: Programming Concepts"", Revision 1.0 Final, java.sun.com, pp. 1-33, Oct. 1997.*;;International Preliminary Search Report dated Mar. 30, 2000 for corresponding application No. PCT/US(9/13158 (7 pages).;;Avrahami, Gideon, et al., ""A Two-View Approach to Constructing User Interfaces,"" Computer Graphics, Jul. 1989, pp. 137-146.;;Bartlett, Joel, ""Don't Fidget with Widgets, Draw!"" Proceedings 6th Annual X Technical Conference, Jan. 13-15, 1992, pp. 117-131.;;Bharat, Krishna, et al., ""Building Distributed, Multi-User Applications by Direct Manipulation,"" Proceedings of the ACM Symposium on User Interface Software and Technology, Nov. 2-4, 1994, pp. 71-81.;;Brown, Marc H., et al., ""MMConf: An Infrastructure for Building Shared Multimedia Applications,"" Proceedings of the Conference on Computer-Supported Cooperative Work, Oct. 7-10, 1990, pp. 329-342.;;Curtis, Pavel, et al., ""Lambda MOO Programmer's Manual,"" Lambda MOO Version 1.8.0p5, May 1996.;;Curtis, Pavel, et al., ""MUDs Grow Up: Social Virtual Reality in the Real World,"" Xerox PARC, May 5, 1993.;;Curtis, Pavel, et al., ""The Jupiter Audio/Video Architecture: Secure Multimedia in Network Places,"" ACM Multimedia 95, pp. 79-90.;;Danskin, John M., ""Previewing PostScript over a Telephone in 3 Seconds Per Page,"" Proceedings 9th Annual X Technical Conference, Jan. 30-Feb. 1, 1995, pp. 23-40.;;Danskin, John, ""Higher Bandwidth X,"" Proceedings ACM Multimedia '94, Oct. 15-20, 1994, pp. 89-96.;;Dewan, Prasun, et. al., ""Primitives for Programming Multi-User Interfaces,"" Proceedings of the ACM Symposium on User Interface Software and Technology, Nov. 11-13, 1991, pp. 69-78.;;Ellis, C. A., et al., ""Concurrency Control in Groupware Systems,"" Proceedings of the 1989 ACM SIGMOD International Conference on the Management of Data Portland, Oregon, Jun. 1989, pp. 399-407.;;Fulton, Jim, et al., ""An Update on Low Bandwidth X (LBX) A Standard for X and Serial Lines,"" Proceedings 7th Annual X Technical Conference, Jan. 18-20, 1993, pp. 251-266.;;Gibbs, S.J., ""LIZA: An Extensible Groupware Toolkit,"" ""Wings for the Mind' Conference Proceedings, Apr. 30-May 4, 1989, pp. 29-35.;;Karsenty, Alain, et al., ""An Algorithm for Distributed Groupware Applications,"" Proceedings The 13th International Conference on Distributed Computing Systems, May 25-28, 1993, pp. 195-202.;;Knister, Michael, et al., ""Issues in the Design of a Toolkit for Supporting Multiple Group Editors,"" Computing Systems, Spring 1993, pp. 135-166.;;Packard, Keith ""Designing LBX An Experiment Based Standard,"" Proceedings 8th Annual X Technical Conference, Jan. 24-26, 1994, pp. 121-133.;;Patet, Dorab, et al., ""A UNIX Toolkit for Distributed Synchronous Collaborative Applications,"" Computing Systems, Spring 1993, pp. 105-133.;;Patterson, John F., et al., ""Rendezvous: An Architecture for Synchronous Multi-User Applications,"" Proceedings of the Conference on Computer-Supported Cooperative Work, Oct. 7-10, 1990, pp. 317-328.;;Pike, R., ""The Blit: A Multiplexed Graphics Terminal,"" AT&T Bell Laboratories Technical Journal Computing Science and Systems, Oct. 1984, pp. 1607-1631.;;Pike Rob, ""The Text Editor sam,"" Software-Practice and Experience, Nov. 1987, pp. 813-845.;;Roseman, Mark, et al., ""GroupKit A Groupware Toolkit for Building Real-Time Conferencing Applications,"" Proceedings of the Conference on Computer-Supported Cooperative Work, Oct. 31-Nov. 4, 1992, pp. 43-50.",EXPIRED
739,DE,A1,DE 3907009 A1,154-182-142-727-972,1989-09-21,1989,DE 3907009 A,1989-03-04,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,Use of 4-(3-phosphono-2-propenyl)piperazine-2-carboxylic acid,"4-(3-Phosphono-2-propenyl)piperazine-2-carboxylic acid for the treatment of conditions characterised by inhibition of drive and/or social withdrawal, sleep disturbances and migraine.",SANDOZ AG,DIXON ARNOLD KEITH DR;;GRAY JULIAN A DR,,https://lens.org/154-182-142-727-972,Patent Application,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,DISCONTINUED
740,US,A1,US 2012/0139760 A1,144-727-770-612-134,2012-06-07,2012,US 201213372317 A,2012-02-13,US 201213372317 A;;US 39294209 A;;US 3107208 P,2008-02-25,VEHICLE SECURITY AND MONITORING SYSTEM,"A vehicle monitoring system includes a communication subsystem configured to provide two-way wireless communication, and a controller mounted in a vehicle and configured to receive data indicative of a location of the vehicle and to control the communication subsystem to transmit the data indicative of the vehicle location toward a remote communication center and receive operational information transmitted from the remote communication center. The controller receives a mode change command included in the operational information and in response changes operating mode between an authorization mode, in which the controller transmits an alert signal to the remote communication center, and a tracking mode, in which the controller transmits the data indicative of vehicle location continuously at predetermined intervals regardless of the authorization signal.",BEVACQUA KURT;;OSMAN MARK A;;DIXON STEVEN C;;RECOVERY SYSTEMS HOLDINGS LLC,BEVACQUA KURT;;OSMAN MARK A;;DIXON STEVEN C,RECOVERY SYSTEMS HOLDINGS LLC (2009-08-14),https://lens.org/144-727-770-612-134,Patent Application,yes,11,29,7,7,0,B60R25/102;;B60R25/33;;B60R2025/1016;;B60R2325/205;;G01S5/0027;;H04W8/24;;H04W64/00;;H04W12/126;;B60R25/33;;G01S5/0027;;B60R2025/1016;;H04W64/00;;B60R25/102;;B60R2325/205;;H04W8/24;;H04W12/126,B60R25/10;;G08G1/123,340/989,0,0,,,,INACTIVE
741,CN,A,CN 104740631 A,187-026-868-409-677,2015-07-01,2015,CN 201510098158 A,2009-10-29,US 10947408 P;;CN 200980153163 A,2008-10-29,Formulations Of Single Domain Antigen Binding Molecules,"The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.",WYETH CORP,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDRE,,https://lens.org/187-026-868-409-677,Patent Application,no,3,1,44,44,0,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K39/395;;A61K9/19;;A61K45/00;;A61P19/02;;A61P29/00,,1,0,,,"张艺等: ""调制式差示扫描量热法在高分子研究中的应用"", 《化学通报》",ACTIVE
742,KR,A,KR 20240007967 A,022-862-717-092-350,2024-01-17,2024,KR 20247000720 A,2016-03-04,US 201562128462 P;;KR 20177028115 A;;US 2016/0020980 W,2015-03-04,CD47 ANTIBODY THERAPEUTICS THAT BIND CD47,"항-CD47 항체와 관련된 또는 이로부터 유도된 조성물 및 방법이 개시되어 있다. 더 구체적으로는, CD47에 결합하는 완전 사람 항체, 상기 항체의 CD47-항체 결합 단편 및 유도체, 및 상기 단편을 포함하는 CD47-결합 폴리펩타이드가 개시되어 있다. 또한 추가로, 상기 항체, 항체 단편 및 유도체 및 폴리펩타이드를 인코딩하는 핵산, 상기 폴리뉴클레오타이드를 포함하는 세포, 상기 항체, 항체 단편 및 유도체 및 폴리펩타이드를 제조하는 방법, 및 질환을 치료하는 방법을 포함하는, 상기 항체, 항체 단편 및 유도체 및 폴리펩타이드를 사용하는 방법이 개시되어 있다.",YUHAN CORP,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,,https://lens.org/022-862-717-092-350,Patent Application,no,0,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;A61K39/00;;A61P9/10;;A61P11/00;;A61P19/02;;A61P35/00;;C07K16/30,,0,0,,,,PENDING
743,US,S,US D0320188 S,045-242-317-012-304,1991-09-24,1991,US 32625289 F,1989-03-21,US 32625289 F,1989-03-21,Hood ornament protector,,RICE JR ALBERT A;;DIXON ERIN G J,RICE JR ALBERT A;;DIXON ERIN G J,,https://lens.org/045-242-317-012-304,Design Right,yes,5,0,1,1,0,,,D12/197,0,0,,,,EXPIRED
744,CN,A,CN 106062207 A,052-271-333-491-778,2016-10-26,2016,CN 201480051354 A,2014-07-18,US 201361856486 P;;US 201361873671 P;;US 2014/0047243 W,2013-07-19,Whole-genome and targeted haplotype reconstruction,The present invention relates to methods for haplotype determination and particularly haplotype determination at the whole genome level as well as targeted haplotype determination.,LUDWIG INST CANCER RES,REN BING;;SELVARAJ SIDDARTH;;DIXON JESSE;;A SCHMITT,,https://lens.org/052-271-333-491-778,Patent Application,no,4,2,12,12,0,C12Q1/6869;;C12Q1/6869;;C12Q1/6874,C12Q1/68,,0,0,,,,ACTIVE
745,TW,B,TW I778518 B,052-007-320-982-292,2022-09-21,2022,TW 110105132 A,2016-03-04,US 201562128462 P,2015-03-04,Antibody therapeutics that bind cd47,,SORRENTO THERAPEUTICS INC,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,,https://lens.org/052-007-320-982-292,Granted Patent,no,2,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,,,0,0,,,,ACTIVE
746,JP,A,JP 2020023532 A,061-486-565-442-734,2020-02-13,2020,JP 2019186564 A,2019-10-10,US 201562128462 P,2015-03-04,ANTIBODY THERAPEUTICS THAT BIND CD47,"To provide antibodies overcoming deficiencies of conventional antibodies used for therapies targeting CD47, also known as integrin-associated protein (IAP), ovarian cancer antigen OA3, Rh-related antigen and MER6, and to provide methods of producing and using the antibodies.SOLUTION: There are disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further still, there are disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.SELECTED DRAWING: Figure 1",SORRENTO THERAPEUTICS INC,BARBARA A SWANSON;;JOHN DIXON GRAY;;ZHOU HEYUE,,https://lens.org/061-486-565-442-734,Patent Application,no,2,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;A61K39/395;;A61P9/10;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00,,0,0,,,,DISCONTINUED
747,US,A1,US 2005/0233346 A1,071-988-670-188-646,2005-10-20,2005,US 95592404 A,2004-09-30,US 95592404 A;;US 50736203 P,2003-09-30,Plant promoters and methods of use thereof,"The current invention provides plant promoter sequences. Compositions comprising these promoter sequence are described, as are plants transformed with such compositions. Further provided are methods for the expression of transgenes in plants comprising the use of these sequences. The methods of the invention include the direct creation of transgenic plants with the promoters by genetic transformation, as well as by plant breeding methods. The sequences of the invention represent valuable new tools for the creation of transgenic plants, preferably having one or more added beneficial characteristics.",SAMUEL ROBERT NOBLE FOUNDATION,DIXON RICHARD A;;WANG LIANGJIANG;;MAY GREGORY D,SAMUEL ROBERTS NOBLE FOUNDATION THE (2004-01-26),https://lens.org/071-988-670-188-646,Patent Application,yes,1,5,3,3,26,C07K14/415;;C07K14/415;;C12N15/8216;;C12N15/8216,A01H1/00;;C07K14/415;;C12N15/82;;C12Q1/68,435/6,0,0,,,,DISCONTINUED
748,CA,A1,CA 2419662 A1,072-638-367-632-659,2002-02-21,2002,CA 2419662 A,2000-08-15,US 0022354 W,2000-08-15,MINERAL-ENHANCED BAKERY PRODUCTS,"A wheat flour, and dough made from the flour, are produced using between 5-5 0 % (desirably 15-45 %, preferably 25-35 %) by weight middlings (e.g. from the first and second breaks) added to straight flour, patent flour, break flour, or clear flour. The flour with middlings can hold more free moisture, and an at least an additional 2-20 % by weight dietary minerals (such as calcium, zinc, iron, manganese, phosphorus, etc.) and/or fibers, and/or other edible materials, can be added without disturbing the fermentation or baking processes. For example, bread having at least 50 % (e.g. 50-200 %) of the RD A of calcium per 32 gm slice may be produced without emulsifiers, calcium citrate, or other equivalent chemical additives.",MARQUEZ JOAQUIM A;;MALDONADO ALFONSO;;EDGE JOE DIXON,MARQUEZ JOAQUIM A;;MALDONADO ALFONSO;;EDGE JOE DIXON,,https://lens.org/072-638-367-632-659,Patent Application,no,0,0,5,5,0,A21D2/18;;A21D2/02;;A21D10/00;;A21D13/02;;A23L7/198,A21D2/02;;A21D2/18;;A21D10/00;;A21D13/02;;A23L7/10,,0,0,,,,DISCONTINUED
749,CA,A1,CA 2334737 A1,122-543-492-142-392,1999-12-16,1999,CA 2334737 A,1999-06-11,US 9610198 A;;US 9913158 W,1998-06-11,COLLABORATIVE OBJECT ARCHITECTURE,"A collaborative object architecture, using applets (210, 220) and pods (250, 260), with one or more of the following technologies: 1) lightweight asychronous messaging; 2) collaborative objects; 3) optimistic concurrency control; and 4) transparent object serialization. Lightweight asynchronous messaging allows highly responsive interactivity and natural interactions wi th minimal network loads. Collaborative objects allow ubiquitous sharing and provide each user with the same copy of the shared object. Optimistic concurrency control allows full-duplex group editing and natural interaction s. Transparent object serialization provides real world persistence and support for asynchronous changes. Thus, combination of these technologies within a network (200) provides a collaborative object architecture with several advantages.",PLACEWARE INC,CURTIS PAVEL;;NICHOLS DAVID A;;DIXON MICHAEL D,,https://lens.org/122-543-492-142-392,Patent Application,no,0,0,8,8,0,H04L67/10;;H04L69/329;;H04L67/131;;H04L69/329;;H04L67/10;;H04L9/40;;H04L67/01;;H04L67/131,G06F15/16;;G06F9/46;;H04L29/06;;H04L29/08,,0,0,,,,DISCONTINUED
750,IL,A,IL 287958 A,141-025-026-041-85X,2022-01-01,2022,IL 28795821 A,2021-11-09,US 201562128462 P;;US 2016/0020980 W,2015-03-04,Antibody therapeutics that bind cd47,,SORRENTO THERAPEUTICS INC;;SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,,https://lens.org/141-025-026-041-85X,Patent Application,no,0,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,,,0,0,,,,PENDING
751,BR,B1,BR 122018013284 B1,151-704-755-426-271,2022-03-03,2022,BR 122018013284 A,2009-10-29,US 2009/0062611 W;;US 10947408 P;;BR PI0919979 A,2008-10-29,"Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab","a invenção refere-se a formulações de moléculas de ligação de antígeno de domínio único, por exemplo, moléculas de nanocorpo, em particular formulações de moléculas de nanocorpo de ligação de tnf. as moléculas de ligação de antígeno de domínio único podem incluir um ou mais domínios de ligação únicos que interagem com, por exemplo, se ligam a, uma ou mais proteínas-alvos. as formulações são úteis, por exemplo, como formulações farmacêuticas. são também descritos métodos para preparar e usar as formulações descritas aqui, para tratar, por exemplo, distúrbios associado a tnf.",ABLYNX NV,PAULSON ANDREA;;DANIEL A DIXON;;JASON E FERNANDEZ,,https://lens.org/151-704-755-426-271,Granted Patent,no,0,0,44,44,0,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/00;;A61K9/19;;A61K39/395;;A61P35/00,,0,0,,,,ACTIVE
752,HK,A1,HK 1011512 A1,161-756-517-796-223,1999-07-09,1999,HK 98112357 A,1998-11-26,US 83449092 A;;US 9301176 W,1992-02-12,Credit card with magnifying lens,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/161-756-517-796-223,Patent Application,no,0,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,EXPIRED
753,EP,A2,EP 1763583 A2,164-819-765-066-961,2007-03-21,2007,EP 05793438 A,2005-07-07,US 2005/0024092 W;;US 58589204 P,2004-07-07,PLANT N-ACYLETHANOLAMINE BINDING PROTEINS,,SAMUEL ROBERTS NOBLE FOUND INC,CHAPMAN KENT D;;TRIPATHY SWATI;;DIXON RICHARD A,,https://lens.org/164-819-765-066-961,Patent Application,yes,0,0,7,7,0,C07K14/415;;C12N15/8261;;C12N15/8279;;Y02A40/146;;C12N15/8279;;C07K14/415;;C12N15/8261;;Y02A40/146,C12N15/82;;A01H1/00;;C07K14/415,,0,0,,,,DISCONTINUED
754,EP,B1,EP 1037615 B1,161-468-706-771-272,2004-03-03,2004,EP 98963170 A,1998-12-14,US 9826560 W;;US 6951097 P;;US 16335198 A,1997-12-15,COMPOSITIONS AND METHODS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE,,NOVEN PHARMA,MANTELLE JUAN;;DIXON TERESE A;;KANIOS DAVID P,,https://lens.org/161-468-706-771-272,Granted Patent,yes,0,0,54,65,0,A61K9/7061;;A61K9/7069;;A61K31/4458;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/26;;A61P25/28;;A61K9/70;;A61K9/7061;;A61K31/4458;;A61K9/7069,A61K9/70;;A61K9/06;;A61K31/435;;A61K31/4458;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61P25/00;;A61P25/26,,3,0,,,"E. Mutschler ""Arzneimittelwirkungen, Lehrbuch der Pharmakologie und Toxikologie"", Sixth Ed., Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 1991, p. 11, 148-149;;K. Thoma ""Dermatika"", Second Ed., Werbe- und Vertriebsgesellschaft Deutscher Apotheker mbH, Frankfurt, 1983, p. 117-119;;H. Gebler et al. ""Pharmazie für die Praxis"", First Ed., Georg Thieme Verlag Stuttgart, 1990, p. 175-176",EXPIRED
755,NZ,A,NZ 538259 A,174-343-605-628-445,2008-03-28,2008,NZ 53825903 A,2003-09-10,US 40944702 P;;US 0328454 W,2002-09-10,Methods and compositions for production of flavonoid and isoflavonoid nutraceuticals,Disclosed is a method of increasing isoflavonoid biosynthesis in a plant comprising: a) down-regulating flavanone 3-hydroxylase in the plant; and b) up-regulating isoflavone synthase and/or production of liquiritigenin or naringenin in the plant.,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;LIU CHANG-JUN;;DEAVOURS BETTINA,,https://lens.org/174-343-605-628-445,Patent Application,no,0,0,10,10,0,C12N9/0071;;C12N9/0077;;C12N15/8243;;C12N15/825;;C12N9/0071;;C12N15/825;;C12N15/8243;;C12N9/0077,A01H1/00;;C12N9/02;;C12N9/90;;C12N15/82,,0,0,,,,PENDING
756,EP,A1,EP 2108178 A1,034-672-775-905-231,2009-10-14,2009,EP 07844679 A,2007-10-29,US 2007/0082842 W;;US 88730707 P;;US 68117407 A,2007-01-30,DELAYED TRANSIT FARE ASSESSMENT,,VISA USA INC,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,,https://lens.org/034-672-775-905-231,Patent Application,yes,0,1,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/14;;G06Q20/36;;G07B15/02,,0,0,,,,DISCONTINUED
757,AU,B2,AU 2013/202856 B2,044-406-098-575-132,2016-02-11,2016,AU 2013/202856 A,2013-04-08,AU 2009/333791 A;;AU 2013/202856 A,2009-10-29,Formulations of single domain antigen binding molecules,"The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody 5 molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.",ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,,https://lens.org/044-406-098-575-132,Granted Patent,no,2,0,2,2,0,,A61K9/19;;A61K9/00;;A61K39/395;;A61P35/00;;G06F19/00,,0,0,,,,ACTIVE
758,WO,A1,WO 1999/064959 A1,052-412-148-066-063,1999-12-16,1999,US 9913158 W,1999-06-11,US 9610198 A,1998-06-11,COLLABORATIVE OBJECT ARCHITECTURE,"A collaborative object architecture, using applets (210, 220) and pods (250, 260), with one or more of the following technologies: 1) lightweight asychronous messaging; 2) collaborative objects; 3) optimistic concurrency control; and 4) transparent object serialization. Lightweight asynchronous messaging allows highly responsive interactivity and natural interactions with minimal network loads. Collaborative objects allow ubiquitous sharing and provide each user with the same copy of the shared object. Optimistic concurrency control allows full-duplex group editing and natural interactions. Transparent object serialization provides real world persistence and support for asynchronous changes. Thus, combination of these technologies within a network (200) provides a collaborative object architecture with several advantages.",PLACEWARE INC,CURTIS PAVEL;;DIXON MICHAEL D;;NICHOLS DAVID A,,https://lens.org/052-412-148-066-063,Patent Application,yes,4,7,8,8,0,H04L67/10;;H04L69/329;;H04L67/131;;H04L69/329;;H04L67/10;;H04L9/40;;H04L67/01;;H04L67/131,G06F9/46;;G06F15/16;;H04L29/06;;H04L29/08,,1,0,,,See also references of EP 1110149A4,PENDING
759,WO,A2,WO 2006/014540 A2,056-811-909-846-130,2006-02-09,2006,US 2005/0024092 W,2005-07-07,US 58589204 P,2004-07-07,PLANT N-ACYLETHANOLAMINE BINDING PROTEINS,"The invention provides plant binding proteins of N-acylethanolamines. Also provided are constructs comprising coding sequences for the binding proteins, plants transformed therewith and methods of use thereof. The invention allows the modification of plant signaling by N-acylethanolamines. Such modification may be used to produce plants that are improved with respect to growth, seed germination, pathogen response and stress tolerance.",SAMUEL ROBERTS NOBLE FOUND INC;;CHAPMAN KENT D;;TRIPATHY SWATI;;DIXON RICHARD A,CHAPMAN KENT D;;TRIPATHY SWATI;;DIXON RICHARD A,,https://lens.org/056-811-909-846-130,Patent Application,yes,0,1,7,7,52,C07K14/415;;C12N15/8261;;C12N15/8279;;Y02A40/146;;C12N15/8279;;C07K14/415;;C12N15/8261;;Y02A40/146,A01H1/00;;C12N15/82;;C07K14/415,,0,0,,,,PENDING
760,US,A,US 5717159 A,061-097-157-985-722,1998-02-10,1998,US 81674797 A,1997-02-19,US 81674797 A,1997-02-19,Lead-free precussion primer mixes based on metastable interstitial composite (MIC) technology,"A lead-free percussion primer composition and a percussion cup containing e composition. The lead-free percussion primer composition is comprised of a mixture of about 45 wt % aluminum powder having an outer coating of aluminum oxide and molybdenum trioxide powder or a mixture of about 50 wt % aluminum powder having an outer coating of aluminum oxide and polytetrafluoroethylene powder. The aluminum powder, molybdenum trioxide powder and polytetrafluoroethylene powder has a particle size of 0.1 .mu.m or less, more preferably a particle size of from about 200-500 angstroms.",US NAVY,DIXON GEORGE P;;MARTIN JOE A;;THOMPSON DON,NAVY UNITED STATES OF AMERICA THE AS REPRESENTED BY THE SECRETARY OF THE (1996-12-19),https://lens.org/061-097-157-985-722,Granted Patent,yes,6,86,3,3,0,C06B33/12;;C06C7/00;;C06B33/12;;C06C7/00,C06B33/12;;C06C7/00,149/40;;149/37;;149/108.2;;102/204;;102/205,0,0,,,,EXPIRED
761,US,B2,US 7750211 B2,073-779-862-500-966,2010-07-06,2010,US 65975503 A,2003-09-10,US 65975503 A;;US 40944702 P,2002-09-10,Methods and compositions for production of flavonoid and isoflavonoid nutraceuticals,The invention provides method and compositions for the modulation of flavanone and/or isoflavone production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of isoflavones in particular in plants may be used to increase the nutritional value of food plants for both human and animal consumption. The invention overcomes limitations of the prior art which prevented accumulation of high levels of isoflavones in plants.,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;LIU CHANG-JUN;;DEAVOURS BETTINA,NOBLE RESEARCH INSTITUTE LLC (2017-05-01);;SAMUEL ROBERTS NOBLE FOUNDATION THE (2003-10-13),https://lens.org/073-779-862-500-966,Granted Patent,yes,13,2,10,10,15,C12N9/0071;;C12N9/0077;;C12N15/8243;;C12N15/825;;C12N9/0071;;C12N15/825;;C12N15/8243;;C12N9/0077,C12N15/29;;A01H1/00;;A01H5/00;;A01H5/10;;C12N9/02;;C12N9/90;;C12N15/52;;C12N15/82,800/312;;800/286;;800/306;;800/314;;800/317.2;;800/317.3;;800/317.4;;800/320;;800/320.1;;800/320.2;;800/320.3,36,26,070-736-162-892-103;;081-153-867-384-605;;068-112-738-052-338;;056-823-544-404-943;;001-417-683-943-112;;005-029-931-343-53X;;030-560-996-409-192;;081-153-867-384-605;;070-736-162-892-103;;070-527-153-985-104;;034-007-398-246-049;;048-425-634-797-396;;016-260-898-220-124;;069-233-849-309-156;;102-449-251-149-642;;001-906-076-969-393;;134-479-221-503-661;;037-600-532-041-631;;041-601-268-755-801;;097-248-889-643-850;;049-414-985-018-203;;017-587-910-142-562;;006-389-101-391-175;;020-609-497-841-564;;100-917-723-194-129;;081-153-867-384-605,pmc22848;;9770503;;10.1073/pnas.95.21.12432;;11027726;;pmc59182;;10.1104/pp.124.2.781;;10.1007/978-94-017-2679-5_101;;24301308;;10.1007/bf00017991;;12877915;;10.1016/s0031-9422(03)00345-5;;pmc102307;;11351096;;10.1104/pp.126.1.330;;pmc137925;;12384577;;10.1073/pnas.212522099;;11027726;;pmc59182;;10.1104/pp.124.2.781;;pmc22848;;9770503;;10.1073/pnas.95.21.12432;;10.1104/pp.121.3.821;;pmc59444;;10557230;;10.1016/0031-9422(88)80666-6;;10.1016/b978-0-08-091283-7.00030-8;;12031439;;10.1016/s0031-9422(02)00116-4;;10.1104/pp.127.1.46;;pmc117961;;11553733;;10.1016/s0031-9422(98)00266-0;;10.1038/72671;;10657130;;8507827;;10.1007/bf00014932;;10.1007/bf00029615;;10.1038/88150;;11329019;;10.1016/s1360-1385(97)87121-x;;10.1006/abbi.1999.1238;;10375412;;11714321;;10.1021/jf010600x;;10.1021/jf000876p;;11262024;;10.1034/j.1399-3054.1999.100119.x;;10634784;;10.1126/science.287.5451.303;;11027726;;pmc59182;;10.1104/pp.124.2.781,"Wisman et al. PNAS, Oct. 1998, vol. 95, pp. 12432-12437.;;Yu O. et al. Plant Physiology, 2000; vol. 124, pp. 781-793.;;Dixon et al., ""Metabolic Engineering of Flavonoid/Isoflavonoid Biosynthesis,"" Abstracts of Papers American Chemical Society, 219, Abstract 152, 2000.;;Liu et al., ""Direction Metabolic Flux Toward Engineered Isoflavone Nutraceuticals in Transgenic Arabidopsis,"" In: Plant Biotechnology 2002 and Beyond: Proceedings of the 10th IAPTC&B Congress, Vasil (ed.), Kulwer Academic Publishers, Dordrecht, 2003.;;Liu et al., ""Metabolic engineering of isoflavonoid biosynthesis in Arabidopsis thaliana,"" Plant Biology, Abstract 209, 2000.;;White and Greenwood, ""Transformation of the forage legume Trifolium repens L. using binary Agrobactrium vectors,"" Plant Molecular Biology, 8:461-469, 1987.;;Yu et al., ""Metabolic engineering to increase isoflavone biosynthesis in soybean seed,"" Phytochemistry, 63:753-763, 2003.;;GenBank GI:166397, Jan. 29, 1997.;;GenBank GI:393000, Jan. 30, 1997.;;GenBank GI:456399, Jan. 28, 1997.;;Kim et al., ""Brassica rapa has three genes that encode proteins associated with different neutral lipids in plastids of specific tissues,"" Plant Physiology, 126:330-341, 2001.;;Liu et al., ""Bottlenecks for metabolic engineering of isoflavone glycoconjugates in Arabidopsis,"" PNAS, 99:14578-14583, 2002.;;Yu et al., ""Production of the isoflavones genistein and daidzein in non-legume dicot and monocot tissues,"" Plant Physiology, 1224:781-793, 2000.;;Wisman et al., ""Knock-out mutants from an En-1 mutagenized Arabidopsis thaliana population generate phenylpropanoid biosynthesis phenotypes,"" Proc. Natl. Acad. Sci. USA, 95:12432-12437, 1998.;;Akashi et al., ""Cloning and functional expression of a cytochrome P450 cDNA encoding 2-hydroxyisoflavanone synthase involved in biosythesis of the isoflavanoid skeleton in licorice,"" Plan Physiol., 121:821-828, 1999.;;Dixon et al., ""Comparative bichemistry of chalcone isomerases,"" Phytochemistry, 27(9):2801-2808, 1988.;;Dixon, In: Comprehensive Natural Products Chemistry, vol. 1, Sankawa (ed.), Elsevier, 773-823, 1999.;;Dixon and Ferriera, ""Molecules of interest: Genistein,"" Phytochemistry, 60:205-211, 2002.;;Dong et al., ""Functional conservation of plant secondary metabolic enzymes revealed by complementation of Arabidopsis flavanoid mutants with maize genes,"" Plant Physiology, 127:46-57, 2001.;;GenBank Accession No. AC092697.;;GenBank Accession No. AF022462.;;GenBank Accession No. AJ278457.;;GenBank Accession No. AJ295587.1.;;GenBank Accession No. M91079.;;Hakamatsuka et al., ""Purification of 2-hydroxyisoflavanone dehydratase from the cell cultures of pueraria lobata,"" Phytochemistry, 49(2):497-505, 1998.;;Jung et al., ""Identification and expression of isoflavone synthase, the key enzyme for biosynthesis of isoflavones in legumes,"" Nature BioTech., 18:208-212, 2000.;;Junghans et al., ""Stress responses in alfalfa (Medicago sativa L.). 15. Characterization and expression patterns of members of a subset of the chalcone synthase multigene family,"" Plant Mol. Biol., 22:239-253, 1993.;;McKhann and Hirsch, ""Isolation of chalcone synthase and chalcone isomerase cDNAs from alfalfa (Medicago sativa L.): highest transcript levels occur in young roods and root tips,"" Plant Mol. Biol., 24(5):767-777, 1994.;;Muir et al., ""Overexpression of petunia chalone isomerase in tomato results in fruit containing increased levels of flavonols,"" Nature Biotech., 19:470-474, 2001.;;Schröder, ""A family of plant-specific polyketide synthases: facts and predictions,"" Trends in Plant Sci., 2(10):373-378, 1997.;;Steele et al., ""Molecular characterization of the enzyme catalyzing the aryl migration reaction of isoflavaniod biosynthesis in soybean,"" Arch. Biochem. Biophys., 367(1):146-150, 1999.;;Stochmal et al., ""Alfalfa (Medicago sativa L.) flavanoids. 2. Tricin and chrysoeriol clycosides from aerial parts,"" J. Agric. Food Chem., 49:5310-5314, 2001.;;Stochmal et al., ""Alfalfa (Medicago sativa L.) flavaniods. 1. Apigenin and luteolin glycosides from aerial parts,"" J. Agric. Food Chem., 49:753-758, 2001.;;Winkel-Shirley, ""Evidence for enzyme complexes in the phenylpropanoid and flavanoid pathways,"" Physiologia Plantarium, 107:142-149, 1999.;;Ye et al., ""Engineering the provitamin A (beta-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm,"" Science, 287:303-305, 2000.;;Yu et al., ""Production of the isoflavones genistein and daidzein in non-legume dicot and monocot tissues,"" Plant Physiology, 124:781-794, 2000.",ACTIVE
762,EP,A4,EP 1555870 A4,084-386-229-222-640,2006-11-02,2006,EP 03752235 A,2003-09-10,US 0328454 W;;US 40944702 P,2002-09-10,METHODS AND COMPOSITIONS FOR PRODUCTION OF FLAVONOID AND ISOFLAVONOID NUTRACEUTICALS,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;LIU CHANG-JUN;;DEAVOURS BETTINA,,https://lens.org/084-386-229-222-640,Search Report,no,3,0,10,10,0,C12N9/0071;;C12N9/0077;;C12N15/8243;;C12N15/825;;C12N9/0071;;C12N15/825;;C12N15/8243;;C12N9/0077,A01H1/00;;C12N9/02;;C12N9/90;;C12N15/82,,4,1,068-112-738-052-338,10.1007/978-94-017-2679-5_101,"LIU, C.J., ET AL.: ""Directing metabolic flux toward engineering isoflavone nutraceuticals in transgenic Arabidopsis, pp. 485-490"", 2003, KLUWER ACADEMIC PUBLISHERS, EDITOR VASIL, I.K., PROCEEDINGS OF THE 10TH IAPTC&B CONGRESS, ORLANDO, FLORIDA, 25-28 JUNE 2002, XP008068377;;LIU, CHANG-JUN ET AL: ""Metabolic engineering of isoflavonoid biosynthesis in Arabidopsis thaliana."", PLANT BIOLOGY (ROCKVILLE) POSTER 29, ABSTRACT#269, vol. 2000, 2000, ANNUAL MEETING OF THE AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS; SAN DIEGO, CALIFORNIA, USA; JULY 15-19, 2000, XP002397321, Retrieved from the Internet <URL:http://abstracts.aspb.org/pb2000/public/P29/0105.html> [retrieved on 20060830];;DIXON RICHARD A ET AL: ""Metabolic engineering of flavonoid/isoflavonoid biosynthesis"", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 219, no. 1-2, 2000, & 219TH MEETING OF THE AMERICAN CHEMICAL SOCIETY.; SAN FRANCISCO, CALIFORNIA, USA; MARCH 26-30, 2000, pages AGFD 152, XP000925561, ISSN: 0065-7727;;DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2000, YU OLIVER ET AL: ""Metabolic engineering of isoflavone synthesis in soybean and non-legume plants."", XP002397323, Database accession no. PREV200300065446",DISCONTINUED
763,EP,A1,EP 2108173 A1,107-009-838-022-74X,2009-10-14,2009,EP 07854499 A,2007-10-29,US 2007/0082898 W;;US 88730707 P;;US 68117907 A,2007-01-30,PROCESSING TRANSACTIONS OF DIFFERENT PAYMENT DEVICES OF THE SAME ISSUER ACCOUNT,,VISA USA INC,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,,https://lens.org/107-009-838-022-74X,Patent Application,yes,0,0,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/36;;G06Q20/14;;G07B15/02,,0,0,,,,DISCONTINUED
764,EP,A2,EP 2362767 A2,106-969-273-068-995,2011-09-07,2011,EP 09748625 A,2009-10-29,US 2009/0062611 W;;US 10947408 P,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,,WYETH LLC,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,ABLYNX N.V. (2012-03-07),https://lens.org/106-969-273-068-995,Patent Application,yes,0,0,44,44,0,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/19;;A61K9/00;;A61K39/395;;A61P35/00;;G06F19/00,,0,0,,,,ACTIVE
765,EP,A1,EP 3011953 A1,146-328-313-347-261,2016-04-27,2016,EP 15189934 A,2009-10-29,US 10947408 P;;EP 09748625 A,2008-10-29,STABILISED FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,"The invention relates to formulations of single domain antigen binding molecules, e.g. nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g. bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.",ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,,https://lens.org/146-328-313-347-261,Patent Application,yes,76,1,44,44,10,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/00;;A61K9/19;;A61K39/395;;A61P35/00;;G06F19/00,,34,21,015-692-072-798-109;;091-234-354-982-068;;090-754-759-154-175;;032-728-154-591-070;;028-862-168-091-90X;;069-778-338-173-349;;050-959-366-576-084;;022-375-749-274-329;;104-212-297-137-759;;078-075-414-981-82X;;085-277-440-303-853;;055-933-943-437-663;;023-676-781-371-861;;005-648-278-768-326;;020-026-345-586-213;;092-023-577-402-127;;039-508-259-975-855;;002-664-741-683-318;;021-641-900-032-887;;025-930-820-482-18X;;038-371-868-499-013,17097246;;10.1016/j.ijpharm.2006.09.015;;8124728;;10.1023/a:1015825027737;;2052513;;10.1016/0022-2836(70)90057-4;;5420325;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;16199666;;pmc2253229;;10.1110/ps.051709505;;10.1038/363446a0;;8502296;;1675655;;10.4049/jimmunol.147.1.60;;10.4049/jimmunol.148.5.1547;;1531669;;4001944;;10.1126/science.4001944;;10.1038/ng0594-13;;8075633;;10.1038/314452a0;;3920533;;10.1126/science.3929380;;3929380;;10.1073/pnas.80.23.7308;;6316357;;pmc390044;;25291284;;10.1016/0167-5699(83)90123-8;;1404388;;10.1016/0022-2836(92)90223-7;;7779254;;10.1016/0167-5699(95)80166-9;;10.1016/0022-2836(92)90224-8;;1404389;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;12052707;;10.1016/s0169-409x(02)00020-0;;10.1093/protein/gzg093;;14600206,"YANG ET AL: ""Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: Preparation and in vitro evaluation"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL LNKD- DOI:10.1016/J.IJPHARM.2006.09.015, vol. 331, no. 1, 31 January 2007 (2007-01-31), pages 123 - 132, XP005867347, ISSN: 0378-5173;;CLELAND ET AL., CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, vol. 10, no. 4, 1993, pages 307 - 377;;PIKAL, M., BIOPHANN., vol. 3, no. 9, 1990, pages 26 - 30;;ARAKAWA ET AL., PHARM. RES., vol. 8, no. 3, 1991, pages 285 - 291;;NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;E. MEYERS; W. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17;;AITSCHUL ET AL., J. MOL. BIOI., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402;;STRELTSOV, PROTEIN SCI., vol. 14, 2005, pages 2901 - 2909;;HAMERS-CASTERMAN, C. ET AL., NATURE, vol. 363, 1993, pages 446 - 448;;CHARLES A HASEMANN; J. DONALD CAPRA: ""Immunoglobulins: Structure and Function"", FUNDAMENTAL IMMUNOLOGY, vol. 209, 1989, pages 210 - 218;;TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60 - 69;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;SMITH, SCIENCE, vol. 228, 1985, pages 1315 - 1317;;GREEN ET AL., NATURE GENETICS, vol. 7, 1994, pages 13 - 21;;MORRISON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1985, pages 6851;;TAKEDA ET AL., NATURE, vol. 314, 1985, pages 452;;MORRISON, SCIENCE, vol. 229, 1985, pages 1202 - 1207;;OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214;;TENG ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 80, 1983, pages 7308 - 7312;;KOZBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 7279;;OLSSON ET AL., METH. ENZYMOL., vol. 92, 1982, pages 3 - 16;;TOMLINSON ET AL., J. MOL. BIOL., vol. 227, 1992, pages 776 - 798;;COOK, G. P. ET AL., LMMUNOL. TODAY, vol. 16, no. 5, 1995, pages 237 - 242;;CHOTHIA, D. ET AL., J. MOL. BIOL., vol. 227, 1992, pages 799 - 817;;TOMLINSON ET AL., EMBOJ., vol. 14, 1995, pages 4628 - 4638;;TOMLINSON, LA ET AL., MRC CENTRE FOR PROTEIN ENGINEERING;;""Current Protocols in Molecuiar Biology"", 1990, WIIEY;;""Remington's Pharmaceutical Sciences"", 1980, MACK PUBLISHING CO.;;CHAPMAN, NAT. BIOTECHNOL., vol. 54, 2002, pages 531 - 545;;VERONESE; HARRIS, ADV. DRUG DELIV. REV., vol. 54, 2003, pages 453 - 456;;HARRIS; CHESS, NAT. REV. DRUG. DISCOV., 2003, pages 2;;YANG ET AL., PROTEIN ENGINEERING, vol. 16, no. 10, 2003, pages 761 - 770;;GUPTA, ET AL., AAPS PHARM. SCI., vol. 5, 2003, pages 1 - 9",DISCONTINUED
766,JP,A,JP 2021054858 A,023-677-242-334-927,2021-04-08,2021,JP 2021000869 A,2021-01-06,US 201562128462 P,2015-03-04,ANTIBODY THERAPEUTICS THAT BIND CD47,"To provide antibody therapeutics that bind CD47.SOLUTION: Disclosed herein are compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, disclosed herein are fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further disclosed are nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.SELECTED DRAWING: Figure 1",SORRENTO THERAPEUTICS INC,BARBARA A SWANSON;;JOHN DIXON GRAY;;ZHOU HEYUE,,https://lens.org/023-677-242-334-927,Patent Application,no,2,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;A61K39/395;;A61P35/00;;A61P35/02,,0,0,,,,ACTIVE
767,WO,A3,WO 1996/015239 A3,037-513-201-380-246,1996-05-23,1996,US US9514149,1995-11-01,"US 8/339,129",1994-11-14,ISOFLAVONE REDUCTASE PROMOTER,The invention relates to a promoter and associated control elements derived from the isoflavone reductase gene. The upstream activating region and portions thereof have been characterized as to their ability to control the transcription of operably linked foreign structural genes in legumes as well as in plants which lack the isoflavonoid pathway.,"THE SAMUEL ROBERTS NOBLE FOUNDATION, INC.","DIXON, Richard, A.;;PAIVA, Nancy, L.;;OOMMEN, Abraham",,https://lens.org/037-513-201-380-246,Search Report,yes,0,0,1,1,0,,C12N9/02;;C12N15/82,,0,0,,,,UNKNOWN
768,WO,A2,WO 2008/134372 A2,073-592-415-663-114,2008-11-06,2008,US 2008/0061301 W,2008-04-23,US 91427907 P,2007-04-26,PRODUCTION OF PROANTHOCYANIDINS TO IMPROVE FORAGE QUALITY,"The invention provides method and compositions for the modulation of anthocyanin and proanthocyanidin production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of anthocyanins and proanthocyanidins in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased proanthocyanidin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content. The invention may also be used to modify plant pigmentation, and for nutraceutical and food colorant production.",SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;MODOLO LUZIA V;;PEEL GREGORY,DIXON RICHARD A;;MODOLO LUZIA V;;PEEL GREGORY,,https://lens.org/073-592-415-663-114,Patent Application,yes,0,8,8,8,97,A23V2002/00;;C07K14/415;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K20/121;;A23K50/10;;A23L5/43;;A23L33/105;;C07K14/415;;A23V2002/00;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K50/10;;A23K20/121;;A23L5/43;;A23L33/105,C12N15/82;;A01H5/00;;A23K10/32;;A23L1/00,,0,0,,,,PENDING
769,BR,A2,BR PI0919979 A2,097-394-265-714-169,2015-12-15,2015,BR PI0919979 A,2009-10-29,US 2009/0062611 W;;US 10947408 P,2008-10-29,formulações de moléculas de ligação de antígeno de domínio único,,WYETH LLC,PAULSON ANDREA;;DIXON DANIEL A;;FERNANDEZ JASON E,ABLYNX N.V. (BE) (2016-06-21),https://lens.org/097-394-265-714-169,Patent Application,no,0,0,44,44,0,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/00;;A61K9/19;;A61K39/395;;A61P35/00;;G06F19/00,,0,0,,,,DISCONTINUED
770,AU,A1,AU 2016/225993 A1,125-298-924-602-384,2017-09-28,2017,AU 2016/225993 A,2016-03-04,US 201562128462 P;;US 2016/0020980 W,2015-03-04,Antibody therapeutics that bind CD47,"There is disclosed compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, there is disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.",SORRENTO THERAPEUTICS INC,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,YUHAN CORPORATION (2023-11-23),https://lens.org/125-298-924-602-384,Patent Application,no,0,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/18;;A61K39/395;;C07K16/28,,0,0,,,,ACTIVE
771,WO,A3,WO 2006/014540 A3,135-525-433-971-572,2006-07-06,2006,US 2005/0024092 W,2005-07-07,US 58589204 P,2004-07-07,PLANT N-ACYLETHANOLAMINE BINDING PROTEINS,"The invention provides plant binding proteins of N-acylethanolamines. Also provided are constructs comprising coding sequences for the binding proteins, plants transformed therewith and methods of use thereof. The invention allows the modification of plant signaling by N-acylethanolamines. Such modification may be used to produce plants that are improved with respect to growth, seed germination, pathogen response and stress tolerance.",SAMUEL ROBERTS NOBLE FOUND INC;;CHAPMAN KENT D;;TRIPATHY SWATI;;DIXON RICHARD A,CHAPMAN KENT D;;TRIPATHY SWATI;;DIXON RICHARD A,,https://lens.org/135-525-433-971-572,Search Report,yes,1,0,7,7,0,C07K14/415;;C12N15/8261;;C12N15/8279;;Y02A40/146;;C12N15/8279;;C07K14/415;;C12N15/8261;;Y02A40/146,C12N15/82;;A01H1/00;;C07K14/415,,3,1,052-342-666-307-92X,pmc166934;;10.1104/pp.102.014936;;12692337,"DATABASE NCBI 3 November 2001 (2001-11-03), XP002359740, Database accession no. AY058066;;DATABASE NCBI 16 January 2003 (2003-01-16), XP002359741, Database accession no. BT003016;;TRIPATHY S ET AL: ""N-ACYLETHANOLAMINE SIGNALING IN TOBACCO IS MEDIATED BY A MEMBRANE-ASSOCIATED, HIGH-AFFINITY BINDING PROTEIN"", PLANT PHYSIOLOGY, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, US, vol. 131, no. 4, April 2003 (2003-04-01), pages 1781 - 1791, XP001204859, ISSN: 0032-0889",PENDING
772,US,B2,US 8420889 B2,132-449-519-341-052,2013-04-16,2013,US 54924809 A,2009-08-27,US 54924809 A;;US 9300608 P,2008-08-29,Epicatechin glucosyltransferase,"The invention provides methods and compositions for the modulation of epicatechin glucosyltransferase activity in plants. Increased expression of epicatechin glucosides, and ultimately anthocyanins and proanthocyanidins, in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased proanthocyanidin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content.",DIXON RICHARD A;;PANG YONGZHEN;;PEEL GREGORY J;;SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;PANG YONGZHEN;;PEEL GREGORY J,THE SAMUEL ROBERTS NOBLE FOUNDATION (2009-09-02);;NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/132-449-519-341-052,Granted Patent,yes,4,0,6,6,66,C12N15/8243;;C12N15/8243;;C12N9/1051;;C12N9/1051,A01H5/00;;C12N9/10;;C12N15/52;;C12N15/85,800/284;;800/298;;800/282;;536/23.2;;530/370;;435/91.1;;435/468;;435/419;;435/320.1,47,27,055-003-061-629-507;;123-127-395-374-005;;131-737-655-070-816;;002-302-213-407-020;;014-921-916-579-046;;021-053-676-958-106;;036-482-370-713-034;;031-383-256-104-133;;015-279-533-554-483;;071-550-833-143-412;;054-383-105-820-129;;027-346-493-289-672;;023-953-046-860-282;;019-903-104-142-431;;017-258-287-454-398;;004-357-768-192-802;;002-485-351-554-971;;027-010-229-028-458;;046-853-221-775-39X;;043-753-762-862-376;;006-470-893-916-774;;147-270-016-436-484;;123-127-395-374-005;;053-728-441-408-680;;061-370-482-530-697;;060-759-452-114-325;;025-934-122-339-691,10.1073/pnas.0403255101;;pmc438954;;15197260;;pmc2544603;;10.1073/pnas.0805954105;;18772380;;17437063;;10.1007/s11103-007-9167-6;;10.1104/pp.107.107326;;17885080;;pmc2048810;;10.1007/s00425-004-1424-1;;15578217;;10.1111/j.1365-313x.2004.02138.x;;15255866;;15695592;;pmc548969;;10.1073/pnas.0406377102;;10.1111/j.1365-313x.2008.03519.x;;18410479;;pmc102225;;10.2307/3871236;;11148285;;10.1105/tpc.12.12.2383;;10.2210/pdb2vce/pdb;;pmc2154415;;18077347;;10.1073/pnas.0706421104;;10.2527/1995.7392760x;;8582869;;10.1104/pp.105.062539;;pmc1183411;;16006598;;10.1105/tpc.13.4.853;;10.2307/3871345;;11283341;;pmc135529;;10.1016/0378-1119(88)90004-2;;2843437;;15278457;;10.1007/s00425-004-1336-0;;14675436;;10.1046/j.1365-313x.2003.01943.x;;10.1007/978-1-4615-3476-1_55;;1417702;;16669768;;10.1146/annurev.arplant.57.032905.105252;;pmc137475;;10.1073/pnas.232580599;;12417742;;10.1104/pp.123.4.1561;;10938372;;pmc59113;;pmc139454;;10.2307/3871430;;10.1105/tpc.13.9.2099;;11549766;;10.1105/tpc.010098;;11041882;;pmc149125;;10.2307/3871198;;10.1105/tpc.12.10.1863;;pmc2544603;;10.1073/pnas.0805954105;;18772380;;10.1111/j.1365-313x.2005.02510.x;;16167896;;10.1246/cl.2007.1292;;17746504;;10.1126/science.248.4963.1637;;10.1242/dev.00681;;12917293,"Guo et al., 2004, Protein tolerance to random amino acid change, PNAS 101(25):9205-9210.;;Pang et al, A transcript profiling approach reveals an epicatechin-specific glycosyltransferas expressed in the seed coat of Medicago truncatula, 2008, PNAS 105:14210-14215.;;Modolo et al., ""A functional genomics approach to (iso)flavonoid glycosylation in the model legume Medicago truncatula,"" Plant Mol. Biol., 64:499-518, 2007.;;Pang et al., ""Early steps in proanthocyanidin biosynthesis in the model legume Medicago truncatula,"" Plant Physiol., 145:601-615, 2007.;;Aziz et at, ""Transcriptome analysis of alfalfa glandular trichomes,"" Planta, 221:28-38, 2005.;;Baudry et al., ""TT2, TT8 and TTG1 synergistically specify the expression of BANYULS and proanthocyanidin biosynthesis in Arabidopsis thaliana,"" The Plant J., 39:366:380, 2004.;;Baxter et al., ""A plasma membrane H+-ATPase is required for the formation of proanthocyanidins in the seed coat endothelium of Arabidopsis thaliana,"" PNAS, 102(7):2649-2654, 2005.;;Benedito et al., ""A gene expression atlas of the model legume Medicago truncatula,"" The Plant J., 55:504-513, 2008.;;Borevitz et al., ""Activation tagging identifies a conserved MYB regulator of phenylpropanoid biosynthesis,"" The Plant Cell, 12:2383-2393, 2000.;;Brazier-Hicks et al., ""Characterization and engineering of the bifunctional N- and O- glucosyltransferase involved in xenobiotic metabolism in plants,"" PNAS, 104(51):20238-20243, 2007.;;Broderick, ""Desirable characteristics of forage legumes for improving protein utilization in ruminants,"" J. Anim. Sci., 73:2760-2773, 1995.;;Database EMBL Accession No. AC1249766, dated Jun. 21, 2002.;;Deavours et al., ""Metabolic engineering of isoflavonoid biosynthesis in alfalfa,"" Plant Physiology, 138:2245-2259, 2005.;;Debeaujon et al., ""The transparent TESTA12 gene of Arabidopsis encodes a multidrug secondary transporter-like protein required for flavonoid sequestration in vacules of the seed coat endothelium,"" The Plant Cell, 13:853-871, 2001.;;di Guan et al., ""Vectors that facilitate the expression and purification of foreign peptides in Escherichia coli by fusion to maltose-binding protein,"" Gene, 67:21-30, 1988.;;GenBank Accession No. AAK53551, dated Dec. 16, 2005.;;GenBank Accession No. AAL92460, dated Dec. 16, 2005.;;GenBank Accession No. AAW56092, dated Mar. 7, 2005.;;GenBank Accession No. AB194020, dated Dec. 12, 2007.;;GenBank Accession No. AB194021, dated Dec. 12, 2007.;;GenBank Accession No. AB194022, dated Dec. 12, 2007.;;GenBank Accession No. AB194023, dated Dec. 12, 2007.;;GenBank Accession No. AB194024, dated Dec. 12, 2007.;;GenBank Accession No. AB194025, dated Dec. 12, 2007.;;GenBank Accession No. AF190298, dated Jan. 25, 2002.;;GenBank Accession No. AJ133743, dated Nov. 14, 2006.;;GenBank Accession No. AJ277509, dated Nov. 2, 2000.;;GenBank Accession No. AJ294464, dated Apr. 30, 2001.;;GenBank Accession No. AJ299452, dated Nov. 14, 2006.;;GenBank Accession No. CAC35167, dated Mar. 29, 2001.;;GenBank Accession No. DQ875465, dated Jul. 2, 2007.;;GenBank Accession No. EU434684, dated Sep. 23, 2008.;;Grotewold, ""The challenges of moving chemicals within and out of cells: insights into the transport of plant natural products,"" Planta, 219:906-909, 2004.;;Kitamura et al., ""Transparent TESTA 19 is involved in the accumulation of both anthocyanins and proanthocyanidins in arabidopsis,"" The Plant J., 37:104-114, 2004.;;Lees, ""Condensed tannins in some forage legumes: Their role in the prevention of ruminant pasture bloat,"" In: Plant Polyphenols Basic Life Science, Hemingway eds., Plenum Press, pp. 915-934, 1992.;;Lepiniec et al., ""Genetics and biochemistry of seed flavonoids,"" Ann. Rev. Plant Biol., 57:405-530, 2006.;;Liu et al., ""Resistance to the macrolide antibiotic tylosin is conferred by single methylations at 23S rRNA nucleotides G748 and A2058 acting in synergy,"" PNAS, 99(23):14658-14663, 2002.;;Mueller et al., ""AN9, a petunia glutathione S-transferase required for anthocyanin sequestration, is a flavonoid-binding protein,"" Plant Physiology, 123:1561-1570, 2000.;;NCBI Accession No. NP-192016, dated Aug. 21, 2009.;;Nesi et al., ""The arabidopsis TT2 gene encodes an R2R3 MYB domain protein that acts as a key determinant for proanthocyanidin accumulation in developing seed,"" The Plant Cell, 13:2099-2114, 2001.;;Nesi et al., ""The TT8 gene encodes a basic helix-loop-helix domain protein required for expression of DFR and BAN genes in Arabidopsis siliques,"" The Plant Cell, 12:1863-1878, 2000.;;Pang et al., ""A transcript profiling approach reveals an epicatechin-specific glucosyltransferase expressed in the seed coat of Medicago truncatula,""PNAS, 105(37):14210-14215, 2008.;;Peel et al., ""Detection and quantification of engineered proanthocyandins in transgenic plants,"" Natural Product Communications, 2(10):1009-1014, 2007.;;Sharma et al., ""Metabolic engineering of proanthocyanidins by ectopic expression of transcription factors in Arabidopsis thaliana,"" The Plant J., 44:62-75, 2005.;;Shimoda et al., ""Glycosylation and malonylation of quercetin, epicatechin, and catechin by cultured plant cells,"" Chemistry Letters, 36(10):1292-1293, 2007.;;Snyder et al., ""Synthesis of phytoalexins in Sorghum as a site-specific response to fungal ingress,"" Science, 248:1637-1639, 1990.;;Zhang et al., ""A network of redundant bHLH proteins functions in all TTG1-dependent pathways of Arabidopsis,"" Development, 130:4859-4869, 2003.",ACTIVE
773,CA,C,CA 2738243 C,136-155-263-778-745,2020-09-29,2020,CA 2738243 A,2009-10-29,US 10947408 P;;US 2009/0062611 W,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,"The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated dis-orders, are also disclosed.",WYETH LLC,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,,https://lens.org/136-155-263-778-745,Granted Patent,no,0,0,44,44,10,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/19,,0,0,,,,ACTIVE
774,WO,A1,WO 2009/108719 A1,175-762-763-417-582,2009-09-03,2009,US 2009/0035172 W,2009-02-25,US 3107208 P,2008-02-25,VEHICLE SECURITY AND MONITORING SYSTEM,"A vehicle monitoring system includes a communication subsystem configured to provide two-way wireless communication, and a controller mounted in a vehicle and configured to receive data indicative of a location of the vehicle and to control the communication subsystem to transmit the data indicative of the vehicle location toward a remote communication center and receive operational information transmitted from the remote communication center. The controller receives a mode change command included in the operational information and in response changes operating mode between an authorization mode, in which the controller transmits an alert signal to the remote communication center, and a tracking mode, in which the controller transmits the data indicative of vehicle location continuously at predetermined intervals regardless of the authorization signal.",RECOVERY SYSTEMS HOLDINGS LLC;;BEVACQUA KURT;;OSMAN MARK A;;DIXON STEVEN C,BEVACQUA KURT;;OSMAN MARK A;;DIXON STEVEN C,,https://lens.org/175-762-763-417-582,Patent Application,yes,6,3,7,7,0,B60R25/102;;B60R25/33;;B60R2025/1016;;B60R2325/205;;G01S5/0027;;H04W8/24;;H04W64/00;;H04W12/126;;B60R25/33;;G01S5/0027;;B60R2025/1016;;H04W64/00;;B60R25/102;;B60R2325/205;;H04W8/24;;H04W12/126,H04B1/38;;B60R25/10;;G01S5/02;;G08G1/123;;H04B17/00;;H04W64/00,,0,0,,,,PENDING
775,AU,A1,AU 2020/294159 A1,023-535-059-874-948,2021-01-28,2021,AU 2020/294159 A,2020-12-21,AU 2020/294159 A;;AU 2016/225993 A;;US 201562128462 P;;US 2016/0020980 W,2015-03-04,Antibody therapeutics that bind CD47,"Abstract There is disclosed compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, there is disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding 5 polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.",YUHAN CORP,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,YUHAN CORPORATION (2023-11-23),https://lens.org/023-535-059-874-948,Patent Application,no,0,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/18;;A61K39/395;;C07K16/28,,0,0,,,,PENDING
776,US,B2,US 8115656 B2,052-914-528-098-93X,2012-02-14,2012,US 39294209 A,2009-02-25,US 39294209 A;;US 3107208 P,2008-02-25,Vehicle security and monitoring system,"A vehicle monitoring system includes a communication subsystem configured to provide two-way wireless communication, and a controller mounted in a vehicle and configured to receive data indicative of a location of the vehicle and to control the communication subsystem to transmit the data indicative of the vehicle location toward a remote communication center and receive operational information transmitted from the remote communication center. The controller receives a mode change command included in the operational information and in response changes operating mode between an authorization mode, in which the controller transmits an alert signal to the remote communication center, and a tracking mode, in which the controller transmits the data indicative of vehicle location continuously at predetermined intervals regardless of the authorization signal.",BEVACQUA KURT;;OSMAN MARK A;;DIXON STEVEN C;;RECOVERY SYSTEMS HOLDINGS LLC,BEVACQUA KURT;;OSMAN MARK A;;DIXON STEVEN C,RECOVERY SYSTEMS HOLDINGS LLC (2009-08-14),https://lens.org/052-914-528-098-93X,Granted Patent,yes,60,36,7,7,0,B60R25/102;;B60R25/33;;B60R2025/1016;;B60R2325/205;;G01S5/0027;;H04W8/24;;H04W64/00;;H04W12/126;;B60R25/33;;G01S5/0027;;B60R2025/1016;;H04W64/00;;B60R25/102;;B60R2325/205;;H04W8/24;;H04W12/126,B60R25/10;;G08G1/123,340/989;;340/438;;340/995.1,0,0,,,,INACTIVE
777,DE,D1,DE 69608888 D1,053-482-896-344-33X,2000-07-20,2000,DE 69608888 T,1996-03-07,US 40160395 A;;US 9602555 W,1995-03-09,"SUBSTITUIERTE DIBENZ[a,f]AZULENE UND VERFAHREN ZU IHRER HERSTELLUNG","Tetracyclic compounds having the following structure are described: <IMAGE> wherein R1-R10 are as defined. The tetracyclic compounds are capable of potent effects on steroid sensitive tissues and have demonstrated increased uterine weight, antiovulatory effects and potent steroid receptor binding. The compounds have therapeutic utility in reproductive applications such as fertility control, labor induction, ovulation induction and spermatogenesis. Methods for preparing the tetracyclic compounds from substituted indanones are also described.",ORTHO PHARMA CORP,DODD E;;DIXON A;;BULLINGTON L;;SCHWENDER F,,https://lens.org/053-482-896-344-33X,Granted Patent,no,0,0,16,16,0,C07C13/66;;C07C25/22;;C07C39/17;;C07C43/21;;C07C43/215;;C07C43/225;;C07C43/23;;C07C49/755;;C07C49/84;;C07C65/26;;C07C69/017;;C07C69/157;;C07C69/16;;C07C69/63;;C07C205/20;;C07C205/37;;C07C205/42;;C07C211/61;;C07C217/24;;C07C233/07;;C07C233/15;;C07D257/04;;C07F9/12;;C07C2603/40;;A61P13/02;;A61P15/00;;A61P15/08;;C07D257/04;;C07C69/157;;C07C205/37;;C07C13/66;;C07C69/017;;C07C233/15;;C07C43/23;;C07F9/12;;C07C69/63;;C07C205/20;;C07C39/17;;C07C217/24;;C07C205/42;;C07C49/84;;C07C233/07;;C07C43/21;;C07C211/61;;C07C69/16;;C07C25/22;;C07C49/755;;C07C43/225;;C07C43/215;;C07C65/26;;C07C2603/40,A61K31/015;;A61K31/03;;A61K31/04;;A61K31/085;;A61K31/12;;A61K31/135;;A61K31/165;;A61K31/215;;A61P13/02;;A61P15/00;;C07C13/66;;C07C23/46;;C07C25/22;;C07C39/17;;C07C43/21;;C07C43/215;;C07C43/225;;C07C43/23;;C07C49/755;;C07C49/84;;C07C65/26;;C07C69/00;;C07C69/157;;C07C69/65;;C07C69/734;;C07C205/20;;C07C205/37;;C07C205/42;;C07C211/61;;C07C217/16;;C07C217/24;;C07C233/07;;C07C233/11;;C07C233/15;;C07D257/04;;C07F9/12,,0,0,,,,EXPIRED
778,AU,A1,AU 2008/245794 A1,056-338-827-001-811,2008-11-06,2008,AU 2008/245794 A,2008-04-23,US 91427907 P;;US 2008/0061301 W,2007-04-26,Production of proanthocyanidins to improve forage quality,,SAMUEL ROBERTS NOBLE FOUND INC,PEEL GREGORY;;MODOLO LUZIA V;;DIXON RICHARD A,,https://lens.org/056-338-827-001-811,Patent Application,no,0,0,8,8,0,A23V2002/00;;C07K14/415;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K20/121;;A23K50/10;;A23L5/43;;A23L33/105;;C07K14/415;;A23V2002/00;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K50/10;;A23K20/121;;A23L5/43;;A23L33/105,A01H5/00;;A23K10/32;;A23L1/00;;C12N15/82,,0,0,,,,INACTIVE
779,AU,B2,AU 2009/285705 B2,058-338-124-422-401,2013-07-04,2013,AU 2009/285705 A,2009-08-27,US 9300608 P;;US 2009/0055188 W,2008-08-29,Epicatechin glucosyltransferase,"The invention provides methods and compositions for the modulation of epicatechin glucosyltransferase activity in plants. Increased expression of epicatechin glucosides, and ultimately anthocyanins and proanthocyanidins, in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased proanthocyanidin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content.",THE SAMUEL ROBERTS NOBLE FOUNDATION INC,DIXON RICHARD A;;PANG YONGZHEN;;PEEL GREGORY J,,https://lens.org/058-338-124-422-401,Granted Patent,no,2,0,6,6,0,C12N9/1051;;C12N15/8243;;C12N15/8243;;C12N9/1051,C07K14/415;;A01H5/00;;A61K38/45;;C12N9/10;;C12N15/82,,1,0,,,EMBL: AC124966,INACTIVE
780,BR,A,BR PI0513063 A,077-764-768-401-535,2008-04-22,2008,BR PI0513063 A,2005-07-07,US 58589204 P;;US 2005/0024092 W,2004-07-07,proteìnas de ligação a n-aciletanolamina de plantas,"PROTEìNAS DE LIGAçãO A N-ACILETANOLAMINA DE PLANTAS. A presente invenção refere-se a proteínas de ligação a N-aciletanolaminas de planta. Também se apresentam construtos compreendendo seqüências codificadoras para as proteínas de ligação, plantas transformadas com eles e métodos de seu uso. A invenção permite a modificação da sinalização em plantas por N-aciletanolaminas. Essa modificação pode ser usada para produzir plantas que sejam aperfeiçoadas com relação ao crescimento, germinação de sementes, resposta a patógenos e tolerância a estresse.",SAMUEL ROBERTS NOBLE FOUND INC,CHAPMAN KENT D;;TRIPATHY SWATI;;DIXON RICHARD A,,https://lens.org/077-764-768-401-535,Patent Application,no,0,0,7,7,0,C07K14/415;;C12N15/8261;;C12N15/8279;;Y02A40/146;;C12N15/8279;;C07K14/415;;C12N15/8261;;Y02A40/146,C12N15/82;;A01H1/00;;C07K14/415,,0,0,,,,DISCONTINUED
781,AU,B2,AU 2016/225993 B2,102-510-157-086-040,2020-09-24,2020,AU 2016/225993 A,2016-03-04,US 201562128462 P;;US 2016/0020980 W,2015-03-04,Antibody therapeutics that bind CD47,"There is disclosed compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, there is disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.",YUHAN CORP,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,YUHAN CORPORATION (2023-11-23),https://lens.org/102-510-157-086-040,Granted Patent,no,1,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/18;;A61K39/395;;C07K16/28,,0,0,,,,ACTIVE
782,SG,A1,SG 48280 A1,144-833-989-123-051,1998-04-17,1998,SG 1996008680 A,1993-02-09,US 83449092 A,1992-02-12,Credit card with magnifying lens,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/144-833-989-123-051,Patent Application,no,0,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,PENDING
783,DE,D1,DE 60203408 D1,161-143-806-056-174,2005-04-28,2005,DE 60203408 T,2002-10-04,US 32733701 P;;US 0233230 W,2001-10-05,VERFAHREN ZUR HERSTELLUNG VON BAUMATERIALIEN AUS ROHEN LACKSCHLÄMMEN,"A process for producing building materials, such as asphalt, cement, concrete, mortar, or plaster board from liquid paint sludge containing water and paint solids produced from overspray in commercial paint booth operations. The preferred embodiment comprises adding the liquid paint sludge as the hydrating agent directly to the building material mix.",DU PONT,MATHESON R;;DIXON M;;MOORE R;;FISCHER A,"E.I. DU PONT DE NEMOURS AND CO., WILMINGTON, DEL., (2005-06-02)",https://lens.org/161-143-806-056-174,Granted Patent,no,0,0,17,18,0,C04B18/0418;;C04B22/002;;C04B22/0046;;C04B26/26;;C04B28/04;;C04B28/14;;C04B2111/00586;;C04B2111/0075;;C08J11/00;;C08L95/005;;Y02W30/91;;C04B18/04;;C04B22/0046;;C04B28/14;;C04B22/002;;C04B28/04;;C08J11/00;;C04B18/0418;;C04B26/26;;C04B2111/00586;;C08L95/005;;C04B2111/0075;;Y02W30/91,C04B28/02;;C04B18/04;;C04B18/30;;C04B22/00;;C04B28/10;;C04B28/16;;C08J11/00;;C08L95/00,,0,0,,,,EXPIRED
784,IL,A0,IL 254321 A0,189-270-154-982-671,2017-11-30,2017,IL 25432117 A,2017-09-04,US 201562128462 P;;US 2016/0020980 W,2015-03-04,Antibody therapeutics that bind cd47,,SORRENTO THERAPEUTICS INC;;GRAY JOHN DIXON;;ZHOU HEYUE;;SWANSON BARBARA A,GRAY JOHN DIXON;;ZHOU HEYUE;;SWANSON BARBARA A,,https://lens.org/189-270-154-982-671,Patent Application,no,0,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,,,0,0,,,,PENDING
785,US,A1,US 2016/0257751 A1,198-620-812-706-286,2016-09-08,2016,US 201615061771 A,2016-03-04,US 201615061771 A;;US 201562128462 P,2015-03-04,ANTIBODY THERAPEUTICS THAT BIND CD47,"There is disclosed compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, there is disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.",SORRENTO THERAPEUTICS INC,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,YUHAN CORPORATION (2023-11-02);;SORRENTO THERAPEUTICS INC (2017-04-07),https://lens.org/198-620-812-706-286,Patent Application,yes,0,10,34,34,32,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;C07K16/30,,11,11,027-477-313-726-928;;095-334-545-560-259;;014-113-432-888-031;;045-942-104-775-903;;051-707-000-800-833;;001-779-867-387-972;;013-142-717-038-23X;;045-872-081-200-101;;008-841-048-374-253;;037-732-210-958-572;;093-507-762-980-276,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1006/jmbi.1996.0548;;8876650;;12218124;;10.4049/jimmunol.169.6.3076;;12850000;;10.1016/s0006-291x(03)01131-8;;12079396;;10.1016/s0022-2836(02)00264-4;;10.1006/jmbi.1999.3192;;10543973;;10556035;;10.1006/jmbi.1999.3141;;pmc297746;;10.1073/pnas.86.15.5938;;2762305;;10.2210/pdb3hfm/pdb;;11451948;;10.1074/jbc.m102367200;;10.1146/annurev.med.52.1.125;;11160771;;10.1002/9783527609628,"Rudikoff et al. (Proc Natl Acad Sci USA 1982 Vol 79 page 1979).;;MacCallum et al. J. Mol. Biol. (1996) 262, 732-745;;Pascalis et al. (The Journal of Immunology (2002) 169, 3076-3084);;Casset et al. (BBRC 2003, 307:198-205);;Vajdos et al. (J. Mol. Biol. (2002) 320, 415-428);;Chen et al. (J. Mol. Bio. (1999) 293, 865-881);;Wu et al. (J. Mol. Biol. (1999) 294, 151-162);;Padlan et al. (PNAS 1989, 86:5938-5942);;Lamminmaki et al. (JBC 2001, 276:36687-36694);;White et al. (2001, Ann. Rev. Med., 2001, 52:125-145);;Meibohm (Pharmacokinetics and Pharmacodynamics of Biotech Drugs, Wiley-VHC, 2006, chapter 3, p. 45-91)",ACTIVE
786,US,B2,US 8256666 B2,006-215-517-219-07X,2012-09-04,2012,US 68117907 A,2007-03-01,US 68117907 A;;US 88730707 P,2007-01-30,Processing transactions of different payment devices of the same issuer account,"Each portable payment device associated with a single account within a payment processing system is distinguished using track data. The track data from the portable payment device is read at each of a plurality of merchant point of sale terminals (POS). Rather than relying on the PAN alone, a merchant may utilizes the track data, or a proxy thereof, as the unique identifier for the portable payment device. The merchant may then process transactions involving the portable payment device based on the unique identifier. For example, in the transit environment the transit fare for each rider with different portable payment devices but the same account can be calculated using the unique identifier, such as the full track data read from both tracks of the corresponding portable payment devices.",DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,VISA U.S.A. INC (2007-05-11),https://lens.org/006-215-517-219-07X,Granted Patent,yes,43,22,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/36;;G06K5/00;;G07B15/02;;G06Q20/14,235/380;;235/375;;235/379;;235/383,4,0,,,"Office Action in U.S. Appl. No. 11/681,174 dated Mar. 14, 2011.;;Office Action in U.S. Appl. No. 11/681,176 dated Apr. 19, 2011.;;English Translation of Japanese Publication 2004-48193, Masanao, et al.;;Nationamaster.com http://www.statemaster.com/encyclopedia/Mybi. Retrieved online May 10, 2010. © 2003-2005.",ACTIVE
787,KR,A,KR 20110061646 A,015-842-141-745-678,2011-06-09,2011,KR 20117009665 A,2009-10-29,US 10947408 P,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,,WYETH LLC,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,,https://lens.org/015-842-141-745-678,Patent Application,no,1,1,44,44,20,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/19;;A61K39/395;;A61P35/00;;G06F19/00,,0,0,,,,ACTIVE
788,US,A1,US 2005/0241772 A1,028-894-891-456-492,2005-11-03,2005,US 17332305 A,2005-07-01,US 17332305 A;;GB 0003713 A;;GB 0004245 A;;GB 0018404 A;;GB 0101372 A;;US 20406102 A;;GB 0100647 W,2000-02-17,Fabrication of hoses or other elongated articles,"Armouring tape ( 102 ) for wrapping around a hose ( 300 ) during its fabrication by a hose-wrapping machine ( 200; 400 ). The tape ( 102 ) is coiled into a roll ( 100 ) having a hollow core ( 109 ) from which the tape ( 102 ) is unwound to be wrapped onto the hose ( 300 ). The hose-wrapping machine ( 200; 400 ) rotatably mounts the roll ( 100 ) with the hose ( 300 ) passing through the roll core ( 109 ), the roll axis ( 108 ) being skewed to the hose axis ( 304 ) by the helix angle at which the tape ( 102 ) is to be wrapped onto and along the hose ( 300 ). The hose ( 300 ) is moved longitudinally through the longitudinally static roll ( 100 ) and at the same time, the roll ( 100 ) is rotated around the longitudinal axis ( 304 ) of the non-rotating hose ( 300 ). The armouring tape ( 102 ) unwinds from the inside ( 109 ) of the roll onto and along the hose ( 300 ) so as to wrap the hose ( 300 ) with a uniform helix of armouring tape ( 102 ). The use of a tape ( 102 ) containing an elastomer-embedded array of armouring cables ( 104 ) enables armouring wires and elastomer layers to be applied without a stabilising layer of fabric, and greatly simplifies setting-up of machinery for hose fabrication. The use of a tape roll ( 100 ) which can be unwound from its inside ( 109 ) enables hoses to be wrapped without having to orbit rolls that are very large and heavy.",DIXON-ROCHE KEITH;;BOURGEOIS LUC JULIEN P A,DIXON-ROCHE KEITH;;BOURGEOIS LUC JULIEN P A,,https://lens.org/028-894-891-456-492,Patent Application,yes,6,1,19,23,0,B29C53/582;;B29C53/68;;B29C53/8016;;B29C63/0021;;B29C63/105;;B29C2053/8025;;B29L2023/005;;B32B1/08;;B32B37/00;;B65H81/08;;F16L11/081;;F16L11/24;;B29C48/09;;B29C48/10;;B29C48/0018;;B29C48/151;;B29C48/156;;B29C48/21;;Y10T428/2913;;Y10T428/2913;;B32B2305/08;;B32B27/06;;B32B25/04;;B32B2597/00;;B32B1/08;;F16L11/24;;B29C63/0021;;B29C53/8016;;B29C63/105;;B29C53/68;;B65H81/08;;B29C2053/8025;;B29C53/582;;B29L2023/005;;F16L11/081;;B32B37/00;;B29C48/09;;B29C48/21;;B29C48/156;;B29C48/151;;B29C48/0018;;B29C48/10,A61M39/00;;B29C48/09;;B29C48/10;;B29C48/151;;B29C48/156;;B29C48/21;;B29C53/58;;B29C53/68;;B29C53/80;;B29C63/10;;B32B1/08;;B65H81/08;;F16L11/08;;F16L11/24,156/428,0,0,,,,DISCONTINUED
789,AU,A1,AU 2007/345583 A1,050-512-045-655-100,2008-08-07,2008,AU 2007/345583 A,2007-10-29,US 88730707 P;;US 68117907 A;;US 2007/0082898 W,2007-01-30,Processing transactions of different payment devices of the same issuer account,,VISA USA INC,EL-AWADY KHALID;;HAMMAD AYMAN A;;DIXON PHIL,,https://lens.org/050-512-045-655-100,Patent Application,no,0,0,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/14;;G06Q20/36;;G07B15/02,,0,0,,,,ACTIVE
790,EP,A4,EP 1110149 A4,058-500-210-259-420,2004-06-09,2004,EP 99927450 A,1999-06-11,US 9913158 W;;US 9610198 A,1998-06-11,COLLABORATIVE OBJECT ARCHITECTURE,,PLACEWARE INC,CURTIS PAVEL;;DIXON MICHAEL D;;NICHOLS DAVID A,,https://lens.org/058-500-210-259-420,Search Report,no,3,0,8,8,0,H04L67/10;;H04L69/329;;H04L67/131;;H04L69/329;;H04L67/10;;H04L9/40;;H04L67/01;;H04L67/131,G06F15/16;;G06F9/46;;H04L29/06;;H04L29/08,,3,2,119-569-296-919-528;;115-485-539-932-02X,10.1145/215585.215706;;10.1109/4236.589191,"DAVID A. NICHOLS ET AL: ""HIGH-LATENCY, LOW-BANDWIDTH WINDOWING IN THE JUPITER COLLABORATION SYSTEM"", UIST '95, 14 July 1995 (1995-07-14), Pittsburg PA, pages 111 - 120, XP002273091;;ERIC LY: ""Distributed Java Applet for Project Management on the Web"", INTERNET COMPUTING IEEE, vol. 1, no. 3, 1 May 1997 (1997-05-01), pages 21 - 26, XP002272931;;See also references of WO 9964959A1",DISCONTINUED
791,NZ,A,NZ 500887 A,062-139-237-301-166,2002-02-01,2002,NZ 50088798 A,1998-05-14,US 4647597 P;;US 9809863 W,1997-05-14,Nucleic acid encoding lipid transfer protein which exhibits SAR (systemic acquired resistance) by specific process,"A nucleic acid molecule which encodes a lipid transfer protein wherein the encoded lipid transfer protein exhibits a SAR signal transducing property. The nucleic acid molecule is obtained by the steps of: a) growing wild type and T-DNA transformed plants and observing for disease symptoms; b) isolating SAR mutants showing disease symptoms; c) performing SAR competence tests to validate the SAR mutation in the SAR mutants, wherein the SAR is comprised in a SAR mutant plant upon first being treated on one leaf of the plant with an avirulent inoculum and later being treated on other leaves if the plant with virulent inoculum as compared to a wild type plant which exhibits SAR upon first being treated on one leaf with an avirulent inoculum and later being treated on other leaves with a virulent inoculum; d) testing the SAR mutants to determine the position of the mutant gene in relation to the point of salicylic acid action in the signal transduction pathway, wherein the SAR mutants which are first sprayed with substance that mimics salicylic acid and acts at about the same point as salicylic acid in the SAR signal transduction pathway, challenged with a virulent inoculum, and then remain symptomless exhibit a SAR mutant gene upstream of the point of salicylic acid action in the signal transduction pathway; e) isolating DNA from those plants which are homozygous for SAR mutant gene, and where the gene is found to encode a protein which acts upstream from the site of salicylic acid action alone the signal transduction pathway; and f) probing the DNA to isolate cDNA.",SALK INST FOR BIOLOGICAL STUDI;;SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;CAMERON ROBIN;;LAMB CHRISTOPHER J,,https://lens.org/062-139-237-301-166,Patent Application,no,0,0,7,7,0,C07K14/415;;C12N15/8281,C07K14/415;;C07K16/16;;C12N5/10;;C12N15/09;;C12N15/29;;A01H5/00;;C12N15/82,,0,0,,,,PENDING
792,EP,B1,EP 2362767 B1,064-351-990-194-98X,2017-12-06,2017,EP 09748625 A,2009-10-29,US 2009/0062611 W;;US 10947408 P,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,,ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,ABLYNX N.V. (2012-03-07),https://lens.org/064-351-990-194-98X,Granted Patent,yes,4,0,44,44,0,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/00;;A61K9/16;;A61K9/19;;A61K39/00;;A61K39/395;;A61K47/10;;A61K47/26;;A61P35/00;;C07K16/18;;C07K16/24;;G01N33/15;;G06F19/00;;G06Q99/00,,1,0,,,"YANG ET AL: ""Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: Preparation and in vitro evaluation"" INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL LNKD- DOI:10.1016/J.IJPHARM.2006.09.015, vol. 331, no. 1, 31 January 2007 (2007-01-31), pages 123-132, XP005867347 ISSN: 0378-5173",ACTIVE
793,US,A1,US 2009/0309709 A1,099-752-529-583-44X,2009-12-17,2009,US 39294209 A,2009-02-25,US 39294209 A;;US 3107208 P,2008-02-25,Vehicle Security And Monitoring System,"A vehicle monitoring system includes a communication subsystem configured to provide two-way wireless communication, and a controller mounted in a vehicle and configured to receive data indicative of a location of the vehicle and to control the communication subsystem to transmit the data indicative of the vehicle location toward a remote communication center and receive operational information transmitted from the remote communication center. The controller receives a mode change command included in the operational information and in response changes operating mode between an authorization mode, in which the controller transmits an alert signal to the remote communication center, and a tracking mode, in which the controller transmits the data indicative of vehicle location continuously at predetermined intervals regardless of the authorization signal.",RECOVERY SYSTEMS HOLDINGS LLC,BEVACQUA KURT;;OSMAN MARK A;;DIXON STEVEN C,RECOVERY SYSTEMS HOLDINGS LLC (2009-08-14),https://lens.org/099-752-529-583-44X,Patent Application,yes,57,105,7,7,0,B60R25/102;;B60R25/33;;B60R2025/1016;;B60R2325/205;;G01S5/0027;;H04W8/24;;H04W64/00;;H04W12/126;;B60R25/33;;G01S5/0027;;B60R2025/1016;;H04W64/00;;B60R25/102;;B60R2325/205;;H04W8/24;;H04W12/126,B60R25/10,340/426.18,0,0,,,,INACTIVE
794,CA,C,CA 2162893 C,104-855-999-410-608,2002-03-05,2002,CA 2162893 A,1994-08-19,US 19721894 A;;US 25080194 A;;US 9409448 W,1994-02-16,CREDIT CARD WITH MAGNIFYING LENS,"A financial transaction card adapted for use in reading externally stored information including a substantially non-foldable, substantially rectangular rigid base and machine-readable information carried on the base. The rigid base comprises a magnifying lens.",FINKELSTEIN ALAN,BOEDE ROBERT H;;DIXON DONALD A;;FINKELSTEIN ALAN,,https://lens.org/104-855-999-410-608,Granted Patent,no,0,0,5,54,0,G06K19/041,G06K19/04,,0,0,,,,EXPIRED
795,US,A1,US 2002/0052932 A1,112-967-361-861-22X,2002-05-02,2002,US 99363901 A,2001-11-27,US 99363901 A;;US 9610198 A,1998-06-11,Collaborative object architecture,"
   A collaborative object architecture with one or more of the following technologies: 1) lightweight asynchronous messaging; 2) collaborative objects; 3) optimistic concurrency control; and 4) transparent object serialization. Lightweight asynchronous messaging allows highly responsive interactivity and natural interactions with minimal network loads. Collaborative objects allow ubiquitous sharing and provides each user with the same copy of the shared object. Optimistic concurrency control allows full-duplex group editing and natural interactions. Transparent object serialization provides real world persistence and support for asynchronous changes. Thus, combination of these technologies provides a collaborative object architecture with several advantages over the prior art. 
",PLACEWARE INC,CURTIS PAVEL;;DIXON MICHEAL D;;NICHOLS DAVID A,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14),https://lens.org/112-967-361-861-22X,Patent Application,yes,41,53,8,8,0,H04L67/10;;H04L69/329;;H04L67/131;;H04L69/329;;H04L67/10;;H04L9/40;;H04L67/01;;H04L67/131,G06F9/46;;H04L29/06;;G06F15/16;;H04L29/08,709/218;;709/315,0,0,,,,DISCONTINUED
796,US,A1,US 2008/0183565 A1,104-578-284-111-329,2008-07-31,2008,US 68117407 A,2007-03-01,US 68117407 A;;US 88730707 P,2007-01-30,DELAYED TRANSIT FARE ASSESSMENT,"At each of a plurality of point of sale terminals (POS) of a merchant, for each of a plurality of consumers, where each consumer seeks to conduct a transaction with the merchant for a good or service at a cost by using a payment device issued by an issuer in a payment system, data is read from a payment device. The data can include an identifier for an account issued by an issuer. Information is stored for each transaction and the consumer is permitted to receive the good or service from the merchant. After the consumer has received the good or service, a batch of the transaction are processed to derive there from the respective costs that are assessable to the respective accounts, where the merchant can be a transit system, the consumer a rider thereon, and the transaction can be access to a facility thereof.",DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,VISA U.S.A. INC (2007-05-11),https://lens.org/104-578-284-111-329,Patent Application,yes,67,33,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/36;;G06Q20/14;;G07B15/02,705/13;;235/380,1,0,,,"Federal Circuit Case ""Smart Systems Innovations, LLC. vs. Chicago Transit Authority"" 2016-1233, Decided: October 18, 2017",ACTIVE
797,WO,A3,WO 1996/015239 A3,134-911-953-069-469,1996-09-06,1996,US 9514149 W,1995-11-01,US 33912994 A,1994-11-14,Isoflavone reductase promoter,The invention relates to a promoter and associated control elements derived from the isoflavone reductase gene. The upstream activating region and portions thereof have been characterized as to their ability to control the transcription of operably linked foreign structural genes in legumes as well as in plants which lack the isoflavonoid pathway.,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;PAIVA NANCY L;;OOMMEN ABRAHAM,,https://lens.org/134-911-953-069-469,Search Report,yes,0,0,9,9,0,C12N9/001;;C12N15/8239;;C12N9/001;;C12N15/8239,C12N5/10;;C12N9/02;;C12N15/00;;A01H5/00;;C12N15/09;;C12N15/82;;C12R1/91,,4,2,025-481-537-150-533;;163-472-490-948-263,10.2307/3869908;;pmc160562;;7866024;;10.1105/tpc.6.12.1789;;10.1007/bf00033879,"B. MIAO ET AL.: ""Analysis of cis-elements regulating alfalfa isoflavone reductase"", PLANT PHYSIOLOGY (ROCKVILLE), vol. 108, no. (2 suppl.), 1995, pages 140, XP002007274;;A. OOMMEN ET AL.: ""The elicitor inducible alfalfa IFR promoter confers different patterns of developmental expression in homologous and heterologous transgenic plants"", PLANT CELL, vol. 6, 1994, pages 1789 - 1803, XP002007275;;N.L. PAIVA ET AL.: ""Regulation of isoflavonoid metabolisn in alfalfa"", PLANT CELL, TISSUE AND ORGAN CULTURE, vol. 38, 1994, pages 213 - 220, XP002007276;;A. OOMMEN ET AL.: ""Analysis of a genomic clone for isoflavone reductase. A defense response gene from alfalfa"", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. suppl 0 (16 part F), 1992, pages 220, XP002007277",PENDING
798,AU,B2,AU 699316 B2,163-352-267-966-104,1998-12-03,1998,AU 1996/070578 A,1996-11-04,AU 1996/070578 A;;AU 1993/036613 A;;US 83449092 A,1992-02-12,Credit card with magnifying lens,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/163-352-267-966-104,Granted Patent,no,3,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,EXPIRED
799,US,A,US 4803216 A,160-428-758-149-095,1989-02-07,1989,US 4665687 A,1987-05-05,GB 8611102 A;;GB 8630906 A,1986-05-07,Pyrazole-3-amines as anti-inflammatory agents,"There are described compounds of formula I, ##STR1## in which R.sub.1 represents hydrogen, alkyl, alkanoyl or alkyl substituted by Ar.sub.1, R.sub.3, R.sub.4 and R.sub.5, which may be the same or different, each independently represent hydrogen, alkyl or Ar.sub.3, Ar.sub.1, Ar.sub.2 and Ar.sub.3, which may be the same or different, independently represent phenyl or phenyl substituted by one or more of alkyl, hydroxy, alkoxy, NR.sub.6 R.sub.7 or halogen, R.sub.6 and R.sub.7, which may be the same or different, independently represent hydrogen or alkyl, and pharmaceutically acceptable acid addition salts thereof. Compositions containing the compounds and methods for their preparation are also described. The compounds are indicated for use as pharmaceutical, e.g. anti-inflammatory, agents.",FISONS PLC,APPLETON RICHARD A;;DIXON JOHN;;BURFORD SIDNEY C,FISONS PLC OF FISON HOUSE (1987-04-03),https://lens.org/160-428-758-149-095,Granted Patent,yes,0,28,20,25,0,C07D231/38;;C07D231/38;;C07D231/38,A61K31/415;;C07D231/38,514/407;;548/375,2,0,,,"Chem. Abst., 105 (1986) 42796f.;;Chem Abst. 71 (1969) 22058t.",EXPIRED
800,CN,A,CN 114380912 A,168-919-030-795-761,2022-04-22,2022,CN 202210050901 A,2016-03-04,US 201562128462 P;;CN 201680024600 A;;US 2016/0020980 W,2015-03-04,Antibody therapeutics that bind CD47,"Disclosed herein are compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, disclosed herein are fully human antibodies that bind to CD47, CD47 antibody binding fragments and derivatives of such antibodies, and CD47 binding polypeptides comprising such fragments. Furthermore, disclosed herein are nucleic acids encoding such antibodies, antibody fragments and derivatives, and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives, and polypeptides, and methods of using such antibodies, antibody fragments and derivatives, and polypeptides, including methods of treating disease.",SORENCH PHARMACEUTICAL CO LTD,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,,https://lens.org/168-919-030-795-761,Patent Application,no,1,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;A61K39/395;;A61P35/00;;A61P35/02,,0,0,,,,PENDING
801,US,A1,US 2009/0083874 A1,174-171-022-222-947,2009-03-26,2009,US 10833208 A,2008-04-23,US 10833208 A;;US 91427907 P,2007-04-26,PRODUCTION OF PROANTHOCYANIDINS TO IMPROVE FORAGE QUALITY,"The invention provides method and compositions for the modulation of anthocyanin and proanthocyanidin production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of anthocyanins and proanthocyanidins in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased proanthocyanidin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content. The invention may also be used to modify plant pigmentation, and for nutraceutical and food colorant production.",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;MODOLO LUZIA V;;PEEL GREGORY,NOBLE RESEARCH INSTITUTE LLC (2008-07-24),https://lens.org/174-171-022-222-947,Patent Application,yes,4,7,8,8,97,A23V2002/00;;C07K14/415;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K20/121;;A23K50/10;;A23L5/43;;A23L33/105;;C07K14/415;;A23V2002/00;;C12N9/1051;;C12N15/825;;A23K10/30;;A23K50/10;;A23K20/121;;A23L5/43;;A23L33/105,A23J1/00;;A01H5/00;;A23K1/10;;A23K1/14;;A23K10/32;;A23L1/00;;A23L1/0522;;C07H21/00;;C07K2/00;;C12N5/10;;C12N15/82,800/260;;536/23.1;;435/320.1;;530/350;;800/298;;435/419;;800/278;;426/615;;426/635;;426/636;;426/622;;426/656;;426/661,0,0,,,,ACTIVE
802,US,A1,US 2004/0128711 A1,002-690-477-716-190,2004-07-01,2004,US 65975503 A,2003-09-10,US 65975503 A;;US 40944702 P,2002-09-10,Methods and compositions for production of flavonoid and isoflavonoid nutraceuticals,"
   The invention provides method and compositions for the modulation of flavanone and/or isoflavone production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of isoflavones in particular in plants may be used to increase the nutritional value of food plants for both human and animal consumption. The invention overcomes limitations of the prior art which prevented accumulation of high levels of isoflavones in plants. 
",SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;LIU CHANG-JUN;;DEAVOURS BETTINA,NOBLE RESEARCH INSTITUTE LLC (2017-05-01);;SAMUEL ROBERTS NOBLE FOUNDATION THE (2003-10-13),https://lens.org/002-690-477-716-190,Patent Application,yes,6,2,10,10,14,C12N9/0071;;C12N9/0077;;C12N15/8243;;C12N15/825;;C12N9/0071;;C12N15/825;;C12N15/8243;;C12N9/0077,A01H1/00;;C12N9/02;;C12N9/90;;C12N15/82,800/278;;435/468;;435/233,0,0,,,,EXPIRED
803,GR,T3,GR 3027719 T3,008-825-614-419-429,1998-11-30,1998,GR 980401897 T,1998-08-26,US 83449092 A;;US 9301176 W,1992-02-12,CREDIT CARD WITH MAGNIFYING LENS.,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/008-825-614-419-429,Granted Patent,no,0,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,EXPIRED
804,AU,A8,AU 2003/213674 A8,030-240-810-714-429,2003-09-09,2003,AU 2003/213674 A,2003-02-27,US 8771402 A;;US 0306397 W,2002-02-28,Vanillin biosynthetic pathway enzyme from vanilla planifolia,,DAVID MICHAEL AND CO INC,HAVKIN-FRENKEL DAPHNA;;DIXON RICHARD A;;PODSTOLSKI ANDRZEJ,,https://lens.org/030-240-810-714-429,Patent Application,no,0,0,5,5,0,C07C2/32;;C07C2531/22;;C07D213/53;;C07F15/02;;C07F15/025;;C08F10/00;;C12N5/04;;C12N9/00;;C12N9/0006;;C12N9/0077;;C12N15/8207;;C12N15/8243;;C12P7/24;;A01H4/002;;C08F10/00;;C12N9/0077;;C12N5/04;;C07C2531/22;;C07F15/02;;C07F15/025;;C12P7/24;;C12N9/0006;;C12N9/00;;C07C2/32;;C07D213/53;;C12N15/8243;;C12N15/8207;;A01H4/002,A01H4/00;;C07C2/32;;C07D213/53;;C07F15/02;;C08F10/00;;C12N5/04;;C12N9/00;;C12N9/02;;C12N9/04;;C12N15/29;;C12N15/82;;C12P7/24,,0,0,,,,DISCONTINUED
805,AU,A,AU 1998/074875 A,033-804-773-898-678,1998-12-08,1998,AU 1998/074875 A,1998-05-14,US 4647597 P;;US 9809863 W,1997-05-14,Gene encoding for systemic acquired resistance in arabidopsis,,SALK INST FOR BIOLOGICAL STUDI;;SAMUEL ROBERTS NOBLE FOUNDATION INC,DIXON RICHARD A;;CAMERON ROBIN;;LAMB CHRISTOPHER J,"THE SAMUEL ROBERTS NOBLE FOUNDATION, INC., SALK IN (2001-01-11)",https://lens.org/033-804-773-898-678,Patent Application,no,0,0,7,7,0,C07K14/415;;C12N15/8281,A01H5/00;;C07K14/415;;C07K16/16;;C12N5/10;;C12N15/09;;C12N15/29;;C12N15/82,,0,0,,,,DISCONTINUED
806,CA,A1,CA 2289751 A1,036-950-778-909-14X,1998-11-19,1998,CA 2289751 A,1998-05-14,US 4647597 P;;US 9809863 W,1997-05-14,GENE ENCODING FOR SYSTEMIC ACQUIRED RESISTANCE IN ARABIDOPSIS,The invention relates to genes which are related to the transmission of Systemic Acquired Resistance (SAR) in plants via the signal transduction pathway. A gene has been characterized as to its ability to encode for a protein which acts upstream from salicylic acid in the signal transduction pathway.,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;LAMB CHRISTOPHER J;;CAMERON ROBIN,,https://lens.org/036-950-778-909-14X,Patent Application,no,0,0,7,7,2,C07K14/415;;C12N15/8281,C07K14/415;;C07K16/16;;C12N5/10;;C12N15/09;;C12N15/29;;A01H5/00;;C12N15/82,,0,0,,,,DISCONTINUED
807,AU,B2,AU 2007/345583 B2,090-449-753-996-100,2013-05-09,2013,AU 2007/345583 A,2007-10-29,US 88730707 P;;US 68117907 A;;US 2007/0082898 W,2007-01-30,Processing transactions of different payment devices of the same issuer account,"Each portable payment device associated with a single account within a payment processing system is distinguished using track data. The track data from the portable payment device is read at each of a plurality of merchant point of sale terminals (POS). Rather than relying on the PAN alone, a merchant may utilizes the track data, or a proxy thereof, as the unique identifier for the portable payment device. The merchant may then process transactions involving the portable payment device based on the unique identifier. For example, in the transit environment the transit fare for each rider with different portable payment devices but the same account can be calculated using the unique identifier, such as the full track data read from both tracks of the corresponding portable payment devices.",VISA USA INC,DIXON PHIL;;EL-AWADY KHALID;;HAMMAD AYMAN A,,https://lens.org/090-449-753-996-100,Granted Patent,no,6,0,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/14;;G06Q40/00;;G06Q20/36;;G07B15/02,,0,0,,,,ACTIVE
808,AU,A1,AU 2009/333791 A1,093-111-420-942-543,2010-07-08,2010,AU 2009/333791 A,2009-10-29,US 10947408 P;;US 2009/0062611 W,2008-10-29,Formulations of single domain antigen binding molecules,,WYETH LLC,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,ABLYNX N.V. (2012-05-10),https://lens.org/093-111-420-942-543,Patent Application,no,0,0,44,44,0,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/19;;A61K9/00;;A61K39/395;;A61P35/00;;G06F19/00,,0,0,,,,INACTIVE
809,CA,C,CA 1305157 C,091-950-161-633-168,1992-07-14,1992,CA 536506 A,1987-05-06,GB 8611102 A;;GB 8630906 A,1986-05-07,PYRAZOL-3-AMINES,"29 There are described compounds of formula I, <IMG> I in which R1 represents hydrogen, alkyl, alkanoyl or alkyl substituted by Ar1, R3, R4 and R5, which may be the same or different, each independently represent hydrogen, alkyl or Ar3, Ar1, Ar2 and Ar3, which may be the same or different, independently represent phenyl or phenyl substituted by one or more of alkyl, hydroxy, alkoxy, NR6R7 or halogen, R6 and R7, which may be the same or different, independently represent hydrogen or alkyl, and pharmaceutically acceptable acid addition salts thereof. Compositions containing the compounds and methods for their preparation are also described. The compounds are indicated for use as pharmaceutical, eg anti-inflammatory, agents. 4804K(ir)/ac",FISONS PLC,APPLETON RICHARD A;;DIXON JOHN;;BURFORD SIDNEY C,,https://lens.org/091-950-161-633-168,Granted Patent,no,0,0,20,25,0,C07D231/38;;C07D231/38;;C07D231/38,A61K31/415;;C07D231/38,D426003153   M;;1670238    S,0,0,,,,EXPIRED
810,DK,T3,DK 0626085 T3,109-471-594-245-690,1999-03-22,1999,DK 93905847 T,1993-02-09,US 83449092 A;;US 9301176 W,1992-02-12,Kreditkort med forstørrelseslinse,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/109-471-594-245-690,Granted Patent,no,0,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,EXPIRED
811,EP,A1,EP 0698258 A1,126-011-051-415-090,1996-02-28,1996,EP 94927201 A,1994-08-19,US 19721894 A;;US 25080194 A;;US 9409448 W,1994-02-16,CREDIT CARD WITH MAGNIFYING LENS,,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/126-011-051-415-090,Patent Application,yes,0,0,5,54,0,G06K19/041,G06K19/04,,1,0,,,See references of WO 9522805A1,DISCONTINUED
812,AU,A,AU 1995/039727 A,067-952-293-613-336,1996-06-06,1996,AU 1995/039727 A,1995-11-01,US 33912994 A;;US 9514149 W,1994-11-14,Isoflavone reductase promoter,,SAMUEL ROBERTS NOBLE FOUNDATION INC,DIXON RICHARD A;;PAIVA NANCY L;;OOMMEN ABRAHAM,,https://lens.org/067-952-293-613-336,Patent Application,no,0,0,9,9,0,C12N9/001;;C12N15/8239;;C12N9/001;;C12N15/8239,A01H5/00;;C12N5/10;;C12N9/02;;C12N15/00;;C12N15/09;;C12N15/82;;C12R1/91,,0,0,,,,EXPIRED
813,EP,A4,EP 0626085 A4,072-495-677-368-835,1995-02-22,1995,EP 93905847 A,1993-02-09,US 83449092 A;;US 9301176 W,1992-02-12,CREDIT CARD WITH MAGNIFYING LENS.,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/072-495-677-368-835,Search Report,no,1,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,EXPIRED
814,US,A1,US 2022/0175923 A1,091-680-838-856-404,2022-06-09,2022,US 202117531916 A,2021-11-22,US 202117531916 A;;US 201815969896 A;;US 201615041690 A;;US 60855309 A;;US 10947408 P,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,"The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.",ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,ABLYNX N.V (2011-11-18);;WYETH LLC (2009-12-18),https://lens.org/091-680-838-856-404,Patent Application,yes,0,0,44,44,10,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K39/395;;A61K9/00;;A61K9/16;;A61K9/19;;A61K47/10;;A61K47/26;;C07K16/18;;C07K16/24;;G01N33/15;;G06Q99/00,,0,0,,,,PENDING
815,WO,A1,WO 1998/051801 A1,097-810-067-316-987,1998-11-19,1998,US 9809863 W,1998-05-14,US 4647597 P,1997-05-14,GENE ENCODING FOR SYSTEMIC ACQUIRED RESISTANCE IN ARABIDOPSIS,The invention relates to genes which are related to the transmission of Systemic Acquired Resistance (SAR) in plants via the signal transduction pathway. A gene has been characterized as to its ability to encode for a protein which acts upstream from salicylic acid in the signal transduction pathway.,SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;CAMERON ROBIN;;LAMB CHRISTOPHER J,DIXON RICHARD A;;CAMERON ROBIN;;LAMB CHRISTOPHER J,,https://lens.org/097-810-067-316-987,Patent Application,yes,2,3,7,7,2,C07K14/415;;C12N15/8281,C07K14/415;;C07K16/16;;C12N5/10;;C12N15/09;;C12N15/29;;A01H5/00;;C12N15/82,,10,8,050-230-374-861-882;;046-217-618-962-663;;064-544-370-915-257;;109-373-743-711-01X;;005-843-322-509-430;;051-069-548-397-230;;020-330-219-926-199;;124-373-545-359-610,7866028;;10.2307/3869912;;10.1105/tpc.6.12.1845;;pmc160566;;8187176;;10.1016/0092-8674(94)90218-6;;8953768;;10.1105/tpc.8.11.2033;;08953768;;pmc161332;;10.2307/3870410;;10.1111/j.1365-313x.1994.00715.x;;10.1105/tpc.8.10.1809;;pmc161316;;10.2307/3870231;;12239363;;9008385;;pmc158109;;10.1104/pp.113.1.5;;8639743;;10.1007/bf00020816;;10.1094/mpmi-8-0228,"BOWLING, S.A., ET AL.: ""A mutation in Arabidopsis that leads to constitutive expression of systemic acquired resistance"", THE PLANT CELL, vol. 6, December 1994 (1994-12-01), pages 1845 - 1857, XP002075327;;DIETRICH, R.A., ET A.: ""Arabidopsis mutants simulating disease resistance response"", CELL, vol. 77, 1994, pages 565 - 577, XP002075328;;PARKER, J.E., ET AL.: ""Characterization of eds1, a mutation in Arabidopsis suppressing reistance to Peronospora parasitica specified by several different RPP genes"", THE PLANT CELL, vol. 8, November 1996 (1996-11-01), pages 2033 - 2046, XP002074726;;CENTURY, K.S.: ""Genetic and molecular analysis of disease resistance in Arabidopsis thaliana"", PHD THESIS. UNIVERSITY OF CALIFORNIA, BERKELEY, 1996, XP002074727;;CAMERON, R.K., ET AL.: ""Biologically induced systemic acquired resistance in Arabidopsis thaliana"", THE PLANT JOURNAL, vol. 5, no. 5, 1994, pages 715 - 725, XP002074728;;CAMERON, R.K., ET AL.: ""Isolation of Arabidopsis mutants affected in the establishment of biologically induced systemic acquires resistance"", JOUNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT, vol. 18A, 1994, pages 92, XP002074729;;RYALS, J.A., ET AL.: ""Systemic acquired resistance"", THE PLANT CELL, vol. 6, October 1996 (1996-10-01), pages 1809 - 1819, XP002075329;;DELANEY, T.P., ET AL.: ""Genetic dissection of acquired resistance to disease"", PLANT PHYSIOLOGY, vol. 113, January 1997 (1997-01-01), pages 5 - 12, XP002074731;;CHOI, D.-W., ET AL.: ""Isolation of a root-specific cDNA encoding a ns-LTP-like protein from the roots of bean (Phaseolus vulgaris L.) seedlings"", PLANT MOLECULAR BIOLOGY, vol. 30, 1995, pages 1059 - 1066, XP002074732;;VERNOOIJ, B., ET AL.: ""2,6-didichloroisonicotinic acid-induced resistance to pathogens without the accumulation of salicylic acid"", MOL. PLANT-MICROBE INTERACT., vol. 8, no. 2, 1995, pages 228 - 234, XP002075162",PENDING
816,WO,A1,WO 2010/025247 A1,096-250-570-296-339,2010-03-04,2010,US 2009/0055188 W,2009-08-27,US 9300608 P,2008-08-29,EPICATECHIN GLUCOSYLTRANSFERASE,"The invention provides methods and compositions for the modulation of epicatechin glucosyltransferase activity in plants. Increased expression of epicatechin glucosides, and ultimately anthocyanins and proanthocyanidins, in plants may be used to increase the nutritional value of food plants for both human and animal consumption. Increased proanthocyanidin content also reduces the potential for bloat in animals fed certain forage plants low in condensed tannin content.",SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;PANG YONGZHEN;;PEEL GREGORY J,DIXON RICHARD A;;PANG YONGZHEN;;PEEL GREGORY J,,https://lens.org/096-250-570-296-339,Patent Application,yes,1,5,6,6,66,C12N15/8243;;C12N15/8243;;C12N9/1051;;C12N9/1051,C07K14/415;;A01H5/00;;A61K38/45;;C12N9/10;;C12N15/82,,6,5,053-728-441-408-680;;054-383-105-820-129;;019-903-104-142-431;;061-370-482-530-697;;123-127-395-374-005,10.1111/j.1365-313x.2005.02510.x;;16167896;;10.2527/1995.7392760x;;8582869;;10.1016/0378-1119(88)90004-2;;2843437;;10.1246/cl.2007.1292;;pmc2544603;;10.1073/pnas.0805954105;;18772380,"DATABASE EMBL [online] 21 June 2002 (2002-06-21), ""Medicago truncatula chromosome 8 clone mth2-8i15, complete sequence."", XP002559728, retrieved from EBI accession no. EMBL:AC124966 Database accession no. AC124966;;SHARMA S B ET AL: ""Metabolic engineering of proanthocyanidins by ectopic expression of transcription factors in Arabidopsis thaliana"", PLANT JOURNAL, BLACKWELL SCIENCE, OXFORD, GB, vol. 44, no. 1, 16 August 2005 (2005-08-16), pages 62 - 75, XP002363652, ISSN: 1365-313X;;BRODERICK GLEN A: ""Desirable characteristics of forage legumes for improving protein utilization in ruminants"", JOURNAL OF ANIMAL SCIENCE, vol. 73, no. 9, 1995, pages 2760 - 2773, XP009127036, ISSN: 0021-8812;;DI GUANA C ET AL: ""Vectors that facilitate the expression and purification of foreign peptides in Escherichia coli by fusion to maltose-binding protein"", GENE, ELSEVIER, AMSTERDAM, NL, vol. 67, no. 1, 15 July 1988 (1988-07-15), pages 21 - 30, XP023544178, ISSN: 0378-1119, [retrieved on 19880715];;SHIMODA, KEI: ""Glycosylation and malonylation of quercetin, epicatechin, and catechin by cultured plant cells"", CHEMISTRY LETTERS, vol. 36, no. 10, 5 October 2007 (2007-10-05), 1-5 KANDA-SURUGADAI CHIYODA-KU, TOKYO, 101-8307, JAPAN, pages 1292 - 1293, XP009127108, ISSN: 0366-7022;;PANG YONGZHEN ET AL: ""A transcript profiling approach reveals an epicatechin-specific glucosyltransferase expressed in the seed coat of Medicago truncatula"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 105, no. 37, September 2008 (2008-09-01), pages 14210 - 14215, XP009127069, ISSN: 0027-8424",PENDING
817,HK,A1,HK 1160376 A1,118-210-412-682-824,2012-08-17,2012,HK 11113681 A,2011-12-19,US 2009/0062611 W;;US 10947408 P,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES,,ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,,https://lens.org/118-210-412-682-824,Patent Application,no,0,0,44,44,0,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K/;;A61P/;;G06F/;;G06Q/,,0,0,,,,PENDING
818,ES,T3,ES 2119891 T3,131-329-455-812-114,1998-10-16,1998,ES 93905847 T,1993-02-09,US 83449092 A,1992-02-12,TARJETA DE CREDITO CON LENTE DE AUMENTO.,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/131-329-455-812-114,Granted Patent,no,0,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,EXPIRED
819,US,B2,US 8973818 B2,142-767-412-996-864,2015-03-10,2015,US 201213564625 A,2012-08-01,US 201213564625 A;;US 68117907 A;;US 88730707 P,2007-01-30,Processing transactions of different payment devices of the same issuer account,"Each portable payment device associated with a single account within a payment processing system is distinguished using track data. The track data from the portable payment device is read at each of a plurality of merchant point of sale terminals (POS). Rather than relying on the PAN alone, a merchant may utilizes the track data, or a proxy thereof, as the unique identifier for the portable payment device. The merchant may then process transactions involving the portable payment device based on the unique identifier. For example, in the transit environment the transit fare for each rider with different portable payment devices but the same account can be calculated using the unique identifier, such as the full track data read from both tracks of the corresponding portable payment devices.",DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID;;VISA USA INC,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,,https://lens.org/142-767-412-996-864,Granted Patent,yes,85,17,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06K5/00;;G06Q20/02;;G06Q20/14;;G06Q20/04;;G06Q20/08;;G06Q20/20;;G06Q20/32;;G06Q20/34;;G06Q20/36;;G06Q20/38;;G06Q20/40;;G07B15/00;;G07B15/02,235/380;;235/492,36,0,,,"ISO/IEC 7812 Standard, en.wikipedia.org/w/index.php?title=ISO/IEC-7812&oldid=103608433, Jan. 27, 2007.;;U.S. Appl. No. 13/776,421, filed Feb. 25, 2013, Titled: Aggregation of Validated Transactions for Settlement.;;U.S. Appl. No. 13/872,637, filed Apr. 29, 2013, Titled: Open System Account Remote Validation for Access.;;U.S. Appl. No. 11/681,174, Final Office Action, mailed on Oct. 19, 2009 (22 pages).;;U.S. Appl. No. 11/681,174, Final Office Action, mailed on Mar. 14, 2011 (9 pages).;;U.S. Appl. No. 11/681,174, Non-Final Office Action, mailed on Nov. 21, 2008 (22 pages).;;U.S. Appl. No. 11/681,174, Non-Final Office Action, mailed on May 14, 2010 (23 pages).;;U.S. Appl. No. 11/681,175, Final Office Action, mailed on Jun. 29, 2010 (13 pages).;;U.S. Appl. No. 11/681,175, Non-Final Office Action, mailed on Dec. 24, 2009 (13 pages).;;U.S. Appl. No. 11/681,175, Non-Final Office Action, mailed on Aug. 19, 2011 (14 pages).;;U.S. Appl. No. 11/681,175, Non-Final Office Action, mailed on Jan. 14, 2011 (15 pages).;;U.S. Appl. No. 11/681,175, Notice of Allowance, mailed on Mar. 27, 2012 (8 pages).;;U.S. Appl. No. 11/681,175, Notice of Allowance, mailed on Jan. 28, 2013 (9 pages).;;U.S. Appl. No. 11/681,176, Final Office Action, mailed on Apr. 19, 2011 (13 pages).;;U.S. Appl. No. 11/681,176, Non-Final Office Action, mailed on Oct. 13, 2010 (13 pages).;;U.S. Appl. No. 11/681,176, Notice of Allowance, mailed on Nov. 27, 2012 (19 pages).;;U.S. Appl. No. 11/681,176, Office Action, mailed on Nov. 2, 2011 (15 pages).;;U.S. Appl. No. 11/681,176, Office Action, mailed on Mar. 7, 2012 (16 pages).;;U.S. Appl. No. 11/681,176, Restriction Requirement, mailed on Jun. 28, 2010 (7 pages).;;U.S. Appl. No. 11/681,179, Final Office Action, mailed on Jul. 21, 2010 (20 pages).;;U.S. Appl. No. 11/681,179, Non-Final Office Action, mailed on May 5, 2011 (20 pages).;;U.S. Appl. No. 11/681,179, Notice of Allowance, mailed on Jan. 6, 2012 (11 pages).;;U.S. Appl. No. 11/681,179, Notice of Allowance, mailed on May 3, 2012 (9 pages).;;U.S. Appl. No. 11/713,307, Non-Final Office Action, mailed on Sep. 9, 2009 (17 pages).;;U.S. Appl. No. 11/713,307, Notice of Allowance, mailed on Jun. 1, 2010 (10 pages).;;U.S. Appl. No. 12/883,919, Notice of Allowance, mailed on Nov. 29, 2012 (17 pages).;;U.S. Appl. No. 12/883,919, Office Action, mailed on Jun. 5, 2012 (19 pages).;;International Patent Application No. PCT/US07/82887, Search Report and Written Opinion issued May 7, 2008 (7 pages).;;Mybi [online]. NationMaster.com, 2003-2005 [retrieved on May 10, 2010]. Retrieved from the Internet: .;;U.S. Appl. No. 13/872,637, Office Action, mailed on Oct. 10, 2013 (6 pages).;;U.S. Appl. No. 13/872,637, Notice of Allowance, mailed Dec. 16, 2013 (11 pages).;;KR Patent Application No. 10-2008-7017975, Office Action with English translation, mailed Nov. 13, 2013 (8 pages).;;KR Patent Application No. 10-2009-7017980, Office Action with English translation, mailed Nov. 30, 2013 (6 pages).;;U.S. Appl. No. 11/681,174, Non-Final Office Action, mailed Aug. 13, 2014.;;KR10-2009-7017975 , ""Office Action"", Sep. 10, 2014, 8 pages.;;KR10-2009-7017982 , ""Office Action"", Sep. 10, 2014, 11 pages.",ACTIVE
820,US,A,US 4374766 A,159-528-006-424-800,1983-02-22,1983,US 38340482 A,1982-06-01,US 38340482 A,1982-06-01,Combined allantoin-hydrolyzed animal protein product and method,"A stable form of allantoin is provided which takes the form of a combined allantoin-hydrolyzed animal protein product which may be employed in the form of a hydroalcoholic solution, such as a cologne, after-shave lotion or skin toner, containing at least about 0.5% by weight allantoin which remains in solution, without crystallizing out, over extended periods of time. Methods for increasing the stability of allantoin and for forming a stable form of allantoin are also provided.",RITZ GROUP LTD CHARLES,PUCHALSKI EUGENE;;DONAHUE FRANCES A;;DIXON RICHARD P,YVES SAINT LAURENT PARFUMS CORP (1987-12-29);;CRG-YSL INC (1987-08-04);;CRG HOLDING INC (1982-08-10);;CHARLES OF THE RITZ GROUP LTD. FORMERLY KNOWN AS CRG ACQUISITION CORP. INC (1987-08-04),https://lens.org/159-528-006-424-800,Granted Patent,yes,1,18,1,10,0,A61K8/4946;;A61K8/4946;;A61K8/65;;A61K8/65;;A61Q19/00;;A61Q19/00;;A61Q19/002;;A61Q19/002;;C07D233/88;;C07D233/88,A61K8/49;;A61K8/65;;A61Q19/00;;C07D233/88;;C07K1/12;;C08L89/06,260/123.7;;X260112R;;X260112B;;260/121;;424/177,4,0,,,"""Allantoin"" brochures I, and II, Schuylkil Chemical Co., Phila., Pa.;;""DL-Panthenol""--Product Data-Roche.;;""Proteins in Cosmetics and Toiletries"", V. L. Johnson, D&Cl/Jun. 1980, pp. 36-38.;;Croda 77--Crotein Specification Sheets, pp. 23 and 24.",EXPIRED
821,US,B2,US 10055735 B2,166-140-113-646-17X,2018-08-21,2018,US 68117407 A,2007-03-01,US 68117407 A;;US 88730707 P,2007-01-30,Delayed transit fare assessment,"At each of a plurality of point of sale terminals (POS) of a merchant, for each of a plurality of consumers, where each consumer seeks to conduct a transaction with the merchant for a good or service at a cost by using a payment device issued by an issuer in a payment system, data is read from a payment device. The data can include an identifier for an account issued by an issuer. Information is stored for each transaction and the consumer is permitted to receive the good or service from the merchant. After the consumer has received the good or service, a batch of the transaction are processed to derive there from the respective costs that are assessable to the respective accounts, where the merchant can be a transit system, the consumer a rider thereon, and the transaction can be access to a facility thereof.",DIXON PHIL;;HAMMAD AYMAN A;;EL AWADY KHALID;;VISA USA INC,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,VISA U.S.A. INC (2007-05-11),https://lens.org/166-140-113-646-17X,Granted Patent,yes,77,5,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/14;;G06Q20/02;;G06Q40/00;;G06Q20/04;;G06Q20/08;;G06Q20/20;;G06Q20/32;;G06Q20/34;;G06Q20/36;;G06Q20/38;;G06Q20/40;;G07B15/00;;G07B15/02,,17,0,,,"Federal Circuit Case “Smart Systems Innovations, LLC. vs. Chicago Transit Authority” 2016-1233, Decided: Oct. 18, 2017.;;Office Action dated Jun. 5, 2012 in U.S. Appl. No. 12/883,919, 17 pages.;;Office Action dated Oct. 10, 2013 in U.S. Appl. No. 13/872,637, 6 pages.;;Office Action in U.S. Appl. No. 11/681,176 dated Apr. 19, 2011.;;Office Action dated Dec. 19, 2012 in U.S. Appl. No. 13/564,625, 13 pages.;;Nationmaster.com http://www.statemaster.com/encyclopedia/Mybi. Retrieved online May 10, 2010, copyright 2003-2005.;;Notice of Allowance dated Nov. 29, 2012 in U.S. Appl. No. 12/883,919, 16 pages.;;Office Action dated Mar. 24, 2014 in U.S. Appl. No. 13/564,625, 13 pages.;;Office Action dated Mar. 6, 2014 in U.S. Appl. No. 13/776,421, 12 pages.;;Office Action dated Nov. 18, 2013 in U.S. Appl. No. 13/776,421, 15 pages.;;Notice of Allowance dated Dec. 16, 2013 in U.S. Appl. No. 13/872,637, 11 pages.;;ISO/IEC 7812; http://en.wikipedia.org/wiki/wlindex.php?title=IS0/1EC_7812&oldid=10360843 3; printed Mar. 8, 2014; 3 pages.;;Office Action (English Translation) dated Feb. 12, 2015 in Korean Patent Application No. 10-2009-7017982, 10 pages.;;Notice of Office Action dated Sep. 10, 2014, for Korean Patent Application No. 10-2009-7017975, 8 pages (with translation).;;Notice of Office Action dated Sep. 10, 2014, for Korean Patent Application No. 10-2009-7017982, 11 pages (with translation).;;Notice of Allowance dated Oct. 31, 2014, for U.S. Appl. No. 13/564,625, 12 pages.;;Office Action dated Jul. 25, 2013 in U.S. Appl. No. 13/564,625,13 pages.",ACTIVE
822,WO,A3,WO 2004/024079 A3,046-758-992-727-649,2005-05-19,2005,US 0328454 W,2003-09-10,US 40944702 P,2002-09-10,METHODS AND COMPOSITIONS FOR PRODUCTION OF FLAVONOID AND ISOFLAVONOID NUTRACEUTICALS,The invention provides method and compositions for the modulation of flavanone and/or isoflavone production in plants. The methods of the invention allow creation of plants having novel phenotypes. Increased expression of isoflavones in particular in plants may be used to increase the nutritional value of food plants for both human and animal consumption. The invention overcomes limitations of the prior art which prevented accumulation of high levels of isoflavones in plants.,SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;LIU CHANG-JUN;;DEAVOURS BETTINA,DIXON RICHARD A;;LIU CHANG-JUN;;DEAVOURS BETTINA,,https://lens.org/046-758-992-727-649,Search Report,yes,1,0,10,10,0,C12N9/0071;;C12N9/0077;;C12N15/8243;;C12N15/825;;C12N9/0071;;C12N15/825;;C12N15/8243;;C12N9/0077,A01H1/00;;C12N9/02;;C12N9/90;;C12N15/82,,9,6,070-736-162-892-103;;081-153-867-384-605;;016-260-898-220-124;;001-906-076-969-393;;030-560-996-409-192;;005-029-931-343-53X,pmc22848;;9770503;;10.1073/pnas.95.21.12432;;11027726;;pmc59182;;10.1104/pp.124.2.781;;12031439;;10.1016/s0031-9422(02)00116-4;;10.1038/72671;;10657130;;pmc137925;;12384577;;10.1073/pnas.212522099;;pmc102307;;11351096;;10.1104/pp.126.1.330,"WISMAN, E. ET AL.: ""Knock-out mutants from an En-1 mutagenized Arabidopsis thaliana population generate phenypropanoid biosynthesis phenotypes"", PNAS, vol. 95, October 1998 (1998-10-01), pages 12432 - 12437, XP002154815;;YU, W. ET AL.: ""Production of the Isoflavones Genistein and Daidzein in Non-Legume Dicot and Monocot Tissues"", PLANT PHYSIOLOGY, vol. 124, October 2000 (2000-10-01), pages 781 - 793, XP002982897;;DIXON, R.A. ET AL.: ""Genistein"", PHYTOCHEMISTRY, vol. 60, 2002, pages 205 - 211, XP004354712;;JUNG, W. ET AL.: ""Identification and expression of isoflavone synthase, the key enzyme for biosynthesis of isoflavones in legumes"", NATURE BIOTECHNOLOGY, vol. 18, February 2000 (2000-02-01), pages 208 - 212, XP002143676;;DATABASE GENBANK [online] 29 January 1997 (1997-01-29), XP002982898, Database accession no. M91079;;DATABASE GENBANK [online] 28 January 1997 (1997-01-28), XP002982899, Database accession no. M91080;;DATABASE GENBANK [online] 30 January 1997 (1997-01-30), XP002982900, Database accession no. U01021;;LIU, C. ET AL.: ""Bottlenecks for metabolic engineering of isoflavone glycoconjugates in Arabidopsis"", PNAS, vol. 99, no. 22, 29 October 2002 (2002-10-29), pages 14578 - 14583, XP002983901;;KIM, H. ET AL.: ""Brassica rapa Has Three Genes That Encode Proteins Associated with Different Neutral Lipids in Plastids of Specific Tissues"", PLANT PHYSIOLOGY, vol. 126, May 2001 (2001-05-01), pages 330 - 341, XP002983902",PENDING
823,MX,A,MX 2011004557 A,051-701-771-468-210,2011-07-20,2011,MX 2011004557 A,2009-10-29,US 10947408 P;;US 2009/0062611 W,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES.,"The invention relates to formulations of single domain antigen binding molecules, <i>e.g.</i>, nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful,<i> e.g.</i>, as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, <i>e.g.</i>, TNF-associated disorders, are also disclosed.",WYETH LLC,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,ABLYNX N.V. (2012-07-09),https://lens.org/051-701-771-468-210,Patent Application,no,0,0,44,44,0,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/19;;A61K9/00;;A61K39/395;;A61P35/00;;G06F19/00,,0,0,,,,ACTIVE
824,AU,A,AU 1993/036613 A,060-692-290-729-656,1993-09-03,1993,AU 1993/036613 A,1993-02-09,US 83449092 A,1992-02-12,Credit card with magnifying lens,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/060-692-290-729-656,Patent Application,no,0,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,PENDING
825,US,A1,US 2012/0248707 A1,065-013-703-312-352,2012-10-04,2012,US 201213420100 A,2012-03-14,GB 201105182 A,2011-03-29,ASSEMBLY COMPRISING A ROTATABLE COMPONENT,"An assembly, for example in a gas turbine engine, includes a rotatable component supported by a bearing in a support structure. A sealing arrangement includes a non-rotating sealing ring which makes sealing contact with sealing features on the rotatable component. The non-rotating sealing ring is radially displaceable with respect to the support structure by means of ribs which engage axially facing support faces of the support structure. The non-rotating sealing ring is radially located by an outer, non-rotating, race of the bearing, by means of a locating surface on a locating body of the non-rotating sealing ring. As a result of this arrangement, the running clearance at the sealing arrangement can be maintained, despite radial displacement of the rotatable component with respect to the support structure, and despite thermal and mechanical deflections of the support structure.",DIXON JEFFREY A;;UDALL KENNETH F;;NICHOLSON RICHARD;;ROLLS ROYCE PLC,DIXON JEFFREY A;;UDALL KENNETH F;;NICHOLSON RICHARD,ROLLS-ROYCE PLC (2012-02-22),https://lens.org/065-013-703-312-352,Patent Application,yes,6,5,5,5,0,F01D25/183;;F01D25/183;;F01D11/04;;F01D11/04;;F05D2240/55;;F05D2240/55,F16J15/16;;F16J15/447,277/412;;277/500,0,0,,,,INACTIVE
826,BR,A2,BR PI0721132 A2,061-195-098-959-389,2014-04-01,2014,BR PI0721132 A,2007-10-29,US 88730707 P;;US 68117907 A;;US 2007/0082898 W,2007-01-30,"MÉTODO, E, MEIO LEGÍVEL POR COMPUTADOR.",,VISA USA INC,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,,https://lens.org/061-195-098-959-389,Patent Application,no,0,0,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/14;;G06Q40/00;;G06Q20/36;;G07B15/02,,0,0,,,,DISCONTINUED
827,AU,B2,AU 2009/333791 B2,083-382-270-524-419,2013-04-04,2013,AU 2009/333791 A,2009-10-29,US 10947408 P;;US 2009/0062611 W,2008-10-29,Formulations of single domain antigen binding molecules,"The invention relates to formulations of single domain antigen binding molecules,",ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,ABLYNX N.V. (2012-05-10),https://lens.org/083-382-270-524-419,Granted Patent,no,2,0,44,44,0,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K9/19;;A61K9/00;;A61K39/395;;A61P35/00;;G06F19/00,,0,0,,,,INACTIVE
828,US,A1,US 2006/0046263 A1,072-391-690-803-460,2006-03-02,2006,US 21237005 A,2005-08-25,GB 0419482 A,2004-09-02,Analysis,"A method for processing results, particularly from, the method comprising: obtaining from the results information concerning the single nucleotide polymorphisms implied for one or more loci, the information including identity information on the single nucleotide polymorphism or polymorphisms of a locus and a value related to the level detected for each identity; comparing each value with a first threshold and a second threshold, the comparison for the value or values for a locus determining the single nucleotide polymorphism identities considered to be possible for that locus.",SEC DEP HOME DEPT,GILL PETER D;;DIXON LINDSEY A;;KOUMI PIERIS,FORENSIC SCIENCE SERVICE LTD (2005-12-06);;SECRETARY OF STATE FOR THE HOME DEPARTMENT THE (2005-10-25),https://lens.org/072-391-690-803-460,Patent Application,yes,5,2,4,4,0,G16B20/00;;G16B20/40;;G16B20/20;;G16B20/00;;G16B20/40;;G16B20/20,C12Q1/68;;G16B20/20;;G16B20/40,435/6;;702/20,0,0,,,,DISCONTINUED
829,CH,A5,CH 677611 A5,086-331-556-070-124,1991-06-14,1991,CH 88989 A,1989-03-09,GB 8805875 A;;GB 8819192 A;;GB 8820344 A,1988-03-11,CH 677611 A5,,SANDOZ AG,DIXON ARNOLD KEITH DR;;GRAY JULIAN A DR,,https://lens.org/086-331-556-070-124,Granted Patent,no,0,0,25,32,0,A61K31/675;;C07F9/650952;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;A61K31/675;;C07F9/650952,A61K31/675;;A61P25/04;;A61P25/06;;A61P25/20;;A61P25/24;;A61P25/26;;C07F9/6509,,0,0,,,,EXPIRED
830,WO,A1,WO 2008/094327 A1,106-651-605-469-286,2008-08-07,2008,US 2007/0082898 W,2007-10-29,US 88730707 P;;US 68117907 A,2007-01-30,PROCESSING TRANSACTIONS OF DIFFERENT PAYMENT DEVICES OF THE SAME ISSUER ACCOUNT,"Each portable payment device associated with a single account within a payment processing system is distinguished using track data. The track data from the portable payment device is read at each of a plurality of merchant point of sale terminals (POS). Rather than relying on the PAN alone, a merchant may utilizes the track data, or a proxy thereof, as the unique identifier for the portable payment device. The merchant may then process transactions involving the portable payment device based on the unique identifier. For example, in the transit environment the transit fare for each rider with different portable payment devices but the same account can be calculated using the unique identifier, such as the full track data read from both tracks of the corresponding portable payment devices.",VISA USA INC;;DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,,https://lens.org/106-651-605-469-286,Patent Application,yes,4,0,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/14;;G06Q20/36;;G07B15/02,,0,0,,,,PENDING
831,NZ,A,NZ 190785 A,131-806-482-960-103,1981-12-15,1981,NZ 19078579 A,1979-01-21,NZ 19078579 A,1979-01-21,EVENT RATE COMPARATOR MONITORING EQUIPMENT,,KENNETH GRAHAM MILL,DIXON A;;MILL K;;LYNCH C;;STRATHIE R,,https://lens.org/131-806-482-960-103,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
832,US,A,US 5608203 A,125-499-584-767-22X,1997-03-04,1997,US 58260196 A,1996-01-03,US 58260196 A;;US 25080194 A;;US 19721894 A;;US 83449092 A,1992-02-12,Credit card with magnifying lens,"A financial transaction card adapted for use in reading externally stored information includes a substantially non-foldable rigid base and a strip for carrying machine readable information, The rigid base comprises a magnifying lens.",FINKELSTEIN; ALAN;;DIXON; DONALD A.;;BOEDE; ROBERT H.,FINKELSTEIN ALAN;;DIXON DONALD A;;BOEDE ROBERT H,UNIVERSAL MAGNIFIER LLC (1998-03-22);;INNOVATIVE CARD TECHNOLOGIES INC (2004-06-02);;FINKELSTEIN ALAN (1997-12-28);;LENSCARD US LLC (1999-01-08),https://lens.org/125-499-584-767-22X,Granted Patent,yes,27,269,1,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;B42D25/20;;B42D25/425;;B42D25/318;;B42D25/328;;G02B3/08;;G02B25/002;;G06K19/077;;G06K19/041;;Y10S283/904;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/04;;G06K19/077,235/487;;283/109;;283/904;;359/802;;359/806;;359/809,0,0,,,,EXPIRED
833,JP,A,JP 2021054859 A,002-874-485-413-647,2021-04-08,2021,JP 2021000870 A,2021-01-06,US 201562128462 P,2015-03-04,ANTIBODY THERAPEUTICS THAT BIND CD47,"To provide antibody therapeutics that bind CD47.SOLUTION: Disclosed herein are compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, disclosed herein are fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further disclosed are nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.SELECTED DRAWING: Figure 1",SORRENTO THERAPEUTICS INC,BARBARA A SWANSON;;JOHN DIXON GRAY;;ZHOU HEYUE,,https://lens.org/002-874-485-413-647,Patent Application,no,2,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;A61K39/395;;A61P9/10;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00,,0,0,,,,ACTIVE
834,IL,B,IL 254321 B,023-614-003-448-216,2021-12-01,2021,IL 25432117 A,2017-09-04,US 201562128462 P;;US 2016/0020980 W,2015-03-04,Antibody therapeutics that bind cd47,,SORRENTO THERAPEUTICS INC;;GRAY JOHN DIXON;;ZHOU HEYUE;;SWANSON BARBARA A,ZHOU HEYUE;;GRAY JOHN DIXON;;SWANSON BARBARA A,,https://lens.org/023-614-003-448-216,Unknown,no,0,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,,,0,0,,,,PENDING
835,WO,A1,WO 1998/037041 A1,073-408-397-819-580,1998-08-27,1998,US 9723989 W,1997-12-22,US 81674797 A,1997-02-19,LEAD-FREE PERCUSSION PRIMER COMPOSITION,"A lead-free percussion primer composition and a percussion cup containing the composition. The lead-free percussion primer composition is comprised of a mixture of about 45 wt.% aluminum powder having an outer coating of aluminum oxide and molybdenum trioxide powder or a mixture of about 50 wt.% aluminum powder having an outer coating of aluminum oxide and polytetrafluoroethylene powder. The aluminum powder, molybdenum trioxide powder and polytetrafluoroethylene powder have a particle size of 0.1 mm or less, more preferably a particle size of from about about 200-500 Angstroms.",US NAVY;;DIXON GEORGE P;;THOMPSON DON;;MARTIN JOE A,DIXON GEORGE P;;THOMPSON DON;;MARTIN JOE A,,https://lens.org/073-408-397-819-580,Patent Application,yes,6,0,3,3,0,C06B33/12;;C06C7/00;;C06B33/12;;C06C7/00,C06B33/12;;C06C7/00,,0,0,,,,PENDING
836,KR,A,KR 20180006369 A,090-345-101-737-262,2018-01-17,2018,KR 20177028115 A,2016-03-04,US 201562128462 P;;US 2016/0020980 W,2015-03-04,CD47에 결합하는 항체 치료제,"항-CD47 항체와 관련된 또는 이로부터 유도된 조성물 및 방법이 개시되어 있다. 더 구체적으로는, CD47에 결합하는 완전 사람 항체, 상기 항체의 CD47-항체 결합 단편 및 유도체, 및 상기 단편을 포함하는 CD47-결합 폴리펩타이드가 개시되어 있다. 또한 추가로, 상기 항체, 항체 단편 및 유도체 및 폴리펩타이드를 인코딩하는 핵산, 상기 폴리뉴클레오타이드를 포함하는 세포, 상기 항체, 항체 단편 및 유도체 및 폴리펩타이드를 제조하는 방법, 및 질환을 치료하는 방법을 포함하는, 상기 항체, 항체 단편 및 유도체 및 폴리펩타이드를 사용하는 방법이 개시되어 있다.",SORRENTO THERAPEUTICS INC,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,,https://lens.org/090-345-101-737-262,Patent Application,no,3,2,34,34,64,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;C07K16/30,,0,0,,,,ACTIVE
837,US,A1,US 2008/0179395 A1,123-324-580-010-409,2008-07-31,2008,US 68117907 A,2007-03-01,US 68117907 A;;US 88730707 P,2007-01-30,PROCESSING TRANSACTIONS OF DIFFERENT PAYMENT DEVICES OF THE SAME ISSUER ACCOUNT,"Each portable payment device associated with a single account within a payment processing system is distinguished using track data. The track data from the portable payment device is read at each of a plurality of merchant point of sale terminals (POS). Rather than relying on the PAN alone, a merchant may utilizes the track data, or a proxy thereof, as the unique identifier for the portable payment device. The merchant may then process transactions involving the portable payment device based on the unique identifier. For example, in the transit environment the transit fare for each rider with different portable payment devices but the same account can be calculated using the unique identifier, such as the full track data read from both tracks of the corresponding portable payment devices.",DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,VISA U.S.A. INC (2007-05-11),https://lens.org/123-324-580-010-409,Patent Application,yes,41,69,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06K5/00;;G06Q20/36;;G06Q20/14;;G07B15/02,235/380,0,0,,,,ACTIVE
838,WO,A3,WO 2016/141328 A3,136-825-525-636-81X,2016-10-27,2016,US 2016/0020980 W,2016-03-04,US 201562128462 P,2015-03-04,ANTIBODY THERAPEUTICS THAT BIND CD47,"There is disclosed compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, there is disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.",SORRENTO THERAPEUTICS INC,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,,https://lens.org/136-825-525-636-81X,Search Report,yes,3,0,34,34,32,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,A61K39/395;;C07K16/18;;C07K16/28,,0,0,,,,PENDING
839,AU,A1,AU 2007/345580 A1,148-624-032-978-891,2008-08-07,2008,AU 2007/345580 A,2007-10-29,US 88730707 P;;US 68117407 A;;US 2007/0082842 W,2007-01-30,Delayed transit fare assessment,,VISA USA INC,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,,https://lens.org/148-624-032-978-891,Patent Application,no,0,0,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/14;;G06Q20/36;;G07B15/02,,0,0,,,,ACTIVE
840,AU,B2,AU 2003/270537 B2,182-428-386-403-010,2008-03-20,2008,AU 2003/270537 A,2003-09-10,US 40944702 P;;US 0328454 W,2002-09-10,Methods and compositions for production of flavonoid and isoflavonoid nutraceuticals,,THE SAMUEL ROBERTS NOBLE FOUNDATION INC,DEAVOURS BETTINA;;LIU CHANG-JUN;;DIXON RICHARD A,,https://lens.org/182-428-386-403-010,Granted Patent,no,1,0,10,10,0,C12N9/0071;;C12N9/0077;;C12N15/8243;;C12N15/825;;C12N9/0071;;C12N15/825;;C12N15/8243;;C12N9/0077,C12N9/02;;A01H1/00;;C12N9/90;;C12N15/82,,2,1,070-736-162-892-103,pmc22848;;9770503;;10.1073/pnas.95.21.12432,"Wisman E. et. al., PNAS, October 1998, 95, pg 12432-12437;;Liu C-J. et. al., Kluwer Academic Publishers, Editor Vasil, I.K., Proceedings of the 10th IAPTC&B Congress, Orlando, Florida, 25th-28th June 2002, pg 485-490",EXPIRED
841,WO,A2,WO 2016/141328 A2,186-974-656-709-540,2016-09-09,2016,US 2016/0020980 W,2016-03-04,US 201562128462 P,2015-03-04,ANTIBODY THERAPEUTICS THAT BIND CD47,"There is disclosed compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, there is disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.",SORRENTO THERAPEUTICS INC,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,,https://lens.org/186-974-656-709-540,Patent Application,yes,0,32,34,34,32,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;C07K16/30,,0,0,,,,PENDING
842,CA,A,CA 3149 A,001-804-335-233-309,1874-03-03,1874,CA 3149D A,,CA 3149T A,,IMPROVEMENTS ON EXTRACTING TREES AND STUMPS BY THE ROOTS AND ENGINE THEREFOR,,HUNTLEY THOMAS S;;GILCHRIST ANDREW;;DIXON JOSEPH A,HUNTLEY THOMAS S;;GILCHRIST ANDREW;;DIXON JOSEPH A,,https://lens.org/001-804-335-233-309,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
843,AU,A1,AU 2005/269908 A1,015-349-033-761-129,2006-02-09,2006,AU 2005/269908 A,2005-07-07,US 58589204 P;;US 2005/0024092 W,2004-07-07,Plant N-acylethanolamine binding proteins,,THE SAMUEL ROBERTS NOBLE FOUNDATION INC,DIXON RICHARD A;;CHAPMAN KENT D;;TRIPATHY SWATI,,https://lens.org/015-349-033-761-129,Patent Application,no,0,0,7,7,0,C07K14/415;;C12N15/8261;;C12N15/8279;;Y02A40/146;;C12N15/8279;;C07K14/415;;C12N15/8261;;Y02A40/146,A01H1/00;;C07K14/415;;C12N15/82,,0,0,,,,DISCONTINUED
844,AU,A1,AU 2013/202856 A1,027-211-943-699-399,2013-05-02,2013,AU 2013/202856 A,2013-04-08,AU 2009/333791 A;;AU 2013/202856 A,2009-10-29,Formulations of single domain antigen binding molecules,"The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody 5 molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.",ABLYNX NV,FERNANDEZ JASON E;;DIXON DANIEL A;;PAULSON ANDREA,,https://lens.org/027-211-943-699-399,Patent Application,no,0,1,2,2,0,,A61K9/19;;A61K9/00;;A61K39/395;;A61P35/00;;G06F19/00,,0,0,,,,ACTIVE
845,WO,A3,WO 2005/033309 A3,026-664-635-327-53X,2005-07-28,2005,US 2004/0032365 W,2004-09-30,US 50736203 P,2003-09-30,PLANT PROMOTERS AND METHODS OF USE THEREOF,"The current invention provides plant promoter sequences. Compositions comprising these promoter sequence are described, as are plants transformed with such compositions. Further provided are methods for the expression of transgenes in plants comprising the use of these sequences. The methods of the invention include the direct creation of transgenic plants with the promoters by genetic transformation, as well as by plant breeding methods. The sequences of the invention represent valuable new tools for the creation of transgenic plants, preferably having one or more added beneficial characteristics.",SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;WANG LIANGJIANG;;MAY GREGORY D,DIXON RICHARD A;;WANG LIANGJIANG;;MAY GREGORY D,,https://lens.org/026-664-635-327-53X,Search Report,yes,0,0,3,3,0,C07K14/415;;C07K14/415;;C12N15/8216;;C12N15/8216,A01H1/00;;C07K14/415;;C12N15/82;;C12Q1/68,,4,3,064-982-528-864-93X;;026-771-702-357-776;;029-415-574-026-312,10.1105/tpc.004861;;12368495;;pmc151226;;10.1105/tpc.014373;;12953113;;pmc181333;;pmc29836;;10.1093/nar/29.1.114;;11125064,"DATABASE EMBL [online] 23 October 2002 (2002-10-23), ""Medicago truncatula clone mth2-24j8, complete sequence."", XP002315778, retrieved from EBI accession no. EM_PRO:AC135505 Database accession no. AC135505;;HARRISON MARIA J ET AL: ""A phosphate transporter from Medicago truncatula involved in the acquisition of phosphate released by arbuscular mycorrhizal fungi"", PLANT CELL, vol. 14, no. 10, October 2002 (2002-10-01), pages 2413 - 2429, XP002315776, ISSN: 1040-4651;;VINARDELL JOSE MARIA ET AL: ""Endoreduplication mediated by the anaphase-promoting complex activator CCS52A is required for symbiotic cell differentiation in Medicago truncatula nodules."", PLANT CELL, vol. 15, no. 9, September 2003 (2003-09-01), pages 2093 - 2105, XP002315777, ISSN: 1040-4651;;BELL CALLUM J ET AL: ""The Medicago Genome Initiative: A model legume database"", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 29, no. 1, 1 January 2001 (2001-01-01), pages 114 - 117, XP002185439, ISSN: 0305-1048",PENDING
846,EP,B1,EP 0626085 B1,035-695-901-248-091,1998-05-27,1998,EP 93905847 A,1993-02-09,US 83449092 A;;US 9301176 W,1992-02-12,CREDIT CARD WITH MAGNIFYING LENS,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/035-695-901-248-091,Granted Patent,yes,9,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,EXPIRED
847,US,A,US 5434405 A,035-107-875-721-004,1995-07-18,1995,US 19721894 A,1994-02-16,US 19721894 A;;US 83449092 A,1992-02-12,Credit card with a fresnel magnifying lens formed in a section of the transparent core,"A financial transaction card adapted for individual use in reading information stored externally to the card, having machine readable information contained thereon identifying the user and the issuing institution for transacting business at locations remote from the issuing institution, includes: a. a rigid substantially rectangular base comprising a substantially transparent material and having a top surface and a bottom surface; b. machine readable information carried on the base for identifying the user and the issuing institution; and c. a magnifying lens produced by formation of fresnel contour lines on the top surface of the base and in non-interfering relationship with the machine readable information.",FINKELSTEIN; ALAN;;DIXON; DONALD A.;;BOEDE; ROBERT H.,FINKELSTEIN ALAN;;DIXON DONALD A;;BOEDE ROBERT H,UNIVERSAL MAGNIFIER LLC (1998-03-22);;INNOVATIVE CARD TECHNOLOGIES INC (2004-06-02);;FINKELSTEIN ALAN (1997-12-28);;LENSCARD US LLC (1999-01-08),https://lens.org/035-107-875-721-004,Granted Patent,yes,8,184,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,235/487;;283/904;;283/109;;359/802;;359/806;;359/809,0,0,,,,EXPIRED
848,EP,A1,EP 1110149 A1,040-830-543-108-848,2001-06-27,2001,EP 99927450 A,1999-06-11,US 9913158 W;;US 9610198 A,1998-06-11,COLLABORATIVE OBJECT ARCHITECTURE,,PLACEWARE INC,CURTIS PAVEL;;DIXON MICHAEL D;;NICHOLS DAVID A,,https://lens.org/040-830-543-108-848,Patent Application,yes,0,0,8,8,0,H04L67/10;;H04L69/329;;H04L67/131;;H04L69/329;;H04L67/10;;H04L9/40;;H04L67/01;;H04L67/131,G06F15/16;;G06F9/46;;H04L29/06;;H04L29/08,,0,0,,,,DISCONTINUED
849,EP,A1,EP 0626085 A1,052-214-147-852-612,1994-11-30,1994,EP 93905847 A,1993-02-09,US 83449092 A;;US 9301176 W,1992-02-12,CREDIT CARD WITH MAGNIFYING LENS.,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/052-214-147-852-612,Patent Application,yes,0,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,EXPIRED
850,AU,A,AU 1996/070578 A,035-100-902-442-51X,1997-01-16,1997,AU 1996/070578 A,1996-11-04,AU 1996/070578 A;;AU 1993/036613 A;;US 83449092 A,1992-02-12,Credit card with magnifying lens,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/035-100-902-442-51X,Patent Application,no,0,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,EXPIRED
851,AT,T1,AT E166736 T1,050-873-866-671-830,1998-06-15,1998,AT 93905847 T,1993-02-09,US 83449092 A,1992-02-12,KREDITKARTE MIT VERGRÖSSERUNGSLINSE,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/050-873-866-671-830,Granted Patent,no,0,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,DISCONTINUED
852,CA,A1,CA 2129355 A1,051-374-187-557-307,1993-08-19,1993,CA 2129355 A,1993-02-09,US 83449092 A;;US 9301176 W,1992-02-12,CREDIT CARD WITH MAGNIFYING LENS,A credit card includes an integral magnifying lens positioned in the non-data area on the credit card for permitting magnification of the credit card transaction form at the point-of-sale. The placement of the lens assures that the machine readability of the magnetic encoding strip and the embossed indicia associated with the card is not impaired. The magnifying lens incorporates a fresnel-type contour lens mounted in a window provided in the credit card base.,FINKELSTEIN ALAN,BOEDE ROBERT H;;FINKELSTEIN ALAN;;DIXON DONALD A,,https://lens.org/051-374-187-557-307,Patent Application,no,0,0,24,54,0,G02B3/08;;G02B25/002;;G06K19/041;;G06K19/077;;Y10S283/904;;B42D25/00;;G07D9/00;;B42D25/369;;B42D25/20;;G02B25/002;;Y10S283/904;;G06K19/041;;G06K19/077;;G02B3/08;;B42D25/00,B42D15/10;;G02B3/08;;G02B25/00;;G06K19/00;;G06K19/04;;G06K19/06;;G06K19/077;;G06K19/18,,0,0,,,,EXPIRED
853,AU,B2,AU 2007/345580 B2,077-778-092-510-666,2013-07-25,2013,AU 2007/345580 A,2007-10-29,US 88730707 P;;US 68117407 A;;US 2007/0082842 W,2007-01-30,Delayed transit fare assessment,"At each of a plurality of point of sale terminals (POS) of a merchant, for each of a plurality of consumers, where each consumer seeks to conduct a transaction with the merchant for a good or service at a cost by using a payment device issued by an issuer in a payment system, data is read from a payment device. The data can include an identifier for an account issued by an issuer. Information is stored for each transaction and the consumer is permitted to receive the good or service from the merchant. After the consumer has received the good or service, a batch of the transaction are processed to derive there from the respective costs that are assessable to the respective accounts, where the merchant can be a transit system, the consumer a rider thereon, and the transaction can be access to a facility thereof.",VISA USA INC,HAMMAD AYMAN A;;DIXON PHIL;;EL-AWADY KHALID,,https://lens.org/077-778-092-510-666,Granted Patent,no,1,1,48,48,0,G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/36;;G06Q20/401;;G06Q20/32;;G06Q20/027;;G06Q20/04;;G06Q20/085;;G06Q20/0855;;G06Q20/20;;G06Q20/204;;G06Q20/32;;G06Q20/327;;G06Q20/341;;G06Q20/382;;G06Q20/3821;;G06Q20/401;;G07B15/00;;G06Q20/40;;G06Q20/4016,G06Q20/14;;G07B15/02;;G06Q20/36,,0,0,,,,ACTIVE
854,DE,T2,DE 69608888 T2,082-540-704-520-613,2000-11-09,2000,DE 69608888 T,1996-03-07,US 40160395 A;;US 9602555 W,1995-03-09,"SUBSTITUIERTE DIBENZ[a,f]AZULENE UND VERFAHREN ZU IHRER HERSTELLUNG","Tetracyclic compounds having the following structure are described: <IMAGE> wherein R1-R10 are as defined. The tetracyclic compounds are capable of potent effects on steroid sensitive tissues and have demonstrated increased uterine weight, antiovulatory effects and potent steroid receptor binding. The compounds have therapeutic utility in reproductive applications such as fertility control, labor induction, ovulation induction and spermatogenesis. Methods for preparing the tetracyclic compounds from substituted indanones are also described.",ORTHO PHARMA CORP,DODD E;;DIXON A;;BULLINGTON L;;SCHWENDER F,,https://lens.org/082-540-704-520-613,Granted Patent,no,0,0,16,16,0,C07C13/66;;C07C25/22;;C07C39/17;;C07C43/21;;C07C43/215;;C07C43/225;;C07C43/23;;C07C49/755;;C07C49/84;;C07C65/26;;C07C69/017;;C07C69/157;;C07C69/16;;C07C69/63;;C07C205/20;;C07C205/37;;C07C205/42;;C07C211/61;;C07C217/24;;C07C233/07;;C07C233/15;;C07D257/04;;C07F9/12;;C07C2603/40;;A61P13/02;;A61P15/00;;A61P15/08;;C07D257/04;;C07C69/157;;C07C205/37;;C07C13/66;;C07C69/017;;C07C233/15;;C07C43/23;;C07F9/12;;C07C69/63;;C07C205/20;;C07C39/17;;C07C217/24;;C07C205/42;;C07C49/84;;C07C233/07;;C07C43/21;;C07C211/61;;C07C69/16;;C07C25/22;;C07C49/755;;C07C43/225;;C07C43/215;;C07C65/26;;C07C2603/40,A61K31/015;;A61K31/03;;A61K31/04;;A61K31/085;;A61K31/12;;A61K31/135;;A61K31/165;;A61K31/215;;A61P13/02;;A61P15/00;;C07C13/66;;C07C23/46;;C07C25/22;;C07C39/17;;C07C43/21;;C07C43/215;;C07C43/225;;C07C43/23;;C07C49/755;;C07C49/84;;C07C65/26;;C07C69/00;;C07C69/157;;C07C69/65;;C07C69/734;;C07C205/20;;C07C205/37;;C07C205/42;;C07C211/61;;C07C217/16;;C07C217/24;;C07C233/07;;C07C233/11;;C07C233/15;;C07D257/04;;C07F9/12,,0,0,,,,EXPIRED
855,AU,A,AU 1998/062375 A,080-733-201-515-589,1998-09-09,1998,AU 1998/062375 A,1997-12-22,US 81674797 A;;US 9723989 W,1997-02-19,Lead-free percussion primer composition,,US NAVY,DIXON GEORGE P;;THOMPSON DON;;MARTIN JOE A,,https://lens.org/080-733-201-515-589,Patent Application,no,0,0,3,3,0,C06B33/12;;C06C7/00;;C06B33/12;;C06C7/00,C06B33/12;;C06C7/00,,0,0,,,,PENDING
856,AU,A1,AU 2013/213725 A1,091-977-916-892-142,2013-08-29,2013,AU 2013/213725 A,2013-08-08,AU 2007/345583 A;;AU 2013/213725 A,2007-10-29,PROCESSING TRANSACTIONS OF DIFFERENT PAYMENT DEVICES OF THE SAME ISSUER ACCOUNT,"Abstract: Each portable payment device associated with a single account within a payment processing system is distinguished using track data. The track data from the portable payment device is read at each of a plurality of merchant point of sale terminals (POS). Rather than relying on the PAN alone, a merchant may utilizes the track data, or a proxy thereof, as the unique identifier for the portable payment device. The merchant may then process transactions involving the portable payment device based on the o unique identifier. For example, in the transit environment the transit fare for each rider with different portable payment devices but the same account can be calculated using the unique identifier, such as the full track data read from both tracks of the corresponding portable payment devices. WO 2008/094327 PCTIUS2007/082898 RECEIVE DATA, FOR EACH MERCHANT TRANSACTION, FROM A PORTABLE PAYMENT DEVICE INCLUDING AN IDENTIFIER ACCOUNT 710 ASSIGN A UNIQUE IDENTIFIER STATIC DATA 720 PROCESS EACH MERCHANT TRANSACTION BASED ON THE UNIQUE IDENTIFIER AND ACCOUNT (E.G.; VALIDATE MERCHANT TRANSACTION AND/ 730 OR DETERMINE VALUE OF MERCHANT TRANSACTION, E TC.) Figure 7",VISA USA INC,DIXON PHIL;;HAMMAD AYMAN A;;EL-AWADY KHALID,,https://lens.org/091-977-916-892-142,Patent Application,no,0,0,1,1,0,,G06Q40/00;;G07B15/02,,0,0,,,,DISCONTINUED
857,CA,A1,CA 2572294 A1,110-340-342-078-06X,2006-02-09,2006,CA 2572294 A,2005-07-07,US 58589204 P;;US 2005/0024092 W,2004-07-07,PLANT N-ACYLETHANOLAMINE BINDING PROTEINS,,SAMUEL ROBERTS NOBLE FOUND INC,TRIPATHY SWATI;;CHAPMAN KENT D;;DIXON RICHARD A,,https://lens.org/110-340-342-078-06X,Patent Application,no,0,0,7,7,52,C07K14/415;;C12N15/8261;;C12N15/8279;;Y02A40/146;;C12N15/8279;;C07K14/415;;C12N15/8261;;Y02A40/146,C12N15/82;;A01H1/00;;C07K14/415,,0,0,,,,DISCONTINUED
858,EP,A2,EP 3265125 A2,143-742-173-761-683,2018-01-10,2018,EP 16759606 A,2016-03-04,US 201562128462 P;;US 2016/0020980 W,2015-03-04,ANTIBODY THERAPEUTICS THAT BIND CD47,,SORRENTO THERAPEUTICS INC,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HEYUE,YUHAN CORPORATION (2024-01-17),https://lens.org/143-742-173-761-683,Patent Application,yes,0,0,34,34,32,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,A61K39/395;;C07K16/18;;C07K16/28,,0,0,,,,PENDING
859,AU,A,AU 1994/076719 A,160-805-906-485-324,1995-09-04,1995,AU 1994/076719 A,1994-08-19,US 19721894 A;;US 25080194 A;;US 9409448 W,1994-02-16,Credit card with magnifying lens,,FINKELSTEIN ALAN,FINKELSTEIN ALAN;;BOEDE ROBERT H;;DIXON DONALD A,,https://lens.org/160-805-906-485-324,Patent Application,no,0,0,5,54,0,G06K19/041,G06K19/04,,0,0,,,,PENDING
860,JP,A,JP 2017105807 A,182-841-227-147-637,2017-06-15,2017,JP 2017017004 A,2017-02-01,US 10947408 P,2008-10-29,FORMULATIONS OF SINGLE DOMAIN ANTIGEN-BINDING MOLECULES,"PROBLEM TO BE SOLVED: To provide formulations of single domain antigen-binding molecules, in particular, of TNF binding nanobody molecules.SOLUTION: The invention provides a formulation comprising: (a) a TNF binding nanobody molecule at a concentration of about 10-250 mg/ml, preferably about 10-130 mg/ml; (b) a freeze drying protection agent selected from sucrose, sorbitol and trehalose at a concentration of about 5-10%; (c) a surfactant selected from polysorbate 80 and poloxamer 188 at a concentration of about 0.01-0.6%, preferably 0.01-0.02%; and (d) a buffer solution selected from a histidine buffer of about 10-20 mM and a tris buffer of about 20 mM to maintain the formulation pH to about 5.0-7.5, where the TNF-binding nanobody molecule maintains not less than 70% of its binding activity after at least three months storage at 4°C.SELECTED DRAWING: None",ABLYNX NV,JASON E FERNANDEZ;;DANIEL A DIXON;;ANDREA PAULSON,,https://lens.org/182-841-227-147-637,Patent Application,no,2,0,44,44,10,A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61P1/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P3/10;;A61K9/19;;A61K39/395;;G16Z99/00;;A61K9/1623;;A61K9/19;;A61K39/39591;;A61K9/0019;;A61K9/19;;A61K47/10;;A61K47/26;;C07K2317/22;;C07K2317/569;;G06Q99/00;;A61K39/39591;;A61K9/1617;;A61K9/1623;;A61K9/1641;;A61K2039/507;;C07K16/18;;C07K16/241;;C07K2317/24;;C07K2317/565;;G01N33/15,A61K39/395;;A61K9/19;;A61K47/10;;A61K47/18;;A61K47/22;;A61K47/26;;A61K47/34;;A61P1/04;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/02;;A61P43/00,,0,0,,,,PENDING
861,DE,T2,DE 69730803 T2,110-676-698-802-564,2006-01-26,2006,DE 69730803 T,1997-11-19,US 75366096 A,1996-11-27,Rekonfigurierbarer profilierter Reflektor im Orbit mit Speise/Reflektor-Defokussierung und kardanaufgehängtem Reflektor,,HUGHES ELECTRONICS CORP,RAMANUJAM PARTHASARATHY;;FERMELIA LOUIS R;;DIXON CYNTHIA A;;ESTEVEZ MIGUEL A,,https://lens.org/110-676-698-802-564,Granted Patent,no,0,0,8,8,0,H01Q3/18;;H01Q3/18;;H01Q1/18;;H01Q1/18;;H01Q1/288;;H01Q1/288;;H01Q3/16;;H01Q3/16;;H01Q3/20;;H01Q3/20;;H01Q15/141;;H01Q15/141,H01Q19/18;;H01Q1/18;;H01Q1/28;;H01Q3/16;;H01Q3/18;;H01Q3/20;;H01Q15/14,,0,0,,,,EXPIRED
862,EP,A2,EP 0845833 A2,182-380-400-062-508,1998-06-03,1998,EP 97120231 A,1997-11-19,US 75366096 A,1996-11-27,On-orbit reconfigurability of a shaped reflector with feed/reflector defocusing and reflector gimballing,"A system and method for changing the radiation pattern of an antenna assembly (14) of a satellite (12) in orbit is provided. The antenna assembly (14) includes a reflector antenna (16) fed by a feed assembly (18). The reflector antenna transmits and receives signals within a radiation pattern. The reflector antenna (16) and the feed assembly (18) are movably mounted to a sliding mechanism (24) so that they can be displaced with respect to one another. The displacement causes defocusing as the reflector antenna (16) is displaced from the focus point. The defocusing causes the radiation pattern to become more compact or broadened. Thus, the radiation pattern of the satellite (12) provided with a single reflector antenna (16) and a single feed element (22) may be changed while the satellite (12) is in orbit.",HUGHES AIRCRAFT CO,RAMANUJAM PARTHASARATHY;;FERMELIA LOUIS R;;DIXON CYNTHIA A;;ESTEVEZ MIGUEL A,HUGHES ELECTRONICS CORPORATION (1998-11-04),https://lens.org/182-380-400-062-508,Patent Application,yes,0,19,8,8,0,H01Q3/18;;H01Q3/18;;H01Q1/18;;H01Q1/18;;H01Q1/288;;H01Q1/288;;H01Q3/16;;H01Q3/16;;H01Q3/20;;H01Q3/20;;H01Q15/141;;H01Q15/141,H01Q19/18;;H01Q1/18;;H01Q1/28;;H01Q3/16;;H01Q3/18;;H01Q3/20;;H01Q15/14,,0,0,,,,EXPIRED
863,US,A,US 5530187 A,063-307-042-695-915,1996-06-25,1996,US 9337293 A,1993-07-16,US 9337293 A,1993-07-16,Transgenic plants containing multiple disease resistance genes,"In accordance with the present invention, there are provided transgenic plants comprising a plurality of plant-defense-associated proteins that are expressed to produce such proteins in an amount sufficient to increase the plants resistance to plant pathogens, relative to non-transgenic plants of the same species. The transgenic plants are useful to study patterns of development, and to provide increased resistance to plant pathogens when grown in crops as a food source, and the like. Nucleic acid constructs are also provided that are useful in methods for producing the invention transgenic plants.",SALK INST FOR BIOLOGICAL STUDI,LAMB CHRISTOPHER J;;ZHU QUN;;MAHER EILEEN A;;DIXON RICHARD A,SALK INSTITUTE FOR BIOLOGICAL STUDIES (1993-08-19),https://lens.org/063-307-042-695-915,Granted Patent,yes,8,55,7,7,4,C12N15/8282;;C12Y302/01014;;C12Y302/01059;;C12N9/2408;;C12Y302/01014;;C12N15/8282;;C12N9/2408;;C12Y302/01059,A01H5/00;;C12N5/10;;C12N9/24;;C12N15/09;;C12N15/82,800/205;;435/70.1;;435/172.3;;435/200;;435/209;;435/240.4;;435/320.1;;536/23.2;;536/23.6;;X800DIG 43,10,9,072-134-500-890-245;;127-322-021-825-982;;009-083-455-089-27X;;035-134-085-004-573;;021-590-139-883-712;;015-376-411-615-06X;;088-207-271-416-691;;144-067-860-877-194;;024-592-311-652-595,17776411;;10.1126/science.254.5035.1194;;8401605;;10.1046/j.1365-313x.1993.t01-1-00999.x;;2643475;;10.1016/0092-8674(89)90894-5;;1369021;;10.1038/nbt1192-1436;;16666407;;10.1104/pp.88.3.936;;pmc1055685;;10.1007/bf00017924;;1888892;;10.1016/0168-9452(91)90143-v;;1909591;;10.1007/bf00017919;;10.1038/338274a0,"Broglie et al., Transgenic Plants with Enhanced Resistance to the Fungal Pathogen Rhizoctonia solani, Science 254:1194 1197 (1991).;;Collinge, et al., Plant chitinases, The Plant Journal 3:31 40 (1993).;;Lamb et al., Signals and Transduction Mechanisms for Activation of Plant Defenses against Microbial Attack, Cell 56:215 224 (1989).;;Lamb et al., Emerging Strategies for Enhancing Crop Resistance to Microbial Pathogens, Bio/Technology 10:1436 1445 (1992).;;Mauch et al., Antifungal Hydrolases in Pea Tissue, Plant Physiol. 88:936 942 (1988).;;Neuhaus et al., High level expression of a tobacco chitinase gene in Nicotiana sylvestris . Susceptibility of transgenic plants to Cercospora nicotianae infection, 16:141 151 (1991) Plant Mol. Biol.;;Boller, T. 1985. pp. 247 262 In: Cell. Mol. Biol. Plant Stress, Alan R. Liss, Inc.;;Nishizawa et al. 1991. Plant Science 76:211 218.;;Edington et al. 1991. Plant Mol. Biol. 16(1):81 94.;;Shimamoto et al. 1989. Nature 338: 274 276.",EXPIRED
864,EP,A2,EP 0776107 A2,052-345-466-671-034,1997-05-28,1997,EP 96308040 A,1996-11-06,US 726295 P;;US 58613696 A,1995-11-06,Multimedia coordination system,"In a network, a media coordination system (2) provides secure multimedia communication channels in a collaborative network environment. The media coordination system provides automatic encryption, dynamic interconnection of streams of data, and user interface elements that provide users with control over the ultimate destination of their audio and video data. The infrastructure of the system (2) includes a plurality of client workstations (4) that are connected to a central server (22) using point-to-point network connections. The central server (22) maintains a persistent virtual world of network places with objects located therein. Streams of audio and video data are coordinated between client workstations (4) operating in the persistent virtual world by a key manager object using channels, transmitters, and receivers. The client workstations (4) multicast their audio and video data over the network to defined recipients after receiving a multicast address and an encryption key for a specific multicast channel. In order to protect the privacy of all communications and the integrity of the coordination system (2), each client workstation (4) retains significant control over distribution and reception of audio and video data since multicast transmission is tied to specific user interface elements. The multimedia user interface elements include cameras (18), speakers (16), microphones (20), and video panes (12). Since the central server (22) only coordinates where audio and video data is broadcast for a particular interface element, each client workstation (4) ultimately controls the destination of multimedia data through selection of the element at the user interface.",XEROX CORP,CURTIS PAVEL;;NICHOLS DAVID A;;DIXON MICHAEL D;;FREDERICK RONALD A,,https://lens.org/052-345-466-671-034,Patent Application,yes,3,21,10,10,0,H04L12/1822;;H04L63/0428;;H04L63/062;;H04M3/567;;H04L65/403;;H04L65/4038;;H04L65/611;;H04L67/131;;H04L63/0428;;H04M3/567;;H04L12/1822;;H04L63/062;;H04L65/403;;H04L65/4038;;H04L9/40;;H04L65/611;;H04L67/131;;H04L65/1101,G06F12/00;;G06F13/00;;G06F15/00;;G09C1/00;;H04L12/18;;H04L29/06;;H04M3/56,,3,0,,,"HILL ET AL.: ""The Rendezvous Language and Architecture."", COMMUNICATIONS OF THE ACM., vol. 36, no. 1, January 1993 (1993-01-01);;""Proceedings of the 1992 Conference on Directions and Implications of Advanced Computing."", May 1992, BERKELEY., article CURTIS ET AL.: ""Mudding: Social Phenomena in Text-Based Virtual Realities."";;""Proceedings of the 1994 IEEE Computing Conference."", January 1994, article CURTIS ET AL.: ""MUDs Grow Up: Social Virtual Reality in the Real World."", pages: 193 - 200",EXPIRED
865,JP,A,JP H10247812 A,055-152-070-809-592,1998-09-14,1998,JP 32478997 A,1997-11-26,US 75366096 A,1996-11-27,RE-CONFIGURATION METHOD AND COMMUNICATION SYSTEM ON ORBIT OF REFLECTOR FORMED BY DEFOCUS OF FEEDER/REFLECTOR AND GIMBAL OPERATION OF REFLECTOR,"PROBLEM TO BE SOLVED: To provide a method and a system for revising a radiation pattern of a satellite by defocusing an antenna assembly. SOLUTION: This communication system for a satellite circulating around the earth is made up of a sliding mechanism 24, a reflector antenna 16 for sending a radiation pattern of electromagnetic energy, a sub-reflector 20 that emits the radiation pattern of the electromagnetic energy to the reflector antenna, and a feeder 18 consisting of a feed element 22, the reflector antenna 16 sends the electromagnetic energy received from the feeders 22, 20 to the earth by means of a radiation pattern, at least one of the reflector antenna 16 and the feeder 18 is slidably mounted to the sliding mechanism 24, and the distance between them is changed for changing the radiation pattern with defocusing between reflector antenna 16 and the feeder 18.",HUGHES AIRCRAFT CO,RAMANUJAM PARTHASARATHY;;FERMELIA LOUIS R;;DIXON CYNTHIA A;;ESTEVEZ MIGUEL A,,https://lens.org/055-152-070-809-592,Patent Application,no,0,6,8,8,0,H01Q3/18;;H01Q3/18;;H01Q1/18;;H01Q1/18;;H01Q1/288;;H01Q1/288;;H01Q3/16;;H01Q3/16;;H01Q3/20;;H01Q3/20;;H01Q15/141;;H01Q15/141,H01Q19/18;;H01Q1/18;;H01Q1/28;;H01Q3/16;;H01Q3/18;;H01Q3/20;;H01Q15/14,,0,0,,,,EXPIRED
866,US,A1,US 2012/0278914 A1,011-924-341-186-544,2012-11-01,2012,US 201213444507 A,2012-04-11,US 201213444507 A;;US 201161474224 P,2011-04-11,METHODS AND COMPOSITIONS FOR REGULATING PRODUCTION OF PROANTHOCYANIDINS,"The invention provides methods and compositions for the modulation of proanthocynidin (“PA;” condensed tannin) production in plants. The methods of the invention allow creation of plants having novel phenotypes, such as alterations in levels of PA or in the types of tissues in which PAs are produced. Altered expression of PA in plants may be achieved, for instance without significantly affecting anthocyanin content or overall secondary metabolite profiles. Alternatively, expression of PA in plants may be achieved while also affecting anthocyanin content.",VERDIER JEROME A;;ZHAO JIAN;;DIXON RICHARD A;;UDVARDI MICHAEL K,VERDIER JEROME A;;ZHAO JIAN;;DIXON RICHARD A;;UDVARDI MICHAEL K,NOBLE RESEARCH INSTITUTE LLC (2012-04-25),https://lens.org/011-924-341-186-544,Patent Application,yes,0,2,2,2,24,C12N15/825;;C12N15/825;;C07K14/415;;C07K14/415,C12N15/82;;A01H1/02;;A01H5/00;;A01H5/10;;A23K1/00;;A23L19/00;;C07H21/04;;C07K14/415;;C08B31/00;;C12N5/10;;C12N15/63,800/260;;426/615;;426/635;;435/419;;435/320.1;;530/370;;536/23.6;;536/24.5;;536/102;;800/278;;800/287;;800/298,3,3,048-037-153-065-157;;098-471-638-798-338;;005-288-529-101-109,10.1242/dev.126.4.671;;9895315;;10.1046/j.1365-313x.1998.00046.x;;9680994;;23689818;;10.1007/s11103-013-0074-8,"Payne et al. (1999), Development 126:671-682.;;Quattrocchio F. et al. The Plant Journal; 1998, Vol. 13, No. 4 pp. 475-488.;;Heppel et al. Plant Mol. Biol. (2013) vol. 82:457-471.",ACTIVE
867,EP,A1,EP 0712272 A1,059-062-923-457-493,1996-05-22,1996,EP 94923439 A,1994-07-15,US 9407815 W;;US 9337293 A,1993-07-16,TRANSGENIC PLANTS CONTAINING MULTIPLE DISEASE RESISTANCE GENES,,SALK INST FOR BIOLOGICAL STUDI,LAMB CHRISTOPHER J;;ZHU QUN;;MAHER EILEEN A;;DIXON RICHARD A,,https://lens.org/059-062-923-457-493,Patent Application,yes,0,8,7,7,0,C12N15/8282;;C12Y302/01014;;C12Y302/01059;;C12N9/2408;;C12Y302/01014;;C12N15/8282;;C12N9/2408;;C12Y302/01059,A01H5/00;;C12N5/10;;C12N9/24;;C12N15/09;;C12N15/82,,0,0,,,,DISCONTINUED
868,US,A1,US 2002/0101997 A1,158-437-270-626-014,2002-08-01,2002,US 411401 A,2001-12-06,US 411401 A;;US 58613696 A;;US 726295 P,1995-11-06,Multimedia coordination system,"
   In a network, a media coordination system provides secure multimedia communication channels in a collaborative network environment. The media coordination system provides automatic encryption, dynamic interconnection of streams of data, and user interface elements that provide users with control over the ultimate destination of their audio and video data. The infrastructure of the system includes a plurality of client workstations that are connected to a central server using point-to-point network connections. The central server maintains a persistent virtual world of network places with objects located therein. Streams of audio and video data are coordinated between client workstations operating in the persistent virtual world by a key manager object using channels, transmitters, and receivers. The client workstations multicast their audio and video data over the network to defined recipients after receiving a multicast address and an encryption key for a specific multicast channel. In order to protect the privacy of all communications and the integrity of the coordination system, each client workstation retains significant control over distribution and reception of audio and video data since multicast transmission is tied to specific user interface elements. The multimedia user interface elements include cameras, speakers, microphones, and video panes. Since the central server only coordinates where audio and video data is broadcast for a particular interface element, each client workstation ultimately controls the destination of multimedia data through selection of the element at the user interface. 
",XEROX CORP,CURTIS PAVEL;;DIXON MICHAEL D;;FREDERICK RONALD A;;NICHOLS DAVID A,,https://lens.org/158-437-270-626-014,Patent Application,yes,5,46,10,10,0,H04L12/1822;;H04L63/0428;;H04L63/062;;H04M3/567;;H04L65/403;;H04L65/4038;;H04L65/611;;H04L67/131;;H04L63/0428;;H04M3/567;;H04L12/1822;;H04L63/062;;H04L65/403;;H04L65/4038;;H04L9/40;;H04L65/611;;H04L67/131;;H04L65/1101,G06F13/00;;G06F12/00;;G06F15/00;;G09C1/00;;H04L12/18;;H04L29/06;;H04M3/56,380/279,0,0,,,,EXPIRED
869,US,B2,US 6560707 B2,186-958-704-476-308,2003-05-06,2003,US 58613696 A,1996-01-16,US 58613696 A;;US 726295 P,1995-11-06,Multimedia coordination system,"
    In a network, a media coordination system provides secure multimedia communication channels in a collaborative network environment. The media coordination system provides automatic encryption, dynamic interconnection of streams of data, and user interface elements that provide users with control over the ultimate destination of their audio and video data. The infrastructure of the system includes a plurality of client workstations that are connected to a central server using point-to-point network connections. The central server maintains a persistent virtual world of network places with objects located therein. Streams of audio and video data are coordinated between client workstations operating in the persistent virtual world by a key manager object using channels, transmitters, and receivers. The client workstations multicast their audio and video data over the network to defined recipients after receiving a multicast address and an encryption key for a specific multicast channel. In order to protect the privacy of all communications and the integrity of the coordination system, each client workstation retains significant control over distribution and reception of audio and video data since multicast transmission is tied to specific user interface elements. The multimedia user interface elements include cameras, speakers, microphones, and video panes. Since the central server only coordinates where audio and video data is broadcast for a particular interface element, each client workstation ultimately controls the destination of multimedia data through selection of the element at the user interface. 
",XEROX CORP,CURTIS PAVEL;;DIXON MICHAEL D;;FREDERICK RONALD A;;NICHOLS DAVID A,XEROX CORPORATION (1996-01-12),https://lens.org/186-958-704-476-308,Granted Patent,yes,13,177,10,10,0,H04L12/1822;;H04L63/0428;;H04L63/062;;H04M3/567;;H04L65/403;;H04L65/4038;;H04L65/611;;H04L67/131;;H04L63/0428;;H04M3/567;;H04L12/1822;;H04L63/062;;H04L65/403;;H04L65/4038;;H04L9/40;;H04L65/611;;H04L67/131;;H04L65/1101,G06F13/00;;G06F12/00;;G06F15/00;;G09C1/00;;H04L12/18;;H04L29/06;;H04M3/56,713/163;;713/171;;380/33;;380/257;;380/281,12,3,080-598-297-253-86X;;004-776-242-109-484;;147-334-673-323-367,10.1109/cmpcon.1994.282924;;10.1109/comwor.1988.4813;;10.1145/78952.78953,"European Search Report for EPO counterpart Application No. EP 96 30 8040 Sep. 22, 1999.;;Hill et al., ""The Rendezvous Language and Architecture,"" Communications of the ACM, Jan., 1993, vol. 36, No. 1.;;Curtis et al., ""MUDs Grow Up: Social Virtual Reality in the Real World,"" Proceedings of the 1994 IEEE Computer Conference, pp 193-200, Jan. 1994.;;Zellweger et al., ""An Overview of the Etherphone System and its Applications,"" Proceedings of the 2nd IEEE Conference on Computer Workstations, Mar. 1988.;;Bellcore Information Networking Research Laboratory, ""The Touring Machine System,"" Communications of the ACM, Jan. 1993, vol. 36, No. 1.;;Pioch et al., ""A Short IRC Primer,"" Feb. 28, 1993 (available by FTP at cs.bu.edu/irc/support).;;Deering et al., ""Multicast routing in datagram networks and extended LANs,"" ACM Transactions on Computer Systems, May 1990.;;Schulzrinne et al., ""RTP: A Transport Protocol for Real-Time Applications,"" IETF Internet Draft (available from ftp://ftp.internic.net/internet-drafts/draft-ietf-avt-rtp-07.txt).;;Hickman, K.E.B., ""The SSL Protocol"" (available from http://home.mcom.com/newsref/std/SSL.html).;;Curtis et al., LambdaMOO Programmmer's Manual (available as ftp://ftp.parc.xerox.com/pub/MOO/ProgrammersManual.ps).;;Fish et al., ""Video as a Technology for Informal Communication,"" Communications of the ACM, Jan., 1993, vol. 36, No. 1.;;Curtis, P., ""Mudding: Social Phenomena in Text-Based Virtual Realities,"" May 1992 conference on Directions and Implications of Advanced Computing, sponsored by Computer professionals for Social Responsibility, Berkeley, CA.",EXPIRED
870,DE,D1,DE 69730803 D1,001-632-546-970-765,2004-10-28,2004,DE 69730803 T,1997-11-19,US 75366096 A,1996-11-27,Rekonfigurierbarer profilierter Reflektor im Orbit mit Speise/Reflektor-Defokussierung und kardanaufgehängtem Reflektor,,HUGHES ELECTRONICS CORP,RAMANUJAM PARTHASARATHY;;FERMELIA LOUIS R;;DIXON CYNTHIA A;;ESTEVEZ MIGUEL A,,https://lens.org/001-632-546-970-765,Granted Patent,no,0,0,8,8,0,H01Q3/18;;H01Q3/18;;H01Q1/18;;H01Q1/18;;H01Q1/288;;H01Q1/288;;H01Q3/16;;H01Q3/16;;H01Q3/20;;H01Q3/20;;H01Q15/141;;H01Q15/141,H01Q19/18;;H01Q1/18;;H01Q1/28;;H01Q3/16;;H01Q3/18;;H01Q3/20;;H01Q15/14,,0,0,,,,EXPIRED
871,DE,D1,DE 69631866 D1,041-415-647-345-184,2004-04-22,2004,DE 69631866 T,1996-11-06,US 726295 P;;US 58613696 A,1995-11-06,Multimediakoordinationssystem,,XEROX CORP,CURTIS PAVEL;;NICHOLS DAVID A;;DIXON MICHAEL D;;FREDERICK RONALD A,,https://lens.org/041-415-647-345-184,Granted Patent,no,0,0,10,10,0,H04L12/1822;;H04L63/0428;;H04L63/062;;H04M3/567;;H04L65/403;;H04L65/4038;;H04L65/611;;H04L67/131;;H04L63/0428;;H04M3/567;;H04L12/1822;;H04L63/062;;H04L65/403;;H04L65/4038;;H04L9/40;;H04L65/611;;H04L67/131;;H04L65/1101,G06F12/00;;G06F13/00;;G06F15/00;;G09C1/00;;H04L12/18;;H04L29/06;;H04M3/56,,0,0,,,,EXPIRED
872,EP,A3,EP 0845833 A3,037-220-396-377-776,1999-10-13,1999,EP 97120231 A,1997-11-19,US 75366096 A,1996-11-27,On-orbit reconfigurability of a shaped reflector with feed/reflector defocusing and reflector gimballing,"A system and method for changing the radiation pattern of an antenna assembly (14) of a satellite (12) in orbit is provided. The antenna assembly (14) includes a reflector antenna (16) fed by a feed assembly (18). The reflector antenna transmits and receives signals within a radiation pattern. The reflector antenna (16) and the feed assembly (18) are movably mounted to a sliding mechanism (24) so that they can be displaced with respect to one another. The displacement causes defocusing as the reflector antenna (16) is displaced from the focus point. The defocusing causes the radiation pattern to become more compact or broadened. Thus, the radiation pattern of the satellite (12) provided with a single reflector antenna (16) and a single feed element (22) may be changed while the satellite (12) is in orbit.",HUGHES AIRCRAFT CO,RAMANUJAM PARTHASARATHY;;FERMELIA LOUIS R;;DIXON CYNTHIA A;;ESTEVEZ MIGUEL A,HUGHES ELECTRONICS CORPORATION (1998-11-04),https://lens.org/037-220-396-377-776,Search Report,yes,5,0,8,8,0,H01Q3/18;;H01Q3/18;;H01Q1/18;;H01Q1/18;;H01Q1/288;;H01Q1/288;;H01Q3/16;;H01Q3/16;;H01Q3/20;;H01Q3/20;;H01Q15/141;;H01Q15/141,H01Q19/18;;H01Q1/18;;H01Q1/28;;H01Q3/16;;H01Q3/18;;H01Q3/20;;H01Q15/14,,0,0,,,,EXPIRED
873,EP,B1,EP 0776107 B1,013-756-616-917-469,2004-03-17,2004,EP 96308040 A,1996-11-06,US 726295 P;;US 58613696 A,1995-11-06,Multimedia coordination system,,XEROX CORP,CURTIS PAVEL;;NICHOLS DAVID A;;DIXON MICHAEL D;;FREDERICK RONALD A,,https://lens.org/013-756-616-917-469,Granted Patent,yes,2,0,10,10,0,H04L12/1822;;H04L63/0428;;H04L63/062;;H04M3/567;;H04L65/403;;H04L65/4038;;H04L65/611;;H04L67/131;;H04L63/0428;;H04M3/567;;H04L12/1822;;H04L63/062;;H04L65/403;;H04L65/4038;;H04L9/40;;H04L65/611;;H04L67/131;;H04L65/1101,G06F12/00;;G06F13/00;;G06F15/00;;G09C1/00;;H04L12/18;;H04L29/06;;H04M3/56,,0,0,,,,EXPIRED
874,US,B2,US 9121031 B2,054-174-619-023-45X,2015-09-01,2015,US 201213444507 A,2012-04-11,US 201213444507 A;;US 201161474224 P,2011-04-11,Methods and compositions for regulating production of proanthocyanidins,"The invention provides methods and compositions for the modulation of proanthocynidin (“PA;” condensed tannin) production in plants. The methods of the invention allow creation of plants having novel phenotypes, such as alterations in levels of PA or in the types of tissues in which PAs are produced. Altered expression of PA in plants may be achieved, for instance without significantly affecting anthocyanin content or overall secondary metabolite profiles. Alternatively, expression of PA in plants may be achieved while also affecting anthocyanin content.",VERDIER JEROME A;;ZHAO JIAN;;DIXON RICHARD A;;UDVARDI MICHAEL K;;SAMUEL ROBERTS NOBLE FOUND INC,VERDIER JEROME A;;ZHAO JIAN;;DIXON RICHARD A;;UDVARDI MICHAEL K,NOBLE RESEARCH INSTITUTE LLC (2012-04-25),https://lens.org/054-174-619-023-45X,Granted Patent,yes,2,1,2,2,24,C12N15/825;;C12N15/825;;C07K14/415;;C07K14/415,C12N15/82;;A23L19/00;;C07K14/415,,42,38,048-037-153-065-157;;098-471-638-798-338;;005-288-529-101-109;;007-992-583-894-287;;021-053-676-958-106;;100-482-984-758-877;;031-383-256-104-133;;033-093-660-215-000;;092-867-581-018-187;;011-723-736-277-845;;073-236-401-605-529;;058-950-340-748-925;;024-849-426-107-897;;065-929-544-495-189;;021-156-476-610-801;;010-163-151-302-348;;027-010-229-028-458;;147-270-016-436-484;;006-470-893-916-774;;036-181-789-228-143;;002-302-213-407-020;;062-223-296-623-722;;035-696-008-633-282;;159-115-616-844-217;;173-155-514-931-954;;026-753-097-919-005;;006-191-344-749-449;;052-050-441-875-569;;027-306-014-726-278;;059-116-604-685-035;;002-289-321-628-900;;022-722-154-225-230;;135-926-819-985-421;;089-283-238-428-448;;087-443-222-806-376;;034-228-045-089-243;;123-127-395-374-005;;062-752-237-377-510,10.1242/dev.126.4.671;;9895315;;10.1046/j.1365-313x.1998.00046.x;;9680994;;23689818;;10.1007/s11103-013-0074-8;;10.1016/s0968-0004(96)30009-1;;10.1016/0968-0004(96)30009-1;;8882580;;10.1111/j.1365-313x.2004.02138.x;;15255866;;11752314;;10.1093/nar/30.1.276;;pmc99071;;10.1111/j.1365-313x.2008.03519.x;;18410479;;10.1101/gad.1.10.1183;;2828168;;20931380;;10.1007/978-1-60761-682-5_13;;10.1002/9780470988848;;pmc159763;;2535505;;10.1105/tpc.1.3.301;;10.2307/3869010;;10.1186/1471-2105-8-87;;pmc1828068;;17349060;;pmc2804685;;20028527;;10.1186/1471-2105-10-441;;10.1002/j.1460-2075.1987.tb02730.x;;pmc553867;;3327686;;10.1105/tpc.001404;;12084832;;pmc150785;;10.1021/jf00028a012;;16669768;;10.1146/annurev.arplant.57.032905.105252;;11041882;;pmc149125;;10.2307/3871198;;10.1105/tpc.12.10.1863;;pmc139454;;10.2307/3871430;;10.1105/tpc.13.9.2099;;11549766;;10.1105/tpc.010098;;12368498;;10.1105/tpc.004127;;pmc151229;;10.1104/pp.107.107326;;17885080;;pmc2048810;;19710231;;pmc2773055;;10.1104/pp.109.144022;;10.1111/j.1365-313x.2009.03885.x;;19368693;;10.1094/mpmi-6-699;;21477081;;10.1111/j.1365-313x.2011.04603.x;;10.1101/gad.212702;;11782451;;pmc155310;;10.2307/2446026;;10.1016/s1369-5266(00)00199-0;;11597504;;10.1111/j.1365-313x.2008.03418.x;;18208518;;19098092;;pmc2633825;;10.1104/pp.108.131862;;10.1104/pp.91.4.1575;;pmc1062224;;16667219;;10.2307/3870753;;10.1105/tpc.11.7.1337;;pmc144274;;10402433;;10.1111/j.1365-313x.2006.02655.x;;16507081;;20006535;;10.1016/j.tplants.2009.11.006;;22566493;;10.1104/pp.112.195420;;pmc3387705;;24948832;;10.1104/pp.114.241877;;pmc4119029;;pmc2544603;;10.1073/pnas.0805954105;;18772380;;10.1073/pnas.1120916109;;22307644;;pmc3277187,"Payne et al. (1999), Development 126:671-682.;;Quattrocchio F. et al. The Plant Journal; 1998, vol. 13, No. 4 pp. 475-488.;;Heppel et al. Plant Mol. Biol. (2013) vol. 82:457-471.;;Aasland et al., ""The SANT domain: putative DNA-binding domain in the SWI-SNF and ADA complexes, the transcriptional co-repressor N-CoR and TFIIIB,"" Trends Biochem Sci 21:87-88, 1996.;;Baudry et al., ""TT2, TT8, and TTGI synergistically specify the expression of BANYULS and proanthocyanidin biosynthesis in Arabidopsis thaliana,"" Plant J 39:366-380, 2004.;;Bateman et al., ""The Pfam Protein Families Database,"" Nucleic Acids Research 30:276-280, 2002.;;Benedito at al., ""A gene expression atlas of the model legume Medicago truncatula,"" Plant J 55:504-513, 2008.;;Callis et al., ""Introns increase gene expression in cultured maize cells,"" Genes Dev 1:1183-1200, 1987.;;Cheng et al., ""Reverse genetics in Medicago truncatula using Tnt1 insertion mutants,"" Methods in Mol Biol 678:179-190, 2011.;;DeBeaujon et al., ""Seed Coat Development and Dormancy,"" Seed Development, Dormancy and Germination, eds. K. Bradford and H. Nonogaki, Blackwell, 2007.;;Gallie et al., ""Visualizing mRNA Expression in Plant Protoplasts: Factors Influencing Efficient mRNA Uptake and Translation,"" Plant Cell 1:301-311, Mar. 1989.;;Goffard et al., ""GeneBins: a database for classifying gene expression data, with application to plant genome arrays,"" BMC Bioinformatics 8:87, Mar. 12, 2007.;;He et al., ""The Medicago truncatula gene expression atlas web server,"" BMC Bioinformatics 10:441, Dec. 22, 2009.;;Jefferson et al., ""GUS fusions: beta-glucuronidase as a sensitive and versatile gene fusion marker in higher plants,"" EMBO J 6:3901-3907, 1987.;;Johnson et al., ""Transparent Testa GLABRA2, a Trichome and Seed Coat Development Gene of Arabidopsis, Enclodes a WRKY Transcription Factor,"" Plant Cell 14:1359-1375, Jun. 2002.;;Koupai-Abyazani et al., ""Purification and characterization of a proanthocyanidin polymer from seed of alfalfa (Medicago sativa),"" J Agric Food Chem 41:565-569, 1993.;;Lepiniec et al., ""Genetics and Biochemistry of Seed Flavonoids,"" Annual Review Plant Biol 57:405-30, 2006.;;Nesi et al., ""The TT8 Gene Encodes a Basic Helix-Loop-Helix Domain Protein Required for Expression of DFR and BAN Genes in Arabidopsis Siliques,"" Plant Cell 12:1863-1878, Oct. 2000.;;Nesi et al., ""The Arabidopsis TT2 Gene Encodes an RcR3 MYB Domain Protein that Acts as a Key Determinant for Proanthocyanidin Accumulation in Developing Seed,"" Plant Cell 13:2099-2114, Sep. 2001.;;Nesi et al., ""The Transparent TEXTA16 locus encodes the Arabidopsis Bsister MADS domain protein and is required for proper development and pigmentation of the seed coat,"" Plant Cell 14:2463-2479, 2002.;;Pang et al., ""Early Steps in Proanthocyanidin Biosynthesis in the Model Legume Medicago truncatula,"" Plant Physiol 145:601-615, 2007.;;Pang et al., ""A WD40 repeat protein from Medicago truncatula is necessary for tissue-specific anthocyanin and proanthocyanidin biosynthesis but not for trichome development"" Plant Physiol 151:1114-1129, 2009.;;Peel et al, ""The LAP1 MYB transcription factor orchestrates anthocyanidin biosynthesis and glycosylation in Medicago,"" Plant J 59(1):136-149, 2009.;;Quandt et al., ""Transgenic Root Nodules of Vicia hirsuta: a fast and efficient system for the study of gene expression in indeterminate-type nodules,"" Molelcular Plant-Microbe Interactions, 6:699-706, 1993.;;Appelhagen et al., ""Transparent Testa 1 interacts with R2R3-MYB factors and affects early and late steps of flavonoid biosynthesis in the endothelium of Arabidopsis thaliana seeds,"" The Plant J 67(3):406-19, 2011.;;Sagasser et al., ""A. thaliana Transparent Testa 1 is involved in seed coat development and defines the WIP subfamily of plant zinc finger proteins,"" Genes & Dev 16:138-149, 2002.;;Skadhauge et al., ""Leucocyanidin reductase activity and accumulation of Proanthocyanidins in developing legume tissues,"" Am J Bot 84:494-503, 1997.;;Stracke et al., ""The R2R3-MYB gene family in Arabidopsis thaliana,"" Curr Opinion PI Biol (5):447-456, 2001.;;Tadege et al., ""Large-scale insertional mutagenesis using the Tnt1 retrotransposon in the model legume M. truncatula,"" Plant J 54:335-347, 2008.;;Terrier et al., ""Ectopic expression of VvMybPA2 promotes proanthocyanidin biosynthesis in grapevine and suggests additional targets in the pathway,"" Plant Physiol 149:1028-1041, 2009.;;Vasil et al., ""Increased Gene Expression by the First Intron of Maize Shrunken-1 Locus in Grass Species,"" Plant Physiol 91:1575-1579, 1989.;;Verdier et al., ""Functional genomics of M. truncatula seed development,"" Presentation at the 10th International Conference on Seed Science, Costa do Sauipe, Brazil, Apr. 11, 2011.;;Walker et al., ""The Transparent Testa Glabrai Locus, which regulates trichome differentiation and anthocyanin biosynthesis in Arabidopsis, encodes a WD40 repeat protein,"" Plant Cell 11:1337-1349, 1999.;;Xie et al., ""Metabolic engineering of proanthocyanidins through co-expression of anthocyanidin reductase and the PAP1 MYB transcription factor,"" Plant J 45:895-907, 2004.;;Zhao et al., ""The 'ins' and 'outs' of flavonoid transport,"" Trends Plant Sci 15:72-80, 2010.;;GenBank Accession No. EU040206, ""Medicago truncatula WD40-1 protein mRNA, complete cds,"", Nov. 6, 2009.;;GenBank Accession No. AJ299452, ""Arabidopsis thaliana TT2 gene for transparent testa 2 protein, exons 1-3,"" Nov. 14, 2006.;;GenBank Accession No. Q0PJG9, protein sequence, ""MYB transcription factor MYB115,"" Nov. 28, 2006.;;Hancock et al., Expression of the R2R3-MYB Transcription Factor TaMYB14 from Trifolium arvense Activates Proanthocyanidin Biosynthesis in the Legumes Trifolium repens and Medicago sativa; Plant Physiology; vol. 159; pp. 1204-1220; 2012.;;Liu et al., MYB5 and MYB14 Play Pivotal Roles in Seed Coat Polymer Biosynthesis in Medicago truncatula; Plant Physiology; vol. 165; pp. 1-16; 2014.;;Pang et al.,""A transcript profiling approach reveals an epicatechin-specific glucosyltransferase expressed in the seed coat of Medicago truncatula,"" PNAS; vol. 105, No. 37; pp. 14210-14215; 2008.;;Verdier et al, .MtPAR MYB transcription factor acts as an on switch for proanthocyanidin biosynthesis in Medicago truncatula; PNAS; Early Edition; pp. 1-6; 2011.",ACTIVE
875,US,B2,US 6772335 B2,155-659-596-789-336,2004-08-03,2004,US 411401 A,2001-12-06,US 411401 A;;US 58613696 A;;US 726295 P,1995-11-06,Multimedia coordination system,"
    In a network, a media coordination system provides secure multimedia communication channels in a collaborative network environment. The media coordination system provides automatic encryption, dynamic interconnection of streams of data, and user interface elements that provide users with control over the ultimate destination of their audio and video data. The infrastructure of the system includes a plurality of client workstations that are connected to a central server using point-to-point network connections. The central server maintains a persistent virtual world of network places with objects located therein. Streams of audio and video data are coordinated between client workstations operating in the persistent virtual world by a key manager object using channels, transmitters, and receivers. The client workstations multicast their audio and video data over the network to defined recipients after receiving a multicast address and an encryption key for a specific multicast channel. In order to protect the privacy of all communications and the integrity of the coordination system, each client workstation retains significant control over distribution and reception of audio and video data since multicast transmission is tied to specific user interface elements. The multimedia user interface elements include cameras, speakers, microphones, and video panes. Since the central server only coordinates where audio and video data is broadcast for a particular interface element, each client workstation ultimately controls the destination of multimedia data through selection of the element at the user interface. 
",XEROX CORP,CURTIS PAVEL;;DIXON MICHAEL D;;FREDERICK RONALD A;;NICHOLS DAVID A,,https://lens.org/155-659-596-789-336,Granted Patent,yes,5,112,10,10,0,H04L12/1822;;H04L63/0428;;H04L63/062;;H04M3/567;;H04L65/403;;H04L65/4038;;H04L65/611;;H04L67/131;;H04L63/0428;;H04M3/567;;H04L12/1822;;H04L63/062;;H04L65/403;;H04L65/4038;;H04L9/40;;H04L65/611;;H04L67/131;;H04L65/1101,G06F13/00;;G06F12/00;;G06F15/00;;G09C1/00;;H04L12/18;;H04L29/06;;H04M3/56,713/163;;713/162;;370/236;;370/432;;380/279;;345/716;;345/737;;345/738;;345/748;;345/756;;345/764;;345/747,0,0,,,,EXPIRED
876,EP,B1,EP 0845833 B1,176-189-651-471-514,2004-09-22,2004,EP 97120231 A,1997-11-19,US 75366096 A,1996-11-27,On-orbit reconfigurability of a shaped reflector with feed/reflector defocusing and reflector gimballing,,HUGHES ELECTRONICS CORP,RAMANUJAM PARTHASARATHY;;FERMELIA LOUIS R;;DIXON CYNTHIA A;;ESTEVEZ MIGUEL A,HUGHES ELECTRONICS CORPORATION (1998-11-04),https://lens.org/176-189-651-471-514,Granted Patent,yes,1,0,8,8,0,H01Q3/18;;H01Q3/18;;H01Q1/18;;H01Q1/18;;H01Q1/288;;H01Q1/288;;H01Q3/16;;H01Q3/16;;H01Q3/20;;H01Q3/20;;H01Q15/141;;H01Q15/141,H01Q19/18;;H01Q1/18;;H01Q1/28;;H01Q3/16;;H01Q3/18;;H01Q3/20;;H01Q15/14,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 1996, no. 06 28 June 1996 (1996-06-28)",EXPIRED
877,US,A1,US 2003/0051136 A1,099-239-366-821-185,2003-03-13,2003,US 58613696 D,1996-01-16,US 726295 P;;US 58613696 A,1995-11-06,MULTIMEDIA COORDINATION SYSTEM,"
   In a network, a media coordination system provides secure multimedia communication channels in a collaborative network environment. The media coordination system provides automatic encryption, dynamic interconnection of streams of data, and user interface elements that provide users with control over the ultimate destination of their audio and video data. The infrastructure of the system includes a plurality of client workstations that are connected to a central server using point-to-point network connections. The central server maintains a persistent virtual world of network places with objects located therein. Streams of audio and video data are coordinated between client workstations operating in the persistent virtual world by a key manager object using channels, transmitters, and receivers. The client workstations multicast their audio and video data over the network to defined recipients after receiving a multicast address and an encryption key for a specific multicast channel. In order to protect the privacy of all communications and the integrity of the coordination system, each client workstation retains significant control over distribution and reception of audio and video data since multicast transmission is tied to specific user interface elements. The multimedia user interface elements include cameras, speakers, microphones, and video panes. Since the central server only coordinates where audio and video data is broadcast for a particular interface element, each client workstation ultimately controls the destination of multimedia data through selection of the element at the user interface. 
",CURTIS PAVEL;;DIXON MICHAEL D.;;FREDERICK RONALD A.;;NICHOLS DAVID A.,CURTIS PAVEL;;DIXON MICHAEL D;;FREDERICK RONALD A;;NICHOLS DAVID A,XEROX CORPORATION (1996-01-12),https://lens.org/099-239-366-821-185,Patent Application,yes,0,183,10,10,0,H04L12/1822;;H04L63/0428;;H04L63/062;;H04M3/567;;H04L65/403;;H04L65/4038;;H04L65/611;;H04L67/131;;H04L63/0428;;H04M3/567;;H04L12/1822;;H04L63/062;;H04L65/403;;H04L65/4038;;H04L9/40;;H04L65/611;;H04L67/131;;H04L65/1101,G06F13/00;;G06F12/00;;G06F15/00;;G09C1/00;;H04L12/18;;H04L29/06;;H04M3/56,713/163,0,0,,,,PENDING
878,EP,A3,EP 0776107 A3,114-492-864-997-360,1999-11-10,1999,EP 96308040 A,1996-11-06,US 726295 P;;US 58613696 A,1995-11-06,Multimedia coordination system,"In a network, a media coordination system (2) provides secure multimedia communication channels in a collaborative network environment. The media coordination system provides automatic encryption, dynamic interconnection of streams of data, and user interface elements that provide users with control over the ultimate destination of their audio and video data. The infrastructure of the system (2) includes a plurality of client workstations (4) that are connected to a central server (22) using point-to-point network connections. The central server (22) maintains a persistent virtual world of network places with objects located therein. Streams of audio and video data are coordinated between client workstations (4) operating in the persistent virtual world by a key manager object using channels, transmitters, and receivers. The client workstations (4) multicast their audio and video data over the network to defined recipients after receiving a multicast address and an encryption key for a specific multicast channel. In order to protect the privacy of all communications and the integrity of the coordination system (2), each client workstation (4) retains significant control over distribution and reception of audio and video data since multicast transmission is tied to specific user interface elements. The multimedia user interface elements include cameras (18), speakers (16), microphones (20), and video panes (12). Since the central server (22) only coordinates where audio and video data is broadcast for a particular interface element, each client workstation (4) ultimately controls the destination of multimedia data through selection of the element at the user interface.",XEROX CORP,CURTIS PAVEL;;NICHOLS DAVID A;;DIXON MICHAEL D;;FREDERICK RONALD A,,https://lens.org/114-492-864-997-360,Search Report,yes,2,0,10,10,0,H04L12/1822;;H04L63/0428;;H04L63/062;;H04M3/567;;H04L65/403;;H04L65/4038;;H04L65/611;;H04L67/131;;H04L63/0428;;H04M3/567;;H04L12/1822;;H04L63/062;;H04L65/403;;H04L65/4038;;H04L9/40;;H04L65/611;;H04L67/131;;H04L65/1101,G06F12/00;;G06F13/00;;G06F15/00;;G09C1/00;;H04L12/18;;H04L29/06;;H04M3/56,,0,0,,,,EXPIRED
879,AU,A,AU 1994/073303 A,061-363-052-508-777,1995-02-13,1995,AU 1994/073303 A,1994-07-15,US 9337293 A;;US 9407815 W,1993-07-16,Transgenic plants containing multiple disease resistance genes,,SALK INST FOR BIOLOGICAL STUDI,LAMB CHRISTOPHER J;;ZHU QUN;;MAHER EILEEN A;;DIXON RICHARD A,,https://lens.org/061-363-052-508-777,Patent Application,no,0,0,7,7,0,C12N15/8282;;C12Y302/01014;;C12Y302/01059;;C12N9/2408;;C12Y302/01014;;C12N15/8282;;C12N9/2408;;C12Y302/01059,A01H5/00;;C12N5/10;;C12N9/24;;C12N15/09;;C12N15/82,,0,0,,,,PENDING
880,US,A,US 4994268 A,070-504-087-991-503,1991-02-19,1991,US 26942688 A,1988-11-10,US 26942688 A,1988-11-10,Pheromone formulation for attracting spruce beetles,Novel compositions and methods for the attraction of spruce beetles Dendroctonus rufipennis are provided. The compositions are comprised of both insect and tree-produced semiochemicals alone or in combination to attract populations of spruce beetles. The compositions are effective for the attraction and manipulation of the spruce beetle populations.,UNIV CALGARY,WIESER HELMUT;;DIXON ELISABETH A;;CEREZKE HERBERT F;;MACKENZIE ALAN A,SEMIOCHEMICALS INTERNATIONAL LTD (1991-02-15);;CALGARY UNIVERSITY OF (1988-12-21),https://lens.org/070-504-087-991-503,Granted Patent,yes,2,3,1,1,0,A01N31/06;;A01N31/06,A01N31/06,424/84,1,0,,,"The Merck Index Tenth Edition, p. 391, (1983).",EXPIRED
881,DE,T2,DE 69631866 T2,045-880-982-895-326,2004-08-05,2004,DE 69631866 T,1996-11-06,US 726295 P;;US 58613696 A,1995-11-06,Multimediakoordinationssystem,,XEROX CORP,CURTIS PAVEL;;NICHOLS DAVID A;;DIXON MICHAEL D;;FREDERICK RONALD A,,https://lens.org/045-880-982-895-326,Granted Patent,no,0,0,10,10,0,H04L12/1822;;H04L63/0428;;H04L63/062;;H04M3/567;;H04L65/403;;H04L65/4038;;H04L65/611;;H04L67/131;;H04L63/0428;;H04M3/567;;H04L12/1822;;H04L63/062;;H04L65/403;;H04L65/4038;;H04L9/40;;H04L65/611;;H04L67/131;;H04L65/1101,G06F12/00;;G06F13/00;;G06F15/00;;G09C1/00;;H04L12/18;;H04L29/06;;H04M3/56,,0,0,,,,EXPIRED
882,WO,A1,WO 1995/002319 A1,182-556-364-477-162,1995-01-26,1995,US 9407815 W,1994-07-15,US 9337293 A,1993-07-16,TRANSGENIC PLANTS CONTAINING MULTIPLE DISEASE RESISTANCE GENES,"In accordance with the present invention, there are provided transgenic plants comprising a plurality of plant-defense-associated proteins that are expressed to produce such proteins in an amount sufficient to increase the plants' resistance to plant pathogens, relative to non-transgenic plants of the same species. The transgenic plants are useful to study patterns of development, and to provide increased resistance to plant pathogens when grown in crops as a food source, and the like. Nucleic acid constructs are also provided that are useful in methods for producing the invention transgenic plants.",SALK INST FOR BIOLOGICAL STUDI,LAMB CHRISTOPHER J;;ZHU QUN;;MAHER EILEEN A;;DIXON RICHARD A,,https://lens.org/182-556-364-477-162,Patent Application,yes,1,24,7,7,0,C12N15/8282;;C12Y302/01014;;C12Y302/01059;;C12N9/2408;;C12Y302/01014;;C12N15/8282;;C12N9/2408;;C12Y302/01059,A01H5/00;;C12N5/10;;C12N9/24;;C12N15/09;;C12N15/82,,5,4,072-134-500-890-245;;088-207-271-416-691;;144-067-860-877-194;;024-592-311-652-595,17776411;;10.1126/science.254.5035.1194;;10.1016/0168-9452(91)90143-v;;1909591;;10.1007/bf00017919;;10.1038/338274a0,"SCIENCE, Volume 254, issued 22 November 1991, K. BROGLIE et al.: ""Transgenic Plants with Enhanced Resistance to the Fungal Pathogen Rhizoctonia solani"", pages 1194-1197, see pages 1195-1196.;;PLANT SCIENCE, Volume 76, issued 1991, Y. NISHIZAWA et al.: ""Rice Chitinase Gene: cDNA Cloning and Stress-Induced Expression"", pages 211-218, see page 214.;;PLANT MOLECULAR BIOLOGY, Volume 16, No. 1, issued January 1991, B.V. EDINGTON et al.: ""cDNA Cloning and Characterization of a Putative 1,3-Beta-D-Glucanase Transcript Induced by a Fungal Elicitor in Bean Cell Suspension Cultures"", pages 81-94, see page 86.;;NATURE, Volume 338, issued 16 march 1989, K. SHIMAMOTO et al.: ""Fertile Transgenic Rice Plants Regenerated from Transformed Protoplasts"", pages 274-276, see page 274.;;See also references of EP 0712272A4",PENDING
883,CA,A1,CA 2166405 A1,105-314-433-805-453,1995-01-26,1995,CA 2166405 A,1994-07-15,US 9337293 A,1993-07-16,TRANSGENIC PLANTS CONTAINING MULTIPLE DISEASE RESISTANCE GENES,"In accordance with the present invention, there are provided transgenic plants comprising a plurality of plant-defense-associated proteins that are expressed to produce such proteins in an amount sufficient to increase the plants' resistance to plant pathogens, relative to non-transgenic plants of the same species. The transgenic plants are useful to study patterns of development, and to provide increased resistance to plant pathogens when grown in crops as a food source, and the like. Nucleic acid constructs are also provided that are useful in methods for producing the invention transgenic plants.",SALK INST FOR BIOLOGICAL STUDI,LAMB CHRISTOPHER J;;ZHU QUN;;MAHER EILEEN A;;DIXON RICHARD A,,https://lens.org/105-314-433-805-453,Patent Application,no,0,0,7,7,0,C12N15/8282;;C12Y302/01014;;C12Y302/01059;;C12N9/2408;;C12Y302/01014;;C12N15/8282;;C12N9/2408;;C12Y302/01059,A01H5/00;;C12N5/10;;C12N9/24;;C12N15/09;;C12N15/82,,0,0,,,,DISCONTINUED
884,EP,A4,EP 0712272 A4,133-221-715-868-316,1997-08-20,1997,EP 94923439 A,1994-07-15,US 9407815 W;;US 9337293 A,1993-07-16,TRANSGENIC PLANTS CONTAINING MULTIPLE DISEASE RESISTANCE GENES,,SALK INST FOR BIOLOGICAL STUDI,LAMB CHRISTOPHER J;;ZHU QUN;;MAHER EILEEN A;;DIXON RICHARD A,,https://lens.org/133-221-715-868-316,Search Report,no,10,0,7,7,0,C12N15/8282;;C12Y302/01014;;C12Y302/01059;;C12N9/2408;;C12Y302/01014;;C12N15/8282;;C12N9/2408;;C12Y302/01059,A01H5/00;;C12N5/10;;C12N9/24;;C12N15/09;;C12N15/82,,9,3,035-134-085-004-573;;019-879-169-527-802;;016-996-536-873-082,1369021;;10.1038/nbt1192-1436;;10.1104/pp.101.3.857;;12231736;;pmc158700;;10.1007/bf01168337,"LAMB, C.J., ET AL.: ""Emerging strategies for enhancing crop resistance to microbial pathogens"", BIOTECHNOLOGY, vol. 10, November 1992 (1992-11-01), pages 1436 - 1445, XP002032892;;MASOUD S ET AL: ""EXPRESSION OF HYDROLASES IN TRANSGENIC ALFALFA PLANTS."", PLANT PHYSIOLOGY SUPPLEMENT, vol. 102, no. 1, May 1993 (1993-05-01), pages 167, XP002032893;;SELA-BUURLAGE, M.B., ET AL.: ""Only specific tobacco (Nicotiana tabacum) chitinases and beta-1,3-glucanases exhibit antifungal activity"", PLANT PHYSIOLOGY, vol. 101, March 1993 (1993-03-01), pages 857 - 863, XP002032894;;VAN DEN ELZEN, P.J.M., ET AL.: ""Virus and fungal resistance: from laboratory to field"", PHIL. TRANS. R. SOC. LOND. B, vol. 342, 1993, pages 271 - 278, XP002032895;;MAHER E A ET AL: ""EXPRESSION OF DEFENSE-RELATED HYDROLASES IN ALFALFA."", SYMPOSIUM ON THE GENETIC DISSECTION OF PLANT CELL PROCESSES HELD AT THE 20TH ANNUAL MEETING OF THE KEYSTONE SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY, KEYSTONE, COLORADO, USA, JANUARY 10-17, 1991. J CELL BIOCHEM SUPPL 0 (15 PART A). 1991. 45., XP002032896;;YOSHIKAWA, M., ET AL.: ""Resistance to fungal diseases in transgenic tobacco plants expressing the phytoalexin elicitor-releasing factor, beta-1,3-endoglucanase fro soybean"", NATURWISSENSCHAFTEN, vol. 80, 1993, pages 417 - 420, XP002032897;;DATABASE WPI Section Ch Week 9252, Derwent World Patents Index; Class C06, AN 92-426642, XP002032899;;MELCHERS, L.S., ET AL.: ""In vitro anti-microbial activities of defense proteins and biotechnology"", DEV. PLANT PATHOL. 2(MECHANISMS OF PLANT DEFENSE RESPONSES). CONFERENCE HELD AUGUST 24-27, 1992, pages 401 - 410, XP002032898;;See also references of WO 9502319A1",DISCONTINUED
885,US,A,US 6031502 A,180-614-131-805-399,2000-02-29,2000,US 75366096 A,1996-11-27,US 75366096 A,1996-11-27,On-orbit reconfigurability of a shaped reflector with feed/reflector defocusing and reflector gimballing,"A system and method for changing the radiation pattern of an antenna assembly of a satellite in orbit is provided. The antenna assembly includes a reflector antenna fed by a feed assembly. The reflector antenna transmits and receives signals within a radiation pattern. The reflector antenna and the feed assembly are movably mounted to a sliding mechanism so that they can be displaced with respect to one another. The displacement causes defocusing as the reflector antenna is displaced from the focus point. The defocusing causes the radiation pattern to become more compact or broadened. Thus, the radiation pattern of the satellite provided with a single reflector antenna and a single feed element may be changed while the satellite is in orbit. The system and method include gimballing the reflector antenna to steer the radiation pattern.",HUGHES ELECTRONICS CORP,RAMANUJAM PARTHASARATHY;;FERMELIA LOUIS R;;DIXON CYNTHIA A;;ESTEVEZ MIGUEL A,HUGHES ELECTRONICS CORPORATION (1997-12-16);;HUGHES ELECTRONICS (1997-02-24),https://lens.org/180-614-131-805-399,Granted Patent,yes,7,26,8,8,0,H01Q3/18;;H01Q3/18;;H01Q1/18;;H01Q1/18;;H01Q1/288;;H01Q1/288;;H01Q3/16;;H01Q3/16;;H01Q3/20;;H01Q3/20;;H01Q15/141;;H01Q15/141,H01Q19/18;;H01Q1/18;;H01Q1/28;;H01Q3/16;;H01Q3/18;;H01Q3/20;;H01Q15/14,343/761;;X343781 P;;343/839,0,0,,,,EXPIRED
886,MX,A,MX 9402222 A,129-501-932-491-836,1995-01-31,1995,MX 9402222 A,1994-03-25,US 3702593 A;;US 21580194 A,1993-03-25,MOLECULAS ANTISENTIDO DIRIGIDAS CONTRA UN GENE TENASCINA.,"La presente invención se refiere a un polinucleótido de menos deaproximadamente 50 bases de ácidos nucléicos en longitud, estepolinucleótido hibridiza al gene tenascina. La presente invención serefiere también a una composición farmacéutica que comprende elpolinucleótido anterior disuelto o disperso en un diluyentefisiológicamente tolerable. La presente invención además se dirige a unproceso para inhibir proliferación de músculo liso vascular, esteprocedimiento comprende inhibir la expresión de tenascina en células demúsculo liso vascular.",TEXAS BIOTECHNOLOGY CORP,DENNER LARRY A;;DIXON RICHARD A F;;STACY DAVID LOWELL;;REGE AJAY A,,https://lens.org/129-501-932-491-836,Patent Application,no,0,0,2,4,0,,C07H/;;C07H19/00;;C12N15/56,,0,0,,,,PENDING
887,WO,A1,WO 1994/021664 A1,138-203-635-042-082,1994-09-29,1994,US 9403206 W,1994-03-24,US 3702593 A,1993-03-25,ANTISENSE MOLECULES DIRECTED AGAINST A TENASCIN GENE,"The present invention is directed to a polynucleotide of less than about 50 nucleic acid bases in length, which polynucleotide hybridizes to the tenascin gene. The present invention is also directed to a pharmaceutical composition comprising the above polynucleotide dissolved or dispersed in a physiologically tolerable diluent. The present invention is further directed to a process for inhibiting vascular smooth muscle cell proliferation which process comprises inhibiting the expression of tenascin in vascular smooth muscle cells.",TEXAS BIOTECHNOLOGY CORP;;DENNER LARRY A;;REGE AJAY A;;DIXON RICHARD A F;;STACY DAVID L,DENNER LARRY A;;REGE AJAY A;;DIXON RICHARD A F;;STACY DAVID L,,https://lens.org/138-203-635-042-082,Patent Application,yes,0,6,2,4,0,C12N15/113;;C07H21/00;;C12N2310/315,C07H21/00;;C12N15/113,,3,3,073-823-820-340-349;;016-006-083-080-390;;048-907-112-707-295,pmc2288827;;10.1083/jcb.112.2.355;;1703162;;1680858;;10.1016/s0021-9258(18)55250-9;;1881900;;10.1073/pnas.88.17.7595;;pmc52348,"JOURNAL OF CELL BIOL., Volume 112, Number 2, issued January 1991, WELLER et al., ""Amino Acid Sequence of Mouse Tenascin and Differential Expression of Two Tenascin Isoforms During Embryogenesis"", pages 355-362.;;JOURNAL OF BIOL. CHEM., Volume 266, Number 27, issued 25 September 1991, CHIANG et al., ""Antisense Oligonucleotides Inhibit Intercellular Adhesion Molecule 1 Expression by Two Distinct Mechanisms"", pages 18162-18171.;;PROC. NATL. ACAD. SCI. USA, Volume 88, issued September 1991, AGRAWAL et al., ""Pharmacokinetics, Biodistribution, and Stability of Oligodeoxynucleotide Phosphorothioates in Mice"", pages 7595-7599.",PENDING
888,AU,A,AU 1994/065242 A,005-220-979-475-115,1994-10-11,1994,AU 1994/065242 A,1994-03-24,US 3702593 A;;US 9403206 W,1993-03-25,Antisense molecules directed against a tenascin gene,,TEXAS BIOTECHNOLOGY CORP,DENNER LARRY A;;REGE AJAY A;;DIXON RICHARD A F;;STACY DAVID L,,https://lens.org/005-220-979-475-115,Patent Application,no,0,0,2,4,0,C12N15/113;;C07H21/00;;C12N2310/315,C07H21/00;;C12N15/113,,0,0,,,,PENDING
889,WO,A1,WO 1994/021666 A1,079-474-708-608-603,1994-09-29,1994,US 9403253 W,1994-03-24,US 3834693 A,1993-03-25,ANTISENSE MOLECULES DIRECTED AGAINST A GENE FOR THE CATALYTIC SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE,"The present invention is directed to a polynucleotide of less than about 50 nucleic acid bases in length, which polynucleotide hybridizes to the gene for the catalytic subunit of phosphatidylinositol 3-kinase. The present invention is also directed to a pharmaceutical composition comprising the above polynucleotide dissolved or dispersed in a physiologically tolerable diluent. The present invention is further directed to a process for inhibiting vascular smooth muscle cell proliferation which process comprises inhibiting the expression of the catalytic subunit of phosphatidylinositol 3-kinase in vascular smooth muscle cells.",TEXAS BIOTECHNOLOGY CORP,DENNER LARRY A;;REGE AJAY A;;DIXON RICHARD A F;;STEPHAN CLIFFORD C,,https://lens.org/079-474-708-608-603,Patent Application,yes,0,0,2,2,0,C12N15/1137;;C07H21/00;;C12N2310/315;;C12Y207/01137,C07H21/00;;C12N15/113,,3,3,015-505-100-135-710;;016-006-083-080-390;;048-907-112-707-295,1322797;;10.1016/0092-8674(92)90166-a;;1680858;;10.1016/s0021-9258(18)55250-9;;1881900;;10.1073/pnas.88.17.7595;;pmc52348,"CELL, Volume 70, issued 07 August 1992, HILES et al., ""Phosphatidylinositol 3-Kinase: Structure and Expression of the 110 kd Catalytic Subunit"", pages 419-429.;;JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 266, Number 27, issued 25 September 1991, CHIANG et al., ""Antisense Oligonucleotides Inhibit Intercellular Adhesion Molecule 1 Expression by Two Distinct Mechanisms"", pages 18162-18171.;;PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Volume 88, issued September 1991, AGRAWAL et al., ""Pharmacokinetics, Biodistribution, and Stability of Oligodeoxynucleotide Phosphorothioates in Mice"", pages 7595-7599.",PENDING
890,AU,A,AU 1994/065521 A,177-019-000-608-534,1994-10-11,1994,AU 1994/065521 A,1994-03-24,US 3834693 A;;US 9403253 W,1993-03-25,Antisense molecules directed against a gene for the catalytic subunit of phosphatidylinositol 3-kinase,,TEXAS BIOTECHNOLOGY CORP,DENNER LARRY A;;REGE AJAY A;;DIXON RICHARD A F;;STEPHAN CLIFFORD C,,https://lens.org/177-019-000-608-534,Patent Application,no,0,0,2,2,0,C12N15/1137;;C07H21/00;;C12N2310/315;;C12Y207/01137,C07H21/00;;C12N15/113,,0,0,,,,PENDING
891,US,A1,US 2014/0262839 A1,019-206-665-521-681,2014-09-18,2014,US 201414212582 A,2014-03-14,US 201414212582 A;;US 201361837632 P;;US 201361837621 P;;US 201361799617 P,2013-03-15,PACKAGES AND PACKAGING KITS WITH DEACTIVATABLE AND ACTIVATABLE LOCKING FEATURES,"A package including an outer sleeve including a first locking structure, a lockable receptacle lockably retained within the outer sleeve for sliding movement between a fully inserted position and an outwardly extended position, the lockable receptacle comprising a second locking structure, and a deactivating component removably associated with the first locking structure of the outer sleeve. When the deactivating component associates with the outer sleeve, the first locking structure is prevented from engaging with the second locking structure of the lockable receptacle such that the lockable receptacle is slidable to the outwardly extended position.",MEADWESTVACO CORP,LE THANHHUNG N;;PATWARDHAN TANUJA A;;DIXON RODNEY D,WESTROCK MWV LLC (2014-04-02),https://lens.org/019-206-665-521-681,Patent Application,yes,6,26,1,1,0,B65D83/0463;;B65D83/0463,B65D55/04;;B65D25/20;;B65D59/04,206/1.5;;220/694;;53/396,0,0,,,,DISCONTINUED
892,US,B1,US 10538749 B1,058-933-047-900-575,2020-01-21,2020,US 201815875071 A,2018-01-19,US 201815875071 A,2018-01-19,Mutant OPAA enzymes with increased catalytic efficiency on cyclosarin,"The invention comprises isolated, mutant, non-wild-type organophosphorus acid anhydrolase (OPAA) enzymes having two site mutations, methods of production, and methods of use to effectively degrade cylcosarin (GF) (cyclohexyl methylphosphonofluoridate) with greater catalytic efficiency than the wild-type OPAA.",U S ARMY EDGEWOOD CHEMICAL BIOLOGICAL CENTER;;US ARMY,HARVEY STEVEN P;;DIXON MELISSA M;;GUELTA MARK A,THE UNITED STATES OF AMERICA (2018-01-17),https://lens.org/058-933-047-900-575,Granted Patent,yes,7,0,1,1,2,A61K38/00;;C12N9/16;;C12Y301/08002;;C12N9/16;;A61K38/00;;C12Y301/08002,C12N9/16;;A61K38/00;;A61K38/46,,1,1,063-998-500-376-328,10.1016/j.enzmictec.2005.04.004,"Harvey et al., Enzyme and Microbial Technology, 37, 547-555, 2005.",ACTIVE
893,TW,A,TW 202120555 A,063-052-637-344-450,2021-06-01,2021,TW 110105132 A,2016-03-04,US 201562128462 P,2015-03-04,Antibody therapeutics that bind CD47,"There is disclosed compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, there is disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.",SORRENTO THERAPEUTICS INC,SWANSON BARBARA A;;GRAY JOHN DIXON;;ZHOU HE-YUE,,https://lens.org/063-052-637-344-450,Patent of Addition,no,0,0,34,34,0,C07K16/2803;;A61P35/00;;A61P35/02;;C07K2317/56;;C07K2317/92;;C07K2317/55;;C07K2317/622;;C07K2317/565;;C07K2317/76;;A61K2039/505;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/92;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;C07K16/2803;;C07K16/30;;A61P35/00;;A61P35/02;;C07K2317/21;;C07K2317/92;;C07K16/2803;;C07K16/30;;C07K2317/56;;C07K2317/567;;C07K2317/565;;C07K2317/92;;C07K2317/90;;C07K2317/76;;C07K2317/21;;C07K2317/56;;C07K2317/567;;C07K2317/90;;C07K16/2803;;C07K16/30;;C07K2317/21;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;A61K39/395;;A61P9/10;;A61P11/00;;A61P19/02;;A61P35/00,,0,0,,,,ACTIVE
894,US,A,US 1458840 A,049-796-499-432-720,1923-06-12,1923,US 53125022 A,1922-01-23,US 53125022 A,1922-01-23,Signal,,MONTGOMERY JOHN N;;MONTGOMERY GEORGE D;;DIXON HERBERT A,MONTGOMERY JOHN N;;MONTGOMERY GEORGE D;;DIXON HERBERT A,,https://lens.org/049-796-499-432-720,Granted Patent,no,0,4,1,1,0,B60Q1/34;;B60Q1/34,B60Q1/34,C3M M133          ML;;C3M M146          ML,0,0,,,,EXPIRED
895,US,A,US 5259010 A,087-097-761-678-132,1993-11-02,1993,US 76758291 A,1991-09-30,US 76758291 A,1991-09-30,Replacement spacer pin with locking keys,"The spacer pin of this invention is preferably threadably secured to a thermal shield normally found within reactor vessels. It comprises a main body having a cavity therein which houses a locking assembly that alternately engages or disengages the threads of the thermal shield as desired. Ideally, as bolt means are is rotated within the main body, locking keys are either moved into engagement with the threads of the thermal shield or the locking keys are removed from such engagement with the thermal shield. In this fashion, the spacer pin may be locked onto or unlocked from the thermal shield as desired. A locking cap prevents the bolt means from coming unthreaded during use and also insures that the spacer pin remains secured to the thermal shield.",B & W NUCLEAR SERVICE,BROWN STEVE K;;DIXON LARRY D;;ORR JOHN A,B&W NUCLEAR SERVICE COMPANY A PARTNERSHIP OF DE (1991-09-25),https://lens.org/087-097-761-678-132,Granted Patent,yes,4,11,1,1,0,G21C11/08;;G21C11/08;;Y02E30/30;;Y02E30/30,G21C11/08,376/446;;376/364,0,0,,,,EXPIRED
896,US,A,US 2876894 A,075-471-735-657-583,1959-03-10,1959,US 52578255 A,1955-08-01,US 52578255 A,1955-08-01,Adhesive tapes and liners having low-adhesion coatings,,MINNESOTA MINING & MFG,DAHLQUIST CARL A;;AHLBRECHT ARTHUR H;;DIXON GEORGE M,,https://lens.org/075-471-735-657-583,Granted Patent,no,5,29,3,3,0,C09J2203/31;;C09J2400/283;;C09J2401/006;;C09J2421/00;;C09J2429/005;;C09J7/201;;C09J7/21;;Y10T428/14;;Y10T428/265;;Y10T428/2857;;Y10T428/2839;;Y10T428/277;;Y10T428/31891;;C09J2301/302;;C09J2301/414;;Y10T428/14;;Y10T428/265;;Y10T428/2857;;Y10T428/2839;;Y10T428/277;;Y10T428/31891;;C09J7/21;;C09J2400/283;;C09J2203/31;;C09J2401/006;;C09J2421/00;;C09J2429/005;;C09J7/201;;C09J2301/302;;C09J2301/414,C09J7/21,,0,0,,,,EXPIRED
897,US,A1,US 2021/0355743 A1,086-737-873-221-395,2021-11-18,2021,US 202117318538 A,2021-05-12,US 202117318538 A;;US 202063025328 P,2020-05-15,DOOR-READY MOLDING,"A door system including a primary door molding attachable to a primary door frame, the primary door molding including a first vertical member and a first hinge member extending from the first vertical member. One of a horizontal member from which the first vertical member downwardly extends and the first vertical member includes a first rotatably engageable element, and the first hinge member includes a second rotatably engageable element vertically spaced from the first rotatably engageable element.",LARSON MFG COMPANY OF SOUTH DAKOTA LLC,DIXON ALAN M;;KONDRATUK MICHAEL W;;RAWDEN JAMMEY A,LARSON MANUFACTURING COMPANY OF SOUTH DAKOTA LLC (2021-06-10),https://lens.org/086-737-873-221-395,Patent Application,yes,19,0,3,4,0,E06B5/003;;E06B2009/527;;E06B3/725;;E06B2003/7074;;E06B2003/7082;;E06B3/325;;E06B3/36;;E06B1/52;;E05Y2900/132;;E06B3/06,E06B1/52;;E06B3/06,,0,0,,,,ACTIVE
898,CA,A,CA 310004 A,092-385-862-633-299,1931-04-07,1931,CA 310004D A,,CA 310004T A,,METHOD OF MAKING SHREDDERS,,DIXON ALBERT HERBERT;;ROBSON THOMAS SIMPSON;;HENSCHELL FERDINAND A,DIXON ALBERT HERBERT;;HENSCHELL FERDINAND A;;ROBSON THOMAS SIMPSON,,https://lens.org/092-385-862-633-299,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
899,GB,B,GB 2512478 B,127-026-421-179-370,2017-08-30,2017,GB 201402964 A,2014-02-20,US 201313844729 A,2013-03-15,"Processors, methods, and systems to relax synchronization of accesses to shared memory",,INTEL CORP,MARTIN G DIXON;;WILLIAM C RASH;;YASMIN A SANTIAGO,,https://lens.org/127-026-421-179-370,Granted Patent,no,2,0,20,20,0,G06F9/06;;G06F9/30087;;G06F9/30087;;G06F9/30087;;G06F12/0804;;G06F9/30087;;G06F9/38;;G06F9/522;;G06F12/0804;;G06F12/0804;;G06F12/0804;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/14;;G06F12/14;;G06F2212/1052;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G11C7/1072;;Y02D10/00;;Y02D10/00;;Y02D10/00,G06F9/30;;G06F9/38;;G06F9/52;;G06F12/0804;;G06F12/0815;;G06F12/0862,,1,1,016-937-283-180-041,10.1145/605398.605400,"""Speculative Synchronization: Applying Thread-Level Speculation to Explicitly Parallel Applications""; Martínez & Torellas; Proceedings of the 10th International Conference on Architectural Support for Programming Languages and Operating Systems; Pages 18-29; October 2002",INACTIVE
900,US,A1,US 2005/0251420 A1,115-580-248-158-762,2005-11-10,2005,US 8790005 A,2005-03-23,US 8790005 A;;US 55574904 P,2004-03-23,System and method for managing an office,"A system and method for managing an office involve an integrated website on a remote server computer. The website is accessed remotely by a user using conventional computer hardware. All office management software and graphic user interfaces are stored on the server computer, which is connected to the user's hardware using a web browser. All office management functions are performed at the server computer at the user's direction. The web site provides a completely integrated office management capability, with user information stored securely at the server computer. Communications between the server computer and the user, as well as data storage, are encrypted to meet or exceed federal medical privacy standards.",TURBOOFFICE COM INC,DIXON ROBERT A;;LIST ETHAN F;;SMITH ROBERT Q,TURBOOFFICE.COM INC (2005-03-23),https://lens.org/115-580-248-158-762,Patent Application,yes,8,8,1,1,0,G06Q10/10;;G16H40/20;;G06Q10/10;;G16H40/20,G06Q10/00;;G16H40/20,705/2,0,0,,,,DISCONTINUED
901,US,B2,US 10073513 B2,146-533-481-583-792,2018-09-11,2018,US 201615133688 A,2016-04-20,US 201615133688 A;;US 201313930044 A,2013-06-28,Protected power management mode in a processor,"In an embodiment, a processor includes a plurality of cores. Each core includes a core power unit to detect one or more power management events, and in response to the one or more power management events, initiate a protected power management mode in the core. Software interrupts to the core may be disabled during the protected power management mode. The core is to execute power management code during the protected power management mode. Other embodiments are described and claimed.",INTEL CORP,RASH WILLIAM C;;DIXON MARTIN G;;SANTIAGO YAZMIN A,,https://lens.org/146-533-481-583-792,Granted Patent,yes,15,1,6,6,0,G06F1/3203;;G06F1/3234;;G06F9/30083;;G06F9/30101;;G06F9/30189;;G06F9/30083;;G06F9/30101;;G06F9/30189;;G06F1/3203;;G06F1/3234;;G06F1/26;;G06F1/3206;;G06F1/3246;;G06F1/3275;;G06F1/3287,G06F1/32;;G06F1/26;;G06F9/30,,1,0,,,"European Patent Office, European Search Report on European Patent Application No. EP14174594, dated Dec. 2, 2014, in European Patent Application No. 14174594.3.",ACTIVE
902,US,A1,US 2020/0026051 A1,174-203-388-526-869,2020-01-23,2020,US 201916514158 A,2019-07-17,US 201916514158 A;;US 201862699448 P,2018-07-17,SCANNING MICROSCOPE USING PULSED ILLUMINATION AND MSIA,"According to one aspect, an instrument for scanning a specimen. The instrument includes a scanning stage for supporting the specimen, a detector having a plurality of pixels, the scanning stage and the detector movable relative to each other to move the specimen in a scan direction during a scan, and a pulsed illumination source synchronized with the motion of the specimen on the scanning stage. At least some of the pixels of the detector are operable to collect light emitted from the specimen during the scan due to the pulsed illumination source and generate corresponding image data. The instrument may further include a processor operable to perform MSIA on the image data to generate an image of the specimen.",DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER,DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER,HURON TECHNOLOGIES INTERNATIONAL INC (2019-08-10),https://lens.org/174-203-388-526-869,Patent Application,yes,2,8,6,6,0,G02B21/002;;G02B21/12;;G02B21/16;;G02B21/367;;G02B5/201;;G01N21/6458;;H04N23/60;;H04N23/74;;H04N25/711;;H04N23/125;;H04N23/10;;G02B21/0084;;G02B21/0036;;G02B21/0032;;G02B21/0076;;H04N23/73;;H04N23/84;;H04N25/13,G02B21/00;;H04N5/235;;H04N9/04,,0,0,,,,ACTIVE
903,TW,A,TW 200417812 A,181-630-551-006-231,2004-09-16,2004,TW 92123435 A,2003-08-26,US 38868803 A,2003-03-14,Adaptive image display,"A display system(40) may include an identifier(64) configured to identify an image display condition associated with the display of an image produced by the display system(40), an apparatus(46) configured to produce a plurality of differently colored images, and a display device(48). The images have color characteristics based on image information(62) and the identified display condition. Differently colored images may be directed along associated portions of an optical path(56). The display device(48) may be coupled to the apparatus (46) and may be configured to display a color image formed of the differently colored images.",HEWLETT PACKARD DEVELOPMENT CO,PATE MICHAEL A;;ALLEN WILLIAM J;;DIXON BRIAN S,,https://lens.org/181-630-551-006-231,Patent of Addition,no,0,2,6,6,0,G02B26/008;;H04N9/3114;;H04N9/3155;;H04N9/3182;;H04N9/73;;H04N9/73;;H04N9/3155;;G02B26/008;;H04N9/3182;;H04N9/3114,H04N9/31;;H04N9/73,,0,0,,,,EXPIRED
904,EP,A4,EP 3273786 A4,188-963-387-530-17X,2018-12-19,2018,EP 16769494 A,2016-03-21,US 201562138002 P;;US 2016/0023419 W,2015-03-25,VERTICAL ELECTRIC COOKER AND SMOKER AND SMOKE BOX,,BRADLEY W C CO,DIXON WILLIAM A;;ABDALLAH SLEIMAN ASSAAD;;MCQUAGG MARK STEPHEN,W.C. BRADLEY CO. (2020-02-19),https://lens.org/188-963-387-530-17X,Search Report,no,4,0,12,12,0,A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;Y02A40/90;;A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;A23V2002/00,A23B4/044;;A23B4/052;;A23B4/056;;A47J37/06;;A47J37/07,,1,0,,,See also references of WO 2016154114A1,ACTIVE
905,US,A1,US 2016/0216967 A1,196-152-815-488-379,2016-07-28,2016,US 201615089883 A,2016-04-04,US 201615089883 A;;US 201313844729 A,2013-03-15,"PROCESSORS, METHODS, AND SYSTEMS TO RELAX SYNCHRONIZATION OF ACCESSES TO SHARED MEMORY",A processor of an aspect includes a plurality of logical processors. A first logical processor of the plurality is to execute software that includes a memory access synchronization instruction that is to synchronize accesses to a memory. The processor also includes memory access synchronization relaxation logic that is to prevent the memory access synchronization instruction from synchronizing accesses to the memory when the processor is in a relaxed memory access synchronization mode.,INTEL CORP,DIXON MARTIN G;;RASH WILLIAM C;;SANTIAGO YAZMIN A,,https://lens.org/196-152-815-488-379,Patent Application,yes,0,2,20,20,0,G06F9/06;;G06F9/30087;;G06F9/30087;;G06F9/30087;;G06F12/0804;;G06F9/30087;;G06F9/38;;G06F9/522;;G06F12/0804;;G06F12/0804;;G06F12/0804;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/14;;G06F12/14;;G06F2212/1052;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G11C7/1072;;Y02D10/00;;Y02D10/00;;Y02D10/00,G06F9/30;;G06F12/14;;G11C7/10,,0,0,,,,ACTIVE
906,US,A1,US 2015/0006917 A1,000-654-510-524-326,2015-01-01,2015,US 201313930044 A,2013-06-28,US 201313930044 A,2013-06-28,Protected Power Management Mode In A Processor,"In an embodiment, a processor includes a plurality of cores. Each core includes a core power unit to detect one or more power management events, and in response to the one or more power management events, initiate a protected power management mode in the core. Software interrupts to the core may be disabled during the protected power management mode. The core is to execute power management code during the protected power management mode. Other embodiments are described and claimed.",RASH WILLIAM C;;DIXON MARTIN G;;SANTIAGO YAZMIN A,RASH WILLIAM C;;DIXON MARTIN G;;SANTIAGO YAZMIN A,INTEL CORPORATION (2013-06-03),https://lens.org/000-654-510-524-326,Patent Application,yes,13,3,6,6,0,G06F1/3203;;G06F1/3234;;G06F9/30083;;G06F9/30101;;G06F9/30189;;G06F9/30083;;G06F9/30101;;G06F9/30189;;G06F1/3203;;G06F1/3234;;G06F1/26;;G06F1/3206;;G06F1/3246;;G06F1/3275;;G06F1/3287,G06F1/26,713/300,0,0,,,,INACTIVE
907,TW,A,TW 200418317 A,013-901-966-691-218,2004-09-16,2004,TW 92125252 A,2003-09-12,US 38872003 A,2003-03-14,Display image generation with differential illumination,"A method of producing a display image (154) comprises receiving image information (112) representing an image to be displayed, producing an image formed of a plurality of images of different colors, and projecting the produced image along an optical path (141). The differently colored images have color intensities related to energy applied to a light source (52). A level (310) of energy is applied to the light source (52) during production of the image of one color that is different than the level (304, 306, 308) of energy applied to the light source (52) during production of the image of another color.",HEWLETT PACKARD DEVELOPMENT CO,PATE MICHAEL A;;ALLEN WILLIAM J;;DIXON BRIAN S,,https://lens.org/013-901-966-691-218,Patent of Addition,no,0,0,5,5,0,G02B26/008;;H04N9/3114;;H04N9/3155;;H04N9/3182;;H04N9/73;;H04N9/3114;;H04N9/3155;;H04N9/3182;;H04N9/73;;G02B26/008,H04N1/60;;H04N9/31;;H04N9/73,,0,0,,,,EXPIRED
908,EP,A3,EP 1465437 A3,031-046-462-226-88X,2007-07-25,2007,EP 03255752 A,2003-09-15,US 38868803 A,2003-03-14,Adaptive image display,"A display system (40) may include an identifier (64) configured to identify an image display condition associated with the display of an image produced by the display system (40), an apparatus (46) configured to produce a plurality of differently colored images, and a display device (48). The images have color characteristics based on image information (62) and the identified display condition. Differently colored images may be directed along associated portions of an optical path (56). The display device (48) may be coupled to the apparatus (46) and may be configured to display a color image formed of the differently colored images.
",HEWLETT PACKARD DEVELOPMENT CO,PATE MICHAEL A;;ALLEN WILLIAM J;;DIXON BRIAN S,,https://lens.org/031-046-462-226-88X,Search Report,yes,6,0,6,6,0,G02B26/008;;H04N9/3114;;H04N9/3155;;H04N9/3182;;H04N9/73;;H04N9/73;;H04N9/3155;;G02B26/008;;H04N9/3182;;H04N9/3114,H04N9/73;;H04N9/31,,0,0,,,,DISCONTINUED
909,CA,A,CA 522807 A,034-950-926-314-218,1956-03-20,1956,CA 522807D A,,CA 522807T A,,ISOMERIC POLYBROMOPYRAZINES AND PREPARATION THEREOF,,DIXON JAMES K;;MILLER ALEXANDER A;;BRUESCH JOHN F,MILLER ALEXANDER A;;DIXON JAMES K;;BRUESCH JOHN F,,https://lens.org/034-950-926-314-218,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
910,US,B2,US 9354681 B2,067-885-146-056-94X,2016-05-31,2016,US 201313930044 A,2013-06-28,US 201313930044 A,2013-06-28,Protected power management mode in a processor,"In an embodiment, a processor includes a plurality of cores. Each core includes a core power unit to detect one or more power management events, and in response to the one or more power management events, initiate a protected power management mode in the core. Software interrupts to the core may be disabled during the protected power management mode. The core is to execute power management code during the protected power management mode. Other embodiments are described and claimed.",INTEL CORP,RASH WILLIAM C;;DIXON MARTIN G;;SANTIAGO YAZMIN A,INTEL CORPORATION (2013-06-03),https://lens.org/067-885-146-056-94X,Granted Patent,yes,14,2,6,6,0,G06F1/3203;;G06F1/3234;;G06F9/30083;;G06F9/30101;;G06F9/30189;;G06F9/30083;;G06F9/30101;;G06F9/30189;;G06F1/3203;;G06F1/3234;;G06F1/26;;G06F1/3206;;G06F1/3246;;G06F1/3275;;G06F1/3287,G06F1/26;;G06F1/32;;G06F9/30,,1,0,,,"European Patent Office, European Search Report on European Patent Application No. EP14174594, mailed Dec. 2, 2014, in European Patent Application No. 14174594.3.",INACTIVE
911,TW,A,TW 201510861 A,056-913-958-883-824,2015-03-16,2015,TW 103121587 A,2014-06-23,US 201313931544 A,2013-06-28,"Instruction order enforcement pairs of instructions, processors, methods, and systems","A processor of an aspect includes an instruction fetch unit to fetch a pair of instruction order enforcement instructions. The pair of instruction order enforcement instructions are part of an instruction set of the processor. The pair of instruction order enforcement instructions includes an activation instruction and an enforcement instruction. The activation instruction is to occur before the enforcement instruction in a program order. The processor also includes an instruction order enforcement module. The instruction order enforcement module, in response to the pair of the instruction order enforcement instructions, is to prevent instructions occurring after the enforcement instruction in the program order, from being processed prior to the activation instruction, in an out-of-order portion of the processor. Other processors are also disclosed, as are various methods, systems, and instructions.",INTEL CORP,DIXON MARTIN G;;RASH WILLIAM C;;SANTIAGO YAZMIN A,,https://lens.org/056-913-958-883-824,Patent of Addition,no,0,4,16,16,0,G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/3891;;G06F9/3856;;G06F9/3836;;G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3856,G06F9/30;;G06F9/38,,0,0,,,,INACTIVE
912,CA,A,CA 1110367 A,070-311-002-738-218,1981-10-06,1981,CA 296524 A,1978-02-09,US 77332077 A,1977-03-01,CURRENT CONFINEMENT IN SEMICONDUCTOR DEVICES,"CURRENT CONFINEMENT IN SEMICONDUCTOR DEVICES Abstract of the Disclosure Current confinement in semiconductor device by means of buried high resistivity zones is described. For example, in a stripe geometry, semiconductor, junction laser the laterally separate, high resistivity zones, which confine current flow in a narrow channel between the upper and lower electrical contacts, are buried below the upper contact. This configuration permits current to flow from the upper contact into the body of the semiconductor over greatly increased area before it enters the channel. The current density at the interface between the upper contact and the semiconductor body is thereby reduced, making the quality of that interface less important. Several processes which employ proton bombard-ment for fabricating the laser are also described: (1) in one the normal sequence of Zn diffusion and proton bombardment is reversed, and (2) in the other the profiles of Zn doping and proton damage are suitably tailored. - i -",WESTERN ELECTRIC CO,DIXON RICHARD W;;KOSZI LOUIS A;;NASH FRANKLIN R,,https://lens.org/070-311-002-738-218,Granted Patent,no,0,0,5,5,0,H01L33/145;;H01S5/20;;H01S5/2059;;Y10S257/915;;H01S5/20;;H01S5/2059;;H01L33/145;;Y10S257/915,H01L33/14;;H01S5/00;;H01S5/042;;H01S5/20,356-147,0,0,,,,EXPIRED
913,EP,B1,EP 3014424 B1,064-910-224-843-520,2019-11-27,2019,EP 14818771 A,2014-06-12,US 201313931544 A;;US 2014/0042153 W,2013-06-28,"INSTRUCTION ORDER ENFORCEMENT PAIRS OF INSTRUCTIONS, PROCESSORS, METHODS, AND SYSTEMS",,INTEL CORP,DIXON MARTIN G;;RASH WILLIAM C;;SANTIAGO YAZMIN A,,https://lens.org/064-910-224-843-520,Granted Patent,yes,7,0,16,16,0,G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/3891;;G06F9/3856;;G06F9/3836;;G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3856,G06F9/38,,0,0,,,,ACTIVE
914,WO,A1,WO 2001/023847 A1,133-837-703-888-470,2001-04-05,2001,US 0026406 W,2000-09-26,US 15658199 P,1999-09-29,LOAD CELL APPARATUS,"A load cell apparatus (100) includes a cell block (70) adapted to couple to a first structure, and a mount (82) adapted to couple to a second structure. The mount (82) is made of a first material and is formed to include a bore (140). The apparatus (100) also includes a stud (78) extending from the cell block (70), and a liner (142) positioned to lie in the bore (140). The stud (78) engages the liner (142). The liner (142) is made of a second material that is more lubrous than the first material.",HILL ROM CO INC,MOBLEY DONALD L;;DIXON STEVE A;;HOPKINS RANDALL K,,https://lens.org/133-837-703-888-470,Patent Application,yes,5,14,9,10,0,G01G19/445,A61B5/11;;A61G7/05;;G01G19/52;;G01G19/44;;G01L1/22,,0,0,,,,PENDING
915,US,B2,US 7460179 B2,147-116-065-636-866,2008-12-02,2008,US 38868803 A,2003-03-14,US 38868803 A;;US 6264402 A;;US 10339402 A,2002-01-31,Adaptive image display,"A display system may include an identifier configured to identify an image display condition associated with the display of an image produced by the display system, an apparatus configured to produce a plurality of differently colored images, and a display device. The images have color characteristics based on image information and the identified display condition. Differently colored images may be directed along associated portions of an optical path. The display device may be coupled to the apparatus and may be configured to display a color image formed of the differently colored images.",HEWLETT PACKARD DEVELOPMENT CO,PATE MICHAEL A;;ALLEN WILLIAM J;;DIXON BRIAN S,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2003-05-22),https://lens.org/147-116-065-636-866,Granted Patent,yes,49,36,6,6,0,G02B26/008;;H04N9/3114;;H04N9/3155;;H04N9/3182;;H04N9/73;;H04N9/73;;H04N9/3155;;G02B26/008;;H04N9/3182;;H04N9/3114,H04N5/57;;H04N17/00;;H04N5/58;;H04N5/64;;H04N9/12;;H04N9/31;;H04N9/73;;H04N17/02,348/602;;348/603;;348/742;;348/657;;348/744;;348/177;;348/191;;348/189,1,0,,,"European Search Report for Application No. EP 03 25 5752. Report issued Mar. 1, 2007.",EXPIRED
916,AU,B2,AU 511749 B2,007-153-525-979-082,1980-09-04,1980,AU 1978/032207 A,1977-01-07,AU PC869277 A,1977-01-07,GRAFT COPOLYMERS,,ICI AUSTRALIA LTD,BOLTO B A;;ELDRIDGE R J;;DIXON D R,,https://lens.org/007-153-525-979-082,Granted Patent,no,0,3,10,10,0,B01J20/28009;;B01J20/3293;;C02F1/288;;C02F1/488;;C02F1/54;;C08F261/04;;C08F265/10;;C08F291/00;;C08F292/00;;C09C1/22;;C09C1/24;;G11B5/7027;;H01F1/113;;H01F1/37;;H01F1/42;;B01J39/17;;B01J47/016;;B01J47/018;;B01J49/45;;C01P2004/61;;C01P2006/42;;H01F1/42;;B01J20/3293;;H01F1/37;;B01J20/28009;;H01F1/113;;C09C1/22;;G11B5/7027;;C08F261/04;;C02F1/488;;C08F265/10;;C02F1/288;;C02F1/54;;C08F291/00;;C08F292/00;;C09C1/24;;B01J47/016;;B01J39/17;;B01J49/45;;B01J47/018,C08F2/00;;B01J39/16;;B01J39/17;;B01J41/08;;B01J41/14;;B01J47/00;;B01J47/016;;B01J47/018;;B01J49/00;;B01J49/45;;C02F1/28;;C02F1/48;;C02F1/54;;C08F2/44;;C08F4/00;;C08F4/40;;C08F261/04;;C08F265/10;;C08F291/00;;C08F292/00;;C08J5/20;;C08K3/22;;C09C1/22;;C09C1/24;;G11B5/702;;H01F1/113;;H01F1/37;;H01F1/42,,0,0,,,,EXPIRED
917,CA,A1,CA 2977120 A1,003-506-760-975-669,2016-09-29,2016,CA 2977120 A,2016-03-21,US 201562138002 P;;US 2016/0023419 W,2015-03-25,VERTICAL ELECTRIC COOKER AND SMOKER AND SMOKE BOX,"A vertical electric cooker and smoker having lower air intake vents and upper exhaust vents which together create a more balanced flow and distribution of smoke and reduce the operating pressure of the system to allow a much larger load of wood chips to be used without refilling. A smoke box is also provided for holding and properly combusting the larger quantity of wood chips in an oxygen deficient environment. The smoke box has a false bottom and discharges the smoke through a circuitous exhaust flow path. Also, the electric heating elements of the cooking and smoking apparatus are contained in an assembly which provides an air gap beneath the smoker box and also shields the smoker box to prevent the wood chips in the smoker box from becoming overheated.",BRADLEY W C CO,DIXON WILLIAM A;;ABDALLAH SLEIMAN ASSAAD;;MCQUAGG MARK STEPHEN,,https://lens.org/003-506-760-975-669,Patent Application,no,0,0,12,12,0,A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;Y02A40/90;;A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;A23V2002/00,A23B4/044;;A23B4/052;;A23B4/056;;A47J37/06;;A47J37/07,,0,0,,,,PENDING
918,US,A,US 4726275 A,031-286-672-674-907,1988-02-23,1988,US 3140087 A,1987-03-27,GB 8312842 A;;GB 8329585 A;;GB 8404247 A;;GB 8405436 A;;GB 8519204 A,1983-05-10,Electronic musical instrument,"A guitar-like electronic musical instrument for use with a synthesizer has six pitch strings on the neck which the player depresses onto conductive frets to determine the selected semitone. A transducer senses if the player forces the string laterally on the fret and if the string is so laterally forced (bent) beyond a threshold, further pitch detection is inhibited. The fret construction can be much simplified and there is no danger of spurious notes being caused by contact with adjacent strings.",SYNTHAXE LTD,AITKEN WILLIAM A;;SEDIVY ANTHONY J;;DIXON MICHAEL S,,https://lens.org/031-286-672-674-907,Granted Patent,yes,9,12,1,22,0,G10H1/342;;G10H1/342;;G10H2210/225;;G10H2210/225;;G10H2220/171;;G10H2220/171;;G10H2220/521;;G10H2220/521;;G10H2230/101;;G10H2230/101;;G10H2230/115;;G10H2230/115;;G10H2230/151;;G10H2230/151,G10H1/34,84/1.15;;84/1.16,0,0,,,,EXPIRED
919,GB,B,GB 2548511 B,009-345-040-812-232,2018-01-17,2018,GB 201709375 A,2014-02-20,US 201313844729 A;;GB 201402964 A,2013-03-15,"Processors, methods, and systems to relax synchronization of accesses to shared memory",,INTEL CORP,MARTIN G DIXON;;WILLIAM C RASH;;YASMIN A SANTIAGO,,https://lens.org/009-345-040-812-232,Granted Patent,no,2,0,20,20,0,G06F9/06;;G06F9/30087;;G06F9/30087;;G06F9/30087;;G06F12/0804;;G06F9/30087;;G06F9/38;;G06F9/522;;G06F12/0804;;G06F12/0804;;G06F12/0804;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/14;;G06F12/14;;G06F2212/1052;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G11C7/1072;;Y02D10/00;;Y02D10/00;;Y02D10/00,G06F9/30;;G06F9/38;;G06F9/52;;G06F12/0804;;G06F12/0815;;G06F12/0862,,0,0,,,,INACTIVE
920,KR,A,KR 20150139931 A,027-206-874-677-500,2015-12-14,2015,KR 20157031766 A,2014-06-19,US 201313931070 A;;US 2014/0043159 W,2013-06-28,"MODE DEPENDENT PARTIAL WIDTH LOAD TO WIDER REGISTER PROCESSORS, METHODS, AND SYSTEMS","양태의 발명은 프로세서에 의해 수행된다. 방법은 부분 폭 로드 명령어를 수신하는 것을 포함한다. 부분 폭 로드 명령어는 메모리의 메모리 위치를 소스 피연산자로서 표시하고, 레지스터를 목적지 피연산자로서 표시한다. 방법은 부분 폭 로드 명령어에 응답하여 표시된 메모리 위치로부터의 데이터를 프로세서에 로딩하는 것을 포함한다. 방법은 부분 폭 로드 명령어에 응답하여 로드된 데이터의 적어도 일부를 레지스터의 부분 폭에 기입하는 것을 포함한다. 방법은 프로세서의 부분 폭 로드 모드에 의존하는 비트 값들을 갖는 레지스터의 나머지 폭 내에 저장된 비트들의 세트를 갖는 레지스터를 기입하는 것을 종료하는 것을 포함한다. 부분 폭 로드 명령어는 부분 폭 로드 모드를 표시하지 않는다. 다른 방법들, 프로세서들 및 시스템들이 또한 개시된다.",INTEL CORP,RASH WILLIAM C;;SANTIAGO YAZMIN A;;DIXON MARTIN GUY,,https://lens.org/027-206-874-677-500,Patent Application,no,0,0,17,17,0,G06F9/30043;;G06F9/30189;;G06F9/3836;;G06F9/3836;;G06F9/30145;;G06F9/30189;;G06F9/30;;G06F9/30043;;G06F9/30145;;G06F9/30189;;G06F9/30043;;G06F9/3836,,,0,0,,,,ACTIVE
921,EP,B8,EP 3273786 B8,029-166-999-961-643,2020-03-04,2020,EP 16769494 A,2016-03-21,US 201562138002 P;;US 2016/0023419 W,2015-03-25,VERTICAL ELECTRIC COOKER AND SMOKER WITH SMOKE BOX,,BRADLEY W C CO,DIXON WILLIAM A;;ABDALLAH SLEIMAN ASSAAD;;MCQUAGG MARK STEPHEN,W.C. BRADLEY CO. (2020-02-19),https://lens.org/029-166-999-961-643,Amended Patent,yes,8,0,12,12,0,A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;Y02A40/90;;A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;A23V2002/00,A23B4/048;;A23B4/044;;A23B4/052;;A23B4/056;;A47J37/06;;A47J37/07,,0,0,,,,ACTIVE
922,EP,A1,EP 3014422 A1,039-411-994-762-601,2016-05-04,2016,EP 14816582 A,2014-06-19,US 201313931070 A;;US 2014/0043159 W,2013-06-28,"MODE DEPENDENT PARTIAL WIDTH LOAD TO WIDER REGISTER PROCESSORS, METHODS, AND SYSTEMS",,INTEL CORP,RASH WILLIAM C;;SANTIAGO YAZMIN A;;DIXON MARTIN GUY,,https://lens.org/039-411-994-762-601,Patent Application,yes,0,0,17,17,0,G06F9/30043;;G06F9/30189;;G06F9/3836;;G06F9/3836;;G06F9/30145;;G06F9/30189;;G06F9/30;;G06F9/30043;;G06F9/30145;;G06F9/30189;;G06F9/30043;;G06F9/3836,G06F9/312,,0,0,,,,ACTIVE
923,US,B1,US 8762909 B1,064-414-115-975-492,2014-06-24,2014,US 201313796078 A,2013-03-12,US 201313796078 A,2013-03-12,System and method for automatic timing-based register placement and register location adjustment in an integrated circuit (IC),"An embodiment of a method for register placement in an integrated circuit (IC) includes determining a data path between circuit elements, placing at least one register along the data path, performing a static timing analysis on the data path, extracting top-level timing data to develop an extended timing path, the extended timing path comprising a plurality of timing path segments; processing the top-level timing data to determine whether the extended timing path violates a timing requirement, and moving the at least one register along the data path to satisfy the timing requirement if the timing requirement is violated.",AVAGO TECHNOLOGIES GENERAL IP,KOENIG BRADY A;;DIXON STEPHEN L;;GENTRY JASON TODD,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2013-03-12);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2023-02-02);;BROADCOM INTERNATIONAL PTE. LTD (2020-08-26),https://lens.org/064-414-115-975-492,Granted Patent,yes,13,2,1,1,0,G06F30/3312;;G06F30/392;;G06F2119/12;;G06F30/392;;G06F30/3312;;G06F2119/12;;G06F30/3315,G06F17/50,716/108,0,0,,,,ACTIVE
924,US,A,US 6158771 A,049-980-771-095-55X,2000-12-12,2000,US 17825598 A,1998-10-23,US 17825598 A,1998-10-23,Honeycomb crash pad,A crash pad for use in vehicle interiors. The crash pad includes an energy-absorbing honeycomb which has a cover plate attached thereon to prevent noise from being generated due to contact between the crash pad and vehicle interior surface during normal vehicle operation. The cover plate is attached on one side to the honeycomb with the other side being molded to match the shape of the interior surface of the vehicle. The cover plate includes positioning devices which locate and hold the crash pad during interior panel fabrication. The cover plate protects the honeycomb and the technician during handling and installation. The cover plate also helps to retain the shape of the honeycomb and provides a suitable surface for labels that may contain product identification and other information needed during use of the pads in mass production of vehicles.,HEXCEL CORP,NUSSER LORI A;;DIXON G DOUGLASS;;HULL H ROBERT,HEXCEL CORPORATION (1998-11-02),https://lens.org/049-980-771-095-55X,Granted Patent,yes,26,40,5,5,0,B60R21/04;;B60R21/04;;B60R13/0225;;B60R13/0225;;B60R2021/0421;;B60R2021/0421;;F16F7/121;;F16F7/121,B60R13/02;;B60R21/04;;F16F7/12,280/752;;296/189,0,0,,,,EXPIRED
925,JP,A,JP 2016207231 A,069-896-842-498-895,2016-12-08,2016,JP 2016175660 A,2016-09-08,US 201313844873 A,2013-03-16,"INSTRUCTION EMULATION PROCESSORS, METHODS AND SYSTEMS",PROBLEM TO BE SOLVED: To provide a processor that includes decode logic to receive a first instruction and to determine that the first instruction is to be emulated.SOLUTION: The processor includes emulation mode aware post-decode instruction processor logic coupled with the decode logic. The emulation mode aware post-decode instruction processor logic is to process one or more control signals decoded from an instruction. The instruction is one of a set of one or more instructions used to emulate the first instruction. The one or more control signals are to be processed differently by the emulation mode aware post-decode instruction processor logic when in an emulation mode than when not in the emulation mode.SELECTED DRAWING: Figure 1,INTEL CORP,WILLIAM C RASH;;DIXON MARTIN G;;YAZMIN A SANTIAGO,,https://lens.org/069-896-842-498-895,Patent Application,no,3,0,14,14,0,G06F9/3017;;G06F9/30189;;G06F9/382;;G06F9/455;;G06F9/3017;;G06F9/30189;;G06F9/382;;G06F9/30174;;G06F9/3017;;G06F9/3017;;G06F9/30189;;G06F9/382;;G06F9/455,G06F9/30;;G06F9/455,,2,0,,,"邑中 雅樹: ""「第１章 組込みにおける仮想化」"", 組込みプレス, vol. 第17巻, JPN6017040870, 10 December 2009 (2009-12-10), JP, pages 2 - 12, ISSN: 0003668301;;インテル株式会社, インテル・アーキテクチャ・ソフトウェア・ディベロッパーズ・マニュアル 下巻：システム・プログラミング, JPN6017040872, 1997, JP, pages 5 - 27, ISSN: 0003668302",INACTIVE
926,US,A1,US 2003/0231260 A1,093-394-279-936-779,2003-12-18,2003,US 38872003 A,2003-03-14,US 38872003 A;;US 6264402 A;;US 10339402 A,2002-01-31,Display image generation with differential illumination,"
   A method of producing a display image comprises receiving image information representing an image to be displayed, producing an image formed of a plurality of images of different colors, and projecting the produced image along an optical path. The differently colored images have color intensities related to energy applied to a light source. A level of energy is applied to the light source during production of the image of one color that is different than the level of energy applied to the light source during production of the image of another color. 
",PATE MICHAEL A.;;ALLEN WILLIAM J.;;DIXON BRIAN S.,PATE MICHAEL A;;ALLEN WILLIAM J;;DIXON BRIAN S,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2003-07-17),https://lens.org/093-394-279-936-779,Patent Application,yes,42,46,5,5,0,G02B26/008;;H04N9/3114;;H04N9/3155;;H04N9/3182;;H04N9/73;;H04N9/3114;;H04N9/3155;;H04N9/3182;;H04N9/73;;G02B26/008,H04N1/60;;H04N9/31;;H04N9/73,348/744;;348/602,0,0,,,,EXPIRED
927,KR,A,KR 20140113585 A,099-475-784-684-333,2014-09-24,2014,KR 20140031017 A,2014-03-17,US 201313844873 A,2013-03-16,"INSTRUCTION EMULATION PROCESSORS, METHODS, AND SYSTEMS",A processor of an aspect includes decode logic to receive a first instruction and determine whether the first instruction is to be emulated. The processor also includes instruction processor logic after emulation mode awareness decode which is connected with the decode logic. The instruction processor logic after emulation mode awareness decode processes one or more control signals decoded from an instruction. The instruction is one of one or more instructions in a set used to emulate the first instruction. The one or more control signals are processed differently by the instruction processor logic after emulation mode awareness decode by distinguishing the cases that the one or more control signals are in an emulation mode and not in the emulation mode. Other apparatus are also disclosed as well as methods and systems.,INTEL CORP,RASH WILLIAM C;;DIXON MARTIN G;;SANTIAGO YAZMIN A,,https://lens.org/099-475-784-684-333,Patent Application,no,0,0,14,14,0,G06F9/3017;;G06F9/30189;;G06F9/382;;G06F9/455;;G06F9/3017;;G06F9/30189;;G06F9/382;;G06F9/30174;;G06F9/3017;;G06F9/3017;;G06F9/30189;;G06F9/382;;G06F9/455,G06F9/455,,0,0,,,,ACTIVE
928,EP,A1,EP 1123226 A1,104-685-926-047-423,2001-08-16,2001,EP 99955056 A,1999-10-20,US 9924463 W;;US 17825598 A,1998-10-23,HONEYCOMB CRASH PAD,,HEXCEL CORP,NUSSER LORI A;;DIXON G DOUGLAS;;HULL H ROBERT,,https://lens.org/104-685-926-047-423,Patent Application,yes,0,1,5,5,0,B60R21/04;;B60R21/04;;B60R13/0225;;B60R13/0225;;B60R2021/0421;;B60R2021/0421;;F16F7/121;;F16F7/121,B60R13/02;;B60R21/04;;F16F7/12,,0,0,,,,DISCONTINUED
929,US,A1,US 2015/0006856 A1,120-236-322-371-851,2015-01-01,2015,US 201313931070 A,2013-06-28,US 201313931070 A,2013-06-28,"MODE DEPENDENT PARTIAL WIDTH LOAD TO WIDER REGISTER PROCESSORS, METHODS, AND SYSTEMS","A method of an aspect is performed by a processor. The method includes receiving a partial width load instruction. The partial width load instruction indicates a memory location of a memory as a source operand and indicates a register as a destination operand. The method includes loading data from the indicated memory location to the processor in response to the partial width load instruction. The method includes writing at least a portion of the loaded data to a partial width of the register in response to the partial width load instruction. The method includes finishing writing the register with a set of bits stored in a remaining width of the register that have bit values that depend on a partial width load mode of the processor. The partial width load instruction does not indicate the partial width load mode. Other methods, processors, and systems are also disclosed.",INTEL CORP,RASH WILLIAM C;;SANTIAGO YAZMIN A;;DIXON MARTIN GUY,INTEL CORPORATION INC (2014-03-13),https://lens.org/120-236-322-371-851,Patent Application,yes,2,8,17,17,0,G06F9/30043;;G06F9/30189;;G06F9/3836;;G06F9/3836;;G06F9/30145;;G06F9/30189;;G06F9/30;;G06F9/30043;;G06F9/30145;;G06F9/30189;;G06F9/30043;;G06F9/3836,G06F9/30,712/208,0,0,,,,ACTIVE
930,US,A,US 5482866 A,145-794-072-204-340,1996-01-09,1996,US 28180894 A,1994-07-28,US 28180894 A;;US 99636192 A;;US 76522591 A;;US 45138689 A,1989-12-15,Method for quantitation of calcium and magnesium and the novel reagent compositions,The present invention provides novel reagent compositions incorporating chlorophosphonazo III and a chelating agent and methods utilizing such compositions for the determination of magnesium and magnesium concurrently with calcium in an analytical sample as well as diagnostic test kits for such determinations.,HOFFMANN LA ROCHE,DENTON JAMES B;;DIXON DIANE J;;KAUFMAN RICHARD A,ROCHE DIAGNOSTICS CORPORATION (1998-12-11);;ROCHE DIAGNOSTIC SYSTEMS INC (1997-01-06),https://lens.org/145-794-072-204-340,Granted Patent,yes,7,35,13,13,0,G01N33/84;;G01N33/84;;G01N31/22;;G01N31/22;;Y10T436/25125;;Y10T436/25125;;Y10T436/2525;;Y10T436/2525,G01N31/00;;G01N31/22;;G01N33/84,436/79;;436/175;;436/176;;422/61,9,4,074-608-840-443-77X;;098-921-721-669-495;;044-518-515-199-331;;064-824-511-428-775,10.1021/ac60210a028;;10.1016/s0003-2670(00)84153-7;;10.1016/s0003-2670(01)93887-5;;10.1016/0143-4160(83)90048-9;;6682713,"Package Insert LANCER, Magnesium Rapid Stat diagnostic Kit 1982 Ferguson, et al., Analytical Chemistry, 36:796 (1964).;;Package Insert Roche Magnesium test.;;Package Insert Magensium B WAKO.;;Package Insert American Monitor Corp. 60 second magnesium.;;Clinical Chemistry, vol. 34, No. 6 (1988).;;Package Insert Boeringher, Mannheim Magnesium.;;Youxian, Anal. Chim. Acta, 212:291 295 (1988).;;Kaneko et al., Anal. Chem. Acta. 132:165 173 (1981).;;Durham et al., A Survey of the Available Colorimetric Indicators for Ca 2 and Mg 21 Ions in Biological Equipment , Cell Calcium, 4: 47 55 (1983).",EXPIRED
931,AU,A1,AU 2005/266927 A1,178-391-467-820-093,2006-02-02,2006,AU 2005/266927 A,2005-07-25,US 59099104 P;;US 2005/0026253 W,2004-07-24,Modification of lignin biosynthesis,,SAMUEL ROBERTS NOBLE FOUND INC,REDDY M S SRINIVASA;;DIXON RICHARD A;;CHEN FANG,,https://lens.org/178-391-467-820-093,Patent Application,no,0,1,9,9,0,C12N15/827;;C12N15/827;;C12N15/8255;;C12N15/8255;;C12N15/8261;;C12N15/8261;;Y02A40/146;;Y02A40/146,C12N15/82,,0,0,,,,INACTIVE
932,US,A,US 4490782 A,017-981-012-928-876,1984-12-25,1984,US 27095181 A,1981-06-05,US 27095181 A,1981-06-05,I/O Storage controller cache system with prefetch determined by requested record's position within data block,"In a data processing system of the type wherein a host processor transfers data to or from a plurality of attachment devices, a cache memory is provided for storing blocks of data which are most likely to be needed by the host processor in the near future. The host processor can then merely retrieve the necessary information from the cache memory without the necessity of accessing the attachment devices. When transferring data to cache from an attachment disk, additional unrequested information can be transferred at the same time if it is likely that this additional data will soon be requested. Further, a directory table is maintained wherein all data in cache is listed at a ""home"" position and, if more than one block of data in cache have the same home position, a conflict chain is set-up so that checking the contents of the cache can be done simply and quickly.",IBM,DIXON JERRY D;;MARAZAS GERALD A;;MERCKEL GERALD U,INTERNATIONAL BUSINESS MACHINES CORPORATION A CORP. OF NY (1981-06-02);;INTERNATIONAL BUSINESS MACHINES CORPORATION ARMONK NY 10504 A CORP. OF NY (1982-11-04),https://lens.org/017-981-012-928-876,Granted Patent,yes,17,96,3,13,0,G06F12/0862;;G06F12/0866;;G06F13/122;;G06F2212/502;;G06F12/0862;;G06F13/122;;G06F12/0866;;G06F2212/502,G06F12/00;;G06F12/08;;G06F13/00;;G06F13/12,364/200,2,0,,,"IBM Technical Disclosure Bulletin, vol. 21, No. 6, Nov. 1978, pp. 2468 2469, Data Processing System with Second Level Cache, F. J. Sparacio.;;Electronic Design, Oct. 25, 1980, pp. 38 40, Cache Memory Makes a Hit by Processing I/O Data Quickly, T. Williams.",EXPIRED
933,EP,A2,EP 1465437 A2,054-673-559-020-64X,2004-10-06,2004,EP 03255752 A,2003-09-15,US 38868803 A,2003-03-14,Adaptive image display,"A display system (40) may include an identifier (64) configured to identify an image display condition associated with the display of an image produced by the display system (40), an apparatus (46) configured to produce a plurality of differently colored images, and a display device (48). The images have color characteristics based on image information (62) and the identified display condition. Differently colored images may be directed along associated portions of an optical path (56). The display device (48) may be coupled to the apparatus (46) and may be configured to display a color image formed of the differently colored images.",HEWLETT PACKARD DEVELOPMENT CO,PATE MICHAEL A;;ALLEN WILLIAM J;;DIXON BRIAN S,,https://lens.org/054-673-559-020-64X,Patent Application,yes,0,8,6,6,0,G02B26/008;;H04N9/3114;;H04N9/3155;;H04N9/3182;;H04N9/73;;H04N9/73;;H04N9/3155;;G02B26/008;;H04N9/3182;;H04N9/3114,H04N9/31;;H04N9/73,,0,0,,,,DISCONTINUED
934,CA,C,CA 2977120 C,051-009-542-133-053,2023-02-21,2023,CA 2977120 A,2016-03-21,US 201562138002 P;;US 2016/0023419 W,2015-03-25,VERTICAL ELECTRIC COOKER AND SMOKER AND SMOKE BOX,"A vertical electric cooker and smoker having lower air intake vents and upper exhaust vents which together create a more balanced flow and distribution of smoke and reduce the operating pressure of the system to allow a much larger load of wood chips to be used without refilling. A smoke box is also provided for holding and properly combusting the larger quantity of wood chips in an oxygen deficient environment. The smoke box has a false bottom and discharges the smoke through a circuitous exhaust flow path. Also, the electric heating elements of the cooking and smoking apparatus are contained in an assembly which provides an air gap beneath the smoker box and also shields the smoker box to prevent the wood chips in the smoker box from becoming overheated.",BRADLEY W C CO,DIXON WILLIAM A;;ABDALLAH SLEIMAN ASSAAD;;MCQUAGG MARK STEPHEN,,https://lens.org/051-009-542-133-053,Granted Patent,no,0,0,12,12,0,A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;Y02A40/90;;A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;A23V2002/00,A23B4/044;;A23B4/052;;A23B4/056;;A47J37/06;;A47J37/07,,0,0,,,,PENDING
935,CA,A1,CA 3106449 A1,077-210-038-421-986,2020-01-23,2020,CA 3106449 A,2019-07-17,US 201862699448 P;;CA 2019050985 W,2018-07-17,SCANNING MICROSCOPE USING PULSED ILLUMINATION,"According to one aspect, an instrument for scanning a specimen. The instrument includes a scanning stage for supporting the specimen, a detector having a plurality of pixels, the scanning stage and the detector movable relative to each other to move the specimen in a scan direction during a scan, and a pulsed illumination source synchronized with the motion of the specimen on the scanning stage. At least some of the pixels of the detector are operable to collect light emitted from the specimen during the scan due to the pulsed illumination source and generate corresponding image data. The instrument may further include a processor operable to perform MSIA on the image data to generate an image of the specimen.",DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER,DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER,,https://lens.org/077-210-038-421-986,Patent Application,no,0,0,6,6,0,G02B21/002;;G02B21/12;;G02B21/16;;G02B21/367;;G02B5/201;;G01N21/6458;;H04N23/60;;H04N23/74;;H04N25/711;;H04N23/125;;H04N23/10;;G02B21/0084;;G02B21/0036;;G02B21/0032;;G02B21/0076;;H04N23/73;;H04N23/84;;H04N25/13,G01N21/84;;G01J3/32;;G01N21/25;;G01N21/64,,0,0,,,,PENDING
936,CA,A1,CA 3072858 A1,104-828-187-802-67X,2018-11-01,2018,CA 3072858 A,2018-04-24,US 201762489230 P;;CA 2018050484 W,2017-04-24,SCANNING MICROSCOPE FOR 3D IMAGING USING MSIA,"According to some examples, an instrument for scanning a specimen on a specimen holder. The instrument includes a scanning stage for supporting the specimen, and a detector having a plurality of pixels. The scanning stage and the detector are movable relative to each other to move the specimen in a scan direction during a scan. At least some of the pixels of the detector are operable to collect light from different depths inside the specimen during the scan and generate corresponding image data. The instrument also includes a processor operable to perform MSIA on the image data to generate a 3D image of the specimen.",HURON TECH INTERNATIONAL INC,DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER;;DIXON A E,,https://lens.org/104-828-187-802-67X,Patent Application,no,0,0,6,6,0,G02B21/0036;;G02B21/26;;G02B21/367;;G02B21/0076;;G02B21/0036;;G02B21/0052;;G02B21/006;;G02B21/361;;G02B21/26;;G02B21/365,G01N21/13;;G01N21/64;;G01N21/84;;G02B21/00;;H04N5/351;;H04N13/221,,0,0,,,,PENDING
937,WO,A1,WO 2000/024613 A1,157-268-116-612-991,2000-05-04,2000,US 9924463 W,1999-10-20,US 17825598 A,1998-10-23,HONEYCOMB CRASH PAD,A crash pad (10) for use in vehicle interiors. The crash pad (10) includes an energy-absorbing honeycomb (12) which has a cover plate (20) attached thereon to prevent noise from being generated due to contact between the crash pad (10) and vehicle interior surface during normal vehicle operation. The cover plate (20) is attached on one side to the honeycomb (12) with the other side being molded to match the shape of the interior surface of the vehicle. The cover plate (20) includes positioning devices (23) which locate and hold the crash pad (10) during interior panel fabrication. The cover plate (20) protects the honeycomb (12) and the technician during handling and installation. The cover plate (20) also helps to retain the shape of the honeycomb (12) and provides a suitable surface for labels (21) that may contain product identification and other information needed during use of the pads (10) in mass production of vehicles.,HEXCEL CORP,NUSSER LORI A;;DIXON G DOUGLAS;;HULL H ROBERT,,https://lens.org/157-268-116-612-991,Patent Application,yes,6,4,5,5,0,B60R21/04;;B60R21/04;;B60R13/0225;;B60R13/0225;;B60R2021/0421;;B60R2021/0421;;F16F7/121;;F16F7/121,B60R13/02;;B60R21/04;;F16F7/12,,1,0,,,See also references of EP 1123226A4,PENDING
938,US,A,US 2289351 A,168-334-653-227-53X,1942-07-14,1942,US 26633639 A,1939-04-06,US 26633639 A,1939-04-06,Method of cleaning heater tubes,,TEXAS CO,DIXON ENSLO S;;GARRARD THOMAS E;;BARR HAROLD A,,https://lens.org/168-334-653-227-53X,Granted Patent,no,0,38,1,1,0,C10G9/16;;C10G9/16;;F28G13/005;;F28G13/005,C10G9/16;;F28G13/00,,0,0,,,,EXPIRED
939,US,A,US 2728702 A,182-511-275-684-021,1955-12-27,1955,US 23651851 A,1951-07-13,US 23651851 A,1951-07-13,Composite cellular plastic structure,,LOCKHEED AIRCRAFT CORP,ELI SIMON;;THOMAS FRANK W;;DIXON JR LLOYD A,,https://lens.org/182-511-275-684-021,Granted Patent,no,21,120,1,1,0,B29C44/18;;B29C70/865;;B29D99/0025;;B29K2105/04;;B29K2105/0809;;B29L2031/087;;B29L2031/3085;;Y10S264/53;;Y10S52/07;;Y10S273/08;;Y10S220/14;;Y10S220/902;;Y10T428/24996;;Y10T428/24996;;B29D99/0025;;B29L2031/087;;B29C70/865;;B29C44/18;;B29K2105/0809;;B29K2105/04;;B29L2031/3085;;Y10S220/902;;Y10S273/08;;Y10S264/53;;Y10S220/14;;Y10S52/07,B29C44/18;;B29C70/86;;B29D99/00,B5S S17X          KA          -;;B5S S17Y          KA          -;;B5S S172          KA          -;;B5S S184          KA          -;;B5S S19X          KA          -;;B5S S209          KA          -;;B5S S214          KA          -;;B5S S241          KA          -;;B5S S25X          KA          -;;B5S S25Y          KA          -;;B5S S252          KA          -;;B5S S253          KA          -;;B5S S29Y          KA          -;;B5S S298          KA          -;;B5S S30Y          KA          -;;B5S S300          KA          -;;B5S S301          KA          -;;B5S S32X          KA          -;;B5S S320          KA          -;;B5S S326          KA          -;;B5S S33X          KA          -;;B5S S334          KA          -;;B5S S42X          KA          -;;B5S S449          KA          -;;B5S S45Y          KA          -;;B5S S55Y          KA          -;;B5S S582          KA          -;;B5S S598          KA          -;;B5S S657          KA          -;;B5S S669          KA          -;;B5S S71X          KA          -;;B5S S713          KA          -;;B5S S73X          KA          -;;B5S S745          KA          -;;B5S S756          KA          -;;B5S S779          KA          -;;B5S S787          KA          -;;B5S S788          KA          -;;B5S S789          KA          -,0,0,,,,EXPIRED
940,EP,A2,EP 1771568 A2,180-760-220-425-254,2007-04-11,2007,EP 05775291 A,2005-07-25,US 2005/0026253 W;;US 59099104 P,2004-07-24,MODIFICATION OF LIGNIN BIOSYNTHESIS,,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;REDDY M S SRINIVASA;;CHEN FANG,,https://lens.org/180-760-220-425-254,Patent Application,yes,0,0,9,9,0,C12N15/827;;C12N15/827;;C12N15/8255;;C12N15/8255;;C12N15/8261;;C12N15/8261;;Y02A40/146;;Y02A40/146,C12N15/82,,1,0,,,See references of WO 2006012594A3,DISCONTINUED
941,EP,A1,EP 3615916 A1,199-311-522-711-041,2020-03-04,2020,EP 18791217 A,2018-04-24,US 201762489230 P;;CA 2018050484 W,2017-04-24,SCANNING MICROSCOPE FOR 3D IMAGING USING MSIA,,DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER,DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER,HURON TECHNOLOGIES INTERNATIONAL INC. (2020-03-25),https://lens.org/199-311-522-711-041,Patent Application,yes,0,0,6,6,0,G02B21/0036;;G02B21/0036;;G02B21/0052;;G02B21/006;;G02B21/0076;;G02B21/26;;G02B21/26;;G02B21/361;;G02B21/365;;G02B21/367,G01N21/13;;G01N21/64;;G01N21/84;;G02B21/00;;H04N5/351;;H04N13/221,,0,0,,,,PENDING
942,TW,B,TW I515653 B,028-789-918-088-067,2016-01-01,2016,TW 103121587 A,2014-06-23,US 201313931544 A,2013-06-28,"Instruction order enforcement pairs of instructions, processors, methods, and systems",,INTEL CORP,DIXON MARTIN G;;RASH WILLIAM C;;SANTIAGO YAZMIN A,,https://lens.org/028-789-918-088-067,Granted Patent,no,0,0,16,16,0,G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/3891;;G06F9/3856;;G06F9/3836;;G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3856,,,0,0,,,,INACTIVE
943,US,B1,US 10238904 B1,033-610-038-885-875,2019-03-26,2019,US 201715703123 A,2017-09-13,US 201715703123 A,2017-09-13,Mutant organophosphorus acid anhydrolases and uses thereof,"Disclosed herein are non-wild-type organophosphorus acid anhydrolases having two site mutations, methods of production, and methods of use to effectively degrade toxic chemicals such as ((RS)-Propan-2-yl methylphosphonofluoridate) (Sarin) and other organophosphorus compounds.",U S ARMY EDGEWOOD CHEMICAL BIOLOGICAL CENTER;;US ARMY,GUELTA MARK A;;DIXON MELISSA M;;HARVEY STEVEN P,THE UNITED STATES OF AMERICA (2017-09-05),https://lens.org/033-610-038-885-875,Granted Patent,yes,4,1,1,1,3,A62D3/02;;A62D3/02;;A62D2101/02;;A62D2101/02;;A62D2101/26;;A62D2101/26;;C12N9/16;;C12N9/16;;C12Y301/03;;C12Y301/03,A61K38/46;;A62D3/02;;A62D101/02;;A62D101/26;;C12N9/14;;C12N9/16,,0,0,,,,ACTIVE
944,US,A,US 3862083 A,070-284-246-115-163,1975-01-21,1975,US 31051872 A,1972-11-29,US 31051872 A,1972-11-29,HIGH TEMPERATURE BRUSHING COMPOUND,"A high temperature polyester brushing compound is disclosed which comprises a polyunsaturated cyclic monomer or prepolymer, a free-radical generator, an inorganic thixotrope, and the reaction product of (1) an aromatic polycarboxylic acid, acid halide, ester to C6, or anhydride, (2) a polyol, and (3) an unsaturated carboxylic acid, acid halide, ester to C6, or anhydride. Optional ingredients include an inorganic filler and a free-radical inhibitor.",WESTINGHOUSE ELECTRIC CORP,DIXON GEORGE D;;MENDELSOHN MORRIS A;;RUFFING CHARLES R,,https://lens.org/070-284-246-115-163,Granted Patent,no,7,2,4,4,0,C08F283/01;;C08G63/54;;C09D167/06;;H01B3/421;;H02K3/325;;C08K3/34;;C08K3/36;;C08K7/12;;C08L1/26;;C08L33/02;;C08L67/06;;H02K3/325;;C09D167/06;;C08F283/01;;H01B3/421;;C08G63/54;;C08K7/12;;C08L1/26;;C08K3/36;;C08L67/06;;C08L33/02;;C08K3/34,C08F2/38;;C08F2/00;;C08F283/01;;C08F299/00;;C08G63/54;;C09D167/06;;H01B3/42;;H02K3/32,C3V VBF           VBF,0,0,,,,EXPIRED
945,WO,A3,WO 2006/012594 A3,106-113-989-050-637,2006-09-28,2006,US 2005/0026253 W,2005-07-25,US 59099104 P,2004-07-24,MODIFICATION OF LIGNIN BIOSYNTHESIS,The invention provides methods for decreasing lignin content and improving lignin profiles. Also provided are the plants prepared by the methods of the invention. Such plants may exhibit improved digestibility relative to prior plants.,SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;REDDY M S SRINIVASA;;CHEN FANG,DIXON RICHARD A;;REDDY M S SRINIVASA;;CHEN FANG,,https://lens.org/106-113-989-050-637,Search Report,yes,6,0,9,9,0,C12N15/827;;C12N15/827;;C12N15/8255;;C12N15/8255;;C12N15/8261;;C12N15/8261;;Y02A40/146;;Y02A40/146,C12N15/82;;A01H5/00;;A01H5/10,,6,6,017-610-229-506-858;;082-701-013-165-901;;039-231-167-687-603;;018-667-643-178-785;;046-334-945-126-761;;029-409-447-008-102,11967092;;10.1046/j.1365-313x.2002.01267.x;;10.1071/pp00093;;pmc102215;;10.1105/tpc.13.1.73;;11158530;;10.2307/3871154;;10.1023/a:1012278106147;;11708655;;10.1016/s0031-9422(02)00211-x;;12359514;;pmc1283808;;10.1073/pnas.0505749102;;16263933,"FRANKE R ET AL: ""Changes in secondary metabolism and deposition of an unusual lignin in the ref8 mutant of arabidopsis"", PLANT JOURNAL, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 30, no. 1, April 2002 (2002-04-01), pages 47 - 59, XP002223725, ISSN: 0960-7412;;RAE ANNE L ET AL: ""Antisense suppression of the lignin biosynthetic enzyme, caffeate O-methyltransferase, improves in vitro digestibility of the tropical pasture legume, Stylosanthes humilis"", AUSTRALIAN JOURNAL OF PLANT PHYSIOLOGY, vol. 28, no. 4, 2001, pages 289 - 297, XP009066101, ISSN: 0310-7841;;DIANJING G ET AL: ""Downregulation of Caffeic Acid 3-O-Methyltransferase and Caffeoyl 3-O-Methyltransferase in Transgenic Alfalfa: Impacts on Lignin Structure and Implications for the Biosynthesis of G and S Lignin"", PLANT CELL, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, US, vol. 13, January 2001 (2001-01-01), pages 73 - 88, XP002187460, ISSN: 1040-4651;;GUO D ET AL: ""IMPROVEMENT OF IN-RUMEN DIGESTIBILITY OF ALFALFA FORAGE BY GENETIC MANIPULATION OF LIGNIN O-METHYLTRANSFERASES"", TRANSGENIC RESEARCH, LONDON, GB, vol. 10, no. 5, October 2001 (2001-10-01), pages 457 - 464, XP008006402, ISSN: 0962-8819;;ANTEROLA A M ET AL: ""Trends in lignin modification: a comprehensive analysis of the effects of genetic manipulations/mutations on lignification and vascular integrity"", PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 61, no. 3, October 2002 (2002-10-01), pages 221 - 294, XP004383441, ISSN: 0031-9422;;SRINIVASA REDDY M S ET AL: ""Targeted down-regulation of cytochrome P450 enzymes for forage quality improvement in alfalfa (Medicago sativa L.)"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 46, November 2005 (2005-11-01), pages 16573 - 16578, XP002379754, ISSN: 0027-8424",PENDING
946,DE,A1,DE 2401948 A1,113-477-409-535-269,1974-11-28,1974,DE 2401948 A,1974-01-16,US 35898573 A,1973-05-10,VERFAHREN ZUR HERSTELLUNG VON BLASGEFORMTEN THERMOPLASTISCHEN ERZEUGNISSEN,,AIR PROD & CHEM,DIXON DALE A;;MANLY DONALD G;;RECKTENWALD GERALD W,,https://lens.org/113-477-409-535-269,Patent Application,no,0,2,15,15,0,B29C49/46;;B29C49/46;;B29C2035/1683;;B29C2035/1683;;B29C2049/4605;;B29C2049/4605;;B29C2049/4608;;B29C2049/4608;;B29C2049/4614;;B29C2049/4614;;B29C2049/4617;;B29C2049/4617;;B29C2049/462;;B29C2049/462;;B29C2049/4623;;B29C2049/4623;;B29K2023/06;;B29K2023/06,B29C65/00;;B29B11/10;;B29C35/16;;B29C49/00;;B29C49/04;;B29C49/46;;B29C49/48;;B29C49/58,,0,0,,,,EXPIRED
947,EP,A4,EP 3014422 A4,162-251-011-628-268,2017-03-01,2017,EP 14816582 A,2014-06-19,US 201313931070 A;;US 2014/0043159 W,2013-06-28,"MODE DEPENDENT PARTIAL WIDTH LOAD TO WIDER REGISTER PROCESSORS, METHODS, AND SYSTEMS",,INTEL CORP,RASH WILLIAM C;;SANTIAGO YAZMIN A;;DIXON MARTIN GUY,,https://lens.org/162-251-011-628-268,Search Report,no,3,0,17,17,0,G06F9/30043;;G06F9/30189;;G06F9/3836;;G06F9/3836;;G06F9/30145;;G06F9/30189;;G06F9/30;;G06F9/30043;;G06F9/30145;;G06F9/30189;;G06F9/30043;;G06F9/3836,G06F9/312,,0,0,,,,ACTIVE
948,US,A,US 2524431 A,168-261-031-056-057,1950-10-03,1950,US 2598648 A,1948-05-08,US 2598648 A,1948-05-08,Isomeric polychloropyrazines and preparation thereof,,AMERICAN CYANAMID CO,DIXON JAMES K;;MILLER ALEXANDER A;;BRUESCH JOHN F,,https://lens.org/168-261-031-056-057,Granted Patent,no,1,1,1,1,0,C07D241/16;;C07D241/16,C07D241/16,,0,0,,,,EXPIRED
949,US,B2,US 7663023 B2,166-883-765-494-092,2010-02-16,2010,US 18910905 A,2005-07-25,US 18910905 A;;US 59099104 P,2004-07-24,Modification of lignin biosynthesis,The invention provides methods for decreasing lignin content and improving lignin profiles. Also provided are the plants prepared by the methods of the invention. Such plants may exhibit improved digestibility relative to prior plants.,SAMUEL ROBERTS NOBLE FOUND INC,DIXON RICHARD A;;REDDY M S SRINIVASA;;CHEN FANG,NOBLE RESEARCH INSTITUTE LLC (2017-05-01);;SAMUEL ROBERTS NOBLE FOUNDATION THE (2005-10-18),https://lens.org/166-883-765-494-092,Granted Patent,yes,12,14,9,9,45,C12N15/827;;C12N15/827;;C12N15/8255;;C12N15/8255;;C12N15/8261;;C12N15/8261;;Y02A40/146;;Y02A40/146,A01H1/00;;C12N15/82;;C12N15/87,800/285;;800/278;;800/286,50,17,002-177-793-287-079;;122-319-270-282-844;;019-899-624-692-294;;000-047-739-257-25X;;046-334-945-126-761;;017-610-229-506-858;;082-701-013-165-901;;029-409-447-008-102;;137-763-157-344-033;;031-132-193-330-865;;064-020-317-605-308;;100-259-571-345-271;;016-686-242-147-938;;067-999-241-399-305;;016-576-805-396-659;;044-544-955-770-983;;102-694-481-185-381,11982391;;10.1021/jf011429s;;pmc490038;;10.1105/tpc.020297;;15161961;;12000452;;10.1046/j.1365-313x.2002.01283.x;;10.1046/j.1365-313x.2001.00976.x;;11260498;;10.1016/s0031-9422(02)00211-x;;12359514;;11967092;;10.1046/j.1365-313x.2002.01267.x;;10.1071/pp00093;;pmc1283808;;10.1073/pnas.0505749102;;16263933;;10092173;;10.1023/a:1006182925584;;10.2135/cropsci1988.0011183x002800030026x;;10.2135/cropsci1987.0011183x002700050021x;;11967091;;10.1046/j.1365-313x.2002.01266.x;;10.2135/cropsci1992.0011183x003200030046x;;10.1021/jf970029v;;11086019;;pmc381444;;10.1172/jci11631;;14659706;;10.1016/j.tplants.2003.10.001;;10.1074/jbc.m209362200;;12381722,"Jeandet et al. 2002, J. Agric. Food Chem. 50:2731-2741.;;Hoffmann et al. first published online on May 25, 2004, The Plant Cell 16:1446-1465.;;Buhr et al. 2002, The Plant Journal 30:155-163.;;Thomas et al. 2001, The Plant Journal 25(4):417-425.;;Anterola et al., ""Trends in lignin modification: a comprehensive analysis of the effects of genetic manipulations/mutations on lignification and vascular integrity,"" Phytochemistry, 61:221-294, 2002.;;Franke et al., ""Changes in secondary metabolism and deposition of an unusual lignin in the ref8 mutant of arabidopsis,"" Plant Journal, 30:47-59, 2002.;;Rae et al., ""Antisense suppression of the lignin biosynthetic enzyme, caffeate O-methyltransferase, improves in vitro digestibility of the tropical pasture legume, Stylosanthes humilis,"" Australian Journal of Plant Physiology, 28:289-297, 2001.;;Reddy et al., ""Targeted down-regulation of cytochrome P450 enzymes for forage quality improvement in alfalfa (Medicago sativa L.),"" Proceedings of the National Academy of Sciences of the United States of America, 202:16573-16578, 2005.;;Baucher et al., ""Down-regulation of cinnamyl alcohol dehydrogenase in transgenic alfalfa (Medicago sativa L.) and the effect on lignin composition and digestibility,"" Plant Mol Biol, 39:437-447, 1999.;;Buxton and Russell, ""Lignin constituents and cell wall digestibility of grass and legume stems,"" Crop Sci, 28:553-558, 1988.;;Casler, ""Invitro digestibility of dry matter and cell wall constituents of smooth bromegrass forage,"" Crop Sci, 27:931-934, 1987.;;Dixon et al., ""Genetic manipulation of lignin and phenylpropanoid compounds involved in interactions with microorganisms,"" Rec Adv Phytochem, 28:153178, 1994.;;Franke et al., ""The arabidopsis ref8 gene encodes the 3-hydroxylase of phenylpropanoid metabolism,"" Plant J., 301:33-45, 2002.;;Grabber, et al., ""Digestion kinetics of parachyma and sclerenchyma cell walls isolated from orchadgrass and switchgrass,"" Crop Sci, 32:806-810, 1992.;;Grabber, et al., ""P-hydroxyphenyl, guaiacyl, and syringyl lignins have similar inhibitory effects on wall degradability,"" J Agric Food Chem, 45:2530-2532, 1997.;;GenBank Accession No. AB035183.1, Jun. 29, 2000.;;GenBank Accession No. AB185953.1, Jan. 23, 2008.;;GenBank Accession No. AB185954.1, Jan. 23, 2008.;;GenBank Accession No. AJ507825.1, Jan. 2, 2003.;;GenBank Accession No. AJ555865.1, Jun. 8, 2004.;;GenBank Accession No. AJ582651.1, Jun. 10, 2004.;;GenBank Accession No. AJ582652.1, Jun. 10, 2004.;;GenBank Accession No. AM116757.1, Oct. 21, 2006.;;GenBank Accession No. AM283092.1, Dec. 2, 2006.;;GenBank Accession No. AY084652.1, Jan. 27, 2006.;;GenBank Accession No. BT026488.1, Aug. 2, 2006.;;GenBank Accession No. BX830476.1, Feb. 6, 2004.;;GenBank Accession No. BX830698.1, Feb. 6, 2004.;;GenBank Accession No. BX830912.1, Feb. 6, 2004.;;GenBank Accession No. BX831467.1, Feb. 6, 2004.;;GenBank Accession No. BX832315.1, Feb. 6, 2004.;;GenBank Accession No. BX832778.1, Feb. 6, 2004.;;GenBank Accession No. DQ104740.1, Apr. 10, 2007.;;GenBank Accession No. EF121452, Jul. 12, 2007.;;GenBank Accession No. EF121452.1, Jul. 12, 2007.;;GenBank Accession No. EF137954.1, Apr. 22, 2007.;;GenBank Accession No. EF143341.1, Apr. 22, 2007.;;GenBank Accession No. EF153929.1, Apr. 22, 2007.;;GenBank Accession No. EF153930, Apr. 22, 2007.;;GenBank Accession No. EF153930.1, Apr. 22, 2007.;;GenBank Accession No. EF153931, Apr. 22, 2007.;;GenBank Accession No. EF153931.1, Apr. 22, 2007.;;GenBank Accession No. EF450248, Dec. 1, 2007.;;GenBank Accession No. EU124731.1, Sep. 30, 2007.;;GenBank Accession No. NM 124270.3, Apr. 20, 2007.;;Medicago Accession No. TC106825, undated.;;Klug, ""The discovery of zinc fingers and their development for practical applications in gene regulation,"" Proc. Japan Acad., 81B(4):87-102, 2005.;;Usman et al., ""Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics,"" J. of Clinical Investigation, 106(10):1197-1202, 2000.;;Boudet et al., ""Lignins and lignocellulosics: a better control of synthesis for new and improved uses,"" TRENDS in Plant Science, 8(12): 576-581, 2003.;;Hoffmann et al., ""Purification, Cloning, and Properties of an Acyltransferase Controlling Shikimate and Quinate Ester Intermediates in Phenylpropanoid Metabolism,"" J. Biol. Chem., 278:95-103, 2003.",ACTIVE
950,CA,A,CA 51102 A,186-674-488-857-59X,1896-01-22,1896,CA 51102D A,1895-08-10,CA 51102T A,1895-08-10,ROCK DRILL,,GARTMANN JOHN E;;DIXON WILLIAM H;;FOSLIN FRANK A,GARTMANN JOHN E;;DIXON WILLIAM H;;FOSLIN FRANK A,,https://lens.org/186-674-488-857-59X,Granted Patent,no,0,1,1,1,0,,,,0,0,,,,EXPIRED
951,US,S,US D0289900 S,197-478-089-320-497,1987-05-19,1987,US 63837584 F,1984-08-07,GB 1017947 F,1984-02-17,Electronic musical instrument,,SYNTHAXE LTD,AITKEN WILLIAM A;;SEDIVY ANTHONY J;;DIXON MICHAEL S,SYNTHAXE LIMITED (1984-07-31),https://lens.org/197-478-089-320-497,Design Right,yes,16,29,2,2,0,,,D17/14,7,0,,,"Sound International, ""Avatar"", Paddy Kingsland, Dec. 1978.;;Sound International, Steve Hackett, ""Roland G500"", Dec. 1978.;;Advertisement, ""The Touch"".;;Guitar Player, ""Guitars of Tomorrow?"", Tom Mulhern, pp. 58-60, Oct. 1982.;;Sound International, ""Oh, Atlanta . . . "", Report of NAMM trade show, Jun. 9 to 12, Atlanta, Georgia, Sep. 1979.;;Various covers of ""The Guitar Book"".;;Sound International, ""Electro-Harmonix Guitar Synthesiser"", Robin Millar, Nov. 1980.",EXPIRED
952,US,A1,US 2008/0063178 A1,008-069-287-528-132,2008-03-13,2008,US 50466906 A,2006-08-16,US 50466906 A,2006-08-16,Agent call flow monitoring and evaluation,Agent performance is monitored. Multiple segments of a first communications session are monitored based on corresponding triggers that trigger the monitoring of the multiple segments. Characteristic data of the multiple segments is obtained. The characteristic data of the first communications session and characteristic data of a second communications session are grouped. The characteristic data of the first communications session is subject to common evaluation with the characteristic data of the second communications session.,SBC KNOWLEDGE VENTURES LP,PADEN JONATHAN;;HARRIS JON;;DIXON MATTHEW A;;JOSEPH KURT,SBC KNOWLEDGE VENTURES L.P (2006-09-07),https://lens.org/008-069-287-528-132,Patent Application,yes,22,16,1,1,0,H04M3/5175;;H04M3/5175,H04M3/00,379/265.06,0,0,,,,DISCONTINUED
953,BR,A2,BR 112015029955 A2,021-485-318-074-609,2017-07-25,2017,BR 112015029955 A,2014-06-19,US 2014/0043159 W;;US 201313931070 A,2013-06-28,"carga de largura parcial dependente de modo para pro-cessadores registradores mais amplos, métodos e siste-mas","carga de largura parcial dependente de modo para processadores registradores mais amplos, métodos e sistemas a presente invenção refere-se a um método de um aspecto que é realizado por um processador. o método inclui receber uma instrução de carga de largura parcial. a instrução de carga de largura parcial indica uma localiza-ção de memória de uma memória como um operando de origem e indica um registrador como um operando de destino. o método inclui carregar dados a partir da localização de memória indicada no processador em resposta à ins-trução de carga de largura parcial. o método inclui gravar pelo menos uma porção dos dados carregados em uma largura parcial do registrador em respos-ta à instrução de carga de largura parcial. o método inclui concluir a gravação do registrador com um conjunto de bits armazenados em uma largura restante do registrador que têm valores de bit que dependem de um modo de carga de largura parcial do processador. a instrução de carga de largura parcial não in-dica o modo de carga de largura parcial. outros métodos, processadores e sis-temas também são revelado.",INTEL CORP,MARTIN GUY DIXON;;WILLIAM C RASH;;YAZMIN A SANTIAGO,,https://lens.org/021-485-318-074-609,Patent Application,no,0,0,17,17,0,G06F9/30043;;G06F9/30189;;G06F9/3836;;G06F9/3836;;G06F9/30145;;G06F9/30189;;G06F9/30;;G06F9/30043;;G06F9/30145;;G06F9/30189;;G06F9/30043;;G06F9/3836,G06F9/312,,0,0,,,,PENDING
954,DK,T3,DK 3273786 T3,025-404-145-309-817,2020-03-16,2020,DK 16769494 T,2016-03-21,US 201562138002 P;;US 2016/0023419 W,2015-03-25,Vertikal elektrisk tilberednings- og rygeovn med røgkasse,,BRADLEY W C CO,DIXON WILLIAM A;;ABDALLAH SLEIMAN ASSAAD;;MCQUAGG MARK STEPHEN,,https://lens.org/025-404-145-309-817,Granted Patent,no,0,0,12,12,0,A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;Y02A40/90;;A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;A23V2002/00,A23B4/048;;A23B4/044;;A23B4/052;;A23B4/056;;A47J37/06;;A47J37/07,,0,0,,,,ACTIVE
955,US,B1,US 9976130 B1,045-118-740-685-129,2018-05-22,2018,US 201615395412 A,2016-12-30,US 201615395412 A,2016-12-30,OPAA FL—a mutant enzyme with increased catalytic efficiency on organophosphorus compound GD,"This invention is directed toward a non-wild-type organophosphorus acid anhydrolase enzyme having two site mutations, method of production, and method of use to more effectively degrade toxic organophosphorus compounds and, in particular, toxic chemical GD (3,3-Dimethylbutan-2-ylmethylphosphonofluoridate), than the wild type organophosphorus acid anhydrolase.",U S ARMY EDGEWOOD CHEMICAL BIOLOGICAL CENTER;;US ARMY,GUELTA MARK A;;DIXON MELISSA M;;HARVEY STEVEN P,THE UNITED STATES OF AMERICA (2017-01-03),https://lens.org/045-118-740-685-129,Granted Patent,yes,10,4,1,1,2,A61K38/00;;A61K38/00;;A61K38/465;;A61K38/465;;A62D3/02;;A62D3/02;;A62D2101/02;;A62D2101/02;;A62D2101/04;;A62D2101/04;;A62D2101/26;;A62D2101/26;;C12N9/16;;C12N9/16;;C12Y301/08002;;C12Y301/08002,C12N9/16;;A61K38/00;;A61K38/46;;A62D3/02;;A62D101/02;;A62D101/04;;A62D101/26,,0,0,,,,INACTIVE
956,EP,A1,EP 1460855 A1,104-065-965-685-789,2004-09-22,2004,EP 03255594 A,2003-09-09,US 38872003 A,2003-03-14,Display image generation with differential illumination,"A method of producing a display image (154) comprises receiving image information (112) representing an image to be displayed, producing an image formed of a plurality of images of different colors, and projecting the produced image along an optical path (141). The differently colored images have color intensities related to energy applied to a light source (52). A level (310) of energy is applied to the light source (52) during production of the image of one color that is different than the level (304, 306, 308) of energy applied to the light source (52) during production of the image of another color.",HEWLETT PACKARD DEVELOPMENT CO,PATE MICHAEL A;;ALLEN WILLIAM J;;DIXON BRIAN S,,https://lens.org/104-065-965-685-789,Patent Application,yes,5,4,5,5,0,G02B26/008;;H04N9/3114;;H04N9/3155;;H04N9/3182;;H04N9/73;;H04N9/3114;;H04N9/3155;;H04N9/3182;;H04N9/73;;G02B26/008,H04N1/60;;H04N9/31;;H04N9/73,,0,0,,,,DISCONTINUED
957,US,B2,US 11143855 B2,127-312-394-400-830,2021-10-12,2021,US 201916514158 A,2019-07-17,US 201916514158 A;;US 201862699448 P,2018-07-17,Scanning microscope using pulsed illumination and MSIA,"According to one aspect, an instrument for scanning a specimen. The instrument includes a scanning stage for supporting the specimen, a detector having a plurality of pixels, the scanning stage and the detector movable relative to each other to move the specimen in a scan direction during a scan, and a pulsed illumination source synchronized with the motion of the specimen on the scanning stage. At least some of the pixels of the detector are operable to collect light emitted from the specimen during the scan due to the pulsed illumination source and generate corresponding image data. The instrument may further include a processor operable to perform MSIA on the image data to generate an image of the specimen.",DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER;;HURON TECH INTERNATIONAL INC,DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER,HURON TECHNOLOGIES INTERNATIONAL INC (2019-08-10),https://lens.org/127-312-394-400-830,Granted Patent,yes,8,0,6,6,0,G02B21/002;;G02B21/12;;G02B21/16;;G02B21/367;;G02B5/201;;G01N21/6458;;H04N23/60;;H04N23/74;;H04N25/711;;H04N23/125;;H04N23/10;;G02B21/0084;;G02B21/0036;;G02B21/0032;;G02B21/0076;;H04N23/73;;H04N23/84;;H04N25/13,G02B21/00;;H04N5/235;;H04N9/04,,0,0,,,,ACTIVE
958,AU,A,AU 2000/077173 A,128-546-351-486-601,2001-04-30,2001,AU 2000/077173 A,2000-09-26,US 15658199 P;;US 0026406 W,1999-09-29,Load cell apparatus,"A load cell apparatus (100) includes a cell block (70) adapted to couple to a first structure, and a mount (82) adapted to couple to a second structure. The mount (82) is made of a first material and is formed to include a bore (140). The apparatus (100) also includes a stud (78) extending from the cell block (70), and a liner (142) positioned to lie in the bore (140). The stud (78) engages the liner (142). The liner (142) is made of a second material that is more lubrous than the first material.",HILL ROM CO INC,MOBLEY DONALD L;;DIXON STEVE A;;HOPKINS RANDALL K,,https://lens.org/128-546-351-486-601,Patent Application,no,0,0,9,10,0,G01G19/445,G01G19/52;;A61B5/11;;A61G7/05;;G01G19/44;;G01L1/22,,0,0,,,,DISCONTINUED
959,CA,A1,CA 2032053 A1,140-169-305-562-726,1991-06-16,1991,CA 2032053 A,1990-12-12,US 45138689 A,1989-12-15,METHOD FOR QUANTITATION OF CALCIUM AND MAGNESIUM,A method for determining the quantity of calcium or magnesium in an analytical sample and the novel reagent compositions.,HOFFMANN LA ROCHE,DENTON JAMES B;;DIXON DIANE J;;KAUFMAN RICHARD A,,https://lens.org/140-169-305-562-726,Patent Application,no,0,0,13,13,0,G01N33/84;;G01N33/84;;G01N31/22;;G01N31/22;;Y10T436/25125;;Y10T436/25125;;Y10T436/2525;;Y10T436/2525,G01N31/00;;G01N31/22;;G01N33/84,D21500007    M;;1500009    S;;1500019    S,0,0,,,,EXPIRED
960,CN,A,CN 104049948 A,151-006-919-765-926,2014-09-17,2014,CN 201410098131 A,2014-03-17,US 201313844873 A,2013-03-16,"Instruction Emulation Processors, Methods, And Systems",A processor of an aspect includes decode logic to receive a first instruction and to determine that the first instruction is to be emulated. The processor also includes emulation mode aware post-decode instruction processor logic coupled with the decode logic. The emulation mode aware post-decode instruction processor logic is to process one or more control signals decoded from an instruction. The instruction is one of a set of one or more instructions used to emulate the first instruction. The one or more control signals are to be processed differently by the emulation mode aware post-decode instruction processor logic when in an emulation mode than when not in the emulation mode. Other apparatus are also disclosed as well as methods and systems.,INTEL CORP,SANTIAGO YAZMIN A;;DIXON MARTIN G;;RASH WILLIAM C,,https://lens.org/151-006-919-765-926,Patent Application,no,5,7,14,14,0,G06F9/3017;;G06F9/30189;;G06F9/382;;G06F9/455;;G06F9/3017;;G06F9/30189;;G06F9/382;;G06F9/30174;;G06F9/3017;;G06F9/3017;;G06F9/30189;;G06F9/382;;G06F9/455,G06F9/30;;G06F9/455,,1,0,,,"李又容: ""《MC68020／MC68EC020微处理器用户手册》"", 30 April 1998",ACTIVE
961,US,A1,US 2009/0041014 A1,161-439-193-017-705,2009-02-12,2009,US 83555607 A,2007-08-08,US 83555607 A,2007-08-08,Obtaining Information From Tunnel Layers Of A Packet At A Midpoint,"In one embodiment, a midpoint obtains information from packets by monitoring a communication session between a subscriber side endpoint and a network side provider. The communication session involves a packet flow comprising one or more packets, where a packet comprises tunnel layers. The midpoint establishes one or more target layers of the tunnel layers and performs the following for each tunnel layer at least until a last target layer is reached: identifies a protocol associated with a tunnel layer, parses the packet according to the identified protocol, and extracts target information from the tunnel layer if the tunnel layer is a target layer.",DIXON WALTER G;;MACKIE ROBERT A;;GRAY RICHARD L,DIXON WALTER G;;MACKIE ROBERT A;;GRAY RICHARD L,CISCO TECHNOLOGY INC (2007-07-26),https://lens.org/161-439-193-017-705,Patent Application,yes,48,3,1,1,0,H04L12/14;;H04L43/026;;H04L12/14;;H04L43/026;;H04L41/0893,H04L12/56,370/392,0,0,,,,DISCONTINUED
962,WO,A1,WO 2020/014783 A1,008-474-997-777-95X,2020-01-23,2020,CA 2019050985 W,2019-07-17,US 201862699448 P,2018-07-17,SCANNING MICROSCOPE USING PULSED ILLUMINATION,"According to one aspect, an instrument for scanning a specimen. The instrument includes a scanning stage for supporting the specimen, a detector having a plurality of pixels, the scanning stage and the detector movable relative to each other to move the specimen in a scan direction during a scan, and a pulsed illumination source synchronized with the motion of the specimen on the scanning stage. At least some of the pixels of the detector are operable to collect light emitted from the specimen during the scan due to the pulsed illumination source and generate corresponding image data. The instrument may further include a processor operable to perform MSIA on the image data to generate an image of the specimen.",DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER,DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER,,https://lens.org/008-474-997-777-95X,Patent Application,yes,3,0,6,6,0,G02B21/002;;G02B21/12;;G02B21/16;;G02B21/367;;G02B5/201;;G01N21/6458;;H04N23/60;;H04N23/74;;H04N25/711;;H04N23/125;;H04N23/10;;G02B21/0084;;G02B21/0036;;G02B21/0032;;G02B21/0076;;H04N23/73;;H04N23/84;;H04N25/13,G01N21/84;;G01J3/32;;G01N21/25;;G01N21/64,,1,0,,,See also references of EP 3824277A4,PENDING
963,EP,B1,EP 3273786 B1,046-425-062-440-347,2020-01-08,2020,EP 16769494 A,2016-03-21,US 201562138002 P;;US 2016/0023419 W,2015-03-25,VERTICAL ELECTRIC COOKER AND SMOKER WITH SMOKE BOX,,BRADLEY W C CO,DIXON WILLIAM A;;ABDALLAH SLEIMAN ASSAAD;;MCQUAGG MARK STEPHEN,W.C. BRADLEY CO. (2020-02-19),https://lens.org/046-425-062-440-347,Granted Patent,yes,8,0,12,12,0,A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;Y02A40/90;;A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;A23V2002/00,A23B4/048;;A23B4/044;;A23B4/052;;A23B4/056;;A47J37/06;;A47J37/07,,0,0,,,,ACTIVE
964,US,A1,US 2014/0283032 A1,051-084-029-631-588,2014-09-18,2014,US 201313839048 A,2013-03-15,US 201313839048 A,2013-03-15,INTER-PROCESSOR ATTESTATION HARDWARE,"Embodiments of an invention for inter-processor attestation hardware are disclosed. In one embodiment, an apparatus includes first attestation hardware associated with a first portion of a system. The first attestation hardware is to attest to a second portion of the system that the first portion of the system is secure.",RASH WILLIAM C;;DIXON MARTIN G;;SANTIAGO YAZMIN A,RASH WILLIAM C;;DIXON MARTIN G;;SANTIAGO YAZMIN A,INTEL CORPORATION (2013-06-26),https://lens.org/051-084-029-631-588,Patent Application,yes,14,8,2,2,0,G06F21/57;;G06F21/57,G06F21/57,726/22,0,0,,,,INACTIVE
965,US,B2,US 10235175 B2,055-556-731-284-529,2019-03-19,2019,US 201615089883 A,2016-04-04,US 201615089883 A;;US 201313844729 A,2013-03-15,"Processors, methods, and systems to relax synchronization of accesses to shared memory",A processor of an aspect includes a plurality of logical processors. A first logical processor of the plurality is to execute software that includes a memory access synchronization instruction that is to synchronize accesses to a memory. The processor also includes memory access synchronization relaxation logic that is to prevent the memory access synchronization instruction from synchronizing accesses to the memory when the processor is in a relaxed memory access synchronization mode.,INTEL CORP,DIXON MARTIN G;;RASH WILLIAM C;;SANTIAGO YAZMIN A,,https://lens.org/055-556-731-284-529,Granted Patent,yes,22,1,20,20,0,G06F9/06;;G06F9/30087;;G06F9/30087;;G06F9/30087;;G06F12/0804;;G06F9/30087;;G06F9/38;;G06F9/522;;G06F12/0804;;G06F12/0804;;G06F12/0804;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/14;;G06F12/14;;G06F2212/1052;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G11C7/1072;;Y02D10/00;;Y02D10/00;;Y02D10/00,G06F12/00;;G06F9/30;;G06F12/0804;;G06F12/0815;;G06F12/0862;;G06F12/14;;G11C7/10,,27,1,016-937-283-180-041,10.1145/605398.605400,"Office Action received for Chinese Patent Application No. 201410097357.6, dated Nov. 6, 2017, 26 pages of Chinese Office Action including 16 pages of English Translation.;;Response for Korean Patent Application No. 10-2014-0029403 filed on Jul. 27, 2015 to Office Action dated May 27, 2015, 21 pages.;;Response for U.S. Appl. No. 13/844,729, filed Jun. 9, 2015 to Non-Final Office Action dated Jan. 6, 2015, 10 pages.;;Response for United Kingdom Patent Application No. 1402964.9 filed on Feb. 26, 2016 to Examination Report dated Nov. 4, 2015, 3 pages.;;Response for United Kingdom Patent Application No. 1402964.9 filed on Mar. 9, 2015 to Combined Search and Examination Report dated Jul. 25, 2014, 4 pages.;;Response for Japanese Patent Application No. 2014-028277, filed on Aug. 12, 2015 to Office Action dated Feb. 17, 2015, 27 pages of Japanese Response to Office Action including 1 page of partial English Translation.;;Response for Japanese Patent Application No. 2014-028277, filed on Mar. 15, 2016 to Office Action dated Sep. 15, 2015, 23 pages of Japanese Response to Office Action including 1 page of partial English Translation.;;Response for Chinese Patent Application No. 201410097357.6 filed on Jun. 15, 2017 to Office Action dated Nov. 30, 2016, 14 pages.;;Notice of Allowance received for Japanese Patent Application No. 2014-028277, dated Aug. 9, 2016, 4 pages of Japanese Notice of Allowance including 2 pages of Partial English Translation.;;Office Action received for Chinese Patent Application No. 201410097357.6, dated Nov. 30, 2016, 11 pages of Chinese Office Action Only.;;Kawachiya, et al., “Accelerating Java Locks by Utilizing Their Thread Locality”, vol. 44, No. SIG 15 (PRO19), Nov. 2003, pp. 13-23. (English Abstract Included).;;Intel, “Intel 64 and IA-32 Architectures Software Developer's Manual”, vol. 1: Basic Architecture, Order No. 253665-040US, Oct. 2011, 548 pages.;;Intel, “Intel 64 and IA-32 Architectures Software Developer's Manual”, vol. 2 (2A, 2B & 2C): Instruction Set Reference, A-Z, Order No. 325383-040US, Oct. 2011, 1721 pages.;;Intel, “Intel 64 and IA-32 Architectures Software Developer's Manual”, vol. 3 (3A, 3B & 3C): System Programming Guide, Order No. 325384-040US, Oct. 2011, 1916 pages.;;Notice of Allowance received for United Kingdom Application No. 1402964.9, dated Jun. 22, 2017, 2 pages.;;Notice of Allowance received for United Kingdom Patent Application No. 1709375.8, dated Oct. 20, 2017, 2 pages.;;Office Action received for United Kingdom Patent Application No. 1709375.8, dated Aug. 15, 2017, 1 page.;;Office Action received for Chinese Patent Application No. 201410097357.6, dated Nov. 30, 2016, 25 pages of Chinese Office Action including 14 pages of English Translation.;;Notice of Allowance received for Korean Patent Application No. 10-2014-0029403, dated Nov. 4, 2015, 2 pages of Notice of Allowance only.;;Office Action received for Korean Patent Application No. 10-2014-0029403, dated May 27, 2015, 4 pages of English Translation and 5 pages of Korean Office Action.;;Notice of Allowance received for U.S. Appl. No. 13/844,729, dated Sep. 14, 2015, 7 pages.;;Non-Final Office Action received for U.S. Appl. No. 13/844,729, dated Jan. 6, 2015, 12 Pages.;;Combined Search and Examination Report received for United Kingdom Patent Application No. 1402964.9, dated Jul. 25, 2014, 6 Pages.;;Examination Report received for United Kingdom Application No. GB1402964.9, dated Nov. 4, 2015, 3 pages.;;Office Action received for Japanese Patent Application No. 2014-028277, dated Feb. 17, 2015, 12 pages of English Translation and 1 page of Japanese Office Action.;;Office Action received for Japanese Patent Application No. 2014-028277, dated Sep. 15, 2015, 9 pages of English Translation and 6 page of Japanese Office Action.;;Martinez, et al., “Speculative Synchronization: Applying Thread-Level Speculation to Explicitly Parallel Applications” Proceedings of the 10th International Conference on Architectural Support for Programming Languages and Operating Systems, Oct. 2002, 12 Pages.",ACTIVE
966,US,A,US 2289350 A,078-556-776-366-450,1942-07-14,1942,US 18217437 A,1937-12-29,US 18217437 A,1937-12-29,Method of reconditioning furnace tubes,,TEXAS CO,DIXON ENSLO S;;GARRARD THOMAS E;;BARR HAROLD A,,https://lens.org/078-556-776-366-450,Granted Patent,no,0,7,1,1,0,C10G9/16;;C10G9/16,C10G9/16,,0,0,,,,EXPIRED
967,WO,A1,WO 2018/195659 A1,103-238-241-087-050,2018-11-01,2018,CA 2018050484 W,2018-04-24,US 201762489230 P,2017-04-24,SCANNING MICROSCOPE FOR 3D IMAGING USING MSIA,"According to some examples, an instrument for scanning a specimen on a specimen holder. The instrument includes a scanning stage for supporting the specimen, and a detector having a plurality of pixels. The scanning stage and the detector are movable relative to each other to move the specimen in a scan direction during a scan. At least some of the pixels of the detector are operable to collect light from different depths inside the specimen during the scan and generate corresponding image data. The instrument also includes a processor operable to perform MSIA on the image data to generate a 3D image of the specimen.",DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER,DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER,,https://lens.org/103-238-241-087-050,Patent Application,yes,2,0,6,6,0,G02B21/0036;;G02B21/0036;;G02B21/0052;;G02B21/006;;G02B21/0076;;G02B21/26;;G02B21/26;;G02B21/361;;G02B21/365;;G02B21/367,G01N21/13;;G01N21/64;;G01N21/84;;G02B21/00;;H04N5/351;;H04N13/221,,1,0,,,See also references of EP 3615916A4,PENDING
968,BR,B1,BR 112015029930 B1,125-793-441-176-550,2022-01-11,2022,BR 112015029930 A,2014-06-12,US 2014/0042153 W;;US 201313931544 A,2013-06-28,"Pares de imposição de ordem de instrução de instruções, processadores, métodos e sistemas","pares de imposição de ordem de instrução de instruções, processadores, métodos e sistemas. trata-se de um processador de um aspecto que inclui uma unidade de busca de instrução para buscar um par de instruções de imposição de ordem de instrução. o par de instruções de imposição de ordem de instrução é parte de um conjunto de instrução do processador. o par de instruções de imposição de ordem de instrução inclui uma instrução de ativação e uma instrução de imposição. a instrução de ativação deve ocorrer antes da instrução de imposição em uma ordem de programa. o processador também inclui um módulo de imposição de ordem de instrução. o módulo de imposição de ordem de instrução, em resposta ao par das instruções de imposição de ordem de instrução, deve impedir que as instruções que ocorrem após a instrução de imposição na ordem de programa sejam processadas antes da instrução de ativação, em uma porção fora de ordem do processador. outros processadores também são revelados, como são vários métodos, sistemas e instruções.",INTEL CORP,MARTIN G DIXON;;WILLIAM C RASH;;YAZMIN A SANTIAGO,,https://lens.org/125-793-441-176-550,Granted Patent,no,0,0,16,16,0,G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/3891;;G06F9/3856;;G06F9/3836;;G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3856,G06F9/38,,0,0,,,,INACTIVE
969,EP,A4,EP 3014424 A4,137-103-064-979-757,2017-03-01,2017,EP 14818771 A,2014-06-12,US 201313931544 A;;US 2014/0042153 W,2013-06-28,"INSTRUCTION ORDER ENFORCEMENT PAIRS OF INSTRUCTIONS, PROCESSORS, METHODS, AND SYSTEMS",,INTEL CORP,DIXON MARTIN G;;RASH WILLIAM C;;SANTIAGO YAZMIN A,,https://lens.org/137-103-064-979-757,Search Report,no,3,0,16,16,0,G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/3891;;G06F9/3856;;G06F9/3836;;G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3856,G06F9/38,,1,0,,,See also references of WO 2014209627A1,ACTIVE
970,US,A1,US 2004/0008288 A1,133-732-765-136-88X,2004-01-15,2004,US 38868803 A,2003-03-14,US 38868803 A;;US 6264402 A;;US 10339402 A,2002-01-31,Adaptive image display,"
   A display system may include an identifier configured to identify an image display condition associated with the display of an image produced by the display system, an apparatus configured to produce a plurality of differently colored images, and a display device. The images have color characteristics based on image information and the identified display condition. Differently colored images may be directed along associated portions of an optical path. The display device may be coupled to the apparatus and may be configured to display a color image formed of the differently colored images. 
",PATE MICHAEL A.;;ALLEN WILLIAM J.;;DIXON BRIAN S.,PATE MICHAEL A;;ALLEN WILLIAM J;;DIXON BRIAN S,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2003-05-22),https://lens.org/133-732-765-136-88X,Patent Application,yes,44,66,6,6,0,G02B26/008;;H04N9/3114;;H04N9/3155;;H04N9/3182;;H04N9/73;;H04N9/73;;H04N9/3155;;G02B26/008;;H04N9/3182;;H04N9/3114,H04N9/31;;H04N9/73,348/742;;348/602,0,0,,,,EXPIRED
971,WO,A3,WO 2003/025755 A3,158-502-637-557-448,2003-06-19,2003,US 0147805 W,2001-12-11,US 32249301 P,2001-09-14,sETHOD AND SYSTEM FOR CACHE MANAGEMENT ALGORITHM SELECTION,"In a data storage device, a system of method of optimizing cache management. A method includes selecting a set of cache management algorithms associated with a predetermined pattern in a sequence of commands. Statistics based on a sequence of commands are gathered and a pattern is detected from the statistics. The pattern is associated with predetermined known patterns to identify a set of cache management algorithms that are optimized for the known pattern. A sytem includes usage statistics that are correlated among a set of known usage patterns. A switch chooses the set of cache management algorithms associated with the known pattern that most closely matches the usage statistics.",SEAGATE TECHNOLOGY LLC,HERBST JAMES A;;BAUM CAROL M;;DIXON ROBERT W,,https://lens.org/158-502-637-557-448,Search Report,yes,4,0,4,4,0,G06F2003/0697;;G06F3/0601;;G06F12/0862;;G06F12/0871;;G06F2003/0697;;G06F3/0601;;G06F12/0871;;G06F12/0862,G06F3/06;;G06F12/00;;G06F12/08,,0,0,,,,PENDING
972,US,A1,US 2014/0281196 A1,184-761-319-130-931,2014-09-18,2014,US 201313844729 A,2013-03-15,US 201313844729 A,2013-03-15,"PROCESSORS, METHODS, AND SYSTEMS TO RELAX SYNCHRONIZATION OF ACCESSES TO SHARED MEMORY",A processor of an aspect includes a plurality of logical processors. A first logical processor of the plurality is to execute software that includes a memory access synchronization instruction that is to synchronize accesses to a memory. The processor also includes memory access synchronization relaxation logic that is to prevent the memory access synchronization instruction from synchronizing accesses to the memory when the processor is in a relaxed memory access synchronization mode.,DIXON MARTIN G;;RASH WILLIAM C;;SANTIAGO YAZMIN A,DIXON MARTIN G;;RASH WILLIAM C;;SANTIAGO YAZMIN A,INTEL CORPORATION (2013-03-14),https://lens.org/184-761-319-130-931,Patent Application,yes,5,18,20,20,0,G06F9/06;;G06F9/30087;;G06F9/30087;;G06F9/30087;;G06F12/0804;;G06F9/30087;;G06F9/38;;G06F9/522;;G06F12/0804;;G06F12/0804;;G06F12/0804;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/14;;G06F12/14;;G06F2212/1052;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G11C7/1072;;Y02D10/00;;Y02D10/00;;Y02D10/00,G06F12/14,711/105;;711/152,0,0,,,,ACTIVE
973,WO,A1,WO 2014/209627 A1,197-276-017-145-487,2014-12-31,2014,US 2014/0042153 W,2014-06-12,US 201313931544 A,2013-06-28,"INSTRUCTION ORDER ENFORCEMENT PAIRS OF INSTRUCTIONS, PROCESSORS, METHODS, AND SYSTEMS","A processor of an aspect includes an instruction fetch unit to fetch a pair of instruction order enforcement instructions. The pair of instruction order enforcement instructions are part of an instruction set of the processor. The pair of instruction order enforcement instructions includes an activation instruction and an enforcement instruction. The activation instruction is to occur before the enforcement instruction in a program order. The processor also includes an instruction order enforcement module. The instruction order enforcement module, in response to the pair of the instruction order enforcement instructions, is to prevent instructions occurring after the enforcement instruction in the program order, from being processed prior to the activation instruction, in an out-of-order portion of the processor. Other processors are also disclosed, as are various methods, systems, and instructions.",INTEL CORP,DIXON MARTIN G;;RASH WILLIAM C;;SANTIAGO YAZMIN A,,https://lens.org/197-276-017-145-487,Patent Application,yes,4,1,16,16,0,G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/3891;;G06F9/3856;;G06F9/3836;;G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3856,G06F9/38,,1,0,,,See also references of EP 3014424A4,PENDING
974,DE,A1,DE 102014003671 A1,002-089-444-860-658,2014-09-18,2014,DE 102014003671 A,2014-03-14,US 201313844729 A,2013-03-15,"PROZESSOREN, VERFAHREN UND SYSTEME ZUM ENTSPANNEN DER SYNCHRONISATION VON ZUGRIFFEN AUF EINEN GEMEINSAM GENUTZTEN SPEICHER","Ein Prozessor eines Aspekts beinhaltet mehrere logische Prozessoren. Ein erster der mehreren logischen Prozessoren dient dazu, Software auszuführen, die einen Speicherzugriffsynchronisations-Befehl beinhaltet, der die Zugriffe auf einen Speicher synchronisieren soll. Der Prozessor beinhaltet außerdem eine Logik zur Entspannung der Speicherzugriffsynchronisation, die dazu dient, den Speicherzugriffsynchronisations-Befehl daran zu hindern, Zugriffe auf den Speicher zu synchronisieren, wenn sich der Prozessor in einem entspannten Speicherzugriffsynchronisationsmodus befindet.",INTEL CORP,DIXON MARTIN G;;RASH WILLIAM C;;SANTIAGO YAZMIN A,,https://lens.org/002-089-444-860-658,Patent Application,no,0,0,20,20,0,G06F9/06;;G06F9/30087;;G06F9/30087;;G06F9/30087;;G06F12/0804;;G06F9/30087;;G06F9/38;;G06F9/522;;G06F12/0804;;G06F12/0804;;G06F12/0804;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/14;;G06F12/14;;G06F2212/1052;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G11C7/1072;;Y02D10/00;;Y02D10/00;;Y02D10/00,G06F9/30,,0,0,,,,PENDING
975,US,B2,US 11891851 B2,008-908-514-636-374,2024-02-06,2024,US 202117318538 A,2021-05-12,US 202117318538 A;;US 202063025328 P,2020-05-15,Door-ready molding,"A door system including a primary door molding attachable to a primary door frame, the primary door molding including a first vertical member and a first hinge member extending from the first vertical member. One of a horizontal member from which the first vertical member downwardly extends and the first vertical member includes a first rotatably engageable element, and the first hinge member includes a second rotatably engageable element vertically spaced from the first rotatably engageable element.",LARSON MFG COMPANY OF SOUTH DAKOTA LLC,DIXON ALAN M;;KONDRATUK MICHAEL W;;RAWDEN JAMMEY A,LARSON MANUFACTURING COMPANY OF SOUTH DAKOTA LLC (2021-06-10),https://lens.org/008-908-514-636-374,Granted Patent,yes,37,0,3,4,0,E06B5/003;;E06B2009/527;;E06B3/725;;E06B2003/7074;;E06B2003/7082;;E06B3/325;;E06B3/36;;E06B1/52;;E05Y2900/132;;E06B3/06,E06B1/04;;E06B1/52;;E06B3/06,,0,0,,,,ACTIVE
976,US,B2,US 11106026 B2,049-186-536-065-344,2021-08-31,2021,US 201815961390 A,2018-04-24,US 201815961390 A;;US 201762489230 P,2017-04-24,Scanning microscope for 3D imaging using MSIA,"According to some examples, an instrument for scanning a specimen on a specimen holder. The instrument includes a scanning stage for supporting the specimen, and a detector having a plurality of pixels. The scanning stage and the detector are movable relative to each other to move the specimen in a scan direction during a scan. At least some of the pixels of the detector are operable to collect light from different depths inside the specimen during the scan and generate corresponding image data. The instrument also includes a processor operable to perform MSIA on the image data to generate a 3D image of the specimen.",DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER;;HURON TECH INTERNATIONAL INC,DIXON A E;;DAMASKINOS SAVVAS;;RIBES ALFONSO;;HAYES JASPER,HURON TECHNOLOGIES INTERNATIONAL INC (2020-02-12),https://lens.org/049-186-536-065-344,Granted Patent,yes,10,0,6,6,0,G02B21/0036;;G02B21/0036;;G02B21/0052;;G02B21/006;;G02B21/0076;;G02B21/26;;G02B21/26;;G02B21/361;;G02B21/365;;G02B21/367,H04N7/18;;G02B21/00;;G02B21/26;;G02B21/36,,1,1,030-802-761-799-041,pmc1330446;;10.1016/s0006-3495(89)82783-3;;2495031,"Peter J. Shaw et al., Tilted view reconstruction in optical microscopy, Jan. 1989, vol. 55 pp. 101-110.",ACTIVE
977,TW,B,TW I248553 B,059-707-940-575-446,2006-02-01,2006,TW 92123435 A,2003-08-26,US 38868803 A,2003-03-14,Adaptive image display,"A display system (40) may include an identifier (64) configured to identify an image display condition associated with the display of an image produced by the display system (40), an apparatus (46) configured to produce a plurality of differently colored images, and a display device (48). The images have color characteristics based on image information (62) and the identified display condition. Differently colored images may be directed along associated portions of an optical path (56). The display device (48) may be coupled to the apparatus (46) and may be configured to display a color image formed of the differently colored images.",HEWLETT PACKARD DEVELOPMENT CO,PATE MICHAEL A;;ALLEN WILLIAM J;;DIXON BRIAN S,,https://lens.org/059-707-940-575-446,Granted Patent,no,0,0,6,6,0,G02B26/008;;H04N9/3114;;H04N9/3155;;H04N9/3182;;H04N9/73;;H04N9/73;;H04N9/3155;;G02B26/008;;H04N9/3182;;H04N9/3114,H04N9/31;;G03B25/00;;H04N9/73,,0,0,,,,EXPIRED
978,WO,A9,WO 2006/012594 A9,064-644-414-966-266,2006-03-23,2006,US 2005/0026253 W,2005-07-25,US 59099104 P,2004-07-24,MODIFICATION OF LIGNIN BIOSYNTHESIS,The invention provides methods for decreasing lignin content and improving lignin profiles. Also provided are the plants prepared by the methods of the invention. Such plants may exhibit improved digestibility relative to prior plants.,SAMUEL ROBERTS NOBLE FOUND INC;;DIXON RICHARD A;;REDDY M S SRINIVASA;;CHEN FANG,DIXON RICHARD A;;REDDY M S SRINIVASA;;CHEN FANG,,https://lens.org/064-644-414-966-266,Patent Application,no,0,0,9,9,0,C12N15/827;;C12N15/827;;C12N15/8255;;C12N15/8255;;C12N15/8261;;C12N15/8261;;Y02A40/146;;Y02A40/146,C12N15/82,,0,0,,,,PENDING
979,KR,A,KR 20140113444 A,092-518-744-201-416,2014-09-24,2014,KR 20140029403 A,2014-03-13,US 201313844729 A,2013-03-15,"PROCESSORS, METHODS, AND SYSTEMS TO RELAX SYNCHRONIZATION OF ACCESSES TO SHARED MEMORY",A processor of an aspect includes a plurality of logical processors. A first logical processor of the processors executes software that includes a memory access synchronization instruction for synchronizing accesses to a memory. The processor also includes memory access synchronization relaxation logic that prevents the memory access synchronization instruction from synchronizing the accesses to the memory when the processor is in a relaxed memory access synchronization mode.,INTEL CORP,DIXON MARTIN G;;RASH WILLIAM C;;SANTIAGO YAZMIN A,,https://lens.org/092-518-744-201-416,Patent Application,no,0,0,20,20,0,G06F9/06;;G06F9/30087;;G06F9/30087;;G06F9/30087;;G06F12/0804;;G06F9/30087;;G06F9/38;;G06F9/522;;G06F12/0804;;G06F12/0804;;G06F12/0804;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/14;;G06F12/14;;G06F2212/1052;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G11C7/1072;;Y02D10/00;;Y02D10/00;;Y02D10/00,G06F9/06;;G06F9/30,,0,0,,,,ACTIVE
980,NZ,A,NZ 200673 A,103-850-460-102-047,1985-11-08,1985,NZ 20067382 A,1982-05-19,GB 8116633 A,1981-06-01,TIME BREAK ON SEISMIC RECORD DETECTED WHEN EXPLOSION BREAKS CURRENT LOOP,"A method and apparatus for indicating the time-break on a seismic record wherein the time-break is marked in response to the rupture of an electric circuit by the explosive charge used to generate the seismic waves. The preferred rupturable electric circuit is connected to the same energy source as the electric detonator used to initiate the explosive charge and the preferred electric detonator is one connected to a high frequency A.C. firing energy source through a transformer, the rupturable electric circuit being the primary or secondary circuit of the transformer. The method is more accurate than the present method of marking the time-break at the initial application of current to the detonator.",ICI PLC,DIXON R M;;KING A G;;THOMPSON S R,,https://lens.org/103-850-460-102-047,Patent Application,no,0,0,20,23,0,G01V1/26;;G01V1/26,G01V1/26;;G01V1/24,,0,0,,,,DISCONTINUED
981,KR,A,KR 20150138306 A,138-967-677-310-989,2015-12-09,2015,KR 20157031073 A,2014-06-12,US 201313931544 A;;US 2014/0042153 W,2013-06-28,"INSTRUCTION ORDER ENFORCEMENT PAIRS OF INSTRUCTIONS, PROCESSORS, METHODS, AND SYSTEMS","한 양태의 프로세서는 명령어 순서 강제 명령어들의 쌍을 페치하기 위한 명령어 페치 유닛을 포함한다. 명령어 순서 강제 명령어들의 쌍은 프로세서의 명령어 세트의 일부이다. 명령어 순서 강제 명령어들의 쌍은 활성화 명령어와 강제 명령어를 포함한다. 활성화 명령어는 프로그램 순서에서 강제 명령어 전에 발생하는 것이다. 프로세서는 또한 명령어 순서 강제 모듈을 포함한다. 명령어 순서 강제 모듈은, 명령어 순서 강제 명령어들의 쌍에 응답하여, 프로세서의 비순차적 부분에서, 프로그램 순서에서 강제 명령어 후에 발생하는 명령어들이, 활성화 명령어 전에 처리되는 것을 방지하는 것이다. 다른 프로세서들도, 다양한 방법들, 시스템들 및 명령어들과 같이 개시된다.",INTEL CORP,DIXON MARTIN G;;RASH WILLIAM C;;SANTIAGO YAZMIN A,,https://lens.org/138-967-677-310-989,Patent Application,no,0,0,16,16,0,G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/3891;;G06F9/3856;;G06F9/3836;;G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3856,,,0,0,,,,ACTIVE
982,US,A,US 5257716 A,154-434-180-808-472,1993-11-02,1993,US 94296592 A,1992-09-10,US 94296592 A,1992-09-10,Pipe manufacturing method and apparatus,A method and apparatus for transferring tubular products from one mill to another including a connecting table having the shape of a reverse curve. The table includes a base and two spaced apart walls attached to the base defining a passageway between the base and the sidewalls. A diverter is associated with the connecting table to divert metal product in a hot working state from a first conveying table onto the connecting table leading to a second conveying table. The connecting table preferably is associated with a welding and forming mill and a stretch reducing mill.,ARMCO INC,SLOAN ROBERT C;;MARTIN WILLIAM A;;DIXON WOODROW S,ARMCO INC (1992-09-08);;JOHN MANEELY COMPANY (2002-05-03),https://lens.org/154-434-180-808-472,Granted Patent,yes,16,1,1,1,0,B21C37/0807;;B21C37/0807;;B21B17/14;;B21B17/14;;B21B23/00;;B21B23/00;;B21B39/18;;B21B39/18;;B23K37/047;;B23K37/047;;Y10T29/53539;;Y10T29/53539,B21B17/14;;B21B23/00;;B21B39/18;;B21C37/08;;B23K37/047,228/147;;228/47;;228/155;;198/367;;29/822,1,0,,,"Chapter 32, The Making, Shaping and Treating of Steel, 10th Edition, United States Steel (no date given).",EXPIRED
983,US,S,US D0873990 S,188-365-472-299-160,2020-01-28,2020,US 201829637765 F,2018-02-21,US 201829637765 F,2018-02-21,Handle for vacuum delivery device,,CLINICAL INNOVATIONS LLC,DIXON RICHARD A;;MOON BRANDON D;;THOMAS SPENCER R,CLINICAL INNOVATIONS LLC (2018-02-21),https://lens.org/188-365-472-299-160,Design Right,no,16,1,1,1,0,,,2402;;D24/108;;D24/133,1,0,,,"AAAWholesaleCompany. Link: https://www.aaawholesalecompany.com/mdl-kmewmvac60mth.html?utm_source=googleshopping&utm_medium=cse&gclid=EAIaIQobChM14_XFIZC54QIVEonICh17WAAkEAQYAyABEglfwfD_BwE. Visited Apr. 5, 2019. Kiwi Vacuum Delivery. (Year: 2019).",ACTIVE
984,AU,B2,AU 2005/266927 B2,189-086-978-719-825,2011-07-14,2011,AU 2005/266927 A,2005-07-25,US 59099104 P;;US 2005/0026253 W,2004-07-24,Modification of lignin biosynthesis,The invention provides methods for decreasing lignin content and improving lignin profiles. Also provided are the plants prepared by the methods of the invention. Such plants may exhibit improved digestibility relative to prior plants.,THE SAMUEL ROBERTS NOBLE FOUNDATION INC,SRINIVASA REDDY M S;;DIXON RICHARD A;;FANG CHEN,,https://lens.org/189-086-978-719-825,Granted Patent,no,0,0,9,9,0,C12N15/827;;C12N15/827;;C12N15/8255;;C12N15/8255;;C12N15/8261;;C12N15/8261;;Y02A40/146;;Y02A40/146,C12N15/82;;A01H5/00;;A01H5/10,,1,0,,,"Hoffman et al, The Plant Cell, 2004, Vol. 16, pages 1444-1465",INACTIVE
985,JP,A,JP 2014182813 A,004-196-136-592-125,2014-09-29,2014,JP 2014045403 A,2014-03-07,US 201313844873 A,2013-03-16,"INSTRUCTION EMULATION PROCESSORS, METHODS, AND SYSTEMS",PROBLEM TO BE SOLVED: To provide a processor including decode logic to receive a first instruction and to determine that the first instruction is to be emulated.SOLUTION: The processor also includes emulation mode aware post-decode instruction processor logic coupled with the decode logic. The emulation mode aware post-decode instruction processor logic processes one or more control signals decoded from an instruction. The instruction is one of a set of one or more instructions used to emulate the first instruction. The one or more control signals are processed differently by the emulation mode aware post-decode instruction processor logic when in an emulation mode than when not in the emulation mode.,INTEL CORP,WILLIAM C RASH;;DIXON MARTIN G;;YAZMIN A SANTIAGO,,https://lens.org/004-196-136-592-125,Patent Application,no,15,5,14,14,0,G06F9/3017;;G06F9/30189;;G06F9/382;;G06F9/455;;G06F9/3017;;G06F9/30189;;G06F9/382;;G06F9/30174;;G06F9/3017;;G06F9/3017;;G06F9/30189;;G06F9/382;;G06F9/455,G06F9/30;;G06F9/318,,7,0,,,"JPN6015006821; 千田 大介: '「ＯＳ・フォント Ｗｉｎｄｏｗｓ Ｖｉｓｔａ ＆ Ｏｆｆｉｃｅ ２００７」' 漢字文献情報処理研究 第７号 , 20061001, １２６頁〜１３８頁, 株式会社好文出版;;JPN6015006823; インテル株式会社: インテル・アーキテクチャ・ソフトウェア・ディベロッパーズ・マニュアル 中巻：命令セット・リファレンス , 1997, ３-２８６頁〜３-２８８頁, ＣＱ出版株式会社;;JPN6015006821; 千田 大介: '「ＯＳ・フォント Ｗｉｎｄｏｗｓ Ｖｉｓｔａ ＆ Ｏｆｆｉｃｅ ２００７」' 漢字文献情報処理研究 第７号 , 20061001, １２６頁〜１３８頁, 株式会社好文出版;;JPN6015006823; インテル株式会社: インテル・アーキテクチャ・ソフトウェア・ディベロッパーズ・マニュアル 中巻：命令セット・リファレンス , 1997, ３-２８６頁〜３-２８８頁, ＣＱ出版株式会社;;JPN6015052394; インテル株式会社: インテル・アーキテクチャ・ソフトウェア・ディベロッパーズ・マニュアル 下巻：システム・プログラミング , 1997, ６-１頁〜６-２０頁，１５-９頁〜１５-１４頁, ＣＱ出版株式会社;;JPN6015052396; インテル株式会社: インテル・アーキテクチャ・ソフトウェア・ディベロッパーズ・マニュアル 中巻：命令セット・リファレンス , 1997, ３-３８頁〜３-４８頁, ＣＱ出版株式会社;;CSND200601552009; 千田 大介: '「ＯＳ・フォント Ｗｉｎｄｏｗｓ Ｖｉｓｔａ ＆ Ｏｆｆｉｃｅ ２００７」' 漢字文献情報処理研究 第７号 , 20061001, １２６頁〜１３８頁, 株式会社好文出版",ACTIVE
986,US,A1,US 2015/0006851 A1,005-963-430-928-567,2015-01-01,2015,US 201313931544 A,2013-06-28,US 201313931544 A,2013-06-28,"INSTRUCTION ORDER ENFORCEMENT PAIRS OF INSTRUCTIONS, PROCESSORS, METHODS, AND SYSTEMS","A processor of an aspect includes an instruction fetch unit to fetch a pair of instruction order enforcement instructions. The pair of instruction order enforcement instructions are part of an instruction set of the processor. The pair of instruction order enforcement instructions includes an activation instruction and an enforcement instruction. The activation instruction is to occur before the enforcement instruction in a program order. The processor also includes an instruction order enforcement module. The instruction order enforcement module, in response to the pair of the instruction order enforcement instructions, is to prevent instructions occurring after the enforcement instruction in the program order, from being processed prior to the activation instruction, in an out-of-order portion of the processor. Other processors are also disclosed, as are various methods, systems, and instructions.",INTEL CORP,DIXON MARTIN GUY;;RASH WILLIAM C;;SANTIAGO YAZMIN A,INTEL CORPORATION (2013-09-16),https://lens.org/005-963-430-928-567,Patent Application,yes,2,2,16,16,0,G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/30079;;G06F9/30087;;G06F9/3836;;G06F9/3891;;G06F9/3856;;G06F9/3836;;G06F9/3891;;G06F9/30079;;G06F9/30087;;G06F9/3856,G06F9/38,712/205,0,0,,,,ACTIVE
987,CA,A,CA 1176381 A,008-314-539-846-302,1984-10-16,1984,CA 404524 A,1982-06-04,US 27075081 A,1981-06-05,DYNAMICALLY ASSIGNABLE I/O CONTROLLER CACHE,"DYNAMICALLY ASSIGNABLE I/O CONTROLLER CACHE In a data processing system of the type wherein a host processor transfers data to or from a plurality of attachment devices, a cache memory is provided for storing blocks of data which are most likely to be needed by the host processor in the near future. The host processor can then merely retrieve the necessary information from the cache memory without the necessity of accessing the attachment devices. When transferring data to cache from an attachment disk, additional unrequested information can be transferred at the same time if it is likely that this additional data will soon be requested. Further, a directory table is maintained wherein all data in cache is listed at a ""home"" position and, if more than one block of data in cache have the same home position, a conflict chaim is set-up so that checking the contents of the cache can be done simply and quickly.",IBM,DIXON JERRY D;;MARAZAS GERALD A;;MERCKEL GERALD U,,https://lens.org/008-314-539-846-302,Granted Patent,no,0,0,4,13,0,G06F12/0862;;G06F12/0862;;G06F12/0866;;G06F12/0866;;G06F13/122;;G06F13/122;;G06F2212/502;;G06F2212/502,G06F12/08;;G06F13/12,354-237,0,0,,,,EXPIRED
988,CA,A,CA 551512 A,023-849-209-722-045,1958-01-14,1958,CA 551512D A,,CA 551512T A,,ISOMERIC POLYCHLOROPYRAZINES AND PREPARATION THEREOF,,AMERICAN CYANAMID CO,DIXON JAMES K;;BRUESCH JOHN F;;MILLER ALEXANDER A,,https://lens.org/023-849-209-722-045,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
989,EP,A4,EP 1123226 A4,036-564-113-507-941,2002-01-23,2002,EP 99955056 A,1999-10-20,US 9924463 W;;US 17825598 A,1998-10-23,HONEYCOMB CRASH PAD,,HEXCEL CORP,NUSSER LORI A;;DIXON G DOUGLAS;;HULL H ROBERT,,https://lens.org/036-564-113-507-941,Search Report,no,2,0,5,5,0,B60R21/04;;B60R21/04;;B60R13/0225;;B60R13/0225;;B60R2021/0421;;B60R2021/0421;;F16F7/121;;F16F7/121,B60R13/02;;B60R21/04;;F16F7/12,,1,0,,,See also references of WO 0024613A1,DISCONTINUED
990,CN,A,CN 109508206 A,072-239-366-132-910,2019-03-22,2019,CN 201910081033 A,2014-06-19,CN 201910081033 A;;CN 201480030091 A;;US 2014/0043159 W;;US 201313931070 A,2013-06-28,"Mode dependent partial width load to wider register processors, methods, and systems","A method of an aspect is performed by a processor. The method includes receiving a partial width load instruction. The partial width load instruction indicates a memory location of a memory as a source operand and indicates a register as a destination operand. The method includes loading data from the indicated memory location to the processor in response to the partial width load instruction. Themethod includes writing at least a portion of the loaded data to a partial width of the register in response to the partial width load instruction. The method includes finishing writing the registerwith a set of bits stored in a remaining width of the register that have bit values that depend on a partial width load mode of the processor. The partial width load instruction does not indicate thepartial width load mode. Other methods, processors, and systems are also disclosed.",INTEL CORP,WILLIAM C RASH;;YAZMIN A SANTIAGO;;MARTIN GUY DIXON,,https://lens.org/072-239-366-132-910,Patent Application,no,9,0,17,17,0,G06F9/30043;;G06F9/30189;;G06F9/3836;;G06F9/3836;;G06F9/30145;;G06F9/30189;;G06F9/30;;G06F9/30043;;G06F9/30145;;G06F9/30189;;G06F9/30043;;G06F9/3836,G06F9/30;;G06F9/38,,3,1,047-486-097-388-513,10.1109/iccae.2010.5452006,"ARTHUR GRIFFITH: ""《GCC技术参考大全》"", 31 July 2004;;AHMAD M. SHAFIEE ET AL: ""Facing pipeline false dependencies using VRB table"", 《 2010 THE 2ND INTERNATIONAL CONFERENCE ON COMPUTER AND AUTOMATION ENGINEERING (ICCAE)》;;蔡卫光等: ""RISC-DSP处理器中指令数据相关性的提前判断方法"", 《电子与信息学报》",ACTIVE
991,US,A1,US 2008/0317880 A1,091-662-196-747-038,2008-12-25,2008,US 84003207 A,2007-08-16,US 84003207 A;;US 83807206 P,2006-08-16,PLANT ISOFLAVONE AND ISOFLAVANONE O-METHYLTRANSFERASE GENES,"The invention provides enzymes that encode O-methyltransferases (OMTs) from Medicago truncatula that allow modification to plant (iso)flavonoid biosynthetic pathways. In certain aspects of the invention, the genes encoding these enzymes are provided. The invention therefore allows the modification of plants for isoflavonoid content. Transgenic plants comprising such enzymes are also provided, as well as methods for improving disease resistance in plants. Methods for producing food and nutraceuticals, and the resulting compositions, are also provided.",SAMUEL ROBERTS NOBLE FOUND INC,BROECKLING BETTINA E;;LIU CHANG-JUN;;DIXON RICHARD A,THE SAMUEL ROBERTS NOBLE FOUNDATION (2008-05-22);;NOBLE RESEARCH INSTITUTE LLC (2017-05-01),https://lens.org/091-662-196-747-038,Patent Application,yes,2,2,4,4,29,A61P3/02;;C12N9/1007;;C12N9/1007;;C12N15/8243;;C12N15/8243;;C12N15/8279;;C12N15/8279,A61K36/00;;A01H5/00;;A23L19/00;;A61P3/02;;C12N5/10;;C12N15/54;;C12N15/82,424/725;;536/23.2;;435/320.1;;435/419;;800/298;;800/282;;800/279;;426/615,1,0,,,"Lin et al. (GenBank Accession No. AC146549.1, accessed 9/23/2013, published August 30, 2003).",ACTIVE
992,EP,A1,EP 3273786 A1,097-698-650-637-73X,2018-01-31,2018,EP 16769494 A,2016-03-21,US 201562138002 P;;US 2016/0023419 W,2015-03-25,VERTICAL ELECTRIC COOKER AND SMOKER WITH SMOKE BOX,,BRADLEY W C CO,DIXON WILLIAM A;;ABDALLAH SLEIMAN ASSAAD;;MCQUAGG MARK STEPHEN,W.C. BRADLEY CO. (2020-02-19),https://lens.org/097-698-650-637-73X,Patent Application,yes,0,0,12,12,0,A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;Y02A40/90;;A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;A23V2002/00,A23B4/048;;A23B4/044;;A23B4/052;;A23B4/056;;A47J37/06;;A47J37/07,,0,0,,,,ACTIVE
993,CN,A,CN 104050026 A,128-578-879-557-670,2014-09-17,2014,CN 201410097357 A,2014-03-17,US 201313844729 A,2013-03-15,"PROCESSORS, METHODS, AND SYSTEMS TO RELAX SYNCHRONIZATION OF ACCESSES TO SHARED MEMORY",A processor of an aspect includes a plurality of logical processors. A first logical processor of the plurality is to execute software that includes a memory access synchronization instruction that is to synchronize accesses to a memory. The processor also includes memory access synchronization relaxation logic that is to prevent the memory access synchronization instruction from synchronizing accesses to the memory when the processor is in a relaxed memory access synchronization mode.,INTEL CORP,DIXON MARTIN G;;RASH WILLIAM C;;SANTIAGO YAZMIN A,,https://lens.org/128-578-879-557-670,Patent Application,no,5,2,20,20,0,G06F9/06;;G06F9/30087;;G06F9/30087;;G06F9/30087;;G06F12/0804;;G06F9/30087;;G06F9/38;;G06F9/522;;G06F12/0804;;G06F12/0804;;G06F12/0804;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/14;;G06F12/14;;G06F2212/1052;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G11C7/1072;;Y02D10/00;;Y02D10/00;;Y02D10/00,G06F9/46;;G06F12/02,,0,0,,,,ACTIVE
994,GB,A,GB 2548511 A,146-804-020-197-030,2017-09-20,2017,GB 201709375 A,2014-02-20,US 201313844729 A;;GB 201402964 A,2013-03-15,"Processors, methods, and systems to relax synchronization of accesses to shared memory","A processor comprises a plurality of logical processors, with a first of these processors executing software including conditional memory instructions; with a decode unit to convert the conditional memory access instruction(s) to unconditional memory access operations when the processor is in a relaxed memory access synchronisation mode. The unconditional memory access instructions preferably access a first portion of a memory without respecting memory access synchronisation. The conditional memory access instructions preferably comprise conditional load or conditional store instructions which are converted into respective unconditional instructions; or a load-link and store-conditional pair of instructions which are converted into a single unconditional store operation; or a read-modify-write instruction that is converted into a single unconditional write operation. The processor preferably has one or more architecturally visible bits to indicate being in the relaxed mode, with these bits preferably modifiable by software. Preferably, the processor is in the relaxed mode when only a single thread is running, and/or or when only one thread will access an associated shared memory, and/or no other thread will be observing the associated shared memory.",INTEL CORP,MARTIN G DIXON;;WILLIAM C RASH;;YASMIN A SANTIAGO,,https://lens.org/146-804-020-197-030,Patent Application,no,2,0,20,20,0,G06F9/06;;G06F9/30087;;G06F9/30087;;G06F9/30087;;G06F12/0804;;G06F9/30087;;G06F9/38;;G06F9/522;;G06F12/0804;;G06F12/0804;;G06F12/0804;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0815;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/0862;;G06F12/14;;G06F12/14;;G06F2212/1052;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G06F2212/6028;;G11C7/1072;;Y02D10/00;;Y02D10/00;;Y02D10/00,G06F9/30;;G06F9/38;;G06F9/52;;G06F12/0804;;G06F12/0815;;G06F12/0862,,0,0,,,,INACTIVE
995,CA,A,CA 589094 A,176-217-632-074-922,1959-12-15,1959,CA 589094D A,,CA 589094T A,,MANUFACTURE OF REGENERATED CELLULOSE,,INT PAPER CANADA,CHARLES FRANK R;;SAXTON WILLIAM R;;DIXON JULIAN A,,https://lens.org/176-217-632-074-922,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
996,WO,A1,WO 2016/154114 A1,007-933-772-171-942,2016-09-29,2016,US 2016/0023419 W,2016-03-21,US 201562138002 P,2015-03-25,VERTICAL ELECTRIC COOKER AND SMOKER AND SMOKE BOX,"A vertical electric cooker and smoker having lower air intake vents and upper exhaust vents which together create a more balanced flow and distribution of smoke and reduce the operating pressure of the system to allow a much larger load of wood chips to be used without refilling. A smoke box is also provided for holding and properly combusting the larger quantity of wood chips in an oxygen deficient environment. The smoke box has a false bottom and discharges the smoke through a circuitous exhaust flow path. Also, the electric heating elements of the cooking and smoking apparatus are contained in an assembly which provides an air gap beneath the smoker box and also shields the smoker box to prevent the wood chips in the smoker box from becoming overheated.",BRADLEY W C CO,DIXON WILLIAM A;;ABDALLAH SLEIMAN ASSAAD;;MCQUAGG MARK STEPHEN,,https://lens.org/007-933-772-171-942,Patent Application,yes,12,71,12,12,0,A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;Y02A40/90;;A23B4/052;;A23B4/048;;A23B4/0523;;A47J37/0629;;A23B4/056;;A23V2002/00,A23B4/044;;A23B4/052;;A23B4/056;;A47J37/06;;A47J37/07,,1,0,,,See also references of EP 3273786A4,PENDING
997,US,B2,US 9202056 B2,044-412-021-948-210,2015-12-01,2015,US 201313839048 A,2013-03-15,US 201313839048 A,2013-03-15,Inter-processor attestation hardware,"Embodiments of an invention for inter-processor attestation hardware are disclosed. In one embodiment, an apparatus includes first attestation hardware associated with a first portion of a system. The first attestation hardware is to attest to a second portion of the system that the first portion of the system is secure.",INTEL CORP,RASH WILLIAM C;;DIXON MARTIN G;;SANTIAGO YAZMIN A,INTEL CORPORATION (2013-06-26),https://lens.org/044-412-021-948-210,Granted Patent,yes,14,0,2,2,0,G06F21/57;;G06F21/57,G06F11/00;;G06F7/04;;G06F12/14;;G06F21/57,,0,0,,,,INACTIVE
998,EP,A1,EP 1216400 A1,049-686-934-064-065,2002-06-26,2002,EP 00966895 A,2000-09-26,US 0026406 W;;US 15658199 P,1999-09-29,LOAD CELL APPARATUS,"A load cell apparatus (100) includes a cell block (70) adapted to couple to a first structure, and a mount (82) adapted to couple to a second structure. The mount (82) is made of a first material and is formed to include a bore (140). The apparatus (100) also includes a stud (78) extending from the cell block (70), and a liner (142) positioned to lie in the bore (140). The stud (78) engages the liner (142). The liner (142) is made of a second material that is more lubrous than the first material.",HILL ROM CO INC,MOBLEY DONALD L;;DIXON STEVE A;;HOPKINS RANDALL K,"HILL-ROM SERVICES, INC. (2009-09-09)",https://lens.org/049-686-934-064-065,Patent Application,yes,0,0,9,10,0,G01G19/445,G01G19/52;;A61B5/11;;A61G7/05;;G01G19/44;;G01L1/22,,0,0,,,,EXPIRED
999,DE,D1,DE 60043230 D1,065-846-902-803-361,2009-12-10,2009,DE 60043230 T,2000-09-26,US 15658199 P;;US 0026406 W,1999-09-29,WÄGEZELLENGERÄT,"A load cell apparatus (100) includes a cell block (70) adapted to couple to a first structure, and a mount (82) adapted to couple to a second structure. The mount (82) is made of a first material and is formed to include a bore (140). The apparatus (100) also includes a stud (78) extending from the cell block (70), and a liner (142) positioned to lie in the bore (140). The stud (78) engages the liner (142). The liner (142) is made of a second material that is more lubrous than the first material.",HILL ROM SERVICES INC,MOBLEY DONALD L;;DIXON STEVE A;;HOPKINS RANDALL K,,https://lens.org/065-846-902-803-361,Granted Patent,no,0,0,9,10,0,G01G19/445,G01G19/44;;G01G19/52;;A61B5/11;;A61G7/05;;G01L1/22,,0,0,,,,EXPIRED
1000,WO,A1,WO 1986/004965 A1,085-554-032-640-343,1986-08-28,1986,US 8600275 W,1986-02-11,US 70134785 A,1985-02-13,FASTENING SYSTEM AND FASTENER FOR SHIPPING CONTAINERS AND THE LIKE,"A fastener (10) including a tubular sleeve (22) and an elongated pin (20) with the sleeve (22) having an elongated sleeve shank (26) with a through bore (34, 36) and the pin (20) having an enlarged pin head (40) and a shank (43), the shank (43) having a lock ridge (42) and a lock groove (46) located adjacent thereto; a splined portion (48) on the pin shank (43) having ridges (50) and grooves (52) and adapted to engage a preselected portion of the sleeve shank bore (34) to move the sleeve material into the spline grooves (52), the lock ridge (42) being adapted to engage the material of the preselected sleeve shank portion after it has moved through the splined portion (48) for moving that engaged material radially inwardly into the lock groove (46). The fastener (110) may also include a sealing sleeve (161).",HUCK MFG CO,DIXON RICHARD D;;JOHNSON WALTER A;;HICKS MARVIN R,,https://lens.org/085-554-032-640-343,Patent Application,yes,4,10,7,7,0,F16B19/10;;F16B19/1054;;F16B19/1027,F16B19/10,F2H H11B1D        H11BZ;;F2H H11B3         H11BZ;;F2H H11B4         H11BZ,0,0,,,,PENDING
